Clustering O 0 0.0002526025637052953
of O 0 3.121673580608331e-05
missense O 0 0.0001703304296825081
mutations O 0 2.2372214516508393e-05
in O 0 2.642080835357774e-05
the O 0 0.00023931486066430807
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 0.0009447639458812773
in O 0 5.080231130705215e-05
a O 0 4.855966835748404e-05
sporadic B-Disease 1 0.9998238682746887
T I-Disease 1 1.0
- I-Disease 1 0.9999598264694214
cell I-Disease 1 0.999972939491272
leukaemia I-Disease 1 0.9999951124191284
. O 0 8.74116722116014e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999995231628418
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3175744243199006e-05
is O 0 8.360732408618787e-07
a O 0 2.2828539840702433e-06
recessive B-Disease 0 0.0002450447645969689
multi I-Disease 1 0.9760453104972839
- I-Disease 1 0.9869351387023926
system I-Disease 0 0.00019560921646188945
disorder I-Disease 0 0.0010010813130065799
caused O 0 3.6341725717647932e-06
by O 0 6.507819705348084e-08
mutations O 0 1.0197019406632535e-07
in O 0 9.932203965945519e-07
the O 0 2.932627694463008e-06
ATM O 0 4.438604446477257e-05
gene O 0 8.772951332502998e-06
at O 0 5.914348002988845e-05
11q22 O 0 6.236002809600905e-05
- O 0 3.380427369847894e-05
q23 O 0 9.994242282118648e-05
( O 0 3.5988759918836877e-06
ref O 0 4.954599717166275e-05
. O 0 4.4021646772307577e-07
3 O 0 5.654643700836459e-06
) O 0 4.7064085606507433e-07
. O 0 9.020866968967312e-07

The O 0 5.2916991990059614e-05
risk O 0 3.733288758667186e-05
of O 0 7.669383194297552e-05
cancer B-Disease 1 0.9802790880203247
, O 0 1.083852203009883e-05
especially O 0 1.075664931704523e-05
lymphoid B-Disease 0 0.0010873149149119854
neoplasias I-Disease 0 0.005740674678236246
, O 0 2.1793807718495373e-06
is O 0 7.530837820013403e-07
substantially O 0 4.770554824062856e-06
elevated O 0 0.0017575382953509688
in O 0 0.00015950425586197525
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 9.136695734923705e-05
and O 0 2.125848141076858e-06
has O 0 1.5375308066722937e-06
long O 0 6.694406806673214e-07
been O 0 4.591290405642212e-07
associated O 0 1.2667520650211372e-06
with O 0 8.12198322819313e-07
chromosomal O 1 1.0
instability O 1 0.9999997615814209
. O 0 3.535426003509201e-05

By O 0 1.7761369235813618e-05
analysing O 0 0.00017295157886110246
tumour B-Disease 1 0.9999998807907104
DNA O 0 6.805862085457193e-06
from O 0 1.5577184058201965e-06
patients O 0 2.1884292777940573e-07
with O 0 5.402525360409527e-08
sporadic B-Disease 0 0.0004165824211668223
T I-Disease 1 0.9998817443847656
- I-Disease 1 0.9705854654312134
cell I-Disease 1 0.9998098015785217
prolymphocytic I-Disease 1 0.9981516003608704
leukaemia I-Disease 1 0.9999995231628418
( O 0 5.493681601365097e-05
T B-Disease 0 0.003279355587437749
- I-Disease 0 0.00021848127653356642
PLL I-Disease 0 0.0006812288193032146
) O 0 2.608363445233408e-07
, O 0 4.290443555987622e-08
a O 0 1.5991300017503818e-07
rare O 0 3.0445996799244313e-06
clonal B-Disease 0 8.489616448059678e-05
malignancy I-Disease 0 4.663302388507873e-05
with O 0 1.2892084555460315e-07
similarities O 0 4.4163314782963425e-07
to O 0 5.021186666454014e-07
a O 0 1.0317005035176408e-05
mature B-Disease 0 7.41781695978716e-05
T I-Disease 0 0.001905300305224955
- I-Disease 0 0.0002605650224722922
cell I-Disease 0 0.0008163813035935163
leukaemia I-Disease 0 0.035617414861917496
seen O 0 4.926801557303406e-05
in O 0 2.3979286197572947e-05
A B-Disease 1 0.9999794960021973
- I-Disease 1 0.864220917224884
T I-Disease 1 0.9999736547470093
, O 0 2.245449195470428e-07
we O 0 1.82405575088751e-08
demonstrate O 0 1.409263603591171e-07
a O 0 1.8324882944398269e-07
high O 0 1.8452989252182306e-06
frequency O 0 8.471121191178099e-07
of O 0 3.606902510000509e-06
ATM O 0 7.05547136021778e-05
mutations O 0 5.176613740331959e-06
in O 0 5.986663018120453e-05
T B-Disease 0 0.002451275009661913
- I-Disease 0 0.0002310693816980347
PLL I-Disease 0 0.001069323974661529
. O 0 3.194826604158152e-06

In O 0 4.686501779360697e-05
marked O 0 4.801849718205631e-05
contrast O 0 3.853473572235089e-06
to O 0 6.659277005383046e-07
the O 0 5.0639177970879246e-06
ATM O 0 6.489424413302913e-05
mutation O 0 4.079583504790207e-06
pattern O 0 5.219295417191461e-05
in O 0 0.00010589648445602506
A B-Disease 1 1.0
- I-Disease 1 0.9999969005584717
T I-Disease 1 1.0
, O 0 1.0449884939589538e-06
the O 0 1.326767460341216e-07
most O 0 2.2570269209154503e-08
frequent O 0 8.070554002870267e-08
nucleotide O 0 4.920050287182676e-07
changes O 0 8.966952691480401e-08
in O 0 2.0342881157375814e-07
this O 0 1.5664600994114153e-07
leukaemia B-Disease 0 0.00010591343743726611
were O 0 1.7932902665052097e-06
missense O 0 1.3832608601660468e-05
mutations O 0 6.534233762067743e-06
. O 0 2.16927628571284e-06

These O 0 1.1965908015554305e-05
clustered O 0 3.660252332338132e-05
in O 0 5.176741979084909e-06
the O 0 4.475533842196455e-06
region O 0 3.0875976335664745e-06
corresponding O 0 1.6200276149902493e-05
to O 0 3.874957201333018e-06
the O 0 4.20767319155857e-05
kinase O 0 7.009902037680149e-05
domain O 0 2.3444559701601975e-05
, O 0 7.500025844819902e-07
which O 0 1.3766798190317786e-07
is O 0 1.5038719425319869e-07
highly O 0 3.0005588769199676e-07
conserved O 0 1.190999455502606e-06
in O 0 2.281269644299755e-06
ATM O 0 2.1906998881604522e-05
- O 0 4.05850096285576e-06
related O 0 2.0510267404461047e-06
proteins O 0 8.341093007402378e-07
in O 0 3.395967951291823e-06
mouse O 0 5.6039871196844615e-06
, O 0 3.6211568499311397e-07
yeast O 0 3.555543798938743e-06
and O 0 2.890324367399444e-06
Drosophila O 0 7.138129149097949e-05
. O 0 2.748069164226763e-06

The O 0 0.0003028059145435691
resulting O 0 0.00030310978763736784
amino O 0 8.634512778371572e-05
- O 0 7.665550947422162e-05
acid O 0 1.0265578566759359e-05
substitutions O 0 4.585454007610679e-06
are O 0 9.168973633677524e-07
predicted O 0 5.9292192418070044e-06
to O 0 5.157348255124816e-07
interfere O 0 4.378798621473834e-06
with O 0 2.0211627997923642e-06
ATP O 0 0.007879829965531826
binding O 0 1.1490333235997241e-05
or O 0 3.1166134704108117e-06
substrate O 0 1.2866004908573814e-05
recognition O 0 1.7524605937069282e-05
. O 0 5.6626568039064296e-06

Two O 0 6.201098585734144e-05
of O 0 0.00013432122068479657
seventeen O 0 0.00044956925557926297
mutated O 0 0.00029900422669015825
T B-Disease 0 0.001184204826131463
- I-Disease 0 6.977875455049798e-05
PLL I-Disease 0 0.00020850123837590218
samples O 0 7.037905902507191e-07
had O 0 2.0489505914156325e-06
a O 0 1.4999058066678117e-06
previously O 0 9.615083399694413e-06
reported O 0 3.920842209481634e-05
A B-Disease 1 0.9999812841415405
- I-Disease 1 0.9999727010726929
T I-Disease 1 1.0
allele O 0 8.775753667578101e-05
. O 0 5.783292181149591e-06

In O 0 0.00022715984960086644
contrast O 0 4.7405985242221504e-05
, O 0 2.601784899525228e-06
no O 0 7.698081958551484e-07
mutations O 0 4.921730010210013e-07
were O 0 1.3169640169508057e-06
detected O 0 2.5317272047686856e-06
in O 0 1.0964074590447126e-06
the O 0 2.3875168153608683e-06
p53 O 0 6.87534520693589e-06
gene O 0 2.328043592569884e-06
, O 0 5.133842932991683e-07
suggesting O 0 1.0563753676251508e-06
that O 0 3.522289659940725e-07
this O 0 4.648739832191495e-06
tumour B-Disease 1 1.0
suppressor O 0 0.09459343552589417
is O 0 7.168712272687117e-07
not O 0 8.716900623539914e-08
frequently O 0 9.555818536455263e-08
altered O 0 4.770586201630067e-07
in O 0 4.98596136822016e-07
this O 0 7.222574254228675e-07
leukaemia B-Disease 0 0.002485769335180521
. O 0 4.720843207906e-06

Occasional O 0 0.0007031219429336488
missense O 0 0.0009553067502565682
mutations O 0 3.389990160940215e-05
in O 0 3.33425632561557e-05
ATM O 0 0.00011257828737143427
were O 0 4.988424279872561e-06
also O 0 5.089578962724772e-07
found O 0 2.8098435223000706e-07
in O 0 2.015100108110346e-06
tumour B-Disease 1 1.0
DNA O 0 4.127628471906064e-06
from O 0 1.6685935406712815e-06
patients O 0 8.637638870823139e-07
with O 0 6.214805807758239e-07
B B-Disease 0 0.19486571848392487
- I-Disease 1 0.7232277393341064
cell I-Disease 1 0.9999938011169434
non I-Disease 1 0.9999827146530151
- I-Disease 1 0.999875545501709
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.9995599389076233
( O 0 8.025583156268112e-06
B B-Disease 0 6.092670082580298e-05
- I-Disease 0 5.0467351684346795e-06
NHL I-Disease 0 1.741976484481711e-05
) O 0 1.1309666092529369e-07
and O 0 1.1246800113440258e-07
a O 0 3.0648582196590723e-06
B B-Disease 0 6.66578343953006e-05
- I-Disease 0 2.8122716685174964e-05
NHL I-Disease 0 7.368466322077438e-05
cell O 0 4.826732765650377e-05
line O 0 1.930322832777165e-05
. O 0 7.852967200960848e-07

The O 0 1.5775927749928087e-05
evidence O 0 2.1628950435115257e-06
of O 0 5.8701884881884325e-06
a O 0 1.5367289734058431e-06
significant O 0 8.38146490877989e-07
proportion O 0 1.2385010450088885e-05
of O 0 0.00011772650759667158
loss O 0 0.0006017389241605997
- O 0 3.0331842935993336e-05
of O 0 0.0001252633228432387
- O 0 3.337148154969327e-05
function O 0 1.2323063856456429e-05
mutations O 0 2.2025832890903985e-07
and O 0 1.2762050971559802e-07
a O 0 3.110304760411964e-07
complete O 0 2.3067434540280374e-06
absence O 0 1.2156288903497625e-05
of O 0 9.852112270891666e-06
the O 0 2.631610641401494e-06
normal O 0 4.910411917080637e-06
copy O 0 1.7245707795154885e-06
of O 0 3.880807980749523e-06
ATM O 0 1.6681524357409216e-05
in O 0 6.691387852697517e-07
the O 0 4.5496733491745545e-07
majority O 0 1.0106190018177585e-07
of O 0 3.7729089399363147e-06
mutated O 0 7.522509986301884e-05
tumours B-Disease 1 1.0
establishes O 0 4.464878293219954e-05
somatic O 0 2.805457370413933e-05
inactivation O 0 0.00014023065159562975
of O 0 6.889279120514402e-06
this O 0 2.3135810067742568e-07
gene O 0 3.22622952353413e-07
in O 0 4.759362184358906e-07
the O 0 1.8788821307680337e-06
pathogenesis O 0 4.8542817239649594e-05
of O 0 4.487079058890231e-05
sporadic B-Disease 0 0.006135500501841307
T I-Disease 1 0.9813856482505798
- I-Disease 0 0.001472417963668704
PLL I-Disease 0 0.0009979939786717296
and O 0 7.525646879003034e-07
suggests O 0 2.5253029889427125e-07
that O 0 4.1088487279239416e-08
ATM O 0 9.739709639688954e-06
acts O 0 3.305076461401768e-06
as O 0 3.0723997497261735e-06
a O 0 2.0511444745352492e-05
tumour B-Disease 1 1.0
suppressor O 0 0.01487859059125185
. O 0 2.6719997094915016e-06

As O 0 7.041006756480783e-05
constitutional O 0 6.290821329457685e-05
DNA O 0 4.720379820355447e-06
was O 0 9.585438419890124e-06
not O 0 1.5936825548124034e-07
available O 0 1.6400242941472243e-07
, O 0 1.751266438532184e-07
a O 0 3.3319167869194644e-06
putative O 0 0.00027822345145978034
hereditary O 1 0.9999969005584717
predisposition O 1 0.9998414516448975
to O 0 0.0004977526259608567
T B-Disease 1 0.9979023933410645
- I-Disease 0 0.0013788265641778708
PLL I-Disease 0 0.002214984269812703
will O 0 6.126587663857208e-07
require O 0 9.709447823524897e-08
further O 0 3.544198818872246e-07
investigation O 0 1.7192010091093834e-06
. O 0 5.285026531964832e-07
. O 0 9.479091431785491e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0024684276431798935
kinase O 0 9.61163459578529e-05
is O 0 3.1917582532514643e-07
involved O 0 3.8025216753112545e-08
in O 0 2.9376943544434653e-08
the O 0 4.0882966345634486e-08
modulation O 0 1.469096417849869e-07
of O 0 2.4384002017541206e-07
the O 0 8.686873798069428e-07
Ca2 O 0 1.9314866221975535e-05
+ O 0 0.00010878409375436604
homeostasis O 0 0.00013921092613600194
in O 0 4.640486804419197e-05
skeletal O 1 0.9838882088661194
muscle O 0 0.0005619167350232601
cells O 0 5.235811113379896e-05
. O 0 3.5713221677724505e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.17044281959533691
DM B-Disease 1 1.0
) O 0 3.306629150756635e-05
, O 0 1.1877145880134776e-06
the O 0 1.9257365693192696e-06
most O 0 4.216189608996501e-06
prevalent O 0 0.012690304778516293
muscular B-Disease 1 0.9999983310699463
disorder I-Disease 1 0.9999566078186035
in O 0 8.486196747981012e-06
adults O 0 1.7423750477973954e-06
, O 0 4.921035383631533e-07
is O 0 6.391113629433676e-07
caused O 0 1.1210160664631985e-05
by O 0 1.341707275059889e-06
( O 0 1.8722782897384604e-06
CTG O 0 0.00014038664812687784
) O 0 1.0443768587720115e-06
n O 0 6.086705525376601e-06
- O 0 1.2194152532174485e-06
repeat O 0 9.683035386842676e-07
expansion O 0 1.7870313513412839e-06
in O 0 2.3147596550643357e-07
a O 0 2.931568872099888e-07
gene O 0 2.290123148895873e-07
encoding O 0 7.323046702367719e-07
a O 0 3.526757382132928e-06
protein O 0 1.2052961210429203e-05
kinase O 0 3.0401228286791593e-05
( O 0 5.231547675066395e-06
DM B-Disease 1 0.994753360748291
protein O 0 7.597557851113379e-05
kinase O 0 3.959989771828987e-05
; O 0 9.678327614892623e-07
DMPK O 0 2.496487468306441e-05
) O 0 3.802790260465372e-08
and O 0 2.994995185190419e-08
involves O 0 5.069117747780183e-08
changes O 0 1.5362118688244664e-07
in O 0 1.370035874970199e-06
cytoarchitecture O 0 5.366525147110224e-05
and O 0 5.26813164469786e-06
ion O 0 0.0003541467012837529
homeostasis O 0 0.0011245077475905418
. O 0 9.367876373289619e-06

To O 0 5.605349997495068e-06
obtain O 0 6.044345354894176e-06
clues O 0 8.344773050339427e-06
to O 0 3.382281761332706e-07
the O 0 2.2324061319523025e-06
normal O 0 1.1930003893212415e-05
biological O 0 1.6289199265884236e-05
role O 0 1.7441241652704775e-05
of O 0 8.481677650706843e-05
DMPK O 0 0.001292081200517714
in O 0 0.00011023463594028726
cellular O 0 0.0005056186928413808
ion O 0 0.0004705477913375944
homeostasis O 0 0.00034402994788251817
, O 0 1.3177427717891987e-06
we O 0 6.25706491064193e-08
have O 0 4.3544353900415445e-08
compared O 0 4.438337839474116e-07
the O 0 5.719572868656542e-07
resting O 0 9.774389582162257e-06
[ O 0 1.5458541611224064e-06
Ca2 O 0 2.8398587801348185e-06
+ O 0 1.064854131982429e-05
] O 0 3.904567165591288e-06
i O 0 1.6640486819596845e-06
, O 0 9.232908126932671e-08
the O 0 2.2003997912634077e-07
amplitude O 0 1.6737762962293345e-06
and O 0 5.603610588877928e-07
shape O 0 4.485511453822255e-06
of O 0 9.141391274170019e-06
depolarization O 0 3.671379454317503e-05
- O 0 2.0509234673227184e-05
induced O 0 3.942280090996064e-05
Ca2 O 0 1.3966954611532856e-05
+ O 0 1.33152234411682e-05
transients O 0 1.1689970051520504e-05
, O 0 1.591635054865037e-07
and O 0 7.453258632494908e-08
the O 0 3.567352564459725e-07
content O 0 7.136189310585905e-07
of O 0 1.2924752809340134e-05
ATP O 0 0.0007629788597114384
- O 0 2.34858689509565e-05
driven O 0 3.784021828323603e-05
ion O 0 2.013612538576126e-05
pumps O 0 1.1392199667170644e-05
in O 0 6.8397557697608136e-06
cultured O 0 0.0002687284431885928
skeletal O 0 0.004181977827101946
muscle O 0 5.6164179113693535e-05
cells O 0 4.798758709512185e-06
of O 0 1.289373994950438e-05
wild O 0 1.8320547496841755e-06
- O 0 7.77527986883797e-07
type O 0 1.1266696446909918e-06
and O 0 8.56861390730046e-07
DMPK O 0 9.308643348049372e-05
[ O 0 7.351529802690493e-06
- O 0 1.0228922292299103e-05
/ O 0 2.41085872403346e-05
- O 0 2.0882742319372483e-05
] O 0 1.4634538274549413e-05
knockout O 0 0.00022156337217893451
mice O 0 3.30170696543064e-05
. O 0 2.5089320843108e-06

In O 0 0.00044175711809657514
vitro O 0 0.0010240771807730198
- O 0 0.0002751400461420417
differentiated O 0 0.00010194295464316383
DMPK O 0 0.0016485543455928564
[ O 0 5.601104930974543e-05
- O 0 3.952726910938509e-05
/ O 0 6.026747723808512e-05
- O 0 3.347928577568382e-05
] O 0 8.153708222380374e-06
myotubes O 0 1.1027811524400022e-05
exhibit O 0 3.2049701985670254e-06
a O 0 2.2260028345044702e-06
higher O 0 5.813762072648387e-06
resting O 0 3.0156021239235997e-05
[ O 0 3.407581516512437e-06
Ca2 O 0 5.658646387018962e-06
+ O 0 3.0074803362367675e-05
] O 0 1.8082144379150122e-05
i O 0 5.878501269762637e-06
than O 0 1.000562633635127e-06
do O 0 5.096339918964077e-07
wild O 0 1.9308340597490314e-06
- O 0 3.365650854902924e-06
type O 0 5.2561372285708785e-06
myotubes O 0 1.335878641839372e-05
because O 0 2.1512526870992588e-07
of O 0 1.0165749699808657e-06
an O 0 1.8771113730053912e-07
altered O 0 9.700412419988425e-07
open O 0 6.860496796434745e-06
probability O 0 5.466549282573396e-06
of O 0 2.354819116590079e-05
voltage O 0 0.0002091571077471599
- O 0 1.3028183275309857e-05
dependent O 0 6.507958005386172e-06
l O 0 8.850709491525777e-06
- O 0 4.468637087029492e-07
type O 0 3.5140126897204027e-07
Ca2 O 0 8.157294359989464e-07
+ O 0 7.314845333894482e-07
and O 0 2.538239982641244e-07
Na O 0 4.952672952640569e-06
+ O 0 1.8624942867973004e-06
channels O 0 1.02137744306674e-06
. O 0 9.495957442595682e-07

The O 0 0.0003685801348183304
mutant O 0 0.00032805497176013887
myotubes O 0 0.0006945999339222908
exhibit O 0 3.865911639877595e-05
smaller O 0 1.7089582797780167e-06
and O 0 5.738909862884611e-07
slower O 0 5.395463176682824e-06
Ca2 O 0 5.610055723082041e-06
+ O 0 2.7359094474377343e-06
responses O 0 2.687238236376288e-07
upon O 0 1.1132228792121168e-06
triggering O 0 5.592822617472848e-06
by O 0 2.3208737331970042e-07
acetylcholine O 0 8.368666385649703e-06
or O 0 1.7004264236675226e-06
high O 0 1.9103141312371008e-05
external O 0 2.2733447622158565e-05
K O 0 9.372990461997688e-05
+ O 0 2.1687508706236258e-05
. O 0 1.1791868246291415e-06

In O 0 0.00017861976812127978
addition O 0 9.298425538872834e-06
, O 0 1.0763827731352649e-06
we O 0 7.586834982475921e-08
observed O 0 1.7625626469452982e-07
that O 0 2.445367286441069e-08
these O 0 5.369497912965926e-08
Ca2 O 0 7.848244422348216e-06
+ O 0 2.845703056664206e-05
transients O 0 2.5147188353003003e-05
partially O 0 5.2873788263241295e-06
result O 0 5.171927455194236e-07
from O 0 1.4694747108023876e-07
an O 0 2.036442126041038e-08
influx O 0 9.114521759556737e-08
of O 0 8.834871323415427e-07
extracellular O 0 3.2690118132450152e-06
Ca2 O 0 4.136420102440752e-06
+ O 0 4.943655767419841e-06
through O 0 6.241473897716787e-07
the O 0 1.927259745571064e-06
l O 0 5.625528501695953e-06
- O 0 6.462325927714119e-07
type O 0 4.186222213320434e-07
Ca2 O 0 2.6552063445706153e-06
+ O 0 3.0035189411137253e-06
channel O 0 3.6344326872495003e-06
. O 0 1.0244181112284423e-06

Neither O 0 0.00012199599586892873
the O 0 1.4613687199016567e-05
content O 0 2.4990672500280198e-06
nor O 0 2.290807742610923e-06
the O 0 3.9288548236982024e-07
activity O 0 1.1949425697821425e-06
of O 0 2.5968718091462506e-06
Na O 0 2.1740232114098035e-05
+ O 0 1.490577960794326e-05
/ O 0 1.4554398148902692e-05
K O 0 2.2263902792474255e-05
+ O 0 5.276472620607819e-06
ATPase O 0 8.550193342671264e-06
and O 0 1.1250301668042084e-06
sarcoplasmic O 0 2.737584145506844e-05
reticulum O 0 1.4456541975960135e-05
Ca2 O 0 3.433902020333335e-05
+ O 0 4.0387567423749715e-05
- O 0 2.885934736696072e-05
ATPase O 0 3.6365447158459574e-05
are O 0 1.3497547968199797e-07
affected O 0 2.5112632329182816e-07
by O 0 2.5157939376185823e-07
DMPK O 0 0.00029645240283571184
absence O 0 7.179191015893593e-05
. O 0 6.046887847332982e-06

In O 0 0.00017173799278680235
conclusion O 0 3.443838795647025e-05
, O 0 2.4113674044201616e-06
our O 0 5.26976180026395e-07
data O 0 8.201585615097429e-07
suggest O 0 5.040425890001643e-07
that O 0 2.4688660005267593e-07
DMPK O 0 7.263076986419037e-05
is O 0 4.0913943166742683e-07
involved O 0 3.2491215051777544e-07
in O 0 6.780976491427282e-07
modulating O 0 6.663388830929762e-06
the O 0 7.00899704497715e-07
initial O 0 7.193380611170141e-07
events O 0 1.2117617416151916e-06
of O 0 1.1000502126989886e-05
excitation O 0 0.0003024475590791553
- O 0 0.001060942537151277
contraction O 0 0.0017074326751753688
coupling O 0 3.968514647567645e-05
in O 0 2.293767647643108e-05
skeletal O 0 0.007845953106880188
muscle O 0 5.274701106827706e-05
. O 0 6.606761076000112e-07
. O 0 6.464766784120002e-07

Constitutional O 0 0.021327001973986626
RB1 O 1 0.9691019058227539
- O 0 0.001653520856052637
gene O 0 1.496280401624972e-05
mutations O 0 1.9550311662897e-06
in O 0 7.231486165437673e-07
patients O 0 3.2252944492938695e-07
with O 0 1.11713298167615e-07
isolated O 0 9.673689419287257e-06
unilateral B-Disease 0 0.00020205795590300113
retinoblastoma I-Disease 1 0.9999287128448486
. O 0 2.7984722692053765e-05

In O 0 8.259579044533893e-05
most O 0 2.3932798285386525e-06
patients O 0 1.553145125399169e-06
with O 0 1.5342996562139888e-07
isolated O 0 9.535728167975321e-06
unilateral B-Disease 0 0.00021313309844117612
retinoblastoma I-Disease 1 0.999990701675415
, O 0 6.772905635443749e-06
tumor B-Disease 0 0.0016815627459436655
development O 0 2.645596396178007e-06
is O 0 7.394142897965139e-08
initiated O 0 3.2695430718376883e-07
by O 0 3.2076375333645046e-08
somatic O 0 8.774012485446292e-07
inactivation O 0 1.8800197722157463e-05
of O 0 2.825271621986758e-06
both O 0 4.887137379228079e-07
alleles O 0 6.933737495273817e-07
of O 0 4.051439645991195e-06
the O 0 1.3084611964586657e-05
RB1 O 0 0.0005981677095405757
gene O 0 1.448251168767456e-05
. O 0 4.3838749661517795e-06

However O 0 3.455563637544401e-05
, O 0 7.786729838699102e-07
some O 0 1.885841882653949e-08
of O 0 2.8689265718639945e-07
these O 0 1.6004206315756164e-07
patients O 0 1.4967308743507601e-06
can O 0 6.796527713959222e-07
transmit O 0 2.1025642126915045e-05
retinoblastoma B-Disease 0 0.09407605230808258
predisposition O 0 0.0004319350409787148
to O 0 9.572453336659237e-07
their O 0 1.2985112789465347e-06
offspring O 0 1.664449882810004e-05
. O 0 1.8132662944481126e-06

To O 0 2.2431470370065654e-06
determine O 0 8.562650464227772e-07
the O 0 9.584775852999883e-07
frequency O 0 2.0763477550644893e-06
and O 0 4.2656097321014386e-07
nature O 0 2.474839902788517e-06
of O 0 1.2003659321635496e-05
constitutional O 0 0.0004989518201909959
RB1 O 0 0.003092959988862276
- O 0 9.007554763229564e-05
gene O 0 2.0124959974054946e-06
mutations O 0 3.105784287527058e-07
in O 0 2.6135302277907613e-07
patients O 0 1.612969953157517e-07
with O 0 5.123375856896928e-08
isolated O 0 2.9842747153452365e-06
unilateral B-Disease 0 1.713889287202619e-05
retinoblastoma I-Disease 0 0.0056578852236270905
, O 0 9.976251931220759e-07
we O 0 6.388658135847436e-08
analyzed O 0 2.443246671646193e-07
DNA O 0 5.183032385502884e-07
from O 0 1.6339840840373654e-06
peripheral O 0 2.938693796750158e-05
blood O 0 8.686726687301416e-06
and O 0 4.419062861416023e-06
from O 0 2.701388075365685e-05
tumor B-Disease 1 0.9958373308181763
tissue O 0 0.0013006444787606597
. O 0 4.8492206587980036e-06

The O 0 0.00012537410657387227
analysis O 0 2.4143535483744927e-05
of O 0 0.00027239444898441434
tumors B-Disease 1 1.0
from O 0 0.0002480585826560855
54 O 0 0.00012949506344739348
( O 0 2.1850853499927325e-06
71 O 0 2.3708969820290804e-05
% O 0 8.441990644314501e-07
) O 0 1.1100726737822697e-07
of O 0 1.979153466891148e-06
76 O 0 5.941079871263355e-05
informative O 0 3.0005612643435597e-06
patients O 0 1.7010655710691935e-06
showed O 0 9.266618690162431e-06
loss O 0 2.096731259371154e-05
of O 0 2.303223664057441e-05
constitutional O 0 0.00032156528322957456
heterozygosity O 0 0.0020124060101807117
( O 0 2.375314579694532e-05
LOH O 0 0.08381916582584381
) O 0 3.86975125366007e-06
at O 0 4.9281548854196444e-05
intragenic O 0 0.00026255054399371147
loci O 0 6.899196887388825e-05
. O 0 5.088504622108303e-06

Three O 0 0.00011317263124510646
of O 0 8.138137491187081e-05
13 O 0 0.0002699291508179158
uninformative O 0 0.0018229088746011257
patients O 0 1.0127595487574581e-05
had O 0 1.5800360415596515e-05
constitutional O 0 0.00016543555830139667
deletions O 0 0.00010079432104248554
. O 0 8.698390956851654e-06

For O 0 5.138499545864761e-05
39 O 0 0.00013768351345788687
randomly O 0 1.1970153536822181e-05
selected O 0 0.00013919537013862282
tumors B-Disease 1 1.0
, O 0 7.973525498528033e-05
SSCP O 0 0.0019763882737606764
, O 0 1.1465508578112349e-05
hetero O 0 0.00015021006402093917
- O 0 2.8465256036724895e-05
duplex O 0 0.0003425258619245142
analysis O 0 3.547807409631787e-06
, O 0 8.491066978422168e-07
sequencing O 0 3.1801380373508437e-06
, O 0 7.295046202671074e-07
and O 0 8.495311476508505e-07
Southern O 0 4.309990799811203e-06
blot O 0 2.9527622245950624e-05
analysis O 0 7.215173809527187e-07
were O 0 3.6915463397235726e-07
used O 0 7.463059858991983e-08
to O 0 5.44328813134598e-08
identify O 0 3.191051973772119e-07
mutations O 0 5.710586265195161e-06
. O 0 5.985070401948178e-06

Mutations O 0 3.707686482812278e-05
were O 0 1.208263074659044e-05
detected O 0 5.039463758294005e-06
in O 0 2.966138254123507e-06
21 O 0 1.3966794540465344e-05
( O 0 3.732468485395657e-07
91 O 0 7.682983778067864e-06
% O 0 8.514550131621945e-07
) O 0 3.5632999129120435e-07
of O 0 3.4706827136687934e-05
23 O 1 0.9987900853157043
tumors B-Disease 1 1.0
with O 0 0.003156497608870268
LOH O 1 1.0
. O 0 7.781892054481432e-05

In O 0 0.00021902417938690633
6 O 0 9.13763651624322e-05
( O 0 3.156293360007112e-06
38 O 0 2.2919877665117383e-05
% O 0 1.7115156651925645e-06
) O 0 7.542697062490333e-07
of O 0 5.4037358495406806e-05
16 O 0 0.30811652541160583
tumors B-Disease 1 1.0
without O 0 0.0009154070285148919
LOH O 1 0.9999771118164062
, O 0 2.4555456548114307e-06
one O 0 2.781112584671064e-07
mutation O 0 3.5461090419630636e-07
was O 0 5.725806659029331e-06
detected O 0 2.474835355315008e-06
, O 0 1.488229202095681e-07
and O 0 1.0818025231174033e-07
in O 0 8.67997528075648e-07
9 O 0 6.136597676231759e-06
( O 0 3.8041073935346503e-07
56 O 0 5.2363748181960545e-06
% O 0 1.0437813671160256e-06
) O 0 5.70453266846016e-07
of O 0 6.6499735112302e-05
the O 1 0.5633717179298401
tumors B-Disease 1 1.0
without O 1 0.6940475106239319
LOH O 1 0.9999997615814209
, O 0 3.881837074004579e-06
both O 0 8.436606435680005e-07
mutations O 0 9.648312015997362e-07
were O 0 1.6982273791654734e-06
found O 0 8.842288821142574e-07
. O 0 4.674247406910581e-07

Thus O 0 5.871974281035364e-05
, O 0 1.5718504755568574e-06
a O 0 6.778183205824462e-07
total O 0 1.8259479475091211e-06
of O 0 1.0020275112765376e-05
45 O 0 1.533951399323996e-05
mutations O 0 2.3237116693053395e-06
were O 0 6.5914705373870675e-06
identified O 0 3.0041976515349234e-06
in O 0 6.88029058437678e-06
tumors B-Disease 1 1.0
of O 0 7.909796840976924e-05
36 O 0 0.0001677110994933173
patients O 0 1.3152470273780636e-05
. O 0 5.199739007366588e-06

Thirty O 0 0.0005234759300947189
- O 0 8.828700083540753e-05
nine O 0 3.60000049113296e-05
of O 0 2.7467998734209687e-05
the O 0 9.929477528203279e-06
mutations O 0 1.935572299771593e-06
- O 0 4.440380052983528e-06
including O 0 1.9680001059896313e-06
34 O 0 6.95386870575021e-06
small O 0 5.441797839011997e-07
mutations O 0 7.665715884286328e-07
, O 0 9.891282388707623e-07
2 O 0 7.554700459877495e-06
large O 0 4.873221314483089e-06
structural O 0 0.0004883387009613216
alterations O 0 0.004861447960138321
, O 0 1.8459271814208478e-05
and O 0 5.888589839742053e-06
hypermethylation O 0 0.0019469860708341002
in O 0 0.0001717052364256233
3 O 0 0.000703412399161607
tumors O 1 1.0
- O 0 1.5502195310546085e-05
were O 0 4.782831410921062e-07
not O 0 2.1241261194404615e-08
detected O 0 2.2448475078817864e-07
in O 0 1.3869306769720424e-07
the O 0 3.5733216918742983e-07
corresponding O 0 5.434808826976223e-06
peripheral O 0 0.0001175353754661046
blood O 0 3.1683735869592056e-05
DNA O 0 9.135639629676007e-06
. O 0 2.297417040608707e-06

In O 0 0.00027286363183520734
6 O 0 0.0002219866873929277
( O 0 4.496154360822402e-06
17 O 0 1.4710056348121725e-05
% O 0 8.409976999246283e-07
) O 0 1.0392209759402249e-07
of O 0 2.447911583658424e-06
the O 0 1.0041731911769602e-05
36 O 0 5.077111563878134e-05
patients O 0 2.6790651190822246e-06
, O 0 5.709273409593152e-07
a O 0 1.1299408697595936e-06
mutation O 0 1.1036038358724909e-06
was O 0 1.55220041051507e-05
detected O 0 2.129657104887883e-06
in O 0 9.72922521214059e-07
constitutional O 0 1.0096639016410336e-05
DNA O 0 9.159481919596146e-07
, O 0 2.9615858920806204e-07
and O 0 4.726586837477953e-07
1 O 0 6.152230525913183e-06
of O 0 3.998144165962003e-06
these O 0 5.788837142972625e-07
mutations O 0 2.205968485213816e-06
is O 0 1.0853941603272688e-06
known O 0 6.322133003777708e-07
to O 0 3.2574170916177536e-08
be O 0 1.1758981344200947e-07
associated O 0 1.337369894827134e-07
with O 0 7.586907457834968e-08
reduced O 0 8.777060429565609e-06
expressivity O 0 0.00028626315179280937
. O 0 9.331338333140593e-06

The O 0 6.724764534737915e-05
presence O 0 8.88421436684439e-06
of O 0 2.884270179492887e-05
a O 0 1.2674912795773707e-05
constitutional O 0 5.388380668591708e-05
mutation O 0 2.445559402985964e-06
was O 0 1.1514246580190957e-05
not O 0 1.283202948343387e-07
associated O 0 8.412176555339101e-08
with O 0 1.1699345492388602e-08
an O 0 5.364205435398617e-08
early O 0 5.436118044599425e-07
age O 0 4.660254489863291e-06
at O 0 1.916198198159691e-05
treatment O 0 1.2706244888249785e-05
. O 0 2.754586830633343e-06

In O 0 9.238473285222426e-05
1 O 0 0.00023022051027510315
patient O 0 6.958677113289014e-05
, O 0 5.373090971261263e-06
somatic O 0 4.782400355907157e-05
mosaicism O 0 0.00037636765046045184
was O 0 8.19618162495317e-06
demonstrated O 0 1.6703273786333739e-06
by O 0 2.557088230048521e-08
molecular O 0 5.039935331296874e-07
analysis O 0 2.6927581942004508e-08
of O 0 3.149123699586198e-07
DNA O 0 3.190081656612165e-07
and O 0 8.576355412515113e-07
RNA O 0 9.857910299615469e-06
from O 0 8.435909876425285e-06
peripheral O 0 0.0003941940376535058
blood O 0 0.0001456500613130629
. O 0 9.365063306177035e-06

In O 0 5.7276556617580354e-05
2 O 0 3.91505855077412e-05
patients O 0 1.6556336959183682e-06
without O 0 5.83088592520653e-07
a O 0 2.8860165457444964e-06
detectable O 0 7.190969336079434e-05
mutation O 0 4.285350769350771e-06
in O 0 8.780342795944307e-06
peripheral O 0 0.0003444193280301988
blood O 0 0.00010841956827789545
, O 0 3.9829228626331314e-06
mosaicism O 0 0.0001081711016013287
was O 0 9.552221854391973e-06
suggested O 0 5.168126335775014e-07
because O 0 6.884623360292608e-08
1 O 0 7.029380526546447e-07
of O 0 4.3655705894707353e-07
the O 0 2.0947688881278737e-06
patients O 0 2.1114516130182892e-05
showed O 0 0.0006354963988997042
multifocal O 1 0.9999991655349731
tumors B-Disease 1 1.0
and O 0 2.294887599418871e-05
the O 0 4.003501544502797e-06
other O 0 1.0943227124471377e-07
later O 0 1.1809840998466825e-06
developed O 0 2.528546929170261e-06
bilateral B-Disease 0 0.00018899394490290433
retinoblastoma I-Disease 1 0.9971380233764648
. O 0 2.129893437086139e-05

In O 0 0.00018452099175192416
conclusion O 0 4.85942218801938e-05
, O 0 3.276340294178226e-06
our O 0 1.253371578968654e-06
results O 0 1.8074275658364058e-06
emphasize O 0 3.377063819698378e-07
that O 0 1.5516661733272485e-07
the O 0 1.735923206069856e-06
manifestation O 0 3.983731221524067e-05
and O 0 2.5070758056244813e-06
transmissibility O 0 0.00013337166456039995
of O 0 1.7583597582415678e-05
retinoblastoma B-Disease 0 0.00013803975889459252
depend O 0 3.4186193715868285e-06
on O 0 8.515625268046279e-06
the O 0 2.4305813894898165e-06
nature O 0 2.3046059141051956e-06
of O 0 8.165177860064432e-06
the O 0 3.489508117127116e-06
first O 0 4.8062515816127416e-06
mutation O 0 4.352679354724387e-07
, O 0 2.6383654017081426e-07
its O 0 1.8579849836442008e-07
time O 0 4.112824569801887e-07
in O 0 1.2544477385745267e-06
development O 0 6.6711081672110595e-06
, O 0 4.2747521433739166e-07
and O 0 2.868267188205209e-07
the O 0 1.236010461980186e-06
number O 0 1.8438564666212187e-06
and O 0 3.3961330245801946e-06
types O 0 8.253464329754934e-06
of O 0 0.0002613193355500698
cells O 0 1.9301829524920322e-05
that O 0 5.808624337078072e-07
are O 0 2.7602408181337523e-07
affected O 0 4.0078614915728394e-07
. O 0 8.872700618667295e-08
. O 0 5.090209924674127e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9967116117477417
the I-Disease 0 0.0008200207957997918
fifth I-Disease 0 0.003614029148593545
component I-Disease 0 3.0263105145422742e-05
of I-Disease 0 1.8655642634257674e-05
complement I-Disease 0 2.3422617232427e-05
in O 0 6.611402932321653e-05
man O 0 0.00032291331444866955
. O 0 5.705741386918817e-06

I O 0 0.009296011179685593
. O 0 0.00011022664693882689

Clinical O 1 0.9563184380531311
, O 0 0.0001573939371155575
immunochemical O 0 0.002403685124590993
, O 0 5.091067578177899e-06
and O 0 1.13003136448242e-06
family O 0 1.272060671908548e-06
studies O 0 6.223444870556705e-06
. O 0 2.2357596662914148e-06

The O 0 1.2594760846695863e-05
first O 0 3.008139856319758e-06
recognized O 0 6.305024726316333e-06
human O 0 2.7087533453595825e-05
kindred O 0 0.0002982554433401674
with O 0 3.767565885937074e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 0.9999436140060425
fifth I-Disease 1 0.9999955892562866
component I-Disease 0 0.08791214227676392
of I-Disease 0 0.3757416009902954
complement I-Disease 0 0.0010777813149616122
( O 0 7.925637328298762e-05
C5 O 0 0.05046466365456581
) O 0 1.5921497151794028e-06
is O 0 5.384583232626028e-07
described O 0 2.3182997210824396e-06
. O 0 6.967383683331718e-07

The O 0 0.0013773139799013734
proband O 0 0.0032027389388531446
, O 0 3.263864709879272e-05
a O 0 2.99155326501932e-05
20 O 0 3.688459764816798e-05
- O 0 2.0964933355571702e-05
year O 0 1.0698793630581349e-05
- O 0 1.801039616111666e-05
old O 0 1.5326340871979482e-05
black O 0 1.1993861335213296e-06
female O 0 2.6897814677795395e-06
with O 0 8.864342817105353e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 1.0
age O 1 0.9999970197677612
11 O 0 0.0013803914189338684
, O 0 2.130331495209248e-06
lacked O 0 6.817933899583295e-05
serum O 0 0.00040958818863146007
hemolytic O 1 0.9973081350326538
complement O 0 2.124175261997152e-05
activity O 0 2.5863262635539286e-05
, O 0 2.3435511309344292e-07
even O 0 5.6205028187150674e-08
during O 0 2.2821834591013612e-06
remission O 0 2.276134728163015e-05
. O 0 1.2545159506771597e-06

C5 O 0 0.11509718745946884
was O 0 0.0011506747687235475
undetectable O 0 0.00037840192089788616
in O 0 2.6512896056374302e-06
her O 0 1.2735172276734374e-06
serum O 0 1.0151963579119183e-05
by O 0 2.872901916362025e-07
both O 0 8.650646350361058e-07
immunodiffusion O 0 0.00018800972611643374
and O 0 7.639525392733049e-06
hemolytic O 1 0.999996542930603
assays O 0 0.0003103257331531495
. O 0 1.5993105989764445e-05

Other O 0 6.377509180310881e-06
complement O 0 9.452431186218746e-06
components O 0 1.1672368600557093e-05
were O 0 1.83539668796584e-06
normal O 0 5.821268132422119e-06
during O 0 7.299790013348684e-06
remission O 0 3.763780841836706e-05
of O 0 2.2467083908850327e-05
lupus O 0 0.0007484693778678775
, O 0 5.7675401876622345e-06
but O 0 2.4366433990508085e-06
C1 O 0 0.00032346052466891706
, O 0 1.1778080988733564e-05
C4 O 0 0.00036902239662595093
, O 0 6.01850797465886e-06
C2 O 0 5.057000817032531e-05
, O 0 8.102015840449894e-07
and O 0 1.554963660055364e-06
C3 O 0 0.0017059905221685767
levels O 0 0.00028563800151459873
fell O 0 0.0663093626499176
during O 0 9.243567183148116e-05
exacerbations O 0 0.008699706755578518
. O 0 1.5846961105125956e-05

A O 0 0.004248698242008686
younger O 0 0.0002186920028179884
half O 0 5.5287524446612224e-05
- O 0 5.6908564147306606e-05
sister O 0 8.387165144085884e-05
, O 0 2.3951110961206723e-06
who O 0 1.3009829444854404e-06
had O 0 1.1248338523728307e-05
no O 0 3.595241651055403e-05
underlying O 1 0.9974159002304077
disease O 1 0.9997965693473816
, O 0 1.903473503261921e-06
was O 0 1.4351280697155744e-05
also O 0 3.856981436456408e-07
found O 0 2.568833394889225e-07
to O 0 1.7352267889236828e-07
lack O 0 7.460280903615057e-05
immunochemically O 0 0.2495543360710144
detectable O 1 0.999363124370575
C5 O 1 0.9925944209098816
. O 0 1.3983853932586499e-05

By O 0 0.0002796680782921612
hemolytic O 1 0.9999901056289673
assay O 0 0.0018205373780801892
, O 0 7.756204468023498e-06
she O 0 2.5618151084927376e-06
exhibited O 0 3.294181078672409e-05
1 O 0 5.665460321324645e-06
- O 0 5.493466801453906e-07
2 O 0 9.55162477112026e-07
% O 0 1.1769987651177871e-07
of O 0 9.799942972676945e-07
the O 0 2.9100194751663366e-06
normal O 0 4.493416054174304e-05
serum O 0 9.717265493236482e-05
C5 O 0 0.00015779411478433758
level O 0 1.6977584891719744e-05
and O 0 4.571436988953792e-07
normal O 0 2.5181416276609525e-06
concentrations O 0 3.570903345462284e-06
of O 0 1.6190401765925344e-06
other O 0 1.9010138885278138e-07
complement O 0 2.0995148588554002e-06
components O 0 2.2067339159548283e-05
. O 0 2.2616050046053715e-06

C5 O 0 0.01931871846318245
levels O 0 0.0005282555357553065
of O 0 0.00012738753866869956
other O 0 4.90394450025633e-06
family O 0 3.940929673262872e-06
members O 0 9.814776831262861e-07
were O 0 4.15473277826095e-06
either O 0 1.6730390370867099e-06
normal O 0 1.3613456758321263e-05
or O 0 1.3695486131837242e-06
approximately O 0 1.3527010196412448e-06
half O 0 2.4448436306556687e-06
- O 0 7.621667919011088e-06
normal O 0 6.392670911736786e-06
, O 0 1.1256241805313039e-07
consistent O 0 3.029796857845213e-07
with O 0 5.3733906213437876e-08
autosomal O 0 3.164644294884056e-05
codominant O 0 3.0088889616308734e-05
inheritance O 0 7.683435683247808e-07
of O 0 1.3201479305280373e-06
the O 0 2.621516159706516e-06
gene O 0 4.5783679524902254e-05
determining O 0 0.0008669436210766435
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.597313116188161e-05

Normal O 0 0.026968734338879585
hemolytic O 1 0.9998051524162292
titers O 0 0.004844945389777422
were O 0 1.8751603420241736e-05
restored O 0 2.135156864824239e-05
to O 0 2.8180818389955675e-07
both O 0 2.4735704755585175e-06
homozygous O 0 0.00024280999787151814
C5 B-Disease 1 1.0
- I-Disease 1 0.9999971389770508
deficient I-Disease 1 1.0
( O 0 5.857808355358429e-05
C5D B-Disease 1 1.0
) O 0 1.1838980071843253e-06
sera O 0 9.444961506233085e-06
by O 0 2.407501220602626e-08
addition O 0 5.771826039335792e-08
of O 0 1.2460801599445404e-06
highly O 0 6.654352091572946e-06
purified O 0 4.713601083494723e-05
human O 0 9.831197530729696e-05
C5 O 0 0.0018265167018398643
. O 0 4.765875473822234e-06

In O 0 0.0003107538213953376
specific O 0 0.00010933182784356177
C5 O 0 0.007810240611433983
titrations O 0 0.0012844046577811241
, O 0 1.2900321053166408e-05
however O 0 2.7553119252843317e-06
, O 0 4.249542939760431e-07
it O 0 8.101321924414151e-08
was O 0 6.2451226767734624e-06
noted O 0 7.34532363821927e-07
that O 0 3.395314962517659e-08
when O 0 4.8526118234804017e-08
limited O 0 6.632973281739396e-08
amounts O 0 3.8222060538828373e-07
of O 0 1.2995051292818971e-05
C5 O 0 0.00013626093277707696
were O 0 6.47289425614872e-06
assayed O 0 1.1156503205711488e-05
in O 0 4.4886215277983865e-07
the O 0 2.1804711991535441e-07
presence O 0 2.7245184242019604e-07
of O 0 3.1302138268074486e-06
low O 0 2.7263136871624738e-05
dilutions O 0 0.000148154838825576
of O 0 0.00016051366401370615
either O 0 0.00016679696273058653
C5D B-Disease 1 0.9999992847442627
serum O 0 0.0005591268418356776
, O 0 1.1268887647020165e-05
curving O 0 4.9492260586703196e-05
rather O 0 5.302459271661064e-07
than O 0 1.3639524354402965e-07
linear O 0 3.0417936613957863e-06
dose O 0 6.9310735852923244e-06
- O 0 8.285711373900995e-06
response O 0 1.3831692058374756e-06
plots O 0 2.7202993351238547e-06
were O 0 1.52918255480472e-06
consistently O 0 1.0930539247056004e-06
obtained O 0 1.832301222748356e-06
, O 0 2.4970250933620264e-07
suggesting O 0 2.18381757122188e-07
some O 0 2.9011440361159657e-08
inhibitory O 0 9.312952897744253e-06
effect O 0 1.7232803656952456e-05
. O 0 3.132892743451521e-06

Further O 0 3.981077043135883e-06
studies O 0 4.405744675750611e-06
suggested O 0 1.5390933185699396e-06
that O 0 1.5256298979693383e-07
low O 0 2.1987769287079573e-05
dilutions O 0 0.00016720332496333867
of O 0 0.00024232754367403686
C5D B-Disease 1 0.999998927116394
serum O 0 0.00020709291857201606
contain O 0 1.0133778232557233e-05
a O 0 1.3666305676451884e-05
factor O 0 7.628248567925766e-06
( O 0 6.547593329742085e-07
or O 0 5.692310764970898e-07
factors O 0 5.867752861377085e-07
) O 0 1.6918293965773046e-07
interfering O 0 1.1174926157764276e-06
at O 0 4.555287887342274e-06
some O 0 8.379477378639422e-08
step O 0 1.7631322180022835e-06
in O 0 2.4544242478441447e-06
the O 0 1.0312096492270939e-05
hemolytic O 0 0.48511800169944763
assay O 0 0.0002271767589263618
of O 0 0.0003917347057722509
C5 O 0 0.0013921434292569757
, O 0 1.0390747320343507e-06
rather O 0 1.4376016110873024e-07
than O 0 6.449877076875055e-08
a O 0 1.2919842902192613e-06
true O 0 1.1409355465730187e-05
C5 O 0 0.0002953372895717621
inhibitor O 0 9.009969653561711e-05
or O 0 3.99222790292697e-06
inactivator O 0 6.402140570571646e-05
. O 0 1.6141898413479794e-06

Of O 0 0.00043597494368441403
clinical O 0 0.001825300743803382
interest O 0 5.776908801635727e-05
are O 0 2.1318596736819018e-06
( O 0 3.7138877928555303e-07
a O 0 2.484170522620843e-07
) O 0 2.380465247142638e-08
the O 0 5.411704151470076e-08
documentation O 0 2.1085163552925223e-06
of O 0 8.641941531095654e-05
membranous O 1 0.9999998807907104
glomerulonephritis B-Disease 1 1.0
, O 1 0.9999486207962036
vasculitis B-Disease 1 1.0
, O 0 0.12110017985105515
and O 0 0.027589503675699234
arthritis B-Disease 1 1.0
in O 0 0.0008434054325334728
an O 0 2.0482437321334146e-05
individual O 0 1.0446196938573848e-05
lacking O 0 0.0030170269310474396
C5 O 0 0.20705454051494598
( O 0 2.7824357857753057e-06
and O 0 6.668987566627038e-07
its O 0 9.513243526271253e-07
biologic O 0 0.00013534874597098678
functions O 0 1.7239328371942975e-05
) O 0 4.4258095499571937e-07
, O 0 2.05586658807988e-07
and O 0 2.2545472688761947e-07
( O 0 3.291201267074939e-07
b O 0 1.8020677998720203e-06
) O 0 2.8541402130599636e-08
a O 0 1.075841424835744e-07
remarkable O 0 1.7015279354382074e-06
propensity O 0 1.530954432382714e-05
to O 0 3.592572966226726e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 0.00020568315812852234
the O 0 4.8445144784636796e-05
proband O 0 0.00018654832092579454
, O 0 5.073785587228485e-07
even O 0 7.254156741964835e-08
during O 0 1.007587229651108e-06
periods O 0 2.9938128136564046e-06
of O 0 7.546304004790727e-06
low O 0 3.18707425321918e-05
- O 0 6.588817996089347e-06
dose O 0 9.718638466438279e-06
or O 0 2.3632078409718815e-06
alternate O 0 1.942518110809033e-06
- O 0 6.691395356028806e-06
day O 0 9.230861905962229e-06
corticosteroid O 0 0.0009303443366661668
therapy O 0 9.64287537499331e-05
. O 0 1.3487142496160232e-06

Other O 0 1.3218044841778465e-05
observations O 0 2.672265691217035e-05
indicate O 0 1.684795643086545e-05
that O 0 1.0054966423922451e-06
the O 0 1.6815502021927387e-05
C5D B-Disease 1 0.9999537467956543
state O 0 3.855590875900816e-06
is O 0 6.520965598610928e-07
compatible O 0 1.1316684549456113e-06
with O 0 1.3901751572120702e-07
normal O 0 2.1814996216562577e-05
coagulation O 0 4.048254049848765e-05
function O 0 1.3563692846219055e-05
and O 0 5.639352593789226e-07
the O 0 3.8722731687812484e-07
capacity O 0 1.8310171299162903e-06
to O 0 2.6032194000435993e-07
mount O 0 3.22547166433651e-05
a O 0 1.0148285582545213e-05
neutrophilic O 0 0.0034021742176264524
leukocytosis O 0 0.03297796472907066
during O 0 0.0005682668415829539
pyogenic B-Disease 0 0.01570443995296955
infection I-Disease 0 0.0006267046555876732
. O 0 1.0190170769419638e-06
. O 0 1.0441457334309234e-06

Susceptibility O 1 0.9949800372123718
to O 0 0.00270127528347075
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9979357719421387
twins O 0 0.002556725637987256
: O 0 5.235952471593919e-07
the O 0 5.299613121678703e-07
role O 0 1.2552543466881616e-06
of O 0 9.63796082942281e-06
genes O 0 3.938434929295909e-06
, O 0 3.0798216812399914e-06
HLA O 0 5.024697020417079e-05
, O 0 8.778632718531298e-07
and O 0 5.966606408946973e-07
the O 0 4.685692147177178e-06
environment O 0 1.584155143063981e-05
. O 0 3.180444537065341e-06

OBJECTIVE O 0 8.805242396192625e-05
To O 0 5.763333206232346e-07
determine O 0 3.3668055721136625e-07
the O 0 3.129104584331799e-07
relative O 0 6.856820618850179e-06
effects O 0 7.287415883183712e-06
of O 0 8.063897212196025e-07
genetic O 0 1.3557864804170094e-06
and O 0 1.5629622396318155e-07
environmental O 0 9.938106586560025e-07
factors O 0 6.065556590328924e-07
in O 0 1.205231569656462e-06
susceptibility O 0 0.001188513357192278
to O 0 0.00044186681043356657
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.006414324045181274
AS B-Disease 1 1.0
) O 0 1.4332364344227244e-06
. O 0 5.491842784977052e-07

METHODS O 0 0.0031466553919017315
Twins O 0 0.0011143155861645937
with O 0 2.5880406155920355e-06
AS B-Disease 1 0.978826105594635
were O 0 6.984827791711723e-07
identified O 0 7.21682624771347e-08
from O 0 2.2433873425597994e-08
the O 0 4.955045440624417e-08
Royal O 0 1.5176995475485455e-05
National O 0 0.00010681919229682535
Hospital O 1 0.9129575490951538
for O 0 2.9873937819502316e-05
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.0013150088489055634
. O 0 1.0293635568814352e-05

Clinical O 0 0.0028742998838424683
and O 0 1.894013439596165e-05
radiographic O 0 0.00024211463460233063
examinations O 0 0.0002196298009948805
were O 0 6.040997050149599e-06
performed O 0 3.349538246766315e-06
to O 0 1.1703210844871137e-07
establish O 0 2.0675981886597583e-06
diagnoses O 0 0.0009521309402771294
, O 0 6.220418526936555e-06
and O 0 7.329863365157507e-06
disease O 1 0.995354413986206
severity O 0 0.006373319774866104
was O 0 0.00016520495410077274
assessed O 0 5.904199497308582e-06
using O 0 2.4709200374672946e-07
a O 0 3.791644473949418e-07
combination O 0 8.061383027779812e-07
of O 0 2.483801381458761e-06
validated O 0 1.2434668860805687e-05
scoring O 0 2.4103230316541158e-05
systems O 0 2.6689242076827213e-05
. O 0 2.0541333469736855e-06

HLA O 0 0.02132224850356579
typing O 0 0.001064507756382227
for O 0 0.0001253920199815184
HLA O 0 0.0010604847921058536
- O 0 0.00043324389844201505
B27 O 0 0.0008876966312527657
, O 0 1.4585452845494729e-05
HLA O 0 8.979374979389831e-05
- O 0 3.803797153523192e-05
B60 O 0 0.00010401197505416349
, O 0 2.352885758227785e-06
and O 0 1.490386694058543e-06
HLA O 0 4.158123192610219e-05
- O 0 2.3876738850958645e-05
DR1 O 0 0.0012866772012785077
was O 0 1.6954189050011337e-05
performed O 0 1.8997938013853854e-06
by O 0 2.0822797353048372e-07
polymerase O 0 1.1503939276735764e-05
chain O 0 5.516027158591896e-06
reaction O 0 9.443559179089789e-07
with O 0 1.7703085575249133e-07
sequence O 0 2.638609430505312e-06
- O 0 3.373887466295855e-06
specific O 0 2.7882430231329636e-07
primers O 0 1.0731360816862434e-05
, O 0 5.19041748248128e-07
and O 0 4.318019932725292e-07
zygosity O 0 3.2607440516585484e-05
was O 0 7.018239557510242e-06
assessed O 0 3.052071178899496e-06
using O 0 4.166690246165672e-07
microsatellite O 0 1.75721688719932e-05
markers O 0 2.1937959900242276e-05
. O 0 2.330486950086197e-06

Genetic O 0 0.0004262358997948468
and O 0 1.641459130041767e-05
environmental O 0 2.874840356525965e-05
variance O 0 1.2850677194364835e-05
components O 0 3.791975905187428e-05
were O 0 4.844131581194233e-06
assessed O 0 4.34555977335549e-06
with O 0 2.474565974353027e-07
the O 0 3.858209765894571e-06
program O 0 2.702410938582034e-06
Mx O 0 3.30405673594214e-05
, O 0 2.688263407435443e-07
using O 0 1.4407034143459896e-07
data O 0 5.737284141105192e-07
from O 0 2.265723111349871e-07
this O 0 2.3312502150929504e-08
and O 0 9.913705412145646e-08
previous O 0 1.3900971680413932e-06
studies O 0 1.2542587910502334e-06
of O 0 6.511130322905956e-06
twins O 0 4.835274376091547e-05
with O 0 1.8858762587115052e-06
AS B-Disease 1 0.9999668598175049
. O 0 3.238518502257648e-06

RESULTS O 0 0.0008763234945945442
Six O 0 5.4158284910954535e-05
of O 0 0.0001273220987059176
8 O 0 0.0007642450509592891
monozygotic O 0 0.0010651746997609735
( O 0 3.840802310151048e-05
MZ O 0 0.0032594073563814163
) O 0 8.025492206797935e-06
twin O 0 0.00010081508662551641
pairs O 0 9.311034773418214e-06
were O 0 1.3608849258162081e-05
disease O 0 0.00018111786630470306
concordant O 0 6.326424045255408e-05
, O 0 4.322172912907263e-07
compared O 0 9.053401299752295e-07
with O 0 6.505263172584819e-08
4 O 0 8.208455255953595e-06
of O 0 1.6090096323750913e-05
15 O 0 6.873271195217967e-05
B27 O 0 0.00013667682651430368
- O 0 6.48803252261132e-05
positive O 0 1.2617518223123625e-05
dizygotic O 0 0.00013657337694894522
( O 0 5.232301191426814e-06
DZ O 0 0.0003228579298593104
) O 0 1.9089197849098127e-06
twin O 0 2.3273745682672597e-05
pairs O 0 7.987839012457698e-07
( O 0 2.9688959557461203e-07
27 O 0 5.714705366699491e-06
% O 0 2.7185359385839547e-07
) O 0 3.217662225551976e-08
and O 0 2.0372041831251408e-07
4 O 0 9.119587048189715e-06
of O 0 5.4427353461505845e-05
32 O 0 0.0007269377238117158
DZ O 0 0.041903864592313766
twin O 0 0.0007765119662508368
pairs O 0 7.473852747352794e-06
overall O 0 4.1893839807016775e-05
( O 0 9.712149449114804e-07
12 O 0 1.8634323168953415e-06
. O 0 4.789787766412701e-08
5 O 0 6.471848337241681e-07
% O 0 3.131021060198691e-07
) O 0 1.586829085908903e-07
. O 0 4.364234484910412e-07

Nonsignificant O 0 0.005132716149091721
increases O 0 1.784340201993473e-05
in O 0 1.3591330798590207e-06
similarity O 0 1.2831018239012337e-06
with O 0 4.328533265152146e-08
regard O 0 5.605903652394773e-07
to O 0 2.0440155878986843e-07
age O 0 1.8118291336577386e-05
at O 0 0.00011524833826115355
disease O 0 0.00013537264021579176
onset O 0 0.0007786519709043205
and O 0 8.586634976381902e-07
all O 0 1.7789498940601334e-07
of O 0 2.622506144689396e-06
the O 0 5.272273028822383e-06
disease O 0 0.00023151659115683287
severity O 0 3.140709304716438e-05
scores O 0 7.860318874008954e-06
assessed O 0 2.171449750676402e-06
were O 0 9.651413392930408e-07
noted O 0 1.354144160359283e-06
in O 0 2.533091901568696e-06
disease O 0 0.00022454520512837917
- O 0 9.557126031722873e-05
concordant O 0 0.0005079509573988616
MZ O 0 0.25939828157424927
twins O 0 8.120393613353372e-05
compared O 0 3.8379744182748254e-06
with O 0 7.496957437069796e-07
concordant O 0 0.0015993067063391209
DZ O 1 0.9996564388275146
twins O 0 0.002232716651633382
. O 0 9.305868843512144e-06

HLA O 0 0.035905297845602036
- O 0 0.0022640421520918608
B27 O 0 0.0010813339613378048
and O 0 1.645832344365772e-05
B60 O 0 0.00013718944683205336
were O 0 4.738949428428896e-06
associated O 0 1.2672427374127437e-06
with O 0 3.3654603726063215e-07
the O 0 2.00693539227359e-05
disease O 0 0.04584832489490509
in O 0 4.349562732386403e-05
probands O 0 0.0012794536305591464
, O 0 8.10277299478912e-07
and O 0 2.223108168664112e-07
the O 0 7.952388045850967e-07
rate O 0 5.7687939261086285e-06
of O 0 5.085996690468164e-06
disease O 0 0.00012110272655263543
concordance O 0 6.44683968857862e-05
was O 0 4.0728664316702634e-05
significantly O 0 2.8097786071157316e-06
increased O 0 7.710169484198559e-06
among O 0 5.806558419862995e-06
DZ O 0 0.00038356721051968634
twin O 0 8.977653487818316e-05
pairs O 0 2.6167501800955506e-06
in O 0 2.648711642905255e-06
which O 0 1.3997778296470642e-06
the O 0 4.011607416032348e-06
co O 0 1.8303993783774786e-05
- O 0 1.1512402124935761e-05
twin O 0 4.4633889046963304e-05
was O 0 7.0354080889956094e-06
positive O 0 2.4661881070642266e-07
for O 0 2.57059554087391e-07
both O 0 1.0355322501709452e-06
B27 O 0 0.00012496256385929883
and O 0 1.3227212548372336e-05
DR1 O 0 0.04254261404275894
. O 0 1.47137880048831e-05

Additive O 0 0.0014541784767061472
genetic O 0 3.913169712177478e-05
effects O 0 5.837470598635264e-05
were O 0 2.684625087567838e-06
estimated O 0 2.671329752956808e-07
to O 0 2.4161220579799192e-08
contribute O 0 9.017153246304588e-08
97 O 0 4.7160601752693765e-06
% O 0 1.5220490467982017e-07
of O 0 2.1574615516328777e-07
the O 0 3.0198071954146144e-07
population O 0 8.521895722424233e-08
variance O 0 1.6172547248061164e-06
. O 0 3.4828422030841466e-06

CONCLUSION O 0 0.0016748569905757904
Susceptibility O 0 0.0034993805456906557
to O 0 8.670114038977772e-05
AS B-Disease 1 0.999871015548706
is O 0 2.5783983801375143e-06
largely O 0 1.5017479881862528e-06
genetically O 0 2.1125912041952688e-07
determined O 0 4.76666656368252e-07
, O 0 1.2909013946682535e-07
and O 0 8.171623022690255e-08
the O 0 8.567216127630672e-07
environmental O 0 5.511767540156143e-06
trigger O 0 1.0079745152324904e-05
for O 0 2.491896793799242e-06
the O 0 3.7075944419484586e-05
disease O 0 0.1259930282831192
is O 0 7.508458566007903e-06
probably O 0 1.377375429001404e-05
ubiquitous O 0 2.9244918550830334e-05
. O 0 1.2485686511354288e-06

HLA O 0 0.022187884896993637
- O 0 0.000688395812176168
B27 O 0 0.0002799791982397437
accounts O 0 5.518039642993244e-07
for O 0 1.6940832381351356e-07
a O 0 5.00305191053485e-07
minority O 0 8.764598646848754e-08
of O 0 5.528585234060301e-07
the O 0 9.939016081261798e-07
overall O 0 1.432641965948278e-05
genetic O 0 1.4446713976212777e-05
susceptibility O 0 0.00016895437147468328
to O 0 2.9418175472528674e-05
AS B-Disease 1 0.9999998807907104
. O 0 1.0619150998536497e-05

Cell O 0 0.008744561113417149
cycle O 0 0.0003061861789319664
- O 0 3.7756948586320505e-05
dependent O 0 1.2381408851069864e-05
colocalization O 0 7.11443935870193e-05
of O 0 3.3410931791877374e-05
BARD1 O 0 0.00046066363574936986
and O 0 3.0950268410379067e-06
BRCA1 O 0 5.408589913713513e-06
proteins O 0 7.67362962506013e-07
in O 0 1.131564886236447e-06
discrete O 0 1.943114875757601e-05
nuclear O 0 8.505456935381517e-05
domains O 0 7.789458322804421e-05
. O 0 4.28645853389753e-06

Germ O 0 0.04409341514110565
- O 0 0.0006754255737178028
line O 0 4.197165617370047e-05
mutations O 0 8.07815979442239e-07
of O 0 2.799935145958443e-06
the O 0 5.328542556526372e-06
BRCA1 O 0 1.8992242985405028e-05
gene O 0 3.2378979994973633e-06
predispose O 0 4.568940312310588e-06
women O 0 2.0157064284376247e-07
to O 0 2.1779184677939156e-08
early O 0 3.835925326711731e-06
- O 0 0.000894614786375314
onset O 1 0.9999996423721313
breast B-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 6.141095241218864e-07
compromising O 0 1.638857838770491e-06
the O 0 1.0660870657375199e-06
genes O 0 2.055016921076458e-06
presumptive O 0 3.6356224882183596e-05
function O 0 9.127739758696407e-06
as O 0 1.1580202681216178e-06
a O 0 2.7823243726743385e-06
tumor B-Disease 0 0.001201661303639412
suppressor O 0 0.0010644181165844202
. O 0 1.6939553688644082e-06

Although O 0 4.967785207554698e-05
the O 0 3.625951649155468e-05
biochemical O 0 0.0004693483642768115
properties O 0 0.0007190192700363696
of O 0 0.00027896452229470015
BRCA1 O 0 0.00024083521566353738
polypeptides O 0 2.8241156542208046e-05
are O 0 6.163149919302668e-07
not O 0 6.396912510808761e-08
understood O 0 3.243987976020435e-07
, O 0 3.333570930408314e-08
their O 0 2.6782725370821936e-08
expression O 0 2.905624342020019e-06
pattern O 0 6.6584912019607145e-06
and O 0 1.445822476853209e-06
subcellular O 0 0.00018852672656066716
localization O 0 8.388556307181716e-05
suggest O 0 6.495803290818003e-07
a O 0 8.280539987026714e-07
role O 0 2.240775756945368e-06
in O 0 6.658097390754847e-06
cell O 0 5.8351994084659964e-05
- O 0 2.6342211640439928e-05
cycle O 0 1.9663790226331912e-05
regulation O 0 8.270869329862762e-06
. O 0 1.2138134479755536e-06

When O 0 0.0008707800880074501
resting O 0 0.004209307953715324
cells O 0 5.649308513966389e-05
are O 0 1.606329078640556e-06
induced O 0 1.502282884757733e-05
to O 0 5.884127176614129e-07
proliferate O 0 2.1227790512057254e-06
, O 0 2.1720697418459167e-07
the O 0 4.03282143679462e-07
steady O 0 7.70594306231942e-06
- O 0 4.1884743495756993e-07
state O 0 1.300668799331106e-07
levels O 0 2.39587166106503e-06
of O 0 2.7081900952907745e-06
BRCA1 O 0 3.046313395316247e-06
increase O 0 1.7437797623642837e-06
in O 0 7.923811608634423e-06
late O 0 3.828525950666517e-05
G1 O 0 1.273161979042925e-05
and O 0 5.98499099169203e-08
reach O 0 1.1929576260172325e-07
a O 0 2.1557298168772832e-07
maximum O 0 2.8906551960972138e-06
during O 0 4.087628985871561e-05
S O 0 0.00033125808113254607
phase O 0 5.8587185776559636e-05
. O 0 4.715277555078501e-06

Moreover O 0 0.00024796585785225034
, O 0 1.1259005987085402e-05
in O 0 3.23180211125873e-05
S O 0 0.0011107048485428095
phase O 0 0.00028461535112001
cells O 0 3.061144525418058e-05
, O 0 5.633656655845698e-06
BRCA1 O 0 1.8979641026817262e-05
polypeptides O 0 5.372660780267324e-06
are O 0 2.446272731049248e-07
hyperphosphorylated O 0 4.258251010469394e-06
and O 0 1.7738219071361527e-07
accumulate O 0 2.651284489729733e-07
into O 0 1.6306948680266942e-07
discrete O 0 9.452052836422808e-06
subnuclear O 0 9.402207797393203e-05
foci O 0 0.00015263684326782823
termed O 0 8.553943189326674e-05
" O 0 1.762022657203488e-05
BRCA1 O 0 1.6171612514881417e-05
nuclear O 0 4.11826949857641e-05
dots O 0 5.834476905874908e-05
. O 0 3.7968727610859787e-06

" O 0 0.0012105486821383238
BRCA1 O 0 0.0008055053767748177
associates O 0 0.00014559287228621542
in O 0 2.6250786504533608e-06
vivo O 0 3.136570012429729e-05
with O 0 1.6123546231483488e-07
a O 0 4.993126367480727e-06
structurally O 0 0.00010667760216165334
related O 0 2.154156936740037e-05
protein O 0 0.00026653558597899973
termed O 0 0.0009549154783599079
BARD1 O 0 0.09249836951494217
. O 0 1.5451671060873196e-05

Here O 0 0.0003251514572184533
we O 0 3.6282820019550854e-06
show O 0 1.7612499050301267e-06
that O 0 3.2176140507544915e-07
the O 0 9.542083034830284e-07
steady O 0 1.01839832495898e-05
- O 0 7.41319240660232e-07
state O 0 3.567182602637331e-07
levels O 0 7.695286512898747e-06
of O 0 2.3140864868764766e-05
BARD1 O 0 0.0005183820612728596
, O 0 2.8307547381700715e-06
unlike O 0 9.524027291263337e-07
those O 0 2.412861874745431e-07
of O 0 1.705994577605452e-06
BRCA1 O 0 4.641829036700074e-06
, O 0 1.0285526030884284e-07
remain O 0 1.1326407189926613e-07
relatively O 0 3.2352566847748676e-08
constant O 0 3.53934154873059e-07
during O 0 4.6563450268877205e-06
cell O 0 5.844656698172912e-05
cycle O 0 3.484744956949726e-05
progression O 0 0.0001313099783146754
. O 0 1.8189923594036372e-06

However O 0 0.00020657388085965067
, O 0 3.4296670492039993e-05
immunostaining O 0 0.0003988277749158442
revealed O 0 4.556620478979312e-05
that O 0 3.528473371261498e-06
BARD1 O 0 0.0006092573166824877
resides O 0 4.1971332393586636e-05
within O 0 5.838954621140147e-06
BRCA1 O 0 1.5200504094536882e-05
nuclear O 0 5.561717989621684e-05
dots O 0 2.9099199309712276e-05
during O 0 0.00010215226939180866
S O 0 0.0002367512643104419
phase O 0 3.277626456110738e-05
of O 0 4.6208446292439476e-05
the O 0 2.644619053171482e-05
cell O 0 3.602579454309307e-05
cycle O 0 4.9862269406730775e-06
, O 0 9.6605326405097e-08
but O 0 9.076110529804282e-09
not O 0 1.5060930280696994e-08
during O 0 7.418178142870602e-07
the O 0 1.2564017879412859e-06
G1 O 0 3.55890515493229e-05
phase O 0 1.821582918637432e-05
. O 0 3.843908871203894e-06

Nevertheless O 0 0.002417763927951455
, O 0 0.00011016654752893373
BARD1 O 0 0.0007167826988734305
polypeptides O 0 2.141235199815128e-05
are O 0 2.7027797955270216e-07
found O 0 1.2816863659281807e-07
exclusively O 0 6.47829523359178e-08
in O 0 7.094268426044437e-07
the O 0 1.9739734398172004e-06
nuclear O 0 5.819924808747601e-06
fractions O 0 5.446296199806966e-06
of O 0 2.5027758965734392e-05
both O 0 9.483826033829246e-06
G1 O 0 9.120140020968392e-05
- O 0 9.83416430244688e-06
and O 0 2.4570142613811186e-06
S O 0 0.00010406139335827902
- O 0 9.107602636504453e-06
phase O 0 2.699956348806154e-05
cells O 0 8.071113370533567e-06
. O 0 1.7738925635057967e-06

Therefore O 0 0.00017761619528755546
, O 0 2.1106603526277468e-05
progression O 0 0.0001448463590350002
to O 0 3.9776919038558844e-06
S O 0 0.0001448842085665092
phase O 0 1.5658355550840497e-05
is O 0 6.176188094286772e-07
accompanied O 0 7.029212270026619e-07
by O 0 4.600165226520403e-08
the O 0 1.9540175344445743e-07
aggregation O 0 1.1363945304765366e-06
of O 0 4.208360223856289e-06
nuclear O 0 4.1114966734312475e-05
BARD1 O 0 0.0002547054027672857
polypeptides O 0 1.2310847523622215e-05
into O 0 4.193912900518626e-06
BRCA1 O 0 3.55582196789328e-05
nuclear O 0 8.90248702489771e-05
dots O 0 0.00010829163511516526
. O 0 6.783642675145529e-06

This O 0 8.438485383521765e-05
cell O 0 0.00035924804979003966
cycle O 0 7.402624032692984e-05
- O 0 2.0619290808099322e-05
dependent O 0 8.179252290574368e-06
colocalization O 0 4.29430183430668e-05
of O 0 3.129017204628326e-05
BARD1 O 0 0.00042617309372872114
and O 0 3.176736981913564e-06
BRCA1 O 0 9.290341949963477e-06
indicates O 0 4.075539436598774e-06
a O 0 9.523645871922781e-07
role O 0 1.8954468714582617e-06
for O 0 2.9169241315685213e-06
BARD1 O 0 0.00039054115768522024
in O 0 2.284962283738423e-05
BRCA1 O 0 7.430603727698326e-05
- O 0 0.00011501395783852786
mediated O 0 0.0010440596379339695
tumor B-Disease 1 0.9996091723442078
suppression O 0 0.014439129270613194
. O 0 6.547732937178807e-06

Ethnic O 0 5.127456006448483e-06
differences O 0 8.372297997993883e-06
in O 0 2.4069808205240406e-05
the O 0 3.396885949769057e-05
HFE O 0 0.002986131701618433
codon O 0 0.00029128979076631367
282 O 0 0.0001475317549193278
( O 0 1.4873431609885301e-05
Cys O 0 0.010617830790579319
/ O 0 0.0009566493099555373
Tyr O 0 0.0007850773399695754
) O 0 3.6247784009901807e-06
polymorphism O 0 3.259516233811155e-05
. O 0 4.937158792017726e-06

Recent O 0 6.484306140919216e-06
studies O 0 3.421075234655291e-06
have O 0 5.681550874214736e-07
shown O 0 9.456344741920475e-06
that O 0 5.019099262426607e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.6080833077430725
HH B-Disease 1 1.0
) O 0 9.12125688046217e-06
is O 0 1.6341460877811187e-06
likely O 0 5.926115704824042e-07
to O 0 9.102829778839805e-08
be O 0 3.545821698480722e-07
caused O 0 2.614978939163848e-06
by O 0 1.585197111353409e-07
homozygosity O 0 7.827084118616767e-06
for O 0 4.7292738258875033e-07
a O 0 2.081272214127239e-06
Cys282Tyr O 0 4.0486400394001976e-05
mutation O 0 6.568149615304719e-07
in O 0 1.3540446843762766e-06
the O 0 3.102405798927066e-06
HFE O 0 0.00017365238454658538
gene O 0 4.232311312080128e-06
located O 0 7.710684258199763e-06
4 O 0 1.102029546018457e-05
. O 0 2.1043781543994555e-06

5 O 0 0.00093031523283571
Mb O 0 0.0035221579018980265
telomeric O 0 0.0015852495562285185
to O 0 6.902421591803432e-05
HLA O 0 0.005416323896497488
- O 0 0.0006902058958075941
A O 0 0.00016746213077567518
. O 0 3.41974100592779e-06

Population O 0 2.8180709250591462e-06
studies O 0 4.735014499601675e-06
of O 0 6.092262992751785e-06
this O 0 4.010541942989221e-07
polymorphism O 0 1.4375442560776719e-06
are O 0 7.7269895371046e-08
facilitated O 0 7.078907060531492e-07
by O 0 5.8458361706925643e-08
the O 0 1.0484109935759989e-07
fact O 0 4.838840794718635e-08
that O 0 4.242286877342849e-08
the O 0 1.5763148439873476e-06
Cys282Tyr O 0 0.00011201843881281093
mutation O 0 3.227908337066765e-06
creates O 0 6.843194569228217e-06
a O 0 9.985903488995973e-06
Rsal O 0 0.0002170616644434631
restriction O 0 2.51609344559256e-05
site O 0 1.5586765584885143e-05
. O 0 2.580661430329201e-06

We O 0 1.773567419149913e-05
have O 0 1.0696576282498427e-06
studied O 0 2.656048491189722e-05
the O 0 1.2085166417818982e-05
codon O 0 7.263846055138856e-05
282 O 0 8.487568265991285e-05
( O 0 1.164592777058715e-05
Cys O 0 0.004051146563142538
/ O 0 0.0003761145635508001
Tyr O 0 0.00023995393712539226
) O 0 2.611746197089815e-07
polymorphism O 0 4.112777673981327e-07
in O 0 1.2401567062170216e-07
different O 0 1.880034439238898e-08
ethnic O 0 1.1532344501574698e-07
groups O 0 1.2286518824566883e-07
. O 0 7.976199754011759e-07

In O 0 7.109218131517991e-05
agreement O 0 1.1761939276766498e-05
with O 0 1.9988960957562085e-06
previous O 0 3.091479084105231e-05
observations O 0 7.426040974678472e-05
the O 0 4.769183215103112e-05
Tyr O 0 0.00024286600819323212
allele O 0 2.4482045773766004e-05
appeared O 0 2.020541433012113e-05
to O 0 4.3498616264514567e-07
be O 0 1.4821714557911037e-06
rare O 0 3.6100509532843716e-06
or O 0 3.945543994632317e-06
absent O 0 2.25940857490059e-05
in O 0 2.4974044663395034e-06
Asiatic O 0 1.8823862774297595e-05
( O 0 4.476758306282136e-07
Indian O 0 9.750422123033786e-07
, O 0 3.2473340638716763e-07
Chinese O 0 1.4770070038139238e-06
) O 0 9.54911385520063e-08
populations O 0 1.4027176575837075e-07
. O 0 3.382417332886689e-07

The O 0 9.839714766712859e-05
highest O 0 0.0002479554386809468
allele O 0 1.2637231520784553e-05
frequency O 0 3.480652958387509e-05
( O 0 1.123585889217793e-06
7 O 0 4.104156232642708e-06
. O 0 7.723541273207957e-08
5 O 0 7.309712373171351e-07
% O 0 2.89914254381074e-07
) O 0 6.615537984089315e-08
was O 0 1.6873448203114094e-06
found O 0 1.6500145250120113e-07
in O 0 4.962811317454907e-07
Swedes O 0 1.5549681847915053e-05
. O 0 2.2256504053075332e-06

Saamis O 0 0.009523866698145866
( O 0 4.742475357488729e-05
2 O 0 5.982724542263895e-05
% O 0 5.156491170055233e-06
) O 0 9.695658036434907e-07
and O 0 2.592323880890035e-06
Mordvinians O 0 0.00014185093459673226
( O 0 1.4736906450707465e-06
1 O 0 5.4755128076067194e-06
. O 0 1.545973589145433e-07
8 O 0 2.0511247385002207e-06
% O 0 2.288952885010076e-07
) O 0 3.0087594637961956e-08
had O 0 3.4014183825092914e-07
significantly O 0 6.523596880469995e-07
lower O 0 3.7379008972493466e-06
frequencies O 0 1.0232942031507264e-06
of O 0 6.065208253858145e-06
the O 0 1.3340109944692813e-05
Tyr O 0 0.00019814037659671158
allele O 0 3.8526879507116973e-05
. O 0 4.5725455493084155e-06

Comparisons O 0 2.8318043405306526e-05
with O 0 1.1975072311543045e-06
allele O 0 4.986649855709402e-06
frequencies O 0 4.366243047115859e-06
based O 0 4.450616870599333e-07
on O 0 2.6314903607271845e-06
prevalence O 0 4.087360139237717e-05
estimates O 0 4.3644654397212435e-06
of O 0 2.0419169231900014e-05
HH B-Disease 1 0.9997637867927551
showed O 0 0.0002818556095007807
some O 0 8.51560571391019e-07
disagreements O 0 7.92430273577338e-06
with O 0 6.472545805991103e-07
the O 0 7.832288247300312e-06
RFLP O 0 3.7207388231763616e-05
data O 0 1.6933803408392123e-06
, O 0 1.138269425382532e-07
particularly O 0 1.0890526169760051e-07
in O 0 5.56721886368905e-07
Finns O 0 9.071888598555233e-06
. O 0 2.079760406559217e-06

The O 0 0.0002392300229985267
newly O 0 0.00032295117853209376
described O 0 0.00013809780648443848
HFE O 0 0.0053182002156972885
marker O 0 0.00021949707297608256
provides O 0 3.8987068364804145e-06
a O 0 2.216292841694667e-06
new O 0 4.6615605242550373e-07
approach O 0 9.300235888076713e-07
to O 0 1.813967145380957e-07
the O 0 1.0713666824813117e-06
screening O 0 3.193465090589598e-06
of O 0 5.478765888256021e-05
HH B-Disease 1 0.9588670134544373
as O 0 5.933789452683413e-06
well O 0 2.6089506377502403e-07
as O 0 1.0257021187953796e-07
studies O 0 5.973847549967104e-08
of O 0 1.8233538412459893e-07
the O 0 2.191106318605307e-07
relationship O 0 6.014647055962996e-07
between O 0 4.4451844587456435e-06
the O 0 1.59889277711045e-05
HFE O 0 0.003712868085131049
Tyr O 0 0.00019974628230556846
allele O 0 6.0483412198664155e-06
and O 0 5.21422180099762e-07
different O 0 1.964639977813931e-06
disorders O 1 0.9999984502792358
including O 0 0.00023892591707408428
cancer B-Disease 1 0.9999997615814209

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999979734420776
associated O 0 4.719177741208114e-05
with O 0 6.762764428458468e-07
a O 0 1.0831402505573351e-05
missense O 0 3.509731686790474e-05
mutation O 0 5.487693670147564e-06
encoding O 0 7.385266144410707e-06
Gly23 O 0 0.00024209247203543782
- O 0 5.0567112339194864e-05
- O 0 7.843437197152525e-05
> O 0 4.356009230832569e-05
Val O 0 0.00012642983347177505
in O 0 1.6238715033978224e-05
neurophysin O 0 0.0019649644382297993
II O 1 0.9997308850288391
. O 0 2.2059850380173884e-05

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.0007337941788136959
ADNDI B-Disease 1 0.9999849796295166
) O 0 3.0852015697746538e-06
is O 0 6.719755560880003e-07
an O 0 2.3280213099496905e-06
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999388456344604
by O 0 1.1098924005636945e-05
progressive O 1 0.9999415874481201
degeneration O 1 1.0
of O 0 0.0019410455133765936
the O 0 0.00014138479309622198
magnocellular O 0 0.0003512416733428836
neurons O 0 2.2533751689479686e-05
of O 0 5.169414362171665e-05
the O 0 4.345142951933667e-05
hypothalamus O 0 0.0001173574200947769
leading O 0 3.9015441871015355e-05
to O 0 2.646234804615233e-07
decreased O 0 3.297792500234209e-05
ability O 0 3.946207414173841e-07
to O 0 2.8762218562405906e-07
produce O 0 1.567585513839731e-06
the O 0 2.8260690669412725e-05
hormone O 0 0.00028335905517451465
arginine O 0 0.00014388866838999093
vasopressin O 0 0.00013863692583981901
( O 0 1.218061242980184e-05
AVP O 0 0.0003701161767821759
) O 0 1.0986776715071755e-06
. O 0 8.39267102037411e-07

Affected O 0 0.0002605933404993266
individuals O 0 2.3632642296433914e-06
are O 0 8.872647754287755e-07
not O 0 5.872287260899611e-07
symptomatic O 0 0.00011226523929508403
at O 0 4.0205686673289165e-05
birth O 0 2.5764593374333344e-05
, O 0 2.4997987679853395e-07
but O 0 5.784169587741417e-08
usually O 0 5.271229497338936e-07
develop O 0 4.816552518605022e-06
diabetes B-Disease 1 0.9998728036880493
insipidus I-Disease 0 0.17355915904045105
at O 0 0.0006528588128276169
1 O 0 3.383259172551334e-05
- O 0 2.6907924620900303e-05
6 O 0 0.00011687163350870833
yr O 0 0.00046251536696217954
of O 0 1.4199377801560331e-05
age O 0 4.288118361728266e-05
. O 0 4.545255251287017e-06

The O 0 1.6711364878574386e-05
genetic O 0 1.8515762349124998e-05
locus O 0 5.342444637790322e-05
of O 0 3.9251823181984946e-05
the O 0 5.331166903488338e-05
disease O 0 0.021443285048007965
is O 0 1.55760226334678e-05
the O 0 5.111364953336306e-05
AVP O 0 0.0014707656810060143
- O 0 0.0002475980145391077
neurophysin O 0 0.0007422740454785526
II O 1 0.9996362924575806
( O 0 1.6052606952143833e-05
NPII O 0 0.00038576856604777277
) O 0 1.9775950477196602e-06
gene O 0 2.4050057163549354e-06
, O 0 4.7304740746767493e-07
and O 0 1.0383862445451086e-06
mutations O 0 2.1473019842233043e-06
that O 0 1.3871665487386053e-06
cause O 0 3.550582914613187e-05
ADNDI B-Disease 0 0.00043454268597997725
have O 0 1.0539059758229996e-06
been O 0 9.54019014898222e-07
found O 0 8.115441829659176e-08
in O 0 1.2058782772328414e-07
both O 0 1.3896210759867245e-07
the O 0 1.003346142169903e-06
signal O 0 9.449367098568473e-06
peptide O 0 6.481097443611361e-06
of O 0 2.9591783459181897e-05
the O 0 7.760511653032154e-05
prepro O 0 0.0018073992105200887
- O 0 0.002429538406431675
AVP O 0 0.012387184426188469
- O 0 0.00020602506992872804
NPII O 0 0.0006580000626854599
precursor O 0 4.376374272396788e-05
and O 0 1.148059823208314e-06
within O 0 3.433331585256383e-06
NPII O 0 0.0004876450984738767
itself O 0 3.6962142075935844e-06
. O 0 3.0864905511407414e-06

An O 0 0.000168193771969527
affected O 0 0.00010646307055139914
girl O 0 0.00010709190974012017
who O 0 6.170699180074735e-06
presented O 0 1.3357742318476085e-05
at O 0 5.4120282584335655e-05
9 O 0 2.116570067300927e-05
months O 0 3.3585329219931737e-06
of O 0 5.250781214272138e-06
age O 0 2.6107425583177246e-05
and O 0 4.5113160922483075e-06
her O 0 1.6249574400717393e-05
similarly O 0 5.595670154434629e-05
affected O 0 4.2741110519273207e-05
younger O 0 9.060864977072924e-05
brother O 0 0.00025169094442389905
and O 0 9.718221917864867e-06
father O 0 3.4147888072766364e-05
were O 0 2.401421170361573e-06
all O 0 1.1168283720053296e-07
found O 0 4.526082975075951e-08
to O 0 1.4981168305894244e-08
have O 0 4.9756348374785375e-08
a O 0 4.747141133520927e-07
novel O 0 1.9783419702434912e-06
missense O 0 1.544725091662258e-05
mutation O 0 5.180999778531259e-06
( O 0 1.9039691778743872e-06
G1758 O 0 3.0355164199136198e-05
- O 0 1.7774618754629046e-05
- O 0 3.596819078666158e-05
> O 0 1.7008391296258196e-05
T O 0 8.308919859700836e-06
) O 0 4.3874326394188756e-08
encoding O 0 2.143041513136268e-07
the O 0 2.678038299563923e-06
amino O 0 3.320968971820548e-06
acid O 0 1.9019801129616098e-06
substitution O 0 6.9595348577422556e-06
Gly23 O 0 7.598304364364594e-05
- O 0 3.903397737303749e-05
- O 0 6.299550295807421e-05
> O 0 3.72647336916998e-05
Val O 0 0.00013274616503622383
within O 0 1.666962998569943e-05
NPII O 0 0.0013315322576090693
. O 0 9.904886610456742e-06

The O 0 6.915961421327665e-05
mutation O 0 1.2995398719795048e-05
was O 0 1.6464086002088152e-05
confirmed O 0 5.303793955135916e-07
by O 0 3.264981174311288e-08
restriction O 0 1.6585842104177573e-06
endonuclease O 0 2.5577730411896482e-05
analysis O 0 1.5713542325102026e-06
. O 0 1.505669956713973e-06

A O 0 0.002192331710830331
T1 O 0 0.004011302720755339
- O 0 3.232227390981279e-05
weighted O 0 2.7430958652985282e-05
magnetic O 0 1.3387239050643984e-05
resonance O 0 1.77433539647609e-05
imaging O 0 9.532751573715359e-05
of O 0 5.9618687373586e-05
the O 0 0.00021126361389178783
fathers O 0 0.0013696019304916263
pituitary O 0 0.21617284417152405
gland O 0 0.0014365455135703087
demonstrates O 0 2.3181795768323354e-05
an O 0 7.329198979277862e-06
attenuated O 0 0.0008477555238641798
posterior O 1 0.5406993627548218
pituitary O 1 0.9999997615814209
bright O 1 0.7904108166694641
spot O 0 0.0012160438345745206
. O 0 5.559050805459265e-06

This O 0 2.943262916232925e-05
mutation O 0 9.753150152391754e-06
may O 0 5.251908078207634e-06
be O 0 6.476627163465309e-07
valuable O 0 1.3172013950679684e-06
for O 0 5.294576794767636e-07
developing O 0 1.9800484096776927e-06
models O 0 3.3204844385181786e-06
of O 0 5.127153781359084e-05
dominantly B-Disease 1 0.9898142218589783
inherited I-Disease 1 0.9999994039535522
neurodegeneration I-Disease 1 1.0
, O 0 7.517149697378045e-06
as O 0 3.292403505383845e-07
the O 0 8.176518662139642e-08
early O 0 3.0376085646821593e-07
age O 0 7.855993544580997e-07
of O 0 2.632012410686002e-06
onset O 1 0.8021171689033508
of O 0 0.0007677543326281011
symptoms O 1 0.999514102935791
suggests O 0 1.0241230484098196e-05
that O 0 2.9184553795857937e-07
this O 0 2.38577030131637e-07
mutation O 0 9.383437600263278e-07
may O 0 7.296256967492809e-07
be O 0 1.2648855829411332e-07
particularly O 0 6.633454319171506e-08
deleterious O 0 1.5319470776375965e-06
to O 0 3.6973739270251826e-07
the O 0 8.51120876177447e-06
magnocellular O 0 0.00029093175544403493
neuron O 0 0.00011258234735578299
. O 0 1.0706291959650116e-06
. O 0 2.124757884303108e-06

Frequent O 0 0.000107245818071533
inactivation O 0 0.005849267356097698
of O 0 0.0031668124720454216
PTEN O 1 0.999995231628418
/ O 1 0.6251168251037598
MMAC1 O 1 0.5040179491043091
in O 0 0.00014859427756164223
primary O 1 0.9999990463256836
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.453725003055297e-05

Sporadic B-Disease 1 0.9999998807907104
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 1 0.9853274822235107
the O 0 0.0001409844117006287
most O 0 4.560121851682197e-06
common O 0 1.3039022633165587e-05
male B-Disease 0 0.00020373445295263082
cancer I-Disease 0 0.0013537212507799268
in O 0 1.2885984688182361e-05
the O 0 1.8313756299903616e-05
Western O 0 1.5711904779891483e-05
world O 0 7.354418357863324e-06
, O 0 1.5203575287614512e-07
yet O 0 4.211617721239236e-08
many O 0 6.077359948619687e-09
of O 0 9.337200168602067e-08
the O 0 1.6286494997075351e-07
major O 0 1.0997342769769602e-06
genetic O 0 3.217405151190178e-07
events O 0 4.205493269182625e-07
involved O 0 1.1995150828170154e-07
in O 0 2.770404705643159e-07
the O 0 1.2060755807397072e-06
progression O 0 5.390817386796698e-05
of O 0 2.7076710011897376e-06
this O 0 1.1806034763139905e-06
often O 0 1.502474788139807e-05
fatal O 1 0.9042977690696716
cancer B-Disease 0 0.18404893577098846
remain O 0 8.718081517145038e-06
to O 0 1.6405655856033263e-07
be O 0 1.0530459348956356e-06
elucidated O 0 8.282087947009131e-05
. O 0 3.7345268992794445e-06

Numerous O 0 0.0003312403568997979
cytogenetic O 1 0.9055501222610474
and O 0 8.722706843400374e-05
allelotype O 0 0.0012430743081495166
studies O 0 4.042388809466502e-06
have O 0 3.089265590006107e-07
reported O 0 8.492718848174263e-07
frequent O 0 8.790109973233484e-07
loss O 0 4.373436968307942e-05
of O 0 3.237440614611842e-05
heterozygosity O 1 0.9954025745391846
on O 0 0.0025926828384399414
chromosomal O 1 0.9999872446060181
arm O 1 0.6863638758659363
10q O 0 0.0008912426419556141
in O 0 3.91832654713653e-05
sporadic B-Disease 1 0.9999997615814209
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.525050124153495e-05

Deletion O 0 0.0008266238146461546
mapping O 0 0.00015845253074076027
studies O 0 3.558335083653219e-05
have O 0 5.255044470686698e-06
unambiguously O 0 2.084255356749054e-05
identified O 0 2.7268004032521276e-06
a O 0 4.475760306377197e-06
region O 0 4.887547220278066e-06
of O 0 6.781900447094813e-05
chromosome O 0 0.0012552853440865874
10q23 O 0 0.000571412849240005
to O 0 2.05481524062634e-06
be O 0 1.385890527672018e-06
the O 0 1.293389686907176e-06
minimal O 0 8.985938620753586e-06
area O 0 5.521952971321298e-06
of O 0 6.137569016573252e-06
loss O 0 0.00013462551578413695
. O 0 5.254458301351406e-06

A O 0 0.0002042685664491728
new O 0 2.5170485969283618e-05
tumor B-Disease 0 0.005071314983069897
suppressor O 0 0.0031328231561928988
gene O 0 2.4393995772697963e-05
, O 0 7.440741228492698e-06
PTEN O 0 0.0015866818139329553
/ O 0 0.00030419419636018574
MMAC1 O 0 0.0019360294099897146
, O 0 1.1795729733421467e-05
was O 0 9.494612459093332e-05
isolated O 0 1.1205051123397425e-05
recently O 0 9.957572729035746e-06
at O 0 1.841234916355461e-05
this O 0 2.884272589653847e-07
region O 0 2.576191263869987e-06
of O 0 3.998987085651606e-05
chromosome O 0 0.0012905366020277143
10q23 O 0 0.00033660265034995973
and O 0 3.752820930458256e-06
found O 0 4.522096332948422e-07
to O 0 1.0498473201892011e-08
be O 0 1.1567346192009609e-08
inactivated O 0 1.3369451323796966e-07
by O 0 7.58548601709208e-09
mutation O 0 6.832662080569207e-08
in O 0 5.035112167206535e-07
three O 0 1.9850207536364906e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.34785887598991394
lines O 0 3.1415955163538456e-05
. O 0 3.2707268928788835e-06

We O 0 2.4112083337968215e-05
screened O 0 0.00020063041301909834
80 O 0 0.001028012135066092
prostate B-Disease 1 0.9999946355819702
tumors I-Disease 1 1.0
by O 0 3.4244960716023343e-06
microsatellite O 0 2.929700531240087e-05
analysis O 0 1.2050913937855512e-06
and O 0 9.651247410147334e-07
found O 0 2.8286119686526945e-06
chromosome O 0 3.1942487112246454e-05
10q23 O 0 8.008020813576877e-05
to O 0 1.3061694517091382e-06
be O 0 1.8096454823535169e-06
deleted O 0 1.0408232355985092e-06
in O 0 8.165280291905219e-07
23 O 0 1.1478220585559029e-05
cases O 0 8.524625059180835e-07
. O 0 2.571645154603175e-06

We O 0 5.133048489369685e-06
then O 0 2.2448560343946156e-07
proceeded O 0 1.5459794155958662e-07
with O 0 4.9395865175938525e-09
sequence O 0 6.853049683286372e-08
analysis O 0 9.104930853709448e-08
of O 0 1.2669345323956804e-06
the O 0 4.5583387873193715e-06
entire O 0 0.0001114237675210461
PTEN O 0 0.004768885672092438
/ O 0 0.00039896296220831573
MMAC1 O 0 0.0010149552254006267
coding O 0 8.106389577733353e-05
region O 0 1.4606679542339407e-05
and O 0 4.178064500592882e-06
tested O 0 4.585698661685456e-06
for O 0 7.493376301681565e-07
homozygous O 0 2.3244940621225396e-06
deletion O 0 3.590025016819709e-06
with O 0 2.5482785304120625e-07
new O 0 1.1623164937191177e-06
intragenic O 0 5.205114575801417e-05
markers O 0 6.454136837419355e-06
in O 0 7.413644880216452e-07
these O 0 1.0591357835210147e-07
23 O 0 6.527588084281888e-06
cases O 0 2.159371632615148e-07
with O 0 5.513825840353093e-07
10q23 O 0 0.00038352300180122256
loss O 0 0.0006180423661135137
of O 0 0.00033077903208322823
heterozygosity O 0 0.45452937483787537
. O 0 2.7267584300716408e-05

The O 0 3.124908107565716e-05
identification O 0 3.375123242221889e-06
of O 0 1.2953984878549818e-05
the O 0 9.130012585956138e-06
second O 0 2.7280642825644463e-05
mutational O 0 7.744033791823313e-05
event O 0 1.4482469850918278e-05
in O 0 2.4301828034367645e-06
10 O 0 2.292287263117032e-06
( O 0 4.031260232295608e-07
43 O 0 1.6685469745425507e-05
% O 0 2.242852860945277e-05
) O 0 3.7066962249809876e-05
tumors B-Disease 1 1.0
establishes O 1 0.9600250720977783
PTEN O 1 0.9999961853027344
/ O 0 0.00408486183732748
MMAC1 O 0 0.0019973067101091146
as O 0 3.4806573694368126e-06
a O 0 1.090251316782087e-06
main O 0 4.334430286689894e-06
inactivation O 0 2.7995001801173203e-05
target O 0 5.136683398632158e-07
of O 0 1.1103115866717417e-06
10q O 0 4.3380634451750666e-05
loss O 0 1.0805114470713306e-05
in O 0 5.538503501156811e-06
sporadic B-Disease 1 0.999907374382019
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.234923835610971e-06
. O 0 1.8208355641036178e-06

Risk O 0 6.933612894499674e-05
reversals O 0 4.732716115540825e-05
in O 0 5.508008484866878e-07
predictive O 0 1.3866645531379618e-05
testing O 0 5.987062650092412e-06
for O 0 3.070570528507233e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 7.668475518585183e-06

The O 0 1.5168227037065662e-05
first O 0 4.736903065349907e-06
predictive O 0 3.1869771191850305e-05
testing O 0 2.0115645384066738e-05
for O 0 8.386797708226368e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.6277336928615114e-06
HD B-Disease 0 4.149891537963413e-05
) O 0 2.1601461241971265e-07
was O 0 1.1684056744343252e-06
based O 0 6.399036323045948e-08
on O 0 6.474774636444636e-07
analysis O 0 1.552484576450297e-07
of O 0 1.410633899467939e-06
linked O 0 1.2606067684828304e-05
polymorphic O 0 5.971734481136082e-06
DNA O 0 1.4095285223447718e-06
markers O 0 1.7385275441483827e-06
to O 0 8.439175758212514e-08
estimate O 0 2.4438733703391335e-07
the O 0 2.1040197850652476e-07
likelihood O 0 5.039714210397506e-07
of O 0 5.5324162531178445e-06
inheriting O 0 1.7051557733793743e-05
the O 0 2.2285432805801975e-06
mutation O 0 8.407362770412874e-07
for O 0 7.932482617434289e-07
HD B-Disease 0 0.00014866911806166172
. O 0 3.3432545478717657e-06

Limits O 0 2.2533837181981653e-05
to O 0 4.4057307491129905e-07
accuracy O 0 2.1008709154557437e-06
included O 0 6.184870358083572e-07
recombination O 0 2.1759676371857495e-07
between O 0 7.947331255309109e-07
the O 0 1.1941747288801707e-06
DNA O 0 9.577182709108456e-07
markers O 0 5.184073870623251e-06
and O 0 2.5177214411087334e-06
the O 0 1.322881507803686e-05
mutation O 0 8.060974323598202e-06
, O 0 4.016097591375001e-06
pedigree O 0 2.2857315343571827e-05
structure O 0 2.5044302674359642e-05
, O 0 5.443666282189952e-07
and O 0 1.864090251046946e-07
whether O 0 1.2034853114073485e-07
DNA O 0 5.094474317957065e-07
samples O 0 7.084843218763126e-07
were O 0 8.027244007280387e-07
available O 0 1.3005272592181427e-07
from O 0 5.510141249942535e-07
family O 0 3.915494062312064e-07
members O 0 2.928855451500567e-07
. O 0 7.949476525936916e-07

With O 0 5.603308181889588e-06
direct O 0 1.2435167263902258e-05
tests O 0 5.513240012078313e-06
for O 0 3.28852320308215e-06
the O 0 1.2870043065049686e-05
HD B-Disease 0 0.000213169667404145
mutation O 0 3.5328807825862896e-06
, O 0 3.5158532796231157e-07
we O 0 7.070831031796843e-08
have O 0 2.3631073986507545e-08
assessed O 0 1.629146595405473e-07
the O 0 1.037707662021603e-07
accuracy O 0 6.979088311709347e-07
of O 0 2.993727321154438e-06
results O 0 2.65541916633083e-06
obtained O 0 4.034170160593931e-06
by O 0 1.1917197753064102e-06
linkage O 0 1.2449929272406735e-05
approaches O 0 4.354163138486911e-06
when O 0 7.221458417916438e-07
requested O 0 5.134127150085988e-07
to O 0 3.706637983214023e-07
do O 0 1.9754867253141128e-07
so O 0 5.4199780663566344e-08
by O 0 3.761125100254503e-08
the O 0 1.2606513166701916e-07
test O 0 1.817177377461121e-07
individuals O 0 1.4090808519995335e-07
. O 0 1.2498683190642623e-06

For O 0 0.00010549373109824955
six O 0 1.4882229152135551e-05
such O 0 6.200253892529872e-07
individuals O 0 1.4046948138002335e-07
, O 0 1.7870847557333036e-07
there O 0 8.719927535594252e-08
was O 0 1.2751530675814138e-06
significant O 0 5.331788770490675e-07
disparity O 0 2.6789680305228103e-06
between O 0 1.8411802784612519e-06
the O 0 2.9156449272704776e-06
tests O 0 1.6440408217022195e-06
. O 0 1.5481247146453825e-06

Three O 0 0.00015126648941077292
went O 0 0.00016785477055236697
from O 0 6.064305580366636e-06
a O 0 4.6599698180216365e-06
decreased O 0 0.0002659600868355483
risk O 0 5.353562301024795e-06
to O 0 2.4695467004676175e-07
an O 0 3.3340069194309763e-07
increased O 0 6.635746558458777e-06
risk O 0 5.812785730086034e-06
, O 0 6.284550408963696e-07
while O 0 2.618939447529556e-07
in O 0 4.2910821207442496e-07
another O 0 2.48910311029249e-07
three O 0 2.073133344993039e-07
the O 0 7.266605734912446e-07
risk O 0 2.1808173187309876e-06
was O 0 1.934104147949256e-05
decreased O 0 0.00018187827663496137
. O 0 3.4772299386531813e-06

Knowledge O 0 0.00017895919154398143
of O 0 0.00012898436398245394
the O 0 1.336081277258927e-05
potential O 0 3.8745988604205195e-06
reasons O 0 1.0795902198879048e-06
for O 0 1.5874543635163718e-07
these O 0 3.116762314903099e-08
changes O 0 9.730342043212659e-08
in O 0 8.799403303783038e-07
results O 0 1.003207330541045e-06
and O 0 3.1311645898313145e-07
impact O 0 2.970452442241367e-06
of O 0 3.2727675716159865e-06
these O 0 3.6133087633061223e-07
risk O 0 6.20729861111613e-06
reversals O 0 9.020233119372278e-05
on O 0 1.4279646165960003e-05
both O 0 1.6276927681246889e-06
patients O 0 9.94728452496929e-07
and O 0 5.027319502914906e-07
the O 0 2.469596665832796e-06
counseling O 0 4.804097898158943e-06
team O 0 1.0266567187500186e-06
can O 0 1.2010053751509986e-07
assist O 0 5.339584276953246e-07
in O 0 1.2518628409452504e-06
the O 0 2.5180504508170998e-06
development O 0 5.212071755522629e-06
of O 0 8.517899914295413e-06
strategies O 0 3.3660296594462125e-06
for O 0 1.2979293160242378e-06
the O 0 5.250841695669806e-06
prevention O 0 9.920257980411407e-06
and O 0 1.660421617089014e-06
, O 0 3.384679416740255e-07
where O 0 4.2492757756917854e-07
necessary O 0 1.122818957810523e-06
, O 0 6.114925099609536e-07
management O 0 1.7490909840489621e-06
of O 0 1.1779886790463934e-06
a O 0 3.943076080759056e-06
risk O 0 2.823725480993744e-06
reversal O 0 1.1285384971415624e-05
in O 0 3.7817565612385806e-07
any O 0 6.949864683747364e-08
predictive O 0 2.769456159512629e-06
testing O 0 5.913718723604688e-07
program O 0 5.036120569457125e-07
. O 0 8.735491974221077e-08
. O 0 5.555789357458707e-07

A O 0 6.3811254221946e-05
novel O 0 1.1086683116445784e-05
common O 0 5.948549187451135e-06
missense O 0 3.268667933298275e-05
mutation O 0 3.912727152055595e-06
G301C O 0 5.0387658120598644e-05
in O 0 6.930207746336237e-06
the O 0 1.569670348544605e-05
N O 0 9.538971789879724e-05
- O 0 2.1419540644274093e-05
acetylgalactosamine O 0 0.00013836064317729324
- O 0 2.678260898392182e-05
6 O 0 8.582901500631124e-05
- O 0 2.5021648980327882e-05
sulfate O 0 8.028474258026108e-05
sulfatase O 0 0.0005289992550387979
gene O 0 7.666953933949117e-06
in O 0 6.18469130131416e-06
mucopolysaccharidosis B-Disease 0 0.0008918967796489596
IVA I-Disease 0 0.025361312553286552
. O 0 1.4501319128612522e-05

Mucopolysaccharidosis B-Disease 1 0.9793620109558105
IVA I-Disease 1 0.9999918937683105
( O 0 0.005012421868741512
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 1.1962918506469578e-05
is O 0 7.868402462918311e-07
an O 0 1.288763883167121e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999977350234985
by O 0 9.822354513744358e-06
a O 0 0.2847844362258911
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 1 0.9967299699783325
N O 0 0.09233609586954117
- O 0 0.00030288731795735657
acetylgalactosamine O 0 0.012635445222258568
- O 0 0.00031135851168073714
6 O 0 0.0011062778066843748
- O 0 0.0002597950224298984
sulfate O 0 0.0011116432724520564
sulfatase O 0 0.010775378905236721
( O 0 1.013255041470984e-05
GALNS O 0 0.00046622479567304254
) O 0 1.511410232524213e-06
. O 0 8.10356141300872e-07

In O 0 0.0004978013457730412
previous O 0 0.00019346167391631752
studies O 0 3.711241515702568e-05
, O 0 1.929361587826861e-06
we O 0 4.2386716359033016e-07
have O 0 1.7457901435591339e-07
found O 0 2.423900014036917e-07
two O 0 9.934147726653464e-08
common O 0 3.4188207109764335e-07
mutations O 0 4.5224714995129034e-07
in O 0 3.875829406752018e-06
Caucasians O 0 5.155537110113073e-06
and O 0 9.336662856185285e-07
Japanese O 0 1.405463171977317e-05
, O 0 1.465731088501343e-06
respectively O 0 2.0391807993291877e-05
. O 0 1.6160413451871136e-06

To O 0 3.238533827243373e-05
characterize O 0 0.00010860332986339927
the O 0 4.4937332859262824e-05
mutational O 0 0.00046492001274600625
spectrum O 0 2.129036329279188e-05
in O 0 7.841965725674527e-07
various O 0 1.745963231769565e-07
ethnic O 0 2.2461881599156186e-07
groups O 0 8.010055552176709e-08
, O 0 9.044541116054461e-08
mutations O 0 8.105588022999655e-08
in O 0 6.009785238347831e-07
the O 0 2.5610820557631087e-06
GALNS O 0 8.9994166046381e-05
gene O 0 3.7810027606610674e-06
in O 0 1.1978581824223511e-05
Colombian O 0 0.00042652306728996336
MPS B-Disease 1 0.9998854398727417
IVA I-Disease 1 1.0
patients O 0 0.00013632381160277873
were O 0 2.4747627321630716e-05
investigated O 0 1.0400402061350178e-05
, O 0 7.362266956079111e-07
and O 0 2.8465296963986475e-07
genetic O 0 1.4023044059285894e-06
backgrounds O 0 2.9350684371820535e-07
were O 0 2.2027303714367008e-07
extensively O 0 1.4298626638264977e-07
analyzed O 0 1.2510460578596394e-07
to O 0 2.750548944163711e-08
identify O 0 6.962309839764202e-08
racial O 0 2.0813030232602614e-07
origin O 0 1.7558015485974465e-07
, O 0 4.693007582545761e-08
based O 0 6.359504567399199e-08
on O 0 1.7069402247216203e-06
mitochondrial O 0 1.76871308212867e-05
DNA O 0 3.2944874419627013e-06
( O 0 9.4433340791511e-07
mtDNA O 0 2.3770453481120057e-06
) O 0 7.611321848344232e-07
lineages O 0 4.776787136506755e-06
. O 0 1.2166749456810066e-06

Three O 0 9.278707148041576e-05
novel O 0 8.873273327481002e-05
missense O 0 0.0004563791735563427
mutations O 0 7.58113746996969e-05
never O 0 7.916528556961566e-05
identified O 0 7.19132140147849e-06
previously O 0 7.346307938860264e-06
in O 0 1.9669403172883904e-06
other O 0 1.5219836768665118e-07
populations O 0 5.65347804126759e-08
and O 0 7.986104577639708e-08
found O 0 1.5722567070497462e-07
in O 0 7.612853210048343e-07
16 O 0 5.4507077038579155e-06
out O 0 2.1846049946816493e-07
of O 0 1.0499299605726264e-05
19 O 0 0.00042058664257638156
Colombian O 0 0.0005824462277814746
MPS B-Disease 1 0.9936712980270386
IVA I-Disease 1 0.999904990196228
unrelated O 0 1.1328388609399553e-05
alleles O 0 8.163598295141128e-07
account O 0 1.579854540523229e-07
for O 0 6.533427381327783e-07
84 O 0 5.2679544751299545e-05
. O 0 3.2907380500546424e-06

2 O 0 9.859550482360646e-05
% O 0 4.123135568079306e-06
of O 0 3.221401129849255e-06
the O 0 2.296703087267815e-06
alleles O 0 1.2723238569378736e-06
in O 0 7.129659138627176e-07
this O 0 1.1307563596574255e-07
study O 0 1.1272759365965612e-06
. O 0 1.0096563300976413e-06

The O 0 0.0002731780696194619
G301C O 0 0.0009813981596380472
and O 0 1.1271778930677101e-05
S162F O 0 6.5925283706747e-05
mutations O 0 1.6576433381487732e-06
account O 0 5.195022936277383e-07
for O 0 2.1611199372273404e-06
68 O 0 0.00010884667426580563
. O 0 6.240894890652271e-06

4 O 0 0.0003348026075400412
% O 0 1.4876793102303054e-05
and O 0 6.257463155634468e-06
10 O 0 2.0605648387572728e-05
. O 0 5.34173022970208e-06

5 O 0 0.00012836154201067984
% O 0 1.0841912626347039e-05
of O 0 2.870284515665844e-05
mutations O 0 8.321513632836286e-06
, O 0 4.801404884346994e-06
respectively O 0 2.5493032808299176e-05
, O 0 6.526590254907205e-07
whereas O 0 1.6382687135774177e-06
the O 0 3.1512765872321324e-06
remaining O 0 7.73192095948616e-06
F69V O 0 0.0001248132175533101
is O 0 3.643753814230877e-07
limited O 0 1.7005288555083098e-07
to O 0 7.074298480347352e-08
a O 0 1.0085918802360538e-06
single O 0 2.197714366047876e-06
allele O 0 8.64288904267596e-06
. O 0 2.38298548538296e-06

The O 0 0.00010263088915962726
skewed O 0 7.5494812335819e-05
prevalence O 0 0.00013940074131824076
of O 0 5.747560862801038e-05
G301C O 0 0.00019255494407843798
in O 0 5.027060069551226e-06
only O 0 7.232196708173433e-07
Colombian O 0 1.5086946405062918e-05
patients O 0 6.647633199463598e-07
and O 0 1.5400917163788108e-07
haplotype O 0 5.055164365330711e-06
analysis O 0 1.3982513280552666e-07
by O 0 3.3664900200847114e-08
restriction O 0 6.3629499891249e-07
fragment O 0 1.7218214907188667e-06
length O 0 1.7614631815376924e-06
polymorphisms O 0 4.92544404551154e-06
in O 0 3.6010146686749067e-06
the O 0 1.1263420674367808e-05
GALNS O 0 0.0002879967796616256
gene O 0 3.709371640070458e-06
suggest O 0 6.414788344955014e-07
that O 0 1.324514613543215e-07
G301C O 0 1.5191229977062903e-05
originated O 0 1.3389923196882592e-06
from O 0 7.376829671557061e-07
a O 0 1.0714779818954412e-06
common O 0 2.004133875743719e-06
ancestor O 0 3.9880491385702044e-05
. O 0 2.9724021715082927e-06

Investigation O 0 3.583794750738889e-05
of O 0 9.01470866665477e-06
the O 0 2.6987972887582146e-06
genetic O 0 3.3132218959508464e-06
background O 0 2.616380925246631e-06
by O 0 1.1104650639026659e-06
means O 0 4.021379481855547e-06
of O 0 4.688415356213227e-05
mtDNA O 0 1.4550497326126788e-05
lineages O 0 6.3562943068973254e-06
indicate O 0 2.056514858850278e-06
that O 0 1.2597139686931769e-07
all O 0 2.7729103635465435e-07
our O 0 5.529170721274568e-07
patients O 0 3.1811921985536173e-07
are O 0 7.262033818733471e-08
probably O 0 3.402437016575277e-07
of O 0 5.207398885431758e-07
native O 0 1.4741953009433928e-06
American O 0 1.2352042176644318e-05
descent O 0 0.0004492963198572397

Low O 0 4.836787047679536e-05
frequency O 0 5.433596015791409e-06
of O 0 6.641102572757518e-06
BRCA1 O 0 1.9532106307451613e-05
germline O 0 7.178556188591756e-06
mutations O 0 8.756177294344525e-08
in O 0 1.2557256923173554e-07
45 O 0 3.242826551286271e-06
German O 1 0.997162401676178
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.7752206986187957e-05
. O 0 2.658536004673806e-06

In O 0 2.773962933133589e-06
this O 0 4.746570425595564e-08
study O 0 3.334823617251459e-08
we O 0 6.268829011446542e-09
investigated O 0 7.696512938082378e-08
45 O 0 3.0487517506117e-06
German O 1 0.9544343948364258
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1615917401286424e-06
for O 0 1.075982481779647e-06
germline O 0 5.156588304089382e-05
mutations O 0 1.0834291970240884e-06
in O 0 2.152741672034608e-06
the O 0 3.6278320294513833e-06
BRCA1 O 0 2.7989741283818148e-05
gene O 0 1.330558916379232e-05
. O 0 1.7737436337483814e-06

We O 0 3.09708557324484e-05
identified O 0 1.4318101420940366e-05
four O 0 7.2039997576212045e-06
germline O 0 6.86492639943026e-05
mutations O 0 1.6070630408648867e-06
in O 0 1.7503158460385748e-06
three O 0 4.069911483384203e-06
breast B-Disease 1 0.9476367235183716
cancer I-Disease 1 0.8607555031776428
families O 0 1.0489849699979459e-07
and O 0 2.569933599261276e-07
in O 0 1.710410106170457e-05
one O 1 0.8503066301345825
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 8.563101437175646e-05
. O 0 1.1421383305787458e-07
among O 0 2.9568633763688013e-08
these O 0 9.993589955570314e-09
were O 0 3.669898660518811e-07
one O 0 3.823022893811867e-07
frameshift O 0 1.9156244889018126e-05
mutation O 0 1.3495942994268262e-06
, O 0 4.969764404449961e-07
one O 0 4.226513112826069e-07
nonsense O 0 8.17106592876371e-06
mutation O 0 1.856585186033044e-06
, O 0 3.470679246220243e-07
one O 0 1.5342645554028422e-07
novel O 0 1.770509015841526e-06
splice O 0 1.6307742043863982e-05
site O 0 3.492944188110414e-06
mutation O 0 8.804565254649788e-07
, O 0 2.0734496786189993e-07
and O 0 1.3378928542806534e-07
one O 0 5.189912712921796e-07
missense O 0 3.705487688421272e-05
mutation O 0 2.607134956633672e-05
. O 0 6.0658326219709124e-06

The O 0 0.0002848987642209977
missense O 0 0.00039467174792662263
mutation O 0 1.9990062355645932e-05
was O 0 7.228411413962021e-05
also O 0 1.1244649158470565e-06
found O 0 2.92510947019764e-07
in O 0 8.007837664081308e-07
2 O 0 1.6354262697859667e-05
. O 0 2.2963986339163966e-06

8 O 0 0.0005862052785232663
% O 0 2.4751403543632478e-05
of O 0 3.821828431682661e-05
the O 0 1.9395434719626792e-05
general O 0 2.5881001420202665e-05
population O 0 6.792847102587984e-07
, O 0 2.7583936912378704e-07
suggesting O 0 2.9462469797181257e-07
that O 0 3.160306150107317e-08
it O 0 2.9459313211077642e-08
is O 0 1.8614238683767326e-07
not O 0 3.6644115652961773e-07
disease O 0 3.336817098897882e-05
associated O 0 8.269813406514004e-06
. O 0 5.125876668898854e-06

The O 0 1.6997024431475438e-05
average O 0 1.2389996300044004e-05
age O 0 1.4153815754980315e-05
of O 0 1.2561653420561925e-05
disease O 0 0.30034130811691284
onset O 1 0.9137239456176758
in O 0 9.77697163762059e-06
those O 0 6.646955057476589e-07
families O 0 4.843826673095464e-07
harbouring O 0 4.984018232789822e-05
causative O 0 2.087211214529816e-05
mutations O 0 3.4672427773330128e-06
was O 0 2.3052651158650406e-05
between O 0 3.503883817757014e-06
32 O 0 4.3854313844349235e-05
. O 0 2.999777507284307e-06

3 O 0 0.00028608986758627
and O 0 1.1550902854651213e-05
37 O 0 0.00012944814807269722
. O 0 5.046672868047608e-06

4 O 0 0.0006659466307610273
years O 0 3.589801417547278e-05
, O 0 1.3477177844833932e-06
whereas O 0 2.619136921566678e-06
the O 0 2.5917997845681384e-06
family O 0 2.6318616619391833e-06
harbouring O 0 8.55773760122247e-05
the O 0 4.610329142451519e-06
missense O 0 3.382533395779319e-05
mutation O 0 2.2493122742162086e-06
had O 0 2.957630385935772e-06
an O 0 2.257397824223517e-07
average O 0 1.35271523049596e-06
age O 0 2.497154355296516e-06
of O 0 1.3046983440290205e-05
onset O 1 0.924584150314331
of O 0 0.0057895602658391
51 O 0 0.006678284611552954
. O 0 2.8333983209449798e-05

2 O 0 0.0004598015802912414
years O 0 5.682862320099957e-05
. O 0 9.53273683990119e-06

These O 0 1.3632268746732734e-05
findings O 0 1.1189278666279279e-05
show O 0 1.017229715216672e-05
that O 0 2.396900299572735e-06
BRCA1 O 0 4.354676275397651e-05
is O 0 2.8062972887710202e-06
implicated O 0 2.776747351163067e-06
in O 0 1.752144953570678e-07
a O 0 9.436386960715026e-08
small O 0 3.9451602873441516e-08
fraction O 0 5.871335702067881e-07
of O 0 6.225937977433205e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0302043165211217e-06
suggesting O 0 6.644020231760805e-07
the O 0 3.085302751060226e-07
involvement O 0 1.332687361355056e-06
of O 0 3.0883277304383228e-06
another O 0 3.252735041314736e-06
susceptibility O 0 0.00010409334936412051
gene O 0 5.260825855657458e-05
( O 0 1.0682226275093853e-05
s O 0 0.00024322426179423928
) O 0 1.2202331163280178e-05

Paternal O 1 0.9769017100334167
transmission O 1 0.9999982118606567
of O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00048521225107833743

We O 0 5.317272552929353e-06
report O 0 3.535199084581109e-07
a O 0 8.381634586385189e-08
rare O 0 2.568727950347238e-07
case O 0 2.523040336654958e-07
of O 0 1.3668522115040105e-05
paternally O 1 0.9999994039535522
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.02390505000948906
DM B-Disease 1 1.0
) O 0 2.162169766961597e-05
. O 0 3.831570666079642e-06

The O 0 0.0004227195749990642
proband O 0 0.0015394540969282389
is O 0 8.745428203837946e-06
a O 0 1.0190103239438031e-05
23 O 0 9.274673357140273e-05
year O 0 1.7198412024299614e-05
old O 0 0.0003421930887270719
, O 0 4.653284850064665e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.0034910428803414106
who O 0 0.0002345424727536738
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.0010521193034946918

He O 0 9.84371145023033e-05
presented O 0 7.284058665391058e-05
with O 0 1.788050212780945e-05
respiratory O 1 1.0
and O 0 1.9720169802894816e-05
feeding O 0 7.127844583010301e-05
difficulties O 0 0.0001734139514155686
at O 0 0.0018710856093093753
birth O 0 0.0005870738532394171
. O 0 5.281361154629849e-06

His O 0 0.00028709101025015116
two O 0 0.0001628295285627246
sibs O 1 0.9999244213104248
suffer O 0 0.006242803763598204
from O 0 3.346546509419568e-05
childhood O 1 0.7513935565948486
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.00040131862624548376

Their O 0 0.00010236298112431541
late O 0 0.0005312923458404839
father O 0 7.711154466960579e-05
had O 0 6.240490165509982e-06
the O 0 1.0764649687189376e-06
adult O 0 1.76744856617006e-06
type O 0 1.411017819918925e-05
of O 0 0.00042394554475322366
DM B-Disease 1 1.0
, O 0 2.3030832380754873e-05
with O 0 1.1656844662866206e-06
onset O 1 0.9986237287521362
around O 0 5.436910214484669e-05
30 O 0 2.5817056666710414e-05
years O 0 3.896495400113054e-06
. O 0 2.048497435680474e-06

Only O 0 3.7326005895010894e-06
six O 0 7.389503480226267e-07
other O 0 1.4074793774909722e-08
cases O 0 7.185975903212238e-08
of O 0 3.928966634703102e-06
paternal O 1 0.9980133771896362
transmission O 1 1.0
of O 1 1.0
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.1486024260520935
been O 0 5.115700696478598e-05
reported O 0 9.209424206346739e-06
recently O 0 9.221306754625402e-06
. O 0 1.6510737168573542e-06

We O 0 2.8410345294105355e-06
review O 0 3.238961596707668e-07
the O 0 1.326319534200593e-07
sex O 0 2.077507303965831e-07
related O 0 4.4544938759827346e-07
effects O 0 5.788650014437735e-06
on O 0 9.292672075389419e-06
transmission O 0 0.0013628327287733555
of O 0 0.004065996035933495
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0010258244583383203

Decreased O 0 0.003267539432272315
fertility O 0 0.00018653088773135096
of O 0 2.4547939574404154e-06
males O 0 2.453969614180096e-07
with O 0 1.6857447349138965e-07
adult O 0 3.2869229471543804e-05
onset O 1 0.9999791383743286
DM B-Disease 1 1.0
and O 0 0.00019415983115322888
contraction O 0 0.014077743515372276
of O 0 2.4574792405474e-05
the O 0 4.3324589569238015e-06
repeat O 0 2.611619493109174e-06
upon O 0 2.0856853097939165e-06
male O 0 3.7468380469363183e-06
transmission O 0 1.5359407825599192e-06
contribute O 0 2.4345052196395045e-08
to O 0 1.9956599928150354e-08
the O 0 1.4975675810546818e-07
almost O 0 3.514358013489982e-07
absent O 0 6.174586815177463e-07
occurrence O 0 2.9837062243132095e-07
of O 0 6.204548412824806e-07
paternal O 0 0.0001421978959115222
transmission O 0 0.008195975795388222
of O 1 0.5379313230514526
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0019228414166718721

Also O 0 0.0002698159369174391
the O 0 6.204067904036492e-05
fathers O 0 6.342673441395164e-05
of O 0 3.332155029056594e-05
the O 0 2.5254639695049264e-05
reported O 0 7.861340418457985e-05
congenitally O 0 0.0014430233277380466
affected O 0 4.331054242356913e-06
children O 0 1.656571839703247e-06
showed O 0 1.3341305930225644e-05
, O 0 4.3546185679588234e-07
on O 0 5.1082888603559695e-06
average O 0 3.23154017678462e-05
, O 0 3.200956371074426e-06
shorter O 0 3.0658484320156276e-05
CTG O 0 0.0008641868480481207
repeat O 0 3.994916187366471e-05
lengths O 0 5.271612826618366e-05
and O 0 1.7744779370332253e-06
hence O 0 1.014865301840473e-05
less O 0 2.3293914637179114e-06
severe O 0 0.0013301684521138668
clinical O 0 0.09894741326570511
symptoms O 0 0.4285731017589569
than O 0 4.2338274397479836e-07
the O 0 4.789646368408285e-07
mothers O 0 5.776705052085163e-07
of O 0 4.1468692302260024e-07
children O 0 1.6896636907404172e-06
with O 0 2.008610863413196e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0005512532661668956

We O 0 9.64136233960744e-06
conclude O 0 8.084780347417109e-06
that O 0 4.882683697360335e-07
paternal O 0 0.0003726760915014893
transmission O 1 0.564346432685852
of O 1 0.9986441731452942
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.11678656935691833
rare O 0 1.629734288144391e-05
and O 0 4.336110919211933e-07
preferentially O 0 4.487440321554459e-07
occurs O 0 2.1453072918120597e-07
with O 0 9.884364260415168e-08
onset O 0 0.0006511412793770432
of O 0 0.0013973221648484468
DM B-Disease 1 1.0
past O 0 0.0001903786469483748
30 O 0 2.157359995180741e-05
years O 0 1.414386929354805e-06
in O 0 1.1189599717909005e-06
the O 0 1.3053140719421208e-06
father O 0 9.55036284722155e-06
. O 0 3.674987567592325e-07
. O 0 5.725881919715903e-07

The O 0 0.00042030768236145377
RB1 O 0 0.0048949518240988255
gene O 0 1.666578282311093e-05
mutation O 0 2.52887980423111e-06
in O 0 9.463068408877007e-07
a O 0 2.1918265247222735e-06
child O 0 1.013949076877907e-05
with O 0 6.178642706800019e-06
ectopic B-Disease 1 0.9999995231628418
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.00033374104532413185

The O 0 0.00045439062523655593
RB1 O 0 0.004684664774686098
gene O 0 2.313676304765977e-05
mutation O 0 6.239335561986081e-06
was O 0 1.6432524716947228e-05
investigated O 0 3.1371323530038353e-06
in O 0 7.988898573785264e-07
a O 0 3.046839310627547e-06
child O 0 1.4195113180903718e-05
with O 0 2.8041836230841e-06
ectopic B-Disease 1 0.9999847412109375
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9999940395355225
using O 0 4.557856300380081e-06
DNA O 0 2.2177684968482936e-06
obtained O 0 6.683939773211023e-06
from O 0 2.610683168313699e-06
both O 0 1.5712853382865433e-06
the O 0 1.5994128261809237e-05
pineal B-Disease 0 0.12445615231990814
and I-Disease 0 3.16136829496827e-05
retinal I-Disease 1 0.9998815059661865
tumours I-Disease 1 1.0
of O 0 7.559256482636556e-05
the O 0 1.0867077435250394e-05
patient O 0 6.159994518384337e-05
. O 0 3.5574564662965713e-06

A O 0 0.0004265563911758363
nonsense O 0 0.00021889452182222158
mutation O 0 3.961107267969055e-06
in O 0 9.99232452159049e-06
exon O 0 1.339495247520972e-05
17 O 0 4.096979682799429e-05
( O 0 1.782871095201699e-06
codon O 0 2.3745218641124666e-05
556 O 0 1.257485018868465e-05
) O 0 3.747219921024225e-07
of O 0 6.595797003683401e-06
the O 0 2.2247835659072734e-05
RB1 O 0 0.0005883100675418973
gene O 0 6.62277943774825e-06
was O 0 2.995155591634102e-05
found O 0 2.9748534302598273e-07
to O 0 6.087490334039103e-08
be O 0 1.6381672196530417e-07
present O 0 5.147692831997119e-07
homozygously O 0 1.7665706764091738e-05
in O 0 2.4461937755404506e-06
both O 0 1.8151954463974107e-06
the O 0 1.2755988791468553e-05
retinal B-Disease 0 0.0006813444197177887
and I-Disease 0 2.1989048036630265e-05
the I-Disease 0 0.00033986475318670273
pineal I-Disease 1 0.9999750852584839
tumours I-Disease 1 1.0
. O 0 3.372004721313715e-05

The O 0 3.5900924558518454e-05
same O 0 9.352434972242918e-06
mutation O 0 3.563038717402378e-06
was O 0 2.4077429770841263e-05
present O 0 2.4686098640813725e-06
heterozygously O 0 2.5690032998682e-05
in O 0 2.5213134904333856e-06
the O 0 2.374666337345843e-06
DNA O 0 1.1560373422980774e-06
from O 0 2.3405968931911048e-06
the O 0 4.329844159656204e-06
constitutional O 0 7.681854913244024e-05
cells O 0 1.2932569916301873e-05
of O 0 3.3547039492987096e-05
the O 0 2.038302227447275e-05
patient O 0 3.671155354822986e-05
, O 0 1.717567215564486e-06
proving O 0 4.170989996055141e-06
it O 0 2.0415679813368115e-08
to O 0 3.5354212002403074e-08
be O 0 1.2656531112043012e-07
of O 0 1.5470797052330454e-06
germline O 0 4.627808084478602e-05
origin O 0 3.308573923277436e-06
. O 0 1.864833279796585e-06

The O 0 6.353933713398874e-05
initial O 0 2.280215085193049e-05
mutation O 0 4.7517251005047e-06
was O 0 1.3380550626607146e-05
shown O 0 6.716962275277183e-07
to O 0 9.508746501296628e-08
have O 0 1.1222135753996554e-07
occurred O 0 4.012468707514927e-06
in O 0 7.72551459249371e-07
the O 0 2.5450367502344307e-06
paternally O 0 3.80461715394631e-05
derived O 0 3.351857958477922e-05
RB1 O 0 0.0008278432069346309
allele O 0 3.951607504859567e-05
. O 0 5.7305869631818496e-06

The O 0 0.00022738694678992033
mutation O 0 1.1465223906270694e-05
is O 0 4.464724042918533e-06
in O 0 1.4151627283354173e-06
an O 0 4.85278803807887e-07
area O 0 1.5047986607896746e-06
of O 0 5.24381084687775e-06
the O 0 4.209829057799652e-06
gene O 0 8.923886980483076e-07
that O 0 5.942754910392978e-07
encodes O 0 2.4319213025592035e-06
the O 0 1.0745555300673004e-05
protein O 0 1.0803610166476574e-05
- O 0 6.959109668969177e-06
binding O 0 1.229407007485861e-05
region O 0 2.0020474039483815e-05
known O 0 3.6548804928315803e-05
as O 0 9.956547728506848e-06
the O 0 1.4336260392155964e-05
pocket O 0 8.140528370859101e-05
region O 0 1.1424010153859854e-05
and O 0 5.669427991961129e-06
has O 0 3.350158067405573e-06
been O 0 1.981002242246177e-06
detected O 0 2.432682322250912e-06
in O 0 2.0478709927829186e-07
other O 0 2.5472502329648705e-08
cases O 0 1.3545248123136844e-07
of O 0 3.414198090467835e-06
retinoblastoma B-Disease 0 0.0006164986407384276
. O 0 2.9001901111769257e-06
. O 0 3.6314493172540097e-06

Low O 0 0.0013798453146591783
levels O 0 0.0001167458831332624
of O 0 4.3588635890046135e-05
beta O 0 0.00021925527835264802
hexosaminidase O 0 0.00023714388953521848
A O 0 8.053313649725169e-06
in O 0 1.1258835002081469e-06
healthy O 0 1.0226415270153666e-06
individuals O 0 1.2491881307141739e-08
with O 0 9.313437487890042e-08
apparent O 0 0.00047125411219894886
deficiency O 1 0.999998927116394
of O 0 0.0008039644453674555
this O 0 1.2542620424937923e-05
enzyme O 0 6.0403781390050426e-05
. O 0 3.4367124044365482e-06

Appreciable O 0 0.007155934814363718
beta O 0 0.003068163525313139
hexosaminidase O 0 0.0034149119164794683
A O 0 0.0006652836455032229
( O 0 1.4182826816977467e-05
hex O 0 9.986248915083706e-05
A O 0 2.6962152332998812e-05
) O 0 4.924176550957782e-07
activity O 0 2.5571821424819063e-06
has O 0 7.351483759521216e-07
been O 0 1.4199050610841368e-06
detected O 0 7.321375051105861e-06
in O 0 1.4665400158264674e-05
cultured O 0 0.0036620416212826967
skin O 1 0.9323031306266785
fibroblasts O 0 0.007322635967284441
and O 0 0.00012535820133052766
melanoma B-Disease 1 0.9999929666519165
tissue O 1 0.9501933455467224
from O 0 9.731613317853771e-06
healthy O 0 2.4341975404240657e-06
individuals O 0 4.1940459993838886e-08
previously O 0 1.8674314787858748e-06
reported O 0 3.4659667562664254e-06
as O 0 4.786034878634382e-06
having O 0 4.9839563871501014e-05
deficiency B-Disease 1 0.999154806137085
of I-Disease 0 0.0003005389589816332
hex I-Disease 0 0.0002652255352586508
A I-Disease 0 8.206928214349318e-06
activity O 0 1.5145889165069093e-06
indistinguishable O 0 3.327317301682342e-07
from O 0 1.0621577395397708e-08
that O 0 6.482936965035435e-10
of O 0 3.310298524183963e-08
patients O 0 4.1483960444566037e-07
with O 0 3.238385716031189e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.0005005290731787682
TSD B-Disease 1 0.9999551773071289
) O 0 7.932528205856215e-06
. O 0 2.8440545065677725e-06

Identification O 0 5.590512591879815e-05
and O 0 2.5301600544480607e-05
quantitation O 0 0.002089220564812422
of O 0 0.0010260565904900432
hex O 0 0.0008923829300329089
A O 0 6.78241704008542e-05
, O 0 8.401663649237889e-07
amounting O 0 5.761713055107975e-06
to O 0 4.481551343360479e-07
3 O 0 1.9247238014941104e-05
. O 0 2.7640392090688692e-06

5 O 0 0.0002695955627132207
% O 0 2.900176332332194e-05
- O 0 4.0013361285673454e-05
6 O 0 6.179451884236187e-05
. O 0 3.534845291142119e-06

9 O 0 0.00016871449770405889
% O 0 4.2707447391876485e-06
of O 0 1.1780754903156776e-05
total O 0 6.859390850877389e-05
beta O 0 0.00018186355009675026
hexosaminidase O 0 0.0002493090578354895
activity O 0 3.2833515433594584e-05
, O 0 4.965523885402945e-07
has O 0 1.4746888155059423e-07
been O 0 1.535303795208165e-07
obtained O 0 1.1074330359406304e-06
by O 0 8.409383553953376e-07
cellulose O 0 6.456424307543784e-05
acetate O 0 2.504425538063515e-05
gel O 0 3.723603003891185e-05
electrophoresis O 0 4.392789560370147e-05
, O 0 5.885704467800679e-06
DEAE O 0 0.00017837890482041985
- O 0 2.925780790974386e-05
cellulose O 0 3.511003524181433e-05
ion O 0 4.108365101274103e-05
- O 0 1.7352580471197143e-05
exchange O 0 5.5734144552843645e-05
chromatography O 0 0.00020142125140409917
, O 0 2.344336280657444e-06
radial O 0 7.09699816070497e-05
immunodiffusion O 0 0.0001689379569143057
, O 0 2.2398060082196025e-06
and O 0 2.1784414911962813e-06
radioimmunoassay O 0 0.00040564723894931376
. O 0 8.862822141963989e-06

Previous O 0 0.0015574553981423378
family O 0 3.675457264762372e-05
studies O 0 1.4810940228926484e-05
suggested O 0 3.5601378840510733e-06
that O 0 1.306584067606309e-07
these O 0 6.366373384025792e-08
individuals O 0 8.412835228455151e-08
may O 0 1.2714335753116757e-06
be O 0 4.531585489075951e-07
compound O 0 7.04789954397711e-06
heterozygotes O 0 3.097737589996541e-06
for O 0 1.3626016936996166e-07
the O 0 5.276772299112054e-07
common O 0 1.7652654378252919e-06
mutant O 0 4.584527778206393e-05
TSD B-Disease 0 0.0007905297679826617
gene O 0 3.582131739676697e-06
and O 0 5.437082677417493e-07
a O 0 1.7999278725255863e-06
rare O 0 4.13533143728273e-06
( O 0 9.580435289535671e-07
allelic O 0 9.773541023605503e-06
) O 0 3.9993398104343214e-07
mutant O 0 7.238625130412402e-06
gene O 0 7.015951268840581e-06
. O 0 1.6135803662109538e-06

Thus O 0 9.116878936765715e-05
, O 0 3.5009682051168056e-06
the O 0 2.110475861627492e-06
postulated O 0 1.0896841558860615e-05
rate O 0 7.1658810156804975e-06
mutant O 0 4.7989783524826635e-06
gene O 0 8.016747869987739e-07
appears O 0 3.3349641626045923e-07
to O 0 1.9398056494424054e-08
code O 0 5.784191614566225e-08
for O 0 6.286696674351333e-08
the O 0 3.564366863884061e-07
expression O 0 1.1625360230027582e-06
of O 0 2.256116204080172e-06
low O 0 7.216451649583178e-06
amounts O 0 1.3384675412453362e-06
of O 0 2.3737973606330343e-05
hex O 0 0.0002784525277093053
A O 0 6.041080996510573e-05
. O 0 4.8580568545730785e-06

Heterozygotes O 0 0.0038549096789211035
for O 0 3.8915557524887845e-05
the O 0 2.1184803699725308e-05
rare O 0 3.2240539439953864e-05
mutant O 0 5.238078665570356e-05
may O 0 4.592950517690042e-06
be O 0 3.344525794091169e-07
indistinguishable O 0 9.79142214418971e-07
from O 0 1.0829565155745513e-07
heterozygotes O 0 9.883927987175412e-07
for O 0 1.238172444573138e-07
the O 0 9.332497370451165e-07
common O 0 6.042570021236315e-06
TSD B-Disease 0 0.0011435823980718851
mutant O 0 8.31980723887682e-05
. O 0 9.079340088646859e-06

However O 0 1.6600526578258723e-05
, O 0 1.5081935771377175e-06
direct O 0 2.797725073833135e-06
visualization O 0 0.00010320470755686983
and O 0 5.7850793382385746e-06
quantitation O 0 0.0007220542174763978
of O 0 0.0004380954778753221
hex O 0 0.000290445372229442
A O 0 7.131099209800595e-06
by O 0 7.450387329299701e-08
the O 0 2.934951055522106e-07
methods O 0 8.677194500705809e-07
described O 0 1.3004173524677753e-06
may O 0 8.912863904697588e-07
prevent O 0 3.867257589718065e-07
false O 0 7.554920671282161e-07
- O 0 2.614562390590436e-06
positive O 0 1.1976557061643689e-06
prenatal O 0 0.0015453698579221964
diagnosis O 0 0.10583988577127457
of O 0 0.0010507450206205249
TSD B-Disease 1 0.9885208606719971
in O 0 8.85833433130756e-05
fetuses O 0 3.731512333615683e-05
having O 0 1.7884364069686853e-06
the O 0 2.3160855562309735e-06
incomplete O 0 1.2365018847049214e-05
hex B-Disease 0 9.757284715306014e-05
A I-Disease 0 5.5570315453223884e-05
deficiency I-Disease 0 0.024657849222421646
of O 0 0.00010160028614336625
the O 0 2.8044620194123127e-05
type O 0 9.426104952581227e-05
described O 0 1.3072713954898063e-05
in O 0 4.0708350752538536e-06
the O 0 6.408767148968764e-06
four O 0 4.87436045659706e-06
healthy O 0 1.8121572793461382e-05
individuals O 0 5.056596819486003e-06

The O 0 0.0005671657272614539
tumor B-Disease 1 0.9750142097473145
suppressor O 0 0.47296565771102905
gene O 0 0.00024222684442065656
Smad4 O 0 0.00269175018183887
/ O 0 0.0003712247416842729
Dpc4 O 0 0.0005343988887034357
is O 0 1.523847004136769e-06
required O 0 9.046599984685599e-07
for O 0 2.094577212119475e-06
gastrulation O 0 7.887562969699502e-05
and O 0 2.128276491930592e-06
later O 0 7.4142626544926316e-06
for O 0 2.340898163311067e-06
anterior O 0 0.0001356454158667475
development O 0 1.9823835827992298e-05
of O 0 2.1396903321146965e-05
the O 0 2.469703213137109e-05
mouse O 0 3.334796929266304e-05
embryo O 0 1.5577998055960052e-05
. O 0 2.3910852178232744e-06

Mutations O 0 7.560887024737895e-05
in O 0 2.8926988306920975e-05
the O 0 6.523076444864273e-05
SMAD4 O 0 0.017705047503113747
/ O 0 0.003130197525024414
DPC4 O 0 0.017747409641742706
tumor B-Disease 0 0.20170508325099945
suppressor O 0 0.0017657502321526408
gene O 0 3.407243639230728e-06
, O 0 5.439473511614779e-07
a O 0 2.7585381303651957e-06
key O 0 2.619621045596432e-05
signal O 0 4.3257070501567796e-05
transducer O 0 4.885652379016392e-05
in O 0 1.784956293704454e-05
most O 0 1.4012553947395645e-05
TGFbeta O 0 0.0011016479693353176
- O 0 0.00027661112835630774
related O 0 9.141741611529142e-05
pathways O 0 1.8140022802981548e-05
, O 0 4.86042992520197e-08
are O 0 2.9256426170576333e-09
involved O 0 7.39181338360595e-09
in O 0 7.581569150261203e-08
50 O 0 1.275155455005006e-06
% O 0 2.0831171241297852e-06
of O 0 0.00010869149264181033
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.00021585430658888072

Homozygous O 0 0.0020586007740348577
Smad4 O 0 0.0074193356558680534
mutant O 0 0.000591195363085717
mice O 0 0.00014791262219659984
die O 0 5.7548713812138885e-05
before O 0 3.3306969271507114e-06
day O 0 5.652766958519351e-06
7 O 0 1.0706010471039917e-05
. O 0 1.2736459211737383e-06

5 O 0 0.00018155584984924644
of O 0 8.512314525432885e-05
embryogenesis O 0 0.0006772642373107374
. O 0 1.8732836906565353e-05

Mutant O 0 0.0003402219736017287
embryos O 0 1.980741581064649e-05
have O 0 2.158806637453381e-06
reduced O 0 4.510417056735605e-06
size O 0 2.144784502888797e-06
, O 0 1.5780008197907591e-06
fail O 0 2.1601638309221016e-06
to O 0 6.984621450101258e-07
gastrulate O 0 0.0001159416715381667
or O 0 4.703219474322395e-06
express O 0 1.3098393765176297e-06
a O 0 3.2936202387645608e-06
mesodermal O 0 7.920803182059899e-05
marker O 0 3.019130053871777e-05
, O 0 1.880562336964431e-07
and O 0 1.6204693054078234e-07
show O 0 3.4605004657350946e-06
abnormal O 0 0.0012672552838921547
visceral O 0 0.0044181616976857185
endoderm O 0 0.0053161922842264175
development O 0 5.3741248848382384e-05
. O 0 2.9818563689332223e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 0.11409732699394226
the O 0 0.001502595143392682
Smad4 O 0 0.11229958385229111
- O 0 0.005420975387096405
deficient O 0 0.000759769813157618
embryos O 0 3.13712962451973e-06
results O 0 3.6089807053940604e-06
from O 0 6.429021368603571e-07
reduced O 0 4.7582002480339725e-06
cell O 0 2.282286004628986e-05
proliferation O 0 9.910669177770615e-06
rather O 0 1.2772083834988734e-07
than O 0 5.0433872189614704e-08
increased O 0 3.1075462629814865e-06
apoptosis O 0 0.00010373583063483238
. O 0 2.3202085230877856e-06

Aggregation O 0 0.00042833315092138946
of O 0 0.00028766421019099653
mutant O 0 0.0010152115719392896
Smad4 O 0 0.005241553299129009
ES O 0 0.00229412573389709
cells O 0 5.064598553872202e-06
with O 0 1.8225610176614282e-07
wild O 0 2.5076858491956955e-06
- O 0 5.46506362297805e-06
type O 0 1.2525324564194307e-05
tetraploid O 0 0.00019714066002052277
morulae O 0 0.0006018795538693666
rescues O 0 0.00016330282960552722
the O 0 5.9170557506149635e-05
gastrulation B-Disease 0 0.005018935073167086
defect I-Disease 0 0.0007252320647239685
. O 0 9.147242053586524e-06

These O 0 3.405510142329149e-05
results O 0 0.00013918675540480763
indicate O 0 2.122788100678008e-05
that O 0 1.225648134095536e-06
Smad4 O 0 4.1944163967855275e-05
is O 0 2.661100211298617e-07
initially O 0 9.587419924628193e-08
required O 0 4.718354063015795e-08
for O 0 1.0651933024519167e-07
the O 0 5.252046548775979e-07
differentiation O 0 2.5954852844733978e-06
of O 0 1.3572946045314893e-05
the O 0 1.7339167243335396e-05
visceral O 0 0.00017917604418471456
endoderm O 0 0.00014399764768313617
and O 0 1.6812811054478516e-06
that O 0 3.460651498699008e-07
the O 0 5.453385711007286e-06
gastrulation B-Disease 0 0.00028748903423547745
defect I-Disease 0 5.181481537874788e-05
in O 0 1.0197004485235084e-05
the O 0 1.5685300240875222e-05
epiblast O 0 0.000451368949143216
is O 0 4.74955004392541e-06
secondary O 0 2.6926973077934235e-05
and O 0 3.935544100386323e-06
non O 0 0.00037603836972266436
- O 0 0.00029166467720642686
cell O 0 0.0004409656976349652
autonomous O 0 9.108910307986662e-05
. O 0 4.773795353685273e-06

Rescued O 0 0.002119421260431409
embryos O 0 0.0001300335570704192
show O 0 0.00027843363932333887
severe O 1 0.9915566444396973
anterior O 1 0.9966866374015808
truncations O 1 0.998350977897644
, O 0 1.8699565771385096e-05
indicating O 0 4.007462121080607e-05
a O 0 3.899302100762725e-06
second O 0 3.7390207126009045e-06
important O 0 1.0805017609527567e-06
role O 0 8.84796645550523e-06
for O 0 7.356277365033748e-06
Smad4 O 0 0.0009873276576399803
in O 0 6.600139749934897e-05
anterior O 0 0.013312965631484985
patterning O 0 0.014082449488341808
during O 0 0.0038378597237169743
embryogenesis O 0 0.00046703097177669406
. O 0 7.345397534663789e-06

Prevalence O 0 0.0013650417095050216
of O 0 0.00021896237740293145
p16 O 0 0.0005277381860651076
and O 0 4.903146327706054e-05
CDK4 O 0 0.006689219269901514
germline O 0 0.00059296446852386
mutations O 0 1.3907261745771393e-05
in O 0 6.80278244544752e-05
48 O 0 0.0007379434537142515
melanoma B-Disease 1 0.9995502829551697
- O 0 0.004607037175446749
prone O 0 0.00015603473002556711
families O 0 3.7225152027531294e-07
in O 0 1.7515063746031956e-06
France O 0 9.026971383718774e-05
. O 0 1.150625575974118e-05

The O 0 4.4678981794277206e-05
French O 0 0.0010208503808826208
Familial B-Disease 1 0.999975323677063
Melanoma I-Disease 1 1.0
Study O 0 0.0003293743066024035
Group O 0 1.428080395271536e-05
. O 0 2.3942591269587865e-06

Germline O 0 0.008048107847571373
mutations O 0 9.509872324997559e-05
in O 0 4.541952148429118e-05
the O 0 4.1584953578421846e-05
p16 O 0 0.00011639208241831511
and O 0 1.257663552678423e-05
CDK4 O 0 0.0003637218032963574
genes O 0 2.9521183932956774e-06
have O 0 7.533847679042083e-07
been O 0 1.0605018587739323e-06
reported O 0 4.4886169803248777e-07
in O 0 6.771244329684123e-07
a O 0 3.960363301303005e-06
subset O 0 5.261658952804282e-05
of O 0 0.00012511028035078198
melanoma B-Disease 1 0.9999457597732544
pedigrees O 0 0.0006873078527860343
, O 0 2.848451686077169e-06
but O 0 1.0254576210400046e-07
their O 0 6.396497553851077e-08
prevalence O 0 1.2931780474900734e-05
is O 0 4.6476264969896874e-07
not O 0 1.7278914299367898e-07
well O 0 9.474473472437239e-07
known O 0 5.0516659939603414e-06
. O 0 1.6814269656606484e-06

We O 0 1.2782145859091543e-05
searched O 0 1.067824359779479e-05
for O 0 4.905180048808688e-07
such O 0 5.380158540901903e-07
germline O 0 2.653357296367176e-05
mutations O 0 1.945020585480961e-06
in O 0 1.1665446436381899e-05
48 O 0 0.0002030401665251702
French O 1 0.7194919586181641
melanoma B-Disease 1 0.9999998807907104
- O 0 0.08876761794090271
prone O 0 0.00032875407487154007
families O 0 3.516473441322887e-07
selected O 0 4.241275348704221e-07
according O 0 1.6340605668574426e-07
to O 0 6.909578331715238e-08
two O 0 4.579531207582477e-07
major O 0 1.0756566553027369e-05
criteria O 0 7.280295903910883e-06
families O 0 3.0982081966612895e-07
with O 0 3.7833510191376263e-07
at O 0 4.266552423359826e-05
least O 0 9.838016694629914e-07
three O 0 9.398393672199745e-07
affected O 0 2.0290096927055856e-06
members O 0 6.965922239032807e-07
( O 0 1.0857771712835529e-06
n O 0 2.717340612434782e-05
= O 0 2.9579197871498764e-05
20 O 0 1.605003490112722e-05
) O 0 7.380094757536426e-07
or O 0 6.583138087989937e-07
families O 0 1.2391387826937716e-07
with O 0 1.6465436658563704e-07
two O 0 2.4980329271784285e-06
affected O 0 8.992848961497657e-06
members O 0 7.809427415850223e-07
, O 0 3.338050760248734e-07
one O 0 1.6963272742032132e-07
of O 0 9.111807912631775e-07
them O 0 4.466242486955707e-08
affected O 0 2.5459246444370365e-07
before O 0 1.1494709042381146e-06
the O 0 7.262697749865765e-07
age O 0 2.046677309408551e-06
of O 0 6.890389613545267e-06
50 O 0 7.036522220005281e-06
( O 0 1.0748482281996985e-06
n O 0 2.1816369553562254e-05
= O 0 2.0611663785530254e-05
28 O 0 2.2795669792685658e-05
) O 0 2.705908173084026e-07
, O 0 6.331497814926479e-08
and O 0 2.6871143532503083e-08
one O 0 5.3091582685738103e-08
additional O 0 1.625806618221759e-07
minor O 0 4.686452666646801e-05
criterion O 0 0.0012090851087123156
. O 0 7.256955541379284e-06

Sixteen O 0 0.00023921747924759984
different O 0 8.310893463203683e-06
p16 O 0 0.00021874620870221406
germline O 0 7.429144170600921e-05
mutations O 0 1.1428174957472947e-06
were O 0 1.28981878333434e-06
found O 0 1.2923746339765785e-07
in O 0 2.3836508944441448e-07
21 O 0 5.944528766121948e-06
families O 0 1.2888838796243363e-07
, O 0 3.3338986327180464e-07
while O 0 9.850288051893585e-07
one O 0 2.6544014417595463e-06
germline O 0 0.0001030197599902749
mutation O 0 7.921801625343505e-06
, O 0 3.4112820230802754e-06
Arg24His O 0 9.525091445539147e-05
, O 0 1.0805770216393284e-06
was O 0 4.224646090733586e-06
detected O 0 2.403387043159455e-06
in O 0 1.5088523923623143e-06
the O 0 5.844230599905131e-06
CDK4 O 0 0.0016372536774724722
gene O 0 2.977782605739776e-05
. O 0 4.440795237314887e-06

The O 0 1.1090997759310994e-05
frequency O 0 1.2650640201172791e-05
of O 0 2.0196379409753717e-05
p16 O 0 5.227394649409689e-05
gene O 0 3.001603317898116e-06
mutation O 0 7.482600494768121e-07
in O 0 1.9221624825149775e-06
our O 0 9.166603831545217e-07
sample O 0 6.972648520786606e-07
( O 0 5.491816637004376e-07
44 O 0 5.685806627298007e-06
% O 0 1.360922851745272e-06
) O 0 2.0961867619462282e-07
is O 0 2.0456340621421987e-07
among O 0 1.4098269218720816e-07
the O 0 7.907851795607712e-07
highest O 0 2.3018623323878273e-05
rates O 0 1.8461015542925452e-06
yet O 0 3.0812950058134447e-07
reported O 0 1.3999900829730905e-06
and O 0 4.830854436477239e-07
the O 0 3.404781637073029e-06
CDK4 O 0 0.00013449348625726998
mutation O 0 7.972009825607529e-07
is O 0 2.2968163193581859e-07
the O 0 2.445568441089563e-07
second O 0 4.573870455715223e-07
mutation O 0 1.7641501415255334e-07
detected O 0 7.961297114889021e-07
in O 0 1.5383024276616197e-07
this O 0 1.0375116943350804e-07
gene O 0 1.2011169019388035e-06
worldwide O 0 4.428416104929056e-06
. O 0 2.367688011872815e-06

In O 0 0.00029026903212070465
summary O 0 0.000682599435094744
, O 0 2.1447049221023917e-06
our O 0 4.914413693768438e-07
results O 0 5.135605647410557e-07
show O 0 1.8015506952906435e-07
frequent O 0 1.8023310133230552e-07
involvement O 0 1.3869932899979176e-06
of O 0 5.089058049634332e-06
the O 0 4.12734925703262e-06
p16 O 0 6.845876487204805e-05
gene O 0 4.888670446234755e-06
in O 0 2.468339289407595e-06
familial B-Disease 0 0.0001356262800982222
melanoma I-Disease 0 0.3419003486633301
and O 0 1.1153683772135992e-06
confirm O 0 4.384584428862581e-07
the O 0 1.3772682905255351e-06
role O 0 4.679234734794591e-06
of O 0 4.4835458538727835e-05
the O 0 6.784487777622417e-05
CDK4 O 0 0.15137451887130737
gene O 0 3.2934050977928564e-05
as O 0 1.0439225661684759e-05
a O 0 2.5045688744285144e-05
melanoma B-Disease 0 0.05831977725028992
- O 0 0.0001721071603242308
predisposing O 0 0.00021039701823610812
gene O 0 8.501896445523016e-06
. O 0 4.910407938041317e-07
. O 0 1.1141469258291181e-06

Progression O 0 0.019821643829345703
of O 0 0.00041570368921384215
somatic O 0 0.0006026022019796073
CTG O 0 0.0005895304493606091
repeat O 0 2.643508423716412e-06
length O 0 4.861691422775039e-07
heterogeneity O 0 2.3418874661729205e-06
in O 0 3.8656315837215516e-07
the O 0 6.733097848155012e-07
blood O 0 1.3564029359258711e-05
cells O 0 2.2832784452475607e-05
of O 0 0.0004940926446579397
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0004669624613597989
. O 0 4.319586878409609e-06

The O 0 2.5726703825057484e-06
genetic O 0 3.929498234356288e-06
basis O 0 2.1235737222013995e-05
of O 0 0.009632800705730915
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00041666225297376513
DM B-Disease 1 1.0
) O 0 3.475731318758335e-06
is O 0 8.815109708848468e-07
the O 0 9.506178457741044e-07
expansion O 0 5.3719431889476255e-06
of O 0 1.1423955584177747e-05
an O 0 6.866302555863513e-06
unstable O 0 7.404149801004678e-05
CTG O 0 8.265496580861509e-05
repeat O 0 2.2353972326527582e-06
in O 0 5.263543698674766e-07
the O 0 1.2253489103386528e-06
34 O 0 6.003190719638951e-06
UTR O 0 4.934301250614226e-05
of O 0 1.537743810331449e-05
the O 0 4.946913759340532e-05
DM B-Disease 1 0.9995414018630981
protein O 0 0.00010272194049321115
kinase O 0 3.440828368184157e-05
gene O 0 2.9318082397367107e-06
on O 0 1.1209572221559938e-05
chromosome O 0 0.00010745996405603364
19 O 0 0.00010272605868522078
. O 0 3.105984887952218e-06

One O 0 3.8128728192532435e-05
of O 0 2.9662020097021013e-05
the O 0 1.3192455298849382e-05
principal O 0 6.907268107170239e-05
features O 0 2.9467796593962703e-06
of O 0 3.772872514673509e-05
the O 0 0.0001863959478214383
DM B-Disease 1 1.0
mutation O 0 2.468591628712602e-05
is O 0 3.0604276162193855e-06
an O 0 4.0226538544629875e-07
extraordinarily O 0 1.1424021977290977e-05
high O 0 6.102141924202442e-05
level O 0 0.0001491409493610263
of O 0 0.00019540787616278976
somatic O 0 0.0012602221686393023
mosaicism O 0 0.045805804431438446
, O 0 2.845551762220566e-06
due O 0 7.608319265273167e-06
to O 0 1.7067091562239511e-07
an O 0 2.5527955926918366e-07
extremely O 0 1.2041733725709491e-06
high O 0 1.1871316928591114e-05
degree O 0 8.787871047388762e-05
of O 0 8.064945723162964e-05
somatic O 0 0.0001532525784568861
instability O 0 3.578682299121283e-05
both O 0 6.418184170797758e-07
within O 0 3.0325372790684924e-07
and O 0 9.065836792387927e-08
between O 0 7.477671601918701e-07
different O 0 4.207675772249786e-07
tissues O 0 2.213828884123359e-05
. O 0 2.6146346954192268e-06

This O 0 0.0001775755372364074
instability O 0 0.0006335270591080189
appears O 0 1.969926779565867e-05
to O 0 6.218053840711946e-07
be O 0 3.8231468124649837e-07
biased O 0 5.693244133908593e-07
towards O 0 5.944614258623915e-07
further O 0 9.673495782180908e-08
expansion O 0 9.213888461090392e-07
and O 0 2.6632329763742746e-07
continuous O 0 5.695836080121808e-06
throughout O 0 1.4165318589220988e-06
the O 0 3.2762338832981186e-06
life O 0 3.193772499798797e-06
of O 0 8.373535820282996e-06
an O 0 2.1605428628390655e-06
individual O 0 5.686418376171787e-07
, O 0 4.977742378287076e-07
features O 0 2.810604655678617e-07
that O 0 5.645869904924439e-08
could O 0 6.88005457050167e-08
be O 0 9.361684760733624e-08
associated O 0 1.8174927163272514e-07
with O 0 4.0778534327046145e-08
the O 0 1.1559459380805492e-06
progressive O 0 2.0401708752615377e-05
nature O 0 1.249280785486917e-06
of O 0 5.792841420770856e-06
the O 0 2.1858688342035748e-05
disease O 0 0.0027287716511636972
. O 0 8.187555977201555e-06

Although O 0 1.8716247723205015e-05
increasing O 0 1.1876469216076657e-05
measured O 0 6.384496373357251e-05
allele O 0 5.35763820153079e-06
size O 0 1.7237058500541025e-06
between O 0 1.7676576362646301e-06
patients O 0 2.2036349491827423e-06
clearly O 0 6.491270028163854e-07
correlates O 0 6.557628466907772e-07
with O 0 1.9482486735000748e-08
an O 0 5.967971361542368e-08
increased O 0 1.0064223943118122e-06
severity O 0 1.929205609485507e-05
of O 0 4.67903955723159e-05
symptoms O 0 0.0015663316007703543
and O 0 1.967528987734113e-06
an O 0 7.034959708107635e-07
earlier O 0 2.0609916191460798e-06
age O 0 3.7728946153947618e-06
of O 0 6.252505954762455e-06
onset O 0 0.0007744038011878729
, O 0 1.0963634622385143e-06
this O 0 1.2732363074974273e-07
correlation O 0 2.4731436951697106e-06
is O 0 4.743855583910772e-07
not O 0 1.076752909057177e-07
precise O 0 1.2747311757266289e-06
and O 0 2.0264358226995682e-06
measured O 0 3.4841999877244234e-05
allele O 0 9.057183888216969e-06
length O 0 7.235650173242902e-06
cannot O 0 3.540020315995207e-06
be O 0 7.66670325447194e-07
used O 0 2.7436175287220976e-07
as O 0 6.634909510694342e-08
an O 0 1.3646702434755298e-08
accurate O 0 3.885942305714707e-07
predictor O 0 1.2379436157061718e-05
of O 0 2.0860593394900206e-06
age O 0 1.7231997844646685e-05
of O 0 5.100945054437034e-05
onset O 1 0.9996329545974731
. O 0 5.773792145191692e-05

In O 0 9.888944987324066e-06
order O 0 7.11177847279032e-07
to O 0 7.586734085407443e-08
further O 0 2.4241310825345863e-07
characterize O 0 2.943173285530065e-06
the O 0 5.03406454299693e-06
dynamics O 0 5.432639591163024e-05
of O 0 0.00044983590487390757
DM B-Disease 1 1.0
CTG O 1 0.9909750819206238
repeat O 0 0.0020111603662371635
somatic O 0 0.0010457808384671807
instability O 0 0.00017097512318287045
, O 0 9.578808430887875e-07
we O 0 1.4896960465193843e-07
have O 0 4.5853784769178674e-08
studied O 0 8.210507758121821e-07
repeat O 0 2.7614336772785464e-07
length O 0 2.3517590364008356e-07
changes O 0 5.37606652528666e-08
over O 0 6.534063601293383e-08
time O 0 1.5284186360986496e-07
in O 0 2.159830046366551e-06
111 O 0 0.0030409866012632847
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.189234467346978e-06
with O 0 2.8561222720213664e-08
varying O 0 2.1401731373771327e-06
clinical O 0 0.0014112788485363126
severity O 0 0.005598368123173714
and O 0 8.499935938743874e-05
CTG O 0 0.0010660081170499325
repeat O 0 1.0692154319258407e-05
size O 0 1.1300647884127102e-06
over O 0 1.1750365729312762e-06
time O 0 5.993501872580964e-07
intervals O 0 1.1729015341188642e-06
of O 0 3.8040129766159225e-06
1 O 0 9.847846740740351e-06
- O 0 3.846028448606376e-06
7 O 0 7.158374501159415e-06
years O 0 2.6311388410249492e-06
. O 0 1.336587388323096e-06

We O 0 5.2769846661249176e-05
have O 0 9.256683597413939e-07
found O 0 5.180685320738121e-07
a O 0 2.9081311936351995e-07
direct O 0 1.058940370057826e-06
progression O 0 5.139459972269833e-05
of O 0 8.564196832594462e-06
the O 0 2.3809886897652177e-06
size O 0 8.884688327270851e-07
heterogeneity O 0 4.019117113784887e-06
over O 0 1.7800813338908483e-06
time O 0 1.0710846254369244e-06
related O 0 1.5727215441074804e-06
to O 0 5.066034987066814e-07
initial O 0 1.728761890262831e-05
CTG O 0 0.00033675014856271446
repeat O 0 1.4345095223688986e-05
size O 0 4.35044876212487e-06
and O 0 1.2737601764456485e-06
the O 0 1.512507537881902e-06
time O 0 4.995728204448824e-07
interval O 0 5.040420091972919e-06
and O 0 3.0586951993427647e-07
always O 0 2.3092738388186262e-07
biased O 0 3.4312918728574004e-07
towards O 0 2.817643860453245e-07
further O 0 1.317897044827987e-07
expansion O 0 5.527263965632301e-06
. O 0 1.876446845017199e-06

Attempts O 0 9.53494236455299e-05
to O 0 7.063402790663531e-06
mathematically O 0 4.229840851621702e-05
model O 0 2.7621454137261026e-05
the O 0 8.98697635420831e-06
dynamics O 0 2.100199526466895e-05
have O 0 1.006045181384252e-06
proved O 0 5.306118055159459e-06
only O 0 2.709549278279155e-07
partially O 0 3.0999838145362446e-06
successful O 0 2.501926132936205e-07
suggesting O 0 1.1816526779284686e-07
that O 0 3.6077905107845254e-09
individual O 0 9.62571178320104e-09
specific O 0 9.943304490889204e-08
genetic O 0 4.656255896406947e-06
and O 0 2.102419784932863e-05
/ O 0 0.002009000163525343
or O 0 1.5326309949159622e-05
environmental O 0 1.6872540072654374e-05
factors O 0 3.133977770630736e-06
also O 0 1.2325309626248782e-06
play O 0 1.1970893183388398e-06
a O 0 9.935708931152476e-07
role O 0 2.306452870470821e-06
in O 0 6.135391686257208e-06
somatic O 0 4.959090438205749e-05
mosaicism O 0 0.00027844321448355913
. O 0 7.265233534781146e-07
. O 0 1.1231552434765035e-06

Aspartylglucosaminuria B-Disease 1 0.9999978542327881
among O 0 2.03709914785577e-05
Palestinian O 0 0.00013502083311323076
Arabs O 0 3.830932837445289e-05
. O 0 5.118070930620888e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9948853850364685
AGU B-Disease 1 1.0
) O 0 7.808317604940385e-06
is O 0 4.741919497064373e-07
a O 0 6.947670954104979e-07
rare O 0 1.5137951777433045e-05
disorder B-Disease 1 0.9999972581863403
of I-Disease 1 0.9970445036888123
glycoprotein I-Disease 1 0.9999997615814209
metabolism I-Disease 1 0.9999992847442627
caused O 0 0.000379219331080094
by O 0 3.899484681824106e-07
the O 0 6.048202976671746e-06
deficiency B-Disease 1 0.9998288154602051
of I-Disease 0 0.0003033326647710055
the I-Disease 0 0.0005261346814222634
lysosomal I-Disease 1 0.9998297691345215
enzyme I-Disease 0 0.0004926804103888571
aspartylglucosaminidase I-Disease 0 0.003511900082230568
( O 0 1.203443571284879e-05
AGA O 0 0.0013238750398159027
) O 0 2.2360325147019466e-06
. O 0 1.631284021641477e-06

AGU B-Disease 1 1.0
is O 0 0.0005972536746412516
inherited O 0 0.17434024810791016
as O 0 1.8540886230766773e-05
an O 0 6.4385953919554595e-06
autosomal O 1 0.9994456171989441
recessive O 1 0.9970188140869141
trait O 0 0.0004652128554880619
and O 0 1.1869256923091598e-05
occurs O 0 2.1970583929942222e-06
with O 0 1.3608472215764778e-07
a O 0 3.102115897490876e-06
high O 0 0.00010921492503257468
frequency O 0 1.111325400415808e-05
in O 0 4.056593297718791e-06
Finland O 0 7.4601516644179355e-06
because O 0 6.087897190809599e-07
of O 0 8.980336133390665e-06
a O 0 1.6398835214204155e-05
founder O 0 5.970431448076852e-05
effect O 0 6.270898211369058e-06
. O 0 1.4298587984740152e-06

While O 0 0.00013494849554263055
very O 0 8.867345059115905e-06
few O 0 4.648726189770969e-06
patients O 0 6.642685093538603e-06
with O 0 6.202399163157679e-06
AGU B-Disease 1 0.9999997615814209
have O 0 5.312933808454545e-06
been O 0 4.1288844840892125e-06
reported O 0 2.5334204565297114e-06
from O 0 1.2663691677516908e-06
non O 0 1.3079546988592483e-05
- O 0 7.095599357853644e-06
Finnish O 0 0.00011232692486373708
origin O 0 6.72244868837879e-06
, O 0 1.7758796957423328e-06
we O 0 1.1509529258546536e-06
diagnosed O 0 0.0013499363558366895
the O 0 8.400002116104588e-06
disorder O 0 0.013989766128361225
in O 0 6.5274571170448326e-06
8 O 0 2.229817800980527e-05
patients O 0 7.091866791597567e-07
originating O 0 1.6856527054187609e-06
from O 0 1.9718286239367444e-06
3 O 0 1.276786770176841e-05
unrelated O 0 3.4587551454023924e-06
families O 0 2.598789308194682e-07
, O 0 2.004186256954199e-07
all O 0 1.3989421177029726e-07
Palestinian O 0 6.1949158407514915e-06
Arabs O 0 2.1033608845755225e-06
from O 0 1.0699055792429135e-06
the O 0 4.1187908550455177e-07
region O 0 3.2599473342997953e-07
of O 0 1.9002812905455357e-06
Jerusalem O 0 0.0001299448194913566
. O 0 5.70306519875885e-06

The O 0 8.592269296059385e-05
clinical O 1 0.9526245594024658
diagnosis O 1 0.9999995231628418
of O 1 0.9999988079071045
AGU B-Disease 1 1.0
is O 0 0.0002801901428028941
often O 0 4.051026280649239e-06
difficult O 0 1.3539336123358225e-06
, O 0 1.9355303493284737e-07
in O 0 1.7043799971361295e-07
particular O 0 1.6068990760231827e-07
early O 0 1.8138960058422526e-06
in O 0 1.2418815913406434e-06
the O 0 2.5714193725434598e-06
course O 0 8.175540642696433e-06
of O 0 1.791988506738562e-05
the O 0 3.171671778545715e-05
disease O 0 0.0002400717930868268
, O 0 1.3045138302913983e-06
and O 0 4.1317031218568445e-07
most O 0 2.7216643161409593e-07
of O 0 3.458049150140141e-06
the O 0 6.9786683525308035e-06
patients O 0 7.712059414188843e-06
are O 0 9.325423775408126e-07
diagnosed O 0 0.00023115200747270137
after O 0 7.25238260201877e-06
the O 0 8.9756599663815e-07
age O 0 1.41277996590361e-06
of O 0 2.218678218923742e-06
5 O 0 7.322645615204237e-06
years O 0 6.174319423735142e-06
. O 0 2.7789592422777787e-06

However O 0 0.00012182117643533275
, O 0 5.781605068477802e-06
since O 0 2.1198416106926743e-06
these O 0 9.155013458439498e-08
patients O 0 3.820212839400483e-07
excrete O 0 1.6142391814355506e-06
early O 0 7.519720952586795e-07
large O 0 2.6354607030043553e-07
amounts O 0 6.787576012357022e-07
of O 0 1.679255183262285e-05
aspartylglucosamine O 0 0.00016847463848534971
in O 0 2.0646742996177636e-05
urine O 0 1.7216496416949667e-05
, O 0 4.369485964161868e-07
biochemical O 0 4.030263426102465e-06
screening O 0 2.049923978120205e-06
is O 0 4.208550592466054e-07
easy O 0 3.20134887488166e-07
by O 0 1.4145850002478255e-07
urine O 0 2.8367217055347282e-06
chromatography O 0 4.0053990232991055e-05
. O 0 3.1856581017564167e-07
. O 0 8.258851380560372e-07

Detection O 0 0.00010094061144627631
of O 0 1.939049798238557e-05
heterozygous O 0 7.452188128809212e-06
carriers O 0 1.2764730854541995e-06
of O 0 2.0850726286880672e-05
the O 0 0.0002579439606051892
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0003265316190663725
ATM O 0 0.0014606465119868517
) O 0 3.732094739916647e-07
gene O 0 4.213779334349965e-07
by O 0 2.1891430890264019e-07
G2 O 0 0.00030278050689958036
phase O 0 5.448562660603784e-05
chromosomal O 0 0.00038296871935017407
radiosensitivity O 0 0.0005993384402245283
of O 0 0.0002375346957705915
peripheral O 1 0.6811479330062866
blood O 0 0.0010553936008363962
lymphocytes O 0 0.0004418255412019789
. O 0 5.1541019274736755e-06

In O 0 0.1471230834722519
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.4091050363495015e-05
patients O 0 1.994868398469407e-06
, O 0 1.024286646611472e-07
mutations O 0 1.1011820078010714e-07
in O 0 3.400675723241875e-07
a O 0 7.406733288917167e-07
single O 0 4.09625130259883e-07
gene O 0 4.7129663016676204e-07
, O 0 1.0630662217181452e-07
ATM O 0 3.4084853268723236e-06
, O 0 1.5494503458057807e-08
result O 0 5.621756926643684e-08
in O 0 8.304264724756649e-07
an O 0 0.00014298268069978803
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 5.774133751401678e-05
embraces O 0 7.025438208074775e-06
a O 0 9.370417046739021e-07
variety O 0 3.0764675784666906e-07
of O 0 2.8475218641688116e-05
clinical O 0 0.42430609464645386
features O 0 4.8718666221247986e-05
and O 0 1.5673427697038278e-05
manifests O 0 6.824861338827759e-05
extreme O 0 0.0019250554032623768
radiosensitivity O 0 0.0037813058588653803
and O 0 5.688181772711687e-06
a O 0 1.260906174138654e-05
strong O 0 1.2135044926253613e-05
pre O 0 0.0003588848630897701
- O 0 5.9983318351441994e-05
disposition O 0 0.0001236272946698591
to O 0 3.6336248285806505e-06
malignancy B-Disease 0 0.0011244076304137707
. O 0 3.5610955819720402e-06

Heterozygotes O 0 0.0014133553486317396
for O 0 2.058027712337207e-05
the O 0 1.7127995306509547e-05
ATM O 0 6.790564657421783e-05
gene O 0 9.583249038769281e-07
have O 0 1.287537543248618e-07
no O 0 2.7748285447160015e-07
clinical O 0 1.9435281501500867e-05
expression O 0 5.4963966249488294e-05
of O 0 0.0010900294873863459
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.5171495761023834e-05
may O 0 2.0459399820538238e-05
be O 0 4.2845990719797555e-06
cancer B-Disease 0 7.634786743437871e-05
prone O 0 2.3634038370801136e-06
with O 0 4.3402064164865806e-08
a O 0 4.520587424394762e-07
moderate O 0 1.8118767002306413e-06
increase O 0 6.750869374627655e-07
in O 0 2.409992703178432e-06
in O 0 7.84083840699168e-06
vitro O 0 0.0006739171221852303
radiosensitivity O 0 0.00146977580152452
. O 0 1.0398914128018077e-05

We O 0 3.8069185393396765e-05
performed O 0 6.434058741433546e-05
a O 0 3.3716314646881074e-05
blind O 0 0.00012642091314774007
chromosomal O 0 0.00018691598961595446
analysis O 0 1.484499080106616e-05
on O 0 6.915420817676932e-05
G2 O 0 0.0003602759970817715
- O 0 8.700340913492255e-06
phase O 0 2.423761361569632e-05
lymphocytes O 0 7.347338396357372e-06
from O 0 2.2283879843598697e-06
7 O 0 1.868090475909412e-05
unrelated O 0 2.25218063860666e-05
A B-Disease 1 0.999896764755249
- I-Disease 1 0.9998340606689453
T I-Disease 1 0.9999998807907104
patients O 0 7.0694009082217235e-06
, O 0 8.734223229112104e-07
13 O 0 5.969149242446292e-06
obligate O 0 1.5960986274876632e-05
A B-Disease 1 0.999992847442627
- I-Disease 1 0.9998372793197632
T I-Disease 1 0.9999996423721313
heterozygotes O 0 4.3160038330825046e-05
( O 0 2.8120280148868915e-07
parents O 0 3.9642820581775595e-08
of O 0 5.879061859559442e-07
the O 0 1.0989532484018127e-06
patients O 0 5.734133878831926e-07
) O 0 1.5169538869486132e-07
, O 0 9.880839968445798e-08
and O 0 1.3998629810885177e-07
14 O 0 7.64160904509481e-06
normal O 0 1.6234487702604383e-05
controls O 0 1.574287671246566e-05
following O 0 2.529110679461155e-05
X O 0 0.00015013586380518973
- O 0 6.211811069078976e-06
irradiation O 0 7.270304649864556e-06
with O 0 2.170541506529844e-07
1 O 0 7.802878826623783e-06
Gy O 0 2.9845148674212396e-05
in O 0 2.3209312871586008e-07
order O 0 9.871929762539366e-08
to O 0 5.607225261883286e-08
evaluate O 0 1.785755756600338e-07
this O 0 2.1695234408980468e-07
cytogenetic O 0 4.3845782784046605e-05
method O 0 2.6991706363332924e-06
as O 0 4.759153569011687e-07
a O 0 5.514399390449398e-07
tool O 0 1.4788815860811155e-06
for O 0 1.5040697576296225e-07
detection O 0 2.953061539301416e-06
of O 0 1.5707184502389282e-05
ATM O 0 0.0002612739917822182
carriers O 0 7.248233941936633e-06
. O 0 3.9264118640858214e-06

Both O 0 0.0015255239559337497
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
homozygotes O 0 0.0003395389940124005
and O 0 3.0856840567139443e-06
heterozygotes O 0 1.566981154610403e-05
showed O 0 2.5760484732018085e-06
significantly O 0 3.268243347065436e-07
increased O 0 1.3604933428723598e-06
levels O 0 8.17944783193525e-06
of O 0 1.719168903946411e-05
radiation O 0 0.13284161686897278
- O 0 0.0004820842295885086
induced O 0 0.0023488642182201147
chromatid O 0 0.00169287936296314
damage O 0 8.890084427548572e-05
relative O 0 9.101038813241757e-06
to O 0 9.557331281939696e-08
that O 0 7.13635373017496e-08
of O 0 2.7997054985462455e-06
normal O 0 3.077031942666508e-05
controls O 0 3.249200017307885e-05
. O 0 3.1605279673385667e-06

These O 0 1.4701066902489401e-05
results O 0 2.5849525627563708e-05
show O 0 7.911971806606743e-06
that O 0 9.466344863540144e-07
the O 0 1.0189539352722932e-05
G2 O 0 0.00041659869020804763
- O 0 5.185574627830647e-05
phase O 0 0.00018529551743995398
chromosomal O 0 0.0006543999770656228
radiosensitivity O 0 0.0006738856318406761
assay O 0 4.7073706809896976e-05
can O 0 2.9596293416034314e-07
be O 0 8.609530510739205e-08
used O 0 4.498636840821746e-08
for O 0 3.8716446937314686e-08
the O 0 3.1480936968364404e-07
detection O 0 3.988251137343468e-06
of O 0 0.00010593686602078378
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0015974589623510838
. O 0 1.160654574050568e-05

In O 0 5.77700266148895e-05
combination O 0 4.86115604871884e-05
with O 0 3.3653750506346114e-06
molecular O 0 0.0010697611141949892
genetic O 0 3.793940049945377e-05
analyses O 0 1.1706716577464249e-05
, O 0 1.5902089671726571e-06
this O 0 3.0132252959447214e-07
test O 0 1.471541963837808e-06
may O 0 1.443637302145362e-06
be O 0 8.432401443769777e-08
of O 0 1.1534984167838047e-07
value O 0 2.077008218748233e-07
in O 0 1.0905305458663861e-07
studies O 0 1.855684672591451e-07
of O 0 7.520717986153613e-07
familial B-Disease 0 8.769764463067986e-06
and I-Disease 0 4.505516244535102e-06
sporadic I-Disease 0 0.00019592074386309832
cancers I-Disease 1 0.9267650246620178
aimed O 0 2.9267879654071294e-05
at O 0 1.1731716767826583e-05
determination O 0 4.0208936979979626e-07
of O 0 1.3541840644393233e-06
the O 0 6.391168767549971e-07
potential O 0 7.630763434463006e-07
involvement O 0 1.9802068891294766e-06
of O 0 9.484883776167408e-06
ATM O 0 0.00032303956686519086
mutations O 0 7.821479812264442e-06
in O 0 1.2618830623978283e-05
tumor B-Disease 1 0.9911143779754639
risk O 0 1.1388408893253654e-05
or O 0 1.5922834109005635e-06
development O 0 2.7956073154200567e-06
. O 0 2.1744885714269913e-07
. O 0 8.405406788369874e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 7.949724385980517e-05
identification O 0 2.574889322204399e-06
and O 0 8.380130225305038e-07
detection O 0 2.7431586204329506e-05
of O 0 0.0015547305811196566
founder O 0 0.0714963972568512
- O 0 3.1962750654201955e-05
effect O 0 1.6707890608813614e-05
mutations O 0 6.541470725096588e-07
in O 0 9.65373260441993e-07
the O 0 1.5240228776747244e-06
ATM O 0 1.4508512322208844e-05
gene O 0 2.5640486001066165e-07
in O 0 7.936812806974558e-08
ethnic O 0 1.221448115984458e-07
populations O 0 6.040278890395712e-07
. O 0 1.0425676464365097e-06

To O 0 2.5351703243359225e-06
facilitate O 0 4.747376351588173e-06
the O 0 4.48890978077543e-06
evaluation O 0 2.2494521545013413e-05
of O 0 9.529861563351005e-05
ATM O 0 0.0016533320304006338
heterozygotes O 0 0.00015293566684704274
for O 0 4.27557779403287e-06
susceptibility O 0 0.00012641801731660962
to O 0 3.100078401985229e-06
other O 0 3.162445636917255e-06
diseases O 0 0.20247113704681396
, O 0 8.725215252525231e-07
such O 0 6.14977466284472e-07
as O 0 4.123213511775248e-05
breast B-Disease 1 0.9984879493713379
cancer I-Disease 1 0.9976600408554077
, O 0 2.5906088012561668e-06
we O 0 1.4346214527449774e-07
have O 0 1.1455615123168172e-07
attempted O 0 4.577767356295226e-07
to O 0 6.79857663499206e-08
define O 0 5.975147701064998e-07
the O 0 5.593327614406007e-07
most O 0 1.033673910910693e-07
common O 0 9.806620937524713e-08
mutations O 0 6.26727754138301e-08
and O 0 9.096356023974295e-08
their O 0 9.39800273158653e-08
frequencies O 0 1.097938456950942e-05
in O 0 5.151973164174706e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999247789382935
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.906403435394168e-06
homozygotes O 0 1.2737122233374976e-05
from O 0 4.239423390117736e-07
10 O 0 2.92344736863015e-07
ethnic O 0 4.04587225943942e-08
populations O 0 1.4926128244496795e-07
. O 0 3.0588529398301034e-07

Both O 0 4.1643535951152444e-05
genomic O 0 8.601024455856532e-05
mutations O 0 5.64546689929557e-06
and O 0 6.466197532972728e-07
their O 0 3.3443404845456826e-07
effects O 0 7.914024536148645e-06
on O 0 4.825136329600355e-06
cDNA O 0 1.1602936865529045e-05
were O 0 1.7304653283645166e-06
characterized O 0 5.1826996241288725e-06
. O 0 1.5523870615652413e-06

Protein O 0 0.0006232846062630415
- O 0 5.3593492339132354e-05
truncation O 0 0.00010433005809318274
testing O 0 2.4172204575734213e-06
of O 0 3.9238962017407175e-06
the O 0 1.2751773965646862e-06
entire O 0 4.385689862829167e-06
ATM O 0 1.7203956304001622e-05
cDNA O 0 6.5114095377794e-06
detected O 0 9.243581189366523e-06
92 O 0 4.277201514923945e-05
( O 0 8.61112198435876e-07
66 O 0 8.385922228626441e-06
% O 0 6.617366921091161e-07
) O 0 1.5343640313858486e-07
truncating O 0 2.9524928777391324e-06
mutations O 0 4.298864553220483e-07
in O 0 9.84451162366895e-07
140 O 0 3.3830183383543044e-06
mutant O 0 5.635516117763473e-06
alleles O 0 1.758198777679354e-06
screened O 0 1.2808417523046955e-05
. O 0 2.2758285922463983e-06

The O 0 0.0003641015209723264
haplotyping O 0 0.001851800363510847
of O 0 8.928604802349582e-05
patients O 0 2.13043786061462e-05
with O 0 2.500466280253022e-06
identical O 0 6.406795000657439e-05
mutations O 0 1.9954542949562892e-05
indicates O 0 4.0746064769336954e-05
that O 0 3.6774417822016403e-07
almost O 0 1.1560836128410301e-06
all O 0 9.061635353191377e-08
of O 0 5.11431551331043e-07
these O 0 6.679236008722e-08
represent O 0 7.40749555916409e-07
common O 0 8.090650567282864e-07
ancestry O 0 4.03972734375202e-07
and O 0 1.6445115136320965e-07
that O 0 4.0645435461783563e-08
very O 0 1.5954982757193648e-07
few O 0 2.73505690984166e-07
spontaneously O 0 2.7338489871908678e-06
recurring O 0 3.4768407203955576e-05
ATM O 0 0.00011839804938063025
mutations O 0 4.546252512227511e-06
exist O 0 2.2521865048474865e-06
. O 0 1.8352128563492442e-06

Assays O 0 7.025889499345794e-05
requiring O 0 8.513879947713576e-06
minimal O 0 3.419660424697213e-05
amounts O 0 4.386605723993853e-06
of O 0 1.3549912182497792e-05
genomic O 0 1.595925095898565e-05
DNA O 0 1.998623474719352e-06
were O 0 8.30715578103991e-07
designed O 0 2.534432610445947e-07
to O 0 1.2692254358626087e-08
allow O 0 2.5960737559671543e-08
rapid O 0 1.0030878456745995e-06
screening O 0 3.382536704066297e-07
for O 0 1.988612297054715e-07
common O 0 5.042570023761073e-07
ethnic O 0 3.73020895949594e-07
mutations O 0 5.048722869105404e-06
. O 0 2.537598675189656e-06

These O 0 1.740823790896684e-06
rapid O 0 2.54167625826085e-05
assays O 0 8.2635533544817e-06
detected O 0 5.966167009319179e-06
mutations O 0 4.1603649947319354e-07
in O 0 1.4308340041679912e-06
76 O 0 1.534491457277909e-05
% O 0 7.62476247473387e-07
of O 0 8.378488928428851e-06
Costa O 0 6.486095662694424e-05
Rican O 0 0.0003326401056256145
patients O 0 8.86882480699569e-06
( O 0 8.156796980074432e-07
3 O 0 2.6367156351625454e-06
) O 0 8.126843198397182e-08
, O 0 8.046254151850007e-08
50 O 0 2.2922689879578684e-07
% O 0 1.146313337585525e-07
of O 0 1.0204854561379761e-06
Norwegian O 0 6.912222306709737e-05
patients O 0 5.39656912224018e-06
( O 0 7.460824917870923e-07
1 O 0 4.743918907479383e-06
) O 0 9.34758830339888e-08
, O 0 7.851651417922767e-08
25 O 0 8.995111784315668e-07
% O 0 3.664677024062257e-07
of O 0 3.1617519198334776e-06
Polish O 0 0.00024833803763613105
patients O 0 2.6112678824574687e-05
( O 0 1.7836550796346273e-06
4 O 0 1.1470911886135582e-05
) O 0 1.5669202468870935e-07
, O 0 6.721062817405254e-08
and O 0 1.1986826109477988e-07
14 O 0 2.4822195427987026e-06
% O 0 4.6026318045733206e-07
of O 0 3.357191189934383e-06
Italian O 0 0.00022571462613996118
patients O 0 2.341194158361759e-05
( O 0 2.8078072773496388e-06
1 O 0 2.1200085029704496e-05
) O 0 5.487120802172285e-07
, O 0 1.6867208785242838e-07
as O 0 2.058218626643793e-07
well O 0 1.0452203724753417e-07
as O 0 9.810193546400114e-08
in O 0 1.8178219818310026e-07
patients O 0 2.7678166247824265e-07
of O 0 5.562226760957856e-06
Amish O 0 5.928956306888722e-05
/ O 0 7.305790495593101e-05
Mennonite O 0 3.232045492040925e-05
and O 0 8.829076136862568e-07
Irish O 0 1.418504416506039e-05
English O 0 2.474724897183478e-05
backgrounds O 0 6.829601261415519e-06
. O 0 2.844273922164575e-06

Additional O 0 1.7794480299926363e-05
mutations O 0 1.4093502613832243e-05
were O 0 1.0901934729190543e-05
observed O 0 7.452600129909115e-06
in O 0 3.816855041804956e-06
Japanese O 0 1.0154800293094013e-05
, O 0 9.195348980028939e-07
Utah O 0 8.619785148766823e-06
Mormon O 0 2.034607632594998e-06
, O 0 1.2643766922337818e-07
and O 0 1.6473447317366663e-07
African O 0 1.799931283130718e-06
American O 0 2.3768686787661863e-06
patients O 0 2.0642114577640314e-06
. O 0 2.2567273845197633e-06

These O 0 1.1440901062087505e-06
assays O 0 2.8636636670853477e-06
should O 0 1.7488262926690368e-07
facilitate O 0 4.291454445137788e-07
screening O 0 2.6871739464695565e-06
for O 0 1.5443243682966568e-05
A B-Disease 1 0.9999955892562866
- I-Disease 1 0.9999213218688965
T I-Disease 1 0.9999994039535522
heterozygotes O 0 2.3405109459417872e-05
in O 0 5.092725245958718e-07
the O 0 1.986421125366178e-07
populations O 0 3.98643003052257e-08
studied O 0 2.6052462089865003e-06
. O 0 1.8820119862539286e-07
. O 0 6.708038426950225e-07

The O 0 0.0006702524260617793
von B-Disease 1 0.9998475313186646
Hippel I-Disease 1 0.9999992847442627
- I-Disease 1 0.9999985694885254
Lindau I-Disease 1 0.9999994039535522
tumor I-Disease 1 0.9999983310699463
suppressor O 0 0.1423765867948532
gene O 0 9.097620363718306e-07
is O 0 4.809598408428428e-08
required O 0 3.298984552202455e-08
for O 0 1.7362695814426843e-07
cell O 0 7.370497314695967e-06
cycle O 0 4.232347691868199e-06
exit O 0 1.3441687087833998e-06
upon O 0 6.773672680537857e-07
serum O 0 1.582631557539571e-05
withdrawal O 0 3.166654641972855e-05
. O 0 1.1817934137070552e-05

The O 0 3.768920942093246e-05
inactivation O 0 0.0005724123911932111
of O 0 0.00011427026038290933
the O 0 8.895393693819642e-05
von B-Disease 1 0.9999282360076904
Hippel I-Disease 1 0.9999996423721313
- I-Disease 1 0.9999998807907104
Lindau I-Disease 1 1.0
( I-Disease 0 0.0067529259249567986
VHL I-Disease 1 0.9999991655349731
) I-Disease 0 7.610923057654873e-05
tumor I-Disease 1 0.999970555305481
suppressor O 1 0.9675312042236328
gene O 0 6.736920568073401e-06
predisposes O 0 3.5308091810293263e-06
affected O 0 1.50673443499727e-07
individuals O 0 8.251386240942793e-09
to O 0 4.218869875671771e-08
the O 0 9.596504241926596e-06
human O 1 0.9999996423721313
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.8762843012609665e-07
is O 0 5.533597047246985e-08
associated O 0 7.115355060705042e-08
with O 0 6.785919737239965e-08
sporadic B-Disease 1 0.9998760223388672
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.03879368677735329
RCC B-Disease 1 0.9999997615814209
) O 0 8.172375601134263e-06
and O 0 1.7257638319279067e-05
brain B-Disease 1 0.9999998807907104
hemangioblastomas I-Disease 1 0.9995848536491394
. O 0 2.3165750462794676e-05

VHL O 1 0.5756581425666809
- O 0 0.0020254652481526136
negative O 0 0.0002839881053660065
786 O 0 0.0036233344580978155
- O 0 0.00150776794180274
0 O 0 0.0007387118530459702
RCC B-Disease 0 0.008451411500573158
cells O 0 2.978628981509246e-05
are O 0 3.130252935079625e-06
tumorigenic O 0 0.0001272617664653808
in O 0 1.4536518392560538e-05
nude O 0 0.00038770868559367955
mice O 0 5.956990662525641e-06
which O 0 1.3973661339150567e-07
is O 0 2.891487582701302e-08
suppressed O 0 1.287827302576261e-07
by O 0 8.694082787030766e-09
the O 0 6.835934129867383e-08
reintroduction O 0 2.3833288196328795e-06
of O 0 7.415875188598875e-06
VHL B-Disease 0 0.0021014881785959005
. O 0 1.09289985630312e-05

Remarkably O 0 0.006408100016415119
, O 0 7.087031917762943e-06
this O 0 3.100623189311591e-07
occurs O 0 4.943335625284817e-07
without O 0 2.2844081115636072e-07
affecting O 0 1.0582841696304968e-06
the O 0 6.872689937154064e-07
growth O 0 2.4522084913769504e-06
rate O 0 1.864232103798713e-06
and O 0 4.1195215771949734e-07
cell O 0 1.0575008673185948e-05
cycle O 0 3.474176992313005e-06
profile O 0 4.4338619886730157e-07
of O 0 9.409173458152509e-07
these O 0 1.534776714606778e-07
cells O 0 1.0540546782067395e-06
in O 0 7.329495588237478e-07
culture O 0 1.944104269568925e-06
. O 0 5.6911380852398e-07

The O 0 0.000691122084390372
786 O 0 0.0018454230157658458
- O 0 0.00023589168267790228
0 O 0 0.00017707962251733989
cell O 0 9.281042002839968e-05
line O 0 3.4678207157412544e-05
, O 0 7.831174571037991e-07
like O 0 3.2750043033047405e-07
many O 0 1.6602112395958102e-07
cancer B-Disease 0 2.5318158805021085e-05
cells O 0 2.7844798751175404e-06
, O 0 1.392916857412274e-07
fails O 0 1.6053122919856833e-07
to O 0 7.084479136665323e-08
exit O 0 2.467113290549605e-06
the O 0 8.684190220265009e-07
cell O 0 1.0322004527552053e-05
cycle O 0 2.416330744381412e-06
upon O 0 6.932665996828291e-07
serum O 0 1.2931805940752383e-05
withdrawal O 0 1.9915511074941605e-05
. O 0 6.639348157477798e-06

Here O 0 0.0007331063388846815
, O 0 4.720533070212696e-06
it O 0 8.489691794011378e-08
is O 0 3.7773730809931294e-08
shown O 0 7.356681663850395e-08
that O 0 1.9086503044718484e-08
reintroduction O 0 1.0718572411860805e-06
of O 0 1.3074557045911206e-06
the O 0 2.6381844691059086e-06
wild O 0 6.414313702407526e-06
- O 0 2.7135132768307813e-05
type O 0 4.453086876310408e-05
VHL B-Disease 0 0.0006522347684949636
gene O 0 3.135603947157506e-06
restores O 0 1.1787666153395548e-05
the O 0 2.827897105817101e-06
ability O 0 1.937897650350351e-06
of O 0 0.000110283748654183
VHL O 1 0.968350350856781
- O 0 0.003972290549427271
negative O 0 0.00019928626716136932
RCC B-Disease 1 0.5908777713775635
cancer I-Disease 0 3.491697134450078e-05
cells O 0 4.075715480666986e-07
to O 0 6.338373026437694e-08
exit O 0 1.6838886267578346e-06
the O 0 9.718532965052873e-07
cell O 0 1.188429905596422e-05
cycle O 0 3.7616061945300316e-06
and O 0 5.992164346935169e-07
enter O 0 6.654111075476976e-06
G0 O 0 0.0005838380893692374
/ O 0 5.226238499744795e-05
quiescence O 0 7.861551421228796e-05
in O 0 4.944754437019583e-06
low O 0 5.483031418407336e-05
serum O 0 0.00010204381396761164
. O 0 3.6755486689799e-06

Both O 0 0.0005449939635582268
VHL O 0 0.09368723630905151
- O 0 0.0004508995043579489
positive O 0 3.370689591974951e-05
and O 0 2.7093088647234254e-05
VHL O 0 0.010473384521901608
- O 0 0.00016907685494516045
negative O 0 1.9981045625172555e-05
RCC B-Disease 0 0.000997822848148644
cells O 0 2.7588325792748947e-06
exit O 0 5.632555257761851e-06
the O 0 1.626857965675299e-06
cell O 0 9.4686183729209e-06
cycle O 0 1.665098011471855e-06
by O 0 1.4530530734191416e-07
contact O 0 3.894645033142297e-06
inhibition O 0 0.00011433217150624841
. O 0 5.966611297480995e-06

The O 0 0.0005213639233261347
cyclin O 0 0.000866457587108016
- O 0 0.00018970204109791666
dependent O 0 4.524348696577363e-05
kinase O 0 6.851936632301658e-05
inhibitor O 0 3.452585588092916e-05
, O 0 5.513852556759957e-07
p27 O 0 1.310431798628997e-05
, O 0 4.3144962091901107e-07
accumulates O 0 1.3021696076975786e-06
upon O 0 1.2876741948275594e-06
serum O 0 7.242471383506199e-06
withdrawal O 0 1.6565905752941035e-05
, O 0 1.0058083717012778e-06
only O 0 2.505913698769291e-07
in O 0 1.4360233535626321e-06
the O 0 2.254249466204783e-06
presence O 0 4.957247256243136e-06
of O 0 7.282898150151595e-05
VHL B-Disease 0 0.001205852604471147
, O 0 1.2416766139722313e-06
as O 0 2.3096791323951038e-07
a O 0 2.615934135974385e-07
result O 0 2.327010548697217e-07
of O 0 1.2852621011916199e-06
the O 0 1.1405420536902966e-06
stabilization O 0 9.711301572679076e-06
of O 0 2.1112602553330362e-05
the O 0 2.661365579115227e-05
protein O 0 6.903329631313682e-05
. O 0 6.022543402650626e-06

We O 0 1.456433892599307e-05
propose O 0 3.6168603401165456e-06
that O 0 3.0606881296080246e-07
the O 0 1.5374312170024496e-06
loss O 0 8.78782338986639e-06
of O 0 1.1274863936705515e-05
wild O 0 1.0522245247557294e-05
- O 0 6.48881759843789e-05
type O 0 0.00011942011769860983
VHL B-Disease 0 0.002970626810565591
gene O 0 3.3529674965393497e-06
results O 0 2.489072812750237e-06
in O 0 8.052201110331225e-07
a O 0 1.7062191091099521e-06
specific O 0 2.7851119739352725e-06
cellular O 0 0.02117021195590496
defect O 0 0.0003010511281900108
in O 0 4.415688454173505e-05
serum O 0 0.0004132502945140004
- O 0 0.0001473276352044195
dependent O 0 2.820463305397425e-05
growth O 0 2.699786637094803e-05
control O 0 6.023250080033904e-06
, O 0 2.475821645475662e-07
which O 0 1.3046216906786867e-07
may O 0 7.942141451167117e-07
initiate O 0 3.3374249142070767e-06
tumor B-Disease 0 0.00037274762871675193
formation O 0 2.9472035748767667e-05
. O 0 3.205954499208019e-06

This O 0 2.03067138500046e-05
is O 0 6.932746146048885e-06
corrected O 0 8.631120181235019e-06
by O 0 1.2533149629234686e-07
the O 0 4.842025873585953e-07
reintroduction O 0 3.5434725305094616e-06
of O 0 5.4946581258263905e-06
wild O 0 1.4419736544368789e-05
- O 0 0.00013439117174129933
type O 0 0.000748440099414438
VHL B-Disease 1 0.9863834381103516
, O 0 3.027493949048221e-05
implicating O 0 0.0011252493131905794
VHL B-Disease 0 0.017780732363462448
as O 0 8.103336767817382e-06
the O 0 5.256668828224065e-06
first O 0 7.232676580315456e-06
tumor B-Disease 0 0.0003060548333451152
suppressor O 0 0.00013924477389082313
involved O 0 1.3088255172988283e-06
in O 0 2.32516117648629e-06
the O 0 4.714243459602585e-06
regulation O 0 7.345432550209807e-06
of O 0 9.234614844899625e-05
cell O 0 0.0005695025320164859
cycle O 0 0.00010576468775980175
exit O 0 3.206368273822591e-05
, O 0 7.155140906434099e-07
which O 0 1.3682779353985097e-07
is O 0 1.5333283442942047e-07
consistent O 0 4.415649357270013e-07
with O 0 4.0418999702751535e-08
its O 0 4.874197543358605e-07
gatekeeper O 0 8.546075696358457e-05
function O 0 1.3737482731812634e-05
in O 0 3.232566314181895e-06
the O 0 8.941051419242285e-06
kidney O 0 0.003183041699230671
. O 0 7.447609391419974e-07
. O 0 1.0659254030542797e-06

Piebaldism B-Disease 1 1.0
with O 0 0.020018145442008972
deafness B-Disease 1 1.0
: O 0 3.454304896877147e-05
molecular O 0 1.3547419257520232e-05
evidence O 0 4.541995508589025e-07
for O 0 2.956168145828997e-07
an O 0 1.0185535757045727e-06
expanded O 0 0.0006204060046002269
syndrome O 1 1.0
. O 0 2.804654650390148e-05

In O 0 8.694605639902875e-05
a O 0 3.248070061090402e-05
South O 0 6.001479505357565e-06
African O 0 2.7882770154974423e-06
girl O 0 1.7562213088240242e-06
of O 0 1.8584028111945372e-06
Xhosa O 0 9.67151572695002e-05
stock O 0 1.654841071285773e-05
with O 0 2.435685644286423e-07
severe O 1 0.9994887113571167
piebaldism B-Disease 1 0.9999972581863403
and O 0 0.21797747910022736
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 7.448636461049318e-05
identified O 0 1.5716990446890122e-06
a O 0 4.2067367189702054e-07
novel O 0 6.899680897731741e-07
missense O 0 2.4101721010083565e-06
substitution O 0 4.212704880046658e-06
at O 0 6.659964128630236e-06
a O 0 6.890271038173523e-07
highly O 0 8.679528491484234e-07
conserved O 0 4.173142315266887e-06
residue O 0 1.3645419130625669e-05
in O 0 3.179949999321252e-06
the O 0 5.398525445343694e-06
intracellular O 0 1.660993257246446e-05
kinase O 0 2.9494472983060405e-05
domain O 0 1.660757334320806e-05
of O 0 3.53631294274237e-05
the O 0 4.1331295506097376e-05
KIT O 0 0.00016769318608567119
proto O 0 0.0008659697487019002
- O 0 0.0002869648742489517
oncogene O 0 0.0015779396053403616
, O 0 5.698693712474778e-06
R796G O 0 0.0001305110490648076
. O 0 4.039005489175906e-06

Though O 0 0.0006512918043881655
auditory B-Disease 0 0.420553058385849
anomalies I-Disease 0 0.03197113797068596
have O 0 4.200348939775722e-06
been O 0 2.4241783194156596e-06
observed O 0 2.932912821052014e-06
in O 0 2.6174939193879254e-06
mice O 0 3.195545787093579e-06
with O 0 4.315928663345403e-07
dominant O 0 3.4506669180700555e-05
white O 0 6.62496495351661e-06
spotting O 0 8.325919043272734e-05
( O 0 2.1055479010101408e-05
W O 1 0.9548485279083252
) O 0 1.9827034520858433e-06
due O 0 0.00013503190712071955
to O 0 1.5774212442920543e-05
KIT O 0 0.03815365210175514
mutations O 0 0.019927529618144035
, O 0 0.0005121616995893419
deafness B-Disease 1 1.0
is O 0 8.847266144584864e-06
not O 0 2.3838872209580586e-07
typical O 0 1.4054212442715652e-06
in O 0 1.2211515922899707e-06
human O 0 1.125331618823111e-05
piebaldism B-Disease 0 0.00015577574959024787
. O 0 3.988380740338471e-06

Thus O 0 1.5834406440262683e-05
, O 0 6.35961328043777e-07
the O 0 6.114511279520229e-07
occurrence O 0 3.119334360235371e-05
of O 0 0.0414610430598259
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 1 0.9998573064804077
this O 0 9.263560968975071e-06
patient O 0 2.1389312678365968e-05
extends O 0 9.865575520962011e-06
considerably O 0 2.1931689389020903e-06
the O 0 8.134416020766366e-07
phenotypic O 0 8.60923682921566e-06
range O 0 1.2152521776442882e-05
of O 0 2.5227704099961556e-05
piebaldism B-Disease 0 0.00016259695985354483
due O 0 4.083031672053039e-05
to O 0 1.8446619378664764e-06
KIT O 0 1.973548023670446e-05
gene O 0 2.9904854272899684e-06
mutation O 0 6.023159926371591e-07
in O 0 8.799638635537121e-07
humans O 0 4.093064660537493e-07
and O 0 2.3888574673947005e-07
tightens O 0 5.752328888775082e-07
the O 0 1.4235033063414448e-07
clinical O 0 3.396188049009652e-06
similarity O 0 2.1829857814736897e-06
between O 0 4.664300377044128e-06
piebaldism B-Disease 0 6.504031625809148e-05
and O 0 1.09708345519266e-07
the O 0 4.559380784030509e-08
various O 0 2.805579768505595e-08
forms O 0 2.266925548610743e-06
of O 0 0.0015380973927676678
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.634856956428848e-06
. O 0 4.753487701236736e-06

Cycloheximide O 0 0.005189023446291685
facilitates O 0 5.5758762755431235e-05
the O 0 7.508773705922067e-06
identification O 0 1.8237552694699843e-06
of O 0 9.417438377568033e-06
aberrant O 0 7.289818313438445e-05
transcripts O 0 3.546989319147542e-05
resulting O 0 1.2617242646228988e-05
from O 0 3.4628410503501073e-06
a O 0 4.104214895050973e-06
novel O 0 7.28931263438426e-06
splice O 0 3.2316293072653934e-05
- O 0 8.452047950413544e-06
site O 0 1.2291375242057256e-06
mutation O 0 1.951857058202222e-07
in O 0 2.766708178114641e-07
COL17A1 O 0 3.397271575522609e-05
in O 0 2.851232920875191e-07
a O 0 1.0215819656878011e-06
patient O 0 8.690654794918373e-06
with O 0 1.6206622603931464e-06
generalized O 1 0.9998502731323242
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999994039535522
. O 0 7.28833838365972e-05

Patients O 0 0.0005286315572448075
with O 0 1.785471977200359e-05
generalized O 1 0.9999923706054688
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9998075366020203
often O 0 1.8382380631010165e-06
show O 0 1.7080800489566172e-06
decreased O 0 7.453234866261482e-05
expression O 0 7.80312348069856e-06
of O 0 1.4352429388964083e-05
type O 0 9.785853762878105e-05
XVII O 0 0.05451725050806999
collagen O 0 0.00011113451910205185
, O 0 2.4578346256021177e-06
a O 0 3.876646587741561e-06
transmembrane O 0 1.523444734630175e-05
hemidesmosomal O 0 3.224579631933011e-05
protein O 0 4.168099167145556e-06
encoded O 0 1.1372130757081322e-06
by O 0 8.018811854526575e-07
COL17A1 O 0 0.00017077634402085096
. O 0 2.5734213977557374e-06

This O 0 2.57037299888907e-05
report O 0 6.0186976043041795e-06
documents O 0 5.568186679738574e-06
a O 0 4.718705440609483e-06
novel O 0 8.338791303685866e-06
splice O 0 4.258341868990101e-05
- O 0 9.982494702853728e-06
site O 0 1.1788696383518982e-06
mutation O 0 1.7257670492654142e-07
in O 0 3.6367202937981347e-07
COL17A1 O 0 3.865314647555351e-05
in O 0 2.3983128016880073e-07
a O 0 1.0153928542422364e-06
patient O 0 1.2369535397738218e-05
with O 0 3.105333462372073e-06
generalized O 1 1.0
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 1.4780787751078606e-05
and O 0 9.505661751063599e-07
applies O 0 8.504381980856124e-07
a O 0 3.3207777505595004e-07
new O 0 1.0991779930691337e-07
methodology O 0 3.046241943138739e-07
to O 0 2.9133655488067234e-08
define O 0 3.8715234040864743e-07
and O 0 1.9560236808047193e-07
characterize O 0 6.792820954615308e-07
the O 0 9.136110179497337e-07
resulting O 0 2.3092525225365534e-06
mRNA O 0 6.109991772973444e-06
splice O 0 1.280349533772096e-05
variants O 0 4.494220775086433e-06
. O 0 2.3262791728484444e-06

Mutational O 0 0.006450736429542303
analysis O 0 9.842914005275816e-05
of O 0 0.0003382456779945642
COL17A1 O 0 0.01930950954556465
identified O 0 0.00010903301881626248
a O 0 5.973763109068386e-05
maternally O 0 0.0002640633028931916
inherited O 0 0.004395129159092903
G O 0 0.0014282525517046452
- O 0 6.44457686576061e-05
to O 0 1.6474374206154607e-05
- O 0 0.00031362121808342636
T O 0 0.00047118475777097046
transversion O 0 9.333861089544371e-05
at O 0 4.5900138502474874e-05
the O 0 2.5489255222055363e-06
- O 0 1.0159653811570024e-06
1 O 0 1.7854625866675633e-06
position O 0 8.78452908636973e-07
of O 0 3.464162318778108e-06
exon O 0 8.384404281969182e-06
32 O 0 2.603790744615253e-05
. O 0 3.645022616183269e-06

This O 0 5.621985110337846e-05
acceptor O 0 2.0719227904919535e-05
splice O 0 5.6955086620291695e-05
- O 0 1.4963089597586077e-05
site O 0 2.516374706829083e-06
mutation O 0 2.2254245379826898e-07
led O 0 1.1959231187574915e-06
to O 0 7.05045479776345e-08
the O 0 1.0328083135391353e-06
formation O 0 8.614073522039689e-06
of O 0 4.72073515993543e-05
aberrant O 0 0.00016435241559520364
transcripts O 0 7.41475450922735e-05
present O 0 1.6450461771455593e-05
at O 0 0.00027735953335650265
extremely O 0 2.2831500245956704e-05
low O 0 0.00011614417599048465
levels O 0 3.114804712822661e-05
. O 0 1.7765165694072493e-06

Based O 0 4.444975274964236e-05
on O 0 1.890308703877963e-05
our O 0 3.389955736565753e-06
recent O 0 1.924646085171844e-06
finding O 0 1.2103133713026182e-06
that O 0 8.410971759076347e-07
cycloheximide O 0 0.00016110463184304535
stabilized O 0 0.0005836118361912668
mutant O 0 8.198903378797695e-05
COL17A1 O 0 0.00029252961394377053
transcripts O 0 1.6968309864751063e-05
in O 0 2.2299166175798746e-06
keratinocytes O 0 6.1061937230988406e-06
homozygous O 0 1.0001333521358902e-06
for O 0 4.5987707153472e-07
a O 0 2.8874314921267796e-06
frameshift O 0 2.5211760657839477e-05
mutation O 0 1.4699837720399955e-06
, O 0 9.006425329971535e-07
the O 0 1.9886704194505e-06
effects O 0 5.064471406512894e-05
of O 0 0.00014911178732290864
the O 0 5.4189793445402756e-05
splice O 0 5.3918451158097014e-05
- O 0 2.9387134418357164e-05
site O 0 3.7757383779535303e-06
mutation O 0 4.026188662464847e-07
on O 0 2.910832790803397e-06
splicing O 0 2.3335605874308385e-06
of O 0 1.2464396604627836e-05
COL17A1 O 0 8.850263111526147e-05
transcripts O 0 6.33369927527383e-06
were O 0 5.37012169843365e-07
determined O 0 1.7077397274078976e-07
using O 0 9.550770840860423e-08
reverse O 0 1.911814706545556e-06
transcriptase O 0 1.0252966603729874e-05
polymerase O 0 1.7536995073896833e-05
chain O 0 4.518390596786048e-06
reaction O 0 4.742480257391435e-07
of O 0 2.2259177967498545e-06
total O 0 5.871067514817696e-06
RNA O 0 5.098146630189149e-06
from O 0 1.6857075024745427e-06
keratinocytes O 0 5.530158887268044e-06
incubated O 0 6.200074949447298e-06
for O 0 5.787622967545758e-07
2 O 0 8.254984095401596e-06
. O 0 1.1199816754015046e-06

5 O 0 0.0005871374160051346
h O 0 0.00041867452091537416
in O 0 1.7698706869850866e-05
the O 0 4.681631708081113e-06
presence O 0 5.537700872082496e-06
or O 0 5.214254088059533e-06
absence O 0 1.6823007172206417e-05
of O 0 1.627263191039674e-05
10 O 0 1.7415877664461732e-05
microg O 0 0.00014863397518638521
cycloheximide O 0 0.00016219992539845407
per O 0 4.035295933135785e-05
ml O 0 7.549848669441417e-05
. O 0 3.732308414328145e-06

Using O 0 6.331258191494271e-05
this O 0 8.181452358257957e-06
approach O 0 1.7582160580786876e-05
, O 0 2.152848310288391e-06
an O 0 1.2359208767520613e-06
abnormally O 0 6.792449858039618e-05
spliced O 0 1.1690761311911047e-05
transcript O 0 2.8000662496197037e-05
was O 0 2.3467711798730306e-05
identified O 0 4.447464334589313e-07
that O 0 4.204795445161835e-08
contains O 0 1.3119505126724107e-07
an O 0 1.210921283245625e-07
extra O 0 4.222758605010313e-07
264 O 0 1.039461130858399e-05
bases O 0 7.935971552797128e-06
upstream O 0 4.1084669646807015e-05
from O 0 6.3677975958853494e-06
exon O 0 7.5848615779250395e-06
32 O 0 1.3683573342859745e-05
, O 0 3.431039772294753e-07
resulting O 0 1.0081649861604092e-06
in O 0 2.3910713480290724e-06
a O 0 1.0347906936658546e-05
premature O 0 4.012299177702516e-05
termination O 0 4.008930045529269e-05
codon O 0 4.572124089463614e-05
27 O 0 6.785826553823426e-05
bp O 0 2.2528422050527297e-05
downstream O 0 1.8547181753092445e-05
from O 0 2.9372711196629098e-06
the O 0 3.6421245113160694e-06
cryptic O 0 2.1400695914053358e-05
splice O 0 3.434956670389511e-05
site O 0 1.5019647435110528e-05
. O 0 3.0850192160869483e-06

Three O 0 0.00011175214604008943
other O 0 5.570136181631824e-06
splice O 0 2.786201730486937e-05
variants O 0 5.274666818877449e-06
, O 0 1.1349897022228106e-06
including O 0 6.047056899660674e-07
one O 0 7.013148888290743e-07
derived O 0 1.4495943787551369e-06
from O 0 1.8207209677711944e-06
the O 0 2.285147502334439e-06
skipping O 0 3.7789334328408586e-06
of O 0 1.2809028703486547e-05
exon O 0 9.420743481314275e-06
32 O 0 3.1650663004256785e-05
, O 0 1.155763925453357e-06
were O 0 1.1949472309424891e-06
also O 0 7.765461305098142e-07
identified O 0 2.5433480459469138e-06
. O 0 2.1024984562245663e-06

These O 0 4.83617350255372e-06
results O 0 9.676864465291146e-06
indicate O 0 5.0355961320747156e-06
the O 0 1.2772902664437424e-06
usefulness O 0 4.628841452358756e-06
of O 0 4.4186249397171196e-06
cycloheximide O 0 5.094533116789535e-05
treatment O 0 2.928625235654181e-06
in O 0 1.1010545222234214e-06
evaluating O 0 1.8917826309916563e-06
the O 0 6.463056251959642e-06
abnormal O 0 0.00013971692533232272
processing O 0 7.791351526975632e-05
of O 0 4.9376289098290727e-05
mRNA O 0 3.4940556361107156e-05
due O 0 7.913584704510868e-05
to O 0 3.0973596949479543e-06
splice O 0 1.7338817997369915e-05
- O 0 1.5681454897276126e-05
site O 0 5.311302174959565e-06
mutations O 0 1.6940346085903002e-06
, O 0 1.1102713415311882e-06
because O 0 6.747940801687946e-07
( O 0 9.935026810126146e-07
i O 0 3.693796770676272e-06
) O 0 4.712418046892708e-07
aberrant O 0 6.479607691289857e-06
splicing O 0 1.9894196157110855e-06
often O 0 5.09282244820497e-07
generates O 0 9.59692215474206e-07
a O 0 2.987831521750195e-06
premature O 0 3.456572085269727e-05
termination O 0 4.831808473682031e-05
codon O 0 5.769493509433232e-05
, O 0 1.5802991129021393e-06
( O 0 2.630503956879693e-07
ii O 0 2.119620330631733e-05
) O 0 2.3625243272817897e-07
transcripts O 0 3.2423411084891995e-06
with O 0 3.695177497320401e-07
premature O 0 6.360808038152754e-05
termination O 0 4.0773822547635064e-05
codons O 0 2.0819985365960747e-05
can O 0 5.695243316949927e-07
occur O 0 1.5675345821364317e-06
at O 0 3.189506605849601e-05
low O 0 2.6798094040714204e-05
or O 0 4.943528438161593e-06
undetectable O 0 7.304298924282193e-05
levels O 0 8.12907273939345e-06
due O 0 1.119019725592807e-05
to O 0 9.320507388110855e-07
nonsense O 0 1.4251335414883215e-05
- O 0 2.922821749962168e-06
mediated O 0 2.0224188119755127e-05
mRNA O 0 1.29104737425223e-05
decay O 0 2.0862999008386396e-05
, O 0 3.7356556958911824e-07
and O 0 1.6729548235616676e-07
( O 0 2.951404383111367e-07
iii O 0 3.2589039619779214e-05
) O 0 4.353792064648587e-07
the O 0 1.2817869219361455e-06
levels O 0 5.285301085677929e-06
of O 0 3.4755391880025854e-06
these O 0 2.0992436589040153e-07
transcripts O 0 3.0544472338078776e-06
can O 0 9.938128187059192e-08
be O 0 7.908690946578645e-08
increased O 0 6.961140570638236e-07
by O 0 5.307204560267564e-07
cycloheximide O 0 4.886999158770777e-05
. O 0 2.9448131044773618e-06

A O 0 0.00029497878858819604
deletion O 0 0.0001496001350460574
mutation O 0 9.022010090120602e-06
in O 0 5.023661742598051e-06
COL17A1 O 0 9.775166108738631e-05
in O 0 4.24168405288583e-07
five O 0 1.6128345237120811e-07
Austrian O 0 1.8964386981679127e-05
families O 0 1.5137918296659336e-07
with O 0 8.901361638891103e-07
generalized O 1 0.9999048709869385
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999998807907104
represents O 0 0.00015511055244132876
propagation O 0 0.00010781365563161671
of O 0 1.3413870874501299e-05
an O 0 1.4571650126526947e-06
ancestral O 0 7.038054172880948e-05
allele O 0 3.261456367908977e-05
. O 0 3.9748401832184754e-06

Patients O 0 0.0004758813010994345
with O 0 1.4458774785452988e-05
generalized O 1 0.9999948740005493
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999994039535522
, O 0 6.956893230380956e-06
a O 0 1.187896941701183e-06
usually O 0 5.480583240569104e-07
nonlethal O 0 1.4403546629182529e-05
form O 0 2.660537120391382e-06
of O 0 0.000103380334621761
junctional B-Disease 1 0.9999997615814209
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9998959302902222
, O 0 2.863472900571651e-06
have O 0 6.140257937659044e-07
generalized O 0 0.00015171225822996348
blistering B-Disease 0 0.34658753871917725
, O 0 9.469313954468817e-05
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 6.368383765220642e-05
patchy B-Disease 1 0.9999980926513672
alopecia I-Disease 1 1.0
, O 0 0.00010140069935005158
and O 0 0.00223356019705534
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.8403828740119934

Skin B-Disease 1 0.9999990463256836
fragility I-Disease 1 0.9993403553962708
in O 0 8.139161946019158e-05
most O 0 7.554207286375458e-07
cases O 0 2.5514958679195843e-07
is O 0 9.276968881977155e-08
due O 0 4.194358496079076e-07
to O 0 2.3545860372564675e-08
mutations O 0 6.533701935040881e-08
in O 0 2.987287928135629e-07
the O 0 6.99183260621794e-07
gene O 0 1.6377407519030385e-06
encoding O 0 6.4837554418772925e-06
type O 0 0.00019807425269391388
XVII O 1 0.9506823420524597
collagen O 0 0.0024345070123672485
( O 0 3.119402390439063e-05
COL17A1 O 0 0.0013439897447824478
) O 0 2.588380993984174e-06
. O 0 1.3866704193787882e-06

Recently O 0 0.0002780373324640095
, O 0 1.932823806782835e-06
we O 0 1.1099773900014043e-07
reported O 0 1.9691327679538517e-07
five O 0 6.419867304430227e-08
Austrian O 0 5.383528332458809e-06
families O 0 2.422150657821476e-07
with O 0 1.8290328398506972e-06
generalized O 1 0.9999740123748779
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999992847442627
who O 0 4.280551729607396e-05
share O 0 5.391394552134443e-06
the O 0 2.800597258101334e-06
same O 0 9.99419171421323e-06
COL17A1 O 0 0.004952018614858389
mutation O 0 1.8642551367520355e-05
. O 0 4.609757070284104e-06

Affected O 0 0.0001324054755968973
individuals O 0 1.4767620086786337e-06
in O 0 3.722245764947729e-06
three O 0 1.9837491436192067e-06
families O 0 1.840579955114663e-07
are O 0 1.641504638882907e-07
homozygous O 0 1.1013117955371854e-06
for O 0 1.5675884696975118e-06
4003delTC O 0 2.404606311756652e-05
, O 0 1.086978954845108e-06
whereas O 0 8.405494895669108e-07
those O 0 1.1600712923609535e-07
in O 0 8.424522661698575e-07
two O 0 6.578280249414092e-07
others O 0 8.092703183137928e-07
are O 0 2.836238195413898e-07
compound O 0 1.8313108739675954e-05
heterozygotes O 0 2.3505162971559912e-05
. O 0 2.225955995527329e-06

To O 0 8.755107955948915e-06
determine O 0 4.58275644632522e-06
if O 0 8.83684265318152e-07
the O 0 1.3441866713037598e-06
occurrence O 0 5.522248102352023e-06
of O 0 8.99359474715311e-06
4003delTC O 0 1.3353729627851862e-05
in O 0 8.189065852093336e-07
these O 0 8.940822482372823e-08
unrelated O 0 8.353750331480114e-07
families O 0 6.470317970297401e-08
signifies O 0 2.441286142129684e-06
propagation O 0 6.263092018343741e-06
of O 0 5.312649591360241e-06
an O 0 2.518040901122731e-06
ancestral O 0 3.7267935113050044e-05
allele O 0 2.5699124307720922e-05
or O 0 9.472257261222694e-06
a O 0 1.7937514712684788e-05
mutational O 0 0.001084638643078506
hot O 0 0.0010991671588271856
spot O 0 0.0001463881490053609
, O 0 1.0069397831102833e-06
haplotypes O 0 5.29668477611267e-06
were O 0 1.0586404641799163e-06
determined O 0 9.98313225863967e-07
for O 0 6.332155635391246e-07
polymorphisms O 0 4.991160494682845e-06
both O 0 2.6315103696106235e-06
within O 0 4.731791250378592e-06
and O 0 8.953005817602389e-06
flanking O 0 0.002119794487953186
COL17A1 O 0 0.45380738377571106
. O 0 1.8272552551934496e-05

Five O 0 0.00034132268046960235
intragenic O 0 0.0008062522974796593
polymorphisms O 0 6.667397974524647e-05
were O 0 1.6790758309070952e-05
chosen O 0 4.188556886219885e-06
based O 0 6.012450626258214e-07
on O 0 3.690726089189411e-06
their O 0 1.720249088066339e-06
informativeness O 0 0.0005075724911876023
. O 0 1.4625204130425118e-05

One O 0 9.15920318220742e-05
of O 0 6.991215923335403e-05
these O 0 1.4838147990303696e-06
, O 0 8.569863894081209e-07
not O 0 4.880379265159718e-07
previously O 0 3.1442609724763315e-06
reported O 0 4.751973847305635e-06
, O 0 1.3197324051361647e-06
was O 0 3.9196158468257636e-05
2988 O 0 9.145640069618821e-05
A O 0 6.200394273037091e-05
or O 0 1.367584991385229e-05
C O 0 8.654898556414992e-05
that O 0 3.216957225049555e-07
introduces O 0 1.3987969396112021e-06
a O 0 1.336549075858784e-06
new O 0 3.714886815942009e-07
restriction O 0 2.9846846700820606e-06
site O 0 1.5889294218141004e-06
for O 0 9.969298844225705e-07
Eco0109 O 0 5.7098714023595676e-05
I O 0 5.017495641368441e-05
. O 0 3.725214355654316e-06

All O 0 2.5610435841372237e-05
the O 0 2.2520043785334565e-05
4003delTC O 0 0.00010724244202720001
alleles O 0 7.764396286802366e-06
showed O 0 1.1803437701018993e-05
the O 0 1.2493893564169412e-06
same O 0 5.851904916198691e-07
haplotype O 0 9.901071280182805e-06
for O 0 3.5225116334913764e-07
these O 0 1.422686324303868e-07
five O 0 1.5148417560340022e-06
polymorphic O 0 1.2808918654627632e-05
markers O 0 4.182190605206415e-05
. O 0 4.600148713507224e-06

Fourteen O 0 0.0006694942712783813
microsatellite O 0 0.00044462340883910656
polymorphisms O 0 0.00014707974332850426
were O 0 2.521630267438013e-05
selected O 0 4.788673777511576e-06
based O 0 8.233214998654148e-07
on O 0 4.580065251502674e-06
their O 0 8.924967005441431e-07
high O 0 6.121795013314113e-05
heterozygosity O 0 0.00011661749158520252
and O 0 8.883823738869978e-07
their O 0 5.073596867077868e-07
location O 0 1.3508173651644029e-05
within O 0 5.542825419979636e-06
10q23 O 0 0.00011550336785148829
- O 0 0.00010900662164203823
q25 O 0 0.0004801333125215024
near O 0 0.0017674579285085201
COL17A1 O 0 0.0033752198796719313
. O 0 1.2521753887995146e-05

Three O 0 3.061395909753628e-05
families O 0 1.3842314956491464e-06
shared O 0 7.179924978117924e-06
microsatellite O 0 7.908629049779847e-05
polymorphisms O 0 8.24208909762092e-05
covering O 0 0.00040195457404479384
at O 0 0.0030185130890458822
most O 0 6.254718755371869e-06
19 O 0 7.626571459695697e-05
cM O 0 6.69667060719803e-05
, O 0 2.943664640042698e-06
whereas O 0 3.255872570662177e-06
the O 0 3.446441041887738e-06
others O 0 1.1017782526323572e-06
shared O 0 1.6087712992884917e-06
smaller O 0 2.413659103694954e-06
regions O 0 4.938373876939295e-06
consistent O 0 1.6539434000151232e-05
with O 0 7.940323598631949e-07
cross O 0 1.0687016583688091e-05
- O 0 1.981336708922754e-06
over O 0 3.74153529492105e-07
events O 0 3.3099865959229646e-07
during O 0 6.493988280453777e-07
passage O 0 1.8769966914078395e-07
of O 0 6.05294161459824e-08
this O 0 5.907830669116265e-09
mutation O 0 3.368378287404994e-08
through O 0 4.955064270006915e-08
several O 0 8.18466361351966e-08
generations O 0 5.603108093055198e-07
. O 0 8.81621133430599e-07

These O 0 1.971902202058118e-05
results O 0 5.518375837709755e-05
indicate O 0 1.432200770068448e-05
that O 0 6.131480176918558e-07
4003delTC O 0 1.6535679606022313e-05
occurs O 0 7.238600119308103e-07
on O 0 2.119611053785775e-06
a O 0 1.849544673859782e-06
single O 0 1.6243200207100017e-06
ancestral O 0 1.696743674983736e-05
allele O 0 8.271264050563332e-06
. O 0 4.582406063491362e-07
. O 0 1.0625457207424915e-06

The O 0 0.00020243419567123055
haptoglobin O 0 0.002144950907677412
- O 0 0.00011125963646918535
gene O 0 6.479292551375693e-06
deletion O 0 1.3071266948827542e-05
responsible O 0 6.543849849549588e-06
for O 0 4.950207767251413e-06
anhaptoglobinemia B-Disease 0 0.0020053726620972157
. O 0 2.5191044187522493e-05

We O 0 4.780014933203347e-05
have O 0 1.3940186818217626e-06
found O 0 3.5497023986863496e-07
an O 0 8.41726475186988e-08
allelic O 0 3.1187062177195912e-06
deletion O 0 9.78288608166622e-06
of O 0 7.637008093297482e-05
the O 0 0.00014221621677279472
haptoglobin O 0 0.002821811707690358
( O 0 2.62413432210451e-05
Hp O 0 0.00021237664623185992
) O 0 1.6246330005742493e-06
gene O 0 1.0679106026145746e-06
from O 0 1.1910176453966415e-06
an O 0 1.5690076793362095e-07
individual O 0 1.2053529019340203e-07
with O 0 5.810430820929469e-07
anhaptoglobinemia B-Disease 0 0.0017486162250861526
. O 0 1.840662480390165e-05

The O 0 0.0007437836611643434
Hp O 0 0.0005187562201172113
gene O 0 7.294702299986966e-06
cluster O 0 1.8601138435769826e-05
consists O 0 1.4792822184972465e-06
of O 0 1.0549141734372824e-05
coding O 0 1.0220331205346156e-05
regions O 0 4.730428827315336e-06
of O 0 0.00012502238678280264
the O 0 0.00012368224270176142
alpha O 0 9.918375144479796e-05
chain O 0 6.163141279103002e-06
and O 0 6.036213449078787e-07
beta O 0 6.2519875427824445e-06
chain O 0 2.7642552140605403e-06
of O 0 5.652195795846637e-06
the O 0 7.698780791542958e-06
haptoglobin O 0 8.4588275058195e-05
gene O 0 4.141243607591605e-06
( O 0 1.4921288311597891e-06
Hp O 0 1.698087180557195e-05
) O 0 1.332392116637493e-07
and O 0 1.6577841677190008e-07
of O 0 4.489817456487799e-06
the O 0 9.16534372663591e-06
alpha O 0 2.8629609005292878e-05
chain O 0 3.318768676763284e-06
and O 0 5.459893372972147e-07
beta O 0 6.9467300818359945e-06
chain O 0 2.862809196813032e-06
of O 0 4.518799414654495e-06
the O 0 5.7772895161178894e-06
haptoglobin O 0 9.386586316395551e-05
- O 0 2.288933865202125e-05
related O 0 1.2254494322405662e-05
gene O 0 3.575275059120031e-06
( O 0 1.182856294690282e-06
Hpr O 0 2.529945231799502e-05
) O 0 7.75356227222801e-07
, O 0 4.408202016747964e-07
in O 0 2.070953087240923e-06
tandem O 0 6.25836692051962e-05
from O 0 3.688956212499761e-06
the O 0 5.020113349019084e-06
5 O 0 1.4475648640654981e-05
side O 0 1.3216873412602581e-05
. O 0 2.5363526674482273e-06

Southern O 0 0.0007972182356752455
blot O 0 0.0010540871880948544
and O 0 4.40488729509525e-05
PCR O 0 5.271216286928393e-05
analyses O 0 6.3041766225069296e-06
have O 0 1.4081057315706857e-06
indicated O 0 3.140506123600062e-06
that O 0 1.7436536836612504e-07
the O 0 7.807178121765901e-07
individual O 0 6.279877595716243e-08
with O 0 1.908978504161496e-07
anhaptoglobinemia B-Disease 0 4.711457222583704e-05
was O 0 2.4187667804653756e-05
homozygous O 0 1.8287485090695554e-06
for O 0 6.975993755986565e-07
the O 0 1.4599971791540156e-06
gene O 0 1.009909624372085e-06
deletion O 0 2.687283995328471e-06
and O 0 3.7395230378933775e-07
that O 0 9.839521197818613e-08
the O 0 8.962008450907888e-07
gene O 0 9.63317006608122e-07
deletion O 0 4.72309011456673e-06
was O 0 4.3994765292154625e-05
included O 0 5.601432803814532e-06
at O 0 2.7977945137536153e-05
least O 0 5.365023412196024e-07
from O 0 1.3869243957742583e-06
the O 0 4.157047442276962e-06
promoter O 0 0.00012348685413599014
region O 0 1.375611282128375e-05
of O 0 0.00032999191898852587
Hp O 0 0.0006094773998484015
to O 0 1.0190705324930605e-05
Hpr O 0 0.0006066935602575541
alpha O 0 8.780867938185111e-05
but O 0 2.940815022611787e-07
not O 0 1.0623364943285196e-07
to O 0 3.4757437106236466e-07
Hpr O 0 4.982117752660997e-05
beta O 0 3.411484794924036e-05
( O 0 2.406887233519228e-06
Hpdel O 0 8.673925913171843e-05
) O 0 1.4533540024785907e-06
. O 0 1.1672707387333503e-06

In O 0 0.0002435795613564551
addition O 0 1.551577224745415e-05
, O 0 3.435791541051003e-06
we O 0 9.378257459502493e-07
found O 0 8.089330663096916e-07
seven O 0 6.80321363688563e-07
individuals O 0 9.028046576986526e-08
with O 0 4.68247066010008e-07
hypohaptoglobinemia B-Disease 0 0.00012825096200685948
in O 0 3.44951513397973e-05
three O 0 6.856173513369868e-06
families O 0 6.531907388307445e-07
, O 0 4.3097341517750465e-07
and O 0 1.0223128583675134e-06
the O 0 7.134806764952373e-06
genotypes O 0 2.263787064293865e-05
of O 0 6.608516559936106e-05
six O 0 2.1375240976340137e-05
of O 0 3.265452687628567e-05
the O 0 1.2340338798821904e-05
seven O 0 3.322137899886002e-06
individuals O 0 1.2138119132032443e-07
were O 0 1.183341510113678e-06
found O 0 3.4895438716375793e-07
to O 0 1.7560091691848356e-07
be O 0 4.050029474456096e-06
Hp2 O 0 0.001253145164810121
/ O 0 0.0007393629057332873
Hpdel O 0 0.0023889655712991953
. O 0 2.477057569194585e-05

The O 0 0.0005345868412405252
phenotypes O 0 0.0003451263182796538
and O 0 2.7340021915733814e-05
genotypes O 0 4.771153180627152e-05
in O 0 1.2443447303667199e-05
one O 0 1.3064934591966448e-06
of O 0 2.5264355372200953e-06
these O 0 1.0500939850999202e-07
three O 0 4.4174100821692264e-07
families O 0 1.271001792702009e-07
showed O 0 9.570951988280285e-06
the O 0 9.537602636555675e-06
father O 0 2.50999401032459e-05
to O 0 1.5161483588599367e-06
be O 0 8.258888556156307e-06
hypohaptoglobinemic B-Disease 0 9.260611841455102e-05
( O 0 4.209419785183854e-06
Hp2 O 0 0.00011789851123467088
) O 0 2.2025717498763697e-06
and O 0 4.918604645354208e-06
Hp2 O 0 0.0014631516532972455
/ O 0 0.0010653878562152386
Hpdel O 0 0.003121404442936182
, O 0 1.4746939086762723e-05
the O 0 1.1966752936132252e-05
mother O 0 1.742491622280795e-05
to O 0 1.2673539231400355e-06
be O 0 2.219473799414118e-06
Hp2 O 0 3.9402584661729634e-05
- O 0 7.1718568506184965e-06
1 O 0 1.0230765838059597e-05
and O 0 2.1926041426922893e-06
Hp1 O 0 0.00020829893765039742
/ O 0 8.397873170906678e-05
Hp2 O 0 0.00020105112344026566
, O 0 3.0525834517902695e-06
one O 0 8.861992455422296e-07
of O 0 5.979530669719679e-06
the O 0 4.644902674044715e-06
two O 0 1.3846354249835713e-06
children O 0 1.2036900898237946e-06
to O 0 6.252650450733199e-07
be O 0 7.795953024469782e-06
hypohaptoglobinemic B-Disease 0 0.0001792430120985955
( O 0 5.9610770222207066e-06
Hp2 O 0 0.00012866339238826185
) O 0 2.2822184746473795e-06
and O 0 6.586525159946177e-06
Hp2 O 0 0.0013643150450661778
/ O 0 0.00137324130628258
Hpdel O 0 0.002488864352926612
, O 0 8.471464752801694e-06
and O 0 9.688004638519487e-07
the O 0 2.6314201022614725e-06
other O 0 2.8009102948090003e-07
child O 0 2.964775148939225e-06
to O 0 5.24292318004882e-07
be O 0 3.0155040349200135e-06
Hp1 O 0 0.00019574393809307367
and O 0 1.2297728972043842e-05
Hp1 O 0 0.0018816000083461404
/ O 0 0.0004881687927991152
Hpdel O 0 0.0002639495360199362
, O 0 1.2107266229577363e-06
showing O 0 4.172720764472615e-06
an O 0 7.339350531765376e-07
anomalous O 0 0.00010403082706034184
inheritance O 0 4.6105447836453095e-05
of O 0 0.0006834104424342513
Hp O 0 0.0007502103107981384
phenotypes O 0 1.3459592082654126e-05
in O 0 3.101027459706529e-06
the O 0 3.7956779124215245e-06
child O 0 9.533719094179105e-06
with O 0 1.8808182176144328e-06
Hp1 O 0 0.0031508549582213163
. O 0 1.7398613636032678e-05

The O 0 0.0013312913943082094
Hp2 O 0 0.034165866672992706
/ O 0 0.005370008293539286
Hpdel O 0 0.0017301758052781224
individuals O 0 2.561458359195967e-06
had O 0 2.768720150925219e-05
an O 0 3.781024133786559e-06
extremely O 0 2.0369086996652186e-05
low O 0 0.00012111151590943336
level O 0 0.0008271911647170782
of O 0 0.0005924160359427333
Hp O 0 0.0006326750735752285
( O 0 1.6979729480226524e-06
mean O 0 1.1879154953930993e-05
+ O 0 5.827539553138195e-06
/ O 0 2.8635326998482924e-06
- O 0 2.0603390566975577e-06
SD O 0 1.0338496394979302e-05
= O 0 4.216575689497404e-06
0 O 0 4.832172066926432e-07
. O 0 1.9411492857557278e-08
049 O 0 2.123686272170744e-06
+ O 0 9.073358455680136e-07
/ O 0 1.1404788438085234e-06
- O 0 7.151941190386424e-07
0 O 0 6.056105803509126e-07
. O 0 2.4705331114205364e-08
043 O 0 4.622184405889129e-06
mg O 0 1.0863243915082421e-05
/ O 0 4.966914730175631e-06
ml O 0 3.2946757073659683e-06
; O 0 3.8186502138159995e-07
n O 0 8.574633284297306e-06
= O 0 6.474579549831105e-06
6 O 0 3.1850795494392514e-06
) O 0 6.890850556828809e-08
, O 0 5.913052802952734e-08
compared O 0 3.2256909321404237e-07
with O 0 4.804252995427305e-08
the O 0 1.8752017467704718e-06
level O 0 1.6051993952714838e-05
( O 0 3.2590648402219813e-07
1 O 0 1.3579035567090614e-06
. O 0 5.930695934353025e-08
64 O 0 1.6306479437844246e-06
+ O 0 8.519601806256105e-07
/ O 0 1.0065155038319062e-06
- O 0 6.151117872832401e-07
1 O 0 1.5218762428048649e-06
. O 0 8.316551003417771e-08
07 O 0 8.302132300741505e-06
mg O 0 1.3215121725806966e-05
/ O 0 3.2903990359045565e-06
ml O 0 1.420293756382307e-06
) O 0 3.606017173751752e-08
obtained O 0 4.4430808543438616e-07
from O 0 1.5028024336061208e-06
52 O 0 2.23341030505253e-05
healthy O 0 2.779714577627601e-06
volunteers O 0 8.393615189561388e-07
having O 0 3.6743044802278746e-06
phenotype O 0 2.5123315936070867e-05
Hp2 O 0 8.826352132018656e-05
, O 0 1.3741170050707296e-06
whereas O 0 1.0791095519380178e-06
the O 0 2.0205422970320797e-06
serum O 0 1.9766748664551415e-05
Hp O 0 5.492188938660547e-05
level O 0 1.3895237316319253e-05
of O 0 4.377738150651567e-06
an O 0 8.735856340535975e-07
individual O 0 3.17873258381951e-07
with O 0 1.2864539939982933e-06
Hp1 O 0 0.0022283769212663174
/ O 0 0.0008607410127297044
Hpdel O 0 0.0024518542923033237
was O 0 0.000707585655618459
0 O 0 2.6048683139379136e-05
. O 0 1.272865233659104e-06

50 O 0 0.0009865305619314313
mg O 0 0.0016587605932727456
/ O 0 0.00027052583754993975
ml O 0 9.243337990483269e-05
, O 0 1.3062229982097051e-06
which O 0 2.4167724177459604e-07
was O 0 3.3302269457635703e-06
approximately O 0 3.203828953246557e-07
half O 0 3.282925433722994e-07
the O 0 8.334922654285037e-07
level O 0 1.4994000594015233e-05
of O 0 2.779270289465785e-05
Hp O 0 9.357459202874452e-05
in O 0 1.1563810403458774e-05
control O 0 4.795287532033399e-05
sera O 0 0.0002773785963654518
from O 0 5.1957931646029465e-06
the O 0 5.1690658438019454e-06
Hp1 O 0 6.731205940013751e-05
phenotype O 0 6.599722837563604e-06
( O 0 4.263027335582592e-07
1 O 0 1.4746044598723529e-06
. O 0 6.1215708058171e-08
26 O 0 3.428580839681672e-06
+ O 0 1.2856470448241453e-06
/ O 0 1.4539723451889586e-06
- O 0 1.0998350035151816e-06
0 O 0 8.724982762942091e-07
. O 0 2.76696070500293e-08
33 O 0 2.0388770280987956e-06
mg O 0 7.27704718883615e-06
/ O 0 4.4984190026298165e-06
ml O 0 3.7582035474770237e-06
; O 0 3.402109598482639e-07
n O 0 8.377689482585993e-06
= O 0 5.932137355557643e-06
9 O 0 4.19610523749725e-06
) O 0 8.348639113364698e-08
, O 0 4.785952256725068e-08
showing O 0 6.935337637514749e-07
a O 0 1.7716101865516976e-06
gene O 0 2.4521407340216683e-06
- O 0 3.8067055356805213e-06
dosage O 0 1.957493986992631e-05
effect O 0 1.8007151084020734e-05
. O 0 3.893527264153818e-06

The O 0 0.00030416989466175437
other O 0 1.0911294339166488e-05
allele O 0 4.4221440475666896e-05
( O 0 5.974628038529772e-06
Hp2 O 0 0.00013355290866456926
) O 0 5.375911769078812e-07
of O 0 1.693800300017756e-06
individuals O 0 2.98770402196169e-07
with O 0 2.850342980309506e-06
Hp2 O 1 0.8973883986473083
/ O 1 0.895013689994812
Hpdel O 1 0.9820902347564697
was O 1 0.7723782062530518
found O 0 5.789616352558369e-06
to O 0 4.6617736870757653e-07
have O 0 5.251620791568712e-07
, O 0 1.37625960405785e-07
in O 0 3.987510694969387e-07
all O 0 2.3317046782267425e-07
exons O 0 4.781700681633083e-06
, O 0 2.1239645775494864e-07
no O 0 1.2145692096510174e-07
mutation O 0 1.049977882416897e-07
, O 0 1.706604280116153e-08
by O 0 5.679121617419014e-09
DNA O 0 1.7027358012455807e-07
sequencing O 0 3.1979357117961626e-06
. O 0 2.14164924727811e-06

On O 0 0.00010119292710442096
the O 0 3.5691973607754335e-06
basis O 0 2.6616028208081843e-06
of O 0 2.9270229333633324e-06
the O 0 1.0488204225111986e-06
present O 0 7.073028882587096e-07
study O 0 6.714752203151875e-07
, O 0 2.2174737068780814e-07
the O 0 5.10538825437834e-07
mechanism O 0 3.950642167183105e-06
of O 0 2.15584623219911e-05
anhaptoglobinemia B-Disease 0 0.00010616815416142344
and O 0 4.313342287787236e-06
the O 0 4.684422947320854e-06
mechanism O 0 6.459149517468177e-06
of O 0 2.0081128241145052e-05
anomalous O 0 0.0007535035838373005
inheritance O 0 0.00015202997019514441
of O 0 0.0008119231788441539
Hp O 0 0.0006957103032618761
phenotypes O 0 3.7366655305959284e-05
were O 0 4.707531388703501e-06
well O 0 1.455952428841556e-06
explained O 0 4.674391220760299e-06
. O 0 1.8606018556965864e-06

However O 0 2.832965947163757e-05
, O 0 2.047208226940711e-06
the O 0 1.1078788020313368e-06
mechanism O 0 5.216691533860285e-06
of O 0 1.9355582480784506e-05
hypohaptoglobinemia B-Disease 0 0.0020276678260415792
remains O 0 0.000422245153458789
unknown O 0 0.0002908981987275183

ATM O 0 0.0060649532824754715
mutations O 0 0.00012391219206620008
and O 0 2.0410894649103284e-05
phenotypes O 0 0.0006760914693586528
in O 0 0.0015622719656676054
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 0.00019832391990348697
in O 0 0.00013260068953968585
the O 0 9.056198905454949e-05
British O 0 8.548056212021038e-05
Isles O 0 0.00015975357382558286
: O 0 7.194862519099843e-07
expression O 0 9.97014581116673e-07
of O 0 1.292353999815532e-06
mutant O 0 5.080077698949026e-06
ATM O 0 8.209872248698957e-06
and O 0 6.282021303150032e-08
the O 0 1.190759348901338e-07
risk O 0 4.821989705305896e-07
of O 0 4.310718395572621e-06
leukemia B-Disease 1 1.0
, O 0 0.01119405310600996
lymphoma B-Disease 1 1.0
, O 0 2.9378927138168365e-05
and O 0 1.1351878129062243e-05
breast B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999990463256836
. O 0 1.7182524970849045e-05

We O 0 6.9293682827265e-06
report O 0 1.0041435416496824e-06
the O 0 4.84073268580687e-07
spectrum O 0 1.989007841984858e-06
of O 0 3.589148946048226e-06
59 O 0 5.298324686009437e-05
ATM O 0 5.821505328640342e-05
mutations O 0 2.793288786051562e-06
observed O 0 1.7438913346268237e-05
in O 0 8.519525727024302e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9997904896736145
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.545974661596119e-06
patients O 0 9.327914654022607e-07
in O 0 1.046753027367231e-06
the O 0 4.943518888467224e-06
British O 0 3.8815149309812114e-05
Isles O 0 0.00011219771840842441
. O 0 4.350370090833167e-06

Of O 0 0.001307465834543109
51 O 0 0.0011933583300560713
ATM O 0 0.0006037792772985995
mutations O 0 1.0735782780102454e-05
identified O 0 4.9023637984646484e-06
in O 0 3.708076974362484e-06
families O 0 4.0489686625733157e-07
native O 0 9.606802677808446e-07
to O 0 5.909478772991861e-07
the O 0 9.80264667305164e-06
British O 0 3.923082476831041e-05
Isles O 0 8.27895273687318e-05
, O 0 7.159835604397813e-06
11 O 0 4.329582952777855e-05
were O 0 1.858923860709183e-05
founder O 0 6.73968461342156e-05
mutations O 0 1.4040977021068102e-06
, O 0 5.778676950285444e-07
and O 0 1.7898560145113152e-07
2 O 0 1.4534011825162452e-06
of O 0 5.252281312095874e-07
these O 0 9.150701885118906e-08
11 O 0 6.210117135196924e-06
conferred O 0 2.8800206564483233e-05
a O 0 2.5884701244649477e-06
milder O 0 8.002059985301457e-06
clinical O 0 1.3235287951829378e-05
phenotype O 0 2.7902294732484734e-06
with O 0 4.878150150489091e-08
respect O 0 7.645521691301838e-07
to O 0 7.88490581271617e-07
both O 0 1.7691381799522787e-05
cerebellar B-Disease 1 0.9999934434890747
degeneration I-Disease 1 1.0
and O 0 2.9471641028067097e-05
cellular O 0 0.000767984427511692
features O 0 6.56562224321533e-06
. O 0 1.99289479496656e-06

We O 0 0.00012508773943409324
report O 0 9.936477908922825e-06
, O 0 8.566971700929571e-07
in O 0 1.5395102082038647e-06
two O 0 4.4807316044170875e-06
A B-Disease 1 0.999970555305481
- I-Disease 1 0.9998748302459717
T I-Disease 1 1.0
families O 0 3.592532038965146e-06
, O 0 9.896114079310792e-07
an O 0 1.1716974768205546e-06
ATM O 0 5.055984001955949e-05
mutation O 0 3.072051185881719e-06
( O 0 1.603300120223139e-06
7271T O 0 4.875306331086904e-05
- O 0 3.952319821109995e-05
- O 0 0.0002785122487694025
> O 0 0.00022664778225589544
G O 0 0.000367461092537269
) O 0 9.079132610168017e-07
that O 0 1.6178780981590535e-07
may O 0 8.297124622913543e-07
be O 0 1.1265746735489301e-07
associated O 0 4.745601955846723e-08
with O 0 3.6401459624357813e-09
an O 0 1.656708725761291e-08
increased O 0 3.11642992301131e-07
risk O 0 6.969663672862225e-07
of O 0 1.410287313774461e-05
breast B-Disease 1 0.9985287189483643
cancer I-Disease 1 0.9785581827163696
in O 0 2.999254320457112e-05
both O 0 8.8865281213657e-06
homozygotes O 0 9.291235619457439e-05
and O 0 4.033962795801926e-06
heterozygotes O 0 2.188813959946856e-05
( O 0 4.4675547883343825e-07
relative O 0 2.915567165473476e-06
risk O 0 1.0476788929736358e-06
12 O 0 9.523283210910449e-07
. O 0 5.187161278286112e-08
7 O 0 4.6185227802197915e-06
; O 0 1.115904638027132e-06
P O 0 0.00032819356420077384
= O 0 2.9675204132217914e-05
. O 0 1.2363499308776227e-06
0025 O 0 6.264659896260127e-05
) O 0 3.3286599432358344e-07
, O 0 5.3124605159382554e-08
although O 0 2.86474808319781e-08
there O 0 4.463687375277914e-08
is O 0 1.1667150090488576e-07
a O 0 5.616557814391854e-07
less O 0 2.616530764498748e-06
severe O 1 0.9997305274009705
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 3.610687826949288e-06
in O 0 1.313818529524724e-07
terms O 0 9.340958229131502e-08
of O 0 1.2860807885317627e-07
the O 0 1.7170663113574847e-07
degree O 0 5.4690357501385733e-05
of O 0 0.00015643711958546191
cerebellar B-Disease 1 0.9999974966049194
degeneration I-Disease 1 0.9999998807907104
. O 0 4.349177106632851e-05

This O 0 3.667911369120702e-05
mutation O 0 9.30152145883767e-06
( O 0 3.845510946121067e-06
7271T O 0 3.859233038383536e-05
- O 0 1.7528618627693504e-05
- O 0 4.721685399999842e-05
> O 0 4.190518302493729e-05
G O 0 5.8439931308384985e-05
) O 0 3.2936472393885197e-07
also O 0 1.6617539699836925e-07
allows O 0 5.5864621373302725e-08
expression O 0 1.6676390259817708e-06
of O 0 3.654019565146882e-06
full O 0 6.56178508506855e-06
- O 0 3.98119846067857e-06
length O 0 3.301872766314773e-06
ATM O 0 4.1604118450777605e-05
protein O 0 1.0102533451572526e-05
at O 0 1.1018802979378961e-05
a O 0 8.497871704093996e-07
level O 0 1.2814385854653665e-06
comparable O 0 3.3847405234155303e-07
with O 0 1.2451751629782848e-08
that O 0 3.1679643797133394e-08
in O 0 4.801688078259758e-07
unaffected O 0 6.368829872371862e-06
individuals O 0 1.2522517067736771e-07
. O 0 9.007619041767612e-07

In O 0 0.00011295204603811726
addition O 0 8.84080509422347e-06
, O 0 2.0192669580865186e-06
we O 0 3.9094570070119516e-07
have O 0 4.1635405523265945e-07
studied O 0 1.592063927091658e-05
18 O 0 0.00023163427249528468
A B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
patients O 0 1.0113647476828191e-05
, O 0 3.1336708161688875e-07
in O 0 3.457870718648337e-07
15 O 0 1.4219173181118094e-06
families O 0 3.67663446354527e-08
, O 0 8.095592107792982e-08
who O 0 4.319906281580188e-07
developed O 0 1.744511791912373e-05
leukemia B-Disease 1 1.0
, O 0 0.0008929345058277249
lymphoma B-Disease 1 1.0
, O 0 0.0006064139888621867
preleukemic O 1 0.99960857629776
T O 1 0.9993568062782288
- O 0 0.00292297825217247
cell O 0 0.0334564670920372
proliferation O 0 0.24738386273384094
, O 0 7.102667950675823e-06
or O 0 0.0004025794623885304
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.2810921361960936e-05
mostly O 0 7.192138582468033e-07
in O 0 1.6546833876418532e-06
childhood O 0 0.00012766676081810147
. O 0 5.291615707392339e-06

A O 0 0.00018819750403054059
wide O 0 3.401939829927869e-05
variety O 0 3.2260711577691836e-06
of O 0 3.1450643291464075e-05
ATM O 0 0.0001456567260902375
mutation O 0 1.8219750472781016e-06
types O 0 1.3126280009601032e-06
, O 0 5.75172521166678e-07
including O 0 6.209153866620909e-07
missense O 0 1.8158923921873793e-05
mutations O 0 5.8821688071475364e-06
and O 0 1.4832723536528647e-05
in O 0 7.887667743489146e-05
- O 0 0.0002348871057620272
frame O 0 0.0004866310046054423
deletions O 0 2.287971437908709e-05
, O 0 1.181415541395836e-06
were O 0 7.26615496660088e-07
seen O 0 8.264461826001934e-07
in O 0 1.7292398979407153e-07
these O 0 5.8120821933016487e-08
patients O 0 1.3470714748109458e-06
. O 0 1.3423447171589942e-06

We O 0 3.930515595129691e-05
also O 0 2.034165390796261e-06
show O 0 8.556739885534626e-07
that O 0 1.3118304309500672e-07
25 O 0 1.744393443914305e-06
% O 0 4.1124638983092154e-07
of O 0 4.042901764478302e-06
all O 0 8.426841304753907e-06
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999954700469971
T I-Disease 1 1.0
patients O 0 7.666712917853147e-06
carried O 0 5.027280622016406e-06
in O 0 7.49063565308461e-06
- O 0 2.313356162630953e-05
frame O 0 0.0001105969276977703
deletions O 0 1.853671346907504e-05
or O 0 9.95109076029621e-06
missense O 0 2.6349447580287233e-05
mutations O 0 2.5091760562645504e-06
, O 0 5.2124414651189e-07
many O 0 1.4571628348392096e-08
of O 0 3.860819788314984e-07
which O 0 1.0319895693555736e-07
were O 0 2.2535606092333182e-07
also O 0 9.07758561652372e-08
associated O 0 5.5942781074236336e-08
with O 0 1.3606364923646197e-08
expression O 0 1.6816098877825425e-06
of O 0 6.854160801594844e-06
mutant O 0 3.9805334381526336e-05
ATM O 0 0.00017508088785689324
protein O 0 4.356370845925994e-05
. O 0 2.482889613020234e-06

The O 0 9.876658441498876e-05
DMPK O 0 0.003448914736509323
gene O 0 4.40077310486231e-05
of O 0 9.839583071880043e-05
severely O 1 0.9999992847442627
affected O 1 0.9999914169311523
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.7808002829551697
is O 0 9.030386536323931e-06
hypermethylated O 0 0.00016624393174424767
proximal O 0 0.00017873544129543006
to O 0 4.762849528106017e-07
the O 0 1.8697909354159492e-06
largely O 0 3.493430540402187e-06
expanded O 0 8.861064088705461e-06
CTG O 0 0.0002803237293846905
repeat O 0 1.122905632655602e-05
. O 0 2.5602787445677677e-06

Using O 0 0.00018937817367259413
methylation O 0 0.0003325598663650453
- O 0 0.00030045874882489443
sensitive O 0 0.0001530195149825886
restriction O 0 6.763248529750854e-05
enzymes O 0 7.0690566644771025e-06
, O 0 4.247841332016833e-07
we O 0 1.4649327795268619e-07
characterized O 0 7.510196269322478e-07
the O 0 7.805123232174083e-07
methylation O 0 2.4502985525032273e-06
pattern O 0 7.993829058250412e-06
on O 0 9.374365617986768e-06
the O 0 3.491891447993112e-06
5 O 0 4.027043814858189e-06
side O 0 2.806621296258527e-06
of O 0 1.734470424707979e-05
the O 0 2.2875503418617882e-05
CTG O 0 0.00022191621246747673
repeat O 0 7.208033821370918e-06
in O 0 5.269055691314861e-06
the O 0 4.349614755483344e-06
DMPK O 0 0.00012676834012381732
gene O 0 1.126115421357099e-06
of O 0 2.10963867175451e-06
normal O 0 6.202967142598936e-06
individuals O 0 2.6645661677093813e-08
and O 0 1.5588180701797683e-07
of O 0 2.6218210678052856e-06
patients O 0 2.3588965632370673e-05
affected O 0 8.401879313169047e-05
with O 0 0.0003960015601478517
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.3454028905689484e-06
showing O 0 2.214492724306183e-06
expansions O 0 1.7320817278232425e-06
of O 0 2.0625016077246983e-06
the O 0 1.8883345092035597e-06
repetitive O 0 3.1097762985154986e-05
sequence O 0 4.177722075837664e-06
. O 0 2.626398099891958e-06

The O 0 5.865555431228131e-05
gene O 0 9.54830557020614e-06
segment O 0 7.578664281027159e-06
analyzed O 0 1.1277596740910667e-06
corresponds O 0 2.211588707723422e-06
to O 0 6.615738925574988e-07
the O 0 6.154354650789173e-06
genomic O 0 6.380358536262065e-05
SacI O 0 0.0010466972598806024
- O 0 4.5647218939848244e-05
HindIII O 0 0.00010339975415263325
fragment O 0 2.178755312343128e-05
carrying O 0 1.0981520063069183e-05
exons O 0 2.871064680221025e-05
11 O 0 3.109524186584167e-05
- O 0 1.5781779438839294e-05
15 O 0 1.844966391217895e-05
. O 0 2.0820862118853256e-06

There O 0 0.00010000562178902328
is O 0 1.66599184012739e-05
constitutive O 0 0.00014608693891204894
methylation O 0 2.0242383470758796e-05
in O 0 8.916688784665894e-06
intron O 0 4.761480522574857e-05
12 O 0 1.8067956261802465e-05
at O 0 1.249733213626314e-05
restriction O 0 1.541625920253864e-06
sites O 0 1.173360260509071e-06
of O 0 5.17620401296881e-06
SacII O 0 0.0001291571679757908
and O 0 7.85866996011464e-06
HhaI O 0 0.00024708654382266104
, O 0 4.288609034119872e-06
localized O 0 2.4034323359956034e-05
1 O 0 2.359407335461583e-05
, O 0 8.412848160332942e-07
159 O 0 2.333031034140731e-06
- O 0 1.6648200471536256e-06
1 O 0 7.108759746188298e-06
, O 0 6.333949613690493e-07
232 O 0 3.2301195460604504e-06
bp O 0 8.687994522915687e-06
upstream O 0 1.944818541232962e-05
of O 0 3.944593481719494e-05
the O 0 8.656309364596382e-05
CTG O 0 0.0006554945721291006
repeat O 0 4.3904448830289766e-05
, O 0 5.461432010633871e-06
whereas O 0 4.2553442654025275e-06
most O 0 7.527678462793119e-07
, O 0 2.8298725851527706e-07
if O 0 8.039335597231911e-08
not O 0 1.4117252078449383e-07
all O 0 1.7316723699423164e-07
, O 0 2.120103346214819e-07
of O 0 1.0570574886514805e-06
the O 0 9.090283015211753e-07
other O 0 1.50551642263963e-07
sites O 0 1.0768982292574947e-06
of O 0 1.3018098798056599e-05
SacII O 0 0.0003223860985599458
, O 0 2.4572660549893044e-05
HhaI O 0 0.0002768224512692541
, O 0 5.317698651197134e-06
and O 0 4.272227670298889e-06
HpaII O 0 0.00016438910097349435
in O 0 8.953389624366537e-06
this O 0 1.178774141408212e-06
region O 0 5.4050269682193175e-06
are O 0 1.1651976592474966e-06
unmethylated O 0 1.913601408887189e-05
, O 0 7.171967695285275e-07
in O 0 1.130878786170797e-06
normal O 0 9.57118027145043e-06
individuals O 0 6.203838864848876e-08
and O 0 1.9914135407361755e-07
most O 0 8.456883904273127e-08
of O 0 6.685365860903403e-07
the O 0 2.271368430228904e-06
patients O 0 2.9739446745224996e-06
. O 0 1.507756451246678e-06

In O 0 7.562075916212052e-05
a O 0 1.9241841073380783e-05
number O 0 8.252275620179716e-06
of O 0 0.0001163273846032098
young O 0 4.364259075373411e-05
and O 0 1.4880923117743805e-05
severely O 0 0.005452074110507965
affected O 0 9.643477824283764e-06
patients O 0 4.9617783588473685e-06
, O 0 4.5061591436024173e-07
however O 0 4.451037227681809e-07
, O 0 1.691326048103292e-07
complete O 0 1.1563714679141412e-06
methylation O 0 4.498556336329784e-06
of O 0 3.8776188375777565e-06
these O 0 1.4168492157295987e-07
restriction O 0 1.775486794031167e-06
sites O 0 4.522104859461251e-07
was O 0 1.2939572116010822e-06
found O 0 4.927816732447354e-08
in O 0 9.340851647721138e-08
the O 0 6.19381864908064e-07
mutated O 0 3.138481815767591e-06
allele O 0 1.6692440112819895e-05
. O 0 3.1456977467314573e-06

In O 0 3.587179890018888e-05
most O 0 4.638058328509942e-07
of O 0 3.7497545690712286e-07
these O 0 4.260076380546707e-08
patients O 0 1.8656642453152017e-07
, O 0 2.1177264386551542e-08
the O 0 6.983722755649069e-08
onset O 0 4.1038110794033855e-05
of O 0 1.537743810331449e-05
the O 0 0.00019235620857216418
disease O 1 0.9999997615814209
was O 1 0.9999938011169434
congenital O 1 1.0
. O 0 8.367051486857235e-05

Preliminary O 0 0.000603294640313834
in O 0 0.00029966459260322154
vivo O 0 0.003484891029074788
footprinting O 0 0.0010932008735835552
data O 0 6.431157999031711e-06
gave O 0 1.5090770375536522e-06
evidence O 0 2.4174278223654255e-06
for O 0 3.116155539828469e-06
protein O 0 1.105099272535881e-05
- O 0 8.893725862435531e-06
DNA O 0 2.5928059130819747e-06
contact O 0 7.875025403336622e-06
in O 0 2.197732828790322e-05
normal O 0 0.00011556340177776292
genes O 0 1.0465400919201784e-05
at O 0 4.764700497617014e-05
an O 0 1.2510847682278836e-06
Sp1 O 0 2.7660888008540496e-05
consensus O 0 2.3526793029304827e-06
binding O 0 1.1856301398438518e-06
site O 0 4.203298431093572e-06
upstream O 0 5.928641712671379e-06
of O 0 7.532772542617749e-06
the O 0 1.6717613107175566e-05
CTG O 0 0.00019080589117947966
repeat O 0 5.5870168580440804e-06
and O 0 2.4734288217587164e-07
for O 0 1.0834255448344265e-07
a O 0 1.6128159074924042e-07
significant O 0 1.4995067942891183e-07
reduction O 0 1.2497444004111458e-06
of O 0 2.674072447916842e-06
this O 0 1.9901833070434805e-07
interaction O 0 8.113428293654579e-07
in O 0 1.9034299612030736e-06
cells O 0 5.013592954128399e-07
with O 0 1.5401697339711973e-07
a O 0 6.594701972062467e-06
hypermethylated O 0 0.00019104490638710558
DMPK O 0 0.0005482082488015294
gene O 0 7.823240594007075e-06
. O 0 5.931673854320252e-07
. O 0 1.533562453914783e-06

The O 0 0.0034368964843451977
hemochromatosis B-Disease 1 1.0
gene O 0 0.0002568210184108466
product O 0 3.521966209518723e-05
complexes O 0 2.4464354282827117e-05
with O 0 4.067483700964658e-07
the O 0 1.2261401934665628e-05
transferrin O 0 0.00018854576046578586
receptor O 0 2.842768662958406e-05
and O 0 1.043518636834051e-06
lowers O 0 5.077854439150542e-06
its O 0 2.2198921101335145e-07
affinity O 0 1.2887785487691872e-06
for O 0 6.266039918045863e-07
ligand O 0 1.5213192455121316e-05
binding O 0 3.6716492104460485e-06
. O 0 1.231877604368492e-06

We O 0 2.759957169473637e-05
recently O 0 5.938544745731633e-06
reported O 0 1.0878044349738047e-06
the O 0 2.1607105793464143e-07
positional O 0 5.397516360972077e-06
cloning O 0 1.3281642168294638e-06
of O 0 4.841730287807877e-07
a O 0 8.56875260524248e-07
candidate O 0 4.614353656506864e-06
gene O 0 1.5131412510527298e-05
for O 0 9.265991684515029e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999997615814209
HFE O 1 0.9999986886978149
. O 0 4.446370076038875e-05

The O 0 8.000015077413991e-05
gene O 0 1.298117967962753e-05
product O 0 8.443910701316781e-06
, O 0 8.459512059744156e-07
a O 0 1.4917403632352944e-06
member O 0 2.0470561139518395e-06
of O 0 1.0653426215867512e-05
the O 0 3.681595990201458e-05
major O 0 0.0009646154940128326
histocompatibility O 1 0.9997145533561707
complex O 1 0.999914288520813
class O 0 0.0003803142753895372
I O 0 0.0006910522934049368
- O 0 2.880707324948162e-05
like O 0 1.774066845428024e-06
family O 0 6.951322006898408e-07
, O 0 1.6512581169081386e-07
was O 0 1.8534786931923009e-06
found O 0 1.1113544218233073e-07
to O 0 3.8447989680889805e-08
have O 0 1.9326547828768526e-07
a O 0 2.1008549992984626e-06
mutation O 0 2.374571295149508e-06
, O 0 3.3154658467537956e-06
Cys O 0 0.00015871351934038103
- O 0 4.002107380074449e-05
282 O 0 0.00010396915604360402
- O 0 8.031951438169926e-05
- O 0 0.00035713333636522293
> O 0 0.0001719454157864675
Tyr O 0 0.0001956890628207475
( O 0 1.78319089627621e-06
C282Y O 0 1.4989768715167884e-05
) O 0 1.279207424431661e-07
, O 0 2.4176431523414976e-08
in O 0 8.686859587214713e-08
85 O 0 1.0624423794070026e-06
% O 0 1.8383521194209607e-07
of O 0 1.5955820344970562e-06
patient O 0 5.1262537454022095e-05
chromosomes O 0 0.00017515235231257975
. O 0 1.7607208064873703e-05

This O 0 8.19780780147994e-06
mutation O 0 5.118749413668411e-06
eliminates O 0 1.2838097063649911e-05
the O 0 4.007382358395262e-06
ability O 0 1.5055035191835486e-06
of O 0 4.821148468181491e-05
HFE O 0 0.0011931299231946468
to O 0 5.711436187993968e-06
associate O 0 6.743528501829132e-05
with O 0 3.023244289579452e-06
beta2 O 0 0.0010334620019420981
- O 0 0.0014680848689749837
microglobulin O 0 0.012614978477358818
( O 0 2.1976742573315278e-05
beta2m O 0 0.0003862340818159282
) O 0 2.026468564508832e-06
and O 0 2.1791834114992525e-06
prevents O 0 8.819298273010645e-06
cell O 0 0.0003719301603268832
- O 0 5.475120633491315e-05
surface O 0 0.00011245511268498376
expression O 0 9.835896344156936e-05
. O 0 2.8554825348692248e-06

A O 0 0.0008821804658509791
second O 0 7.06941937096417e-05
mutation O 0 2.795289901769138e-06
that O 0 7.876961944930372e-07
has O 0 1.0020943363997503e-06
no O 0 1.5200138250293094e-06
effect O 0 1.9580651496653445e-05
on O 0 0.00012752597103826702
beta2m O 0 0.0007924383389763534
association O 0 9.616090392228216e-05
, O 0 3.4155721095885383e-06
H63D O 0 9.24583146115765e-05
, O 0 1.148006276707747e-06
was O 0 8.723554856260307e-06
found O 0 5.1409176649031e-07
in O 0 3.2974313057820837e-07
eight O 0 2.968086221244448e-07
out O 0 4.5916184632233126e-08
of O 0 8.049951247812714e-07
nine O 0 2.8548536192829488e-06
patients O 0 4.865624418926018e-07
heterozygous O 0 4.623665290637291e-07
for O 0 6.694144758512266e-07
the O 0 5.650406365020899e-06
C282Y O 0 0.00015905075997579843
mutant O 0 7.439188630087301e-05
. O 0 7.0866599344299175e-06

In O 0 0.00011173020175192505
this O 0 2.567821866250597e-06
report O 0 1.6169540231203428e-06
, O 0 1.7814319619446906e-07
we O 0 8.054530553636141e-08
demonstrate O 0 7.046126029308653e-07
in O 0 3.566757868611603e-06
cultured O 0 7.027973333606496e-05
293 O 0 5.6436223530909047e-05
cells O 0 1.7035596101777628e-05
overexpressing O 0 0.00010591232421575114
wild O 0 7.677468602196313e-06
- O 0 1.2070330740243662e-05
type O 0 1.3624716302729212e-05
or O 0 6.535392913065152e-06
mutant O 0 2.4191313059418462e-05
HFE O 0 0.00016840046737343073
proteins O 0 8.75260184329818e-07
that O 0 1.0583482179526982e-07
both O 0 3.59814436023953e-07
the O 0 1.103012436942663e-06
wild O 0 8.265131441476115e-07
- O 0 4.144135345995892e-06
type O 0 4.474620709515875e-06
and O 0 5.7156316870532464e-06
H63D O 0 0.004201661329716444
HFE O 0 0.002398785902187228
proteins O 0 7.721861948084552e-06
form O 0 3.9071783248800784e-06
stable O 0 2.6486955903237686e-05
complexes O 0 4.817163699044613e-06
with O 0 1.8363860476711125e-07
the O 0 5.0570210987643804e-06
transferrin O 0 0.00014531242777593434
receptor O 0 6.627183756791055e-05
( O 0 2.6360314677731367e-06
TfR O 0 0.0007256261305883527
) O 0 1.0362415423514904e-06
. O 0 7.895252451817214e-07

The O 0 0.0002386907144682482
C282Y O 0 0.0006787471356801689
mutation O 0 1.1915131835849024e-05
nearly O 0 1.1989597624051385e-05
completely O 0 5.7558968364901375e-06
prevents O 0 5.777288833996863e-07
the O 0 1.687282065176987e-06
association O 0 2.3423808670486324e-06
of O 0 1.8632084675118676e-06
the O 0 3.752241127585876e-06
mutant O 0 4.1514627810101956e-05
HFE O 0 0.0005464348359964788
protein O 0 6.758929430361604e-06
with O 0 2.9509487831091974e-07
the O 0 7.064103556331247e-06
TfR O 0 0.006424604449421167
. O 0 9.263879292120691e-06

Studies O 0 0.0002724918886087835
on O 0 0.00022242208069656044
cell O 0 0.00012951258395332843
- O 0 1.2432583389454521e-05
associated O 0 3.3502763017168036e-06
transferrin O 0 4.970339796273038e-05
at O 0 2.9168601031415164e-05
37 O 0 1.1399915820220485e-05
degrees O 0 0.0001032842556014657
C O 0 6.151940760901198e-05
suggest O 0 9.315291435996187e-07
that O 0 2.903832694300945e-07
the O 0 4.50011384600657e-06
overexpressed O 0 0.00011834375618491322
wild O 0 8.40241409605369e-06
- O 0 8.716917363926768e-06
type O 0 8.23118807602441e-06
HFE O 0 0.00012691106530837715
protein O 0 2.053921662081848e-06
decreases O 0 1.424035758645914e-06
the O 0 4.844067120757245e-07
affinity O 0 7.102906920408714e-07
of O 0 3.4405559290462406e-06
the O 0 5.420709385361988e-06
TfR O 0 0.0007872228743508458
for O 0 8.065819201874547e-06
transferrin O 0 0.00042855675565078855
. O 0 6.74603052175371e-06

The O 0 0.003627137281000614
overexpressed O 0 0.044960588216781616
H63D O 0 0.3258165717124939
protein O 0 0.0006231527077034116
does O 0 3.9148280848166905e-06
not O 0 7.46438331589161e-07
have O 0 2.204722591159225e-07
this O 0 3.9901120629792786e-08
effect O 0 7.5320804171497e-07
, O 0 7.551406611128186e-08
providing O 0 3.0723299460078124e-08
the O 0 3.0414110341325795e-08
first O 0 6.568513555293976e-08
direct O 0 4.673311337910491e-08
evidence O 0 6.954625320076957e-08
for O 0 1.6913840283905301e-07
a O 0 1.0098355005538906e-06
functional O 0 2.3969845642568544e-05
consequence O 0 2.3340469851973467e-05
of O 0 2.102836879203096e-05
the O 0 2.9450457077473402e-05
H63D O 0 0.001334149856120348
mutation O 0 2.5504195946268737e-05
. O 0 5.283336122374749e-06

Addition O 0 6.299850065261126e-05
of O 0 0.0002481053816154599
soluble O 0 0.0008336193859577179
wild O 0 0.00010003070929087698
- O 0 0.0002966904721688479
type O 0 0.0006548169767484069
HFE O 1 0.9978985786437988
/ O 0 0.0013286712346598506
beta2m O 0 0.0005723534268327057
heterodimers O 0 9.6744297479745e-05
to O 0 4.172187345830025e-06
cultured O 0 5.330622661858797e-05
cells O 0 5.540405254578218e-06
also O 0 9.068895110431185e-07
decreased O 0 1.6638530723867007e-05
the O 0 1.2218190477142343e-06
apparent O 0 5.112734015710885e-06
affinity O 0 1.7260548474951065e-06
of O 0 8.87061014509527e-06
the O 0 4.484810233407188e-06
TfR O 0 0.0003008167550433427
for O 0 2.504392114133225e-06
its O 0 1.675103362686059e-06
ligand O 0 2.0896828573313542e-05
under O 0 1.1590970643737819e-05
steady O 0 5.697111555491574e-05
- O 0 3.0249168503360124e-06
state O 0 7.45962950077228e-07
conditions O 0 4.978187462256756e-06
, O 0 2.456418997098808e-07
both O 0 1.8677381774523383e-07
in O 0 9.436815844310331e-07
293 O 0 4.7737448767293245e-06
cells O 0 1.4145083468974917e-06
and O 0 8.021489747989108e-07
in O 0 5.032456556364195e-06
HeLa O 0 0.00016861864423844963
cells O 0 8.360289939446375e-06
. O 0 1.126778215621016e-06

Furthermore O 0 0.00021486415062099695
, O 0 1.0661120541044511e-05
at O 0 3.133684367639944e-05
4 O 0 2.1416090021375567e-05
degrees O 0 0.0002583288587629795
C O 0 0.00015701708616688848
, O 0 8.698098667991871e-07
the O 0 1.895623995551432e-06
added O 0 8.01404985395493e-06
soluble O 0 3.255490446463227e-05
complex O 0 3.1300973205361515e-05
of O 0 6.105920328991488e-05
HFE O 0 0.011972199194133282
/ O 0 0.00029378681210801005
beta2m O 0 0.00011852671741507947
inhibited O 0 1.1798463674494997e-05
binding O 0 4.569180418911856e-06
of O 0 2.084786319755949e-05
transferrin O 0 0.00016217918891925365
to O 0 6.616409791604383e-06
HeLa O 0 0.0003233625029679388
cell O 0 0.00010297182598151267
TfR O 0 0.0012890101643279195
in O 0 8.55202779348474e-06
a O 0 1.1214064215891995e-05
concentration O 0 0.00023989490000531077
- O 0 2.5835530323092826e-05
dependent O 0 3.837659733108012e-06
manner O 0 4.877224455412943e-06
. O 0 9.568454970576568e-07

Scatchard O 0 0.002407384803518653
plots O 0 8.522369171259925e-05
of O 0 2.5071307391044684e-05
these O 0 6.277368811424822e-07
data O 0 3.0123255783109926e-06
indicate O 0 2.8962733722437406e-06
that O 0 2.961438951842865e-07
the O 0 3.458857463556342e-06
added O 0 4.16872717323713e-06
heterodimer O 0 1.9052886273129843e-05
substantially O 0 1.4771859468964976e-06
reduced O 0 9.072165312318248e-07
the O 0 3.3208982586074853e-07
affinity O 0 1.2178649058114388e-06
of O 0 9.262836101697758e-06
TfR O 0 0.0016746098408475518
for O 0 1.3390839740168303e-05
transferrin O 0 0.0006176619208417833
. O 0 1.1554891898413189e-05

These O 0 2.9348520911298692e-06
results O 0 1.1574280506465584e-05
establish O 0 3.1312767987401458e-06
a O 0 7.457505944330478e-06
molecular O 0 2.7968819267698564e-05
link O 0 1.0813846529345028e-05
between O 0 1.56198311742628e-05
HFE O 0 0.0008037334773689508
and O 0 1.0226347512798384e-05
a O 0 1.7339778423774987e-05
key O 0 2.4289372959174216e-05
protein O 0 8.212925422412809e-06
involved O 0 2.4493849650752963e-06
in O 0 1.2497464012994897e-05
iron O 0 0.0005662349867634475
transport O 0 7.387103687506169e-05
, O 0 2.2117701519164257e-06
the O 0 5.5835439525253605e-06
TfR O 0 0.0006126206717453897
, O 0 1.7784828969524824e-06
and O 0 5.997978860250441e-07
raise O 0 5.417476245384023e-07
the O 0 1.5984651327016763e-06
possibility O 0 1.5223611171677476e-06
that O 0 4.126359556266834e-07
alterations O 0 1.744360451993998e-05
in O 0 2.5342203571199207e-06
this O 0 2.0729356720039505e-07
regulatory O 0 1.180647359433351e-06
mechanism O 0 2.491226723577711e-06
may O 0 6.177772888804611e-07
play O 0 1.895257497608327e-07
a O 0 8.55738733207545e-08
role O 0 1.6390987411796232e-07
in O 0 2.919978214777075e-07
the O 0 1.7442404214307317e-06
pathogenesis O 0 0.004388241097331047
of O 0 0.03999832272529602
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00013144112017471343
. O 0 7.975858352438081e-06

Genomic O 0 0.00021803054551128298
organization O 0 2.243659400846809e-05
of O 0 3.772232594201341e-05
the O 0 6.392105569830164e-05
UBE3A O 0 0.006656714715063572
/ O 0 0.0004037557228002697
E6 O 0 0.0004106496344320476
- O 0 0.00013363569451030344
AP O 0 0.00010047447722172365
gene O 0 1.9957647054980043e-06
and O 0 4.3326014065314666e-07
related O 0 7.312094112421619e-06
pseudogenes O 0 9.994671563617885e-05
. O 0 3.531856464178418e-06

The O 0 0.0002577389241196215
UBE3A O 0 0.0031900303438305855
gene O 0 2.1860858396394178e-05
encodes O 0 2.0672985556302592e-05
the O 0 3.058401489397511e-05
E6 O 0 0.00038746613427065313
- O 0 0.0002605153131298721
AP O 0 0.0005770527059212327
ubiquitin O 0 0.00022044318029657006
- O 0 8.543076546629891e-05
protein O 0 3.6319350328994915e-05
ligase O 0 1.7075741197913885e-05
and O 0 1.18131754334172e-06
has O 0 3.6713515783048933e-07
recently O 0 4.148182313201687e-07
been O 0 1.0914919812421431e-07
shown O 0 5.386217338809729e-08
to O 0 1.3595003345301393e-08
be O 0 6.292862764212259e-08
mutated O 0 3.4969302760146093e-06
in O 0 8.986167085822672e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.4110755920410156
who O 0 2.6852942028199323e-05
lack O 0 0.00033106771297752857
15q11 O 0 0.002650660928338766
- O 0 0.0006324562127701938
q13 O 0 0.0008452783804386854
deletions O 0 7.086623372742906e-05
or O 0 1.7112126442953013e-05
chromosome O 0 0.0007735386025160551
15 O 0 0.00016523772501386702
paternal O 1 0.9936510920524597
uniparental B-Disease 1 0.9999979734420776
disomy I-Disease 1 0.9994113445281982
. O 0 4.8953948862617835e-05

Previous O 0 0.0007782439352013171
UBE3A O 0 0.00521231209859252
cDNA O 0 0.00015411291678901762
analysis O 0 5.547563432628522e-06
has O 0 5.706257866222586e-07
shown O 0 9.013419912662357e-07
a O 0 1.833407509366225e-06
coding O 0 5.012875135435024e-06
region O 0 1.7458813772464055e-06
of O 0 4.453144811122911e-06
approximately O 0 7.493307293771068e-06
2 O 0 3.539008685038425e-05
. O 0 4.765061930811498e-06

6 O 0 0.001456372905522585
kb O 0 0.0011953008361160755
and O 0 1.5868239643168636e-05
a O 0 2.2704894945491105e-05
3 O 0 2.5957946490962058e-05
- O 0 2.59247262874851e-05
untranslated O 0 0.0002342101652175188
region O 0 1.4803781596128829e-05
( O 0 2.3235941171151353e-06
UTR O 0 9.013690578285605e-05
) O 0 6.355308528327441e-07
of O 0 1.932472332555335e-05
< O 0 0.00012504980259109288
50 O 0 3.6257544707041234e-05
bp O 0 2.4217719328589737e-05
, O 0 7.640652484042221e-07
whereas O 0 7.199358265097544e-07
Northern O 0 5.959304303360113e-07
analysis O 0 2.501921301245602e-07
has O 0 2.3431623219494213e-07
indicated O 0 5.212795031184214e-07
mRNA O 0 6.508279284389573e-07
sizes O 0 3.319473194096645e-07
of O 0 5.349765160644893e-06
5 O 0 9.567629604134709e-06
- O 0 1.681301546341274e-05
8 O 0 4.1560775571269915e-05
kb O 0 0.00021509005455300212
. O 0 3.878403276758036e-06

We O 0 2.6997555323760025e-05
have O 0 1.1116635505459271e-06
analyzed O 0 1.1923449392270413e-06
additional O 0 8.395424515583727e-07
cDNA O 0 1.834380418586079e-05
clones O 0 3.606035534176044e-06
and O 0 1.3503445472906606e-07
provide O 0 3.8617912423433154e-08
evidence O 0 1.5024068034108495e-07
for O 0 1.0199566702340235e-07
an O 0 1.2672013838255225e-07
additional O 0 7.098748255884857e-07
0 O 0 3.558810203685425e-05
. O 0 3.1888787361822324e-06

5 O 0 0.00046740088146179914
kb O 0 0.0007049512350931764
of O 0 0.00017626042244955897
5 O 0 5.0253198423888534e-05
- O 0 2.3939599486766383e-05
UTR O 0 0.0002450374886393547
and O 0 3.5849820960720535e-06
> O 0 1.2098232218704652e-05
2 O 0 1.307505681324983e-05
kb O 0 5.285022780299187e-05
of O 0 3.1149171263678e-05
3 O 0 9.245408728020266e-05
- O 0 0.0001554404298076406
UTR O 0 0.0010155183263123035
. O 0 5.635548404825386e-06

We O 0 6.877639862068463e-06
have O 0 1.5350549631421018e-07
established O 0 2.233474276636116e-07
the O 0 3.104173629253637e-07
genomic O 0 2.2348388029058697e-06
organization O 0 1.175202442027512e-06
of O 0 7.805906534485985e-06
UBE3A O 0 0.0002034564531641081
and O 0 8.846033665577124e-07
the O 0 1.0606100886434433e-06
sequence O 0 9.95288360172708e-07
of O 0 1.2877532753918786e-05
intron O 0 0.00021832446509506553
- O 0 8.577426342526451e-05
exon O 0 2.4840883270371705e-05
borders O 0 6.916750862728804e-06
. O 0 2.868165211111773e-06

We O 0 0.00011579561396501958
have O 0 6.268237484619021e-06
also O 0 2.5855388230411336e-06
mapped O 0 1.4787166264795815e-06
two O 0 8.64760295371525e-07
highly O 0 3.510931719574728e-06
homologous O 0 7.119954716472421e-06
processed O 0 2.87126731564058e-05
pseudogenes O 0 7.500234642066061e-05
, O 0 6.175661837914959e-06
UBE3AP1 O 0 0.00027608469827100635
and O 0 1.8615337467053905e-05
UBE3AP2 O 0 0.0003545100043993443
, O 0 1.7206182292284211e-06
to O 0 3.150093732529058e-07
chromosomes O 0 3.0677915674459655e-06
2 O 0 8.095211342151742e-06
and O 0 1.3606399988930207e-06
21 O 0 2.4990644305944443e-05
, O 0 8.502152013534214e-07
respectively O 0 2.2403144157578936e-06
, O 0 3.796231595742938e-08
and O 0 1.8821586067474527e-08
determined O 0 8.553095653951459e-08
their O 0 7.325959927584336e-08
genomic O 0 4.9904606385098305e-06
organization O 0 3.7917632198514184e-06
. O 0 1.4150182323646732e-06

These O 0 2.7491294531500898e-05
results O 0 1.55770485434914e-05
will O 0 3.084902573391446e-07
form O 0 6.362282078953285e-08
the O 0 3.5117974306331234e-08
basis O 0 3.292327477311119e-08
for O 0 1.4118915814265165e-08
studies O 0 9.534353750950686e-08
of O 0 3.460955326772819e-07
mutation O 0 3.3562329804226465e-07
and O 0 4.830932880395267e-07
imprinting O 0 3.5510467569110915e-05
of O 0 7.029628613963723e-05
UBE3A O 0 0.012732994742691517
. O 0 2.341428626095876e-05

Mutation O 0 0.00028300427948124707
spectrum O 0 0.00020257184223737568
and O 0 7.2408206506224815e-06
genotype O 0 5.9973372117383406e-05
- O 0 5.141768997418694e-05
phenotype O 0 1.489459646109026e-05
analyses O 0 1.1613702781687607e-06
in O 0 2.2659962723992066e-06
Cowden B-Disease 1 0.9712257385253906
disease I-Disease 1 0.9941062927246094
and O 0 0.000113531386887189
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.1191464131552493e-06
two O 0 3.273579295637319e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 0.9999991655349731
with O 0 2.22156540985452e-05
germline O 1 0.9999912977218628
PTEN O 1 0.9999812841415405
mutation O 0 4.504296157392673e-05
. O 0 5.344757482816931e-06

The O 0 0.00688222935423255
tumour B-Disease 1 1.0
suppressor O 1 0.999942421913147
gene O 0 0.0003505094500724226
PTEN O 0 0.0015047286869958043
, O 0 6.651520720879489e-07
which O 0 6.882233805072246e-08
maps O 0 8.59910755934834e-07
to O 0 9.480926905780507e-07
10q23 O 0 0.00026180787244811654
. O 0 1.1968396393058356e-05

3 O 0 5.026345752412453e-05
and O 0 8.282387966573879e-07
encodes O 0 1.9756346318899887e-06
a O 0 3.1350000426755287e-06
403 O 0 5.485820111061912e-06
amino O 0 5.842129667144036e-06
acid O 0 3.3258534131164197e-06
dual O 0 3.216428740415722e-05
specificity O 0 0.00010970245784847066
phosphatase O 0 0.028465094044804573
( O 0 0.00010622305126162246
protein O 0 0.00023571315978188068
tyrosine O 0 0.0003300960815977305
phosphatase O 0 0.0009716682252474129
; O 0 7.956144145282451e-06
PTPase O 0 0.00013167483848519623
) O 0 4.910594952889369e-07
, O 0 1.1994691817562853e-07
was O 0 1.1154407957292278e-06
shown O 0 3.247201050271542e-07
recently O 0 5.704233103642764e-07
to O 0 3.822424332611263e-08
play O 0 5.48314517345716e-07
a O 0 3.888704043220059e-07
broad O 0 1.0920161912508775e-06
role O 0 2.0361992483231006e-06
in O 0 4.805202024726896e-06
human O 0 3.893415123457089e-05
malignancy B-Disease 0 0.0027107717469334602
. O 0 9.130612852459308e-06

Somatic O 0 0.03828132525086403
PTEN O 0 0.02170228771865368
deletions O 0 8.296332089230418e-05
and O 0 2.83480153484561e-06
mutations O 0 5.778434797321097e-07
were O 0 2.758146422365826e-07
observed O 0 2.137583408057253e-07
in O 0 2.0939931744123896e-07
sporadic B-Disease 0 5.395177868194878e-05
breast I-Disease 1 0.9999854564666748
, I-Disease 0 0.0003272527828812599
brain I-Disease 1 1.0
, I-Disease 0 9.604560909792781e-05
prostate I-Disease 1 1.0
and I-Disease 1 0.99916672706604
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9097265005111694
lines O 0 4.0482491385773756e-06
and O 0 1.246147292022215e-07
in O 0 2.7697572591023345e-07
several O 0 2.6149288601118315e-07
primary O 0 0.000879612925928086
tumours B-Disease 1 1.0
such O 0 4.0738996176514775e-06
as O 0 0.0005144061869941652
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999756813049316
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999991655349731
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.00024215754820033908

In O 0 0.00015500865993089974
addition O 0 3.2526819268241525e-05
, O 0 1.1250053830735851e-05
PTEN O 0 0.0006830726051703095
was O 0 8.809396604192443e-06
identified O 0 2.4670302423146495e-07
as O 0 4.626739524837831e-08
the O 0 6.33323722354362e-08
susceptibility O 0 3.959970399591839e-06
gene O 0 1.3426723626253079e-06
for O 0 1.0076843182105222e-06
two O 0 3.289324740762822e-05
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.470301478751935e-05
CD B-Disease 0 0.0009337402880191803
; O 0 8.862635695550125e-06
MIM O 0 0.007901379838585854
158350 O 0 0.0005680719041265547
) O 0 1.5564115756205865e-06
and O 0 5.752867764385883e-06
Bannayan B-Disease 0 0.0014599665300920606
- I-Disease 0 0.006011482793837786
Zonana I-Disease 1 0.761043131351471
( I-Disease 0 1.510462516307598e-05
BZS I-Disease 0 0.0007523171952925622
) I-Disease 0 2.361202859901823e-06
or I-Disease 0 2.2718945729138795e-06
Ruvalcaba I-Disease 0 0.00013332640810403973
- I-Disease 0 0.00018862451543100178
Riley I-Disease 0 0.0003590813430491835
- I-Disease 1 0.9791064262390137
Smith I-Disease 1 0.940934956073761
syndrome I-Disease 1 1.0
( O 0 3.841996658593416e-05
MIM O 0 0.2575705945491791
153480 O 0 0.0011566691100597382
) O 0 5.748441708419705e-06
. O 0 2.5792196538532153e-06

Constitutive O 0 0.0021584813948720694
DNA O 0 5.0084465328836814e-05
from O 0 3.092127735726535e-05
37 O 0 6.0151840443722904e-05
CD B-Disease 0 2.5440624085604213e-05
families O 0 2.1155588569854444e-07
and O 0 6.631480573560111e-07
seven O 0 3.2688124065316515e-06
BZS B-Disease 0 0.00020971022604499012
families O 0 7.876565888409459e-08
was O 0 1.3715562090510502e-06
screened O 0 2.029495590250008e-06
for O 0 3.4388829135423293e-06
germline O 0 0.0010215158108621836
PTEN O 0 0.004620842635631561
mutations O 0 7.869664841564372e-06
. O 0 2.399480081294314e-06

PTEN O 0 0.011250919662415981
mutations O 0 1.681133289821446e-05
were O 0 7.189579719124595e-06
identified O 0 8.254993417722289e-07
in O 0 1.1022868875443237e-06
30 O 0 3.1718541322334204e-06
of O 0 9.103138836508151e-06
37 O 0 4.100505248061381e-05
( O 0 2.0224874788254965e-06
81 O 0 4.4306663767201826e-05
% O 0 1.2784565797119285e-06
) O 0 2.601231869903131e-07
CD B-Disease 0 4.294330210541375e-06
families O 0 9.082451413178205e-08
, O 0 2.1360958157856658e-07
including O 0 6.607453428841836e-07
missense O 0 2.2466119844466448e-05
and O 0 2.551701618358493e-05
nonsense O 0 0.0003456002741586417
point O 0 7.355240086326376e-05
mutations O 0 1.8529166254666052e-06
, O 0 5.161782041795959e-07
deletions O 0 1.6035570524763898e-06
, O 0 4.3132294536007976e-07
insertions O 0 2.863349891413236e-06
, O 0 2.9420971259241924e-07
a O 0 1.2489186929087737e-06
deletion O 0 2.600338848424144e-05
/ O 0 7.832128903828561e-05
insertion O 0 2.475279507052619e-05
and O 0 1.2057917047059163e-05
splice O 0 0.00024685810785740614
site O 0 4.126780913793482e-05
mutations O 0 1.0564796866674442e-05
. O 0 4.360018010629574e-06

These O 0 9.45587544265436e-06
mutations O 0 5.066332505521132e-06
were O 0 4.125295163248666e-06
scattered O 0 1.7135341749963118e-06
over O 0 5.264562901174941e-07
the O 0 9.916113867802778e-07
entire O 0 4.8645570132066496e-06
length O 0 4.736563823826145e-06
of O 0 0.00011097830429207534
PTEN O 0 0.0007611560868099332
, O 0 1.055295911100984e-06
with O 0 7.283188097062521e-08
the O 0 1.2365504744593636e-06
exception O 0 1.1698004982463317e-06
of O 0 3.887345883413218e-06
the O 0 4.707446350948885e-06
first O 0 8.346723006980028e-06
, O 0 1.2250801546542789e-06
fourth O 0 1.560291821078863e-05
and O 0 8.632507615402574e-07
last O 0 7.633290806552395e-06
exons O 0 3.9993832615436986e-05
. O 0 5.283779501041863e-06

A O 0 0.001704604597762227
hot O 0 0.0009186618262901902
spot O 0 0.0001482687657698989
for O 0 1.1810093383246567e-05
PTEN O 0 0.0004585548012983054
mutation O 0 1.3824807183482335e-06
in O 0 3.716269247888704e-06
CD B-Disease 0 2.050516559393145e-05
was O 0 3.094242129009217e-05
identified O 0 1.045511908159824e-06
in O 0 1.3284453643791494e-06
exon O 0 1.9049954289585003e-06
5 O 0 2.3121128833736293e-06
that O 0 1.1188026860509126e-07
contains O 0 1.0415203632874181e-06
the O 0 8.67790004122071e-06
PTPase O 0 0.00022393246763385832
core O 0 0.00012165539374109358
motif O 0 1.23331037684693e-05
, O 0 2.4016222255340836e-07
with O 0 7.862051631946088e-08
13 O 0 3.7105319279362448e-06
of O 0 6.56902329865261e-06
30 O 0 1.6238915122812614e-05
( O 0 7.960537686813041e-07
43 O 0 7.217869097075891e-06
% O 0 6.99339295806567e-07
) O 0 1.4146741023068898e-07
CD B-Disease 0 3.0204719223547727e-06
mutations O 0 4.4615001115744235e-07
identified O 0 2.7369642907615344e-07
in O 0 4.5803611214978446e-07
this O 0 3.5130076980749436e-07
exon O 0 6.85093209540355e-06
. O 0 1.8536908328314894e-06

Seven O 0 0.00038165884325280786
of O 0 0.00026362360222265124
30 O 0 0.00013084687816444784
( O 0 3.8139296520967036e-06
23 O 0 2.586047412478365e-05
% O 0 1.2173538834758801e-06
) O 0 1.6708644068330614e-07
were O 0 1.0523713172005955e-06
within O 0 1.0422863851999864e-06
the O 0 7.638651368324645e-06
core O 0 6.280140223680064e-05
motif O 0 1.2415011951816268e-05
, O 0 5.98879921653861e-07
the O 0 8.5818697925788e-07
majority O 0 2.8241569793863164e-07
( O 0 3.750899111309991e-07
five O 0 1.0771756251415354e-06
of O 0 1.6966272596619092e-05
seven O 0 1.4091969205765054e-05
) O 0 6.072003770896117e-07
of O 0 3.343152684465167e-06
which O 0 1.6433291420980822e-06
were O 0 8.114309821394272e-06
missense O 0 3.769406248466112e-05
mutations O 0 4.615898433257826e-06
, O 0 1.208859998769185e-06
possibly O 0 5.267470442049671e-07
pointing O 0 1.5072819223860279e-06
to O 0 3.793025271647821e-08
the O 0 3.6997792562942777e-07
functional O 0 3.3708902265061624e-06
significance O 0 2.6251411782141076e-06
of O 0 1.0141309758182615e-05
this O 0 1.0729023642852553e-06
region O 0 4.2042524910357315e-06
. O 0 2.659595793375047e-06

Germline O 0 0.037889644503593445
PTEN O 0 0.01601705141365528
mutations O 0 1.8919463400379755e-05
were O 0 1.4426008419832215e-05
identified O 0 1.2363004771032138e-06
in O 0 1.0313908660464222e-06
four O 0 9.472774991081678e-07
of O 0 8.36840263218619e-06
seven O 0 7.310281944228336e-06
( O 0 2.2880676624481566e-06
57 O 0 5.64170659345109e-05
% O 0 4.8072329263959546e-06
) O 0 2.512245600883034e-06
BZS B-Disease 0 0.0008154682000167668
families O 0 7.818399012649024e-07
studied O 0 8.165547478711233e-05
. O 0 1.297986636927817e-05

Interestingly O 0 0.0007450882694683969
, O 0 6.282396498136222e-06
none O 0 2.2823990093456814e-06
of O 0 2.01169586944161e-06
these O 0 1.4387990177056054e-07
mutations O 0 5.593124683400674e-07
was O 0 6.708564342261525e-06
observed O 0 1.759399765433045e-06
in O 0 1.6668107036821311e-06
the O 0 6.513620974146761e-06
PTPase O 0 0.0006016013212502003
core O 0 0.00021011492935940623
motif O 0 6.120459147496149e-05
. O 0 5.281210178509355e-06

It O 0 2.0205336113576777e-05
is O 0 3.541256091921241e-06
also O 0 6.126932703409693e-07
worthy O 0 2.1352088879211806e-06
of O 0 6.052409389667446e-06
note O 0 2.055281584034674e-06
that O 0 1.6920745338211418e-07
a O 0 2.8750666842825012e-06
single O 0 4.229395017318893e-06
nonsense O 0 4.898271436104551e-05
point O 0 2.880303691199515e-05
mutation O 0 1.081578147932305e-06
, O 0 8.515743274983834e-07
R233X O 0 7.311536592169432e-06
, O 0 2.7281922143629345e-07
was O 0 1.235199761140393e-06
observed O 0 6.82972995491582e-07
in O 0 6.121103979239706e-07
the O 0 2.137992169082281e-06
germline O 0 9.060812772077043e-06
DNA O 0 9.999282610806404e-07
from O 0 1.6865885754668852e-06
two O 0 1.092344291464542e-06
unrelated O 0 5.3841395128984004e-06
CD B-Disease 0 4.5678927563130856e-05
families O 0 4.840881047130097e-07
and O 0 3.506334223857266e-06
one O 0 1.6669566321070306e-05
BZS B-Disease 0 0.013693972490727901
family O 0 2.7940272047999315e-05
. O 0 5.14394696438103e-06

Genotype O 0 0.005220592021942139
- O 0 0.0010566642740741372
phenotype O 0 0.0001063504460034892
studies O 0 9.12669474928407e-06
were O 0 1.7780589587346185e-06
not O 0 1.1927687637580675e-07
performed O 0 1.855201162470621e-06
on O 0 2.111029289153521e-06
this O 0 1.4221436117622943e-07
small O 0 3.2532824434383656e-07
group O 0 4.187032516256295e-07
of O 0 7.0006258283683565e-06
BZS B-Disease 0 0.0016649756580591202
families O 0 2.4525686512788525e-06
. O 0 5.320377113093855e-06

However O 0 9.27975052036345e-05
, O 0 8.281130249088164e-06
genotype O 0 2.5016541258082725e-05
- O 0 1.5545558198937215e-05
phenotype O 0 1.9484368749544956e-05
analysis O 0 2.562271902206703e-06
inthe O 0 6.446163024520501e-05
group O 0 1.502502982475562e-06
of O 0 8.664602319186088e-06
CD B-Disease 0 5.5060070735635236e-05
families O 0 8.324515761160001e-07
revealed O 0 6.372663392539835e-06
two O 0 6.073625513636216e-07
possible O 0 1.1511668844832457e-06
associations O 0 1.55891927988705e-06
worthy O 0 6.19495085629751e-06
of O 0 1.4025763448444195e-05
follow O 0 1.6248390011242009e-06
- O 0 2.3664283617108595e-06
up O 0 4.0936660639090405e-07
in O 0 3.6544861359288916e-07
independent O 0 3.664072778519767e-07
analyses O 0 9.472739179727796e-07
. O 0 2.6830741717276396e-06

The O 0 0.0002716146700549871
first O 0 0.00011299826292088255
was O 0 0.0001507271226728335
an O 0 2.9280613489390817e-06
association O 0 3.2266893867927138e-06
noted O 0 8.996415203910146e-07
in O 0 5.346606144485122e-07
the O 0 1.0437605624247226e-06
group O 0 1.4062213438137405e-07
of O 0 9.018767173074593e-07
CD B-Disease 0 3.213173113181256e-05
families O 0 1.975147512212061e-07
with O 0 2.8050317268935032e-06
breast B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.503715071128681e-05

A O 0 7.892182475188747e-05
correlation O 0 2.6287427317583933e-05
was O 0 2.2968755729380064e-05
observed O 0 1.819565000005241e-06
between O 0 8.934241009228572e-07
the O 0 1.313031134486664e-06
presence O 0 5.229966973274713e-06
/ O 0 4.325711415731348e-05
absence O 0 1.857656752690673e-05
of O 0 1.2488229913287796e-05
a O 0 1.5810943295946345e-05
PTEN O 0 0.00037987076211720705
mutation O 0 3.790107712120516e-07
and O 0 8.413188368194824e-08
the O 0 2.730154733399104e-07
type O 0 2.735105908868718e-06
of O 0 2.7039348424295895e-05
breast O 1 0.999977707862854
involvement O 1 0.9990695118904114
( O 0 0.002141103846952319
unaffected O 1 0.9710894823074341
versus O 1 0.9810133576393127
benign O 1 0.9998542070388794
versus O 0 0.00438727019354701
malignant O 1 0.7950403094291687
) O 0 9.043623663274047e-07
. O 0 4.286443981982302e-07

Specifically O 0 0.00012790948676411062
and O 0 3.4126496757380664e-05
more O 0 2.0946231416019145e-06
directly O 0 7.702614311710931e-06
, O 0 1.2455501519070822e-06
an O 0 8.008051395336224e-07
association O 0 1.786504867595795e-06
was O 0 1.6936711517701042e-06
also O 0 6.015065423525812e-08
observed O 0 1.1087163898082508e-07
between O 0 4.577601231403605e-08
the O 0 8.4231267294399e-08
presence O 0 9.730545968977822e-08
of O 0 7.028508548501122e-07
a O 0 1.830881228670478e-05
PTEN O 1 0.8966294527053833
mutation O 0 5.3261304856278e-05
and O 0 7.947752601467073e-05
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 1.2683607565122657e-05

Secondly O 0 0.004432132001966238
, O 0 4.237649409333244e-05
there O 0 6.393506282620365e-06
appeared O 0 1.1726772754627746e-05
to O 0 3.295972419437021e-07
be O 0 8.504154607180681e-07
an O 0 5.420122306531994e-07
interdependent O 0 1.2826103557017632e-05
association O 0 2.9471982543327613e-06
between O 0 1.6222147678490728e-06
mutations O 0 1.0597365189823904e-06
upstream O 0 1.9344546672073193e-05
and O 0 8.940735369833419e-07
within O 0 1.4611561027777498e-06
the O 0 1.5513613107032143e-05
PTPase O 0 0.0007653149077668786
core O 0 0.0005221439641900361
motif O 0 9.508275252301246e-05
, O 0 3.121110466963728e-06
the O 0 3.4131498978240415e-06
core O 0 1.444215467927279e-05
motif O 0 3.822610779025126e-06
containing O 0 5.89764397318504e-07
the O 0 4.410851204283972e-07
majority O 0 1.9698578057614213e-07
of O 0 7.014941274974262e-06
missense O 0 3.0232009521569125e-05
mutations O 0 4.135134076932445e-06
, O 0 5.873368422726344e-07
and O 0 1.0378798975807513e-07
the O 0 1.9431001874181675e-07
involvement O 0 7.788378297846066e-07
of O 0 3.214729076717049e-06
all O 0 7.472738161595771e-07
major O 0 0.00017657835269346833
organ O 1 1.0
systems O 1 0.999931812286377
( O 0 2.7237645554123446e-05
central O 0 0.04095378890633583
nervous O 1 0.9964397549629211
system O 0 0.3134014904499054
, O 0 5.2964449423598126e-05
thyroid O 1 1.0
, O 0 0.0005747039685957134
breast O 1 1.0
, O 0 0.002019196283072233
skin O 1 0.9999995231628418
and O 1 0.9933488965034485
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 0.00010432568524265662
. O 0 8.203047400456853e-06

However O 0 0.00046591245336458087
, O 0 1.4704080967931077e-05
these O 0 6.933856298019236e-07
observations O 0 8.38239702716237e-06
would O 0 1.2628693184524309e-06
need O 0 4.986845851817634e-07
to O 0 1.6939961255957314e-07
be O 0 3.129695471670857e-07
confirmed O 0 5.116872330290789e-07
by O 0 5.352064391672684e-08
studying O 0 1.7098730609177437e-07
a O 0 1.2133072857523075e-07
larger O 0 4.225158889425984e-08
number O 0 9.165950842771053e-08
of O 0 1.918818043122883e-06
CD B-Disease 0 2.8631957320612855e-05
families O 0 6.156816994007386e-07
. O 0 1.784242044777784e-06

Molecular O 1 0.9998123049736023
defects O 1 0.9994962215423584
leading O 0 0.00010178471711697057
to O 0 7.964570727381215e-07
human O 0 2.0272233086870983e-05
complement B-Disease 0 0.0004903621156699955
component I-Disease 1 0.999998927116394
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.359013008885086e-05
an O 0 1.982372396014398e-06
African O 0 2.7266937649983447e-06
- O 0 5.627095106319757e-06
American O 0 1.2973947605132707e-06
family O 0 1.0612777714413824e-06
. O 0 7.209904993032978e-07

Complement B-Disease 0 0.008232180960476398
component I-Disease 1 0.9999980926513672
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.00010798260336741805
C6D B-Disease 0 0.024160871282219887
) O 0 3.6864064441033406e-06
was O 0 0.00013413181295618415
diagnosed O 0 0.001719317166134715
in O 0 1.511116624897113e-05
a O 0 2.031550684478134e-05
16 O 0 3.6995912523707375e-05
- O 0 8.741325473238248e-06
year O 0 1.557731411594432e-05
- O 0 8.792542757873889e-06
old O 0 2.747263715718873e-05
African O 0 5.865039838681696e-06
- O 0 2.611220907056122e-06
American O 0 6.169653943288722e-07
male O 0 2.1590824417216936e-06
with O 0 1.285050075239269e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.046995905402582e-05

The O 0 0.0004349305818323046
patients O 0 0.00018059209105558693
father O 0 0.0003829169145319611
and O 0 4.3610176362562925e-05
two O 0 3.7933612475171685e-05
brothers O 0 0.000645304739009589
also O 0 2.203138319600839e-05
had O 0 0.00010128048597835004
C6D B-Disease 0 0.0024091077502816916
, O 0 7.081412150000688e-07
but O 0 1.7401278640249984e-08
gave O 0 8.53531645361727e-08
no O 0 1.3285196587276005e-07
history O 0 1.6864695453477907e-06
of O 0 2.0168028640910052e-05
meningitis B-Disease 1 1.0
or O 0 4.298152998671867e-05
other O 0 2.1213259060459677e-06
neisserial B-Disease 0 0.0030945821199566126
infection I-Disease 0 0.10903565585613251
. O 0 7.5534758252615575e-06

By O 0 9.794273864827119e-06
using O 0 4.060153969476232e-06
exon O 0 6.502622909465572e-06
- O 0 3.4329650588915683e-06
specific O 0 5.887360430278932e-07
polymerase O 0 0.00010475892486283556
chain O 0 5.188819341128692e-05
reaction O 0 1.1272757546976209e-05
( O 0 1.0657394113877672e-06
PCR O 0 3.2169496080314275e-06
) O 0 3.4341073273935763e-07
/ O 0 3.1988631690182956e-06
single O 0 1.3908795608585933e-06
- O 0 2.9750053727184422e-06
strand O 0 3.599940100684762e-06
conformation O 0 1.8848224954126636e-06
polymorphism O 0 2.747781309153652e-07
as O 0 6.400391328043042e-08
a O 0 3.3726212933515853e-08
screening O 0 8.833171705191489e-08
step O 0 3.553567182734696e-07
and O 0 1.6709138606074703e-07
nucleotide O 0 6.080991852286388e-07
sequencing O 0 1.672531766416796e-06
of O 0 7.934949280752335e-06
target O 0 1.2636821338674054e-05
exons O 0 2.247211705252994e-05
, O 0 9.685566055850359e-07
we O 0 1.5455489688065427e-07
determined O 0 2.897033652971004e-07
that O 0 9.620796248555052e-08
the O 0 1.132615238930157e-06
proband O 0 2.59031294262968e-05
was O 0 1.4374043530551717e-05
a O 0 2.641965920702205e-06
compound O 0 1.612908636161592e-05
heterozygote O 0 6.570207006006967e-06
for O 0 4.1439002984589024e-07
two O 0 2.087378334181267e-06
C6 O 0 0.0010170339373871684
gene O 0 1.0968886272166856e-05
mutations O 0 7.603560788993491e-06
. O 0 3.629018920037197e-06

The O 0 0.0003300721291452646
first O 0 5.9326608607079834e-05
, O 0 3.788932872339501e-06
1195delC O 0 1.917388362926431e-05
located O 0 9.483979738433845e-06
in O 0 2.396388254055637e-06
exon O 0 5.7408487919019535e-06
7 O 0 2.8623384423553944e-05
, O 0 6.156141694191319e-07
is O 0 2.1100339608892682e-07
a O 0 5.358816679290612e-07
novel O 0 1.3706435311178211e-06
mutation O 0 7.730718039056228e-07
, O 0 5.782977154922264e-07
while O 0 4.5308681251299276e-07
the O 0 1.908137164718937e-06
second O 0 7.265390649990877e-06
, O 0 1.2476580195652787e-06
1936delG O 0 4.2600463530106936e-06
in O 0 8.049159987422172e-06
exon O 0 1.2498309843067545e-05
12 O 0 3.600848503992893e-05
, O 0 2.0991226392652607e-06
has O 0 9.330645980298868e-07
been O 0 2.634634256537538e-06
described O 0 2.7241362658969592e-06
before O 0 1.9196379525965312e-06
to O 0 7.729877893325465e-07
cause O 0 2.4926146579673514e-05
C6D B-Disease 0 0.0005351440631784499
in O 0 9.991752449423075e-06
an O 0 1.7044138758137706e-06
unrelated O 0 6.393414423655486e-06
African O 0 1.2055272236466408e-05
- O 0 9.462569323659409e-06
American O 0 3.286457058493397e-06
individual O 0 4.182510906503012e-07
. O 0 2.9543602977355476e-06

Both O 0 1.3430306353257038e-05
mutations O 0 7.663394171686377e-06
result O 0 2.335257249796996e-06
in O 0 3.2418556656921282e-06
premature O 0 3.5948920412920415e-05
termination O 0 2.102953294524923e-05
codons O 0 2.730927189986687e-05
and O 0 3.8835105442558415e-06
C6 O 0 0.0011258851736783981
null O 0 0.00036509244819171727
alleles O 0 1.882133074104786e-05
. O 0 4.679930952988798e-06

Allele O 0 0.00046202752855606377
- O 0 8.551415521651506e-05
specific O 0 1.6756034710851964e-06
PCR O 0 1.8576674847281538e-05
indicated O 0 2.307110662513878e-06
that O 0 2.3092209744390857e-07
the O 0 4.583753252518363e-06
probands O 0 0.00016600347589701414
two O 0 1.3302175830176566e-05
brothers O 0 0.00010579311492620036
also O 0 8.047793926380109e-06
inherited O 0 0.00018157057638745755
the O 0 3.1928724638419226e-05
1195delC O 0 7.773080869810656e-05
mutation O 0 3.2723150980018545e-06
from O 0 1.6924519741223776e-06
their O 0 3.267339536705549e-07
heterozygous O 0 1.0414786402179743e-06
mother O 0 4.495704160945024e-06
and O 0 4.186485682566854e-07
the O 0 1.2155511512901285e-06
1936delG O 0 1.0252018910250627e-05
mutation O 0 7.340967727031966e-07
from O 0 8.23547679829062e-07
their O 0 1.9227110215069843e-07
homozygous O 0 5.649872946378309e-06
father O 0 8.486585102218669e-06
. O 0 2.57021781635558e-07
. O 0 7.971675586304627e-07

PAX6 O 0 0.035697583109140396
mutations O 0 0.00018097924476023763
reviewed O 0 0.00014211265079211444
. O 0 2.2669693862553686e-05

Mutations O 0 0.0002534597006160766
in O 0 8.519394759787247e-05
PAX6 O 0 0.003891878528520465
are O 0 6.4661076066840906e-06
responsible O 0 1.0278077752445824e-05
for O 0 1.3686470992979594e-05
human O 0 0.01791895553469658
aniridia B-Disease 1 1.0
and O 0 5.1173010433558375e-05
have O 0 1.5737628018541727e-06
also O 0 2.524132867165463e-07
been O 0 1.0156585972254106e-07
found O 0 2.7854939688154445e-08
in O 0 5.996588470225106e-08
patients O 0 2.277104300674182e-07
with O 0 4.777315893988998e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 8.472405897919089e-05
with O 1 0.8893738389015198
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.08702170848846436
with O 0 3.4423283068463206e-05
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 4.6668654249515384e-05
and O 0 3.5059329093201086e-06
with O 0 1.2656480976147577e-05
isolated B-Disease 1 0.9999998807907104
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.005788236856460571

No O 0 0.00024657114408910275
locus O 0 0.00018822084530256689
other O 0 4.007718416687567e-06
than O 0 2.6269067348039243e-06
chromosome O 0 6.440793367801234e-05
11p13 O 0 0.00017786992248147726
has O 0 1.6969701391644776e-05
been O 0 1.6625273929093964e-05
implicated O 0 2.35091065405868e-05
in O 0 3.8739894080208614e-05
aniridia B-Disease 1 0.9999997615814209
, O 0 7.66351877246052e-06
and O 0 6.388277142832521e-06
PAX6 O 0 0.0011631763773038983
is O 0 7.376439498330001e-06
clearly O 0 3.630299943324644e-06
the O 0 3.656644594229874e-06
major O 0 8.758298463362735e-06
, O 0 2.5946093273887527e-07
if O 0 2.2996472281988645e-08
not O 0 1.6189146023748435e-08
only O 0 3.216435118247318e-08
, O 0 8.631629810906816e-08
gene O 0 7.640609283043887e-07
responsible O 0 3.856900093524018e-06
. O 0 4.073293439432746e-06

Twenty O 0 0.00038525459240190685
- O 0 4.3289346649544314e-05
eight O 0 8.19250908534741e-06
percent O 0 7.735298822808545e-06
of O 0 4.028453531645937e-06
identified O 0 1.3333902643353213e-05
PAX6 O 0 0.0007462745998054743
mutations O 0 1.104313378164079e-05
are O 0 4.814743533643195e-06
C O 0 0.0002122897858498618
- O 0 0.00011375884059816599
T O 0 0.000257593987043947
changes O 0 3.314397417852888e-06
at O 0 8.287325908895582e-05
CpG O 0 5.336563117452897e-05
dinucleotides O 0 4.451122003956698e-05
, O 0 7.55022483645007e-07
20 O 0 1.41381235607696e-06
% O 0 4.381123517305241e-07
are O 0 1.814662624610719e-07
splicing O 0 1.9828148651868105e-06
errors O 0 7.798919250490144e-05
, O 0 2.9531881864386378e-06
and O 0 4.3064267174486304e-07
more O 0 7.749379449251137e-08
than O 0 2.3020200501377985e-07
30 O 0 2.0346426481410163e-06
% O 0 3.154398768856481e-07
are O 0 5.778435152592465e-08
deletion O 0 2.059592361547402e-06
or O 0 1.1791248653025832e-06
insertion O 0 4.703860668087145e-06
events O 0 4.982281097909436e-06
. O 0 3.5570358249970013e-06

There O 0 7.475763413822278e-05
is O 0 1.730498843244277e-05
a O 0 2.086719723592978e-05
noticeably O 0 0.00012740066449623555
elevated O 0 0.00044641789281740785
level O 0 7.514889148296788e-05
of O 0 2.172394306398928e-05
mutation O 0 2.131536575689097e-06
in O 0 3.899387138517341e-06
the O 0 3.826309239229886e-06
paired O 0 1.701026576483855e-06
domain O 0 1.1795129921665648e-06
compared O 0 5.857795031261048e-07
with O 0 3.5862903757788445e-08
the O 0 5.513479095498042e-07
rest O 0 4.854380222241161e-07
of O 0 1.6289507129840786e-06
the O 0 5.703859187633498e-06
gene O 0 1.1841636478493456e-05
. O 0 2.557625748522696e-06

Increased O 0 0.00015097799769137055
mutation O 0 1.2910929399367888e-05
in O 0 9.11100778466789e-06
the O 0 4.332867774792248e-06
homeodomain O 0 2.81659285974456e-05
is O 0 5.21472429682035e-07
accounted O 0 2.049409886240028e-06
for O 0 1.365970234701308e-07
by O 0 1.5868306491029216e-07
the O 0 3.3041183087334502e-06
hypermutable O 0 0.00021519916481338441
CpG O 0 0.0003107778320554644
dinucleotide O 0 0.00016833672998473048
in O 0 2.3465652702725492e-05
codon O 0 9.951626998372376e-05
240 O 0 2.1644738808390684e-05
. O 0 1.8266272263645078e-06

Very O 0 8.043118577916175e-05
nearly O 0 2.2091113351052627e-05
all O 0 5.565047445088567e-07
mutations O 0 7.169957143560168e-07
appear O 0 9.375047511639423e-07
to O 0 8.451127797570734e-08
cause O 0 1.3833578123012558e-06
loss O 0 4.463927780307131e-06
of O 0 1.0728710549301468e-05
function O 0 1.8741020539891906e-05
of O 0 2.704795952013228e-05
the O 0 1.677593718341086e-05
mutant O 0 2.6669216822483577e-05
allele O 0 5.876142040506238e-06
, O 0 3.2709527886254364e-07
and O 0 4.386964036484642e-08
more O 0 7.735465601399483e-09
than O 0 3.008988969099846e-08
80 O 0 4.6088820226941607e-07
% O 0 2.3554356687327527e-07
of O 0 1.7306039126196993e-06
exonic O 0 2.713228423090186e-05
substitutions O 0 2.5654085220594425e-06
result O 0 2.1688749711756827e-06
in O 0 2.8116844532632967e-06
nonsense O 0 1.9637818695628084e-05
codons O 0 1.7501257389085367e-05
. O 0 2.2295359940471826e-06

In O 0 7.833219569874927e-05
a O 0 1.1257502592343371e-05
gene O 0 1.2039472494507208e-06
with O 0 1.0107500258982327e-07
such O 0 1.6413292769357213e-07
extraordinarily O 0 1.392102331010392e-05
high O 0 1.6995176338241436e-05
sequence O 0 8.580953476666764e-07
conservation O 0 5.344974738363817e-07
throughout O 0 3.05562821267813e-07
evolution O 0 6.317666816357814e-07
, O 0 8.416141383804643e-08
there O 0 1.1983327397047105e-07
are O 0 2.946865151898237e-07
presumed O 0 3.4078071621479467e-05
undiscovered O 0 0.00027952948585152626
missense O 0 9.719359513837844e-05
mutations O 0 1.3420038158074021e-05
, O 0 1.6848732684593415e-06
these O 0 1.1345228756454162e-07
are O 0 2.08624499009602e-07
hypothesized O 0 2.133474708898575e-06
to O 0 3.8019311432435643e-07
exist O 0 1.3658143416250823e-06
in O 0 6.917080554558197e-06
as O 0 9.683169082563836e-06
- O 0 7.083694072207436e-06
yet O 0 1.2885130900031072e-06
unidentified O 0 5.212956693867454e-06
phenotypes O 0 3.780851102419547e-06
. O 0 2.6884941917160177e-07
. O 0 6.474194265138067e-07

Genetic O 0 9.442839655093849e-05
heterogeneity O 0 8.83397224242799e-05
and O 0 2.410132765362505e-06
penetrance O 0 9.591509297024459e-05
analysis O 0 1.0007973969550221e-06
of O 0 3.685942374431761e-06
the O 0 6.692065653624013e-06
BRCA1 O 0 3.53018767782487e-05
and O 0 4.82883251606836e-06
BRCA2 O 0 3.6801320675294846e-05
genes O 0 4.858131433138624e-06
in O 0 2.0426939954631962e-05
breast B-Disease 1 0.9998359680175781
cancer I-Disease 1 0.9640669822692871
families O 0 1.7342155160804396e-06
. O 0 2.8260988074180204e-06

The O 0 0.002020997926592827
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.8515211939811707
Consortium O 0 0.00025854079285636544
. O 0 4.492104380915407e-06

The O 0 6.7128194132237695e-06
contribution O 0 7.931816980999429e-06
of O 0 2.4514471078873612e-05
BRCA1 O 0 0.00016885581135284156
and O 0 2.1613635908579454e-05
BRCA2 O 0 0.000627365312539041
to O 0 5.3574338380713016e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9443629384040833
assessed O 0 1.8299595467397012e-05
by O 0 2.202137920903624e-07
linkage O 0 1.8197019926446956e-06
and O 0 3.5663185826706467e-07
mutation O 0 5.578900754699134e-07
analysis O 0 4.8493086524104e-07
in O 0 1.9156896087224595e-06
237 O 0 5.837512617290486e-06
families O 0 2.4320229385921266e-07
, O 0 1.1431932023242553e-07
each O 0 2.5705897854777504e-08
with O 0 6.06699686045431e-08
at O 0 4.779211394634331e-06
least O 0 5.778446166004869e-08
four O 0 1.0440228948027652e-07
cases O 0 1.3176142488191545e-07
of O 0 1.0860177098948043e-05
breast B-Disease 1 0.9997937083244324
cancer I-Disease 0 0.09787674993276596
, O 0 1.0613238288215143e-07
collected O 0 6.726180146188199e-08
by O 0 6.222242632247799e-08
the O 0 6.2138610701367725e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0016284054145216942
Consortium O 0 5.8702284150058404e-05
. O 0 4.393111794342985e-06

Families O 0 1.3728536941925995e-05
were O 0 2.2001909201208036e-06
included O 0 2.513544359317166e-07
without O 0 6.944869568314971e-08
regard O 0 9.83484937933099e-08
to O 0 2.5768096989509104e-08
the O 0 2.2326990745114017e-07
occurrence O 0 1.1211540368094575e-05
of O 0 0.0008821514202281833
ovarian B-Disease 1 1.0
or I-Disease 0 0.006374189164489508
other I-Disease 0 1.272289409826044e-05
cancers I-Disease 1 0.999982476234436
. O 0 1.959258588613011e-05

Overall O 0 0.02778094820678234
, O 0 0.0002520682173781097
disease O 1 0.7643795013427734
was O 0 0.001351038459688425
linked O 0 3.1159721402218565e-05
to O 0 4.812048359781329e-07
BRCA1 O 0 3.1920978926791577e-06
in O 0 1.3794121969112894e-06
an O 0 2.42759682578253e-07
estimated O 0 7.913034210105252e-07
52 O 0 6.72614214636269e-06
% O 0 1.275953422918974e-06
of O 0 6.852840670035221e-06
families O 0 1.3324573728823452e-06
, O 0 1.3120021549184457e-06
to O 0 1.0252116453557392e-06
BRCA2 O 0 8.99789301911369e-06
in O 0 1.2363297173578758e-05
32 O 0 1.8587697923067026e-05
% O 0 1.159304133580008e-06
of O 0 3.547502728906693e-06
families O 0 2.76764779982841e-07
, O 0 1.8403710555503494e-07
and O 0 8.483541336090639e-08
to O 0 7.098099530367108e-08
neither O 0 3.552157465946948e-07
gene O 0 2.3632343015833612e-07
in O 0 1.1957508831983432e-06
16 O 0 2.2290084871201543e-06
% O 0 2.0667847877575696e-07
( O 0 7.127647450033692e-08
95 O 0 1.354755113425199e-06
% O 0 5.324176868271024e-07
confidence O 0 1.3532670891436283e-05
interval O 0 5.206235800869763e-05
[ O 0 3.426293915254064e-05
CI O 0 0.0021486894693225622
] O 0 1.2467309716157615e-05
6 O 0 6.616057362407446e-06
% O 0 6.891000339237507e-07
- O 0 1.2727668945444748e-06
28 O 0 1.2079981388524175e-05
% O 0 1.0481645631443826e-06
) O 0 1.640662503632484e-07
, O 0 1.1465736093896339e-07
suggesting O 0 1.1516566473801504e-06
other O 0 2.2658312559542537e-07
predisposition O 0 7.626644219271839e-05
genes O 0 1.3922655853093602e-05
. O 0 6.6899087869387586e-06

The O 0 4.511187216849066e-05
majority O 0 2.0143431811447954e-06
( O 0 1.2399939350871136e-06
81 O 0 2.0023146134917624e-05
% O 0 7.798382171131379e-07
) O 0 1.9678900287090073e-07
of O 0 8.736874406167772e-06
the O 0 0.008781271055340767
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.7726005125950905e-06
were O 0 2.4764549380051903e-06
due O 0 1.3377374671108555e-05
to O 0 8.086715865829319e-07
BRCA1 O 0 8.7145735960803e-06
, O 0 7.195988018793287e-07
with O 0 1.0736459188365188e-07
most O 0 5.335776336323761e-07
others O 0 2.8143219310550194e-07
( O 0 1.5553789012301422e-07
14 O 0 2.298574372616713e-06
% O 0 6.102824841036636e-07
) O 0 1.5462478586414363e-07
due O 0 3.1964023037289735e-06
to O 0 2.4365781428059563e-06
BRCA2 O 0 0.00012504741607699543
. O 0 8.46473722049268e-06

Conversely O 0 0.0006282520480453968
, O 0 9.386817509948742e-06
the O 0 2.523440116419806e-06
majority O 0 3.925790963421605e-07
of O 0 3.976713287556777e-06
families O 0 6.21443803083821e-07
with O 0 7.524606644437881e-07
male B-Disease 0 0.00020510035392362624
and I-Disease 0 1.8564098354545422e-05
female I-Disease 0 0.015780435875058174
breast I-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9999895095825195
were O 0 2.5781850126804784e-05
due O 0 7.459854532498866e-05
to O 0 1.205786929858732e-06
BRCA2 O 0 1.678393891779706e-05
( O 0 1.8248060769110452e-06
76 O 0 4.7304511099355295e-05
% O 0 1.879568458207359e-06
) O 0 7.294225383702724e-07
. O 0 1.4545146314048907e-06

The O 0 6.959593156352639e-05
largest O 0 2.9051752790110186e-05
proportion O 0 6.446589395636693e-06
( O 0 1.5673672351113055e-06
67 O 0 1.8901735529652797e-05
% O 0 2.566485136412666e-06
) O 0 4.2217115492348967e-07
of O 0 1.1960887604800519e-05
families O 0 1.1968427315878216e-06
due O 0 0.00018395515508018434
to O 0 4.6293889681692235e-06
other O 0 3.1469999157707207e-06
genes O 0 4.880197593593039e-06
was O 0 3.871582157444209e-05
found O 0 6.18779097294464e-07
in O 0 3.7415674114527064e-07
families O 0 2.5583956286823195e-08
with O 0 3.856425578874223e-08
four O 0 4.394275094909972e-07
or O 0 2.444714937155368e-07
five O 0 1.39739540827577e-07
cases O 0 1.7838988242147025e-07
of O 0 6.141151061456185e-06
female O 0 0.32627373933792114
breast B-Disease 1 1.0
cancer I-Disease 1 0.999983549118042
only O 0 4.356385034043342e-06
. O 0 2.7775022317655385e-06

These O 0 2.0697701984317973e-05
estimates O 0 1.606332625669893e-05
were O 0 3.620366896939231e-06
not O 0 1.895313630484452e-07
substantially O 0 1.2334505754552083e-06
affected O 0 1.41358981409212e-07
either O 0 4.99622387906129e-08
by O 0 4.4914944652418853e-08
changing O 0 2.1255816307075293e-07
the O 0 4.1547704654476547e-07
assumed O 0 3.689881623358815e-06
penetrance O 0 2.8174017643323168e-05
model O 0 1.9648198303912068e-06
for O 0 7.20049115443544e-07
BRCA1 O 0 1.727492531244934e-06
or O 0 2.3500192014580534e-07
by O 0 2.1019635809693682e-08
including O 0 7.734406182180464e-08
or O 0 3.782578801292402e-07
excluding O 0 7.100723905750783e-06
BRCA1 O 0 2.824859257088974e-05
mutation O 0 4.543525847111596e-06
data O 0 5.64891388421529e-06
. O 0 2.0488412246777443e-06

Among O 0 2.19532594201155e-05
those O 0 2.4356118046853226e-06
families O 0 6.27378369699727e-07
with O 0 1.129560473600577e-06
disease O 0 0.0069226487539708614
due O 0 0.002102222293615341
to O 0 9.335326467407867e-06
BRCA1 O 0 2.185483208450023e-05
that O 0 1.720549221317924e-06
were O 0 2.646550456120167e-06
tested O 0 7.600919502692705e-07
by O 0 6.850095957133817e-08
one O 0 8.2097578513185e-08
of O 0 4.808351263818622e-07
the O 0 4.733199716611125e-07
standard O 0 8.893063636605802e-07
screening O 0 3.2427291785097623e-07
methods O 0 8.774682669354661e-07
, O 0 2.3220161438075593e-07
mutations O 0 1.5615260906542971e-07
were O 0 8.510393740834843e-07
detected O 0 1.937086608450045e-06
in O 0 7.335956411225197e-07
the O 0 1.4048303000890883e-06
coding O 0 5.462229182739975e-06
sequence O 0 2.8017191198159708e-06
or O 0 2.4946311896201223e-06
splice O 0 2.9590860322059598e-06
sites O 0 4.988025352758996e-07
in O 0 3.239054251480411e-07
an O 0 9.136139311749503e-08
estimated O 0 4.6922735918997205e-07
63 O 0 4.3804025153804105e-06
% O 0 5.643839813274099e-07
( O 0 2.7781911171587126e-07
95 O 0 6.244246833375655e-06
% O 0 5.768788923887769e-06
CI O 0 0.006128067150712013
51 O 0 9.357593080494553e-05
% O 0 6.048133855074411e-06
- O 0 2.156097070837859e-05
77 O 0 9.091415267903358e-05
% O 0 2.5148824533971492e-06
) O 0 5.251019388197165e-07
. O 0 1.1779706028391956e-06

The O 0 6.558923632837832e-05
estimated O 0 1.3799707630823832e-05
sensitivity O 0 1.176476689579431e-05
was O 0 1.3275310266180895e-05
identical O 0 4.5369387180471676e-07
for O 0 6.011475761624752e-08
direct O 0 3.04382581362006e-07
sequencing O 0 1.150064122157346e-06
and O 0 4.2769869423864293e-07
other O 0 2.2766090523873572e-07
techniques O 0 1.209622496389784e-05
. O 0 5.187990154809086e-06

The O 0 0.00019462617638055235
penetrance O 0 0.0011448320001363754
of O 0 0.00014932805788703263
BRCA2 O 0 7.492498843930662e-05
was O 0 1.7231192032340914e-05
estimated O 0 4.406314815241785e-07
by O 0 7.301965609940453e-08
maximizing O 0 2.9888146855228115e-06
the O 0 7.656746674911119e-06
LOD O 0 0.0005654567503370345
score O 0 4.100990554434247e-05
in O 0 2.6373732907813974e-05
BRCA2 O 0 6.522677722387016e-05
- O 0 2.8510978154372424e-05
mutation O 0 9.007679295791604e-07
families O 0 5.87284816333522e-08
, O 0 3.35337837498173e-08
over O 0 5.594107577167051e-08
all O 0 7.51658859599047e-08
possible O 0 9.014743227453437e-07
penetrance O 0 0.00021105664200149477
functions O 0 3.403107984922826e-05
. O 0 4.869695203524316e-06

The O 0 4.403598268254427e-06
estimated O 0 1.7032830328389537e-06
cumulative O 0 1.6830419554025866e-05
risk O 0 6.417899385269266e-06
of O 0 2.5383940737810917e-05
breast B-Disease 1 0.9801570177078247
cancer I-Disease 1 0.9933571219444275
reached O 0 0.0007163406116887927
28 O 0 7.013425783952698e-05
% O 0 1.1398439028198482e-06
( O 0 1.629357910815088e-07
95 O 0 3.5424147881712997e-06
% O 0 1.4344096825880115e-06
CI O 0 0.0005544323939830065
9 O 0 3.736793951247819e-05
% O 0 1.647060230425268e-06
- O 0 2.382467300776625e-06
44 O 0 5.931503437750507e-06
% O 0 3.919539892649482e-07
) O 0 3.1624644236671884e-08
by O 0 5.026610239156071e-08
age O 0 1.8182362282459508e-06
50 O 0 1.1074224630647223e-06
years O 0 4.1850486809380527e-07
and O 0 4.714386818704952e-07
84 O 0 8.208853614632972e-06
% O 0 5.85329416935565e-07
( O 0 1.7652878625540325e-07
95 O 0 2.7967219011770794e-06
% O 0 1.5538829529759823e-06
CI O 0 0.00041830926784314215
43 O 0 2.2982823793427087e-05
% O 0 2.020390184043208e-06
- O 0 2.6261902803526027e-06
95 O 0 5.238652647676645e-06
% O 0 3.8553412196051795e-07
) O 0 3.827064176675776e-08
by O 0 3.438137241573713e-08
age O 0 2.9264699605846545e-06
70 O 0 4.139837983530015e-06
years O 0 3.688709966809256e-06
. O 0 2.48583478423825e-06

The O 0 0.00033008979517035186
corresponding O 1 0.9999943971633911
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0004409253888297826
were O 0 1.6666450392222032e-05
0 O 0 9.7607144198264e-06
. O 0 4.088921343736729e-07

4 O 0 0.00029011163860559464
% O 0 1.3327203305379953e-05
( O 0 2.050678631349001e-06
95 O 0 1.372021324641537e-05
% O 0 4.198675014777109e-06
CI O 0 0.001570771331898868
0 O 0 1.617705675016623e-05
% O 0 9.870881285678479e-07
- O 0 1.168060293821327e-06
1 O 0 5.122016318637179e-06
% O 0 2.6476308789824543e-07
) O 0 2.8663494688885294e-08
by O 0 3.150117322547885e-08
age O 0 7.559504524579097e-07
50 O 0 9.027768328451202e-07
years O 0 3.2569300856266636e-07
and O 0 2.459011056998861e-07
27 O 0 4.752884706249461e-06
% O 0 3.9567888165947807e-07
( O 0 7.12827272764116e-08
95 O 0 1.1813051514764084e-06
% O 0 1.202822545565141e-06
CI O 0 0.00025182226090691984
0 O 0 4.2151887100772e-06
% O 0 4.0781108623377804e-07
- O 0 9.738611197462888e-07
47 O 0 4.176885340712033e-06
% O 0 2.367470557373963e-07
) O 0 3.723735986227439e-08
by O 0 5.0253255778898165e-08
age O 0 3.993061909568496e-06
70 O 0 9.664818207966164e-06
years O 0 7.636225745955016e-06
. O 0 2.2864383026899304e-06

The O 0 2.7190255423192866e-05
lifetime O 0 0.0001509559660917148
risk O 0 4.4760356104234233e-05
of O 0 8.588599303038791e-05
breast B-Disease 1 0.9999613761901855
cancer I-Disease 1 0.9957055449485779
appears O 0 1.5635732779628597e-05
similar O 0 4.035299241422763e-07
to O 0 3.657282263702655e-07
the O 0 4.9289119488094e-06
risk O 0 1.0551999366725795e-05
in O 0 1.215814336319454e-05
BRCA1 O 0 2.1377321900217794e-05
carriers O 0 2.361425913477433e-06
, O 0 3.412429805393913e-07
but O 0 5.383875389952664e-08
there O 0 6.209864267248122e-08
was O 0 9.70359565144463e-07
some O 0 2.391510278698661e-08
suggestion O 0 3.994963435616228e-07
of O 0 2.6840159534913255e-06
a O 0 8.297612112073693e-06
lower O 0 6.313237099675462e-05
risk O 0 4.120922312722541e-06
in O 0 4.084153715666616e-06
BRCA2 O 0 1.1002537576132454e-05
carriers O 0 1.391956971019681e-06
< O 0 2.2459007595898584e-05
50 O 0 2.6885811621468747e-06
years O 0 6.069982987355615e-07
of O 0 2.1560763343586586e-06
age O 0 1.590326428413391e-05
. O 0 3.5966527320852038e-06

Eye B-Disease 1 0.9999992847442627
movement I-Disease 1 0.546159029006958
abnormalities I-Disease 1 0.9999203681945801
correlate O 0 8.453724149148911e-06
with O 0 2.8010168762193643e-07
genotype O 0 0.00015645171515643597
in O 0 4.087590059498325e-05
autosomal O 1 1.0
dominant O 1 0.9999998807907104
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 0.0001421619817847386

We O 0 0.00011906512372661382
compared O 0 0.0003379923291504383
horizontal O 0 0.002411413472145796
eye O 0 0.31613418459892273
movements O 0 0.0014968543546274304
( O 0 1.2150331713201012e-05
visually O 0 1.2919428627355956e-05
guided O 0 1.6636005966574885e-05
saccades O 0 0.00012703443644568324
, O 0 2.7480534754431574e-06
antisaccades O 0 2.5642157197580673e-05
, O 0 5.091603725304594e-07
and O 0 4.004507161425863e-07
smooth O 0 1.0899605513259303e-05
pursuit O 0 1.3834587662131526e-05
) O 0 2.69216059223254e-07
in O 0 4.6649316232105775e-07
control O 0 2.709181899263058e-06
subjects O 0 1.9742747099371627e-05
( O 0 1.9772028281295206e-06
n O 0 3.371779530425556e-05
= O 0 1.8144521163776517e-05
14 O 0 6.24781478109071e-06
) O 0 1.0372762204724495e-07
and O 0 3.6822420668158884e-08
patients O 0 3.412989002526956e-08
with O 0 7.904902510347256e-09
three O 0 1.8244148236590263e-07
forms O 0 3.205003849870991e-06
of O 0 0.00012370216427370906
autosomal O 1 0.9999991655349731
dominant O 1 0.9999531507492065
cerebellar B-Disease 1 0.9999996423721313
ataxias I-Disease 1 0.9995704293251038
type I-Disease 0 0.15030652284622192
I I-Disease 0 0.0019552388694137335
spinocerebellar B-Disease 0 0.04013119637966156
ataxias I-Disease 0 0.0011116734240204096
1 I-Disease 0 5.866797437192872e-05
and I-Disease 0 2.183576953029842e-06
2 I-Disease 0 1.2225275895616505e-05
( O 0 9.431453236175003e-07
SCA1 B-Disease 0 5.035423600929789e-05
, O 0 1.5106883211046807e-06
n O 0 1.1933554560528137e-05
= O 0 6.327854862320237e-06
11 O 0 2.531840664232732e-06
; O 0 1.7911077065946301e-07
SCA2 B-Disease 0 1.1209807780687697e-05
, O 0 5.461080831992149e-07
n O 0 6.515603217849275e-06
= O 0 5.039684765506536e-06
10 O 0 1.4436951687457622e-06
) O 0 3.251511486723757e-07
and O 0 4.259708930476336e-06
SCA3 B-Disease 1 0.999998927116394
/ O 0 0.0005858436925336719
Machado B-Disease 0 0.00016223704733420163
- I-Disease 0 0.0001555925700813532
Joseph I-Disease 0 0.007692869286984205
disease I-Disease 0 0.20458392798900604
( O 0 6.039983418304473e-06
MJD B-Disease 1 0.9999969005584717
) O 0 1.921425564432866e-06
( O 0 7.289330028470431e-07
n O 0 1.9413108020671643e-05
= O 0 2.737471913860645e-05
16 O 0 1.8086973796016537e-05
) O 0 7.876856784605479e-07
. O 0 1.4179821619109134e-06

In O 0 0.0005486669833771884
SCA1 B-Disease 0 0.00448460690677166
, O 0 1.0296031177858822e-05
saccade O 0 0.00010359645239077508
amplitude O 0 3.964985080529004e-05
was O 0 1.3292563380673528e-05
significantly O 0 3.8283204162326e-07
increased O 0 1.0754470167739782e-06
, O 0 2.3429166162713955e-07
resulting O 0 1.1924631735382718e-06
in O 0 2.945276492027915e-06
hypermetria B-Disease 0 0.0002033808414125815
. O 0 5.028959094488528e-06

The O 0 0.0001074385509127751
smooth O 0 0.00019183602125849575
pursuit O 0 7.071300933603197e-05
gain O 0 8.269232785096392e-05
was O 0 8.981396240415052e-05
decreased O 0 0.00037187678390182555
. O 0 3.2712136999180075e-06

In O 0 0.0006311862962320447
SCA2 B-Disease 0 0.004502919968217611
, O 0 9.988722922571469e-06
saccade O 0 0.00018194940639659762
velocity O 0 8.609641372459009e-05
was O 0 8.210787927964702e-05
markedly O 0 0.00017960724653676152
decreased O 0 0.0004805050848517567
. O 0 6.134560862847138e-06

The O 0 0.00011763618385884911
percentage O 0 0.00011458867084002122
of O 0 7.574952178401873e-05
errors O 0 0.0026153712533414364
in O 0 0.0001774266129359603
antisaccades O 0 0.00436479551717639
was O 0 0.00013575074262917042
greatly O 0 3.8113332720968174e-06
increased O 0 1.8410133861834765e-06
and O 0 2.420850648832129e-07
was O 0 1.0272816552969743e-06
significantly O 0 9.583032323234875e-08
correlated O 0 1.8794830225488113e-07
with O 0 1.3769904327887161e-08
age O 0 3.2579569051449653e-06
at O 0 3.388651748537086e-05
disease O 0 0.00014033258776180446
onset O 0 0.0016668670577928424
. O 0 5.113640781928552e-06

In O 0 8.459626405965537e-05
addition O 0 4.421955054567661e-06
, O 0 6.78606170367857e-07
a O 0 8.089176617431804e-07
correlation O 0 4.381322014523903e-06
between O 0 1.231683654623339e-05
smooth O 0 7.194233330665156e-05
pursuit O 0 4.259150227881037e-05
gain O 0 1.888281803985592e-05
and O 0 6.225542392712669e-07
the O 0 7.965656436681456e-07
number O 0 7.533624852840148e-07
of O 0 6.22569450570154e-06
trinucleotide O 0 9.027247142512351e-05
repeats O 0 1.1291973351035267e-05
was O 0 3.029833715118002e-05
found O 0 2.3324059839069378e-06
. O 0 8.619567779533099e-07

In O 0 0.02301706001162529
SCA3 B-Disease 1 1.0
, O 0 0.001167639042250812
gaze B-Disease 0 0.15844711661338806
- I-Disease 0 0.0014240407617762685
evoked I-Disease 0 0.0005238134181126952
nystagmus I-Disease 0 0.001245375256985426
was O 0 2.4889872292988002e-05
often O 0 1.3166683743293106e-07
present O 0 1.4788180635605386e-07
as O 0 5.926036692471826e-07
was O 0 9.050543667399324e-06
saccade O 0 5.243365740170702e-05
hypometria O 0 9.49025052250363e-05
and O 0 4.269747023499804e-06
smooth O 0 6.342364940792322e-05
pursuit O 0 6.412809307221323e-05
gain O 0 8.838875510264188e-05
was O 0 8.037575025809929e-05
markedly O 0 0.0001464748493162915
decreased O 0 0.0002852390753105283
. O 0 2.659641495483811e-06

Three O 0 3.708050644490868e-05
major O 0 4.125144187128171e-05
criteria O 0 2.3152564608608373e-05
, O 0 3.4362799397058552e-06
saccade O 0 7.948821439640597e-05
amplitude O 0 5.2401668654056266e-05
, O 0 5.289648015605053e-06
saccade O 0 8.801322837825865e-05
velocity O 0 0.0001272741355933249
, O 0 2.9363834528339794e-06
and O 0 1.023054210236296e-06
presence O 0 7.1813697104516905e-06
of O 0 0.00014455811469815671
gaze B-Disease 0 0.02088555134832859
- I-Disease 0 0.00020983464492019266
evoked I-Disease 0 7.174132770160213e-05
nystagmus I-Disease 0 4.262355651007965e-05
, O 0 1.1014970624501075e-07
permitted O 0 1.0629283053731342e-07
the O 0 3.4200763820990687e-07
correct O 0 9.599750683264574e-07
assignment O 0 1.2967491329618497e-06
of O 0 5.240856353339041e-06
90 O 0 7.3664637056936044e-06
% O 0 1.6412054719694424e-06
of O 0 1.6896226952667348e-05
the O 0 3.3695810998324305e-05
SCA1 B-Disease 0 0.0002536120009608567
, O 0 2.0561972178256838e-06
90 O 0 2.5006095256685512e-06
% O 0 4.616430828718876e-07
of O 0 4.700278168456862e-06
the O 0 1.618449459783733e-05
SCA2 B-Disease 0 0.00022712498321197927
, O 0 9.726071539262193e-07
and O 0 4.2976060399269045e-07
93 O 0 8.764396625338122e-06
% O 0 3.009012630172947e-07
of O 0 1.3262250604384462e-06
the O 0 7.217663096525939e-06
patients O 0 8.462952791887801e-06
with O 0 6.355736331897788e-06
SCA3 B-Disease 1 1.0
to O 0 6.118400051491335e-06
their O 0 2.5791407551878365e-06
genetically O 0 5.961554506939137e-06
confirmed O 0 1.4960380212869495e-05
patient O 0 2.2648147933068685e-05
group O 0 1.980869910767069e-06
and O 0 8.06064463176881e-07
, O 0 4.870322527494864e-07
therefore O 0 1.3754071233051945e-06
, O 0 7.650656357327534e-07
may O 0 2.3117138425732264e-06
help O 0 4.927412646793528e-07
orient O 0 9.44654893828556e-05
diagnoses O 0 5.681512993760407e-05
of O 0 0.0002104020386468619
SCA1 B-Disease 0 0.07744482159614563
, O 0 2.5495490262983367e-05
SCA2 B-Disease 0 0.0009620667551644146
, O 0 3.1513125122728525e-06
and O 0 3.827090040431358e-06
SCA3 B-Disease 1 0.9999996423721313
at O 0 1.3436469089356251e-05
early O 0 1.0176049727306236e-06
clinical O 0 6.407771252270322e-06
stages O 0 1.8242166333948262e-05
of O 0 1.4232837202143855e-05
the O 0 3.041839590878226e-05
diseases O 0 0.4457482695579529
. O 0 1.3384560588747263e-06
. O 0 1.5047269243950723e-06

Genetic O 0 2.8822373678849544e-06
basis O 0 5.770559710072121e-07
and O 0 1.6470605146423623e-07
molecular O 0 1.2855934983235784e-05
mechanism O 0 4.244812225806527e-05
for O 0 0.0002254318242194131
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.0004037180042359978

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999998807907104
causes O 0 0.0007177664083428681
more O 0 1.2408172551658936e-06
than O 0 6.227846256479097e-07
300 O 0 1.1364313650119584e-06
, O 0 1.9039694620914815e-07
000 O 0 4.0562722460890654e-06
sudden O 0 9.267272616853006e-06
deaths O 0 3.0282133138825884e-06
each O 0 1.4687910265820392e-07
year O 0 9.059861554305826e-07
in O 0 1.3502252613761812e-06
the O 0 4.11822338719503e-06
USA O 0 2.708285865082871e-05
alone O 0 4.973204795533093e-06
. O 0 1.3985302302899072e-06

In O 0 0.00022018628078512847
approximately O 0 3.627338810474612e-05
5 O 0 2.5674899006844498e-05
- O 0 8.697088560438715e-06
12 O 0 1.104035345633747e-05
% O 0 4.594912752509117e-07
of O 0 5.704407612938667e-07
these O 0 8.826232544834056e-08
cases O 0 2.529453695387929e-07
, O 0 1.5670158859393268e-07
there O 0 7.66448877698167e-08
are O 0 7.382038802461466e-08
no O 0 5.468783683681977e-07
demonstrable O 0 0.0018923321040347219
cardiac O 1 1.0
or O 0 0.0006345222936943173
non O 1 0.9964622855186462
- O 1 0.998578667640686
cardiac O 1 1.0
causes O 0 3.457547791185789e-05
to O 0 4.2605279304552823e-07
account O 0 2.2435247615248954e-07
for O 0 2.411214836683939e-07
the O 0 7.089209361765825e-07
episode O 0 9.55977156991139e-07
, O 0 2.4838382017833283e-08
which O 0 5.7574962575301925e-09
is O 0 1.2379170577503373e-08
therefore O 0 4.9913090549580374e-08
classified O 0 5.369686277845176e-07
as O 0 1.7256650608032942e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.922187864780426
IVF B-Disease 1 1.0
) O 0 6.080868843127973e-06
. O 0 1.9015012640011264e-06

A O 0 0.00047812197590246797
distinct O 0 4.0818253182806075e-05
group O 0 3.1955958547769114e-05
of O 0 0.00019512750441208482
IVF B-Disease 1 1.0
patients O 0 4.992019239580259e-05
has O 0 2.7843841508001788e-06
been O 0 9.860616501100594e-07
found O 0 4.959706956242371e-08
to O 0 1.065335109018406e-08
present O 0 6.054303725022692e-08
with O 0 6.98557443001846e-08
a O 0 3.3004182569129625e-06
characteristic O 0 0.00031605068943463266
electrocardiographic O 0 0.4555155336856842
pattern O 0 0.0016028305981308222
. O 0 1.2586810953507666e-05

Because O 0 0.00014998849655967206
of O 0 0.00011982939759036526
the O 0 1.4238539733923972e-05
small O 0 1.1427608797021094e-06
size O 0 7.721066026533663e-07
of O 0 6.859175300633069e-06
most O 0 5.985104962746846e-07
pedigrees O 0 1.0996724313372397e-06
and O 0 2.9292829140104004e-07
the O 0 7.510196269322478e-07
high O 0 2.9179172997828573e-05
incidence O 0 0.00012869171041529626
of O 0 5.2212322771083564e-05
sudden B-Disease 0 0.0750848799943924
death I-Disease 0 0.0009804132860153913
, O 0 7.185756203398341e-07
however O 0 2.9800867196172476e-07
, O 0 9.501603415174031e-08
molecular O 0 2.8138815650891047e-06
genetic O 0 1.432214389751607e-06
studies O 0 6.804772056057118e-06
of O 0 8.351076394319534e-05
IVF B-Disease 1 0.9999982118606567
have O 0 2.1306138933141483e-06
not O 0 1.8395762424461282e-07
yet O 0 2.859912058283953e-07
been O 0 7.176811891440593e-07
done O 0 1.1483172102089156e-06
. O 0 1.1018539680662798e-06

Because O 0 0.00022464242647401989
IVF B-Disease 1 1.0
causes O 1 0.6387323141098022
cardiac O 1 1.0
rhythm O 1 0.9999033212661743
disturbance O 0 0.006983862724155188
, O 0 1.8638410210769507e-06
we O 0 3.145074742860743e-07
investigated O 0 6.705325859002187e-07
whether O 0 5.039334496359515e-07
malfunction O 0 0.00045223330380395055
of O 0 8.221122698159888e-06
ion O 0 3.798069883487187e-05
channels O 0 6.829704943811521e-06
could O 0 1.3947420711701852e-06
cause O 0 2.70250893663615e-06
the O 0 5.318574380908103e-07
disorder O 0 5.861723820999032e-06
by O 0 1.4355625133077865e-08
studying O 0 8.904709858370552e-08
mutations O 0 3.7749821046872967e-08
in O 0 9.23755862913822e-08
the O 0 4.6055342295403534e-07
cardiac O 0 0.00026721387985162437
sodium O 0 9.75227612798335e-06
channel O 0 1.5503821487072855e-05
gene O 0 2.1343506887205876e-05
SCN5A O 0 0.0006918016006238759
. O 0 4.186643764114706e-06

We O 0 5.165235779713839e-05
have O 0 3.0241294552979525e-06
now O 0 9.424826998838398e-07
identified O 0 6.829866947555274e-07
a O 0 1.2914717899548123e-06
missense O 0 1.4310210644907784e-05
mutation O 0 2.679169938346604e-06
, O 0 1.0299243058398133e-06
a O 0 2.1644943899445934e-06
splice O 0 1.2123559827159625e-05
- O 0 2.03162053367123e-05
donor O 0 7.172560799517669e-06
mutation O 0 4.38389588452992e-06
, O 0 9.515293868389563e-07
and O 0 5.772992608399363e-07
a O 0 5.578913260251284e-06
frameshift O 0 8.634586265543476e-05
mutation O 0 1.4756693644812913e-06
in O 0 3.240159003325971e-06
the O 0 2.6155973955610534e-06
coding O 0 6.9855136644036975e-06
region O 0 2.245366658826242e-06
of O 0 2.2100490241427906e-05
SCN5A O 0 0.0004127001448068768
in O 0 9.746929208631627e-06
three O 0 1.4633784303441644e-05
IVF B-Disease 1 0.9998631477355957
families O 0 1.130900386669964e-06
. O 0 1.380748130941356e-06

We O 0 7.66993071010802e-06
show O 0 1.3350726248972933e-06
that O 0 1.141077987654171e-07
sodium O 0 4.305815082261688e-07
channels O 0 1.0449811327362113e-07
with O 0 4.467332814783731e-08
the O 0 1.302276473325037e-06
missense O 0 2.3325736037804745e-05
mutation O 0 7.359652499872027e-06
recover O 0 2.126167601090856e-05
from O 0 5.4233673836279195e-06
inactivation O 0 0.00017099990509450436
more O 0 2.3466598975119268e-07
rapidly O 0 7.117165523595759e-07
than O 0 7.339470897704814e-08
normal O 0 6.027687504683854e-07
and O 0 5.025018623427968e-08
that O 0 1.9901181147474745e-08
the O 0 3.5057450986641925e-07
frameshift O 0 5.5915156735864e-06
mutation O 0 3.483631871858961e-07
causes O 0 4.4376139385349234e-07
the O 0 7.853402053115133e-07
sodium O 0 9.169568215838808e-07
channel O 0 9.179157700600626e-07
to O 0 2.428324137326854e-07
be O 0 1.6756242757764994e-06
non O 0 3.083823321503587e-05
- O 0 2.5531477149343118e-05
functional O 0 4.801986870006658e-05
. O 0 2.9654058835149044e-06

Our O 0 4.3777519749710336e-05
results O 0 1.2035422514600214e-05
indicate O 0 1.984562914003618e-06
that O 0 2.31070572453973e-07
mutations O 0 1.7446513993490953e-06
in O 0 8.97494192031445e-06
cardiac O 0 0.006450015120208263
ion O 0 6.126426887931302e-05
- O 0 1.08879075924051e-05
channel O 0 1.7579272935108747e-06
genes O 0 1.4008432458467723e-07
contribute O 0 7.904935728220153e-08
to O 0 4.553948684815623e-08
the O 0 6.635111162722751e-07
risk O 0 1.0074248848468415e-06
of O 0 5.543348379433155e-06
developing O 0 3.4239976230310276e-05
IVF B-Disease 1 0.9999703168869019
. O 0 1.43128863783204e-06
. O 0 1.0348708201490808e-06

Molecular O 0 0.0030054643284529448
heterogeneity O 0 0.0015454310923814774
in O 0 0.0004715383402071893
mucopolysaccharidosis B-Disease 0 0.007692461833357811
IVA I-Disease 0 0.13530626893043518
in O 0 5.794841126771644e-05
Australia O 0 1.6673113805154571e-06
and O 0 4.0816902924234455e-07
Northern O 0 1.4127557506071753e-06
Ireland O 0 5.631264343719522e-07
: O 0 1.4072047349600325e-07
nine O 0 4.0398157352683484e-07
novel O 0 5.303667762746045e-07
mutations O 0 7.934616519378324e-07
including O 0 9.633371291783988e-07
T312S O 0 5.817137207486667e-05
, O 0 4.4609046767618565e-07
a O 0 4.4690207801068027e-07
common O 0 4.979722234565997e-07
allele O 0 1.942391918419162e-06
that O 0 1.5741275660730025e-07
confers O 0 7.293650560313836e-05
a O 0 2.2255049771047197e-05
mild O 0 0.0016541625373065472
phenotype O 0 0.0002982543082907796
. O 0 7.22891854820773e-06

Mucopolysaccharidosis B-Disease 1 0.9908875226974487
IVA I-Disease 1 0.9999967813491821
( O 0 0.007212488446384668
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 9.231680451193824e-06
is O 0 6.30803469903185e-07
an O 0 2.1377436496550217e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.999992847442627
by O 0 1.1263463420618791e-05
a O 0 0.2438966929912567
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 1 0.9998087286949158
N O 1 0.9630873203277588
- O 0 0.002277154941111803
acetylgalactosamine O 1 0.992878258228302
- O 0 0.0007931900909170508
6 O 0 0.0024536990094929934
- O 0 0.0003385799063835293
sulfate O 0 0.0016447046073153615
sulfatase O 0 0.013928255997598171
( O 0 8.604163667769171e-06
GALNS O 0 0.000509676116053015
) O 0 1.2057074627591646e-06
. O 0 5.645029546030855e-07

Previous O 0 0.000158355847815983
studies O 0 3.1402811146108434e-05
of O 0 6.632899749092758e-05
patients O 0 2.282760397065431e-05
from O 0 1.1251835530856624e-05
a O 0 1.0072501027025282e-05
British O 0 1.1962564713030588e-05
- O 0 1.0053815458377358e-05
Irish O 0 2.6888169486483093e-06
population O 0 6.781015571277749e-08
showed O 0 5.889584144824767e-07
that O 0 4.3559637674661644e-08
the O 0 8.96023095720011e-07
I113F O 0 2.0094170395168476e-05
mutation O 0 7.463187330358778e-07
is O 0 2.0422230306849087e-07
the O 0 1.324457628015807e-07
most O 0 4.124662922322386e-08
common O 0 2.019893656779459e-07
single O 0 6.98856581493601e-07
mutation O 0 1.3777964795735897e-06
among O 0 3.56493524122925e-06
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 1.0
patients O 0 3.861743971356191e-05
and O 0 9.880694733510609e-07
produces O 0 1.5853013337618904e-06
a O 0 4.3134532461408526e-06
severe O 1 0.9997267127037048
clinical O 1 0.998126208782196
phenotype O 0 0.0009201671928167343
. O 0 5.437131676444551e-06

We O 0 2.1537092834478244e-05
studied O 0 3.334841676405631e-05
mutations O 0 2.716154085646849e-06
in O 0 3.5334974199940916e-06
the O 0 4.548733159026597e-06
GALNS O 0 4.119392542634159e-05
gene O 0 1.0771899496830883e-06
from O 0 2.1999496766511584e-06
23 O 0 1.5908073692116886e-05
additional O 0 5.505915396497585e-06
MPS B-Disease 1 0.9991441965103149
IVA I-Disease 1 1.0
patients O 0 0.00036978363641537726
( O 0 5.124928520672256e-06
15 O 0 1.546386192785576e-05
from O 0 3.872538854921004e-06
Australia O 0 7.471903700206894e-07
, O 0 3.7099692917763605e-07
8 O 0 3.0619748940807767e-06
from O 0 6.000089456392743e-07
Northern O 0 4.00596633198802e-07
Ireland O 0 1.7182063061227382e-07
) O 0 3.3757427075897795e-08
, O 0 6.28619023501642e-09
with O 0 2.257564135632606e-09
various O 0 1.1665658661286216e-07
clinical O 0 0.00037179814535193145
phenotypes O 0 0.0007692911894991994
( O 0 4.061989966430701e-05
severe O 1 0.9976334571838379
, O 0 4.370388069219189e-06
16 O 0 1.866553611762356e-05
cases O 0 1.5788634755153907e-06
; O 0 8.163146389961184e-07
intermediate O 0 2.4870652850950137e-05
, O 0 6.926612741153804e-07
4 O 0 1.1002495739376172e-05
cases O 0 1.5053827837618883e-06
; O 0 2.0239849618519656e-06
mild O 0 0.00011853475007228553
, O 0 1.153570451606356e-06
3 O 0 4.448501385923009e-06
cases O 0 4.99759607919259e-07
) O 0 6.984081437622081e-07
. O 0 1.5737388139314135e-06

We O 0 0.00012079930456820875
found O 0 7.5495868259167764e-06
two O 0 8.820954349175736e-07
common O 0 4.3775233393716917e-07
mutations O 0 1.3593296444014413e-07
that O 0 3.202923792855472e-08
together O 0 2.135467980224348e-08
accounted O 0 8.478678523715644e-07
for O 0 3.299510638044012e-07
32 O 0 5.0290836952626705e-06
% O 0 6.198823712111334e-07
of O 0 2.4928142465796554e-06
the O 0 7.919822564872447e-06
44 O 0 3.5130793548887596e-05
unrelated O 0 4.445574631972704e-06
alleles O 0 9.603055559637141e-07
in O 0 4.716473256394238e-07
these O 0 1.3283955979659368e-07
patients O 0 1.494847879257577e-06
. O 0 1.4020075695952983e-06

One O 0 5.1156323024770245e-05
is O 0 4.66994424641598e-06
the O 0 4.7855646698735654e-06
T312S O 0 0.00012756040086969733
mutation O 0 3.513644969643792e-06
, O 0 4.462206391053769e-07
a O 0 3.9649859218116035e-07
novel O 0 8.822098607197404e-07
mutation O 0 5.159089937478711e-07
found O 0 1.7153575981865288e-07
exclusively O 0 8.905066550823904e-08
in O 0 3.7368101857282454e-07
milder O 0 1.3914890587329865e-05
patients O 0 5.013204827264417e-06
. O 0 3.3689104839140782e-06

The O 0 0.00047157201333902776
other O 0 7.845423169783317e-06
is O 0 1.5305146234823042e-06
the O 0 1.3181349913793383e-06
previously O 0 5.010862878407352e-06
described O 0 2.7666499136103084e-06
I113F O 0 2.7397780286264606e-05
that O 0 2.3501448254137358e-07
produces O 0 3.202501602572738e-06
a O 0 7.442089099640725e-06
severe O 0 0.2981387674808502
phenotype O 0 0.0015168244717642665
. O 0 1.5819510736037046e-05

The O 0 0.00027636202867142856
I113F O 0 0.0004373527772258967
and O 0 1.4348788681672886e-05
T312S O 0 9.708262950880453e-05
mutations O 0 4.95111908094259e-06
accounted O 0 2.4891249267966487e-05
for O 0 3.48010962625267e-06
8 O 0 1.2863416486652568e-05
( O 0 3.9760502090757655e-07
18 O 0 4.315963451517746e-06
% O 0 8.946022944655851e-07
) O 0 1.5132000896755926e-07
and O 0 5.147648494130408e-07
6 O 0 1.0070963980979286e-05
( O 0 3.239032650981244e-07
14 O 0 2.2041035663278308e-06
% O 0 2.564777332736412e-07
) O 0 4.465969638545175e-08
of O 0 1.4155743883748073e-06
44 O 0 1.463645003241254e-05
unrelated O 0 5.516594683285803e-06
alleles O 0 4.4099697333876975e-06
, O 0 2.114378048645449e-06
respectively O 0 1.8143413399229757e-05
. O 0 2.05910146178212e-06

The O 0 0.00019290705677121878
relatively O 0 0.00011914939386770129
high O 0 0.00030435086227953434
residual O 0 0.0006436279509216547
GALNS O 0 0.0026927946601063013
activity O 0 6.025127731845714e-05
seen O 0 1.4901615031703841e-05
when O 0 8.712161729818035e-07
the O 0 1.2275127119210083e-06
T312S O 0 1.1931188055314124e-05
mutant O 0 7.285101673915051e-06
cDNA O 0 8.474356945953332e-06
is O 0 8.090249252745707e-07
overexpressed O 0 1.0857071174541488e-05
in O 0 1.0331688145015505e-06
mutant O 0 3.065229520871071e-06
cells O 0 3.139045645639271e-07
provides O 0 5.486493037665241e-08
an O 0 2.810550014942237e-08
explanation O 0 1.7483760927916592e-07
for O 0 3.3487384598629433e-07
the O 0 4.537701897788793e-06
mild O 0 0.00034131016582250595
phenotype O 0 2.8205924536450766e-05
in O 0 1.0645550219123834e-06
patients O 0 3.560901689070306e-07
with O 0 1.6438882255442877e-08
this O 0 1.4670466441657481e-07
mutation O 0 2.562902409408707e-06
. O 0 1.6197675449802773e-06

The O 0 1.1201023880857974e-05
distribution O 0 2.3325037545873784e-06
and O 0 6.003043040436751e-07
relative O 0 1.1564846317924093e-05
frequencies O 0 9.584880899637938e-06
of O 0 1.5623123545083217e-05
the O 0 1.9938524928875268e-05
I113F O 0 8.93368196557276e-05
and O 0 7.820778591849376e-06
T312S O 0 4.719182470580563e-05
mutations O 0 1.7706456674204674e-06
in O 0 2.0611309992091265e-06
Australia O 0 2.758125106083753e-07
corresponded O 0 5.472435873343784e-07
to O 0 1.7469693602834013e-07
those O 0 2.837336410266289e-07
observed O 0 2.989339236592059e-06
in O 0 2.754783736236277e-06
Northern O 0 3.6328456189949065e-06
Ireland O 0 1.1661493317660643e-06
and O 0 1.285730490963033e-06
are O 0 2.104736296359988e-07
unique O 0 2.956080606963951e-07
to O 0 1.4525930680520105e-07
these O 0 1.717783675303508e-07
two O 0 3.732482696250372e-07
populations O 0 2.946856909602502e-07
, O 0 2.5010243120959785e-07
suggesting O 0 1.0240811434414354e-06
that O 0 2.6235167638333223e-07
both O 0 1.2179043551441282e-06
mutations O 0 1.4014274256624049e-06
were O 0 3.954279236495495e-06
probably O 0 7.225723379633564e-07
introduced O 0 1.4100325529398106e-07
to O 0 2.6551502330107724e-08
Australia O 0 5.070403830131909e-08
by O 0 3.1339062900315184e-08
Irish O 0 7.153019510042213e-07
migrants O 0 3.5485956573211297e-07
during O 0 1.313575921813026e-06
the O 0 1.5580468470943742e-06
19th O 0 1.9329885617480613e-05
century O 0 1.7972324712900445e-05
. O 0 1.9480501123325666e-06

Haplotype O 0 0.0019146328559145331
analysis O 0 4.6912104153307155e-05
using O 0 1.0257553185510915e-05
6 O 0 5.996226900606416e-05
RFLPs O 0 0.00012308104487601668
provides O 0 5.975592216600489e-07
additional O 0 1.6316998596721533e-07
data O 0 6.245010695238307e-07
that O 0 1.6701936544905038e-07
the O 0 3.959102286898997e-06
I113F O 0 6.551541446242481e-05
mutation O 0 1.4716388250235468e-06
originated O 0 1.92417974176351e-06
from O 0 4.089677929641766e-07
a O 0 9.060630645763013e-07
common O 0 2.0905797555315075e-06
ancestor O 0 4.4590193283511326e-05
. O 0 3.7517793316510506e-06

The O 0 8.345074456883594e-05
other O 0 4.450410415302031e-06
9 O 0 4.2358147766208276e-05
novel O 0 4.867647476203274e-06
mutations O 0 2.4430701159872115e-06
identified O 0 1.0164741297558066e-06
in O 0 8.008341865206603e-07
these O 0 1.5513080597884255e-07
23 O 0 1.0793970432132483e-05
patients O 0 2.754051138253999e-07
were O 0 1.8114258182322374e-07
each O 0 1.600303889404131e-08
limited O 0 1.9157812403136631e-07
to O 0 2.1726208387917723e-07
a O 0 3.517204959280207e-06
single O 0 6.912155186000746e-06
family O 0 3.99862483391189e-06
. O 0 4.237784196448047e-06

These O 0 2.074170879495796e-06
data O 0 9.854129530140199e-07
provide O 0 4.160986932788546e-08
further O 0 7.356091913379714e-08
evidence O 0 3.197675084720686e-07
for O 0 3.8485379150188237e-07
extensive O 0 5.871492703590775e-06
allelic O 0 0.00011209869990125299
heterogeneity O 0 0.0002391837042523548
in O 0 0.0004234774096403271
MPS B-Disease 1 0.9994694590568542
IVA I-Disease 1 0.999998927116394
in O 0 8.516309026163071e-05
British O 0 4.3357969843782485e-05
- O 0 4.1051222069654614e-05
Irish O 0 7.783658475091215e-06
patients O 0 5.982479933663853e-07
and O 0 1.4854258267860132e-07
provide O 0 1.104061198020645e-07
evidence O 0 9.997080496759736e-07
for O 0 8.831636364448059e-07
their O 0 7.403329504995781e-07
transmission O 0 2.5946488676709123e-05
to O 0 7.566933390990016e-07
Australia O 0 5.524679522750375e-07
by O 0 2.50616722041741e-07
British O 0 3.5524185477697756e-06
- O 0 4.0989966691995505e-06
Irish O 0 2.103864289892954e-06
migrants O 0 5.305818149281549e-07
. O 0 6.211179481852014e-08
. O 0 2.982815772156755e-07

Identification O 0 2.906574991357047e-05
of O 0 5.7908084272639826e-05
constitutional O 0 0.0022897643502801657
WT1 O 0 0.05657317116856575
mutations O 0 4.127869033254683e-06
, O 0 1.1634305252528065e-07
in O 0 9.24542007396667e-08
patients O 0 2.4483827587573614e-07
with O 0 2.1490667734269664e-07
isolated O 0 0.0004956535412929952
diffuse B-Disease 1 0.9999979734420776
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.100572368770372e-06
and O 0 3.3472795735178806e-07
analysis O 0 5.660112947225571e-07
of O 0 1.7377124095219187e-05
genotype O 0 0.0014605047181248665
/ O 0 0.0008832199964672327
phenotype O 0 1.0057622603198979e-05
correlations O 0 3.063908479816746e-06
by O 0 4.412138565612622e-08
use O 0 2.84929928540123e-08
of O 0 2.776281462502084e-07
a O 0 6.845079383310804e-07
computerized O 0 8.571321814088151e-06
mutation O 0 2.1577136521955254e-06
database O 0 2.9256495963636553e-06
. O 0 1.6905146367207635e-06

Constitutional O 0 0.00048570879152975976
mutations O 0 2.50757784669986e-05
of O 0 8.69668583618477e-05
the O 0 4.2238712921971455e-05
WT1 O 0 0.0004327782953623682
gene O 0 3.6646110856963787e-06
, O 0 7.613223829139315e-07
encoding O 0 2.5198473849741276e-06
a O 0 1.4115723388385959e-05
zinc O 0 0.0002793078310787678
- O 0 8.464960410492495e-05
finger O 0 0.00014138262486085296
transcription O 0 0.0001473630400141701
factor O 0 6.502225915028248e-06
involved O 0 2.3291361230803886e-06
in O 0 3.800095510086976e-05
renal O 1 1.0
and O 0 0.001771682989783585
gonadal O 1 0.9999996423721313
development O 0 0.0015817272942513227
, O 0 5.980540436212323e-07
are O 0 2.0354869789684926e-08
found O 0 2.368585683143465e-08
in O 0 3.274354298810067e-08
most O 0 2.9203588880477582e-08
patients O 0 1.2858710363161663e-07
with O 0 2.1913280079388642e-07
Denys B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.07640926539897919
DDS B-Disease 1 1.0
) O 0 5.60664375370834e-06
, O 0 1.505148929936695e-06
or O 0 7.879737677285448e-05
diffuse B-Disease 1 0.999994158744812
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.0037023068871349096
DMS B-Disease 1 0.9999990463256836
) O 0 1.0378081469752942e-06
associated O 0 1.7401265495209373e-06
with O 0 1.0920350632659392e-06
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.0030041427817195654
/ O 1 0.9998862743377686
or O 0 0.0013100072974339128
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 0 5.106941898702644e-05
WT B-Disease 1 0.9999994039535522
) O 0 1.6603298718109727e-06
. O 0 9.732185617394862e-07

Most O 0 3.691601523314603e-05
mutations O 0 7.777832797728479e-05
in O 0 0.000123876758152619
DDS B-Disease 1 1.0
patients O 0 0.00012738656369037926
lie O 0 0.00012469878129195422
in O 0 1.3674492947757244e-05
exon O 0 2.2554348106496036e-05
8 O 0 4.7361252654809505e-05
or O 0 4.474748948268825e-06
exon O 0 6.7160153776058e-06
9 O 0 2.933791074610781e-05
, O 0 1.5802507959961076e-06
encoding O 0 5.956809218332637e-06
zinc O 0 0.0005072348867543042
finger O 0 0.0010310575598850846
2 O 0 0.0005226560169830918
or O 0 5.7615710829850286e-05
zinc O 0 0.0011271395487710834
finger O 0 0.0005061395349912345
3 O 0 4.7805395297473297e-05
, O 0 7.285270839929581e-07
respectively O 0 3.0498219985020114e-06
, O 0 1.0107693526606454e-07
with O 0 7.196084084171162e-08
a O 0 8.693257768754847e-06
hot O 0 0.00013000999751966447
spot O 0 5.1436913054203615e-05
( O 0 1.515620624559233e-06
R394W O 0 1.008428353088675e-05
) O 0 1.4610458265451598e-07
in O 0 7.539626381003472e-07
exon O 0 4.0994773371494375e-06
9 O 0 1.9793875253526494e-05
. O 0 1.732997134240577e-06

We O 0 1.3205231880419888e-05
analyzed O 0 3.3001854262693087e-06
a O 0 1.0159507155549363e-06
series O 0 6.699720529468323e-07
of O 0 2.7100916213385062e-06
24 O 0 2.022696571657434e-05
patients O 0 9.191246022055566e-07
, O 0 6.698116408188071e-07
10 O 0 2.459302322677104e-06
with O 0 1.5463260751857888e-06
isolated B-Disease 0 0.00048052548663690686
DMS I-Disease 1 0.9997554421424866
( O 0 3.3026990422513336e-05
IDMS B-Disease 0 0.001052096369676292
) O 0 1.3275006267576828e-06
, O 0 5.256169970380142e-07
10 O 0 2.045551354967756e-06
with O 0 1.3073658919893205e-06
DDS B-Disease 1 1.0
, O 0 2.9268244361446705e-06
and O 0 6.564492878169403e-07
4 O 0 3.055571505683474e-05
with O 0 2.7991982278763317e-06
urogenital B-Disease 1 1.0
abnormalities I-Disease 1 1.0
and O 1 0.8700807690620422
/ O 1 0.9999979734420776
or O 1 0.5301358103752136
WT B-Disease 1 1.0
. O 0 1.2682894521276467e-05

We O 0 0.00013590630260296166
report O 0 5.761746797361411e-05
WT1 O 0 0.0015337952645495534
heterozygous O 0 1.2098439583496656e-05
mutations O 0 2.0483703337959014e-06
in O 0 2.932818006229354e-06
16 O 0 1.2353538295428734e-05
patients O 0 7.686124945394113e-07
, O 0 1.7484261150002567e-07
4 O 0 1.5732210840724292e-06
of O 0 1.5022192201286089e-06
whom O 0 2.817957920342451e-06
presented O 0 1.4701360669278074e-05
with O 0 7.151333193178289e-06
IDMS B-Disease 1 0.6867982149124146
. O 0 1.9590101146604866e-05

One O 0 7.160463428590447e-05
male O 0 3.9051992644090205e-05
and O 0 1.8476021068636328e-06
two O 0 1.7869666635306203e-06
female O 0 9.441137808607891e-05
IDMS B-Disease 1 0.9990131855010986
patients O 0 9.018148375616875e-06
with O 0 2.5026945422723657e-06
WT1 O 1 0.9999850988388062
mutations O 0 0.019860055297613144
underwent O 1 0.9999998807907104
normal O 1 0.9983893632888794
puberty O 1 0.9969421029090881
. O 0 8.352973964065313e-06

Two O 0 0.00022032760898582637
mutations O 0 0.00026894116308540106
associated O 0 8.649253868497908e-05
with O 0 6.319858130154898e-06
IDMS B-Disease 0 0.00545693701133132
are O 0 2.5651834789641725e-07
different O 0 2.435294632618934e-08
from O 0 3.593658846057224e-07
those O 0 1.413126113902763e-07
described O 0 3.4412385048199212e-06
in O 0 2.2627229554927908e-05
DDS B-Disease 1 1.0
patients O 0 8.744326623855159e-05
. O 0 4.497050667850999e-06

No O 0 0.0006600802298635244
WT1 O 0 0.004357676953077316
mutations O 0 1.9442604752839543e-05
were O 0 1.0488151929166634e-05
detected O 0 1.2400776540744118e-05
in O 0 2.2158637875691056e-06
the O 0 2.4567098080297e-06
six O 0 4.140970759181073e-06
other O 0 1.5333151850427384e-06
IDMS B-Disease 1 0.9975912570953369
patients O 0 4.934522621624637e-06
, O 0 1.236864761722245e-07
suggesting O 0 4.171887155735021e-07
genetic O 0 7.448269343512948e-07
heterogeneity O 0 8.208024155464955e-06
of O 0 1.6645910363877192e-05
this O 0 8.342584806086961e-06
disease O 1 0.7144893407821655
. O 0 7.607695351907751e-06

We O 0 5.8337533118901774e-05
analyzed O 0 0.000140451462357305
genotype O 0 0.00035755219869315624
/ O 0 0.0003429977223277092
phenotype O 0 2.956726893899031e-05
correlations O 0 2.0193161617498845e-05
, O 0 4.879844368588238e-07
on O 0 4.6254865537775913e-07
the O 0 7.699801329863476e-08
basis O 0 1.207390454283086e-07
of O 0 4.4822647282671824e-07
the O 0 6.46675232474081e-07
constitution O 0 1.1391516636649612e-06
of O 0 2.095206582453102e-06
a O 0 6.223005584615748e-06
WT1 O 0 0.00011918269592570141
mutation O 0 9.738992048369255e-07
database O 0 2.542057927712449e-06
of O 0 2.3859758584876545e-05
84 O 0 0.0005477003287523985
germ O 0 0.002483308780938387
- O 0 0.000435512833064422
line O 0 0.00013748463243246078
mutations O 0 1.4153031315800035e-06
, O 0 1.3706915069633396e-07
to O 0 2.1990901544199914e-08
compare O 0 1.1084499362823408e-07
the O 0 6.165807349134411e-07
distribution O 0 1.6772116850916063e-06
and O 0 1.0312678568880074e-06
type O 0 9.998052519222256e-06
of O 0 2.805909389280714e-05
mutations O 0 4.239021109242458e-06
, O 0 2.55198756349273e-07
according O 0 2.7019671833272696e-08
to O 0 1.0562706265204724e-08
the O 0 2.2346331718381407e-07
different O 0 2.068377966679691e-07
symptoms O 0 0.00025006107171066105
. O 0 7.473239747923799e-06

This O 0 3.08341441268567e-05
demonstrated O 0 7.338488649111241e-05
( O 0 2.7914777547266567e-06
1 O 0 9.496649909124244e-06
) O 0 2.4616250016151753e-07
the O 0 6.330682253974373e-07
association O 0 5.387911414800328e-07
between O 0 1.8544605495662836e-07
mutations O 0 2.441702235955745e-07
in O 0 2.3489822069677757e-06
exons O 0 5.1945994528068695e-06
8 O 0 1.1922202247660607e-05
and O 0 2.574520976850181e-06
9 O 0 6.440566357923672e-05
and O 0 2.0639949070755392e-05
DMS B-Disease 0 0.189377099275589
; O 0 2.1280166038195603e-06
( O 0 9.346043725599884e-07
2 O 0 3.832700258499244e-06
) O 0 1.2620853340195026e-07
among O 0 7.388630507421112e-08
patients O 0 5.501498208104749e-07
with O 0 6.420155500563851e-07
DMS B-Disease 1 0.8944613337516785
, O 0 9.831583156483248e-07
a O 0 9.146450565822306e-07
higher O 0 2.7566077278606826e-06
frequency O 0 1.292824890697375e-06
of O 0 3.195167892044992e-06
exon O 0 3.7233851344353752e-06
8 O 0 7.2166444624599535e-06
mutations O 0 3.843018134830345e-07
among O 0 4.22504257358014e-07
46 O 0 2.3391186914523132e-05
, O 0 3.5448786093184026e-06
XY O 0 0.001069753896445036
patients O 0 3.003140818691463e-06
with O 0 6.252519142435631e-07
female O 0 1.84160890057683e-05
phenotype O 0 1.7727998056216165e-05
than O 0 5.410098538050079e-07
among O 0 6.108263050919049e-07
46 O 0 3.103830022155307e-05
, O 0 3.3416513360862155e-06
XY O 0 0.0016100391512736678
patients O 0 9.340243423139327e-07
with O 0 2.135859489271752e-07
sexual O 0 2.276959639857523e-05
ambiguity O 0 6.32759474683553e-05
or O 0 5.419051740318537e-05
male O 0 2.3153956135502085e-05
phenotype O 0 7.396953151328489e-06
; O 0 2.2708759672696033e-07
and O 0 3.571819036096713e-07
( O 0 2.2413735223381082e-07
3 O 0 7.237294994411059e-07
) O 0 1.97581382366252e-08
statistically O 0 7.668188573006773e-08
significant O 0 5.660448110234029e-08
evidence O 0 2.8384894790178805e-07
that O 0 1.34202807089423e-07
mutations O 0 4.0778306242827966e-07
in O 0 1.2135565157223027e-06
exons O 0 7.801382707839366e-06
8 O 0 1.2689596587733831e-05
and O 0 1.1121131819891161e-06
9 O 0 1.531893212813884e-05
preferentially O 0 2.5557899334671674e-06
affect O 0 6.0406227930798195e-06
amino O 0 2.5891861241689185e-06
acids O 0 1.5026934363504552e-07
with O 0 5.229926269834095e-09
different O 0 6.581879929967727e-09
functions O 0 9.88126998890948e-07
. O 0 2.1552364160015713e-07
. O 0 6.141792141534097e-07

The O 0 0.0003507062792778015
185delAG O 0 0.0007501590880565345
BRCA1 O 0 8.164768951246515e-05
mutation O 0 3.439821057327208e-06
originated O 0 3.001348432007944e-06
before O 0 9.480131666350644e-07
the O 0 6.87336523697013e-07
dispersion O 0 5.058723672846099e-06
of O 0 4.927638201479567e-06
Jews O 0 2.7945677629759302e-06
in O 0 1.6642994751236984e-06
the O 0 1.5216469364531804e-06
diaspora O 0 1.7476154425821733e-06
and O 0 6.589393706235569e-07
is O 0 2.2548977085534716e-07
not O 0 5.605653186080417e-08
limited O 0 3.6790413560083834e-07
to O 0 8.415175898335292e-07
Ashkenazim O 0 0.00010190340253757313
. O 0 3.720680524565978e-06

The O 0 0.00020999397384002805
185delAG O 0 0.0006757458904758096
mutation O 0 2.7403530111769214e-05
in O 0 1.0544254109845497e-05
BRCA1 O 0 3.017636299773585e-05
is O 0 5.56695340492297e-07
detected O 0 5.745399107581761e-07
in O 0 6.984788569752709e-08
Ashkenazi O 0 5.05996013089316e-07
Jews O 0 1.1891557960552745e-07
both O 0 3.620047905883439e-08
in O 0 4.7441992023777857e-07
familial B-Disease 1 0.996344268321991
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.923866072203964e-05
in O 0 1.1556765457498841e-05
the O 0 7.813621778041124e-06
general O 0 1.1669909326883499e-05
population O 0 7.560492463198898e-07
. O 0 1.246441343027982e-06

All O 0 2.7219884941587225e-05
tested O 0 2.388717075518798e-05
Ashkenazi O 0 2.635326745803468e-05
mutation O 0 7.251568945321196e-07
carriers O 0 2.1666885174909112e-07
share O 0 2.381278676466536e-07
the O 0 2.1013929085711425e-07
same O 0 2.2183387216045958e-07
allelic O 0 8.802519005257636e-06
pattern O 0 1.4578986338165123e-05
at O 0 2.2705198716721497e-05
the O 0 3.389277026144555e-06
BRCA1 O 0 1.7960655895876698e-05
locus O 0 5.050214895163663e-05
. O 0 3.080644319197745e-06

Our O 0 0.0001625518489163369
previous O 0 3.948353696614504e-05
study O 0 7.346119218709646e-06
showed O 0 9.344179488834925e-06
that O 0 3.503442371766141e-07
this O 0 3.906914685103402e-07
Ashkenazi O 0 1.7593980373931117e-05
mutation O 0 2.2765273115510354e-06
also O 0 1.5939090189931449e-06
occurs O 0 4.1797520111686026e-07
in O 0 3.939502732919209e-07
Iraqi O 0 2.7134667561767856e-06
Jews O 0 3.689138736717723e-07
with O 0 4.414966880972315e-08
a O 0 4.583052941597998e-07
similar O 0 7.203911991382483e-07
allelic O 0 8.710837573744357e-05
pattern O 0 0.0003181020147167146
. O 0 1.1735544831026345e-05

We O 0 6.005588875268586e-05
extended O 0 6.060821397113614e-05
our O 0 1.04106729850173e-05
analysis O 0 1.5986145172064425e-06
to O 0 6.695996717098751e-07
other O 0 7.894047939771554e-07
non O 0 1.9621214960352518e-05
- O 0 7.589709184685489e-06
Ashkenazi O 0 1.5695175534347072e-05
subsets O 0 1.7717213268042542e-05
354 O 0 1.6208081433433108e-05
of O 0 1.1764564987970516e-05
Moroccan O 0 0.00021047284826636314
origin O 0 4.990846264263382e-06
, O 0 1.4385550457518548e-06
200 O 0 1.969842060134397e-06
Yemenites O 0 2.350771683268249e-05
and O 0 1.0086948805110296e-06
150 O 0 2.710737817324116e-06
Iranian O 0 1.6569336366956122e-05
Jews O 0 5.350816081772791e-06
. O 0 1.9974668248323724e-06

Heteroduplex O 0 0.0023970662150532007
analysis O 0 6.183965979289496e-06
complemented O 0 4.1583398342481814e-06
by O 0 8.073217827586632e-08
direct O 0 2.703916663904238e-07
DNA O 0 1.7936835092768888e-06
sequencing O 0 6.94574282533722e-06
of O 0 2.554094862716738e-05
abnormally O 0 0.0004226216406095773
migrating O 0 3.227563638574793e-06
bands O 0 2.475642759236507e-06
were O 0 1.0227546454188996e-06
employed O 0 3.009999318237533e-06
. O 0 1.0555143035162473e-06

Four O 0 0.0002622423635330051
of O 0 0.0002594781981315464
Moroccan O 0 0.0015889895148575306
origin O 0 1.7343449144391343e-05
( O 0 7.851342616049806e-07
1 O 0 1.0574780162642128e-06
. O 0 3.970479411918859e-08
1 O 0 1.080451397683646e-06
% O 0 2.724040371049341e-07
) O 0 7.446494976193208e-08
and O 0 2.1535269922878797e-07
none O 0 2.007778221013723e-06
of O 0 2.056466109934263e-05
the O 0 3.0846556910546497e-05
Yemenites O 0 0.00011531892960192636
or O 0 3.2496002404514e-06
Iranians O 0 2.9012630875513423e-06
was O 0 2.919259031841648e-06
a O 0 1.9432205533576052e-07
carrier O 0 3.380514783657418e-07
of O 0 1.0059484338853508e-06
the O 0 4.0120971789292526e-06
185delAG O 0 4.979438381269574e-05
mutation O 0 1.120599245041376e-05
. O 0 6.714798473694827e-06

BRCA1 O 0 0.0016230243491008878
allelic O 0 0.0008174123358912766
patterns O 0 0.00012248323764652014
were O 0 1.6071173376985826e-05
determined O 0 1.8774921954900492e-06
for O 0 7.028910999906657e-07
four O 0 8.720873552192643e-07
of O 0 1.5477555734833004e-06
these O 0 1.2590221842856408e-07
individuals O 0 1.317130511324649e-07
and O 0 5.239824076852528e-07
for O 0 9.122302344621858e-07
12 O 0 1.0412430128781125e-05
additional O 0 2.4930138806666946e-06
non O 0 0.000509201898239553
- O 0 0.00014220034063328058
Ashkenazi O 0 3.708294389070943e-05
185delAG O 0 1.10565279101138e-05
mutation O 0 3.194873556822131e-07
carriers O 0 9.388525512576962e-08
who O 0 1.798690760779209e-07
had O 0 1.4582559742848389e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.614734669099562e-05

Six O 0 0.0028588520362973213
non O 0 0.004606129601597786
- O 0 0.00029774181894026697
Ashkenazi O 0 4.2926396417897195e-05
individuals O 0 2.661600433384592e-07
shared O 0 2.233573013654677e-06
the O 0 6.156667495815782e-06
common O 0 9.566078915668186e-06
Ashkenazi O 0 0.00019244498980697244
haplotype O 0 0.0007986732525750995
, O 0 8.649708433949854e-06
four O 0 2.0568638774420833e-06
had O 0 1.112011250370415e-05
a O 0 5.773869361291872e-06
closely O 0 1.8188449075751123e-06
related O 0 1.7632228264119476e-05
pattern O 0 0.0003589020052459091
, O 0 3.100477442785632e-06
and O 0 1.6276446785923326e-06
the O 0 8.606001756561454e-06
rest O 0 7.16526665200945e-06
( O 0 1.8216588841823977e-06
n O 0 3.598452531150542e-05
= O 0 1.314920973527478e-05
6 O 0 4.99376938023488e-06
) O 0 7.52206688048318e-08
displayed O 0 9.708760444482323e-07
a O 0 4.575192065203737e-07
distinct O 0 7.221851205940766e-07
BRCA1 O 0 1.4297360394266434e-05
allelic O 0 3.518786616041325e-05
pattern O 0 5.100317866890691e-05
. O 0 3.0480773602903355e-06

We O 0 2.0945588403264992e-05
conclude O 0 1.2796233932022005e-05
that O 0 9.290653224525158e-07
the O 0 6.2455987972498406e-06
185delAG O 0 7.581397221656516e-05
BRCA1 O 0 5.2562922064680606e-05
mutation O 0 5.362745014281245e-06
occurs O 0 4.322566383052617e-06
in O 0 4.242143404553644e-06
some O 0 9.605556670067017e-07
non O 0 5.4182866733754054e-05
- O 0 2.5468538296991028e-05
Ashkenazi O 0 1.3948598279966973e-05
populations O 0 4.304764047446952e-07
at O 0 1.8731784621195402e-06
rates O 0 1.0589378263148319e-07
comparable O 0 2.2052188342058798e-07
with O 0 2.2996166748612268e-08
that O 0 1.0504245295805958e-07
of O 0 8.285727744805627e-06
Ashkenazim O 0 0.00019820178567897528
. O 0 3.864469817926874e-06

The O 0 4.0593564335722476e-05
majority O 0 1.739897584229766e-06
of O 0 1.1532576536410488e-05
Jewish O 0 4.6600878704339266e-05
185delAG O 0 0.00010576993372524157
mutation O 0 3.8851408135087695e-06
carriers O 0 5.151042046236398e-07
have O 0 1.5262526176229585e-07
a O 0 4.0499341480426665e-07
common O 0 6.835034014329722e-07
allelic O 0 1.874502413556911e-05
pattern O 0 4.510038343141787e-05
, O 0 1.7722067013892229e-06
supporting O 0 8.523798896931112e-06
the O 0 2.996644252561964e-05
founder O 0 0.00015124730998650193
effect O 0 2.281341585330665e-05
notion O 0 1.207597233587876e-05
, O 0 8.337498229593621e-07
but O 0 9.670008438433797e-08
dating O 0 1.3638762084156042e-06
the O 0 6.313095468613028e-07
mutations O 0 2.895743875797052e-07
origin O 0 6.862819645903073e-07
to O 0 1.943129745995975e-07
an O 0 2.668055287813331e-07
earlier O 0 9.670945928519359e-07
date O 0 4.282948339096038e-06
than O 0 3.714613967531477e-07
currently O 0 1.7080554925996694e-06
estimated O 0 3.0209473607101245e-06
. O 0 2.3397399218083592e-06

However O 0 2.2781632651458494e-05
, O 0 6.898121682752389e-07
the O 0 3.390462097740965e-07
different O 0 7.118558187357849e-08
allelic O 0 6.788425707782153e-06
pattern O 0 6.0011014284100384e-05
at O 0 7.232699863379821e-05
the O 0 6.46378339297371e-06
BRCA1 O 0 1.2206776773382444e-05
locus O 0 1.7766247765393928e-05
even O 0 7.099642402863537e-07
in O 0 5.183551365917083e-07
some O 0 7.966676918158555e-08
Jewish O 0 3.801590310104075e-06
mutation O 0 2.8215501970407786e-06
carriers O 0 1.545479790365789e-06
, O 0 1.7213224623446877e-07
might O 0 6.825654708109141e-08
suggest O 0 5.138809555660373e-08
that O 0 1.1747308903409248e-08
the O 0 9.589523841668779e-08
mutation O 0 1.2662421511322464e-07
arose O 0 3.4913745139419916e-07
independently O 0 1.1851671644080852e-07
. O 0 1.4631233113959752e-07
. O 0 8.380545750696911e-07

Crystal O 0 0.1018868088722229
structure O 0 0.0004619084356818348
of O 0 0.0003288296575192362
the O 0 0.0006770038162358105
hemochromatosis B-Disease 1 1.0
protein O 0 0.0036658330354839563
HFE O 0 0.014414945617318153
and O 0 6.509249487862689e-06
characterization O 0 2.449790008540731e-05
of O 0 1.2190768757136539e-05
its O 0 8.306427048410114e-07
interaction O 0 1.949893885466736e-06
with O 0 9.608525033399928e-07
transferrin O 0 0.0002934265648946166
receptor O 0 9.4289738626685e-05
. O 0 2.2380463633453473e-06

HFE O 1 0.9783985018730164
is O 0 0.0003501969331409782
an O 0 3.078939698752947e-05
MHC O 0 0.0002104068553308025
- O 0 7.87166427471675e-05
related O 0 7.471023764082929e-06
protein O 0 4.263980827090563e-06
that O 0 3.382303859211788e-08
is O 0 5.1767731434892994e-08
mutated O 0 1.0015730111945231e-07
in O 0 4.1131582406706e-07
the O 0 1.2968706869287416e-05
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.12019754201173782

HFE O 0 0.012259628623723984
binds O 0 4.9968202802119777e-05
to O 0 1.732714918034617e-05
transferrin O 0 0.000560420099645853
receptor O 0 0.00013007559755351394
( O 0 5.637311005557422e-06
TfR O 0 0.0004822143237106502
) O 0 4.317431034905894e-07
and O 0 2.4214324412241695e-07
reduces O 0 7.774056598464085e-07
its O 0 3.9010024011076894e-07
affinity O 0 2.2130316210677847e-06
for O 0 3.4663898986764252e-06
iron O 0 0.0004914332530461252
- O 0 2.257003143313341e-05
loaded O 0 7.255025138874771e-06
transferrin O 0 5.4893978813197464e-05
, O 0 1.626411176403053e-06
implicating O 0 7.175905193435028e-05
HFE O 0 0.009318099357187748
in O 0 0.0003145710506942123
iron O 1 0.9999841451644897
metabolism O 1 0.9920768737792969
. O 0 1.113570306188194e-05

The O 0 0.0003922649775631726
2 O 0 0.00025040487525984645
. O 0 1.3697204849449918e-05

6 O 0 0.0016036975430324674
A O 0 0.0003116225416306406
crystal O 0 0.0021771839819848537
structure O 0 0.00014233221008908004
of O 0 5.351296204025857e-05
HFE O 0 0.003973036073148251
reveals O 0 8.49505522637628e-06
the O 0 3.5097534691885812e-06
locations O 0 9.27140899875667e-06
of O 0 0.0005362594965845346
hemochromatosis B-Disease 1 1.0
mutations O 0 0.001019042101688683
and O 0 0.00020004951511509717
a O 0 0.00038592080818489194
patch O 0 0.0320231057703495
of O 0 0.44092610478401184
histidines O 1 0.9288324117660522
that O 0 3.326259275127086e-06
could O 0 1.7658211390880751e-06
be O 0 8.074147217485006e-07
involved O 0 1.401152076141443e-06
in O 0 4.591023753164336e-06
pH O 0 0.00012544992205221206
- O 0 2.072250936180353e-05
dependent O 0 2.997372575919144e-06
interactions O 0 3.35504023496469e-06
. O 0 1.341304255220166e-06

We O 0 5.82372558710631e-05
also O 0 3.4930906167573994e-06
demonstrate O 0 9.315991519542877e-06
that O 0 2.782449200822157e-06
soluble O 0 0.0001193415664602071
TfR O 0 0.0023578349500894547
and O 0 1.163263095804723e-05
HFE O 0 0.0003029494546353817
bind O 0 1.6848380255396478e-06
tightly O 0 4.485759745875839e-06
at O 0 1.5963880287017673e-05
the O 0 1.610301410437387e-06
basic O 0 6.038249466655543e-06
pH O 0 4.6157187171047553e-05
of O 0 0.00014449004083871841
the O 0 9.84931830316782e-05
cell O 0 0.00016273297660518438
surface O 0 6.852668593637645e-05
, O 0 1.1716583685483783e-06
but O 0 1.3657201236583205e-07
not O 0 2.384405490829522e-07
at O 0 6.863566341053229e-06
the O 0 1.254017206520075e-06
acidic O 0 6.696828222629847e-06
pH O 0 3.960156027460471e-05
of O 0 4.389515379443765e-05
intracellular O 0 0.00016445368237327784
vesicles O 0 0.00019014283316209912
. O 0 1.5717434507678263e-05

TfR O 1 0.996370792388916
HFE O 0 0.09169457107782364
stoichiometry O 0 0.0017916254000738263
( O 0 3.7469202652573586e-05
2 O 0 4.163754056207836e-05
1 O 0 1.6337691704393364e-05
) O 0 5.214162115407817e-07
differs O 0 8.984249575405556e-07
from O 0 1.6881560895853909e-06
TfR O 0 0.0004365346976555884
transferrin O 0 0.0001230198104167357
stoichiometry O 0 4.435828668647446e-05
( O 0 1.5301848179660738e-06
2 O 0 7.3261662691948e-06
2 O 0 5.5423815865651704e-06
) O 0 1.7896836368436198e-07
, O 0 6.85512802078847e-08
implying O 0 3.6526986946228135e-07
a O 0 1.3233101014975546e-07
different O 0 1.2284779415949743e-08
mode O 0 1.0813853350555291e-06
of O 0 8.228167871493497e-07
binding O 0 2.4495179786754306e-06
for O 0 7.252029718074482e-06
HFE O 0 0.0008178314892575145
and O 0 1.478054855397204e-05
transferrin O 0 0.00011611205991357565
to O 0 4.842473572352901e-06
TfR O 0 0.0024345091078430414
, O 0 2.0993727503082482e-06
consistent O 0 2.9033139981038403e-06
with O 0 1.493743440050821e-07
our O 0 1.6793773056633654e-06
demonstration O 0 3.513783303787932e-05
that O 0 1.187501652566425e-06
HFE O 0 0.0004547522694338113
, O 0 2.300736696270178e-06
transferrin O 0 4.377663935883902e-05
, O 0 3.4406107829454413e-07
and O 0 2.636360818542016e-07
TfR O 0 0.0003648462879937142
form O 0 2.746803602349246e-06
a O 0 1.626082848815713e-05
ternary O 0 0.0005649972008541226
complex O 0 0.00043774081859737635
. O 0 1.1016438293154351e-05

Identification O 0 3.745534559129737e-05
of O 0 3.371265120222233e-05
three O 0 3.576305061869789e-06
novel O 0 3.3523922411404783e-06
mutations O 0 5.71309669794573e-07
and O 0 2.756889330157719e-07
a O 0 4.488249203404848e-07
high O 0 3.3494170565973036e-06
frequency O 0 1.2211120292704436e-06
of O 0 2.5880997327476507e-06
the O 0 4.382215138321044e-06
Arg778Leu O 0 0.00012499616423156112
mutation O 0 1.0217203225693083e-06
in O 0 1.3227603403720423e-06
Korean O 0 1.8696055121836253e-05
patients O 0 1.506345029156364e-06
with O 0 6.533191481139511e-07
Wilson B-Disease 0 0.00032897075288929045
disease I-Disease 0 0.0019000736065208912
. O 0 3.0103294648142764e-06

Four O 0 0.0003011292137671262
mutations O 0 3.137730891467072e-05
- O 0 6.120097532402724e-05
- O 0 0.00010408223897684366
R778L O 0 0.00023907609283924103
, O 0 5.534485353564378e-06
A874V O 0 5.611412416328676e-05
, O 0 3.7836357478227e-06
L1083F O 0 3.8513357139891014e-05
, O 0 1.9298768165754154e-06
and O 0 1.6649122471790179e-06
2304delC O 0 9.755735845828895e-06
- O 0 4.634428933059098e-06
- O 0 6.8464846663118806e-06
in O 0 1.3840828614775091e-05
the O 0 3.080525857512839e-05
copper O 0 0.00042593793477863073
- O 0 1.0778047908388544e-05
transporting O 0 2.9422442821669392e-05
enzyme O 0 1.5044994142954238e-05
, O 0 4.248685854690848e-06
P O 0 0.00047618240932933986
- O 0 3.488528454909101e-05
type O 0 0.00014409379218704998
ATPase O 0 0.0005099134286865592
( O 0 6.761966233170824e-06
ATP7B O 0 0.00020719031454063952
) O 0 2.4630713824080885e-07
, O 0 5.00390093804981e-08
were O 0 1.0269000938478712e-07
identified O 0 5.870876762514854e-08
in O 0 1.463541963175885e-07
Korean O 0 7.226209618238499e-06
Patients O 0 2.0196484911139123e-06
with O 0 6.607113505197049e-07
Wilson B-Disease 0 0.0008291355916298926
disease I-Disease 1 0.5647290349006653
. O 0 6.330958058242686e-06

Arg778Leu O 0 0.013389510102570057
, O 0 4.089321009814739e-05
the O 0 9.240929102816153e-06
most O 0 6.834604278083134e-07
frequently O 0 1.043176439452509e-06
reported O 0 2.003117288040812e-06
mutation O 0 5.907044169362052e-07
of O 0 9.396472705702763e-06
this O 0 1.1285430900898064e-06
enzyme O 0 2.7594983293965925e-06
, O 0 4.2570712821543566e-07
was O 0 3.4552670058474177e-06
found O 0 1.7744936542385403e-07
in O 0 3.421165786221536e-07
six O 0 3.1522154131380375e-07
of O 0 2.86372392110934e-06
eight O 0 7.645530786248855e-06
unrelated O 0 6.168998424982419e-06
patients O 0 1.4765437299502082e-06
studied O 0 1.1135978638776578e-05
, O 0 2.579337774477608e-07
an O 0 8.037986276576703e-08
allele O 0 6.799730840612028e-07
frequency O 0 2.9608474960696185e-06
of O 0 2.1401288904598914e-05
37 O 0 0.0001727291091810912
. O 0 8.234587767219637e-06

5 O 0 0.0004480282950680703
% O 0 2.1867801478947513e-05
, O 0 2.174705286961398e-06
which O 0 5.256049462332157e-07
is O 0 5.403173304330267e-07
considerably O 0 1.144778821071668e-06
higher O 0 2.096471689583268e-06
than O 0 4.118499674632403e-08
those O 0 3.458822916968529e-08
in O 0 2.796428759666014e-07
other O 0 2.0615013340830046e-07
Asian O 0 9.316721616414725e-07
populations O 0 1.3210680549491371e-07
. O 0 3.391684799680661e-07

The O 0 5.543799125007354e-05
novel O 0 2.150152977264952e-05
single O 0 1.0082427252200432e-05
nucleotide O 0 2.4849887267919257e-05
deletion O 0 4.5772107114316896e-05
, O 0 4.801738668902544e-06
2304delC O 0 2.1768550141132437e-05
, O 0 9.077695040105027e-07
was O 0 3.37865299115947e-06
found O 0 2.457117034282419e-07
in O 0 4.059353670982091e-07
one O 0 9.961886462406255e-07
patient O 0 1.5074508155521471e-05
. O 0 5.4229949455475435e-06

Since O 0 8.342217188328505e-05
a O 0 1.0562751413090155e-05
mutation O 0 3.900718638760736e-06
at O 0 3.835597090073861e-05
cDNA O 0 3.502966865198687e-05
nucleotide O 0 0.00010054290760308504
2302 O 0 0.0008182384190149605
( O 0 5.219075319473632e-06
2302insC O 0 3.5813147405860946e-05
) O 0 8.655416650071857e-07
had O 0 6.2879112192604225e-06
been O 0 4.7860530685284175e-06
previously O 0 3.948197445424739e-06
described O 0 1.187302359539899e-06
, O 0 9.084530461223039e-08
this O 0 4.241639217639204e-08
region O 0 3.8535546309503843e-07
of O 0 8.85539520822931e-06
the O 0 5.224260166869499e-05
ATP7B O 0 0.06208552047610283
gene O 0 6.259512883843854e-05
may O 0 1.1238785191380884e-05
be O 0 9.529614999337355e-07
susceptible O 0 3.1116774152906146e-06
to O 0 2.58658985785587e-07
gene O 0 1.850183616625145e-05
rearrangements O 0 0.0024078062269836664
causing O 1 0.9627158045768738
Wilson B-Disease 0 0.12849067151546478
disease I-Disease 1 0.9520130753517151
. O 0 8.73329281603219e-06

Disruption O 0 0.003883203724399209
of O 0 0.00012943826732225716
splicing O 0 2.9554330467362888e-05
regulated O 0 1.5031770999485161e-05
by O 0 5.094328230370593e-07
a O 0 3.883984845742816e-06
CUG O 0 0.00011016539065167308
- O 0 8.271508704638109e-06
binding O 0 7.2479297159588896e-06
protein O 0 7.917321636341512e-05
in O 0 6.318598025245592e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.6924321244005114e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.014241564087569714
DM B-Disease 1 1.0
) O 0 3.853371163131669e-05
is O 0 7.626553269801661e-06
caused O 0 2.490210135874804e-05
by O 0 8.050388942137943e-07
a O 0 6.6189468270749785e-06
CTG O 0 6.767841114196926e-05
expansion O 0 3.927479156118352e-06
in O 0 5.225023187449551e-07
the O 0 4.874430601375934e-07
3 O 0 1.7346587810607161e-06
untranslated O 0 1.1552191608643625e-05
region O 0 7.505599910473393e-07
of O 0 1.037952461047098e-05
the O 0 9.359449904877692e-05
DM B-Disease 1 1.0
gene O 0 0.00016451894771307707
. O 0 8.617845196567941e-06

One O 0 3.3847307349788025e-05
model O 0 4.416484443936497e-05
of O 0 0.0002161587035516277
DM B-Disease 1 1.0
pathogenesis O 1 0.9984288811683655
suggests O 0 1.3313953786564525e-05
that O 0 5.043868895882042e-07
RNAs O 0 6.1267851378943305e-06
from O 0 7.987755452631973e-07
the O 0 2.4425244760095666e-07
expanded O 0 8.320635060954373e-07
allele O 0 1.1470835943327984e-06
create O 0 5.202757620281773e-07
a O 0 4.92778826810536e-06
gain O 0 1.8630307749845088e-05
- O 0 7.66424182074843e-06
of O 0 4.457926843315363e-05
- O 0 1.4533772628055885e-05
function O 0 1.0683836990210693e-05
mutation O 0 2.9865216788493854e-07
by O 0 1.4996211916695756e-07
the O 0 3.3670076504677127e-07
inappropriate O 0 7.319087558244064e-07
binding O 0 4.322320990013395e-07
of O 0 2.3413758754031733e-06
proteins O 0 4.912548661195615e-07
to O 0 2.66023533868065e-07
the O 0 3.407386657272582e-06
CUG O 0 0.0005193465040065348
repeats O 0 5.267964297672734e-05
. O 0 1.0943037523247767e-05

Data O 0 0.00010327679046895355
presented O 0 2.5630399250076152e-05
here O 0 3.721500206665951e-06
indicate O 0 2.4790779207251035e-06
that O 0 1.9499184134019742e-07
the O 0 1.4427523638005368e-06
conserved O 0 2.0358096662675962e-05
heterogeneous O 0 6.864134047646075e-05
nuclear O 0 0.0002429243759252131
ribonucleoprotein O 0 0.0012561404146254063
, O 0 1.0620669854688458e-05
CUG O 0 0.00018812090274877846
- O 0 1.1629457731032744e-05
binding O 0 1.9306982721900567e-05
protein O 0 3.2475370971951634e-05
( O 0 3.6071364775125403e-06
CUG O 0 0.00025912566343322396
- O 0 6.62118909531273e-05
BP O 0 0.00011096973321400583
) O 0 1.166650918094092e-06
, O 0 5.789466968053603e-07
may O 0 2.557123480073642e-06
mediate O 0 7.776691745675635e-06
the O 0 1.4579946764570195e-05
trans O 0 9.1529236669885e-06
- O 0 8.072591299423948e-06
dominant O 0 3.113422735623317e-06
effect O 0 6.709068429699983e-07
of O 0 1.105795149669575e-06
the O 0 1.9991248336737044e-06
RNA O 0 5.180555035622092e-06
. O 0 1.3809495840177988e-06

CUG O 0 0.3836553394794464
- O 0 0.00969604216516018
BP O 0 0.0017870345618575811
was O 0 2.997367482748814e-05
found O 0 4.121714312077529e-07
to O 0 2.0885279283788805e-08
bind O 0 4.090410499202335e-08
to O 0 7.910048793746682e-08
the O 0 3.146315748381312e-06
human O 0 0.0004681555728893727
cardiac O 1 1.0
troponin O 1 0.9999998807907104
T O 1 0.986635148525238
( O 0 8.600021828897297e-06
cTNT O 0 2.1081999875605106e-05
) O 0 3.6962669014428684e-07
pre O 0 9.589222827344202e-06
- O 0 1.8655482563190162e-06
messenger O 0 5.276752403915452e-07
RNA O 0 8.804005346974009e-08
and O 0 1.862843923561286e-08
regulate O 0 7.319954420381691e-08
its O 0 8.937703199762836e-08
alternative O 0 1.219098976434907e-06
splicing O 0 4.390703452372691e-06
. O 0 1.8335596223550965e-06

Splicing O 0 0.00014588524936698377
of O 0 0.00017092475900426507
cTNT O 0 0.0005582385929301381
was O 0 0.0004919522907584906
disrupted O 0 0.0009588429820723832
in O 0 0.00015308127331081778
DM B-Disease 1 1.0
striated O 0 0.0026944444980472326
muscle O 0 0.00031471028341911733
and O 0 6.609990123251919e-06
in O 0 8.403864740103018e-06
normal O 0 1.729169161990285e-05
cells O 0 1.162460534942511e-06
expressing O 0 2.73776038284268e-07
transcripts O 0 1.1921732721020817e-06
that O 0 1.556999649210411e-07
contain O 0 2.9929992706456687e-06
CUG O 0 0.0003599213669076562
repeats O 0 2.9796177841490135e-05
. O 0 6.1673631535086315e-06

Altered O 0 0.0002083432482322678
expression O 0 8.81781306816265e-05
of O 0 7.656178786419332e-05
genes O 0 1.9982970115961507e-05
regulated O 0 5.808395872008987e-05
posttranscriptionally O 0 0.00012973856064490974
by O 0 5.120423793414375e-06
CUG O 0 0.0010389675153419375
- O 0 0.00018485063628759235
BP O 0 0.0001015867164824158
therefore O 0 1.977432930289069e-06
may O 0 1.3606905895358068e-06
contribute O 0 6.064359467927716e-07
to O 0 3.516286369631416e-06
DM B-Disease 1 1.0
pathogenesis O 0 0.17526336014270782
. O 0 2.44728107645642e-06
. O 0 1.4777946262256592e-06

Identification O 0 1.2109623639844358e-05
of O 0 1.0413780728413258e-05
a O 0 6.244741143746069e-06
novel O 0 6.492176453321008e-06
nonsense O 0 2.6388075639260933e-05
mutation O 0 1.0680918194339029e-06
and O 0 4.073057766618149e-07
a O 0 1.4510272876577801e-06
missense O 0 9.593129107088316e-06
substitution O 0 8.30659791972721e-06
in O 0 4.583211193676107e-06
the O 0 9.938268703990616e-06
vasopressin O 0 3.3858090318972245e-05
- O 0 2.9870745493099093e-05
neurophysin O 0 6.987370579736307e-05
II O 0 0.0013150701997801661
gene O 0 8.391406254304457e-07
in O 0 3.4969494322467654e-07
two O 0 1.0122278837343401e-07
Spanish O 0 3.219248128516483e-06
kindreds O 0 1.8956667190650478e-05
with O 0 3.932164531761373e-07
familial B-Disease 1 0.9989004135131836
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999994039535522
. O 0 3.5635206586448476e-05

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9995763897895813
FNDI B-Disease 1 1.0
) O 0 1.1437245120760053e-05
is O 0 5.545693966269027e-07
an O 0 8.178934649549774e-07
autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999542236328125
by O 0 2.0581022909027524e-05
deficiency O 1 1.0
in O 1 0.6318807601928711
the O 0 0.15250782668590546
antidiuretic O 1 0.9892505407333374
hormone O 0 0.00714535266160965
arginine O 0 0.0003335387445986271
vasopressin O 0 6.480103911599144e-05
( O 0 1.9219296518713236e-06
AVP O 0 2.8451575417420827e-05
) O 0 4.485587368208144e-08
encoded O 0 1.1607208705299854e-07
by O 0 1.2377167024624214e-07
the O 0 4.34720141129219e-06
AVP O 0 0.00029284245101734996
- O 0 0.000124194091768004
neurophysin O 0 0.0008172379457391798
II O 1 0.9998805522918701
( O 0 6.684165418846533e-05
AVP O 0 0.002647939370945096
- O 0 8.368566341232508e-05
NPII O 0 0.00034099468030035496
) O 0 4.775038178195246e-07
gene O 0 5.620029810415872e-07
on O 0 7.1056010710890405e-06
chromosome O 0 0.000211620848858729
20p13 O 0 0.000687102903611958
. O 0 1.0149001354875509e-05

In O 0 0.0001103608519770205
this O 0 1.7812870964917238e-06
study O 0 1.6548981420783093e-06
, O 0 1.8341772545227286e-07
we O 0 5.5791677056049593e-08
analyzed O 0 2.1337707778457116e-07
two O 0 1.9397731421122444e-07
families O 0 1.1543106381850521e-07
with O 0 5.073151214673999e-07
FNDI B-Disease 1 0.9992398023605347
using O 0 5.077409241494024e-06
direct O 0 2.7190670152776875e-05
automated O 0 0.00035432149888947606
fluorescent O 0 5.588172280113213e-05
, O 0 1.6750666418374749e-06
solid O 0 6.9378584157675505e-06
phase O 0 9.855476491793524e-06
, O 0 2.9946471613584436e-07
single O 0 2.9110140076227253e-07
- O 0 4.778723337039992e-07
stranded O 0 4.6155284394444607e-07
DNA O 0 3.92809376137393e-08
sequencing O 0 4.0211349983110267e-07
of O 0 7.321521479752846e-06
PCR O 0 5.454483471112326e-05
- O 0 0.00010712336370488629
amplified O 0 0.00018187602108810097
AVP O 0 0.0010660396656021476
- O 0 4.5557466364698485e-05
NPII O 0 0.00018415364320389926
DNA O 0 3.33260959450854e-06
. O 0 1.4056464578970918e-06

In O 0 0.0003181833017151803
one O 0 1.7643735191086307e-05
of O 0 1.921976036101114e-05
the O 0 5.624874120258028e-06
families O 0 4.178803294507816e-07
, O 0 1.6162634608463122e-07
affected O 0 1.434156331470149e-07
individuals O 0 2.4107452034627386e-08
presented O 0 1.9012002212548396e-06
a O 0 2.1976431980874622e-06
novel O 0 4.489248112804489e-06
nonsense O 0 2.2812131646787748e-05
mutation O 0 6.092148510106199e-07
in O 0 1.4715392353537027e-06
exon O 0 1.4010317954671336e-06
3 O 0 3.6441745123738656e-06
of O 0 3.915926299669081e-06
the O 0 3.2624216146359686e-06
gene O 0 6.742138793924823e-07
, O 0 2.409460932994989e-07
consisting O 0 2.277432287201009e-07
in O 0 1.0646656392054865e-06
a O 0 8.035814971663058e-06
G O 0 0.00021663842198904604
to O 0 7.730637662461959e-06
T O 0 0.0005889821914024651
transition O 0 6.309217133093625e-05
at O 0 0.00011040527169825509
nucleotide O 0 1.2110962416045368e-05
2101 O 0 7.267281762324274e-05
, O 0 2.388885036452848e-07
which O 0 2.8726546474899806e-08
produces O 0 6.239689298581652e-08
a O 0 2.2106030428403756e-07
stop O 0 4.4941086230210203e-07
signal O 0 5.010996574128512e-06
in O 0 3.92026049667038e-06
codon O 0 2.9069686206639744e-05
82 O 0 6.758586096111685e-05
( O 0 2.011576953009353e-06
Glu O 0 0.00013210785982664675
) O 0 7.92011633166112e-07
of O 0 8.826796147332061e-06
NPII O 0 0.002028169808909297
. O 0 1.147910825238796e-05

The O 0 0.00021177063172217458
premature O 0 0.00034531555138528347
termination O 0 5.6501598010072485e-05
eliminates O 0 8.349947165697813e-06
part O 0 3.615246669141925e-06
of O 0 4.666411768994294e-05
the O 0 5.6527354900026694e-05
C O 0 0.0004148241423536092
- O 0 6.143927021184936e-05
terminal O 0 0.0002509842743165791
domain O 0 1.0750824003480375e-05
of O 0 4.1032981243915856e-05
NPII O 0 0.00046356720849871635
, O 0 1.960118424904067e-06
including O 0 1.4701392956339987e-06
a O 0 5.318453986546956e-06
cysteine O 0 1.7924079429576523e-06
residue O 0 1.7938147720997222e-05
in O 0 1.0631320947140921e-05
position O 0 4.902066211798228e-05
85 O 0 4.241574788466096e-05
, O 0 7.670644777135749e-07
which O 0 2.4513218477295595e-07
could O 0 2.2683262557166017e-07
be O 0 3.1308300663113187e-07
involved O 0 1.9509674586970505e-07
in O 0 9.099259727918252e-07
the O 0 1.6332782024619519e-06
correct O 0 6.546896202053176e-06
folding O 0 4.7609319153707474e-05
of O 0 2.7637895982479677e-05
the O 0 4.6783887228230014e-05
prohormone O 0 0.005709847901016474
. O 0 1.936614171427209e-05

In O 0 0.00041496040648780763
the O 0 9.734737977851182e-05
second O 0 0.00011963917495450005
family O 0 8.652134056319483e-06
, O 0 1.6178547639356111e-06
a O 0 3.95772394767846e-06
G279A O 0 3.133137579425238e-05
substitution O 0 1.2022047485515941e-05
at O 0 3.934626511181705e-05
position O 0 3.6721289689012337e-06
- O 0 8.561556228414702e-07
1 O 0 1.6529044160051853e-06
of O 0 1.3301073522598017e-06
the O 0 2.384701929258881e-06
signal O 0 2.0111483536311425e-05
peptide O 0 3.1723743632028345e-06
was O 0 4.415722287376411e-06
observed O 0 5.78444485199725e-07
in O 0 1.5928681307286752e-07
all O 0 8.034706411308434e-08
affected O 0 2.1955743534363137e-07
individuals O 0 9.944764656211191e-08
. O 0 8.778507094575616e-07

This O 0 3.929054219042882e-05
missense O 0 0.00022403005277737975
mutation O 0 2.6630337742972188e-05
, O 0 7.744030881440267e-06
which O 0 5.6024423429335e-06
replaces O 0 0.00019456680456642061
Ala O 0 0.0006306024733930826
with O 0 3.831150934274774e-06
Thr O 0 0.009473374113440514
, O 0 1.2082044122507796e-05
is O 0 2.9246118629089324e-06
frequent O 0 1.4426035704673268e-05
among O 0 3.192193616996519e-05
FNDI B-Disease 1 1.0
patients O 0 9.535960271023214e-05
and O 0 3.2378914056607755e-06
is O 0 8.155863611136738e-07
thought O 0 2.3592394882143708e-07
to O 0 3.251966873563106e-08
reduce O 0 1.474953137403645e-07
the O 0 7.915434139249555e-07
efficiency O 0 2.562386725912802e-06
of O 0 3.452862756603281e-06
cleavage O 0 2.3584128939546645e-05
by O 0 1.5385562619485427e-06
signal O 0 3.9920218114275485e-05
peptidases O 0 6.363404827425256e-05
. O 0 4.940126245855936e-07
. O 0 8.238005761995737e-07

Genetic O 0 0.0003825151943601668
heterogeneity O 0 0.0009376468369737267
of O 0 0.02619270049035549
Saethre B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.1610143701545894e-05
due O 0 9.038333519129083e-05
to O 0 1.849345380833256e-06
TWIST O 0 7.099536014720798e-05
and O 0 1.2565296856337227e-05
FGFR O 0 0.006478152237832546
mutations O 0 2.3859758584876545e-05
. O 0 6.245717941055773e-06

Thirty O 0 0.002095656469464302
- O 0 0.0003432489756960422
two O 0 2.2926828933123033e-06
unrelated O 0 4.521386017586337e-06
patients O 0 2.3615218935901794e-07
with O 0 2.6671390429555686e-08
features O 0 1.2214962907819427e-06
of O 0 0.0005132407532073557
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.104454324580729e-06
a O 0 2.4128351014951477e-06
common O 0 1.9013843484572135e-05
autosomal B-Disease 1 0.9999978542327881
dominant I-Disease 1 0.9999997615814209
condition I-Disease 1 1.0
of O 1 1.0
craniosynostosis B-Disease 1 1.0
and O 1 1.0
limb B-Disease 1 1.0
anomalies I-Disease 1 1.0
, O 0 6.564595423697028e-06
were O 0 1.0777736179079511e-06
screened O 0 1.214889380207751e-06
for O 0 5.46274236512545e-07
mutations O 0 1.3952889048596262e-06
in O 0 5.23722383150016e-06
TWIST O 0 3.6242094211047515e-05
, O 0 2.0695276816695696e-06
FGFR2 O 0 0.00014732791169080883
, O 0 2.1641394596372265e-06
and O 0 3.371620096004335e-06
FGFR3 O 0 0.0008834640611894429
. O 0 1.1873989933519624e-05

Nine O 0 0.0004962137318216264
novel O 0 6.17015321040526e-05
and O 0 1.3803366528009064e-05
three O 0 1.2120057363063097e-05
recurrent O 0 0.0005377226043492556
TWIST O 0 0.00020490762835834175
mutations O 0 7.350379746640101e-06
were O 0 4.389175501273712e-06
found O 0 3.576168126073753e-07
in O 0 3.2712586062189075e-07
12 O 0 1.9335207070980687e-06
families O 0 1.6007045644528262e-07
. O 0 1.073753992386628e-06

Seven O 0 0.0002514774678274989
families O 0 3.924214070138987e-06
were O 0 5.919929662923096e-06
found O 0 6.80064488278731e-07
to O 0 1.7475025515523157e-07
have O 0 7.693017778365174e-07
the O 0 9.265795597457327e-06
FGFR3 O 0 0.0005614653928205371
P250R O 0 0.00019388047803658992
mutation O 0 8.804642675386276e-06
, O 0 3.5788368677458493e-06
and O 0 1.5658656593586784e-06
one O 0 1.083472625396098e-06
individual O 0 5.648261094393092e-07
was O 0 1.9944172890973277e-05
found O 0 8.988971558210324e-07
to O 0 2.0061406758031808e-07
have O 0 8.289895276902826e-07
an O 0 2.526623575249687e-06
FGFR2 O 0 0.00022497530153486878
VV269 O 0 0.00010191836190642789
- O 0 3.397602267796174e-05
270 O 0 2.7555970518733375e-05
deletion O 0 3.0804640118731186e-05
. O 0 7.604148322570836e-06

To O 0 1.354243158857571e-05
date O 0 2.5950273993657902e-05
, O 0 6.786281119275372e-07
our O 0 1.8943683244287968e-07
detection O 0 1.50360233419633e-06
rate O 0 2.708298552533961e-06
for O 0 9.806309435589355e-07
TWIST O 0 1.9579754734877497e-05
or O 0 3.900990577676566e-06
FGFR O 0 4.851745325140655e-05
mutations O 0 4.4567502754944144e-07
is O 0 3.815395928086218e-07
68 O 0 2.2684785108140204e-06
% O 0 2.8467280799304717e-07
in O 0 1.171640519714856e-06
our O 0 2.079163459711708e-05
Saethre B-Disease 1 0.9997373223304749
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00019524047093000263
, O 0 6.315997893580061e-07
including O 0 2.9889579877817596e-07
our O 0 4.1064438960347616e-07
five O 0 3.0202681955415756e-07
patients O 0 3.315790308988653e-07
elsewhere O 0 1.939203428946712e-07
reported O 0 3.6342100884212414e-07
with O 0 9.804563205761951e-08
TWIST O 0 4.1015457100002095e-05
mutations O 0 9.167266398435459e-06
. O 0 3.603718369049602e-06

More O 0 1.50231726365746e-05
than O 0 4.036090558656724e-06
35 O 0 2.890300311264582e-05
different O 0 7.947990638967894e-07
TWIST O 0 2.14236479223473e-05
mutations O 0 1.4842040627627284e-06
are O 0 1.8353075859067758e-07
now O 0 1.1213813166932596e-07
known O 0 1.7276806829613633e-07
in O 0 1.3208287441557331e-07
the O 0 4.042278476390493e-07
literature O 0 4.185841589787742e-06
. O 0 2.116326868417673e-06

The O 0 0.00022180665109772235
most O 0 5.931447049078997e-06
common O 0 2.1390897018136457e-06
phenotypic O 0 3.3080228604376316e-05
features O 0 1.3098283488943707e-05
, O 0 9.9825319921365e-07
present O 0 5.228343411545211e-07
in O 0 1.0787833844005945e-06
more O 0 6.461944224156468e-08
than O 0 1.657885349004573e-07
a O 0 1.4081647350394633e-06
third O 0 4.141310455452185e-06
of O 0 3.12868587570847e-06
our O 0 1.7848275319920504e-06
patients O 0 1.1063984857173637e-06
with O 0 4.501606269968761e-07
TWIST O 0 1.8151375115849078e-05
mutations O 0 2.3348252398136538e-06
, O 0 1.5941492392812506e-06
are O 0 5.633542059513275e-07
coronal B-Disease 0 0.0006774782086722553
synostosis I-Disease 0 0.0002192498359363526
, O 0 5.512519237527158e-06
brachycephaly B-Disease 0 0.00027095378027297556
, O 0 2.702516758290585e-05
low B-Disease 0 0.22472932934761047
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 1 0.9999643564224243
facial B-Disease 1 1.0
asymmetry I-Disease 1 1.0
, O 1 0.6007397770881653
ptosis B-Disease 1 0.9999998807907104
, O 0 0.00010728529741754755
hypertelorism B-Disease 1 0.9924585223197937
, O 0 1.4809316780883819e-05
broad B-Disease 0 0.0007252517389133573
great I-Disease 1 0.9994571805000305
toes I-Disease 1 0.9999978542327881
, O 0 8.108044312393758e-06
and O 0 6.828311143181054e-06
clinodactyly B-Disease 0 0.004143647849559784
. O 0 1.4775882846151944e-05

Significant O 0 0.0017336945747956634
intra O 0 0.02250395528972149
- O 0 0.001416549552232027
and O 0 1.221640832227422e-05
interfamilial O 0 0.0002538670087233186
phenotypic O 0 0.00012750676251016557
variability O 0 0.00010975917393807322
is O 0 7.003003474892466e-07
present O 0 1.9994060096450994e-07
for O 0 3.0980072551756166e-07
either O 0 1.0535683259149664e-06
TWIST O 0 2.3090800823410973e-05
mutations O 0 6.394036518031498e-06
or O 0 8.73015324032167e-06
FGFR O 0 0.0005151382647454739
mutations O 0 1.4901870599715039e-05
. O 0 3.7526667711063055e-06

The O 0 6.586684321518987e-05
overlap O 0 9.170405974145979e-06
in O 0 1.2252098713361192e-05
clinical O 0 7.065940735628828e-05
features O 0 4.419067408889532e-06
and O 0 3.49174183611467e-06
the O 0 6.091990144341253e-06
presence O 0 2.119376631526393e-06
, O 0 6.727533445882727e-07
in O 0 5.166194227967935e-07
the O 0 7.715265724073106e-07
same O 0 4.6315824420162244e-07
genes O 0 4.316084698530176e-07
, O 0 3.6628114230552455e-07
of O 0 1.6164543694685563e-06
mutations O 0 8.451746111859393e-07
for O 0 8.536941891179595e-07
more O 0 1.5422244814544683e-07
than O 0 7.687532388445106e-07
one O 0 2.659953452166519e-06
craniosynostotic B-Disease 0 0.00012172328570159152
condition I-Disease 0 0.00015150684339459985
- O 0 1.936423905135598e-05
such O 0 2.170654624933377e-06
as O 0 9.224745554092806e-06
Saethre B-Disease 0 0.00017355640011373907
- I-Disease 0 5.632879037875682e-05
Chotzen I-Disease 0 0.0003538761811796576
, I-Disease 0 7.870745321270078e-06
Crouzon I-Disease 0 0.0002875298378057778
, I-Disease 0 1.2510151464084629e-05
and I-Disease 0 3.3713196899043396e-05
Pfeiffer I-Disease 1 0.9964578747749329
syndromes I-Disease 1 0.9997887015342712
- O 0 0.0001650141493882984
support O 0 1.3380526070250198e-05
the O 0 1.1600460311456118e-05
hypothesis O 0 4.459749106899835e-06
that O 0 3.7842241340513283e-07
TWIST O 0 6.459445103246253e-06
and O 0 1.4894986861690995e-06
FGFRs O 0 3.80748460884206e-05
are O 0 2.760577899607597e-07
components O 0 1.4696080370413256e-06
of O 0 6.295822458923794e-07
the O 0 6.420786462513206e-07
same O 0 1.36735081923689e-06
molecular O 0 1.1372704648238141e-05
pathway O 0 3.1516942726739217e-06
involved O 0 1.0421228324730691e-07
in O 0 3.285108221007249e-07
the O 0 7.12030953309295e-07
modulation O 0 3.108438977506012e-05
of O 0 0.00012047374184476212
craniofacial O 1 1.0
and O 1 0.5275868773460388
limb O 1 1.0
development O 0 0.002317455830052495
in O 0 8.582920600019861e-06
humans O 0 1.0757127029137337e-06
. O 0 7.688516490134134e-08
. O 0 2.373388952037203e-07

Mutation O 0 7.915300557215232e-06
analysis O 0 1.1929500942642335e-06
of O 0 1.1546673704287969e-05
UBE3A O 1 0.99998939037323
in O 1 0.9992825388908386
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9989519119262695
. O 0 1.8954191546072252e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9996548891067505
AS B-Disease 1 1.0
) O 0 5.223815151111921e-06
is O 0 4.132467381623428e-07
caused O 0 1.946868906088639e-06
by O 0 2.2915783404187096e-07
chromosome O 0 0.0002969273482449353
15q11 O 0 0.0037220728117972612
- O 0 0.0038764916826039553
q13 O 0 0.0010049178963527083
deletions O 0 2.8672011467278935e-05
of O 0 4.466236714506522e-05
maternal O 0 0.011065083555877209
origin O 0 1.223194703925401e-05
, O 0 7.010213494140771e-07
by O 0 8.13637882401963e-07
paternal O 0 0.0015711452579125762
uniparental B-Disease 1 0.9921663999557495
disomy I-Disease 1 0.6158720254898071
( O 0 0.00011560616985661909
UPD B-Disease 1 0.9999984502792358
) O 0 6.587222287635086e-06
15 O 0 1.5457950212294236e-05
, O 0 5.683902486453007e-07
by O 0 1.025243932417652e-06
imprinting O 0 0.0022280632983893156
defects O 1 0.993053138256073
, O 0 2.6946648290504527e-07
and O 0 5.563716598544488e-08
by O 0 2.7097449617485836e-08
mutations O 0 1.860178144852398e-07
in O 0 8.090071332844673e-07
the O 0 9.881619916995987e-06
UBE3A O 0 0.0025527039542794228
gene O 0 2.6456309569766745e-05
. O 0 3.455115347605897e-06

UBE3A O 0 0.052479665726423264
encodes O 0 0.0009975471766665578
a O 0 0.00034292592317797244
ubiquitin O 0 0.000325632281601429
- O 0 5.5963209888432175e-05
protein O 0 1.3565258996095508e-05
ligase O 0 4.481000814848812e-06
and O 0 9.113936698668113e-07
shows O 0 9.682199561211746e-06
brain O 0 0.006670078262686729
- O 0 2.537708860472776e-05
specific O 0 1.7181306475322344e-06
imprinting O 0 0.0002951844362542033
. O 0 5.062256150267785e-06

Here O 0 0.00015341851394623518
we O 0 7.603560788993491e-06
describe O 0 2.396593481535092e-05
UBE3A O 0 0.0016641957918182015
coding O 0 0.00024461871362291276
- O 0 5.319983756635338e-05
region O 0 7.487385573767824e-06
mutations O 0 2.1642590581905097e-06
detected O 0 7.134942734410288e-06
by O 0 5.924200081608433e-07
SSCP O 0 6.352539639919996e-05
analysis O 0 1.3057659771220642e-06
in O 0 2.71068870461022e-06
13 O 0 4.4370724936015904e-05
AS B-Disease 1 0.9995755553245544
individuals O 0 3.6426001770450966e-07
or O 0 1.8327660882277996e-06
families O 0 2.842346873421775e-07
. O 0 1.239076595993538e-06

Two O 0 8.855149644659832e-05
identical O 0 6.368893809849396e-05
de O 0 0.0016068300465121865
novo O 0 0.0004788261721841991
5 O 0 9.941403550328687e-05
- O 0 3.37426972691901e-05
bp O 0 3.4143784432671964e-05
duplications O 0 2.1876661776332185e-05
in O 0 6.671858955087373e-06
exon O 0 1.2210049135319423e-05
16 O 0 1.4901970644132234e-05
were O 0 1.8011571683018701e-06
found O 0 6.777065664209658e-07
. O 0 8.834601317175839e-07

Among O 0 4.45756122644525e-05
the O 0 1.3104842764732894e-05
other O 0 1.1302598750262405e-06
11 O 0 7.899998308857903e-06
unique O 0 1.029145664688258e-06
mutations O 0 1.5876465795372496e-06
, O 0 1.155451059275947e-06
8 O 0 8.83170469023753e-06
were O 0 1.6886729099496733e-06
small O 0 6.3590130139346e-07
deletions O 0 7.062702024995815e-06
or O 0 7.940597242850345e-06
insertions O 0 3.676337291835807e-05
predicted O 0 7.463213114533573e-05
to O 0 1.702185159047076e-06
cause O 0 3.673095488920808e-05
frameshifts O 0 0.00038363158819265664
, O 0 4.136199549975572e-06
1 O 0 1.4063560229260474e-05
was O 0 2.0306209989939816e-05
a O 0 1.1396787158446386e-06
mutation O 0 2.6550421239335265e-07
to O 0 2.419724296487402e-07
a O 0 2.00074623535329e-06
stop O 0 2.560791472205892e-06
codon O 0 9.895114089886192e-06
, O 0 6.0992988437647e-07
1 O 0 3.5750640563492198e-06
was O 0 6.632443728449289e-06
a O 0 2.157516064471565e-06
missense O 0 5.237313871475635e-06
mutation O 0 7.646257813576085e-07
, O 0 1.9890921976184472e-07
and O 0 1.5769327887937834e-07
1 O 0 3.5137857139488915e-06
was O 0 1.2787169907824136e-05
predicted O 0 4.765211997437291e-06
to O 0 2.1911273506702855e-07
cause O 0 4.232912942825351e-06
insertion O 0 1.052672178047942e-05
of O 0 6.282003596425056e-05
an O 0 2.579372812760994e-05
isoleucine O 0 0.00030634470749646425
in O 0 1.7947024389286526e-05
the O 0 3.294636553619057e-05
hect O 0 0.00023098941892385483
domain O 0 3.7374560633907095e-05
of O 0 7.971617014845833e-05
the O 0 9.286664862884209e-05
UBE3A O 0 0.0006373703363351524
protein O 0 1.1768335753004067e-05
, O 0 2.3714702024335566e-07
which O 0 4.620645910335952e-08
functions O 0 5.961191504866292e-07
in O 0 8.435046083832276e-07
E2 O 0 5.3239062253851444e-05
binding O 0 2.3540192159998696e-06
and O 0 1.8980335880769417e-06
ubiquitin O 0 2.7435771698947065e-05
transfer O 0 1.1464918316050898e-05
. O 0 2.4665343971719267e-06

Eight O 0 0.00029264509794302285
of O 0 6.574960571015254e-05
the O 0 1.1634194379439577e-05
cases O 0 2.7893277092516655e-06
were O 0 1.07475025288295e-05
familial O 0 5.2635252359323204e-05
, O 0 4.565513336274307e-06
and O 0 7.52622838717798e-07
five O 0 1.3449714515445521e-06
were O 0 1.92797847375914e-06
sporadic O 0 4.5716704335063696e-05
. O 0 6.854957518953597e-06

In O 0 9.639022027840838e-05
two O 0 7.6595579230343e-06
familial O 0 7.253103103721514e-05
cases O 0 9.036899427883327e-06
and O 0 2.4326266157004284e-06
one O 0 6.497953677353507e-07
sporadic O 0 3.8265076000243425e-05
case O 0 4.928577982354909e-05
, O 0 2.227869572379859e-06
mosaicism O 0 0.00013560686784330755
for O 0 4.808479843632085e-06
UBE3A O 0 0.00041228331974707544
mutations O 0 3.3516314488224452e-06
was O 0 2.59595071838703e-05
detected O 0 2.7019495973945595e-06
in O 0 1.1843936817967915e-06
the O 0 2.143071242244332e-06
mother O 0 8.448905646218918e-06
of O 0 3.0796622013440356e-05
three O 0 3.173499135300517e-05
AS B-Disease 1 0.9999964237213135
sons O 0 0.00012865837197750807
, O 0 1.0321130048396299e-06
in O 0 1.2256410855115973e-06
the O 0 5.065840014140122e-06
maternal O 0 0.00027075340040028095
grandfather O 0 0.0013592673931270838
of O 0 0.0009599828044883907
two O 0 9.715634223539382e-05
AS B-Disease 1 0.9999998807907104
first O 0 0.00015251798322424293
cousins O 0 4.734766116598621e-05
, O 0 1.225173605234886e-06
and O 0 4.670549174079497e-07
in O 0 1.914511585709988e-06
the O 0 4.716185685538221e-06
mother O 0 1.700569919194095e-05
of O 0 6.0972030041739345e-05
an O 0 4.701184298028238e-05
AS B-Disease 1 1.0
daughter O 0 0.005280233919620514
. O 0 1.2975437130080536e-05

The O 0 0.00010422019113320857
frequencies O 0 1.2542190233943984e-05
with O 0 3.455065495927556e-07
which O 0 6.075636065361323e-07
we O 0 3.9570380749864853e-07
detected O 0 1.1229946039748029e-06
mutations O 0 3.2698051199986367e-07
were O 0 1.8188743524660822e-06
5 O 0 1.6675007827871013e-06
( O 0 9.989934568466197e-08
14 O 0 1.584532128617866e-06
% O 0 2.2332483240461443e-07
) O 0 4.9213262798275537e-08
of O 0 2.0124846287217224e-06
35 O 0 6.345597739709774e-06
in O 0 1.3442738691082923e-06
sporadic O 0 1.557948417030275e-05
cases O 0 2.366811941101332e-06
and O 0 3.2925336199696176e-06
8 O 0 1.593035995028913e-05
( O 0 3.5371348872104136e-07
80 O 0 1.681287471910764e-06
% O 0 2.719137341955502e-07
) O 0 2.4571070511569815e-08
of O 0 3.0462825861832243e-07
10 O 0 9.56728626988479e-07
in O 0 8.671511295688106e-07
familial O 0 2.5318349798908457e-05
cases O 0 3.393468659851351e-06
. O 0 7.357620575021429e-07
. O 0 1.4798156371398363e-06

The O 0 0.006309824530035257
hemochromatosis B-Disease 1 1.0
845 O 0 0.027409279718995094
G O 0 0.0027349330484867096
- O 0 0.00010186307190451771
- O 0 5.6281976867467165e-05
> O 0 1.8932892999146134e-05
A O 0 6.5363533394702245e-06
and O 0 9.923256811816827e-07
187 O 0 8.324727787112352e-06
C O 0 2.148703788407147e-05
- O 0 6.5039498622354586e-06
- O 0 3.0157860237522982e-05
> O 0 6.877959822304547e-05
G O 0 0.00020440320076886564
mutations O 0 3.0171784146659775e-06
: O 0 3.648023323421512e-07
prevalence O 0 8.678876838530414e-06
in O 0 3.7117567899258574e-06
non O 0 5.400711597758345e-05
- O 0 1.5799125321791507e-05
Caucasian O 0 1.038765549310483e-05
populations O 0 5.032217131883954e-07
. O 0 3.9184263300739985e-07

Hemochromatosis B-Disease 1 0.9999955892562866
, O 0 0.00018076020933222026
the O 0 0.0017077869269996881
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 2.3612170480191708e-05
leads O 0 1.2935405720782e-05
, O 0 7.643757271580398e-07
if O 0 6.474700740000117e-07
untreated O 0 0.00028627869323827326
, O 0 5.313088990988035e-07
to O 0 1.4757370081497356e-06
progressive O 1 0.9544522166252136
iron B-Disease 1 0.9999994039535522
overload I-Disease 1 0.9998769760131836
and O 0 3.811746137216687e-05
premature B-Disease 0 0.003093389328569174
death I-Disease 0 0.00035419617779552937
. O 0 4.528661975200521e-06

The O 0 0.009440962225198746
hemochromatosis B-Disease 1 1.0
gene O 0 0.002520124427974224
, O 0 5.267125743557699e-05
HFE O 0 0.002610119991004467
, O 0 8.029325726965908e-06
recently O 0 9.441781912755687e-06
has O 0 1.8103480670106364e-06
been O 0 2.3075617718859576e-06
identified O 0 1.4556774203811074e-06
, O 0 2.807105943247734e-07
and O 0 3.828393460025836e-07
characterization O 0 8.736507879802957e-06
of O 0 5.102029535919428e-05
this O 0 6.618327915930422e-06
gene O 0 6.698578090436058e-06
has O 0 1.1517367966007441e-06
shown O 0 3.5311288115735806e-07
that O 0 3.379646784651413e-08
it O 0 9.218686258805064e-09
contains O 0 4.081385895915446e-08
two O 0 4.3133194793654184e-08
mutations O 0 7.372694454943485e-08
that O 0 6.165088706211463e-08
result O 0 1.0268682899550186e-06
in O 0 3.582764065868105e-06
amino O 0 2.273706741107162e-06
acid O 0 1.3017487390243332e-06
substitutions O 0 6.260228246901534e-07
- O 0 2.084088691844954e-06
cDNA O 0 4.705148512584856e-06
nucleotides O 0 1.5992503676898195e-06
845 O 0 2.317889993719291e-05
G O 0 4.0943592466646805e-05
- O 0 8.572605111112352e-06
- O 0 1.83231350092683e-05
> O 0 1.8697142877499573e-05
A O 0 1.5010111383162439e-05
( O 0 3.2776759439911984e-07
C282Y O 0 3.0131786843412556e-06
) O 0 6.632404847550788e-08
and O 0 1.5265291608557163e-07
187 O 0 2.98018790090282e-06
C O 0 1.2269402759557124e-05
- O 0 3.845426817861153e-06
- O 0 2.1687652406399138e-05
> O 0 4.72442370664794e-05
G O 0 0.00020905124256387353
( O 0 2.2962124148762086e-06
H63D O 0 0.00016129860887303948
) O 0 9.363860158373427e-07
. O 0 6.804596068832325e-07

Although O 0 0.003916363697499037
hemochromatosis B-Disease 1 1.0
is O 0 5.6263514125021175e-05
common O 0 7.5219618338451255e-06
in O 0 3.994181042799028e-06
Caucasians O 0 5.892241460969672e-06
, O 0 5.907974127694615e-07
affecting O 0 2.174802602894488e-06
> O 0 5.6942390074254945e-06
= O 0 8.567113582103048e-06
1 O 0 1.4138327969703823e-05
/ O 0 8.317228093801532e-06
300 O 0 1.5318054238377954e-06
individuals O 0 2.6800003638527414e-07
of O 0 1.5064074432302732e-05
northern O 0 4.083857129444368e-05
European O 0 7.610001921420917e-05
origin O 0 7.496967555198353e-06
, O 0 6.691432190564228e-07
it O 0 3.510223933744783e-08
has O 0 6.311024947081023e-08
not O 0 1.2111033953488004e-08
been O 0 3.974578532961459e-08
recognized O 0 3.117344959946422e-08
in O 0 5.86459805163031e-08
other O 0 3.525569169937626e-08
populations O 0 1.283242028193854e-07
. O 0 5.467720143315091e-07

The O 0 3.422355075599626e-05
present O 0 3.3127982987934956e-06
study O 0 2.416936695226468e-06
used O 0 1.8877440197684336e-06
PCR O 0 7.264697615028126e-06
and O 0 1.9277172214060556e-06
restriction O 0 8.439249540970195e-06
- O 0 1.2874261301476508e-06
enzyme O 0 2.556542710863141e-07
digestion O 0 2.7423462256592757e-07
to O 0 2.6574149103453237e-08
analyze O 0 7.163218640471314e-08
the O 0 5.855354174855165e-07
frequency O 0 4.029206593259005e-06
of O 0 2.800974289129954e-05
the O 0 2.9620186978718266e-05
845 O 0 7.965568511281163e-05
G O 0 5.663515912601724e-05
- O 0 4.262484708306147e-06
- O 0 4.6196682887966745e-06
> O 0 4.140682904107962e-06
A O 0 1.8908285710494965e-06
and O 0 4.221582798891177e-07
187 O 0 2.984089860547101e-06
C O 0 8.029487617022824e-06
- O 0 1.130656642089889e-06
- O 0 3.622535814429284e-06
> O 0 1.0182953701587394e-05
G O 0 2.2769685529056005e-05
mutations O 0 7.827128456483479e-07
in O 0 4.945711680193199e-06
HLA O 0 2.8924838261445984e-05
- O 0 9.345097168989014e-06
typed O 0 7.225134595501004e-06
samples O 0 1.7277232018386712e-06
from O 0 2.3362372303381562e-06
non O 0 1.2273194442968816e-05
- O 0 3.3683900255709887e-06
Caucasian O 0 1.3719014759772108e-06
populations O 0 1.213649767350944e-07
, O 0 5.2202022260416925e-08
comprising O 0 2.163420163014962e-07
Australian O 0 4.207517577015096e-06
Aboriginal O 0 2.9032339625700843e-06
, O 0 1.142634459938563e-06
Chinese O 0 3.64136053576658e-06
, O 0 4.1181783672072925e-07
and O 0 5.743727911067253e-07
Pacific O 0 9.609857443138026e-06
Islanders O 0 1.022598644340178e-05
. O 0 1.766459490681882e-06

Results O 0 0.0010444400832057
showed O 0 0.00010235771333100274
that O 0 2.1782066141895484e-06
the O 0 1.0044892405858263e-05
845 O 0 8.863302355166525e-05
G O 0 0.0001914053864311427
- O 0 4.373078263597563e-05
- O 0 9.275310003431514e-05
> O 0 3.788014510064386e-05
A O 0 8.560269634472206e-06
mutation O 0 8.781295832704927e-07
was O 0 4.960207206750056e-06
present O 0 1.4214181476290833e-07
in O 0 1.9659391625737044e-07
these O 0 1.743769395545769e-08
populations O 0 3.102557144529783e-08
( O 0 2.1003966566013332e-08
allele O 0 1.2614187028248125e-07
frequency O 0 1.6480217936987174e-06
0 O 0 9.461435297453136e-07
. O 0 3.9469668422498216e-08
32 O 0 1.725362039906031e-06
% O 0 5.138006713423238e-07
) O 0 1.8309877702904487e-07
, O 0 3.0014405183464987e-07
and O 0 6.933723852853291e-07
, O 0 5.790438422081934e-07
furthermore O 0 1.962572468983126e-06
, O 0 2.0680782597537473e-07
it O 0 4.935050057497392e-08
was O 0 3.5727530303120147e-06
always O 0 1.914017246917865e-07
seen O 0 3.756265130050451e-07
in O 0 1.6846583150709193e-07
conjunction O 0 5.713461632694816e-07
with O 0 5.618337013402197e-07
HLA O 0 0.00015182541392277926
haplotypes O 0 5.719189721276052e-05
common O 0 1.3007723282498773e-05
in O 0 1.1928274943784345e-05
Caucasians O 0 1.4135956917016301e-05
, O 0 8.117545462482667e-07
suggesting O 0 2.5087549602176296e-06
that O 0 5.184164706406591e-07
845 O 0 7.896895112935454e-05
G O 0 0.0003542523772921413
- O 0 0.00015145035285968333
- O 0 0.0007697538821958005
> O 0 0.00031302706338465214
A O 0 9.954132838174701e-05
may O 0 6.993412625888595e-06
have O 0 4.3927960291512136e-07
been O 0 2.58942804975959e-07
introduced O 0 1.0014964857418818e-07
into O 0 1.2115331848860933e-08
these O 0 1.8000210211255308e-09
populations O 0 1.2318096764829534e-08
by O 0 2.3647034552709556e-08
Caucasian O 0 3.821261998382397e-06
admixture O 0 2.1118945369380526e-05
. O 0 5.3624025895260274e-06

187 O 0 0.0005824229447171092
C O 0 0.00036134760011918843
- O 0 2.8906752049806528e-05
- O 0 3.815044692601077e-05
> O 0 4.44677280029282e-05
G O 0 7.0671878347639e-05
was O 0 8.029394848563243e-06
present O 0 3.0640205750387395e-07
at O 0 1.3471562851918861e-06
an O 0 3.2766099167247376e-08
allele O 0 1.569783023569471e-07
frequency O 0 1.0293587138221483e-06
of O 0 3.0047738164284965e-06
2 O 0 1.9853538105962798e-05
. O 0 2.272332494612783e-06

68 O 0 0.001128587988205254
% O 0 1.1938552233914379e-05
in O 0 2.8835818284278503e-06
the O 0 2.3730228804197395e-06
two O 0 5.223822654443211e-07
populations O 0 3.4884990895989176e-07
analyzed O 0 1.3675621630682144e-06
( O 0 5.358959356271953e-07
Australian O 0 6.012042831571307e-06
Aboriginal O 0 3.418700771362637e-06
and O 0 1.188430701404286e-06
Chinese O 0 1.097658878279617e-05
) O 0 7.142569415918842e-07
. O 0 6.446672387028229e-07

In O 0 0.00015831027121748775
the O 0 2.320846942893695e-05
Australian O 0 1.391406749462476e-05
Aboriginal O 0 1.0762805686681531e-05
samples O 0 2.4382425181102008e-06
, O 0 1.0386992244093562e-06
187 O 0 5.16788304594229e-06
C O 0 2.6105582946911454e-05
- O 0 5.251537459116662e-06
- O 0 2.687851338123437e-05
> O 0 4.7701749281259254e-05
G O 0 8.45310278236866e-05
was O 0 1.334565877186833e-05
found O 0 3.5738295878218196e-07
to O 0 7.047833605611231e-08
be O 0 6.09506003002025e-07
associated O 0 2.0065128865098814e-06
with O 0 1.918459474836709e-06
HLA O 0 0.0009170508128590882
haplotypes O 0 0.0001795567077351734
common O 0 2.380557452852372e-05
in O 0 3.027378443221096e-05
Caucasians O 0 2.887536902562715e-05
, O 0 8.268702913483139e-07
suggesting O 0 5.238194944467978e-07
that O 0 2.221272232816318e-08
it O 0 7.272523472323655e-09
was O 0 1.4909383594385872e-07
introduced O 0 3.2292952312218404e-08
by O 0 8.70553229503912e-09
recent O 0 8.980182997220254e-08
admixture O 0 7.572920821985463e-06
. O 0 5.362034244171809e-06

In O 0 0.00016772549133747816
the O 0 2.2228010493563488e-05
Chinese O 0 6.1790669860783964e-06
samples O 0 7.626929345860844e-07
analyzed O 0 1.0879881529035629e-06
, O 0 5.966350045127911e-07
187 O 0 4.712139798357384e-06
C O 0 1.869432526291348e-05
- O 0 3.995129645772977e-06
- O 0 1.7610231225262396e-05
> O 0 3.2243002351606265e-05
G O 0 9.479848813498393e-05
was O 0 1.958838402060792e-05
present O 0 2.0177290025458205e-06
in O 0 3.113280172328814e-06
association O 0 1.4295669643615838e-06
with O 0 4.665731978548138e-08
a O 0 1.1716505241565756e-06
wide O 0 7.069670118653448e-06
variety O 0 3.885748810716905e-06
of O 0 0.00014852416643407196
HLA O 0 0.0018191557610407472
haplotypes O 0 0.0001167019217973575
, O 0 1.4246755881686113e-06
showing O 0 3.1109473184187664e-06
this O 0 1.7557948694957304e-07
mutation O 0 1.7025702447881486e-07
to O 0 7.938463397749729e-08
be O 0 5.74921386942151e-07
widespread O 0 2.4008259060792625e-06
and O 0 1.0721946637204383e-06
likely O 0 2.379601710345014e-06
to O 0 7.685596870032896e-07
predate O 0 3.0261573556344956e-05
the O 0 4.14986971009057e-06
more O 0 1.6977222117020574e-07
genetically O 0 5.329592340785894e-07
restricted O 0 3.0367648378160084e-06
845 O 0 3.0826882721157745e-05
G O 0 7.656683010281995e-05
- O 0 1.4208370885171462e-05
- O 0 1.1155141692142934e-05
> O 0 8.583519047533628e-06
A O 0 2.683396587599418e-06
mutation O 0 1.4176169997881516e-06
. O 0 1.1667488024613704e-06

Genotype O 0 0.0030222779605537653
- O 0 0.0005102870636619627
phenotype O 0 8.00785273895599e-05
correlations O 0 6.377486715791747e-05
in O 0 3.532093614921905e-05
attenuated B-Disease 1 0.9946788549423218
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.00028057859162800014

Germ O 0 0.03862585499882698
- O 0 0.0008089700131677091
line O 0 3.625132376328111e-05
mutations O 0 1.1303654900984839e-06
of O 0 5.531303486350225e-06
the O 0 1.349537524220068e-05
tumor B-Disease 1 0.5354185700416565
suppressor O 0 0.00832430087029934
APC O 0 3.063092299271375e-05
are O 0 1.0692031793269052e-07
implicated O 0 2.6314451133657712e-06
in O 0 4.513631665759021e-06
attenuated B-Disease 1 0.9980778694152832
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9999810457229614
AAPC B-Disease 1 1.0
) O 0 2.151799662897247e-06
, O 0 1.033638383773905e-07
a O 0 3.103548920080357e-07
variant O 0 0.00012830675404984504
of O 1 0.7623245716094971
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9970314502716064
FAP B-Disease 1 0.9817735552787781
) O 0 1.1025918865925632e-05
. O 0 2.8378067327139433e-06

AAPC B-Disease 1 0.9999980926513672
is O 0 7.073163487802958e-06
recognized O 0 7.801982633282023e-07
by O 0 1.2320099074258906e-07
the O 0 4.063358574057929e-07
occurrence O 0 3.94250855606515e-06
of O 0 1.8110811652150005e-05
< O 0 0.0006075626006349921
100 O 0 8.504274592269212e-05
colonic B-Disease 0 0.10402455925941467
adenomas I-Disease 0 0.005383878014981747
and O 0 2.3619678302111424e-07
a O 0 3.093835516665422e-07
later O 0 2.535075736886938e-06
onset O 1 0.9985978007316589
of O 1 0.9998500347137451
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.9840360841481015e-06
age O 0 6.3386905821971595e-06
> O 0 3.410787257962511e-06
40 O 0 2.231771759397816e-06
years O 0 1.2310462125242339e-06
) O 0 5.584117275247991e-07
. O 0 7.839184945623856e-07

The O 0 3.85300736525096e-05
aim O 0 5.920788225921569e-06
of O 0 2.686046627786709e-06
this O 0 1.4344024634738162e-07
study O 0 4.459449769456114e-07
was O 0 1.9362923922017217e-06
to O 0 1.1976312919159682e-07
assess O 0 3.1701335956313414e-06
genotype O 0 6.175404269015417e-05
- O 0 0.00015884038293734193
phenotype O 0 7.489113340852782e-05
correlations O 0 8.51384102134034e-05
in O 0 0.0002280417684232816
AAPC B-Disease 1 0.9999997615814209
families O 0 3.2614570955047384e-06
. O 0 2.4543960535083897e-06

By O 0 3.713581099873409e-05
protein O 0 4.98016997880768e-05
- O 0 2.9315366191440262e-05
truncation O 0 0.00015942032041493803
test O 0 1.53459968714742e-05
( O 0 1.9939800495194504e-06
PTT O 0 4.4177435484016314e-05
) O 0 3.5029745504289167e-07
assay O 0 2.8982103685848415e-06
, O 0 1.5967189881394006e-07
the O 0 3.5380321605771314e-07
entire O 0 1.9431683995208004e-06
coding O 0 7.038200237730052e-06
region O 0 5.9469666666700505e-06
of O 0 4.626850568456575e-05
the O 0 5.5717089708196e-05
APC B-Disease 0 5.604299803962931e-05
gene O 0 1.4194542927725706e-06
was O 0 4.162450750300195e-06
screened O 0 1.178633624476788e-06
in O 0 9.432245064999734e-07
affected O 0 1.0139317510038381e-06
individuals O 0 2.3841646168420993e-07
from O 0 1.0517830560274888e-05
11 O 0 0.0008175330585800111
AAPC B-Disease 1 0.9999996423721313
kindreds O 0 0.0007310350192710757
, O 0 1.6154465356521541e-06
and O 0 1.6166349325885676e-07
their O 0 9.793124888801685e-08
phenotypic O 0 1.302892906096531e-05
differences O 0 4.3923741941398475e-06
were O 0 8.315030754602049e-06
examined O 0 2.0899060473311692e-05
. O 0 2.724583055169205e-06

Five O 0 0.0003003611054737121
novel O 0 0.0001983804686460644
germ O 0 0.004997416865080595
- O 0 0.0005324429366737604
line O 0 0.00010711641516536474
APC B-Disease 0 1.501228689448908e-05
mutations O 0 6.844857693977247e-07
were O 0 8.479155439999886e-07
identified O 0 4.828947339774459e-07
in O 0 1.265224796043185e-06
seven O 0 7.7433805927285e-06
kindreds O 0 0.00016568989667575806
. O 0 7.944036042317748e-06

Mutations O 0 0.00019982912635896355
were O 0 4.78560286865104e-05
located O 0 9.109548045671545e-06
in O 0 1.0993221621902194e-06
three O 0 3.627579303611128e-07
different O 0 8.879862178901021e-08
regions O 0 1.3410650581135997e-06
of O 0 4.063423693878576e-05
the O 0 4.747131242766045e-05
APC B-Disease 0 2.5228546292055398e-05
gene O 0 2.5708261546242284e-06
( O 0 7.979851943673566e-07
1 O 0 4.039506166009232e-06
) O 0 1.3431318279799598e-07
at O 0 3.827893124253023e-06
the O 0 7.462475082320452e-07
5 O 0 1.883684944914421e-06
end O 0 3.986274350609165e-06
spanning O 0 5.8769378483702894e-06
exons O 0 5.288049123919336e-06
4 O 0 7.68179688748205e-06
and O 0 1.4796773939451668e-06
5 O 0 5.430089913716074e-06
, O 0 5.837913477080292e-07
( O 0 1.1641697739150914e-07
2 O 0 1.2394123132253299e-06
) O 0 4.342036419302531e-08
within O 0 1.5876904058131913e-07
exon O 0 5.335583068699634e-07
9 O 0 7.091609404596966e-06
, O 0 4.1932065641958616e-07
and O 0 5.643694294121815e-07
( O 0 2.23497650608806e-07
3 O 0 2.028297785727773e-06
) O 0 1.1177937153661333e-07
at O 0 2.7212333861825755e-06
the O 0 1.025177425617585e-06
3 O 0 4.950774382450618e-06
distal O 0 5.2830891945632175e-06
end O 0 3.3918572626134846e-06
of O 0 3.9986553019843996e-06
the O 0 6.2585481828136835e-06
gene O 0 6.65754487272352e-06
. O 0 2.2102854018157814e-06

Variability O 0 0.0004166833241470158
in O 0 2.082967694150284e-05
the O 0 9.702683200885076e-06
number O 0 1.5592266208841465e-05
of O 0 0.46518322825431824
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.9583663940429688
most O 0 4.5143315219320357e-07
apparent O 0 2.6515297122386983e-06
in O 0 2.3103092416931759e-07
individuals O 0 1.5198262204307866e-08
with O 0 3.336700515887969e-08
mutations O 0 4.1200050304723845e-07
in O 0 4.972493570676306e-06
region O 0 1.6672633137204684e-05
1 O 0 0.0005063465214334428
, O 0 1.1534060831763782e-05
and O 0 4.5361775846686214e-05
upper O 1 0.9999995231628418
- O 1 0.9999996423721313
gastrointestinal O 1 1.0
manifestations O 1 1.0
were O 0 0.0006369234761223197
more O 0 4.475665775771631e-07
severe O 0 0.0004547114949673414
in O 0 4.859966338699451e-06
them O 0 3.735848110864026e-07
. O 0 2.180124965889263e-06

In O 0 6.645295798080042e-05
individuals O 0 1.0867757964660996e-06
with O 0 7.96286144577607e-07
mutations O 0 1.8145360627386253e-06
in O 0 5.616158432530938e-06
either O 0 2.218136614828836e-06
region O 0 4.5025567487755325e-06
2 O 0 1.7325712178717367e-05
or O 0 2.2524613996210974e-06
region O 0 6.713805760227842e-06
3 O 0 1.761931889632251e-05
, O 0 7.517548397117935e-07
the O 0 1.9763281216000905e-06
average O 0 6.6177094595332164e-06
number O 0 3.860477136186091e-06
of O 0 6.263095565373078e-05
adenomas B-Disease 0 0.00202186475507915
tended O 0 4.2957355617545545e-05
to O 0 1.9429589883657172e-06
be O 0 3.6487995203060564e-06
lower O 0 9.687601959740277e-06
than O 0 1.382965848506501e-07
those O 0 4.8981771527678575e-08
in O 0 1.434230227914668e-07
individuals O 0 1.4472163023526718e-08
with O 0 4.215555549080818e-08
mutations O 0 2.7451721962279407e-07
in O 0 1.079860112440656e-06
region O 0 1.8442643749949639e-06
1 O 0 7.50951903683017e-06
, O 0 1.6100283062314702e-07
although O 0 7.077550634448926e-08
age O 0 1.4642445194112952e-06
at O 0 6.370433311531087e-06
diagnosis O 0 9.134131687460467e-06
was O 0 4.221206381771481e-06
similar O 0 2.946530628378241e-07
. O 0 7.276771611941513e-07

In O 0 0.0008130783098749816
all O 0 0.0001984462869586423
AAPC B-Disease 1 0.9999984502792358
kindreds O 0 0.0008261052425950766
, O 0 2.4166579351003747e-06
a O 0 2.8695553737634327e-06
predominance O 0 0.00013640029646921903
of O 0 0.001088892575353384
right O 1 0.9999536275863647
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999970197677612
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999998807907104
sparing O 0 4.4099902879679576e-05
was O 0 3.804987500188872e-05
observed O 0 7.3981736932182685e-06
. O 0 7.641862680429767e-07

No O 0 0.023838266730308533
desmoid B-Disease 1 0.9999465942382812
tumors I-Disease 1 1.0
were O 0 0.00011533717042766511
found O 0 1.5939820059429621e-06
in O 0 6.546987947331218e-07
these O 0 2.168505659483344e-07
kindreds O 0 4.753255416289903e-05
. O 0 2.8582098821061663e-06

Our O 0 0.00022127559350337833
data O 0 4.351276584202424e-05
suggest O 0 4.724117388832383e-06
that O 0 8.80000698089134e-07
, O 0 2.354445769015001e-06
in O 0 1.5088098734850064e-05
AAPC B-Disease 1 0.9999765157699585
families O 0 4.1558323005119746e-07
, O 0 1.3419180788787344e-07
the O 0 2.335089135385715e-07
location O 0 2.7619259981293e-06
of O 0 1.7578018741915002e-05
the O 0 5.6648939789738506e-05
APC B-Disease 0 0.0003641739021986723
mutation O 0 9.480507287662476e-06
may O 0 3.876702066918369e-06
partially O 0 5.214473276282661e-06
predict O 0 2.1852800102806214e-07
specific O 0 5.351819254428847e-08
phenotypic O 0 7.022982026683167e-05
expression O 0 0.0002929102920461446
. O 0 7.5174079938733485e-06

This O 0 1.7146856407634914e-05
should O 0 2.9085465484968154e-06
help O 0 2.1022407281634514e-07
in O 0 1.1159484074596548e-06
the O 0 1.320724663855799e-06
design O 0 6.372717962221941e-06
of O 0 4.306449227442499e-06
tailored O 0 9.584642612026073e-06
clinical O 0 0.0006777493981644511
- O 0 0.00031097259488888085
management O 0 1.3580364793597255e-05
protocols O 0 4.6591167119913734e-06
in O 0 3.111826742951962e-07
this O 0 6.731826829309284e-08
subset O 0 2.0535183011816116e-06
of O 0 3.1852068786974996e-06
FAP B-Disease 0 6.22044171905145e-05
patients O 0 8.702878062649688e-07
. O 0 3.1934084177009936e-07
. O 0 1.2377845450828318e-06

Wilms B-Disease 1 0.9991545677185059
' I-Disease 0 0.00808886531740427
tumor I-Disease 0 0.007888583466410637
1 O 0 7.88757752161473e-05
and O 0 5.939394213783089e-06
Dax O 0 0.05237917974591255
- O 0 2.2527519831783138e-05
1 O 0 1.1184222785232123e-05
modulate O 0 1.0384158485976513e-05
the O 0 4.657108547689859e-06
orphan O 0 4.2520601709838957e-05
nuclear O 0 4.434305810718797e-05
receptor O 0 4.758389331982471e-05
SF O 0 0.0005451287725009024
- O 0 3.4003426208073506e-06
1 O 0 9.908541187542141e-07
in O 0 6.206170155564905e-08
sex O 0 1.1295384894083327e-07
- O 0 2.1076890277527127e-07
specific O 0 1.6737615737838496e-08
gene O 0 9.5780137598922e-07
expression O 0 7.080114755808609e-06
. O 0 1.1851619774461142e-06

Products O 0 0.00029687557253055274
of O 0 0.0002787242119666189
steroidogenic O 0 0.0012483781902119517
factor O 0 7.73315696278587e-05
1 O 0 6.0883314290549606e-05
( O 0 1.8582450138637796e-06
SF O 0 0.0002061140985460952
- O 0 1.0300244866812136e-05
1 O 0 6.408822173398221e-06
) O 0 1.9053153721415583e-07
and O 0 8.793229540060565e-07
Wilms B-Disease 0 0.023926695808768272
tumor I-Disease 1 0.8649601340293884
1 O 0 0.00013052424765191972
( O 0 2.456262336636428e-06
WT1 O 0 7.05797501723282e-05
) O 0 1.2772814272921096e-07
genes O 0 4.742054926509809e-08
are O 0 2.351498196162538e-08
essential O 0 1.7164539656278066e-07
for O 0 1.9184066957222967e-07
mammalian O 0 1.646202872507274e-05
gonadogenesis O 0 1.792274088074919e-05
prior O 0 1.6195621128645143e-06
to O 0 1.9611790946783003e-07
sexual O 0 4.4361681830196176e-06
differentiation O 0 6.111995753599331e-05
. O 0 4.347375579527579e-06

In O 0 0.00016819329175632447
males O 0 1.4047288459551055e-05
, O 0 8.998355951916892e-06
SF O 0 0.0010372941615059972
- O 0 2.4393879357376136e-05
1 O 0 9.089424565900117e-06
participates O 0 3.411931857044692e-07
in O 0 7.095865584005878e-08
sexual O 0 1.7729408341438102e-07
development O 0 2.902686446759617e-07
by O 0 2.0009581547242306e-08
regulating O 0 7.529293384322955e-07
expression O 0 1.8042552483166219e-06
of O 0 4.293785423215013e-06
the O 0 1.7394135284121148e-05
polypeptide O 0 0.00031255025533027947
hormone O 0 0.0002158674760721624
Mullerian O 0 0.0011333189904689789
inhibiting O 0 0.0001433482684660703
substance O 0 0.0001237926771864295
( O 0 1.0893724720517639e-05
MIS O 0 0.0020212249364703894
) O 0 1.5077823718456784e-06
. O 0 7.663932137802476e-07

Here O 0 0.0003697818610817194
, O 0 5.319276169757359e-06
we O 0 6.866446256026393e-07
show O 0 1.1139981097585405e-06
that O 0 7.691389782849001e-07
WT1 O 0 0.00025065854424610734
- O 0 8.581444126321003e-05
KTS O 0 0.0013838749146088958
isoforms O 0 1.880643867480103e-05
associate O 0 2.0893161490675993e-05
and O 0 7.515620268350176e-07
synergize O 0 2.345064058317803e-05
with O 0 3.0499791137117427e-06
SF O 0 0.015077613294124603
- O 0 5.24460592714604e-05
1 O 0 1.940107722475659e-05
to O 0 8.564185804971203e-07
promote O 0 1.5481096852454357e-05
MIS O 1 0.9269692301750183
expression O 0 0.00013836671132594347
. O 0 3.7734089346486144e-06

In O 0 8.116762182908133e-05
contrast O 0 5.714795770472847e-05
, O 0 1.4007449863129295e-05
WT1 O 0 0.0006778922397643328
missense O 0 5.590837827185169e-05
mutations O 0 3.0445853553828783e-06
, O 0 3.489217590413318e-07
associated O 0 5.461664045469661e-07
with O 0 2.6480020665076154e-07
male B-Disease 0 0.0009809354087337852
pseudohermaphroditism I-Disease 1 1.0
in O 1 0.9720764756202698
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 7.942843512864783e-05
fail O 0 1.3773714272247162e-05
to O 0 7.209121122286888e-07
synergize O 0 6.830669735791162e-05
with O 0 9.642631084716413e-06
SF O 1 0.9999792575836182
- O 0 0.013129868544638157
1 O 0 0.0004401729966048151
. O 0 4.9572845455259085e-06

Additionally O 0 0.00017003167886286974
, O 0 1.2571673323691357e-05
the O 0 2.245767791464459e-05
X O 0 0.0009558338788338006
- O 0 0.00019798307039309293
linked O 0 0.00020369811682030559
, O 0 2.5093936528719496e-06
candidate O 0 6.60687692288775e-06
dosage O 0 4.655912198359147e-05
- O 0 2.0706684153992683e-05
sensitive O 0 1.844660255301278e-05
sex O 0 4.613742021319922e-06
- O 0 5.9083395171910524e-06
reversal O 0 5.0826398364733905e-05
gene O 0 1.5438004083989654e-06
, O 0 1.0051898016172345e-06
Dax O 0 0.000940605066716671
- O 0 7.504736004193546e-06
1 O 0 9.1294286903576e-06
, O 0 4.5659948000320583e-07
antagonizes O 0 5.460879947349895e-06
synergy O 0 4.003902176918928e-06
between O 0 1.441860877093859e-05
SF O 0 0.001296201371587813
- O 0 4.3423391616670415e-05
1 O 0 2.458480048517231e-05
and O 0 4.016963430331089e-06
WT1 O 0 0.00018398197425995022
, O 0 7.041430194476561e-07
most O 0 1.3529161435599235e-07
likely O 0 1.306322303662455e-07
through O 0 6.816742370574502e-08
a O 0 2.1655027637734747e-07
direct O 0 4.2642145103855e-07
interaction O 0 1.3232145192887401e-06
with O 0 1.5274349607352633e-06
SF O 0 0.04970923438668251
- O 0 0.00012336234794929624
1 O 0 4.0724120481172577e-05
. O 0 1.3181287386032636e-06

We O 0 6.833353108959273e-05
propose O 0 2.4208206014009193e-05
that O 0 7.375039331236621e-06
WT1 O 0 0.000532367848791182
and O 0 2.5304061637143604e-05
Dax O 0 0.052412066608667374
- O 0 3.0088116545812227e-05
1 O 0 8.828538739180658e-06
functionally O 0 2.016211283262237e-06
oppose O 0 1.114746908115194e-07
each O 0 2.1201069344556345e-08
other O 0 7.550111291720896e-08
in O 0 1.496396862421534e-06
testis O 0 8.885254646884277e-05
development O 0 5.190187039261218e-06
by O 0 1.0243956012345734e-06
modulating O 0 6.60097721265629e-05
SF O 0 0.00260980986058712
- O 0 5.32223675691057e-05
1 O 0 3.0191991754691117e-05
- O 0 4.856287432630779e-06
mediated O 0 2.2628157239523716e-05
transactivation O 0 0.00015024843742139637
. O 0 4.810360110241163e-07
. O 0 7.943535251797584e-07

A O 0 0.00017967660096473992
mouse O 0 3.454120451351628e-05
model O 0 1.1712936611729674e-05
for O 0 2.2650547180091962e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999982118606567
centre O 1 0.9999743700027466
mutations O 0 1.7267697330680676e-05
. O 0 1.568624838910182e-06

Imprinting O 0 0.0039556026458740234
in O 0 0.00022090187121648341
the O 0 0.00014694475976284593
15q11 O 0 0.0007720767753198743
- O 0 0.00011293954594293609
q13 O 0 0.00019706717284861952
region O 0 7.111594186426373e-06
involves O 0 5.4243082558969036e-06
an O 0 3.924764769180911e-06
imprinting O 0 0.00014723466301802546
centre O 0 0.004276440013200045
( O 0 3.984951490565436e-06
IC O 0 6.430323264794424e-05
) O 0 3.236682744045538e-07
, O 0 1.6658668755553663e-07
mapping O 0 1.1386900951038115e-06
in O 0 1.3433652839012211e-06
part O 0 1.4586416909878608e-06
to O 0 5.695590630239167e-07
the O 0 8.246367542597e-06
promoter O 0 6.549405225086957e-05
and O 0 2.1440851014631335e-06
first O 0 7.418018412863603e-06
exon O 0 8.707031156518497e-06
of O 0 2.9829441700712778e-05
SNRPN O 0 0.0013064263621345162
. O 0 8.143014383676928e-06

Deletion O 0 0.0003418246633373201
of O 0 5.9287929616402835e-05
this O 0 5.268221684673335e-06
IC O 0 0.0006133231217972934
abolishes O 0 5.603562749456614e-05
local O 0 1.520067485216714e-06
paternally O 0 4.4244648051972035e-06
derived O 0 3.98362999476376e-07
gene O 0 1.8936495393973019e-07
expression O 0 2.5330507469334407e-07
and O 0 3.271757265110864e-08
results O 0 8.613634463472408e-07
in O 0 1.1793806152127218e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999874830245972
PWS B-Disease 1 1.0
) O 0 3.400415516807698e-05
. O 0 3.867969098791946e-06

We O 0 2.4280270736198872e-05
have O 0 1.298607912758598e-06
created O 0 1.0039653943749727e-06
two O 0 6.026630217093043e-07
deletion O 0 7.631129847140983e-06
mutations O 0 1.7536807490614592e-06
in O 0 6.619919076911174e-06
mice O 0 1.0042402209364809e-05
to O 0 9.875448085949756e-07
understand O 0 7.294737315532984e-06
PWS B-Disease 1 1.0
and O 0 1.7584504803380696e-06
the O 0 1.6335196733052726e-06
mechanism O 0 1.6823732948978432e-06
of O 0 5.253756626188988e-06
this O 0 3.461956112005282e-06
IC O 0 0.0008221211028285325
. O 0 6.4162777562160045e-06

Mice O 0 0.008708136156201363
harbouring O 0 0.005586670711636543
an O 0 4.2200459574814886e-05
intragenic O 0 0.0011773332953453064
deletion O 0 0.0003340711700730026
in O 0 0.0001703224697848782
Snrpn O 0 0.4379176199436188
are O 0 3.434537575230934e-05
phenotypically O 0 0.0012722614919766784
normal O 0 0.00015796451771166176
, O 0 1.5610272612320841e-06
suggesting O 0 7.583325327686907e-07
that O 0 1.0589075571942885e-07
mutations O 0 7.523228759964695e-07
of O 0 8.434157280134968e-06
SNRPN O 0 0.00010480999480932951
are O 0 7.809100566191773e-08
not O 0 1.8323060402281044e-08
sufficient O 0 1.4037077278317156e-07
to O 0 4.079857376382279e-07
induce O 0 0.00021739119256380945
PWS B-Disease 1 1.0
. O 0 2.924745604104828e-05

Mice O 0 0.0002686971565708518
with O 0 9.354782832815545e-07
a O 0 2.074903022730723e-06
larger O 0 5.496448238773155e-07
deletion O 0 4.383795385365374e-06
involving O 0 2.6988720946974354e-06
both O 0 4.91913942823885e-06
Snrpn O 0 0.0004308333445806056
and O 0 1.0425237633171491e-05
the O 0 6.128664972493425e-05
putative O 0 0.0038933572359383106
PWS O 1 1.0
- O 0 0.0027112425304949284
IC O 0 0.0007912193541415036
lack O 0 1.6277925169561058e-05
expression O 0 1.214012718264712e-05
of O 0 1.6441161278635263e-05
the O 0 1.2875174434157088e-05
imprinted O 0 3.3580839954083785e-05
genes O 0 1.0902017493208405e-05
Zfp127 O 0 0.00027273595333099365
( O 0 6.358009613904869e-06
mouse O 0 2.0003753888886422e-05
homologue O 0 7.06952705513686e-05
of O 0 6.164660590002313e-05
ZNF127 O 0 0.0011339751072227955
) O 0 8.829169928503688e-06
, O 0 7.259357971634017e-06
Ndn O 0 0.00026374123990535736
and O 0 6.107748959038872e-06
Ipw O 0 0.00033152723335660994
, O 0 9.19569174584467e-07
and O 0 2.6229363925267535e-07
manifest O 0 3.0498799787892494e-06
several O 0 4.103492301510414e-07
phenotypes O 0 4.3426167394500226e-05
common O 0 1.0145034138986375e-05
to O 0 1.6727437468944117e-05
PWS B-Disease 1 1.0
infants O 1 0.9990252256393433
. O 0 1.3429742466541938e-05

These O 0 9.857186341832858e-06
data O 0 4.249658559274394e-06
demonstrate O 0 2.4221862986451015e-06
that O 0 3.74707695982579e-07
both O 0 1.2496478802859201e-06
the O 0 4.458044259081362e-06
position O 0 1.0979561920976266e-05
of O 0 1.8686499970499426e-05
the O 0 1.2482169950089883e-05
IC O 0 5.783479718957096e-05
and O 0 6.23735616045451e-07
its O 0 3.058409561162989e-07
role O 0 1.1103095403086627e-06
in O 0 1.1690098062899779e-06
the O 0 9.42181657137553e-07
coordinate O 0 8.229580430452188e-07
expression O 0 1.3426541045191698e-05
of O 0 2.5057801394723356e-05
genes O 0 3.926104909623973e-06
is O 0 3.0070154934946913e-06
conserved O 0 4.442116733116563e-06
between O 0 5.8751952565216925e-06
mouse O 0 6.703998224111274e-06
and O 0 1.0419713589726598e-06
human O 0 4.685370186052751e-06
, O 0 3.572640139282157e-07
and O 0 2.410258446161606e-07
indicate O 0 1.1315098618069896e-06
that O 0 2.854935985396878e-07
the O 0 3.8772304833400995e-06
mouse O 0 4.660085323848762e-06
is O 0 8.012719376893074e-07
a O 0 5.63603521186451e-07
suitable O 0 1.2131944231441594e-06
model O 0 1.3564227856477373e-06
system O 0 6.141001449577743e-07
in O 0 1.2501682533638814e-07
which O 0 7.01520335155692e-08
to O 0 3.762876232826784e-08
investigate O 0 3.085102662225836e-07
the O 0 3.6101714613323566e-06
molecular O 0 4.887101749773137e-05
mechanisms O 0 1.6888832760741934e-05
of O 0 3.171995558659546e-05
imprinting O 0 3.0809958843747154e-05
in O 0 2.4807759473333135e-06
this O 0 1.0900709668248965e-07
region O 0 1.788046120054787e-07
of O 0 9.04521129996283e-07
the O 0 1.3034070889261784e-06
genome O 0 1.8946842601508251e-06
. O 0 2.8566162768584036e-07
. O 0 9.600080375093967e-07

Mutations O 0 2.7891339414054528e-05
of O 0 2.4786597350612283e-05
the O 0 1.691260695224628e-05
ATM O 0 0.00017806592222768813
gene O 0 7.220086445158813e-06
detected O 0 1.61825810209848e-05
in O 0 1.5543870176770724e-05
Japanese O 1 0.5729895234107971
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999939203262329
: O 0 4.174963237346674e-07
possible O 0 2.6179830570072227e-07
preponderance O 0 7.082233059918508e-05
of O 0 5.513788346434012e-05
the O 0 2.86608610622352e-05
two O 0 8.055625585257076e-06
founder O 0 0.00018321487004868686
mutations O 0 6.9660954977734946e-06
4612del165 O 0 0.00011499158426886424
and O 0 5.261302703729598e-06
7883del5 O 0 0.00014705085777677596
. O 0 5.5051800700312015e-06

The O 0 0.0009677245980128646
ATM O 0 0.002069155452772975
( O 0 0.0001213157520396635
A O 1 0.9999985694885254
- O 1 0.9999958276748657
T O 1 1.0
, O 0 1.6026306184357964e-06
mutated O 0 5.278523644847155e-07
) O 0 7.559405190704638e-08
gene O 0 1.5407073306050734e-07
on O 0 1.1956357184317312e-06
human O 0 5.6801163736963645e-06
chromosome O 0 0.00015048916975501925
11q22 O 0 0.00029057220672257245
. O 0 5.944234089838574e-06

3 O 0 0.0008351937285624444
has O 0 1.022588912746869e-05
recently O 0 4.163340236118529e-06
been O 0 3.669163675112941e-07
identified O 0 4.23760440071419e-08
as O 0 1.7853668765610564e-08
the O 0 1.3324807035530739e-08
gene O 0 3.2052888343514496e-08
responsible O 0 2.0562737290674704e-08
for O 0 3.008334914511579e-08
the O 0 1.3040187241131207e-06
human O 0 0.0628013089299202
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 0.00016895373119041324
. O 0 5.157986379344948e-06

In O 0 1.7839744032244198e-05
order O 0 1.5463732552234433e-06
to O 0 3.1703345371170144e-07
define O 0 1.5122031982173212e-06
the O 0 8.632483741166652e-07
types O 0 1.3342018974071834e-06
of O 0 3.392489452380687e-05
disease O 1 0.9283580183982849
- O 0 0.0004478715709410608
causing O 0 0.00013775848492514342
ATM O 0 0.00011672284017549828
mutations O 0 1.1785054994106758e-06
in O 0 5.83962855671416e-06
Japanese O 0 0.0002099035045830533
A B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
patients O 0 5.8458640523895156e-06
as O 0 9.561030083204969e-07
well O 0 1.9034737874790153e-07
as O 0 1.780463918521491e-07
to O 0 3.149462557416882e-08
look O 0 8.5557232409883e-08
for O 0 1.4547113380558585e-07
possible O 0 1.0417248859084793e-06
mutational O 0 0.00016233640781138092
hotspots O 0 3.7129233533050865e-05
, O 0 9.553227755532134e-07
reverse O 0 4.424038706929423e-06
- O 0 4.0353402255277615e-06
transcribed O 0 4.851196081290254e-06
RNA O 0 1.1149526244480512e-06
derived O 0 6.680337492070976e-07
from O 0 7.223848683679535e-07
ten O 0 1.3503307627615868e-06
patients O 0 3.5979658719043073e-07
belonging O 0 1.398224867443787e-06
to O 0 1.924273789200015e-07
eight O 0 2.6549632821115665e-06
unrelated O 0 1.6147232599905692e-05
Japanese O 0 0.0011475213104858994
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
families O 0 6.063815476409218e-07
was O 0 2.5620054202590836e-06
analyzed O 0 2.2747948946744145e-07
for O 0 6.023963550205735e-08
mutations O 0 1.3084120098483254e-07
by O 0 3.290337602379623e-08
the O 0 1.0481849699317536e-07
restriction O 0 8.177717631951964e-07
endonuclease O 0 6.192712135089096e-06
fingerprinting O 0 2.113198661390925e-06
method O 0 2.7933581350225722e-06
. O 0 9.673741487858933e-07

As O 0 0.00028727363678626716
has O 0 9.320398930867668e-06
been O 0 2.911787987613934e-06
reported O 0 1.3472152886606636e-06
by O 0 2.2435162350120663e-07
others O 0 1.9477234047826641e-07
, O 0 6.938593344330002e-08
mutations O 0 1.0297893027200189e-07
that O 0 8.018722752467511e-08
lead O 0 1.118537511501927e-06
to O 0 8.223743179769372e-07
exon O 0 1.945577241713181e-05
skipping O 0 3.491560710244812e-05
or O 0 1.5170715414569713e-05
premature O 0 5.430220699054189e-05
protein O 0 1.79988237505313e-05
truncation O 0 8.480610995320603e-05
were O 0 6.047510851203697e-06
also O 0 1.0573671715974342e-06
predominant O 0 2.387910626566736e-06
in O 0 8.807202220850741e-07
our O 0 1.0677954378479626e-06
mutants O 0 7.195822036010213e-06
. O 0 1.8271604176334222e-06

Six O 0 6.513522384921089e-05
different O 0 8.79239053119818e-07
mutations O 0 1.2424845863279188e-06
were O 0 2.810110800055554e-06
identified O 0 5.124929884914309e-07
on O 0 1.3431565548671642e-06
12 O 0 1.618888859411527e-06
of O 0 1.052337211149279e-06
the O 0 2.2172630451677833e-06
16 O 0 1.3616690011986066e-05
alleles O 0 2.0027887330797967e-06
examined O 0 1.4117151295067742e-05
. O 0 4.7473495214944705e-06

Four O 0 0.00012720911763608456
were O 0 1.2931705896335188e-05
deletions O 0 8.822747076919768e-06
involving O 0 5.109663106850348e-06
a O 0 6.588001269847155e-06
loss O 0 4.7842382628005e-05
of O 0 7.9661316704005e-05
a O 0 2.5141553123830818e-05
single O 0 1.3889143701817375e-05
exon O 0 1.546399471408222e-05
exon O 0 1.2771946785505861e-05
7 O 0 4.871829514740966e-05
, O 0 1.5684677237004507e-06
exon O 0 3.949677648051875e-06
16 O 0 1.6853195120347664e-05
, O 0 1.1388876828277716e-06
exon O 0 6.001479505357565e-06
33 O 0 2.734385634539649e-05
or O 0 2.9162902137613855e-06
exon O 0 2.0771358322235756e-05
35 O 0 5.624672121484764e-05
. O 0 7.832422852516174e-06

The O 0 0.0004243594012223184
others O 0 1.3899133591621649e-05
were O 0 6.560965175594902e-06
minute O 0 4.052532858622726e-06
deletions O 0 4.127234660700196e-06
, O 0 5.693809157492069e-07
4649delA O 0 2.2117869775684085e-06
in O 0 1.8849375464924378e-06
exon O 0 6.151233264972689e-06
33 O 0 4.179789902991615e-05
and O 0 1.919273699968471e-06
7883del5 O 0 8.724287908989936e-05
in O 0 2.3873346435721032e-05
exon O 0 7.380441820714623e-05
55 O 0 0.00012618870823644102
. O 0 9.99158055492444e-06

The O 0 0.0007953490130603313
mutations O 0 0.0001539939403301105
4612del165 O 0 0.0007986961281858385
and O 0 3.9228394598467276e-05
7883del5 O 0 0.0003664997057057917
were O 0 3.829157867585309e-05
found O 0 1.626333641979727e-06
in O 0 9.412691497345804e-07
more O 0 7.406168833767879e-08
than O 0 9.971298453592681e-08
two O 0 2.754810282112885e-07
unrelated O 0 1.5940003095238353e-06
families O 0 7.479918906483363e-08
; O 0 7.938084678471569e-08
44 O 0 1.7512508065919974e-06
% O 0 7.453570560755907e-07
( O 0 4.068022860792553e-07
7 O 0 1.1041806828870904e-05
of O 0 2.9764029022771865e-05
16 O 0 7.211756746983156e-05
) O 0 6.37659411495406e-07
of O 0 5.4982024266791996e-06
the O 0 4.272985279385466e-06
mutant O 0 4.743511453852989e-06
alleles O 0 4.537553195405053e-07
had O 0 1.2277000678295735e-06
one O 0 1.4869127085148648e-07
of O 0 5.033115257901954e-07
the O 0 6.815707820351236e-07
two O 0 5.967106631032948e-07
mutations O 0 3.228099103580462e-06
. O 0 3.466247790129273e-06

The O 0 0.0005468391464091837
4612del165 O 0 0.0005925453151576221
mutations O 0 1.6601728930254467e-05
in O 0 1.158142458734801e-05
three O 0 1.5952138028296758e-06
different O 0 8.253436334371145e-08
families O 0 8.170984955313543e-08
were O 0 5.856292659700557e-07
all O 0 1.4042554141724395e-07
ascribed O 0 2.870283424272202e-06
to O 0 6.192991577336215e-07
the O 0 3.548369249983807e-06
same O 0 5.597123617917532e-06
T O 0 3.799541082116775e-05
- O 0 6.089655016694451e-06
- O 0 9.327583939011674e-06
> O 0 4.1954090193030424e-06
A O 0 2.7212022359890398e-06
substitution O 0 1.8108903532265685e-06
at O 0 4.118031029065605e-06
the O 0 2.744486380379385e-07
splice O 0 1.0287169516232098e-06
donor O 0 3.38291727075557e-07
site O 0 7.105202826096502e-07
in O 0 1.4292070318333572e-06
intron O 0 0.00014207254571374506
33 O 0 0.00025505333906039596
. O 0 1.317781880061375e-05

Microsatellite O 0 0.005589824635535479
genotyping O 0 0.0005737074534408748
around O 0 7.353907858487219e-05
the O 0 4.591033939504996e-05
ATM O 0 0.0002618226280901581
locus O 0 7.356446440098807e-05
also O 0 6.738745014445158e-06
indicated O 0 3.615498599174316e-06
that O 0 1.2703958418569528e-07
a O 0 9.606005733076017e-07
common O 0 6.732025781275297e-07
haplotype O 0 1.5148566490097437e-05
was O 0 3.6592887227016035e-06
shared O 0 1.3928212183600408e-07
by O 0 2.761403905537918e-08
the O 0 2.0028984692999074e-07
mutant O 0 8.727978411116055e-07
alleles O 0 4.786075464835449e-07
in O 0 5.101625788483943e-07
both O 0 7.512660999964282e-07
mutations O 0 6.9538955358439125e-06
. O 0 3.303954599687131e-06

This O 0 3.765001383726485e-05
suggests O 0 1.2215861715958454e-05
that O 0 3.2438799735245993e-07
these O 0 3.1766174402036995e-07
two O 0 2.086031372527941e-06
founder O 0 8.448791777482256e-05
mutations O 0 1.4753682080481667e-06
may O 0 1.8736536731012166e-06
be O 0 1.902555482047319e-07
predominant O 0 1.5430130133609055e-06
among O 0 1.1681177625177952e-07
Japanese O 0 3.348998689034488e-06
ATM O 0 7.661941344849765e-05
mutant O 0 2.633588337630499e-05
alleles O 0 1.2287763638596516e-05
. O 0 4.3237910176685546e-06

W474C O 0 0.007071873173117638
amino O 0 0.0001550843589939177
acid O 0 8.84492965269601e-06
substitution O 0 3.6935221032763366e-06
affects O 0 6.695721594951465e-07
early O 0 1.9465794593998e-06
processing O 0 3.466898760962067e-06
of O 0 6.36419144939282e-06
the O 0 6.958884569030488e-06
alpha O 0 8.010595593077596e-06
- O 0 7.637927410542034e-07
subunit O 0 1.3624838857140276e-06
of O 0 7.630031177541241e-06
beta O 0 2.473184395057615e-05
- O 0 9.148036951955874e-06
hexosaminidase O 0 1.452158085157862e-05
A O 0 2.497389914424275e-06
and O 0 1.6783305056833342e-07
is O 0 1.4079994059557066e-07
associated O 0 5.706377237402194e-07
with O 0 1.1028294011339312e-06
subacute O 1 0.9995840191841125
G B-Disease 1 0.9992063641548157
( I-Disease 0 2.251965634059161e-05
M2 I-Disease 0 0.005053264554589987
) I-Disease 0 1.0121811101271305e-05
gangliosidosis I-Disease 0 0.00040702661499381065
. O 0 7.320606982830213e-06

Mutations O 0 0.00015271517622750252
in O 0 3.076221764786169e-05
the O 0 2.718424002523534e-05
HEXA O 0 0.0004833778948523104
gene O 0 2.5270044261560543e-06
, O 0 3.2738677191446186e-07
encoding O 0 3.2361765534005826e-07
the O 0 2.106233296217397e-06
alpha O 0 2.9259063012432307e-06
- O 0 3.079038890518859e-07
subunit O 0 4.7361072574858554e-07
of O 0 5.583049187407596e-06
beta O 0 2.671205766091589e-05
- O 0 2.2319240088108927e-05
hexosaminidase O 0 0.0001322368043474853
A O 0 0.00011183444439666346
( O 0 3.1961674267222406e-06
Hex O 0 4.1152819903800264e-05
A O 0 9.640811185818166e-06
) O 0 6.708947353217809e-08
, O 0 2.04311838558624e-08
that O 0 9.316223348321273e-09
abolish O 0 8.002730851330853e-07
Hex O 0 1.3628277883981355e-05
A O 0 2.687473852347466e-06
enzyme O 0 2.9535713110817596e-06
activity O 0 1.779320700734388e-05
cause O 0 0.0005280773621052504
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 1.5021094441181049e-05
TSD B-Disease 0 0.010547398589551449
) O 0 6.292418675002409e-07
, O 0 2.2768175256260292e-07
the O 0 3.0437929581239587e-06
fatal O 1 0.6465264558792114
infantile B-Disease 1 0.9996602535247803
form I-Disease 0 0.00021247667609713972
of I-Disease 1 0.9998302459716797
G I-Disease 1 0.9996930360794067
( I-Disease 0 1.5933732356643304e-05
M2 I-Disease 0 0.0008302527130581439
) I-Disease 0 1.4973219322200748e-06
gangliosidosis I-Disease 0 2.8920590921188705e-05
, I-Disease 0 3.9764711345924297e-07
Type I-Disease 0 6.494610261142952e-06
1 I-Disease 0 1.663354669290129e-05
. O 0 2.5250121780118207e-06

Less O 0 0.0006178421899676323
severe O 1 0.9999798536300659
, O 0 0.00012718461221084
subacute O 1 0.9999738931655884
( O 0 8.397457713726908e-05
juvenile O 1 0.9997336268424988
- O 0 0.36284103989601135
onset O 1 1.0
) O 0 9.744129056343809e-05
and O 0 0.000566627481020987
chronic O 1 1.0
( O 0 0.0003423699818085879
adult O 1 0.5353609919548035
- O 1 0.998791515827179
onset O 1 0.9999997615814209
) O 0 3.4723054795904318e-06
variants O 0 1.2747128721457557e-06
are O 0 4.820113730374942e-08
characterized O 0 1.6920132850373193e-07
by O 0 1.626655787845266e-08
a O 0 1.8874581542149826e-07
broad O 0 1.0002268027164973e-06
spectrum O 0 1.8593121922094724e-06
of O 0 1.329901806457201e-06
clinical O 0 2.947329994640313e-05
manifestations O 0 7.95991945778951e-05
and O 0 1.271565793103946e-06
are O 0 1.2524176895567507e-07
associated O 0 8.740942547547093e-08
with O 0 2.5021783756074e-08
residual O 0 3.144518268527463e-05
levels O 0 8.549312769901007e-05
of O 0 6.576954910997301e-05
Hex O 0 0.00026190775679424405
A O 0 2.480059629306197e-05
enzyme O 0 4.968312623532256e-06
activity O 0 8.991990398499183e-06
. O 0 8.979632184491493e-07

We O 0 7.579271914437413e-05
identified O 0 2.2808260837337002e-05
a O 0 2.368325112911407e-05
1422 O 0 0.0011679026065394282
G O 0 0.00043935576104559004
- O 0 4.429631371749565e-05
- O 0 8.202860044548288e-05
> O 0 8.303384674945846e-05
C O 0 0.00012324887211434543
( O 0 1.456973336644296e-06
amino O 0 2.5975355129048694e-06
acid O 0 1.4441247913055122e-06
W474C O 0 7.345236554101575e-06
) O 0 1.7695961673780403e-07
substitution O 0 8.26453288027551e-07
in O 0 8.449079018646444e-07
the O 0 1.4409633877221495e-06
first O 0 2.690530664040125e-06
position O 0 2.8982683488720795e-06
of O 0 1.0190045031777117e-05
exon O 0 6.6381644501234405e-06
13 O 0 2.7123955078423023e-05
of O 0 6.812072388129309e-05
HEXA O 0 0.004572140984237194
of O 0 0.00018707377603277564
a O 0 0.0001073563180398196
non O 0 0.00037739877006970346
- O 0 5.3629541071131825e-05
Jewish O 0 2.5231385734514333e-05
proband O 0 0.00013945085811428726
who O 0 1.4050204981685965e-06
manifested O 0 1.1657761206151918e-05
a O 0 4.100392288819421e-06
subacute O 0 0.0005364887765608728
variant O 0 6.4441715949215e-05
of O 1 0.7582457065582275
G B-Disease 1 0.9998618364334106
( I-Disease 0 5.070647603133693e-05
M2 I-Disease 0 0.02207188680768013
) I-Disease 0 1.432351018593181e-05
gangliosidosis I-Disease 0 0.00044673652155324817
. O 0 5.999499535391806e-06

On O 0 0.0005767755792476237
the O 0 9.663042874308303e-05
second O 0 0.0001818742894101888
maternally O 0 0.000311181356664747
inherited O 0 0.0006078481674194336
allele O 0 2.270671393489465e-05
, O 0 5.33221566456632e-07
we O 0 8.497435999288427e-08
identified O 0 2.298468331218828e-07
the O 0 5.72604619719641e-07
common O 0 1.1723038369382266e-05
infantile O 1 0.9999501705169678
disease O 1 0.9997197985649109
- O 0 0.00025027504307217896
causing O 0 0.009779414162039757
4 O 0 0.0004371991672087461
- O 0 0.00011946909944526851
bp O 0 0.00016582422540523112
insertion O 0 3.160590858897194e-05
, O 0 4.60006958746817e-06
+ O 0 2.710559783736244e-05
TATC O 0 0.0002260049368487671
1278 O 0 0.0001308331557083875
, O 0 7.070412380016933e-07
in O 0 1.2507733799793641e-06
exon O 0 8.660628736834042e-06
11 O 0 1.3630759895022493e-05
. O 0 1.8411784594718483e-06

Pulse O 0 0.004234384745359421
- O 0 0.0001469914277549833
chase O 0 1.736406920826994e-05
analysis O 0 2.567951696619275e-06
using O 0 2.6696209260990145e-06
proband O 0 0.00025226728757843375
fibroblasts O 0 8.924757275963202e-05
revealed O 0 3.98507654608693e-05
that O 0 1.58323757659673e-06
the O 0 8.360864740097895e-06
W474C O 0 2.2435031496570446e-05
- O 0 3.899681360053364e-06
containing O 0 2.5315002858405933e-06
alpha O 0 6.878374733787496e-06
- O 0 1.4712318261445034e-06
subunit O 0 5.2224604587536305e-06
precursor O 0 2.702694655454252e-05
was O 0 2.7368923838366754e-05
normally O 0 2.0444535948627163e-06
synthesized O 0 5.565919764194405e-06
, O 0 3.0341863066496444e-07
but O 0 7.05442317894267e-08
not O 0 1.0329524968710757e-07
phosphorylated O 0 1.5648163298465079e-06
or O 0 1.3566479992732638e-06
secreted O 0 1.1433386362114106e-06
, O 0 2.2045649927804334e-07
and O 0 3.780736221870029e-07
the O 0 3.0644930575363105e-06
mature O 0 1.536896343168337e-05
lysosomal O 0 0.00035161987761966884
alpha O 0 6.5008774981834e-05
- O 0 4.487693786359159e-06
subunit O 0 5.420440629677614e-06
was O 0 1.0436955562909134e-05
not O 0 3.934287633455824e-07
detected O 0 9.213078556058463e-06
. O 0 1.5845683947190992e-06

When O 0 0.00010671219206415117
the O 0 3.344705328345299e-05
W474C O 0 0.00014887908764649183
- O 0 1.6380674423999153e-05
containing O 0 7.934548193588853e-06
alpha O 0 1.7096044757636264e-05
- O 0 1.945629037436447e-06
subunit O 0 6.7862697505916e-06
was O 0 4.0715302020544186e-05
transiently O 0 1.4759052646695636e-05
co O 0 4.943330623063957e-06
- O 0 9.241088605449477e-07
expressed O 0 3.9361643189295137e-07
with O 0 8.244216331831922e-08
the O 0 1.43454099088558e-06
beta O 0 1.652494574955199e-06
- O 0 4.0887030650083034e-07
subunit O 0 6.891486918902956e-07
to O 0 2.6692313781495614e-07
produce O 0 1.308970240643248e-06
Hex O 0 6.609140837099403e-05
A O 0 5.184773544897325e-05
( O 0 1.953333594428841e-06
alphabeta O 0 2.755623427219689e-05
) O 0 8.85604492850689e-07
in O 0 6.226092864380917e-06
COS O 0 0.00034207163844257593
- O 0 3.251047382946126e-05
7 O 0 4.801601971848868e-05
cells O 0 1.6390907831009827e-06
, O 0 3.0048857979636523e-07
the O 0 1.0903262364081456e-06
mature O 0 1.1731834774764138e-06
alpha O 0 4.105937478016131e-06
- O 0 7.154124546104867e-07
subunit O 0 1.1465925808806787e-06
was O 0 6.5566241573833395e-06
present O 0 4.615712896338664e-07
, O 0 1.828121014568751e-07
but O 0 5.824889015570989e-08
its O 0 2.52307415848918e-07
level O 0 2.2428592274081893e-05
was O 0 2.35034131037537e-05
much O 0 1.7205148878929322e-06
lower O 0 9.477686944592278e-06
than O 0 1.9946047302710213e-07
that O 0 1.1417179734962701e-07
from O 0 1.6050336171247181e-06
normal O 0 2.573664824012667e-05
alpha O 0 3.226108310627751e-05
- O 0 5.537325705518015e-06
subunit O 0 7.151354111556429e-06
transfections O 0 3.475710400380194e-05
, O 0 5.572180157287221e-07
although O 0 1.6057593654750235e-07
higher O 0 1.1584444337131572e-06
than O 0 5.0489312286572385e-08
in O 0 3.1539894962406834e-07
those O 0 1.3787109764962224e-07
cells O 0 7.429264883285214e-07
transfected O 0 2.799150252030813e-06
with O 0 1.055741307709468e-07
an O 0 6.536930641232175e-07
alpha O 0 7.10534413883579e-06
- O 0 1.2548007362056524e-06
subunit O 0 2.6337172585044755e-06
associated O 0 1.3227868294052314e-06
with O 0 1.192066520161461e-06
infantile O 1 0.9748483300209045
TSD B-Disease 0 0.11443088203668594
. O 0 1.210004211316118e-05

Furthermore O 0 0.00026468565920367837
, O 0 9.97113329503918e-06
the O 0 7.419475878123194e-06
precursor O 0 4.5025695726508275e-05
level O 0 6.114099960541353e-05
of O 0 4.7179044486256316e-05
the O 0 3.086306242039427e-05
W474C O 0 0.00011383251694496721
alpha O 0 5.42566085641738e-05
- O 0 3.7383788367151283e-06
subunit O 0 4.633478965843096e-06
was O 0 8.854904990585055e-06
found O 0 2.788455617519503e-07
to O 0 4.036984435629165e-08
accumulate O 0 1.779798424195178e-07
in O 0 3.648726192295726e-07
comparison O 0 4.92868593937601e-07
to O 0 2.4509620288881706e-07
the O 0 2.611054242152022e-06
normal O 0 2.399671939201653e-05
alpha O 0 1.880217132566031e-05
- O 0 2.7363219032849884e-06
subunit O 0 3.536767508194316e-06
precursor O 0 2.0493651391007006e-05
levels O 0 1.0851419574464671e-05
. O 0 1.147526859313075e-06

We O 0 7.758344145258889e-05
conclude O 0 6.149635009933263e-05
that O 0 2.9591903967229882e-06
the O 0 1.2783219062839635e-05
1422 O 0 0.0005986670730635524
G O 0 0.0002895821526180953
- O 0 2.2258107492234558e-05
- O 0 2.5702676794026047e-05
> O 0 1.2379271538520698e-05
C O 0 1.037241963786073e-05
mutation O 0 8.900192938199325e-08
is O 0 4.386211216456104e-08
the O 0 1.0845833742223476e-07
cause O 0 1.0008470781031065e-06
of O 0 6.438570835598512e-06
Hex B-Disease 0 0.0005557286203838885
A I-Disease 0 0.0027610468678176403
enzyme I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 1.6516909454367124e-05
the O 0 1.4694674973725341e-05
proband O 0 0.00037660342059098184
. O 0 4.514944521361031e-06

The O 0 0.00013159991067368537
resulting O 0 9.41329708439298e-05
W474C O 0 0.0003543113125488162
substitution O 0 3.9745860703988e-05
clearly O 0 1.876174792414531e-05
interferes O 0 7.082491265464341e-06
with O 0 7.124887702048e-07
alpha O 0 1.16494929898181e-05
- O 0 8.876727406459395e-07
subunit O 0 1.57661111188645e-06
processing O 0 3.706729785335483e-06
, O 0 1.1483967199410472e-07
but O 0 1.857660159032548e-08
because O 0 3.539118154094467e-08
the O 0 3.1018743129607174e-07
base O 0 3.2596753953839652e-06
substitution O 0 4.866710241913097e-06
falls O 0 7.004402141319588e-05
at O 0 1.6606036297162063e-05
the O 0 1.8204813159172772e-06
first O 0 3.103784820268629e-06
position O 0 5.239941856416408e-06
of O 0 1.547311148897279e-05
exon O 0 1.0003002898884006e-05
13 O 0 3.252607348258607e-05
, O 0 2.505551037756959e-06
aberrant O 0 1.9690871340571903e-05
splicing O 0 5.405001047620317e-06
may O 0 3.474945970083354e-06
also O 0 4.1747918544388085e-07
contribute O 0 2.9139832236069196e-07
to O 0 1.1698618891387014e-06
Hex B-Disease 0 0.00060738978208974
A I-Disease 0 0.0003648326965048909
deficiency I-Disease 1 0.9937111139297485
in O 0 1.4706044566992205e-05
this O 0 2.2786168756283587e-06
proband O 0 9.161543130176142e-05
. O 0 6.073729537092731e-07
. O 0 1.3018493518757168e-06

Two O 0 2.593144699858385e-06
frequent O 0 5.626676738756942e-06
missense O 0 0.00018020161951426417
mutations O 0 0.00023744140344206244
in O 0 0.157067209482193
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00013178776134736836

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.17623968422412872
an O 1 0.9258163571357727
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 1.0
by O 0 2.8655722417170182e-05
early O 1 0.9999984502792358
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 1.0
goiter B-Disease 1 1.0
. O 0 0.0007382326293736696

A O 0 3.7082449125591666e-05
century O 0 5.042559223511489e-06
after O 0 6.627206516895967e-07
its O 0 5.463967411856174e-08
recognition O 0 1.5379605429188814e-06
as O 0 2.9460236419254215e-06
a O 0 1.9009205061593093e-05
syndrome O 1 0.9997500777244568
by O 0 1.6777589735283982e-06
Vaughan O 0 0.00018083504983223975
Pendred O 0 0.0015856858808547258
, O 0 3.7258573684084695e-06
the O 0 1.3344384569791146e-05
disease O 0 0.18905362486839294
gene O 0 5.342959411791526e-05
( O 0 1.3541902262659278e-05
PDS O 0 0.0004299299616832286
) O 0 6.436727062464342e-07
was O 0 5.12643873662455e-06
mapped O 0 2.168963874282781e-06
to O 0 2.2975661977397976e-06
chromosome O 0 0.001404246548190713
7q22 O 0 0.009842307306826115
- O 0 0.014238265343010426
q31 O 0 0.0031643935944885015
. O 0 1.5265746696968563e-05

1 O 0 0.0011161720613017678
and O 0 2.327103902644012e-05
, O 0 2.6198213163297623e-06
recently O 0 2.7711812435882166e-06
, O 0 1.0486589729907791e-07
found O 0 4.3366732427330135e-08
to O 0 1.7630190640716137e-08
encode O 0 4.644657849439682e-07
a O 0 4.591628112393664e-06
putative O 0 0.00012154385331086814
sulfate O 0 0.00030014009098522365
transporter O 0 0.0020119030959904194
. O 0 1.0058322914119344e-05

We O 0 5.140484972798731e-06
performed O 0 5.088383659312967e-06
mutation O 0 1.212673851114232e-06
analysis O 0 5.866958758815599e-07
of O 0 4.8341771616833284e-06
the O 0 1.426834842277458e-05
PDS B-Disease 0 0.00015778718807268888
gene O 0 2.5430765617784346e-06
in O 0 2.948949941128376e-06
patients O 0 2.2284539227257483e-06
from O 0 6.045625013939571e-06
14 O 0 4.447561514098197e-05
Pendred B-Disease 0 0.00014602889132220298
families O 0 1.2850489383708918e-06
originating O 0 4.921621894027339e-06
from O 0 1.0284147720085457e-06
seven O 0 4.803777073902893e-07
countries O 0 2.668609511147224e-08
and O 0 2.388185578183766e-07
identified O 0 1.4445752185565652e-06
all O 0 6.891986004120554e-07
mutations O 0 7.178693067544373e-06
. O 0 4.2976284930773545e-06

The O 0 7.134168845368549e-05
mutations O 0 8.651803909742739e-06
include O 0 4.3394802560214885e-06
three O 0 6.423275408451445e-06
single O 0 8.70278017828241e-06
base O 0 4.222292409394868e-05
deletions O 0 3.2292664400301874e-05
, O 0 4.60207047581207e-06
one O 0 1.1779616215790156e-06
splice O 0 7.766433554934338e-06
site O 0 1.3862526202501613e-06
mutation O 0 3.522622478158155e-07
and O 0 3.069776539632585e-07
10 O 0 2.429744881737861e-06
missense O 0 1.693704143690411e-05
mutations O 0 1.2408135262376163e-05
. O 0 8.747128958930261e-06

One O 0 0.0001916003820952028
missense O 0 0.0008371816365979612
mutation O 0 6.0012440371792763e-05
( O 0 1.1106621968792751e-05
L236P O 0 7.949056453071535e-05
) O 0 1.470268216507975e-06
was O 0 9.42532642511651e-06
found O 0 4.892206106887897e-07
in O 0 5.31866533037828e-07
a O 0 7.018220458121505e-07
homozygous O 0 4.854028361478413e-07
state O 0 8.169641887434409e-07
in O 0 1.3510341432265704e-06
two O 0 1.0518535873416113e-06
consanguineous O 0 6.253271567402408e-05
families O 0 5.32787453266792e-07
and O 0 8.302372407342773e-07
in O 0 3.0833309665467823e-06
a O 0 3.3481171612947946e-06
heterozygous O 0 1.1666487580441753e-06
state O 0 4.019352388695552e-07
in O 0 7.73186059177533e-07
five O 0 3.4870322451752145e-07
additional O 0 6.291159024840454e-07
non O 0 0.00014149202615953982
- O 0 0.00018404971342533827
consanguineous O 0 0.0009287652792409062
families O 0 1.2737249335259548e-06
. O 0 1.4564648154191673e-06

Another O 0 0.000186579636647366
missense O 0 0.0004269088676664978
mutation O 0 4.663258005166426e-05
( O 0 9.024935934576206e-06
T416P O 0 8.109537156997249e-05
) O 0 1.1622898909990909e-06
was O 0 1.1561614883248694e-05
found O 0 4.2245991949130257e-07
in O 0 6.367757805492147e-07
a O 0 1.3269612963995314e-06
homozygous O 0 1.0760830946310307e-06
state O 0 1.3252996495793923e-06
in O 0 3.977532742283074e-06
one O 0 2.3359341412287904e-06
family O 0 6.711820219607034e-07
and O 0 3.821688778771204e-07
in O 0 1.0967253274429822e-06
a O 0 1.4179903473632294e-06
heterozygous O 0 2.6674425157580117e-07
state O 0 2.3036164975565043e-07
in O 0 7.363763074863527e-07
four O 0 8.202305821214395e-07
families O 0 3.6471470821197727e-07
. O 0 1.8546846831668518e-06

Pendred B-Disease 0 0.18243159353733063
patients O 0 0.0003329630708321929
in O 0 0.00011300743062747642
three O 0 4.638495738618076e-05
non O 0 0.0005858263466507196
- O 0 0.00011724209616659209
consanguineous O 0 0.0006933546392247081
families O 0 6.000839221087517e-07
were O 0 7.639370096512721e-07
shown O 0 5.123991968503105e-07
to O 0 1.4209641108209325e-07
be O 0 1.107194293581415e-06
compound O 0 2.2257301679928787e-05
heterozygotes O 0 1.0014361578214448e-05
for O 0 1.5192457567536621e-06
L236P O 0 6.655391916865483e-05
and O 0 5.459067779156612e-06
T416P O 0 0.0001690615463303402
. O 0 4.950717539031757e-06

In O 0 0.0002696040610317141
total O 0 0.00021269926219247282
, O 0 1.7479622329119593e-05
one O 0 5.1007828005822375e-06
or O 0 2.4584721813880606e-06
both O 0 8.227979719777068e-07
of O 0 6.755108188372105e-06
these O 0 3.7350574189076724e-07
mutations O 0 5.014630346522608e-07
were O 0 1.6620598444205825e-06
found O 0 2.1456877163927857e-07
in O 0 2.491525492587243e-07
nine O 0 8.257906642938906e-07
of O 0 1.0461831152497325e-06
the O 0 8.419173127549584e-07
14 O 0 5.192301159695489e-06
families O 0 1.1693371249066331e-07
analyzed O 0 3.984518116340041e-06
. O 0 2.0861009488726268e-06

The O 0 2.7759961085394025e-05
identification O 0 3.788361937040463e-06
of O 0 8.368059752683621e-06
two O 0 1.5422964452227461e-06
frequent O 0 7.620650194439804e-06
PDS B-Disease 0 0.00010511535947443917
mutations O 0 1.1368113916887523e-07
will O 0 1.4379027746258544e-08
facilitate O 0 4.880114090610732e-08
the O 0 3.519925826367398e-07
molecular O 0 0.00015812063065823168
diagnosis O 1 0.9957488179206848
of O 1 0.9999740123748779
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00042218921589665115

Insertional O 0 0.006348449736833572
mutation O 0 2.388862776570022e-05
by O 0 1.04852745153039e-06
transposable O 0 5.627972132060677e-05
element O 0 2.7711164875654504e-05
, O 0 2.1879545784031507e-06
L1 O 0 3.139568434562534e-05
, O 0 3.089722326876654e-07
in O 0 4.6461821057164343e-07
the O 0 3.849484983220464e-06
DMD B-Disease 1 0.9999997615814209
gene O 0 6.189270152390236e-06
results O 0 9.29341695155017e-06
in O 0 2.6830823117052205e-05
X B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999997615814209
linked I-Disease 1 0.999997615814209
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
. O 0 8.478597010252997e-05

X B-Disease 1 0.9999958276748657
- I-Disease 1 0.999998927116394
linked I-Disease 1 0.9999984502792358
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 0.0012025382602587342
XLDCM B-Disease 1 0.9999475479125977
) O 0 2.7305816274747485e-06
is O 0 5.414743782239384e-07
a O 0 1.70622570294654e-06
clinical O 0 0.00032831027056090534
phenotype O 0 0.0001406001829309389
of O 0 0.00023845255782362074
dystrophinopathy B-Disease 0 0.06360197067260742
which O 0 1.3726042880080058e-06
is O 0 1.9480857815779018e-07
characterized O 0 2.4461235170747386e-07
by O 0 2.8418256192708213e-08
preferential O 0 2.631450115586631e-06
myocardial B-Disease 1 0.999954342842102
involvement I-Disease 0 4.538675966614392e-06
without O 0 1.3932198328348022e-07
any O 0 3.137471082936827e-08
overt O 0 3.6686742532765493e-06
clinical O 0 0.00036797995562665164
signs O 0 0.00040285277646034956
of O 0 0.00828250590711832
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0002149596402887255

To O 0 2.62864091382653e-06
date O 0 3.94784365198575e-06
, O 0 8.943756313328777e-08
several O 0 3.0132621731127074e-08
mutations O 0 3.6694333971354354e-07
in O 0 2.411229615972843e-06
the O 0 0.00013419831520877779
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.11846646666526794
, O 0 0.00011692157568177208
DMD O 1 1.0
, O 0 2.097263632094837e-06
have O 0 3.323293071844091e-07
been O 0 1.004419345917995e-06
identified O 0 4.3232446955698833e-07
in O 0 1.0504821830181754e-06
patients O 0 1.8125713268091204e-06
with O 0 1.1750612429750618e-06
XLDCM B-Disease 0 0.0022783742751926184
, O 0 6.483622883024509e-07
but O 0 5.4990231035390025e-08
a O 0 1.4445446083755087e-07
pathogenic O 0 3.489863331651577e-07
correlation O 0 2.0884697278233944e-06
of O 0 2.112999254677561e-06
these O 0 4.865744926974003e-07
cardiospecific O 0 0.00013548719289246947
mutations O 0 5.889904514333466e-06
in O 0 4.667986650019884e-05
DMD O 1 1.0
with O 0 9.568067980580963e-06
the O 0 0.00015348276065196842
XLDCM B-Disease 0 0.11109519004821777
phenotype O 0 0.0001121398527175188
has O 0 8.824228643788956e-06
remained O 0 2.8465608920669183e-05
to O 0 8.966986797531717e-08
be O 0 6.22789400495094e-07
elucidated O 0 7.373731205007061e-05
. O 0 2.3294915081351064e-06

We O 0 8.05113886599429e-05
report O 0 6.781870524719125e-06
here O 0 8.076588642325078e-07
the O 0 1.809647471873177e-07
identification O 0 9.802619160836912e-08
of O 0 6.572573738594656e-07
a O 0 1.3785403325528023e-06
unique O 0 1.5192398450381006e-06
de O 0 0.0003981039335485548
novo O 0 0.00014795086462982
L1 O 0 6.408614717656747e-05
insertion O 0 7.402337359962985e-06
in O 0 4.795222139364341e-06
the O 0 8.418527613685e-06
muscle O 0 8.647910362924449e-06
exon O 0 4.62933576272917e-06
1 O 0 1.2134664757468272e-05
in O 0 9.426288670510985e-06
DMD O 1 0.9999998807907104
in O 0 2.201027746195905e-05
three O 0 1.3534594472730532e-05
XLDCM B-Disease 0 0.001044056611135602
patients O 0 2.4797161586320726e-06
from O 0 1.1132642612210475e-06
two O 0 3.8739977981094853e-07
unrelated O 0 3.745737558347173e-06
Japanese O 0 1.0696927347453311e-05
families O 0 9.553774589221575e-07
. O 0 1.9636115666799014e-06

The O 0 0.0002669381210580468
insertion O 0 9.862391743808985e-05
was O 0 0.0001548347936477512
a O 0 9.705902812129352e-06
5 O 0 5.282106940285303e-06
- O 0 1.5079145896379487e-06
truncated O 0 4.011412784166168e-06
form O 0 4.4821237565884076e-07
of O 0 6.036838840373093e-06
human O 0 1.4514435861201491e-05
L1 O 0 7.544191612396389e-05
inversely O 0 3.7600286304950714e-05
integrated O 0 4.0006230847211555e-05
in O 0 4.533648734650342e-06
the O 0 5.670677182934014e-06
5 O 0 9.310795576311648e-06
- O 0 7.268980425578775e-06
untranslated O 0 4.903020089841448e-05
region O 0 4.327197984821396e-06
in O 0 1.0013844985223841e-05
the O 0 1.3796904568152968e-05
muscle O 0 1.2170928130217362e-05
exon O 0 5.861942099727457e-06
1 O 0 8.01108490122715e-06
, O 0 1.068563051376259e-07
which O 0 3.131384929133674e-08
affected O 0 1.4398214887023641e-07
the O 0 5.15108638410311e-07
transcription O 0 3.547063215592061e-06
or O 0 1.0015450015998795e-06
the O 0 1.6513729406142375e-06
stability O 0 9.433410923520569e-06
of O 0 1.760472332534846e-05
the O 0 1.9292885554023087e-05
muscle O 0 1.3119372852088418e-05
form O 0 3.4969036732945824e-06
of O 0 3.3184816857101396e-05
dystrophin O 0 3.208537236787379e-05
transcripts O 0 7.599711352668237e-06
but O 0 8.05526809699586e-08
not O 0 2.7367178745407728e-08
that O 0 4.8339700242649997e-08
of O 0 4.967128461430548e-06
the O 0 7.05413258401677e-05
brain O 1 0.9936028122901917
or O 0 0.0002879649691749364
Purkinje O 0 0.020641043782234192
cell O 0 0.001874548732303083
form O 0 2.142319681297522e-05
, O 0 2.3215254714159528e-06
probably O 0 1.7071664615286863e-06
due O 0 1.6266050124613685e-06
to O 0 3.927307190565443e-08
its O 0 3.9592496392515386e-08
unique O 0 1.316640805271163e-07
site O 0 7.679501550228451e-07
of O 0 1.7372415186400758e-06
integration O 0 1.0754054528661072e-05
. O 0 4.925927896692883e-06

We O 0 4.6503086196025833e-05
speculate O 0 3.6606290905183414e-06
that O 0 1.580140747137193e-07
this O 0 9.251346710925645e-08
insertion O 0 6.278422119976312e-07
of O 0 1.9106885247310856e-06
an O 0 6.20878608970088e-07
L1 O 0 4.597899169311859e-05
sequence O 0 8.542278919776436e-06
in O 0 4.780403105542064e-05
DMD O 1 1.0
is O 0 8.430103662249167e-06
responsible O 0 2.6181305656791665e-06
for O 0 2.19263654344104e-07
some O 0 5.017003346097226e-08
of O 0 8.994940117190708e-07
the O 0 4.0712635041018075e-07
population O 0 5.8744497266616236e-08
of O 0 6.506529643957037e-07
Japanese O 0 5.942793904978316e-06
patients O 0 2.4981068236229476e-06
with O 0 1.4329260693557444e-06
XLDCM B-Disease 0 0.001145095913670957
. O 0 1.768440142768668e-06
. O 0 1.860672682596487e-06

Severe O 1 0.9998608827590942
early O 0 0.3108925521373749
- O 1 0.9999994039535522
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9989708662033081
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.03570582717657089
red O 1 0.9999616146087646
hair O 1 0.9999995231628418
pigmentation O 1 1.0
caused O 1 0.9999973773956299
by O 0 3.740615284186788e-05
POMC O 1 0.8599351644515991
mutations O 0 5.142387180967489e-06
in O 0 4.228378202242311e-06
humans O 0 2.574515974629321e-06
. O 0 8.440179612989596e-07

Sequential O 0 0.0004915958270430565
cleavage O 0 0.0004166777362115681
of O 0 0.00035340606700628996
the O 0 7.088462734827772e-05
precursor O 0 9.777869854588062e-05
protein O 0 1.510808306193212e-05
pre O 0 0.00024095532717183232
- O 0 0.00011886002903338522
pro O 0 0.0006399792619049549
- O 0 4.9800371925812215e-05
opiomelanocortin O 0 0.00016454653814435005
( O 0 1.8173208218286163e-06
POMC O 0 5.981800131849013e-05
) O 0 1.4167072492909938e-07
generates O 0 7.287862899829634e-07
the O 0 2.913810249083326e-06
melanocortin O 0 0.0004892420838586986
peptides O 0 2.982753539981786e-05
adrenocorticotrophin O 0 0.0003641907242126763
( O 0 7.82354618422687e-06
ACTH O 0 0.0002411594323348254
) O 0 2.7027795113099273e-06
, O 0 3.7828854146937374e-06
melanocyte O 0 0.0001717950071906671
- O 0 0.00014062512491364032
stimulating O 0 9.980650793295354e-05
hormones O 0 3.089033270953223e-05
( O 0 7.420803171953594e-07
MSH O 0 1.8753464246401563e-05
) O 0 1.770362416664284e-07
alpha O 0 2.405590748821851e-06
, O 0 8.174881571676451e-08
beta O 0 5.993335889797891e-07
and O 0 1.7086293269130692e-07
gamma O 0 3.5272184959467268e-06
as O 0 5.276309025248338e-07
well O 0 1.754974761070116e-07
as O 0 2.1557298168772832e-07
the O 0 3.1110729992178676e-07
opioid O 0 7.766359885863494e-06
- O 0 2.6354082365287468e-06
receptor O 0 6.807452791690594e-06
ligand O 0 2.412958929198794e-05
beta O 0 2.7017978936783038e-05
- O 0 1.6537918781978078e-05
endorphin O 0 0.00012050085933879018
. O 0 1.0309915978723438e-06

While O 0 2.187095014960505e-05
a O 0 2.6321479253965663e-06
few O 0 4.895496203971561e-07
cases O 0 1.2204006907268194e-06
of O 0 0.00013248516188468784
isolated O 0 0.39555439352989197
ACTH B-Disease 1 0.9999871253967285
deficiency I-Disease 1 0.9999997615814209
have O 0 1.3185800526116509e-05
been O 0 1.2322852853685617e-05
reported O 0 9.375939043820836e-06
( O 0 2.608072691145935e-06
OMIM O 0 0.0005242499755695462
201400 O 0 0.00019592317403294146
) O 0 3.887209004460601e-06
, O 0 2.709817636059597e-06
an O 0 1.206919114338234e-05
inherited O 1 0.9999802112579346
POMC O 1 0.9999998807907104
defect O 1 0.9991893172264099
has O 0 4.452568828128278e-05
not O 0 1.4654417554993415e-06
been O 0 3.8294706428132486e-06
described O 0 2.184064214816317e-06
so O 0 2.669893035545101e-07
far O 0 4.4222403516869235e-07
. O 0 4.97295445711643e-07

Recent O 0 2.979151759063825e-05
studies O 0 1.4620978618040681e-05
in O 0 3.501949777273694e-06
animal O 0 2.0509994556050515e-06
models O 0 1.011491349345306e-06
elucidated O 0 1.6608064470347017e-05
a O 0 2.294421847182093e-06
central O 0 3.971112164435908e-06
role O 0 3.879957148456015e-06
of O 0 5.5025582696544006e-05
alpha O 0 0.00012366572627797723
- O 0 3.523722625686787e-05
MSH O 0 0.00018068835197482258
in O 0 2.546971927586128e-06
the O 0 1.6540240039830678e-06
regulation O 0 1.311739424636471e-06
of O 0 3.018986035385751e-06
food O 0 1.6347663631677278e-06
intake O 0 1.1783132549680886e-06
by O 0 8.686677688274358e-08
activation O 0 1.971132860489888e-06
of O 0 1.1880150850629434e-05
the O 0 3.414212187635712e-05
brain O 0 0.0007961827213875949
melanocortin O 0 0.00040174389141611755
- O 0 1.9995210095657967e-05
4 O 0 1.9940083802794106e-05
- O 0 3.1411650525114965e-06
receptor O 0 1.0673113138182089e-05
( O 0 9.48483375395881e-07
MC4 O 0 0.00011479875684017316
- O 0 1.3695885172637645e-05
R O 0 2.9581880880868994e-05
; O 0 6.118355031503597e-07
refs O 0 5.966611297480995e-06
3 O 0 2.562281679274747e-06
- O 0 7.389165261884045e-07
5 O 0 7.320491022255737e-07
) O 0 1.9886838842353427e-08
and O 0 4.5155800876273133e-08
the O 0 5.546614261220384e-07
linkage O 0 8.784563760855235e-06
of O 0 2.087245047732722e-05
human O 0 0.00035029894206672907
obesity B-Disease 1 0.9999998807907104
to O 0 2.222333250756492e-06
chromosome O 0 2.0617640984710306e-05
2 O 0 1.2689003597188275e-05
in O 0 2.247198381155613e-06
close O 0 6.88861609887681e-06
proximity O 0 3.6352366805658676e-06
to O 0 4.898906240669021e-07
the O 0 7.745611583231948e-06
POMC O 0 0.00017364163068123162
locus O 0 2.5527653633616865e-05
, O 0 9.193893788506102e-07
led O 0 1.4996298887126613e-06
to O 0 8.375769766644225e-08
the O 0 5.621606646855071e-07
proposal O 0 7.781904400872008e-07
of O 0 2.4981877686514053e-06
an O 0 1.4397903669305379e-06
association O 0 7.840613761800341e-06
of O 0 9.328554369858466e-06
POMC O 0 0.0019606135319918394
with O 0 2.2817243916506413e-06
human O 0 0.47927722334861755
obesity B-Disease 1 1.0
. O 0 2.4652463253005408e-05

The O 0 8.74519391800277e-05
dual O 0 0.00010316918633179739
role O 0 0.000117816700367257
of O 0 0.0005831787129864097
alpha O 0 0.0007569562876597047
- O 0 0.0001121295863413252
MSH O 0 0.00043501597247086465
in O 0 3.5327761906955857e-06
regulating O 0 2.027072332566604e-05
food O 0 2.4381064577028155e-05
intake O 0 0.00012058603169862181
and O 0 1.0909743650699966e-05
influencing O 0 0.0004975261399522424
hair O 1 0.5130559802055359
pigmentation O 0 0.006346981972455978
predicts O 0 5.023413177696057e-05
that O 0 2.7367605071049184e-07
the O 0 1.3006828112338553e-06
phenotype O 0 5.38458061782876e-06
associated O 0 7.933980441521271e-07
with O 0 1.7717542277750908e-07
a O 0 1.0324800314265303e-05
defect O 0 5.2320574468467385e-05
in O 0 7.430706318700686e-06
POMC O 0 0.0014220514567568898
function O 0 1.5369432730949484e-05
would O 0 5.93792265135562e-07
include O 0 1.0036867024609819e-05
obesity B-Disease 1 1.0
, O 0 6.141385711089242e-06
alteration O 0 0.0009042842430062592
in O 0 0.00022356338740792125
pigmentation O 1 0.9999948740005493
and O 1 0.9147053360939026
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
. O 0 2.821302587108221e-05

The O 0 0.00012659681669902056
observation O 0 0.0008315574959851801
of O 0 9.005476749734953e-05
these O 0 6.4638447838660795e-06
symptoms O 0 0.003771708346903324
in O 0 4.5267221139511093e-05
two O 0 4.564355094771599e-06
probands O 0 0.00011971107596764341
prompted O 0 1.7370260820825933e-06
us O 0 1.0654269289034346e-07
to O 0 1.0234484371096642e-08
search O 0 9.302252124143706e-08
for O 0 8.861487543754265e-08
mutations O 0 6.032173587300349e-07
within O 0 1.2002969924651552e-06
their O 0 2.3637060166947776e-06
POMC O 0 0.000978067982941866
genes O 0 1.0215838301519398e-05
. O 0 4.200172497803578e-06

Patient O 0 0.003305697813630104
1 O 0 0.00046973800635896623
was O 0 0.0001111096134991385
found O 0 1.533610657133977e-06
to O 0 1.7271369756599597e-07
be O 0 4.660658134980622e-07
a O 0 3.0347036954481155e-06
compound O 0 2.1993117115925997e-05
heterozygote O 0 6.2835774770064745e-06
for O 0 6.621855277444411e-07
two O 0 6.414910558305564e-07
mutations O 0 1.1768354397645453e-06
in O 0 7.97899247118039e-06
exon O 0 1.637606692383997e-05
3 O 0 4.718075433629565e-05
( O 0 4.575001185003202e-06
G7013T O 0 8.482898556394503e-05
, O 0 4.648703907150775e-06
C7133delta O 0 4.883085784967989e-05
) O 0 2.0358193353331444e-07
which O 0 5.176259776362713e-08
interfere O 0 9.625274799418548e-08
with O 0 2.450933145325962e-08
appropriate O 0 3.148583118672832e-07
synthesis O 0 1.2454227544367313e-05
of O 0 2.9386432288447395e-05
ACTH O 0 0.000519357156008482
and O 0 2.5637660655775107e-05
alpha O 0 0.0004089927824679762
- O 0 0.00014885848213452846
MSH O 0 0.0009083658806048334
. O 0 2.8057004328729818e-06

Patient O 0 0.0009658861090429127
2 O 0 0.00011108778562629595
was O 0 2.7857684472110122e-05
homozygous O 0 1.850239755185612e-06
for O 0 4.1394565641894587e-07
a O 0 7.9755989190744e-07
mutation O 0 2.7064683649768995e-07
in O 0 1.8323936501474236e-06
exon O 0 7.5552338785200845e-06
2 O 0 1.811046604416333e-05
( O 0 1.1665197234833613e-06
C3804A O 0 2.0215395124978386e-05
) O 0 3.3745749306035577e-07
which O 0 5.075575586488412e-07
abolishes O 0 0.00010224748257314786
POMC O 0 0.001302071730606258
translation O 0 8.58918865560554e-05
. O 0 4.0433028516417835e-06

These O 0 1.4578210993931862e-06
findings O 0 1.1812161346824723e-06
represent O 0 3.744958689821942e-07
the O 0 1.6085519405351079e-07
first O 0 1.5791584928592783e-07
examples O 0 3.9786826278032095e-07
of O 0 2.09880431611964e-06
a O 0 4.7800243919482455e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
within O 0 1.2465633517422248e-05
the O 0 2.3669614165555686e-05
POMC O 0 0.0033216350711882114
gene O 0 2.6239872568112332e-06
and O 0 1.8680570690321474e-07
define O 0 8.432094205090834e-07
a O 0 2.1286944047460565e-06
new O 0 1.2994803910260089e-05
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9962158799171448
resulting O 0 2.1098258002894e-06
in O 0 5.241573148850875e-07
early O 0 1.924125535879284e-05
- O 0 0.24269868433475494
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9842096567153931
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9913282990455627
red O 1 0.9999746084213257
hair O 1 0.9999903440475464
pigmentation O 1 0.9999957084655762
. O 0 9.452179256186355e-06
. O 0 3.181736701662885e-06

A O 0 3.132844722131267e-05
European O 0 1.7129252228187397e-05
multicenter O 0 0.0004761129093822092
study O 0 3.560086770448834e-05
of O 0 0.15561412274837494
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.192108826828189e-05
classification O 0 5.249570313026197e-05
of O 0 4.614300996763632e-05
105 O 0 0.00011022212856914848
mutations O 0 8.974307093012612e-07
and O 0 7.85991289831145e-07
a O 0 1.6637153521514847e-06
general O 0 2.9899038054281846e-06
system O 0 8.890909839465166e-07
for O 0 1.3650404184772924e-07
genotype O 0 2.7404767024563625e-06
- O 0 2.8760757686541183e-06
based O 0 6.145119755274209e-07
prediction O 0 2.551219949964434e-05
of O 0 1.883205186459236e-05
metabolic O 1 0.6448550820350647
phenotype O 0 0.00022928908583708107
. O 0 6.042702807462774e-06

Phenylketonuria B-Disease 1 0.9998290538787842
( O 0 0.0005545824533328414
PKU B-Disease 1 0.9626495242118835
) O 0 2.2667421944788657e-05
and O 0 4.319932122598402e-05
mild B-Disease 1 1.0
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9999997615814209
MHP B-Disease 1 1.0
) O 0 1.730335316096898e-05
are O 0 9.409263839188498e-07
allelic B-Disease 1 0.8661814332008362
disorders I-Disease 1 0.9999998807907104
caused O 0 2.1843081412953325e-05
by O 0 4.35322284886297e-08
mutations O 0 8.026802333915839e-08
in O 0 2.949764166260138e-07
the O 0 1.251673097613093e-06
gene O 0 5.9563549257291015e-06
encoding O 0 3.167926479363814e-05
phenylalanine O 0 0.0014206869527697563
hydroxylase O 0 0.001473895157687366
( O 0 3.866527185891755e-05
PAH O 1 0.9997919201850891
) O 0 1.1321799320285209e-05
. O 0 4.1137482185149565e-06

Previous O 0 6.535142892971635e-05
studies O 0 3.984226168540772e-06
have O 0 1.2201208221540583e-07
suggested O 0 2.267183774051773e-08
that O 0 9.012417478970747e-10
the O 0 1.788113657141821e-08
highly O 0 4.671823319313262e-07
variable O 0 2.1405183360911906e-05
metabolic O 1 0.5167862176895142
phenotypes O 0 0.00031010512611828744
of O 1 0.5809456706047058
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.004281201399862766
with O 0 0.00018777986406348646
PAH O 1 1.0
genotypes O 1 0.9983037710189819
. O 0 2.4059479983407073e-05

We O 0 3.622046278906055e-05
identified O 0 4.654249096347485e-06
both O 0 1.7830751630754094e-06
causative O 0 3.637508416431956e-05
mutations O 0 4.573797014018055e-06
in O 0 4.515857654041611e-06
686 O 0 6.166407547425479e-05
patients O 0 9.207985272041697e-07
from O 0 1.4599094129152945e-06
seven O 0 2.1012535853515146e-06
European O 0 1.0365141861257143e-05
centers O 0 2.5781408112379722e-05
. O 0 3.0600801892433083e-06

On O 0 1.4782957805437036e-05
the O 0 4.7526310709145037e-07
basis O 0 5.788363068859326e-07
of O 0 9.601636747902376e-07
the O 0 8.366929478142993e-07
phenotypic O 0 2.0807619875995442e-05
characteristics O 0 3.206056135240942e-05
of O 0 0.00012794131180271506
297 O 0 0.00026863443781621754
functionally O 0 0.0002742028154898435
hemizygous O 0 0.0002479422546457499
patients O 0 5.137906555319205e-06
, O 0 7.106124826350424e-07
105 O 0 8.514018190908246e-06
of O 0 4.884341706201667e-06
the O 0 3.692109658004483e-06
mutations O 0 4.3406620875430235e-07
were O 0 9.475558044869103e-07
assigned O 0 1.6931286950239155e-07
to O 0 3.660415259787442e-08
one O 0 7.205203900184642e-08
of O 0 3.6413567272575165e-07
four O 0 8.82256188106112e-07
arbitrary O 0 1.4083021596889012e-05
phenotype O 0 4.185055513517e-05
categories O 0 2.2073907530284487e-05
. O 0 2.5042036213562824e-06

We O 0 5.0759401347022504e-05
proposed O 0 8.978408914117608e-06
and O 0 2.0948689325450687e-06
tested O 0 3.4287998005311238e-06
a O 0 5.341071300790645e-07
simple O 0 3.753894475266861e-07
model O 0 1.7199835156134213e-07
for O 0 3.10013774651452e-08
correlation O 0 6.728573112013692e-07
between O 0 6.68994516672683e-07
genotype O 0 2.650222540978575e-06
and O 0 2.52176533876991e-07
phenotypic O 0 2.4171871700673364e-05
outcome O 0 2.0598536139004864e-05
. O 0 2.8406579986040015e-06

The O 0 3.1604642572347075e-05
observed O 0 4.870640259468928e-05
phenotype O 0 4.5873443013988435e-05
matched O 0 1.3740588656219188e-05
the O 0 1.005901322059799e-05
predicted O 0 2.4368979211430997e-05
phenotype O 0 7.780845407978632e-06
in O 0 5.357218924473273e-06
79 O 0 3.19737009704113e-05
% O 0 1.9865283320541494e-06
of O 0 1.1940760487050284e-05
the O 0 1.3344003491511103e-05
cases O 0 4.684936811827356e-06
, O 0 1.3014371234021382e-06
and O 0 5.63555715871189e-07
in O 0 1.065804440258944e-06
only O 0 5.203774549045193e-07
5 O 0 1.9139802134304773e-06
of O 0 2.726095772231929e-06
184 O 0 1.5483783499803394e-05
patients O 0 3.743558863789076e-06
was O 0 2.454069363011513e-05
the O 0 4.941365205013426e-06
observed O 0 1.289469946641475e-05
phenotype O 0 5.2023779062437825e-06
more O 0 1.5026274979845766e-07
than O 0 1.3322879510724306e-07
one O 0 2.977882047616731e-07
category O 0 2.5158396965707652e-06
away O 0 3.244139747948793e-07
from O 0 1.5303889711049123e-07
that O 0 6.353308634743371e-08
expected O 0 2.277135536132846e-06
. O 0 1.547338001728349e-06

Among O 0 3.093950363108888e-05
the O 0 9.8840891951113e-06
seven O 0 3.443602281549829e-06
contributing O 0 4.732369234261569e-06
centers O 0 2.3980730929906713e-06
, O 0 6.123181606199068e-08
the O 0 6.431056931432977e-08
proportion O 0 3.4948192251249566e-07
of O 0 2.125858372892253e-06
patients O 0 2.1577404822892277e-06
for O 0 1.7716879483486991e-06
whom O 0 2.9447792257997207e-06
the O 0 4.78496667710715e-06
observed O 0 1.329920814896468e-05
phenotype O 0 1.3900128578825388e-05
did O 0 1.1056749826821033e-06
not O 0 1.768155470927013e-07
match O 0 3.686213176479214e-06
the O 0 3.0922535643185256e-06
predicted O 0 5.3048379413667135e-06
phenotype O 0 2.230635573141626e-06
was O 0 9.333670277555939e-06
4 O 0 2.167388402085635e-06
% O 0 2.5184536411870795e-07
- O 0 8.127886985676014e-07
23 O 0 1.3163437870389316e-05
% O 0 3.5238829241279745e-06
( O 0 3.5396726616454544e-06
P O 0 0.0011119245318695903
< O 0 9.911453526001424e-05
. O 0 2.2881110908201663e-06
0001 O 0 0.00022205444111023098
) O 0 2.4058584813246853e-07
, O 0 2.6108963879778457e-08
suggesting O 0 2.6943199671336515e-08
that O 0 2.802674092805546e-09
differences O 0 1.1673087385588587e-08
in O 0 1.1433414925932084e-07
methods O 0 2.0189385452340503e-07
used O 0 2.513342849397304e-07
for O 0 2.896315720590792e-07
mutation O 0 1.2744825653498992e-05
detection O 0 6.201145879458636e-05
or O 0 1.973094549612142e-05
phenotype O 0 0.00011518639075802639
classification O 0 2.1424382794066332e-05
may O 0 5.849097988175345e-07
account O 0 2.6028018851320667e-08
for O 0 2.6505153627454092e-08
a O 0 6.518229866969705e-08
considerable O 0 3.3247863484575646e-07
proportion O 0 4.885548150923569e-06
of O 0 5.496710946317762e-05
genotype O 0 0.0004647881432902068
- O 0 0.0020287141669541597
phenotype O 0 0.0002194807311752811
inconsistencies O 0 5.136348772794008e-05
. O 0 3.476732672424987e-06

Our O 0 8.028520096559078e-05
data O 0 2.4717555788811296e-05
indicate O 0 1.9248009266448207e-05
that O 0 2.439056743241963e-06
the O 0 8.202367462217808e-05
PAH O 1 0.9998217225074768
- O 0 0.00010207086597802117
mutation O 0 1.2231353139213752e-06
genotype O 0 1.3002139667150914e-06
is O 0 6.198149549163645e-08
the O 0 9.262912215035612e-08
main O 0 2.2393062408809783e-06
determinant O 0 1.3717805813939776e-05
of O 0 4.6818504415568896e-06
metabolic O 1 0.9248965382575989
phenotype O 0 7.875025403336622e-06
in O 0 6.408869239749038e-07
most O 0 4.0892490460464614e-07
patients O 0 7.320481017814018e-06
with O 0 2.2272504793363623e-05
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00024410920741502196

In O 0 2.6217405320494436e-05
the O 0 3.0289643291325774e-06
present O 0 5.907551212658291e-07
study O 0 6.942829031686415e-07
, O 0 1.8855942585105367e-07
the O 0 3.3414173117307655e-07
classification O 0 5.93557797401445e-06
of O 0 4.90618622279726e-05
105 O 0 0.0015927129425108433
PAH O 1 0.9993595480918884
mutations O 0 1.0049309821624774e-05
may O 0 7.241690582304727e-06
allow O 0 2.5659124958110624e-07
the O 0 1.3943910062153009e-06
prediction O 0 1.22806759463856e-05
of O 0 4.766702659253497e-06
the O 0 8.006479220057372e-06
biochemical O 0 8.439322118647397e-05
phenotype O 0 2.13832754525356e-05
in O 0 1.2707506357401144e-05
> O 0 2.208203477493953e-05
10 O 0 6.579951786989113e-06
, O 0 1.1360444887031917e-06
000 O 0 9.99158055492444e-06
genotypes O 0 1.3386676982918289e-05
, O 0 1.2496549288698588e-06
which O 0 2.3240166058258183e-07
may O 0 5.34389926087897e-07
be O 0 4.581296053629558e-08
useful O 0 9.279215618107628e-08
for O 0 1.0436386332912662e-07
the O 0 1.2289909818719025e-06
management O 0 5.833967406942975e-06
of O 0 1.709783828118816e-05
hyperphenylalaninemia B-Disease 1 0.9999994039535522
in O 0 4.636319863493554e-05
newborns O 0 0.00018701315275393426
. O 0 7.725147042947356e-06

Somatic O 0 0.001230573863722384
instability O 0 0.00062657828675583
of O 0 0.00013488261902239174
the O 0 8.160487050190568e-05
CTG O 0 0.0010664896108210087
repeat O 0 2.8059952455805615e-05
in O 0 1.4059980458114296e-05
mice O 0 2.808254248520825e-05
transgenic O 0 1.9136688933940604e-05
for O 0 1.0286668839398772e-05
the O 0 0.0010977874044328928
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.00021123382612131536
is O 0 6.014531663822709e-06
age O 0 4.73847967441543e-06
dependent O 0 9.303669230575906e-07
but O 0 2.8382125094594812e-08
not O 0 1.1764798024671563e-08
correlated O 0 1.8044978844500292e-07
to O 0 1.60415769556721e-08
the O 0 1.7848942945875024e-07
relative O 0 9.542533007333986e-06
intertissue O 0 8.092140342341736e-05
transcription O 0 7.141124660847709e-05
levels O 0 1.7669430235400796e-05
and O 0 5.736497769248672e-06
proliferative O 0 0.02033204585313797
capacities O 0 0.0008521897252649069
. O 0 2.0712015611934476e-05

A O 0 0.003967712167650461
( O 0 6.010872311890125e-05
CTG O 0 0.0006564829382114112
) O 0 3.128936668872484e-06
nexpansion O 0 4.788514706888236e-05
in O 0 4.182537395536201e-06
the O 0 5.443108420877252e-06
3 O 0 1.2996662917430513e-05
- O 0 9.469304131926037e-06
untranslated O 0 6.863498856546357e-05
region O 0 6.977996235946193e-06
( O 0 1.0393314369139262e-06
UTR O 0 7.01180033502169e-05
) O 0 3.6482461496234464e-07
of O 0 6.341520020214375e-06
the O 0 4.970718873664737e-05
DM O 1 0.9999998807907104
protein O 0 0.000228211865760386
kinase O 0 0.00010314411338185892
gene O 0 4.519536560110282e-06
( O 0 1.0002411272580503e-06
DMPK O 0 2.9422048100968823e-05
) O 0 8.519295846554087e-08
is O 0 3.6294089511557104e-08
responsible O 0 4.824095753974689e-07
for O 0 4.1874263843055815e-06
causing O 1 0.9999673366546631
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0004088035202585161
DM B-Disease 1 1.0
) O 0 1.2513099136413075e-05
. O 0 3.536835038175923e-06

Major O 0 0.26743191480636597
instability O 0 0.009133625775575638
, O 0 1.2362635970930569e-05
with O 0 3.74596226038193e-07
very O 0 4.042594525799359e-07
large O 0 3.9817268771003e-07
expansions O 0 1.6036549368436681e-06
between O 0 7.966431212480529e-07
generations O 0 4.061049594383803e-07
and O 0 2.47909156314563e-07
high O 0 1.4294319953478407e-05
levels O 0 4.857408384850714e-06
of O 0 1.746610905684065e-05
somatic O 0 0.00020803199731744826
mosaicism O 0 0.0005553039372898638
, O 0 3.3692398915263766e-07
is O 0 5.39136699728715e-08
observed O 0 2.2383743214504648e-07
in O 0 2.1682865281036356e-07
patients O 0 6.174751092657971e-07
. O 0 1.0054400263470598e-06

There O 0 7.065651880111545e-05
is O 0 7.848168934287969e-06
a O 0 3.4962502013513586e-06
good O 0 2.202626319558476e-06
correlation O 0 4.870596512773773e-06
between O 0 7.43184727980406e-06
repeat O 0 1.2094333214918151e-05
size O 0 5.7041961554205045e-06
( O 0 1.1802286508100224e-06
at O 0 4.657179943023948e-06
least O 0 1.7157960030544928e-07
in O 0 1.255314259651641e-06
leucocytes O 0 4.4573105697054416e-05
) O 0 2.3074289856594987e-07
, O 0 6.523578122141771e-08
clinical O 0 4.12329654864152e-06
severity O 0 1.4481061043625232e-05
and O 0 1.440927690055105e-06
age O 0 2.5169360014842823e-05
of O 0 3.9575734263053164e-05
onset O 1 0.9994499087333679
. O 0 3.2301195460604504e-05

The O 0 0.00025370364892296493
trinucleotide O 0 0.0033898092806339264
repeat O 0 0.0003247601562179625
instability O 0 0.00025194589397870004
mechanisms O 0 4.612356497091241e-05
involved O 0 6.379935712175211e-06
in O 0 4.100822116015479e-05
DM B-Disease 1 1.0
and O 0 9.924591722665355e-06
other O 0 2.460707491991343e-06
human O 0 0.04649388790130615
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.423643311682099e-06
unknown O 0 1.3015789591008797e-05
. O 0 1.1144497875648085e-06

We O 0 2.2533278752234764e-05
studied O 0 0.0001384890783810988
somatic O 0 0.0001372738479403779
instability O 0 5.238937956164591e-05
by O 0 1.6314957065333147e-06
measuring O 0 0.00027384827262721956
the O 0 5.4396794439526275e-05
CTG O 0 0.0004658522957470268
repeat O 0 1.1429895494075026e-05
length O 0 6.432132977352012e-06
at O 0 1.4997918697190471e-05
several O 0 1.751603804223123e-07
ages O 0 9.055715395334119e-07
in O 0 4.3266308580314217e-07
various O 0 5.585890789916448e-07
tissues O 0 1.0625371032801922e-05
of O 0 3.438732528593391e-05
transgenic O 0 4.300723958294839e-05
mice O 0 1.5765293937874958e-05
carrying O 0 1.2601824892044533e-05
a O 0 9.199715350405313e-06
( O 0 1.52137999975821e-06
CTG O 0 4.902543150819838e-05
) O 0 4.1942982420550834e-07
55expansion O 0 7.85017527960008e-06
surrounded O 0 4.566039933706634e-06
by O 0 1.916391596523681e-07
45 O 0 3.354809905431466e-06
kb O 0 3.2568812457611784e-05
of O 0 3.648333949968219e-05
the O 0 6.762939301552251e-05
human O 0 0.000873645709361881
DM B-Disease 1 1.0
region O 0 0.00022487535898108035
, O 0 6.160543762234738e-06
using O 0 1.8881939922721358e-06
small O 0 2.5731783352966886e-06
- O 0 1.504067586211022e-05
pool O 0 2.3641980078537017e-05
PCR O 0 2.0951221813447773e-05
. O 0 1.3648989352077479e-06

These O 0 7.724062743363902e-05
mice O 0 6.491292879218236e-05
have O 0 9.081262533072731e-07
been O 0 5.343802058632718e-07
shown O 0 2.286627136527386e-07
to O 0 3.136154802518831e-08
reproduce O 0 9.429352587631001e-08
the O 0 2.5519483415337163e-07
intergenerational O 0 2.349271198909264e-06
and O 0 7.340548222600773e-07
somatic O 0 8.99380938790273e-06
instability O 0 1.5413379514939152e-05
of O 0 3.038224167539738e-05
the O 0 4.5321219658944756e-05
55 O 0 9.466542542213574e-05
CTG O 0 0.00022548790730070323
repeat O 0 7.168574484239798e-06
suggesting O 0 2.7087376111012418e-06
that O 0 1.0276015416366135e-07
surrounding O 0 7.691771202189557e-07
sequences O 0 5.072087105872924e-07
and O 0 7.114919640116568e-07
the O 0 2.1785226635984145e-06
chromatin O 0 1.0249827937514056e-05
environment O 0 1.1787785751948832e-06
are O 0 3.825232397502987e-08
involved O 0 6.352085080152392e-08
in O 0 7.0768209070593e-07
instability O 0 2.4175191356334835e-05
mechanisms O 0 4.382922634249553e-05
. O 0 7.984100193425547e-06

As O 0 2.4577206204412505e-05
observed O 0 7.519020982726943e-06
in O 0 1.3755434338236228e-06
some O 0 1.3895866857183137e-07
of O 0 7.003744485700736e-06
the O 0 2.0224690160830505e-05
tissues O 0 5.912441702093929e-05
of O 0 0.001276745111681521
DM B-Disease 1 1.0
patients O 0 0.0007073726155795157
, O 0 2.4946837129391497e-06
there O 0 4.43452989884463e-07
is O 0 3.4886886624008184e-07
a O 0 2.751774843545718e-07
tendency O 0 6.551784963448881e-07
for O 0 2.586841389984329e-07
repeat O 0 1.103092472476419e-06
length O 0 1.849964519351488e-06
and O 0 2.964051418530289e-06
somatic O 0 2.2919048205949366e-05
mosaicism O 0 4.2461037082830444e-05
to O 0 1.420842181687476e-07
increase O 0 2.0742368178616744e-07
with O 0 1.1786701747951156e-07
the O 0 1.9325952962390147e-06
age O 0 8.123602128762286e-06
of O 0 1.2912457350466866e-05
the O 0 1.4137437574390788e-05
mouse O 0 4.074835669598542e-05
. O 0 3.940922397305258e-06

Furthermore O 0 0.00018956173153128475
, O 0 2.329078370166826e-06
we O 0 1.0377354442425712e-07
observed O 0 2.262244720441231e-07
no O 0 3.0053126209850234e-08
correlation O 0 1.8700855264341953e-07
between O 0 2.990363441313093e-07
the O 0 6.938122965038929e-07
somatic O 0 3.8958710320002865e-06
mutation O 0 5.473625606100541e-07
rate O 0 3.863224264932796e-06
and O 0 1.2155790045653703e-06
tissue O 0 7.452716090483591e-05
proliferation O 0 0.0002087029133690521
capacity O 0 6.004071474308148e-05
. O 0 5.639908522425685e-06

The O 0 0.00026898988289758563
somatic O 0 0.0003423660236876458
mutation O 0 2.0002495148219168e-05
rates O 0 1.0681941603252199e-05
in O 0 1.974003453142359e-06
different O 0 2.0365243358355656e-07
tissues O 0 3.984366685472196e-06
were O 0 2.079248588415794e-06
also O 0 2.1090885127250658e-07
not O 0 4.9099064369784173e-08
correlated O 0 6.258043754314713e-07
to O 0 1.7186718537232082e-07
the O 0 1.7618413039599545e-06
relative O 0 4.315411206334829e-05
inter O 0 0.00010115085751749575
- O 0 1.617897032701876e-05
tissue O 0 4.453641395230079e-06
difference O 0 1.937149363584467e-06
in O 0 1.1818967777799116e-06
transcriptional O 0 7.724050192337018e-06
levels O 0 5.104743650008459e-06
of O 0 8.64094454300357e-06
the O 0 6.48852483209339e-06
three O 0 3.1543195291305892e-06
genes O 0 3.359272795933066e-06
( O 0 4.104637810087297e-06
DMAHP O 0 0.00019661146507132798
, O 0 3.1025419957586564e-06
DMPK O 0 0.00010306701733497903
and O 0 5.956167115073185e-06
59 O 0 3.1177696655504405e-05
) O 0 3.2442045494462945e-07
surrounding O 0 1.898341338346654e-06
the O 0 2.396795025561005e-06
repeat O 0 4.796004759555217e-06
. O 0 4.119549146253121e-07
. O 0 9.263173978979466e-07

A O 0 7.370392268057913e-05
novel O 0 2.0193027012282982e-05
missense O 0 0.00011143652227474377
mutation O 0 4.124216957279714e-06
in O 0 2.656751348695252e-06
patients O 0 2.1951066173642175e-06
from O 0 1.947411192304571e-06
a O 0 3.686332775032497e-06
retinoblastoma B-Disease 0 0.0008953869692049921
pedigree O 0 1.9782137314905412e-05
showing O 0 8.594732207711786e-06
only O 0 5.7733450375963e-07
mild O 0 4.895544407190755e-05
expression O 0 1.5066186279000249e-05
of O 0 1.7818985725170933e-05
the O 0 3.848824417218566e-05
tumor B-Disease 1 0.9787451028823853
phenotype O 0 0.0001380957110086456
. O 0 3.368647185197915e-06

We O 0 2.65802755166078e-05
have O 0 8.557711339562957e-07
used O 0 6.043459279680974e-07
single O 0 6.584946277143899e-07
strand O 0 1.9092058209935203e-06
conformation O 0 1.1415627341193613e-06
polymorphism O 0 2.562102849879011e-07
analysis O 0 6.995187362690558e-08
to O 0 3.9627245485007734e-08
study O 0 2.313735478765011e-07
the O 0 1.171356757367903e-06
27 O 0 2.625936576805543e-05
exons O 0 1.1829029972432181e-05
of O 0 1.900804454635363e-05
the O 0 2.895133184210863e-05
RB1 O 0 0.00034532195422798395
gene O 0 1.9538792912499048e-06
in O 0 5.909562901251775e-07
individuals O 0 5.435247985019487e-08
from O 0 2.3703307761024917e-07
a O 0 3.82618878802532e-07
family O 0 7.323612294385384e-07
showing O 0 1.0553588253969792e-05
mild O 0 0.00015421537682414055
expression O 0 3.484409171505831e-05
of O 0 2.1743258912465535e-05
the O 0 4.236655149725266e-05
retinoblastoma B-Disease 0 0.005882055964320898
phenotype O 0 0.00018702706438489258
. O 0 3.882307282765396e-06

In O 0 0.00012931280070915818
this O 0 3.0316980428324314e-06
family O 0 3.517835466482211e-06
affected O 0 2.1052492229500785e-06
individuals O 0 2.0783039644811652e-07
developed O 0 1.4296870176622178e-05
unilateral B-Disease 0 0.046175405383110046
tumors I-Disease 1 1.0
and O 0 0.00012742691615130752
, O 0 9.106108791456791e-07
as O 0 3.0600372724620684e-07
a O 0 2.8998366019550303e-07
result O 0 7.102025847416371e-07
of O 0 4.196584995952435e-06
linkage O 0 2.9096008802298456e-05
analysis O 0 4.468548922886839e-06
, O 0 1.3314335092218244e-06
unaffected O 0 6.08440177529701e-06
mutation O 0 3.572490356873459e-07
carriers O 0 1.9136813023123977e-07
were O 0 2.6143828790736734e-07
also O 0 1.3067983672954142e-07
identified O 0 1.4398682424143772e-07
within O 0 3.2356706469727214e-07
the O 0 1.7691991160972975e-06
pedigree O 0 2.2308387997327372e-05
. O 0 3.082916236962774e-06

A O 0 0.0003295301285106689
single O 0 2.1160736650926992e-05
band O 0 3.5059580113738775e-05
shift O 0 1.5240260836435482e-05
using O 0 5.40833207196556e-06
SSCP O 0 0.00038770484388805926
was O 0 6.614026642637327e-05
identified O 0 1.2994106555197504e-06
in O 0 1.4628542430727975e-06
exon O 0 2.806802967825206e-06
21 O 0 2.8164909053884912e-06
which O 0 6.863252366429151e-08
resulted O 0 4.870406087320589e-07
in O 0 6.524722948597628e-07
a O 0 1.6719544646548457e-06
missense O 0 1.5266517948475666e-05
mutation O 0 3.382670229257201e-06
converting O 0 2.0650011720135808e-05
a O 0 1.2095221791241784e-05
cys O 0 0.0001389443496009335
- O 0 2.1311794625944458e-05
- O 0 2.3813385269022547e-05
> O 0 1.107102525566006e-05
arg O 0 9.323271115135867e-06
at O 0 1.4852227650408167e-05
nucleotide O 0 3.0379119380086195e-06
position O 0 6.827959623478819e-06
28 O 0 1.6188385416171513e-05
in O 0 2.1797507088194834e-06
the O 0 2.9619350243592635e-06
exon O 0 1.08921658465988e-05
. O 0 1.8563019921202795e-06

The O 0 0.00012256152695044875
mutation O 0 1.914121639856603e-05
destroyed O 0 0.00026537218946032226
an O 0 3.47801938005432e-06
NdeI O 0 0.00019318278646096587
restriction O 0 3.5632794606499374e-05
enzyme O 0 9.209837116941344e-06
site O 0 6.383203981386032e-06
. O 0 1.1427608797021094e-06

Analysis O 0 0.00014628727512899786
of O 0 5.496800076798536e-05
all O 0 5.870691893505864e-06
family O 0 1.4376374792846036e-06
members O 0 1.8975036653046118e-07
demonstrated O 0 2.059890903183259e-06
that O 0 1.245230265567443e-07
the O 0 2.2271642592386343e-06
missense O 0 3.518222729326226e-05
mutation O 0 9.377333299198654e-06
co O 0 5.065480945631862e-05
- O 0 1.7115486116381362e-05
segregated O 0 6.6653842623054516e-06
with O 0 3.6685202076114365e-07
patients O 0 3.06790170725435e-05
with O 0 0.00010093897435581312
tumors B-Disease 1 1.0
or O 1 0.9999871253967285
who O 0 0.00027084583416581154
, O 0 2.273837026223191e-06
as O 0 1.317737769568339e-06
a O 0 1.4853679886073223e-06
result O 0 2.295520516781835e-06
of O 0 1.0602524525893386e-05
linkage O 0 4.059186176164076e-05
analysis O 0 2.9517552775359945e-06
had O 0 6.772091637685662e-06
been O 0 2.5688702862680657e-06
predicted O 0 1.035220293488237e-06
to O 0 1.9224428271513716e-08
carry O 0 8.255168637560928e-08
the O 0 7.169998070821748e-07
predisposing O 0 4.374350464786403e-05
mutation O 0 6.9202546910673846e-06
. O 0 4.031055141240358e-06

These O 0 1.0989009751938283e-05
observations O 0 3.994748476543464e-05
point O 0 1.5294892364181578e-05
to O 0 2.2212178407698957e-07
another O 0 4.7176160933304345e-07
region O 0 9.856103133643046e-07
of O 0 6.201760243129684e-06
the O 0 2.541523463150952e-05
RB1 O 0 0.00037502506165765226
gene O 0 2.1573268895735964e-06
where O 0 1.0880742138397181e-06
mutations O 0 2.0411636114658904e-07
only O 0 1.0566498787056844e-07
modify O 0 1.8416054103909119e-07
the O 0 1.076556259249628e-06
function O 0 7.467184332199395e-06
of O 0 1.0311978257959709e-05
the O 0 9.75655439106049e-06
gene O 0 2.0321313058957458e-06
and O 0 4.0249909716294496e-07
raise O 0 1.585363378353577e-07
important O 0 4.091648122539482e-07
questions O 0 1.1170200053811641e-07
for O 0 1.4045622265257407e-07
genetic O 0 1.504071178715094e-06
counseling O 0 1.504426904830325e-06
in O 0 5.034785317548085e-07
families O 0 5.7934109065627126e-08
with O 0 4.973243861172705e-08
these O 0 2.1124823490481504e-07
distinctive O 0 8.763728146732319e-06
phenotypes O 0 5.4396794439526275e-05
. O 0 8.81946618846996e-07
. O 0 8.038213650252146e-07

Maternal B-Disease 1 0.8276786208152771
disomy I-Disease 1 0.9995647072792053
and O 1 0.6317684650421143
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 1.0
with O 0 3.921361712855287e-05
gamete O 1 0.9998569488525391
complementation O 1 0.9992175102233887
in O 0 7.588022526761051e-06
a O 0 3.223269459340372e-06
case O 0 1.9977433112217113e-06
of O 0 1.1865273336297832e-05
familial O 0 0.00026283031911589205
translocation O 0 0.001136105740442872
( O 0 6.019357897457667e-06
3 O 0 1.0590186320769135e-05
; O 0 2.467227773195191e-07
15 O 0 3.1696738460595952e-06
) O 0 2.593194210476213e-07
( O 0 1.8195183315583563e-07
p25 O 0 9.879047865979373e-06
; O 0 1.742898945167326e-07
q11 O 0 4.2789838516910095e-06
. O 0 2.0489923713284952e-07
2 O 0 5.179028448765166e-06
) O 0 3.725970998402772e-07
. O 0 7.898792091509677e-07

Maternal B-Disease 1 0.999902606010437
uniparental I-Disease 1 0.9999957084655762
disomy I-Disease 1 0.9999836683273315
( I-Disease 0 0.0019059114856645465
UPD I-Disease 1 0.9999998807907104
) I-Disease 0 1.243950828211382e-05
for I-Disease 0 7.875852134020533e-06
chromosome I-Disease 0 0.00027966382913291454
15 I-Disease 0 7.92408172856085e-05
is O 0 1.7019254983097198e-06
responsible O 0 5.920518333368818e-07
for O 0 7.122781653379207e-08
an O 0 3.079252408610955e-08
estimated O 0 3.5768771056154947e-08
30 O 0 4.747104753732856e-08
% O 0 1.0523934612649555e-08
of O 0 2.6318659251955978e-08
cases O 0 1.551316870518349e-07
of O 0 0.00023443425016012043
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999973773956299
PWS B-Disease 1 1.0
) O 0 1.750115552567877e-05
. O 0 2.907170937760384e-06

We O 0 6.506477075163275e-05
report O 0 4.633010576071683e-06
on O 0 2.9476902909664204e-06
an O 0 1.826273887672869e-07
unusual O 0 4.96312850373215e-07
case O 0 1.7992172161029885e-06
of O 0 1.8606231606099755e-05
maternal B-Disease 0 0.16004715859889984
disomy I-Disease 1 0.970554769039154
15 I-Disease 0 0.005322727374732494
in O 0 0.0028520526830106974
PWS B-Disease 1 1.0
that O 0 1.298103052249644e-05
is O 0 2.7813825909106527e-06
most O 0 2.3035593699205492e-07
consistent O 0 8.553941484024108e-07
with O 0 9.131453282407165e-08
adjacent O 0 6.4418754845974036e-06
- O 0 2.801110213113134e-06
1 O 0 1.3532167940866202e-05
segregation O 0 5.309357675287174e-06
of O 0 4.67951122118393e-06
a O 0 9.360339390696026e-06
paternal O 0 0.0002718771283980459
t O 0 6.19202692178078e-05
( O 0 7.07744163719326e-07
3 O 0 2.3983225219126325e-06
; O 0 1.1655605902660682e-07
15 O 0 1.929405698319897e-06
) O 0 2.5547709014972497e-07
( O 0 2.3520460956660827e-07
p25 O 0 1.356969733024016e-05
; O 0 1.8988504280059715e-07
q11 O 0 3.6600986277335323e-06
. O 0 6.731442425689238e-08
2 O 0 5.526487143470149e-07
) O 0 7.869309648356193e-09
with O 0 3.39471761812149e-09
simultaneous O 0 2.524267983972095e-06
maternal O 0 0.0004587906878441572
meiotic O 0 0.002428026171401143
nondisjunction O 0 0.001121217617765069
for O 0 6.332213615678484e-06
chromosome O 0 0.00018803373677656054
15 O 0 5.2927185606677085e-05
. O 0 3.685351884996635e-06

The O 0 0.0001852490531746298
patient O 0 0.00010893409489654005
( O 0 1.154374513134826e-05
J O 0 0.0008675295393913984
. O 0 1.928110805238248e-06
B O 0 2.252236481581349e-05
. O 0 1.703674712416614e-07
) O 0 7.431994220041815e-08
, O 0 9.801833300571161e-08
a O 0 1.2436178167263279e-06
17 O 0 1.5311763490899466e-05
- O 0 8.674374839756638e-06
year O 0 1.8461701984051615e-05
- O 0 3.709787051775493e-05
old O 0 0.00016707790200598538
white O 0 1.3136726010998245e-05
male O 0 2.7430749469203874e-05
with O 0 1.3962879165774211e-05
PWS B-Disease 1 1.0
, O 0 2.7341771783540025e-05
was O 0 5.5185126257129014e-05
found O 0 5.940641472079733e-07
to O 0 1.4709188178585464e-07
have O 0 8.93377205102297e-07
47 O 0 2.0387513359310105e-05
chromosomes O 0 1.0013129212893546e-05
with O 0 3.489611344775767e-06
a O 0 9.543866326566786e-05
supernumerary O 0 0.0697648897767067
, O 0 1.3912024769524578e-05
paternal O 0 0.00022212091425899416
der O 0 0.0014218227006495
( O 0 1.3068721500530955e-06
15 O 0 2.2965584776102332e-06
) O 0 7.195370699264458e-08
consisting O 0 2.4987593860714696e-07
of O 0 1.2038177374051884e-05
the O 0 3.2854153687367216e-05
short O 0 8.374801109312102e-05
arm O 0 0.000288080278551206
and O 0 1.5108284969755914e-05
the O 0 5.4144860769156367e-05
proximal O 0 0.001650568563491106
long O 0 9.356897498946637e-05
arm O 0 5.930793849984184e-05
of O 0 2.8505950467661023e-05
chromosome O 0 0.00013253962970338762
15 O 0 6.459460564656183e-05
, O 0 2.4275443593069213e-06
and O 0 3.5970297176390886e-06
distal O 0 0.001257829717360437
chromosome O 1 0.6510089039802551
arm O 0 0.10249003022909164
3p O 0 0.18020451068878174
. O 0 1.2556360161397606e-05

The O 0 0.0014585810713469982
t O 0 0.0004137641517445445
( O 0 4.652793904824648e-06
3 O 0 7.528312835347606e-06
; O 0 3.3384390007995535e-07
15 O 0 2.2982585505815223e-06
) O 0 1.2921552183797758e-07
was O 0 1.3446199318423169e-06
present O 0 1.8416967861867306e-07
in O 0 2.248760182510523e-07
the O 0 3.1590647608936706e-07
balanced O 0 3.0356682145793457e-07
state O 0 1.4092232447637798e-07
in O 0 4.1577195020181534e-07
the O 0 1.2994552207601373e-06
patients O 0 1.603398118277255e-06
father O 0 1.321019408351276e-05
and O 0 2.0034553926961962e-06
a O 0 1.2223294106661342e-05
sister O 0 0.0001386976073263213
. O 0 9.502991815679707e-06

Fluorescent O 0 0.0003895199333783239
in O 0 1.861963392002508e-05
situ O 0 6.262074020924047e-05
hybridization O 0 1.5782145510456758e-06
analysis O 0 1.484385165895219e-06
demonstrated O 0 6.958764970477205e-06
that O 0 1.0169841289098258e-06
the O 0 2.5696352167869918e-05
PWS B-Disease 1 0.9999985694885254
critical O 0 0.00010338841821067035
region O 0 1.8082695532939397e-05
resided O 0 6.260426744120196e-05
on O 0 3.162100983900018e-05
the O 0 1.1983127478742972e-05
derivative O 0 5.239367237663828e-05
chromosome O 0 2.4565561034251004e-05
3 O 0 1.2311951650190167e-05
and O 0 4.3531153437470493e-07
that O 0 9.702358738650219e-08
there O 0 2.442566255922429e-07
was O 0 3.4571655760373687e-06
no O 0 3.8997600881884864e-07
deletion O 0 3.306589860585518e-06
of O 0 2.169950857933145e-05
the O 0 5.453599078464322e-05
PWS B-Disease 1 0.9999996423721313
region O 0 1.6134994439198636e-05
on O 0 3.804102016147226e-05
the O 0 1.1060419637942687e-05
normal O 0 2.4470047719660215e-05
pair O 0 5.6694980230531655e-06
of O 0 8.442968464805745e-06
15s O 0 4.4894924940308556e-05
present O 0 4.109165274712723e-06
in O 0 1.959645487659145e-05
J O 0 0.0028954411391168833
. O 0 8.16548981674714e-06

B O 0 0.018163254484534264
. O 0 7.061718497425318e-05

Methylation O 0 0.00038772885454818606
analysis O 0 3.353543070261367e-05
at O 0 8.495738438796252e-05
exon O 0 1.0536634363234043e-05
alpha O 0 1.8566101061878726e-05
of O 0 6.942424988665152e-06
the O 0 5.647874331771163e-06
small O 0 4.03585227104486e-06
nuclear O 0 6.630901043536142e-05
ribonucleoprotein O 0 0.0005312145804055035
- O 0 3.3472198992967606e-05
associated O 0 2.5312170691904612e-05
polypeptide O 0 0.00014243295299820602
N O 0 0.0001622163108550012
( O 0 1.7903578282130184e-06
SNRPN O 0 6.221450166776776e-05
) O 0 4.802096214007179e-07
gene O 0 1.0465344075782923e-06
showed O 0 4.721360710391309e-06
a O 0 1.5684333902754588e-06
pattern O 0 6.945206678210525e-06
characteristic O 0 3.731522156158462e-06
of O 0 3.849455424642656e-06
only O 0 1.8125629708265478e-07
the O 0 8.529520414413128e-07
maternal O 0 6.11855139140971e-05
chromosome O 0 7.670363265788183e-05
15 O 0 3.924328848370351e-05
in O 0 2.8080050469725393e-05
J O 0 0.0586465485394001
. O 0 1.24651469377568e-05

B O 0 0.01552935317158699
. O 0 8.977610559668392e-05

Maternal B-Disease 0 0.07545328885316849
disomy I-Disease 0 0.007342349737882614
was O 0 9.877590491669253e-05
confirmed O 0 2.223711135229678e-06
by O 0 1.300346212929071e-07
polymerase O 0 9.480399057792965e-06
chain O 0 2.8188019314256962e-06
reaction O 0 4.0123936173586117e-07
analysis O 0 1.788567800531382e-07
of O 0 2.9136378998373402e-06
microsatellite O 0 2.0407331248861738e-05
repeats O 0 1.724710818962194e-05
at O 0 5.441335088107735e-05
the O 0 1.0215108886768576e-05
gamma O 0 3.79246412194334e-05
- O 0 1.972261452465318e-05
aminobutyric O 0 0.00010830743849510327
acid O 0 5.7646807363198604e-06
receptor O 0 1.7727083104546182e-05
beta3 O 0 7.458509207936004e-05
subunit O 0 9.919501280819532e-06
( O 0 2.17616570807877e-06
GABRB3 O 0 0.0001558891381137073
) O 0 1.4712318261445034e-06
locus O 0 2.8507987735792994e-05
. O 0 3.3803482892835746e-06

A O 0 0.004024486523121595
niece O 0 0.006561246234923601
( O 0 4.98344779771287e-05
B O 0 0.00022203389380592853
. O 0 1.1251084970353986e-06
B O 0 1.2701993000518996e-05
. O 0 8.969809783820892e-08
) O 0 2.1114587411830144e-08
with O 0 5.2243958492681486e-08
45 O 0 3.217510993636097e-06
chromosomes O 0 2.1402606762421783e-06
and O 0 1.7558295439812355e-06
the O 0 7.201272637757938e-06
derivative O 0 4.526998600340448e-05
3 O 0 1.030917792377295e-05
but O 0 3.152642307213682e-07
without O 0 6.004743795529066e-07
the O 0 3.953642135456903e-06
der O 0 0.00023119563411455601
( O 0 1.0056749033537926e-06
15 O 0 2.8702559120574733e-06
) O 0 4.0125578948391194e-07
demonstrated O 0 2.374193172727246e-06
a O 0 1.2072712252120255e-06
phenotype O 0 4.6031018428038806e-06
consistent O 0 1.3321321148396237e-06
with O 0 3.6094370159389655e-08
that O 0 5.99576495119436e-08
reported O 0 6.425515266528237e-07
for O 0 4.328174441070587e-07
haploinsufficiency O 0 3.839578857878223e-05
of O 0 4.6017070417292416e-05
distal O 0 0.0027189324609935284
3 O 0 0.0016422776971012354
p O 0 0.006041406188160181
. O 0 7.331205779337324e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999998807907104
associated O 0 0.0005397905479185283
with O 0 1.0623760317685083e-05
unbalanced O 0 0.004329980816692114
segregation O 0 0.00027208845131099224
of O 0 0.00018030904175247997
non O 0 0.0013829191448166966
- O 0 0.0004333418037276715
Robertsonian O 0 0.005074000917375088
translocations O 0 0.0003345412842463702
has O 0 5.062549826106988e-05
been O 0 2.8736423701047897e-05
reported O 0 1.6807354768388905e-05
previously O 0 1.5090601664269343e-05
but O 0 6.510234697998385e-07
has O 0 8.507529400958447e-07
not O 0 2.0009738932458276e-07
, O 0 1.0817220896797153e-07
to O 0 7.217747821641751e-08
our O 0 4.898466841041227e-07
knowledge O 0 2.021428826992633e-06
, O 0 1.9898833159004425e-07
been O 0 1.3137685073161265e-07
observed O 0 2.0713309822895098e-07
in O 0 1.7094426141284202e-07
a O 0 6.52761741548602e-07
case O 0 2.2472904674941674e-06
of O 0 4.606009679264389e-05
PWS B-Disease 1 1.0
. O 0 4.348683432908729e-05

Furthermore O 0 0.0016216833610087633
, O 0 1.4931815712770913e-05
our O 0 1.7924251096701482e-06
findings O 0 1.0184710390603868e-06
are O 0 4.577749379564011e-08
best O 0 6.532842178330611e-08
interpreted O 0 2.2441027169861627e-07
as O 0 8.121481442913137e-08
true O 0 4.3309449893058627e-07
gamete O 0 2.5023868147400208e-05
complementation O 0 9.802647400647402e-05
resulting O 0 4.020274900540244e-06
in O 0 7.247459961945424e-06
maternal B-Disease 1 0.9957886338233948
UPD I-Disease 1 1.0
15 I-Disease 0 0.03474507853388786
and O 0 0.00099840946495533
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.999504804611206
- I-Disease 1 0.9999971389770508
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 1 0.9138404726982117
2 I-Disease 0 0.09030190855264664
and O 0 0.00016767383203841746
Stuve B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 2.9886664378864225e-06
a O 0 9.244076863978989e-07
case O 0 4.7003800318634603e-07
for O 0 2.8665036211350525e-07
" O 0 2.950491534647881e-06
lumping O 0 6.0348070292093325e-06
" O 0 8.566549695387948e-06
. O 0 1.509028152213432e-06

Recent O 0 2.6575358788250014e-05
studies O 0 1.1783115041907877e-05
demonstrated O 0 1.917849112942349e-05
the O 0 2.6530042305239476e-06
existence O 0 2.1605305846605916e-06
of O 0 3.218493020540336e-06
a O 0 2.7606724870565813e-06
genetically O 0 8.159846629496315e-07
distinct O 0 1.9889195357336575e-07
, O 0 7.211858843447772e-08
usually O 0 2.464254933443044e-08
lethal O 0 1.1584660342123243e-07
form O 0 1.0301389608002864e-07
of O 0 2.8690956241916865e-06
the O 0 2.7139942176290788e-05
Schwartz B-Disease 1 0.9423467516899109
- I-Disease 1 0.9999997615814209
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00011991946666967124
SJS B-Disease 1 0.9999737739562988
) O 0 2.171520100091584e-05
of O 0 0.002066944958642125
myotonia B-Disease 1 1.0
and O 1 0.9999945163726807
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 7.788900984451175e-05
which O 0 4.571245881379582e-06
we O 0 9.64705122896703e-07
called O 0 1.0608036973280832e-05
SJS B-Disease 0 0.004898357670754194
type I-Disease 0 4.045213427161798e-05
2 I-Disease 0 5.4470972827402875e-05
. O 0 2.31085641644313e-06

This O 0 5.713902646675706e-05
disorder O 1 0.9987961053848267
is O 0 6.473283065133728e-06
reminiscent O 0 1.3161617971491069e-05
of O 0 2.168217406506301e-06
another O 0 8.376367190976453e-07
rare O 0 4.982048722013133e-06
condition O 0 0.00041242598672397435
, O 0 3.073068000958301e-06
the O 0 3.8305930502247065e-05
Stuve B-Disease 1 0.999964714050293
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.06417976319789886
SWS B-Disease 1 0.999994158744812
) O 0 2.672695472938358e-06
, O 0 3.569547857296129e-07
which O 0 3.9472536172979744e-07
comprises O 0 1.1397828529879916e-05
campomelia B-Disease 1 0.5743047595024109
at O 1 0.9812600612640381
birth O 1 0.9988369345664978
with O 0 0.0004170703759882599
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 0.0008253433043137193
contractures B-Disease 1 0.9999170303344727
, O 0 1.751127228999394e-06
and O 0 3.5659240893437527e-07
early B-Disease 0 1.2290834092709702e-05
death I-Disease 0 0.00018267026462126523
. O 0 3.3922065085789654e-06

To O 0 8.194117981474847e-06
test O 0 3.0579242320527555e-06
for O 0 1.3348434322324465e-06
possible O 0 4.6743284656258766e-06
nosologic O 0 0.00040395514224655926
identity O 0 3.4577194583107485e-06
between O 0 1.0113252756127622e-05
these O 0 4.134085429541301e-06
disorders O 1 0.884178876876831
, O 0 6.92033324867225e-07
we O 0 5.507084210876201e-08
reviewed O 0 2.2666351640054927e-07
the O 0 5.225895733929065e-07
literature O 0 1.5320670172513928e-06
and O 0 4.98772124046809e-07
obtained O 0 3.1187776130536804e-06
a O 0 3.3749042813724373e-06
follow O 0 6.829899916738214e-07
- O 0 1.1531832342370762e-06
up O 0 1.1117695066786837e-06
of O 0 1.580975890647096e-06
the O 0 7.084708499860426e-07
only O 0 1.9735320222480368e-07
two O 0 3.843611864340346e-07
surviving O 0 1.3822783330397215e-05
patients O 0 4.944556167174596e-06
, O 0 8.396337420890632e-07
one O 0 5.177252546673117e-07
with O 0 5.86721569106885e-07
SJS B-Disease 0 0.0011450191959738731
type I-Disease 0 0.00020354472508188337
2 I-Disease 0 0.00024659864720888436
at O 0 0.00023234827676787972
age O 0 1.7308355381828733e-05
10 O 0 3.7931304177618586e-06
years O 0 1.46002639667131e-06
and O 0 3.4510412660893053e-07
another O 0 2.90874140773667e-07
with O 0 2.177225439936592e-07
SWS B-Disease 0 0.00028179591754451394
at O 0 1.639577021705918e-05
age O 0 5.280102413962595e-06
7 O 0 1.648161924094893e-05
years O 0 5.289516593620647e-06
. O 0 1.7227462194568943e-06

Patients O 0 0.00025228314916603267
reported O 0 3.881048542098142e-05
as O 0 5.87578369959374e-06
having O 0 2.403508005954791e-05
either O 0 0.0001050820792443119
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.001994029153138399
SWS B-Disease 1 0.9961853623390198
presented O 0 1.6181418232008582e-06
a O 0 3.9550423025502823e-07
combination O 0 2.832286440934695e-07
of O 0 6.646251335951092e-07
a O 0 2.8679219212790485e-06
severe O 1 0.9271301627159119
, O 0 3.9620631469006184e-06
prenatal O 1 1.0
- O 1 1.0
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 7.665916200494394e-05
with O 0 9.098910231841728e-05
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 0.9998045563697815
feeding O 1 0.9999419450759888
difficulties O 1 0.9950200319290161
, O 0 1.5918210920062847e-05
tendency O 0 2.606732232379727e-05
to O 0 3.743680508705438e-06
hyperthermia B-Disease 0 0.33648431301116943
, O 0 3.353308670739352e-07
and O 0 9.027633751657049e-08
frequent O 0 4.6121490981931856e-07
death O 0 2.0269602828193456e-05
in O 0 2.4068367565632798e-06
infancy O 0 1.9537341358955018e-05
) O 0 3.288580785465456e-08
with O 0 8.65876703670665e-09
a O 0 6.351939418891561e-07
distinct O 0 7.315386483242037e-06
campomelic B-Disease 1 0.9991344809532166
- I-Disease 1 0.9999998807907104
metaphyseal I-Disease 1 1.0
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0001430356060154736

The O 0 2.0923747797496617e-05
similarity O 0 2.2184829504112713e-05
of O 0 3.4398766729282215e-05
the O 0 1.565968523209449e-05
clinical O 0 0.00035581100382842124
and O 0 8.638942745164968e-06
radiographic O 0 0.0029515866190195084
findings O 0 7.350269152084365e-05
is O 0 4.650118626159383e-06
so O 0 4.14078328958567e-07
extensive O 0 4.325527243054239e-06
that O 0 1.65318510880752e-06
these O 0 3.7263796457409626e-06
disorders O 1 0.999962568283081
appear O 0 1.0303634553565644e-05
to O 0 2.115502439892225e-07
be O 0 2.9910566468061006e-07
a O 0 4.272526723525516e-07
single O 0 5.824855975333776e-07
entity O 0 3.530721414790605e-06
. O 0 2.971427193187992e-06

The O 0 0.0003921284805983305
follow O 0 2.9933567930129357e-05
- O 0 1.8539754819357768e-05
up O 0 2.311473508598283e-06
observation O 0 1.2535613677755464e-05
of O 0 9.84686835181492e-07
an O 0 1.0351931223340216e-07
identical O 0 1.542918823815853e-07
and O 0 1.0879605838454154e-07
unique O 0 7.021862415967917e-07
pattern O 0 0.00014976155944168568
of O 1 0.6855934858322144
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 1 0.9314393401145935
the O 0 0.001130330259911716
two O 0 1.3406071047938894e-05
patients O 0 1.5102998077054508e-05
( O 0 1.5587304460495943e-06
one O 0 1.7080018324122648e-06
with O 0 2.1986011233821046e-06
SJS B-Disease 0 0.08250968903303146
type I-Disease 0 0.00046511218533851206
2 I-Disease 0 0.0001438012986909598
, O 0 9.854336440184852e-07
one O 0 6.627402058256848e-07
with O 0 8.282451631203003e-07
SWS B-Disease 0 0.000977971707470715
) O 0 1.2092681345166056e-06
surviving O 0 2.2540800273418427e-05
beyond O 0 4.309526048018597e-05
infancy O 0 4.234199514030479e-05
adds O 0 4.3667571958394547e-07
to O 0 3.357346045618215e-08
the O 0 1.5769283834288217e-07
evidence O 0 1.554999187192152e-07
in O 0 4.792863137481618e-07
favor O 0 1.3297737950779265e-06
of O 0 3.258876631662133e-06
identity O 0 4.693303708336316e-06
. O 0 4.146020728512667e-06

The O 0 0.00020373950246721506
hypothesis O 0 5.153236634214409e-05
that O 0 9.27374367165612e-06
SWS B-Disease 0 0.005812195595353842
and O 0 0.0001151646429207176
SJS B-Disease 1 0.9972666501998901
type I-Disease 0 0.003199417609721422
2 I-Disease 0 0.0005131302168592811
are O 0 1.6974224763544044e-06
the O 0 2.6587742922856705e-06
same O 0 2.8896351977891754e-06
disorder O 0 0.00023386407701764256
should O 0 2.765384010672278e-07
be O 0 8.837940868033911e-08
testable O 0 5.595653647105792e-07
by O 0 4.364854433447363e-08
molecular O 0 1.4512750112771755e-06
methods O 0 6.998790809120692e-07
. O 0 2.655495165981847e-07
. O 0 9.515203487353574e-07

A O 0 4.864457878284156e-05
mouse O 0 7.650943189219106e-06
model O 0 1.1233769328100607e-06
of O 0 2.3805710043234285e-06
severe O 1 0.9999961853027344
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9999668598175049
defects O 1 1.0
in O 0 0.0002265231014462188
hemostasis O 1 0.9999884366989136
and O 0 0.0001481843792134896
thrombosis B-Disease 1 1.0
. O 0 2.4802771804388613e-05

von B-Disease 1 0.9582889080047607
Willebrand I-Disease 1 0.9999984502792358
factor I-Disease 0 0.011036206968128681
( I-Disease 0 0.0003117556625511497
vWf I-Disease 1 0.9993776679039001
) I-Disease 0 0.1471329927444458
deficiency I-Disease 1 1.0
causes O 1 0.9999982118606567
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.9999992847442627
humans O 0 0.0007495449972338974
. O 0 3.790946266235551e-06

We O 0 3.599214323912747e-05
generated O 0 1.0617166481097229e-05
a O 0 7.86175860412186e-06
mouse O 0 5.144879196450347e-06
model O 0 6.06232390509831e-07
for O 0 7.202304885822741e-08
this O 0 3.7242404715698285e-08
disease O 0 4.7338497211057984e-07
by O 0 1.2572363594642866e-08
using O 0 9.318910088040866e-08
gene O 0 8.011374461602827e-07
targeting O 0 3.8288458199531306e-06
. O 0 1.975240820684121e-06

vWf B-Disease 0 0.051343996077775955
- I-Disease 1 0.9735603928565979
deficient I-Disease 1 0.9327353835105896
mice O 0 0.00024344281700905412
appeared O 0 6.456412666011602e-05
normal O 0 5.865471393917687e-05
at O 0 2.2593849280383438e-05
birth O 0 5.427428277471336e-06
; O 0 6.847026412515334e-08
they O 0 1.3278580013320607e-08
were O 0 2.506884300146339e-07
viable O 0 5.424393521025195e-07
and O 0 3.355483784162061e-07
fertile O 0 1.3950580978416838e-05
. O 0 2.727136006797082e-06

Neither O 0 0.001312589505687356
vWf O 0 0.01838221214711666
nor O 0 0.0017246912466362119
vWf O 0 0.0060537937097251415
propolypeptide O 0 0.005219516810029745
( O 0 4.6411241783061996e-05
von B-Disease 0 0.0862341821193695
Willebrand I-Disease 1 0.998002827167511
antigen O 0 0.003785047447308898
II O 1 0.999996542930603
) O 0 4.022798293590313e-06
were O 0 1.8591756543173688e-06
detectable O 0 6.970827143959468e-06
in O 0 2.5657291189418174e-06
plasma O 0 6.260551162995398e-05
, O 0 8.869788530319056e-07
platelets O 0 5.938318281550892e-06
, O 0 7.743313403807406e-07
or O 0 8.781605629337719e-07
endothelial O 0 8.87381611391902e-06
cells O 0 3.688168135340675e-07
of O 0 6.757394430678687e-07
the O 0 1.1911232604688848e-06
homozygous O 0 8.076873200479895e-06
mutant O 0 2.795543332467787e-05
mice O 0 1.7717820810503326e-05
. O 0 1.0697474408516428e-06

The O 0 0.0003403415612410754
mutant O 0 0.0023577699903398752
mice O 0 0.001590527594089508
exhibited O 0 0.23453333973884583
defects O 1 0.9883933663368225
in O 0 5.89111186855007e-06
hemostasis O 0 0.00025771386572159827
with O 0 5.269766916171648e-07
a O 0 1.7185622709803283e-05
highly O 0 0.00035493020550347865
prolonged O 1 0.9999990463256836
bleeding O 1 1.0
time O 0 6.127414235379547e-05
and O 0 5.01283193443669e-06
spontaneous O 0 8.034035272430629e-05
bleeding O 0 0.0010214748326689005
events O 0 8.556658599445655e-07
in O 0 1.2021914130855293e-07
approximately O 0 1.0837645447736577e-07
10 O 0 2.328597759060358e-07
% O 0 2.1657074000813736e-07
of O 0 2.360277449042769e-06
neonates O 0 0.00010032110003521666
. O 0 6.563405804627109e-06

As O 0 3.348586324136704e-05
in O 0 5.2455111472227145e-06
the O 0 8.420638550887816e-06
human O 0 3.933688276447356e-05
disease O 0 0.0001654253137530759
, O 0 1.0101956604557927e-06
the O 0 2.376981910856557e-06
factor O 0 5.770978532382287e-06
VIII O 0 0.0011799673084169626
level O 0 0.0011580940335988998
in O 0 1.8343313058721833e-05
these O 0 1.2416826393746305e-06
mice O 0 6.609384854527889e-06
was O 0 1.094253639166709e-05
reduced O 0 1.8382344251222094e-06
strongly O 0 6.52556309432839e-07
as O 0 1.898205965744637e-07
a O 0 2.526290643345419e-07
result O 0 3.235793712974555e-07
of O 0 6.996815500315279e-07
the O 0 5.640546874019492e-07
lack O 0 1.1033912414859515e-06
of O 0 1.88426531622099e-06
protection O 0 3.978109361923998e-06
provided O 0 1.2546727248263778e-06
by O 0 1.9417771000007633e-06
vWf O 0 0.00022238708334043622
. O 0 8.26663563202601e-06

Defective O 1 0.9996813535690308
thrombosis B-Disease 1 0.9999728202819824
in O 0 0.0009751860052347183
mutant O 0 0.0006267940043471754
mice O 0 8.772222645347938e-05
was O 0 2.0232369934092276e-05
also O 0 2.3817921146473964e-07
evident O 0 4.200086323180585e-07
in O 0 6.186798628959878e-08
an O 0 2.1418191664679398e-08
in O 0 1.923782093626869e-07
vivo O 0 2.119891178153921e-05
model O 0 4.858566626353422e-06
of O 0 9.420804417459294e-05
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 4.33396126027219e-05

In O 0 6.336271326290444e-05
this O 0 2.4764315185166197e-06
model O 0 9.915424016071483e-06
, O 0 8.565059488319093e-07
the O 0 2.2294784685072955e-06
exteriorized O 0 7.69389298511669e-05
mesentery O 0 0.0002128195483237505
was O 0 0.00012355551007203758
superfused O 0 5.191778836888261e-05
with O 0 1.5279449598892825e-06
ferric O 0 0.00018808610911946744
chloride O 0 4.894876474281773e-05
and O 0 5.812835752294632e-06
the O 0 2.720534939726349e-05
accumulation O 0 0.00041069634607993066
of O 0 0.0001541667152196169
fluorescently O 0 0.00023713029804639518
labeled O 0 9.873576345853508e-06
platelets O 0 6.51099389870069e-06
was O 0 3.174044877596316e-06
observed O 0 9.417396427124913e-07
by O 0 1.6952469650277635e-07
intravital O 0 3.068797377636656e-05
microscopy O 0 3.244234176236205e-05
. O 0 1.6697746332283714e-06

We O 0 2.1027846742072143e-05
conclude O 0 1.0332680176361464e-05
that O 0 2.087783599336035e-07
these O 0 2.063212320990715e-07
mice O 0 7.73761530581396e-06
very O 0 5.142721875017742e-07
closely O 0 3.7487679946934804e-06
mimic O 0 0.0005330812418833375
severe O 1 0.9998262524604797
human O 1 0.9996368885040283
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.10760072618722916
will O 0 7.540952083218144e-06
be O 0 4.727772306978295e-07
very O 0 6.121745599330097e-08
useful O 0 6.196612645226196e-08
for O 0 2.6563354182940202e-08
investigating O 0 5.9591911849565804e-08
the O 0 2.1379341319516243e-07
role O 0 8.924081953409768e-07
of O 0 5.07623235534993e-06
vWf O 0 3.7267935113050044e-05
in O 0 7.058345545374323e-06
normal O 0 5.952518404228613e-05
physiology O 0 0.00018240121426060796
and O 0 1.3275739547680132e-06
in O 0 2.290010570504819e-06
disease O 0 3.123987335129641e-05
models O 0 2.1476728306879522e-06
. O 0 2.045575513420772e-07
. O 0 7.029185553619755e-07

Oral O 0 0.0012479110155254602
contraceptives O 0 0.0007162760011851788
and O 0 5.25507232396194e-07
the O 0 1.4741278846486239e-06
risk O 0 2.5476605514995754e-05
of O 0 0.36620867252349854
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.845104846637696e-05

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9999098777770996
Study O 0 0.00010790747182909399
Group O 0 1.2997555131732952e-05
. O 0 2.840693241523695e-06

BACKGROUND O 0 0.0013244438450783491
Women O 0 2.038001002802048e-05
with O 0 6.755312824680004e-07
mutations O 0 1.430997826901148e-06
in O 0 3.96914310840657e-06
either O 0 1.4643128452007659e-06
the O 0 4.171459295321256e-06
BRCA1 O 0 1.3944062629889231e-05
or O 0 2.1997041130816797e-06
the O 0 1.2751737585858791e-06
BRCA2 O 0 5.282933216221863e-06
gene O 0 3.7986583834026533e-07
have O 0 3.466470843704883e-08
a O 0 1.0517055670788977e-07
high O 0 2.3742950361338444e-06
lifetime O 0 9.366197446070146e-06
risk O 0 2.019549356191419e-05
of O 1 0.8333215713500977
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.496139783645049e-05

Oral O 0 0.023917214944958687
contraceptives O 1 0.862379252910614
protect O 0 0.00046818098053336143
against O 1 0.9999881982803345
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 1 0.5315331220626831
general O 0 0.0008232096442952752
, O 0 3.491179086267948e-06
but O 0 2.8594618584065756e-07
it O 0 1.2695019790953666e-07
is O 0 2.971351591440907e-07
not O 0 1.04180294613343e-07
known O 0 4.268104305538145e-07
whether O 0 3.3627873818886655e-08
they O 0 1.0169104669444096e-08
also O 0 2.2133216148745305e-08
protect O 0 2.963536971378744e-08
against O 0 3.9499158788203204e-07
hereditary B-Disease 1 0.9381251335144043
forms I-Disease 0 0.004929827060550451
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.151046495186165e-05

METHODS O 0 8.339490159414709e-05
We O 0 3.7125566905160667e-06
enrolled O 0 1.2974198398296721e-05
207 O 0 9.4140359578887e-06
women O 0 1.9267836250946857e-06
with O 0 5.238048288447317e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.742110367165878e-05
161 O 0 4.645959415938705e-05
of O 0 7.764154725009575e-05
their O 0 6.621869943046477e-06
sisters O 0 0.0003372720966581255
as O 0 1.1255763638473582e-05
controls O 0 7.615011782036163e-06
in O 0 3.056848299820558e-06
a O 0 4.186028945696307e-06
case O 0 4.79768368677469e-06
- O 0 5.628109647659585e-06
control O 0 5.825917014590232e-06
study O 0 2.127939524143585e-06
. O 0 1.6787895447123447e-06

All O 0 8.806641744740773e-06
the O 0 2.9117572921677493e-06
patients O 0 1.3907786069466965e-06
carried O 0 7.070938181641395e-07
a O 0 8.844700687404838e-07
pathogenic O 0 1.1258985068707261e-06
mutation O 0 8.574646130909969e-07
in O 0 2.0590307485690573e-06
either O 0 1.1649709676930797e-06
BRCA1 O 0 2.1027431102993432e-06
( O 0 7.015570417934214e-07
179 O 0 4.1449420677963644e-06
women O 0 2.420355258436757e-06
) O 0 1.0875015732381144e-06
or O 0 3.0439584861596813e-06
BRCA2 O 0 1.4476352589554153e-05
( O 0 2.6808211259776726e-06
28 O 0 7.553851173724979e-05
women O 0 2.9828236165485578e-06
) O 0 7.368047931777255e-07
. O 0 6.421741431950068e-07

The O 0 0.00043208396527916193
control O 0 0.00028803219902329147
women O 0 1.6556256014155224e-05
were O 0 5.33198863195139e-06
enrolled O 0 4.879201696894597e-06
regardless O 0 1.5473437997570727e-06
of O 0 6.140600817161612e-06
whether O 0 1.026211407406663e-06
or O 0 2.1710975488531403e-06
not O 0 2.0210114826113568e-07
they O 0 5.381760459499674e-08
had O 0 9.705205457066768e-07
either O 0 6.239807817109977e-07
mutation O 0 2.1362536699598422e-06
. O 0 1.4957876146581839e-06

Lifetime O 0 0.00039682385977357626
histories O 0 5.841580423293635e-05
of O 0 0.00015453553351107985
oral O 0 0.0009727862779982388
- O 0 0.00020738458260893822
contraceptive O 0 0.00018242310034111142
use O 0 1.6369755257983343e-06
were O 0 2.79270807368448e-06
obtained O 0 2.557130756031256e-06
by O 0 5.448309821076691e-07
interview O 0 1.542271547805285e-06
or O 0 3.928581406853482e-07
by O 0 6.665109708592354e-08
written O 0 1.7307017685652681e-07
questionnaire O 0 2.675087387160602e-07
and O 0 6.087769861551351e-07
were O 0 1.6281538819384878e-06
compared O 0 3.1402964850713033e-06
between O 0 1.877044724096777e-06
patients O 0 3.579160875233356e-06
and O 0 2.283206868014531e-06
control O 0 3.0532934033544734e-05
women O 0 4.848434400628321e-06
, O 0 4.3349700717953965e-07
after O 0 9.486941507930169e-07
adjustment O 0 2.8742579161189497e-06
for O 0 2.851221836408513e-07
year O 0 7.578099143756845e-07
of O 0 1.4715110410179477e-06
birth O 0 3.079988164245151e-05
and O 0 6.502628821181133e-06
parity O 0 0.00010898874461418018
. O 0 4.118192009627819e-06

RESULTS O 0 0.0003818289842456579
The O 0 1.087948930944549e-05
adjusted O 0 5.278343815007247e-05
odds O 0 5.637597860186361e-05
ratio O 0 0.00021422328427433968
for O 0 0.00042958217090927064
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.922000855207443e-05
with O 0 2.6102745209755085e-07
any O 0 1.7953249198399135e-07
past O 0 6.969151513658289e-07
use O 0 7.032042503851699e-08
of O 0 1.1418337635404896e-06
oral O 0 5.570901703322306e-05
contraceptives O 0 0.000178024813067168
was O 0 0.00023361803323496133
0 O 0 2.600272091513034e-05
. O 0 6.751178602826258e-07

5 O 0 0.0002050188195426017
( O 0 8.89336115506012e-06
95 O 0 3.365207521710545e-05
percent O 0 2.6784473448060453e-05
confidence O 0 2.84796733467374e-05
interval O 0 2.8840391678386368e-05
, O 0 1.121658783631574e-06
0 O 0 7.865154429964605e-07
. O 0 1.2872129140362176e-08
3 O 0 2.2834194624010706e-07
to O 0 2.9249465072211933e-08
0 O 0 5.89419755669951e-07
. O 0 4.918642559914588e-08
8 O 0 2.463452574374969e-06
) O 0 3.1059857974469196e-07
. O 0 4.526644090674381e-07

The O 0 7.401706534437835e-05
risk O 0 1.6447747839265503e-05
decreased O 0 1.8058311979984865e-05
with O 0 5.723928353518204e-08
increasing O 0 7.192529665189795e-07
duration O 0 7.303048732865136e-06
of O 0 8.645584784972016e-06
use O 0 1.9231285932619357e-06
( O 0 2.216153234257945e-06
P O 0 0.00010528951679589227
for O 0 1.2062974974469398e-06
trend O 0 7.029640983091667e-06
, O 0 4.292211883694108e-07
< O 0 2.464129238433088e-06
0 O 0 1.2358713092908147e-06
. O 0 6.560212995054826e-08
001 O 0 5.5810528465372045e-06
) O 0 6.969471399997929e-08
; O 0 5.4442850228042516e-08
use O 0 1.46521230703911e-07
for O 0 9.72022917267168e-07
six O 0 4.551701294985833e-06
or O 0 1.540450170978147e-06
more O 0 8.393425332542392e-08
years O 0 1.219580440192658e-06
was O 0 4.271123543730937e-06
associated O 0 1.0972990338586897e-07
with O 0 1.9618967783685548e-08
a O 0 3.149547183056711e-07
60 O 0 8.648733000882203e-07
percent O 0 1.4514176882585161e-06
reduction O 0 2.9926482056907844e-06
in O 0 5.125221832713578e-06
risk O 0 2.6424033421790227e-05
. O 0 6.045942427590489e-06

Oral O 0 0.006180366035550833
- O 0 0.0007553552277386189
contraceptive O 0 0.0005944179138168693
use O 0 5.878703177586431e-06
protected O 0 0.00033325684489682317
against O 1 0.6081478595733643
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.1067953664678498e-06
for O 0 2.2747342143247806e-07
carriers O 0 9.576290693757983e-08
of O 0 2.308252987859305e-06
the O 0 7.14283351044287e-06
BRCA1 O 0 1.6989131836453453e-05
mutation O 0 3.3605708722461713e-06
( O 0 3.74381215806352e-07
odds O 0 3.048542339456617e-06
ratio O 0 2.1454352463479154e-06
, O 0 1.8285255976024928e-07
0 O 0 2.8399000484569115e-07
. O 0 1.2205929600384025e-08
5 O 0 2.2979182290328026e-07
; O 0 7.618795905273146e-08
95 O 0 2.4324015157617396e-06
percent O 0 4.12398912885692e-06
confidence O 0 9.359866453451104e-06
interval O 0 1.173958480649162e-05
, O 0 7.613230650349578e-07
0 O 0 6.486343977485376e-07
. O 0 2.1763073121405796e-08
3 O 0 2.1998667421030405e-07
to O 0 8.637756110374539e-08
0 O 0 8.037739007704658e-07
. O 0 4.972333300656828e-08
9 O 0 1.3713678299609455e-06
) O 0 1.5968675270983113e-08
and O 0 1.9729366584897434e-08
for O 0 5.445666317882569e-08
carriers O 0 1.1293058577166448e-07
of O 0 2.9752948194072815e-06
the O 0 1.0550328624958638e-05
BRCA2 O 0 1.3701632269658148e-05
mutation O 0 2.285197751916712e-06
( O 0 3.951245730604569e-07
odds O 0 2.5001659196277615e-06
ratio O 0 2.052007175734616e-06
, O 0 2.7054232987211435e-07
0 O 0 5.319451474861125e-07
. O 0 3.308209173269461e-08
4 O 0 7.595231181767303e-07
; O 0 8.162432862945934e-08
95 O 0 2.494704858690966e-06
percent O 0 3.6231506328476826e-06
confidence O 0 9.275653610529844e-06
interval O 0 1.17890267574694e-05
, O 0 8.33777619391185e-07
0 O 0 7.528396395173331e-07
. O 0 1.7185692868793012e-08
2 O 0 2.4019612965275883e-07
to O 0 3.9297351150935356e-08
1 O 0 1.0689581131373416e-06
. O 0 1.0322297328002605e-07
1 O 0 3.5048531117354287e-06
) O 0 3.702737387811794e-07
. O 0 5.04886429553153e-07

CONCLUSIONS O 0 0.0010960913496091962
Oral O 0 0.0013564028777182102
- O 0 0.00023201068688649684
contraceptive O 0 0.00010745034524006769
use O 0 4.326371083607228e-07
may O 0 8.722827828933077e-07
reduce O 0 2.985066771543643e-07
the O 0 1.7569954025020706e-06
risk O 0 4.089485082658939e-05
of O 1 0.9916674494743347
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.1420930352178402e-05
women O 0 3.1011020951154933e-07
with O 0 9.793793331880352e-09
pathogenic O 0 1.7919823847023508e-07
mutations O 0 1.5214453696899e-07
in O 0 4.2359195617791556e-07
the O 0 1.3195965493650874e-06
BRCA1 O 0 2.0730334654217586e-05
or O 0 1.0001476766774431e-05
BRCA2 O 0 0.00017828999261837453
gene O 0 0.00016309804050251842

A O 0 0.0008796263136900961
Japanese O 0 0.00034841219894587994
family O 0 1.7773263607523404e-05
with O 0 5.892477474844782e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 2.405834038654575e-06
a O 0 1.4094348443904892e-05
codon O 0 2.100512028846424e-05
291 O 0 8.679538950673304e-06
deletion O 0 7.759674190310761e-06
: O 0 3.03650779187592e-07
a O 0 6.929982987458061e-07
clinical O 0 3.0495508326566778e-05
, O 0 1.9921328657801496e-06
biochemical O 0 0.00026201512082479894
, O 0 3.3829603580670664e-06
pathological O 0 0.010606466792523861
, O 0 7.31871750758728e-07
and O 0 3.4854761565839e-07
genetic O 0 6.097000095905969e-06
report O 0 8.214445188059472e-06
. O 0 4.559934495773632e-06

We O 0 1.945131953107193e-05
report O 0 3.64214542969421e-06
a O 0 3.937627752748085e-06
Japanese O 0 3.086480137426406e-05
family O 0 1.6876676454558037e-05
with O 0 6.480697629740462e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.020602218806743622
ALD B-Disease 1 1.0
) O 0 4.572262241708813e-06
with O 0 9.436366212867142e-07
a O 0 2.44364910031436e-05
three O 0 1.64002431120025e-05
base O 0 0.00010231527267023921
pair O 0 6.956845754757524e-05
deletion O 0 0.00014426716370508075
( O 0 4.9540240070200525e-06
delGAG O 0 3.821660720859654e-05
291 O 0 7.95159303379478e-06
) O 0 2.0731728511691472e-07
in O 0 9.816461670197896e-07
the O 0 2.910847069870215e-05
ALD B-Disease 1 1.0
gene O 0 5.667233563144691e-05
. O 0 5.615531790681416e-06

A O 0 0.00019034561410080642
variety O 0 1.5010024071671069e-05
of O 0 2.9270389859448187e-05
phenotypes O 0 2.2909998733666725e-05
were O 0 2.363942712690914e-06
observed O 0 9.81311131909024e-07
within O 0 1.8022930703409656e-07
this O 0 9.616228169306851e-08
family O 0 9.146650654656696e-07
. O 0 9.586703981767641e-07

While O 0 0.00035051480517722666
the O 0 0.0001161249092547223
proband O 0 0.002122525591403246
( O 0 2.109078923240304e-05
patient O 0 6.71312227495946e-05
1 O 0 8.707000961294398e-05
) O 0 1.2991604307899252e-06
was O 0 8.150209396262653e-06
classified O 0 6.543804147440824e-07
as O 0 1.864888616864846e-07
having O 0 1.9783523441674333e-07
a O 0 2.2864614379614068e-07
rare O 0 5.394276740844361e-07
intermediate O 0 7.008829015830997e-06
type O 0 2.9913810521975392e-06
of O 0 2.139106800314039e-05
adult O 0 0.0017434483161196113
cerebral O 1 0.9999994039535522
and O 0 0.001274607959203422
cerebello O 1 0.999994158744812
- O 1 0.9999752044677734
brain O 1 0.9999966621398926
stem O 0 0.00015205722593236715
forms O 0 6.475407190009719e-06
, O 0 1.5430143776029581e-06
his O 0 1.4347803698910866e-05
younger O 0 3.263154940214008e-05
brother O 0 9.525009954813868e-05
( O 0 1.5977656175891752e-06
patient O 0 7.180246484495001e-06
2 O 0 1.7254445992875844e-05
) O 0 5.804039346912759e-07
and O 0 3.579126996555715e-06
nephew O 0 0.0007587936706840992
( O 0 3.326398882563808e-06
patient O 0 7.099098638718715e-06
3 O 0 1.2481908015615772e-05
) O 0 4.631525030163175e-07
had O 0 3.740275815289351e-06
a O 0 2.2824209736427292e-05
childhood O 1 0.7252898812294006
ALD B-Disease 1 1.0
type O 0 0.0011727487435564399
. O 0 1.4948685020499397e-05

Another O 0 0.002674692077562213
nephew O 0 0.00962325744330883
( O 0 2.7248242986388505e-05
patient O 0 4.263079244992696e-05
4 O 0 5.315754242474213e-05
) O 0 7.229610332615266e-07
of O 0 6.744995062035741e-06
patient O 0 9.427346230950207e-05
1 O 0 0.00021393301722127944
was O 0 0.00011286947119515389
classified O 0 1.3429951195575995e-06
as O 0 3.8645845279461355e-07
having O 0 3.593644919419603e-07
an O 0 1.854538425050123e-07
adolescent O 0 6.472036147897597e-06
form O 0 2.4178659714380046e-06
. O 0 2.1925791315879906e-06

The O 0 0.00017527012096252292
tau O 0 0.00024064310127869248
level O 0 0.0001342717878287658
in O 0 3.116652078460902e-05
the O 0 6.186591781442985e-05
cerebrospinal O 0 0.001237988588400185
fluid O 0 0.001416728482581675
( O 0 2.7887988835573196e-05
CSF O 0 0.0013934895396232605
) O 0 1.3660995819009258e-06
in O 0 3.517869345159852e-06
patient O 0 2.089076951961033e-05
1 O 0 2.874522215279285e-05
was O 0 2.910327930294443e-05
as O 0 6.479809258053137e-07
high O 0 1.242581674887333e-06
as O 0 1.7843591493260647e-08
that O 0 1.517985737109484e-09
of O 0 8.281647723151764e-08
patients O 0 5.559006694966229e-07
with O 0 1.4841149322819547e-06
Alzheimers B-Disease 1 0.9999998807907104
disease I-Disease 1 0.999426007270813
( O 0 2.964404757221928e-06
AD B-Disease 0 3.364055373822339e-05
) O 0 1.0986053666783846e-06
. O 0 1.3331857644516276e-06

His O 0 0.0023339432664215565
brain O 1 0.9987863898277283
magnetic O 0 0.0013810800155624747
resonance O 0 0.00042458943789824843
image O 0 0.00014015486522112042
( O 0 3.74978344552801e-06
MRI O 0 0.0001559416123200208
) O 0 8.29217242426239e-07
showed O 0 1.1646860002656467e-05
abnormalities B-Disease 0 0.0005492644850164652
in I-Disease 0 3.879520590999164e-06
the I-Disease 0 8.881376743374858e-06
bilateral I-Disease 0 0.003066598903387785
cerebellar I-Disease 1 0.9999996423721313
hemispheres I-Disease 1 0.9969242215156555
and O 0 0.00042104156455025077
brain O 1 0.999747097492218
stem O 0 0.00015023225569166243
, O 0 8.058285061451897e-07
but O 0 1.1764286966808868e-07
not O 0 2.158823946274424e-07
in O 0 2.496873321433668e-06
the O 0 1.1594763236644212e-05
cerebral O 0 0.002598536666482687
white O 0 1.2222804798511788e-05
matter O 0 2.115289589710301e-06
, O 0 9.508746501296628e-08
where O 0 1.025837121915174e-07
marked O 0 8.714538353160606e-07
reductions O 0 1.2660069614867098e-06
of O 0 3.1246277103491593e-06
the O 0 8.951264135248493e-06
cerebral O 0 0.0006611590506508946
blood O 0 4.8765661631478e-05
flow O 0 4.217700916342437e-05
and O 0 7.695903150306549e-06
oxygen O 0 2.738140210567508e-05
metabolism O 0 7.830440881662071e-05
were O 0 1.0570162203293876e-06
clearly O 0 3.590034793887753e-07
demonstrated O 0 9.679249615146546e-07
by O 0 1.303734933344458e-07
positron O 0 1.4307400306279305e-05
emission O 0 8.599693501309957e-06
tomography O 0 3.5467084671836346e-05
( O 0 2.5802653453865787e-06
PET O 0 1.1931256267416757e-05
) O 0 3.730674791313504e-07
. O 0 5.508186404767912e-07

In O 0 0.0001800497848307714
patients O 0 3.895714689861052e-05
2 O 0 2.673927701835055e-05
and O 0 2.216328766735387e-06
3 O 0 4.942359737469815e-06
, O 0 1.0588731669258777e-07
the O 0 1.7323827705695294e-07
autopsy O 0 4.748200353787979e-06
findings O 0 1.5624572142769466e-06
showed O 0 3.500171806081198e-05
massive O 0 0.0016273546498268843
demyelination B-Disease 1 1.0
of I-Disease 1 0.9998248219490051
the I-Disease 1 0.9541954398155212
cerebral I-Disease 1 0.9999995231628418
white I-Disease 0 0.0001586209109518677
matter I-Disease 0 1.184249504149193e-05
with O 0 6.945862196516828e-07
sparing O 0 5.724976745113963e-06
of O 0 8.538240217603743e-05
the O 0 0.00033790903398767114
U O 1 0.9996800422668457
- O 0 0.0023248582147061825
fibers O 0 0.00017304577340837568
, O 0 4.901947932012263e-07
compatible O 0 2.8503924909273337e-07
with O 0 6.21560936053811e-09
the O 0 1.5084438587109616e-07
findings O 0 9.221202503795212e-07
of O 0 2.1592804841930047e-05
childhood O 1 0.991692841053009
ALD B-Disease 1 1.0
. O 0 5.816011253045872e-05

Oleic O 0 0.021537281572818756
and O 0 0.0011687051737681031
erucic O 1 0.8587875962257385
acids O 0 0.0007420696201734245
( O 0 4.6965953515609726e-05
Lorenzos O 0 0.0012893348466604948
Oil O 0 0.0004755931149702519
) O 0 8.01115277226927e-07
were O 0 9.019438493851339e-07
administered O 0 2.375164029899679e-07
to O 0 1.2554610862025584e-07
patients O 0 5.523852451005951e-07
1 O 0 5.002887974114856e-06
and O 0 1.0842096571650472e-06
4 O 0 1.3040464182267897e-05
, O 0 1.091935430963531e-07
but O 0 1.2581430119951165e-08
sufficient O 0 1.452094409160054e-07
effectiveness O 0 1.1333943348290632e-06
was O 0 4.646709840017138e-06
not O 0 1.1901735774699773e-07
obtained O 0 1.9353249172127107e-06
. O 0 1.5059816860230058e-06

The O 0 0.00033259857445955276
findings O 0 6.938487058505416e-05
in O 0 2.250812940474134e-05
this O 0 1.5972734672686784e-06
family O 0 1.96305177269096e-06
suggest O 0 3.226663523037132e-07
that O 0 8.825037411952508e-08
delGAG291 O 0 1.970142648133333e-06
is O 0 1.033539831496455e-07
part O 0 8.03455293407751e-08
of O 0 7.912597084214212e-07
the O 0 1.8174438309870311e-06
cause O 0 9.50854882830754e-06
of O 0 5.4748183174524456e-05
Japanese O 0 0.003262091428041458
ALD B-Disease 1 1.0
with O 0 1.929794052557554e-06
phenotypic O 0 0.0007212564232759178
variations O 0 0.0003286340506747365
. O 0 1.5925104889902286e-05

Moreover O 0 0.0003864434256684035
, O 0 4.727831310447073e-06
although O 0 4.5167823259362194e-07
the O 0 6.654185540355684e-07
scale O 0 1.2357969353615772e-05
of O 0 1.6882970157894306e-05
the O 0 8.738724318391178e-06
study O 0 2.79243113254779e-06
is O 0 1.1340765695422306e-06
limited O 0 1.1145252756250557e-06
, O 0 4.523752750174026e-07
there O 0 3.0136965278870775e-07
is O 0 4.5333618459153513e-07
a O 0 8.072137802628276e-07
possibility O 0 1.6812762169138296e-06
that O 0 1.8970961264130892e-06
PET O 0 5.3182644478511065e-05
can O 0 1.6870616263986449e-06
detect O 0 1.68531623785384e-05
an O 0 6.3120874074229505e-06
insidious B-Disease 0 0.00017085729632526636
lesion I-Disease 0 0.03227528929710388
which O 0 2.1412406567833386e-06
is O 0 1.0828363201653701e-06
undetectable O 0 1.129546308220597e-05
by O 0 1.265843678766032e-07
computed O 0 8.772349247010425e-06
tomogram O 0 0.00011417974747018889
( O 0 5.161292847333243e-06
CT O 0 0.0004847627133131027
) O 0 2.2513725070893997e-06
or O 0 2.985231276397826e-06
MRI O 0 0.00010439853213028982
analysis O 0 9.740181212691823e-07
, O 0 1.1169603908456338e-07
and O 0 5.1916149601538564e-08
that O 0 2.6463123248277043e-08
the O 0 2.8875339808109857e-07
higher O 0 1.6095644923552754e-06
level O 0 1.8647441493158112e-06
of O 0 1.2692880773101933e-06
tau O 0 4.389367859403137e-06
reflects O 0 7.283966141358178e-08
the O 0 5.962919402691114e-08
process O 0 1.274443803822578e-07
of O 0 4.785149485542206e-06
neuronal B-Disease 0 0.0017105923034250736
degeneration I-Disease 1 0.9999592304229736
in O 0 0.0005017172079533339
ALD B-Disease 1 1.0
. O 0 4.7600235120626166e-05

Lorenzos O 0 0.03194863349199295
Oil O 0 0.0011681640753522515
should O 0 1.6112461480588536e-06
be O 0 2.6598723934512236e-07
given O 0 1.1422102375036047e-07
in O 0 2.0019092517031822e-07
the O 0 2.127479916680386e-07
early O 0 8.786992111708969e-07
stage O 0 4.1329581108584534e-06
. O 0 1.824091100388614e-07
. O 0 5.061108936388337e-07

Nonsense O 0 0.001343699754215777
mutation O 0 2.0759021936100908e-05
in O 0 1.0061115062853787e-05
exon O 0 1.198060272145085e-05
4 O 0 8.57653867569752e-06
of O 0 2.7197493182029575e-06
human O 0 7.089871360221878e-06
complement O 0 1.544677979836706e-05
C9 O 0 0.000695965311024338
gene O 0 1.30879050175281e-06
is O 0 8.532370543434808e-08
the O 0 9.537627221334333e-08
major O 0 6.312005780273466e-07
cause O 0 8.15703060652595e-07
of O 0 3.5224347811890766e-06
Japanese O 0 8.395135955652222e-05
complement B-Disease 0 0.0008688937523402274
C9 I-Disease 1 0.9999980926513672
deficiency I-Disease 1 0.9999997615814209
. O 0 2.1330728486645967e-05

Deficiency B-Disease 1 0.99997878074646
of I-Disease 0 0.0015480959555134177
the I-Disease 0 0.00018840451957657933
ninth I-Disease 0 0.0009382183197885752
component I-Disease 0 6.038806168362498e-05
of I-Disease 0 3.340504190418869e-05
human I-Disease 0 4.1309307562187314e-05
complement I-Disease 0 1.4491572983388323e-05
( O 0 7.6352425821824e-06
C9 O 0 0.0005447332514449954
) O 0 7.687327183703019e-07
is O 0 2.825838123499125e-07
the O 0 5.278352546156384e-07
most O 0 1.4196438087310526e-06
common O 0 5.8478672144701704e-05
complement B-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
in O 0 0.00016758416313678026
Japan O 0 9.192313882522285e-06
but O 0 1.9155986308305728e-07
is O 0 9.452617888427994e-08
rare O 0 1.9333829470724595e-07
in O 0 2.7251081746726413e-07
other O 0 5.554279880470858e-08
countries O 0 7.373946431243894e-08
. O 0 9.497361475041544e-07

We O 0 1.7939863710125792e-06
studied O 0 2.615320681798039e-06
the O 0 6.400861138899927e-07
molecular O 0 3.6188030207995325e-06
basis O 0 3.3143910513899755e-06
of O 0 6.302128167590126e-05
C9 B-Disease 1 0.999407172203064
deficiency I-Disease 1 0.999984622001648
in O 0 7.182648550951853e-05
four O 0 3.355321678100154e-05
Japanese O 0 0.0008980587008409202
C9 B-Disease 1 0.9999892711639404
- I-Disease 1 0.9989174604415894
deficient I-Disease 1 0.9405621886253357
patients O 0 6.5975141296803486e-06
who O 0 1.955670768438722e-06
had O 0 8.979863196145743e-05
suffered O 1 1.0
from O 1 0.5450540781021118
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.6541671104496345e-05

Direct O 0 2.851361750799697e-05
sequencing O 0 1.881578646134585e-05
of O 0 3.9581474993610755e-05
amplified O 0 0.00011295312287984416
C9 O 0 0.0002633121330291033
cDNA O 0 9.408955520484596e-06
and O 0 8.149161772053048e-07
DNA O 0 1.997545041376725e-06
revealed O 0 9.221165782946628e-06
a O 0 8.231808351411019e-06
nonsense O 0 5.3664742154069245e-05
substitution O 0 1.9675797375384718e-05
( O 0 1.236562184203649e-06
CGA O 0 1.094316212402191e-05
- O 0 3.285093953309115e-06
- O 0 6.238663445401471e-06
> O 0 5.428551958175376e-06
TGA O 0 1.4145880413707346e-05
) O 0 2.0559568270073214e-07
at O 0 3.866125098284101e-06
codon O 0 4.760306183015928e-06
95 O 0 2.1495598048204556e-06
in O 0 8.936286235439184e-07
exon O 0 1.6830152844704571e-06
4 O 0 9.851735740085132e-06
in O 0 4.2396354729135055e-06
the O 0 1.1805689609900583e-05
four O 0 1.9486245946609415e-05
C9 B-Disease 0 0.006259088404476643
- I-Disease 0 0.000907925539650023
deficient I-Disease 0 0.00022900135081727058
individuals O 0 4.140980536249117e-07
. O 0 2.0446952930797124e-06

An O 0 6.785833102185279e-05
allele O 0 3.1916366424411535e-05
- O 0 1.4412270502361935e-05
specific O 0 1.961593852684018e-06
polymerase O 0 0.0002937840181402862
chain O 0 0.0001349883823422715
reaction O 0 7.769062904117163e-06
system O 0 4.249714947945904e-06
designed O 0 2.043817858066177e-06
to O 0 2.03063265757919e-07
detect O 0 6.54888594908698e-07
exclusively O 0 4.4316678327049885e-07
only O 0 2.1432377650398848e-07
one O 0 2.634641589338571e-07
of O 0 2.0695040348073235e-06
the O 0 2.192125293731806e-06
normal O 0 6.83630651110434e-06
and O 0 7.42645283935417e-07
mutant O 0 3.6890160117764026e-06
alleles O 0 6.453309993048606e-07
indicated O 0 5.458164764604589e-07
that O 0 6.495778137605157e-08
all O 0 7.574472249416431e-08
the O 0 3.327009778786305e-07
four O 0 3.140524995615124e-07
patients O 0 1.75937856283781e-07
were O 0 4.5672663873119745e-07
homozygous O 0 1.0001533610193292e-06
for O 0 5.867506729373417e-07
the O 0 1.7480922451795777e-06
mutation O 0 8.800225259619765e-07
in O 0 4.275292667443864e-06
exon O 0 5.266584139462793e-06
4 O 0 1.254819562745979e-05
and O 0 2.636753038132156e-07
that O 0 5.421963322760348e-08
the O 0 4.6111682650007424e-07
parents O 0 1.4985360508035228e-07
of O 0 1.6711413763914607e-06
patient O 0 1.117741885536816e-05
2 O 0 2.778342786768917e-05
were O 0 5.467461505759275e-06
heterozygous O 0 7.507792815886205e-06
. O 0 2.0106142528675264e-06

The O 0 0.0001239095872733742
common O 0 2.0619450879166834e-05
mutation O 0 7.086653567967005e-06
at O 0 4.672512295655906e-05
codon O 0 1.943114875757601e-05
95 O 0 5.086743840365671e-06
in O 0 1.1803343795691035e-06
exon O 0 2.277899966429686e-06
4 O 0 4.5524911911343224e-06
might O 0 1.5411393405884155e-07
be O 0 4.628310890097964e-08
responsible O 0 1.6082083220680943e-07
for O 0 1.129495359464272e-07
most O 0 7.41432359063765e-07
Japanese O 0 0.000102922749647405
C9 B-Disease 1 0.9996612071990967
deficiency I-Disease 1 0.9999114274978638
. O 0 2.1557104901148705e-06
. O 0 2.035583747783676e-06

BRCA1 O 0 0.00017197987472172827
required O 0 1.358318877464626e-05
for O 0 8.987430192064494e-06
transcription O 0 0.00029388038092292845
- O 0 8.659621380502358e-05
coupled O 0 0.00010346455383114517
repair O 0 3.4095399314537644e-05
of O 0 2.1900043066125363e-05
oxidative O 0 0.0002381251542828977
DNA O 0 2.599865365482401e-05
damage O 0 0.0009514272096566856
. O 0 1.4295806067821104e-05

The O 0 0.00013710602070204914
breast B-Disease 1 0.9999978542327881
and I-Disease 1 0.9997747540473938
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9903995394706726
gene O 0 4.317452840041369e-05
BRCA1 O 0 3.0188564778654836e-05
encodes O 0 1.1906545296369586e-05
a O 0 1.637028981349431e-05
zinc O 0 0.00032820511842146516
finger O 0 0.00010134811600437388
protein O 0 9.919785043166485e-06
of O 0 9.084251360036433e-06
unknown O 0 4.336954953032546e-05
function O 0 4.7448589612031356e-05
. O 0 2.6714774321590085e-06

Association O 0 0.0002416102943243459
of O 0 3.428568015806377e-05
the O 0 1.0327449672331568e-05
BRCA1 O 0 5.468082235893235e-06
protein O 0 3.63070830644574e-06
with O 0 1.9526724770457804e-07
the O 0 3.153212446704856e-06
DNA O 0 4.29304009230691e-06
repair O 0 7.254500087583438e-05
protein O 0 5.0730366638163105e-05
Rad51 O 0 0.00018766334687825292
and O 0 3.988300704804715e-06
changes O 0 1.0490196018508868e-06
in O 0 2.4498312996001914e-06
the O 0 1.5117792599994573e-06
phosphorylation O 0 1.0916580777120544e-06
and O 0 1.3364776805246947e-06
cellular O 0 2.3200018404168077e-05
localization O 0 3.559577453415841e-05
of O 0 1.1957717106270138e-05
the O 0 1.0453819413669407e-05
protein O 0 1.1120791896246374e-05
after O 0 8.357229489774909e-06
exposure O 0 1.2785047147190198e-05
to O 0 1.507897309238615e-06
DNA O 0 8.74849774845643e-06
- O 0 2.688927634153515e-05
damaging O 0 2.192823558289092e-05
agents O 0 9.19073784189095e-07
are O 0 5.066140573717348e-08
consistent O 0 2.440046955598518e-07
with O 0 1.466097732105709e-08
a O 0 3.545131619375752e-07
role O 0 1.5090136002982035e-06
for O 0 6.387866164914158e-07
BRCA1 O 0 5.720135959563777e-06
in O 0 4.200036528345663e-06
DNA O 0 1.1320277735649142e-05
repair O 0 0.00010533218301134184
. O 0 1.2138332749600522e-05

Here O 0 0.000313605647534132
, O 0 2.390321242273785e-06
it O 0 6.170382960135612e-08
is O 0 1.1593899529316332e-07
shown O 0 4.4884717453896883e-07
that O 0 5.744522013628739e-07
mouse O 0 2.6950994651997462e-05
embryonic O 0 4.518010973697528e-05
stem O 0 5.351051004254259e-05
cells O 0 1.6109348507598042e-05
deficient B-Disease 0 5.0638151151360944e-05
in I-Disease 0 8.671546311234124e-06
BRCA1 I-Disease 0 2.422855504846666e-05
are O 0 1.3744289617534378e-06
defective O 0 1.0007115633925423e-05
in O 0 9.564604397382936e-07
the O 0 6.06238131695136e-07
ability O 0 9.935303779684546e-08
to O 0 7.281840197492784e-08
carry O 0 2.01306306735205e-07
out O 0 6.835490466983174e-07
transcription O 0 4.7449451813008636e-05
- O 0 3.0118255381239578e-05
coupled O 0 9.375921217724681e-05
repair O 0 8.184288162738085e-05
of O 0 7.217713573481888e-05
oxidative O 0 0.00037925742799416184
DNA O 0 4.404551873449236e-05
damage O 0 0.001345118973404169
, O 0 2.889023562602233e-06
and O 0 8.834500704324455e-07
are O 0 3.7890271187279723e-07
hypersensitive O 0 2.4749608201091178e-05
to O 0 9.872736654870096e-07
ionizing O 0 0.0005406190757639706
radiation O 0 0.0009285909472964704
and O 0 3.390757683519041e-06
hydrogen O 0 8.32900059322128e-06
peroxide O 0 5.760587737313472e-05
. O 0 3.915451998182107e-06

These O 0 3.1203577236738056e-05
results O 0 7.491991709684953e-05
suggest O 0 5.705257080990123e-06
that O 0 5.965285936326836e-07
BRCA1 O 0 5.0857152018579654e-06
participates O 0 1.365078560411348e-06
, O 0 6.809152637288207e-07
directly O 0 4.0202263562605367e-07
or O 0 4.597231679781544e-07
indirectly O 0 1.0883607046707766e-06
, O 0 2.3158725070970831e-07
in O 0 1.1935884458580404e-06
transcription O 0 9.591436537448317e-05
- O 0 0.00010849537648027763
coupled O 0 0.00025782003649510443
repair O 0 7.70791812101379e-05
of O 0 3.0374969355762005e-05
oxidative O 0 0.00014792053843848407
DNA O 0 1.109056483983295e-05
damage O 0 9.810781921260059e-05
. O 0 9.37431366310193e-07
. O 0 1.0053699952550232e-06

Truncation O 0 0.00328772678039968
mutations O 0 3.6695419112220407e-05
in O 0 1.4408052265935112e-05
the O 0 8.550812708563171e-06
transactivation O 0 0.00011499081301735714
region O 0 8.533248546882533e-06
of O 0 6.712693721055984e-05
PAX6 O 0 0.010062566958367825
result O 0 6.397819379344583e-05
in O 0 2.4070541257970035e-05
dominant O 0 0.00010296524851582944
- O 0 1.0133062460226938e-05
negative O 0 3.0106941721896874e-06
mutants O 0 7.261809059855295e-06
. O 0 6.554359401889087e-07

PAX6 O 0 0.026821548119187355
is O 0 3.902720345649868e-05
a O 0 1.9313871234771796e-05
transcription O 0 5.6762011809041724e-05
factor O 0 3.237076498407987e-06
with O 0 3.6313414852884307e-07
two O 0 8.949214702624886e-07
DNA O 0 2.392805072304327e-06
- O 0 1.4247558283386752e-05
binding O 0 2.3766833692207e-05
domains O 0 0.00012350312317721546
( O 0 4.1604425859986804e-06
paired O 0 1.0650165677361656e-05
box O 0 4.938424899592064e-05
and O 0 2.928686853920226e-06
homeobox O 0 2.4466968170600012e-05
) O 0 6.360340876199189e-07
and O 0 1.350879529127269e-06
a O 0 1.4383519555849489e-05
proline O 0 6.579496402991936e-05
- O 0 4.816401269636117e-05
serine O 0 4.072225419804454e-05
- O 0 2.4646915335324593e-05
threonine O 0 3.600247509893961e-05
( O 0 1.4985961342972587e-06
PST O 0 7.200588879641145e-05
) O 0 5.213753979660396e-07
- O 0 3.445984020800097e-06
rich O 0 1.2076789062120952e-06
transactivation O 0 0.00016148664872162044
domain O 0 3.1832681997912005e-05
. O 0 3.7231898204481695e-06

PAX6 O 1 0.9935477375984192
regulates O 0 0.013843713328242302
eye O 1 0.9963359832763672
development O 0 0.000202938390430063
in O 0 1.3484156625054311e-05
animals O 0 1.2267590818737517e-06
ranging O 0 2.5305605959147215e-05
from O 0 5.201087788009318e-06
jellyfish O 0 1.5250609521899605e-06
to O 0 1.413056054389017e-07
Drosophila O 0 7.220637144200737e-06
to O 0 1.9203505985387892e-07
humans O 0 1.6942736920100288e-06
. O 0 9.001573744171765e-07

Heterozygous O 0 3.156909588142298e-05
mutations O 0 4.399505542096449e-06
in O 0 1.1319405075482791e-06
the O 0 1.1475552810225054e-06
human O 0 6.392768682417227e-06
PAX6 O 0 0.000267322437139228
gene O 0 1.4035874755791156e-06
result O 0 3.031253470453521e-07
in O 0 1.3256949671358598e-07
various O 0 1.5080051696259034e-07
phenotypes O 0 4.403014372655889e-06
, O 0 2.6526603846832586e-07
including O 0 1.934391320901341e-06
aniridia B-Disease 1 1.0
, O 0 9.778223466128111e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.1783604097436182e-05
autosomal B-Disease 1 0.9999397993087769
dominant I-Disease 1 0.9995720982551575
keratitis I-Disease 1 1.0
, O 0 1.5806706869625486e-05
and O 0 3.20671679219231e-05
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9995369911193848

It O 0 9.609317203285173e-06
is O 0 1.1262055750194122e-06
believed O 0 5.430791247817979e-07
that O 0 4.133357123237147e-08
the O 0 3.5522759844752727e-07
mutated O 0 8.998586622510629e-07
allele O 0 1.8551127141108736e-06
of O 0 1.4052219739824068e-05
PAX6 O 0 0.001114799757488072
produces O 0 7.080580417095916e-06
an O 0 2.4313674202858238e-06
inactive O 0 3.105029099970125e-05
protein O 0 2.898204911616631e-05
and O 0 1.3706010577152483e-05
aniridia B-Disease 1 1.0
is O 0 7.1248182393901516e-06
caused O 0 2.3896283892099746e-05
due O 0 1.912045627250336e-05
to O 0 1.2403287428242038e-06
genetic O 0 4.437085226527415e-05
haploinsufficiency O 0 0.0016308949561789632
. O 0 1.7947402739082463e-05

However O 0 0.00015365057333838195
, O 0 1.1690527571772691e-05
several O 0 2.2077513222029665e-06
truncation O 0 9.09244772628881e-05
mutations O 0 3.6451685900829034e-06
have O 0 6.90728541030694e-07
been O 0 9.597554253559792e-07
found O 0 6.533938545771889e-08
to O 0 2.4945110865814968e-08
occur O 0 1.4412283633191691e-07
in O 0 1.4506330217045615e-06
the O 0 1.2131689800298773e-05
C O 0 0.00048030843026936054
- O 0 6.330527685349807e-05
terminal O 0 0.0003890421357937157
half O 0 1.676829583630024e-06
of O 0 4.220812115818262e-06
PAX6 O 0 0.00013449823018163443
in O 0 1.4057416137802647e-06
patients O 0 8.529430601811328e-07
with O 0 6.00385590132646e-07
Aniridia B-Disease 1 0.9999966621398926
resulting O 0 3.4155993489548564e-05
in O 0 9.189342563331593e-06
mutant O 0 6.804830263718031e-06
proteins O 0 7.479233090634807e-07
that O 0 1.3024015288465307e-07
retain O 0 5.89351145663386e-07
the O 0 3.6663516311818967e-06
DNA O 0 3.430791821301682e-06
- O 0 6.006312560202787e-06
binding O 0 8.845562661008444e-06
domains O 0 2.717112329264637e-05
but O 0 1.0322725074729533e-06
have O 0 5.853891593687877e-07
lost O 0 5.142048394191079e-06
most O 0 1.4615712018439808e-07
of O 0 8.490548566442158e-07
the O 0 2.7734656669053948e-06
transactivation O 0 0.00021675019524991512
domain O 0 3.784649743465707e-05
. O 0 4.346090463513974e-06

It O 0 2.521445094316732e-05
is O 0 3.4931572372443043e-06
not O 0 3.3390503517694015e-07
clear O 0 9.908522997648106e-07
whether O 0 2.1115720016950945e-07
such O 0 1.5031307611934608e-06
mutants O 0 1.9419700038270094e-05
really O 0 8.930917829275131e-06
behave O 0 3.2814741643960588e-06
as O 0 1.2213286026963033e-06
loss O 0 4.081163751834538e-06
- O 0 1.238790673596668e-06
of O 0 6.938031219760887e-06
- O 0 7.5866555562242866e-06
function O 0 1.0547673809924163e-05
mutants O 0 3.2778871172922663e-06
as O 0 4.7135506520135095e-07
predicted O 0 3.868684871122241e-06
by O 0 3.7740031189059664e-07
haploinsufficiency O 0 7.182909030234441e-05
. O 0 4.316881131671835e-06

Contrary O 0 0.00011401925439713523
to O 0 1.7076222320611123e-06
this O 0 1.1739892897821846e-06
theory O 0 1.491668626840692e-05
, O 0 6.648590442637214e-07
our O 0 8.816253398435947e-07
data O 0 1.8756060171654099e-06
showed O 0 2.9188304324634373e-06
that O 0 2.422420948278159e-07
these O 0 1.5252311413860298e-07
mutants O 0 4.473839908314403e-06
are O 0 4.6050200808167574e-07
dominant O 0 3.6962987906008493e-06
- O 0 8.070267085713567e-07
negative O 0 4.4512921704153996e-07
in O 0 1.2319844699959503e-06
transient O 0 4.6003948227735236e-05
transfection O 0 3.7547109968727455e-05
assays O 0 4.669151621783385e-06
when O 0 8.72344344315934e-07
they O 0 1.1817733280850007e-07
are O 0 6.324280121816628e-08
coexpressed O 0 6.129590474301949e-06
with O 0 2.649586008374172e-07
wild O 0 6.777919679734623e-06
- O 0 5.711406993214041e-05
type O 0 0.00032751529943197966
PAX6 O 1 0.9475647807121277
. O 0 1.5074234397616237e-05

We O 0 5.1819952204823494e-05
found O 0 3.9263554754143115e-06
that O 0 5.307310857460834e-07
the O 0 5.642431460728403e-06
dominant O 0 3.6790439480682835e-05
- O 0 1.1742327842512168e-05
negative O 0 1.5926736978144618e-06
effects O 0 1.6253325156867504e-05
result O 0 2.3555328425572952e-06
from O 0 4.919083380627853e-07
the O 0 1.941642437941482e-07
enhanced O 0 3.833361859051365e-07
DNA O 0 2.7999860208183236e-07
binding O 0 4.11098170616242e-07
ability O 0 3.8199871710276057e-07
of O 0 3.314394461995107e-06
these O 0 6.02556156081846e-07
mutants O 0 1.142043765867129e-05
. O 0 1.4936337038307101e-06

Kinetic O 0 0.0010388664668425918
studies O 0 4.8651119868736714e-05
of O 0 3.767709858948365e-05
binding O 0 1.3928206499258522e-05
and O 0 3.251866473874543e-06
dissociation O 0 3.182603541063145e-05
revealed O 0 8.56664792081574e-06
that O 0 2.3541645077784779e-07
various O 0 9.418636182090268e-07
truncation O 0 5.4127976909512654e-05
mutants O 0 4.782521500601433e-06
have O 0 6.823525495747162e-07
3 O 0 1.6395158581872238e-06
- O 0 8.765858297010709e-07
5 O 0 1.951746980921598e-06
- O 0 1.4946340343158226e-06
fold O 0 1.925657670653891e-06
higher O 0 4.421904577611713e-06
affinity O 0 1.088175963559479e-06
to O 0 4.674657532177662e-07
various O 0 6.874440146020788e-07
DNA O 0 1.374938960907457e-06
- O 0 1.5893190266069723e-06
binding O 0 7.494219858017459e-07
sites O 0 3.438009912315465e-07
when O 0 1.368275377444661e-07
compared O 0 3.7080837955727475e-07
with O 0 3.418774241481515e-08
the O 0 1.0856540484383004e-06
wild O 0 5.121947651787195e-06
- O 0 2.132059853465762e-05
type O 0 5.9707330365199596e-05
PAX6 O 0 0.00370652019046247
. O 0 7.427128821291262e-06

These O 0 6.824099727964494e-06
results O 0 9.166506060864776e-06
provide O 0 4.0188845673583273e-07
a O 0 1.1518378641994786e-06
new O 0 3.9321798794844653e-07
insight O 0 7.263286647685163e-07
into O 0 8.145853058749708e-08
the O 0 1.6668934676999925e-07
role O 0 8.392519248445751e-07
of O 0 5.871263056178577e-06
mutant O 0 5.3258510888554156e-05
PAX6 O 0 0.0017570070922374725
in O 0 2.5748162443051115e-05
causing O 0 0.0002069504262180999
aniridia B-Disease 1 0.9999958276748657
. O 0 1.6878340147741255e-06
. O 0 1.7341559441774734e-06

Reversal O 0 0.004059239290654659
of O 0 0.0007723121671006083
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.21103794872760773
excellent O 1 0.5533396005630493
neuropsychologic O 1 0.938937783241272
outcome O 0 0.00032740290043875575
in O 0 5.938253161730245e-05
very B-Disease 0 6.687128006888088e-06
- I-Disease 0 2.0720650354633108e-05
long I-Disease 0 1.4393961464520544e-05
- I-Disease 0 2.5568635464878753e-05
chain I-Disease 0 4.247780088917352e-05
acyl I-Disease 0 1.7193917301483452e-05
- I-Disease 0 4.4140757381683215e-05
coenzyme I-Disease 0 5.486263762577437e-05
A I-Disease 0 0.0004141437530051917
dehydrogenase I-Disease 0 0.11626117676496506
deficiency I-Disease 1 0.9999631643295288
. O 0 2.3326670998358168e-05

Very B-Disease 0 0.0004100262885913253
- I-Disease 0 0.00018785939028020948
long I-Disease 0 4.242820796207525e-05
- I-Disease 0 4.265405732439831e-05
chain I-Disease 0 2.7770871383836493e-05
acyl I-Disease 0 5.6267413128807675e-06
- I-Disease 0 5.693326784239616e-06
coenzyme I-Disease 0 3.434831569393282e-06
A I-Disease 0 3.108901364612393e-05
dehydrogenase I-Disease 0 5.4947351600276306e-05
( I-Disease 0 8.99760107131442e-06
VLCAD I-Disease 0 0.12871550023555756
) I-Disease 0 2.002265136979986e-05
deficiency I-Disease 1 0.9997186064720154
is O 0 1.621631554371561e-06
a O 0 1.0472060239408165e-05
disorder O 1 0.9999680519104004
of O 1 0.943779468536377
fatty O 0 0.0036903275176882744
acid O 0 0.0001579405798111111
beta O 0 4.693671871791594e-05
oxidation O 0 7.261643077072222e-06
that O 0 5.196429810894188e-07
reportedly O 0 3.5501427646522643e-06
has O 0 3.635284713254805e-07
high O 0 2.994312580995029e-06
rates O 0 2.712719151531928e-07
of O 0 3.6184056284582766e-07
morbidity O 0 5.488262831931934e-05
and O 0 2.6555230761005078e-06
mortality O 0 0.00014845577243249863
. O 0 4.479107701627072e-06

We O 0 5.4381958761950955e-05
describe O 0 1.5943247490213253e-05
the O 0 8.183052159438375e-06
outcome O 0 1.0276098691974767e-05
of O 0 2.7315969418850727e-05
a O 0 2.611113632156048e-05
5 O 0 1.6771487935329787e-05
- O 0 9.878530363494065e-06
year O 0 8.56034330354305e-06
- O 0 1.3283619409776293e-05
old O 0 6.214951281435788e-05
girl O 0 4.814532439922914e-05
with O 0 2.8730421036016196e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 0.00034102227073162794
was O 0 0.00010451226989971474
first O 0 2.6729785531642847e-06
seen O 0 1.8051744063996011e-06
at O 0 8.292971642731573e-07
5 O 0 1.1576575786875765e-07
months O 0 1.8455326156185947e-08
of O 0 4.465858793878397e-08
age O 0 1.8796814629240544e-06
with O 0 9.99084704744746e-07
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999997615814209
hepatomegaly B-Disease 1 1.0
, O 1 0.9999985694885254
encephalopathy B-Disease 1 1.0
, O 0 9.259073522116523e-06
and O 0 8.199832336686086e-06
hypotonia B-Disease 1 0.995712161064148
. O 0 1.5512605386902578e-05

Biochemical O 0 0.01803029328584671
studies O 0 0.00201183813624084
indicated O 1 0.999937891960144
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 1 0.9950300455093384
by O 0 1.3674343790626153e-06
a O 0 3.5816913168673636e-06
stable O 0 3.1135867175180465e-05
yet O 0 1.8202383671450661e-06
inactive O 0 1.4810234461037908e-05
enzyme O 0 7.254714091686765e-06
. O 0 9.9046212653775e-07

Molecular O 0 0.0004692946677096188
genetic O 0 2.1791665858472697e-05
analysis O 0 4.54661631010822e-06
of O 0 2.4420089175691828e-05
her O 0 7.103315147105604e-05
VLCAD O 1 0.9829504489898682
gene O 0 0.00010886452946579084
revealed O 0 0.00013491247955244035
a O 0 4.365441054687835e-05
T1372C O 0 0.0002515481901355088
( O 0 4.531509148364421e-06
F458L O 0 6.393380317604169e-05
) O 0 1.720526370263542e-06
missense O 0 1.8074852050631307e-05
mutation O 0 3.486873538349755e-06
and O 0 4.355961664259667e-06
a O 0 2.9009897843934596e-05
1668 O 0 0.05165831372141838
ACAG O 0 0.029324959963560104
1669 O 0 0.005193882156163454
splice O 0 0.00019667147716972977
site O 0 1.764105945767369e-05
mutation O 0 5.562990736507345e-06
. O 0 1.7120804614023655e-06

After O 0 7.67434248700738e-05
initial O 0 1.9609131413744763e-05
treatment O 0 4.582858309731819e-05
with O 0 1.4653592188551556e-06
intravenous O 0 5.88821349083446e-05
glucose O 0 0.0005601352313533425
and O 0 3.004905920533929e-05
carnitine O 0 0.0005974990781396627
, O 0 3.589532070691348e-06
the O 0 4.427736257639481e-06
patient O 0 1.644766962272115e-05
has O 0 4.718849595519714e-06
thrived O 0 1.88727026397828e-05
on O 0 1.935473301273305e-05
a O 0 1.1983448530372698e-05
low O 0 6.617553299292922e-05
- O 0 1.2366905139060691e-05
fat O 0 1.2924901056976523e-05
diet O 0 2.1269493117870297e-06
supplemented O 0 2.0999804917209985e-07
with O 0 1.1089743878756053e-07
medium O 0 8.813498425297439e-06
- O 0 1.2788633284799289e-05
chain O 0 3.082200055359863e-05
triglyceride O 0 0.00011511665070429444
oil O 0 5.167777999304235e-05
and O 0 1.929126028699102e-06
carnitine O 0 2.775495704554487e-05
and O 0 5.263298135105288e-07
avoidance O 0 1.0474706868990324e-05
of O 0 1.801625512598548e-05
fasting O 0 0.00027074385434389114
. O 0 5.929552571615204e-06

Her O 0 0.013385592959821224
ventricular O 1 0.9999994039535522
hypertrophy O 1 0.9984970092773438
resolved O 0 0.00012873161176685244
significantly O 0 1.1589424502744805e-05
over O 0 7.303703114303062e-06
1 O 0 2.5947527319658548e-05
year O 0 9.493291145190597e-06
, O 0 1.905987460304459e-06
and O 0 2.6667937618185533e-06
cognitively O 0 0.00011058311793021858
, O 0 4.341535770890914e-07
she O 0 3.492240523428336e-07
is O 0 9.287272462188412e-08
in O 0 8.713992372122448e-08
the O 0 3.268470720740879e-07
superior O 0 5.416988642537035e-06
range O 0 2.9889858979004202e-06
for O 0 1.4049240917302086e-06
age O 0 3.511766772135161e-05
. O 0 4.251681275491137e-06

Clinical O 0 0.0033621436450630426
recognition O 0 0.2430073767900467
of O 1 1.0
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 0.0037660845555365086
important O 0 1.0686332643672358e-05
because O 0 2.1761668733688566e-07
it O 0 1.235859770076786e-08
is O 0 1.508116653781144e-08
one O 0 7.220554376630162e-09
of O 0 1.0660469484946589e-07
the O 0 4.3274357608424907e-07
few O 0 9.619728871257394e-07
directly O 0 7.526331046392443e-06
treatable O 1 0.5733510851860046
causes O 0 0.00014427087444346398
of O 0 0.16165365278720856
cardiomyopathy B-Disease 1 1.0
in O 0 0.0007424511713907123
children O 0 1.1697241461661179e-05
. O 0 4.0183059013543243e-07
. O 0 7.293821795428812e-07

Cloning O 0 7.028717664070427e-05
of O 0 2.355423384869937e-05
a O 0 7.054462457745103e-06
novel O 0 4.49820026915404e-06
member O 0 5.8518603509583045e-06
of O 0 1.3315719115780666e-05
the O 0 8.907501978683285e-06
low O 0 9.766613220563158e-05
- O 0 2.2914107830729336e-05
density O 0 3.691992242238484e-05
lipoprotein O 0 0.0023643572349101305
receptor O 0 0.0002982457517646253
family O 0 1.4476311662292574e-05
. O 0 2.1075834411021788e-06

A O 0 0.00017831395962275565
gene O 0 1.237967262568418e-05
encoding O 0 5.615141162707005e-06
a O 0 3.5347777611605125e-06
novel O 0 5.340543339116266e-06
transmembrane O 0 1.6126441551023163e-05
protein O 0 2.9041975722066127e-06
was O 0 3.3703969393172883e-07
identified O 0 6.015120845859201e-09
by O 0 7.305817617542232e-10
DNA O 0 4.923267571399492e-09
sequence O 0 2.681952970817747e-08
analysis O 0 3.8826335924113664e-08
within O 0 1.485061886796757e-07
the O 0 1.9073386283707805e-06
insulin B-Disease 0 0.004480738192796707
- I-Disease 1 0.9999657869338989
dependent I-Disease 1 0.9999904632568359
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.268857315357309e-05
IDDM B-Disease 0 0.0008658291772007942
) O 0 6.445769145102531e-07
locus O 0 8.70806888997322e-06
IDDM4 O 0 8.883628470357507e-05
on O 0 1.187620910059195e-05
chromosome O 0 0.00012477634300012141
11q13 O 0 0.0002309876581421122
. O 0 6.388636393239722e-06

Based O 0 9.083426266442984e-05
on O 0 7.595188799314201e-05
its O 0 1.2688120477832854e-05
chromosomal O 0 0.0007997608045116067
position O 0 0.00011748079850804061
, O 0 8.407635050389217e-07
this O 0 5.273964376328877e-08
gene O 0 2.325047461226859e-07
is O 0 8.371393533934679e-08
a O 0 1.4090674937961012e-07
candidate O 0 1.9339250911798445e-07
for O 0 5.3975711011844396e-08
conferring O 0 8.357276783499401e-06
susceptibility O 0 0.0002413406764389947
to O 0 7.179849944805028e-06
diabetes B-Disease 1 0.9999822378158569
. O 0 2.0793062503798865e-05

The O 0 0.00026170056662522256
gene O 0 2.5611656383262016e-05
, O 0 3.6818109947489575e-06
termed O 0 2.5989580535679124e-05
low O 0 6.321949331322685e-05
- O 0 8.241327122959774e-06
density O 0 7.229767106764484e-06
lipoprotein O 0 0.0002157670824090019
receptor O 0 4.308909774408676e-05
related O 0 3.620250572566874e-05
protein O 0 3.361005656188354e-05
5 O 0 2.170385414501652e-05
( O 0 1.0776769840958877e-06
LRP5 O 0 5.4496955272043124e-05
) O 0 1.2200160881548072e-07
, O 0 6.491604409575302e-08
encodes O 0 2.457360892549332e-07
a O 0 1.8057219222100684e-06
protein O 0 4.496509973250795e-06
of O 0 2.354688876948785e-05
1615 O 0 0.0006231729639694095
amino O 0 1.5299881852115504e-05
acids O 0 1.3883827705285512e-06
that O 0 1.0268569639038105e-07
contains O 0 2.841316870672017e-07
conserved O 0 1.3881392533221515e-06
modules O 0 1.260842850570043e-06
which O 0 6.17296080918095e-08
are O 0 2.4011908905663404e-08
characteristic O 0 7.084397566359257e-07
of O 0 1.8392235006103874e-06
the O 0 4.033404820802389e-06
low O 0 6.628308619838208e-05
- O 0 1.3580261111201253e-05
density O 0 1.651613820286002e-05
lipoprotein O 0 0.0006523191696032882
( O 0 8.503136996296234e-06
LDL O 0 0.0017122061690315604
) O 0 2.6389518552605296e-06
receptor O 0 3.2275023841066286e-05
family O 0 3.022068085556384e-06
. O 0 1.2173005643489887e-06

These O 0 3.945257958548609e-06
modules O 0 2.5926801754394546e-05
include O 0 2.184122649850906e-06
a O 0 4.388044999359408e-06
putative O 0 1.9600118321250193e-05
signal O 0 2.5465673388680443e-05
peptide O 0 5.206795322010294e-06
for O 0 1.437054947928118e-06
protein O 0 1.1521848136908375e-05
export O 0 2.317690996278543e-05
, O 0 2.2436220206145663e-06
four O 0 3.942820512747858e-06
epidermal O 0 5.5987125961109996e-05
growth O 0 2.3160913769970648e-05
factor O 0 4.612035354512045e-06
( O 0 7.450856287505303e-07
EGF O 0 1.386987332807621e-05
) O 0 1.1634771368562724e-07
repeats O 0 4.964411459695839e-07
with O 0 2.0836702674387197e-07
associated O 0 6.475518603110686e-06
spacer O 0 4.0226015698863193e-05
domains O 0 4.953815368935466e-05
, O 0 7.226561137940735e-06
three O 0 7.871676643844694e-06
LDL O 0 0.000522053858730942
- O 0 0.0001344083430012688
receptor O 0 0.00011015109339496121
( O 0 3.5386365198064595e-06
LDLR O 0 0.00011356612958479673
) O 0 5.992015417177754e-07
repeats O 0 2.185850007663248e-06
, O 0 3.1473430794903834e-07
a O 0 1.4870744280415238e-06
single O 0 3.015239599335473e-06
transmembrane O 0 2.770138598862104e-05
spanning O 0 0.00013838584709446877
domain O 0 9.702950774226338e-05
, O 0 3.549750090314774e-06
and O 0 1.8962062995342421e-06
a O 0 8.0388117567054e-06
cytoplasmic O 0 5.220355524215847e-05
domain O 0 7.569709123345092e-05
. O 0 7.555932825198397e-06

The O 0 5.320978380041197e-05
encoded O 0 9.983446943806484e-06
protein O 0 1.1064713362429757e-05
has O 0 4.61824043895831e-07
a O 0 3.5833167544296884e-07
unique O 0 5.067900019639637e-07
organization O 0 2.2532369712280342e-06
of O 0 1.9377630451344885e-05
EGF O 0 0.0003865397593472153
and O 0 2.0054372726008296e-05
LDLR O 0 0.0028010867536067963
repeats O 0 6.224025855772197e-05
; O 0 3.2283917335007573e-06
therefore O 0 6.101850885897875e-06
, O 0 2.914694050559774e-06
LRP5 O 0 0.00019602462998591363
likely O 0 4.1147254705720115e-06
represents O 0 1.316758016400854e-06
a O 0 3.4926870284834877e-07
new O 0 2.596059403003892e-07
category O 0 3.7434876958286623e-06
of O 0 6.777150701964274e-06
the O 0 2.7593496270128526e-05
LDLR O 0 0.0018927373457700014
family O 0 2.5492256099823862e-05
. O 0 8.299606633954681e-06

Both O 0 0.00034076007432304323
human O 0 0.0005787889240309596
and O 0 0.00012682010128628463
mouse O 0 0.0006146101513877511
LRP5 O 0 0.0036411022301763296
cDNAs O 0 0.0002945988089777529
have O 0 4.673718194680987e-06
been O 0 6.400039637810551e-06
isolated O 0 2.7779392439697403e-06
and O 0 6.09501910275867e-07
the O 0 1.3955790336694918e-06
encoded O 0 1.5795154695297242e-06
mature O 0 9.502969646746351e-07
proteins O 0 2.2932442789169727e-07
are O 0 5.920501422451707e-08
95 O 0 6.148273996586795e-07
% O 0 8.530351891522514e-08
identical O 0 9.54525276597451e-08
, O 0 4.2000021238663976e-08
indicating O 0 4.460096363345656e-07
a O 0 5.090957984066335e-07
high O 0 9.431396392756142e-06
degree O 0 2.5105806344072334e-05
of O 0 1.0285491953254677e-05
evolutionary O 0 1.7402229786966927e-05
conservation O 0 1.0431048167447443e-06
. O 0 8.461450562435857e-08
. O 0 3.844594402835355e-07

The O 0 0.0008126871543936431
APC B-Disease 0 0.00037298648385331035
variants O 0 6.326134462142363e-05
I1307K O 0 0.0003931278770323843
and O 0 1.325896391790593e-05
E1317Q O 0 0.0004412962880451232
are O 0 8.275793334178161e-06
associated O 0 0.0005377433844842017
with O 1 0.9928758144378662
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0011619466822594404
but O 0 2.5948222059923864e-07
not O 0 3.004046078558531e-08
always O 0 4.99658590058516e-08
with O 0 1.4483346966187582e-08
a O 0 5.670638074661838e-07
family O 0 6.371730592036329e-07
history O 0 7.980583177413791e-06
. O 0 3.006089400514611e-06

Classical O 1 0.9983522891998291
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9987945556640625
FAP B-Disease 1 0.9997037053108215
) O 0 1.2179300028947182e-05
is O 0 2.988022288263892e-06
a O 0 3.1661533284932375e-05
high O 1 0.9999995231628418
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
that O 0 1.1322655382173252e-06
predisposes O 0 8.12419875728665e-06
to O 0 2.55818889627335e-07
hundreds O 0 7.020918815214827e-07
or O 0 7.898362355263089e-07
thousands O 0 2.6334334961575223e-06
of O 0 0.0013349520741030574
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999701976776123
carcinoma I-Disease 1 1.0
and O 0 4.131283276365139e-06
that O 0 2.1001366690143186e-07
results O 0 1.0369493566031451e-06
from O 0 2.1812199690884881e-07
truncating O 0 1.5208925105980597e-06
mutations O 0 1.5033255351681873e-07
in O 0 6.418263751584163e-07
the O 0 4.258462013240205e-06
APC B-Disease 0 4.743483805214055e-05
gene O 0 7.591352186864242e-06
. O 0 2.2419067136070225e-06

A O 0 8.6757710960228e-05
variant O 0 6.009175558574498e-05
of O 0 8.016196079552174e-05
FAP B-Disease 0 0.0009572373237460852
is O 0 3.450459553278051e-05
attenuated B-Disease 0 0.007724693510681391
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
, O 0 4.715421164291911e-05
which O 0 4.803735919267638e-06
results O 0 7.529636786784977e-05
from O 0 2.84395064227283e-05
germ O 0 0.002887183101847768
- O 0 8.969857299234718e-05
line O 0 5.623111064778641e-05
mutations O 0 6.191042984937667e-07
in O 0 1.6280638419630122e-06
the O 0 2.086210315610515e-06
5 O 0 1.4814846736044274e-06
and O 0 1.8951708113945642e-07
3 O 0 1.2658584864766453e-06
regions O 0 2.0373887821278913e-07
of O 0 3.866789029416395e-06
the O 0 1.3845661669620313e-05
APC B-Disease 0 6.108110392233357e-05
gene O 0 5.152705853106454e-06
. O 0 1.3571707313531078e-06

Attenuated B-Disease 1 0.9999731779098511
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.8768969178199768
have O 0 2.421529461571481e-05
" O 0 0.0001375916472170502
multiple O 1 0.6949702501296997
" O 1 0.9999995231628418
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.9615918063209392e-05
typically O 0 5.411404231381312e-07
fewer O 0 1.2900177637220622e-07
than O 0 1.4640697543200076e-07
100 O 0 9.786214150153683e-07
) O 0 3.460169040181427e-08
without O 0 2.8433706944497317e-08
the O 0 4.736369589863898e-07
florid O 0 1.706781222310383e-05
phenotype O 0 3.5064679195784265e-06
of O 0 6.069697974453447e-06
classical O 0 0.00013226477312855422
FAP B-Disease 0 0.00015290852752514184
. O 0 2.6973875719704665e-06

Another O 0 0.00011533387441886589
group O 0 3.0048081498534884e-06
of O 0 3.92946867577848e-06
patients O 0 3.4433232940500602e-06
with O 0 9.72618295236316e-07
multiple O 0 0.0001855982409324497
adenomas B-Disease 1 0.9999991655349731
has O 0 6.412148650269955e-05
no O 0 4.8599754336464684e-06
mutations O 0 2.468188540660776e-06
in O 0 2.0673202016041614e-05
the O 0 2.607286660349928e-05
APC B-Disease 0 2.9045189876342192e-05
gene O 0 1.7344900697935373e-06
, O 0 2.7694693471858045e-07
and O 0 1.0599057276294843e-07
their O 0 1.621922507411e-07
phenotype O 0 6.472876066254685e-06
probably O 0 1.565738784847781e-06
results O 0 7.123060186131625e-07
from O 0 1.927458583850239e-07
variation O 0 8.980309189610125e-07
at O 0 1.4990554518590216e-05
a O 0 3.836345968011301e-06
locus O 0 1.5098677977221087e-05
, O 0 1.367052277601033e-06
or O 0 1.1810460591732408e-06
loci O 0 2.628575884955353e-06
, O 0 2.0205257555971912e-07
elsewhere O 0 1.4519974911308964e-07
in O 0 2.3196479048692709e-07
the O 0 1.2075786344212247e-06
genome O 0 4.46135709353257e-06
. O 0 1.7524670283819432e-06

Recently O 0 0.00030886882450431585
, O 0 5.886096914764494e-06
however O 0 6.254917366277368e-07
, O 0 2.4685456878614787e-07
a O 0 8.403193874073622e-07
missense O 0 1.208454432344297e-05
variant O 0 7.300873403437436e-05
of O 0 0.004418833646923304
APC B-Disease 0 0.0014542823191732168
( O 0 1.835885450418573e-05
I1307K O 0 0.000186714154551737
) O 0 7.76010836034402e-07
was O 0 1.3414718296189676e-06
described O 0 1.0653680249106401e-07
that O 0 3.6374254719362398e-09
confers O 0 2.2900184148966218e-07
an O 0 3.250949731636865e-08
increased O 0 2.077892759189126e-06
risk O 0 2.855143611668609e-05
of O 1 0.998740017414093
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0004288424097467214
including O 0 1.0178438969887793e-05
multiple O 0 0.0001060738431988284
adenomas B-Disease 1 0.9999842643737793
, O 0 4.833425919059664e-06
in O 0 8.271366823464632e-06
Ashkenazim O 0 0.0010916937608271837
. O 0 4.805683602171484e-06

We O 0 1.3226279406808317e-05
have O 0 5.096573545415595e-07
studied O 0 1.4807643538006232e-06
a O 0 1.905133757418298e-07
set O 0 1.0812124884296281e-07
of O 0 1.7302166099852911e-07
164 O 0 3.079081807300099e-06
patients O 0 5.581705977419915e-07
with O 0 6.343645964079769e-07
multiple O 1 0.9999986886978149
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 0.9980510473251343
carcinoma I-Disease 1 1.0
and O 0 0.00042114872485399246
analyzed O 0 8.065353176789358e-05
codons O 0 9.719582158140838e-05
1263 O 0 0.00018624884251039475
- O 0 2.4683517040102743e-05
1377 O 0 0.00014691826072521508
( O 0 1.0788081681312178e-06
exon O 0 3.538110377121484e-06
15G O 0 1.857477764133364e-05
) O 0 1.568295715514978e-07
of O 0 1.5909431567706633e-06
the O 0 5.421133209893014e-06
APC B-Disease 0 2.328577647858765e-05
gene O 0 3.651852694019908e-06
for O 0 4.123776307096705e-06
germ O 0 0.0004355558194220066
- O 0 6.651978037552908e-05
line O 0 2.709709406190086e-05
variants O 0 2.7145486001245445e-06
. O 0 1.2485304523579543e-06

Three O 0 0.00010021335037890822
patients O 0 1.6520927601959556e-05
with O 0 1.3043520539213205e-06
the O 0 1.9868406525347382e-05
I1307K O 0 0.00012692087329924107
allele O 0 1.5906754924799316e-05
were O 0 5.324833637132542e-06
detected O 0 3.053288082810468e-06
, O 0 7.898696452457443e-08
each O 0 2.2687411060928753e-08
of O 0 2.3035645426716655e-06
Ashkenazi O 0 0.0001053549931384623
descent O 0 0.0006016489933244884
. O 0 8.370038813154679e-06

Four O 0 0.00012705152039416134
patients O 0 2.9836668545613065e-05
had O 0 5.4752512369304895e-05
a O 0 5.8993191487388685e-05
germ O 0 0.0037407707422971725
- O 0 0.00022953690495342016
line O 0 0.0002249298559036106
E1317Q O 0 0.00017659453442320228
missense O 0 4.321604501456022e-05
variant O 0 3.7128382246010005e-05
of O 0 0.0002243675698991865
APC O 0 4.607357914210297e-05
that O 0 9.958694136003032e-07
was O 0 1.5262427041307092e-05
not O 0 2.428476761906495e-07
present O 0 7.082370530042681e-07
in O 0 2.895958687076927e-06
controls O 0 1.183777567348443e-05
; O 0 1.1942715900659095e-06
one O 0 8.454382509626157e-07
of O 0 3.9685755837126635e-06
these O 0 2.495939384061785e-07
individuals O 0 1.8363300569035346e-07
had O 0 2.7351086373528233e-06
an O 0 2.853566627436521e-07
unusually O 0 1.0744936389528448e-06
large O 0 4.0474824913872e-07
number O 0 1.4421525520447176e-06
of O 0 3.637210465967655e-05
metaplastic B-Disease 0 0.003190194023773074
polyps I-Disease 0 0.0009988804813474417
of I-Disease 0 6.839168781880289e-05
the I-Disease 0 5.381874507293105e-05
colorectum I-Disease 0 0.0008126128814183176
. O 0 1.0515885151107796e-05

There O 0 5.069564576842822e-05
is O 0 3.0516519018419785e-06
increasing O 0 9.97099164123938e-07
evidence O 0 1.222960236191284e-06
that O 0 2.6120477514268714e-07
there O 0 5.352942480385536e-07
exist O 0 3.198619197064545e-06
germ O 0 0.00011661292228382081
- O 0 1.1407527381379623e-05
line O 0 1.0107872185471933e-05
variants O 0 6.545108703903679e-07
of O 0 6.187523467815481e-06
the O 0 8.991502909339033e-06
APC B-Disease 0 1.4714868484588806e-05
gene O 0 1.257927664255476e-07
that O 0 1.2202250765369627e-08
predispose O 0 2.3999646714401024e-07
to O 0 1.0025626551168898e-08
the O 0 5.100093147802909e-08
development O 0 7.505170174226805e-07
of O 0 2.056799530691933e-05
multiple O 1 0.9999997615814209
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 6.427251355489716e-05
but O 0 2.7888384579455305e-07
without O 0 3.073133711950504e-07
the O 0 8.376766800211044e-07
florid O 0 4.804194759344682e-05
phenotype O 0 1.4887367797200568e-05
of O 0 2.1766867575934157e-05
classical O 0 0.00030227345996536314
FAP B-Disease 0 5.6274409871548414e-05
, O 0 1.0375948988894379e-07
and O 0 2.0370871212094244e-08
possibly O 0 2.439106516760603e-08
with O 0 3.660343583788972e-09
importance O 0 2.734354893618729e-06
for O 0 0.0010215946240350604
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 6.101216422393918e-05
in O 0 8.759014349379868e-07
the O 0 5.076457227914943e-07
general O 0 4.042941554871504e-07
population O 0 5.194250007889423e-08
. O 0 6.18845064082052e-08
. O 0 5.245464080871898e-07

Genomic O 0 3.710020610014908e-05
structure O 0 5.4423608162323944e-06
of O 0 2.9050756893411744e-06
the O 0 2.9448068744386546e-05
human O 1 0.9999845027923584
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9993013143539429
CLD B-Disease 1 0.9999998807907104
) O 0 9.145297553914133e-06
gene O 0 1.7572401702636853e-05
. O 0 3.2372338409913937e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999953508377075
CLD B-Disease 1 1.0
) O 0 1.766452805895824e-05
is O 0 1.8508575294617913e-06
caused O 0 6.763707460777368e-06
by O 0 1.2792978054676496e-07
mutations O 0 1.8579230243176426e-07
in O 0 4.5054804331812193e-07
a O 0 3.301987874237966e-07
gene O 0 1.21549618370409e-07
which O 0 7.301770210688119e-08
encodes O 0 1.127488758356776e-06
an O 0 1.6810325860205921e-06
intestinal O 1 0.9422755241394043
anion O 0 0.0006941979518160224
transporter O 0 0.0038349947426468134
. O 0 8.362331755051855e-06

We O 0 1.1347743566147983e-05
report O 0 8.887357694220555e-07
here O 0 1.7645287186951464e-07
the O 0 8.950105012672793e-08
complete O 0 5.684997859134455e-07
genomic O 0 1.9961053112638183e-06
organization O 0 1.037560764416412e-06
of O 0 8.565291864215396e-06
the O 0 4.640513361664489e-05
human O 0 0.00022258117678575218
CLD B-Disease 0 0.0028306206222623587
gene O 0 1.0571800885372795e-05
which O 0 2.1502364688785747e-06
spans O 0 1.5242005247273482e-05
approximately O 0 4.229689238854917e-06
39kb O 0 6.574415601789951e-05
, O 0 8.752083999752358e-07
and O 0 5.076354909760994e-07
comprises O 0 2.997035153384786e-06
21 O 0 3.815746822510846e-05
exons O 0 6.166425009723753e-05
. O 0 4.600113243213855e-06

All O 0 0.00011026870197383687
exon O 0 0.00015624210936948657
/ O 0 9.174814476864412e-05
intron O 0 6.847535405540839e-05
boundaries O 0 4.040107342007104e-06
conform O 0 2.4135715648299083e-06
to O 0 7.449889380950481e-07
the O 0 1.1271725270489696e-05
GT O 0 0.0002313976438017562
/ O 0 0.00018799681856762618
AG O 0 0.0023512691259384155
rule O 0 6.938229489605874e-05
. O 0 7.457100309693487e-06

An O 0 1.776391036401037e-05
analysis O 0 4.8922943278739695e-06
of O 0 1.960881127160974e-05
the O 0 1.4221196579455864e-05
putative O 0 0.00013620741083286703
promoter O 0 7.916634785942733e-05
region O 0 2.962417966045905e-06
sequence O 0 4.150562745053321e-06
shows O 0 7.869364708312787e-06
a O 0 3.2411786378361285e-05
putative O 0 0.00043271807953715324
TATA O 0 0.000605646928306669
box O 0 3.520740210660733e-05
and O 0 6.571859216819576e-07
predicts O 0 4.116629042982822e-06
multiple O 0 7.32833484562434e-07
transcription O 0 3.195942917955108e-05
factor O 0 4.805124262929894e-06
binding O 0 2.145680809917394e-06
sites O 0 3.6424094105313998e-06
. O 0 1.1114578910564887e-06

The O 0 0.00017804790695663542
genomic O 0 0.0001350262318737805
structure O 0 0.00010450987610965967
was O 0 5.134948150953278e-05
determined O 0 1.2805920732716913e-06
using O 0 2.2769218332996388e-07
DNA O 0 2.716506628530624e-07
from O 0 3.911690669156087e-07
several O 0 1.156410647240591e-07
sources O 0 2.77553766636629e-07
including O 0 2.703127961467544e-07
multiple O 0 2.360966391279362e-06
large O 0 2.0043531549163163e-05
- O 0 0.00020087274606339633
insert O 0 1.7439646398997866e-05
libaries O 0 0.00017843267414718866
and O 0 9.19290243928117e-07
genomic O 0 5.911794687563088e-06
DNA O 0 2.1752216525783297e-06
from O 0 5.601555585599272e-06
Finnish O 0 0.0013773258542641997
CLD B-Disease 1 0.8820616006851196
patients O 0 2.192438842030242e-05
and O 0 5.33436877958593e-06
controls O 0 7.036497117951512e-05
. O 0 5.012841484131059e-06

Exon O 0 0.0020541443955153227
- O 0 0.0001857039169408381
specific O 0 3.4649224289751146e-06
primers O 0 5.434743070509285e-05
developed O 0 1.6514485423613223e-06
in O 0 1.917510559223956e-07
this O 0 9.35343535957145e-09
study O 0 8.577237586848696e-09
will O 0 2.405397880878013e-09
facilitate O 0 1.1152739176623072e-08
mutation O 0 1.4242250934159983e-08
screening O 0 3.921334013057276e-08
studies O 0 8.128997563972007e-08
of O 0 2.0179606963210972e-07
patients O 0 1.8189405182056362e-07
with O 0 5.658429458321734e-08
the O 0 7.5702782851294614e-06
disease O 0 0.0026751654222607613
. O 0 4.792392701347126e-06

Genomic O 0 0.0001231758069479838
sequencing O 0 6.416766700567678e-05
of O 0 0.00010143977851839736
a O 0 0.00026347936363890767
BAC O 0 0.011369231157004833
clone O 0 0.0013952013105154037
H O 1 0.9999997615814209
_ O 0 1.3475272680807393e-05
RG364P16 O 0 4.258272747392766e-05
revealed O 0 5.983637947792886e-06
the O 0 1.5400358961414895e-06
presence O 0 1.2343825801508501e-06
of O 0 6.883329206175404e-06
another O 0 2.462909833411686e-06
, O 0 2.678451949122973e-07
highly O 0 3.3183147252202616e-07
homologous O 0 7.623591500305338e-07
gene O 0 1.1552107253010035e-06
3 O 0 7.467255727533484e-06
of O 0 2.1764148186775856e-05
the O 0 6.655773177044466e-05
CLD B-Disease 0 0.00446389801800251
gene O 0 1.3158091860532295e-05
, O 0 2.0374878317852563e-07
with O 0 2.4602819337360415e-08
a O 0 2.3372703594759514e-07
similar O 0 1.1561879631472038e-07
genomic O 0 2.2371075374394422e-06
structure O 0 4.369004273030441e-06
, O 0 1.1360830853845982e-07
recently O 0 2.961718337246566e-07
identified O 0 1.704589749351726e-07
as O 0 9.312706197306397e-07
the O 0 3.568625470506959e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.0014445604756474495
( O 0 2.6660776711651124e-05
PDS B-Disease 0 0.00047605964937247336
) O 0 4.952376571054629e-07
. O 0 1.4044255181033805e-07
. O 0 6.804816052863316e-07

The O 0 0.0009983140043914318
APCI1307K O 0 0.16143016517162323
allele O 0 0.0005556369433179498
and O 0 6.0644691984634846e-05
cancer B-Disease 1 0.7585351467132568
risk O 0 1.716599945211783e-05
in O 0 2.1180712792556733e-06
a O 0 1.7073812159651425e-06
community O 0 4.60257894019378e-07
- O 0 4.197399334771035e-07
based O 0 4.3787551362584054e-08
study O 0 7.599565066129799e-08
of O 0 9.130109219768201e-07
Ashkenazi O 0 1.308170521951979e-05
Jews O 0 1.2726292879960965e-05
. O 0 3.421147084736731e-06

Mutations O 0 0.0003749301831703633
in O 0 4.6664074034197256e-05
APC O 0 0.00022291377536021173
are O 0 3.0085072921792744e-07
classically O 0 4.5857956138206646e-05
associated O 0 3.3328510653518606e-06
with O 0 3.2112270673678722e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999945163726807
FAP B-Disease 1 0.9999915361404419
) O 0 3.2081627523439238e-06
, O 0 3.4114012237296265e-07
a O 0 8.14800205262145e-06
highly O 1 0.9999698400497437
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 1.0
by O 0 0.00030056704417802393
multiple O 1 0.9918574690818787
intestinal O 1 1.0
polyps B-Disease 1 1.0
and O 0 5.467018581839511e-06
, O 0 1.6733760332954262e-07
without O 0 1.1674784872184318e-07
surgical O 0 0.000156778609380126
intervention O 0 6.637410933763022e-06
, O 0 8.004786167248312e-08
the O 0 2.574123243448412e-07
development O 0 1.191759747598553e-05
of O 0 0.04084521159529686
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00032115349313244224
CRC B-Disease 0 0.0142291858792305
) O 0 1.0493827176105697e-06
. O 0 7.02939985330886e-07

APC B-Disease 0 0.005679306108504534
is O 0 8.201515447581187e-05
a O 0 0.00012052787496941164
tumour O 1 1.0
- O 0 0.0024843683931976557
suppressor O 0 0.0007632278720848262
gene O 0 1.4289754517449182e-06
, O 0 1.2712247610124905e-07
and O 0 1.4981516471834766e-07
somatic O 0 2.161431621061638e-05
loss O 0 0.00021473861124832183
occurs O 0 3.091853795922361e-05
in O 0 0.00012049580254824832
tumours B-Disease 1 1.0
. O 0 2.3821197828510776e-05

The O 0 0.003086868906393647
germline O 0 0.0047623589634895325
T O 0 0.0008054279605858028
- O 0 1.0903931070060935e-05
to O 0 1.4164319281917415e-06
- O 0 4.697315944213187e-06
A O 0 1.2098947991034947e-05
transversion O 0 3.6204128264216706e-05
responsible O 0 4.793896550836507e-06
for O 0 2.576625774963759e-06
the O 0 2.8635398848564364e-05
APC O 0 0.00013120746007189155
I1307K O 0 7.164957787608728e-05
allele O 0 8.816590707283467e-06
converts O 0 4.069305759912822e-06
the O 0 1.3057858723186655e-06
wild O 0 4.851195853916579e-07
- O 0 8.607114523329074e-07
type O 0 6.311361744337773e-07
sequence O 0 8.489787433063611e-07
to O 0 1.2773584785463754e-06
a O 0 6.7010463681072e-05
homopolymer O 0 0.043168678879737854
tract O 1 0.999767005443573
( O 0 5.824036998092197e-05
A8 O 0 0.0013615217758342624
) O 0 8.049628945627774e-07
that O 0 2.044218234686923e-07
is O 0 2.7592300284595694e-06
genetically O 0 8.644793524581473e-06
unstable O 0 5.675427019014023e-05
and O 0 1.6157639493030729e-06
prone O 0 1.6197636796277948e-05
to O 0 5.518313059837965e-07
somatic O 0 5.0776248826878145e-05
mutation O 0 6.788742666685721e-06
. O 0 2.3362015326711116e-06

The O 0 0.00034903091727755964
I1307K O 0 0.0007742302841506898
allele O 0 4.326280759414658e-05
was O 0 2.7344090995029546e-05
found O 0 8.387597745240782e-07
in O 0 1.0632948033162393e-06
6 O 0 2.0629402570193633e-05
. O 0 2.629039499879582e-06

1 O 0 0.0002826001145876944
% O 0 1.5034638636279851e-05
of O 0 1.911607978399843e-05
unselected O 0 0.0011125410674139857
Ashkenazi O 0 7.040355558274314e-05
Jews O 0 1.0904202099482063e-05
and O 0 2.0858981315541314e-06
higher O 0 1.5674384485464543e-05
proportions O 0 1.4258785085985437e-05
of O 0 5.9262885770294815e-05
Ashkenazim O 0 0.0002565425238572061
with O 0 1.2530202866400941e-06
family O 0 3.8035775560274487e-06
or O 0 2.616390702314675e-06
personal O 0 1.450333911634516e-05
histories O 0 1.7101132470997982e-05
of O 0 0.004670583643019199
CRC B-Disease 1 0.9968729615211487
( O 0 8.515122317476198e-06
ref O 0 0.0002666438522282988
. O 0 7.886462753958767e-07
2 O 0 7.777447535772808e-06
) O 0 6.09055121003621e-07
. O 0 6.613619234485668e-07

To O 0 6.574657618330093e-06
evaluate O 0 3.686061972985044e-06
the O 0 4.236450422467897e-06
role O 0 9.48625984165119e-06
of O 0 5.959891132079065e-05
I1307K O 0 0.0004175624926574528
in O 0 6.57748241792433e-05
cancer B-Disease 0 0.0021483541931957006
, O 0 5.452246568893315e-06
we O 0 1.489770056650741e-06
genotyped O 0 0.00011009701120201498
5 O 0 2.9725253625656478e-05
, O 0 2.70255782197637e-06
081 O 0 0.0001315589906880632
Ashkenazi O 0 1.5861945939832367e-05
volunteers O 0 8.350182270078221e-07
in O 0 4.71510645638773e-07
a O 0 6.884635013193474e-07
community O 0 3.6429824490369356e-07
survey O 0 1.85834778676508e-06
. O 0 1.8452284393788432e-06

Risk O 0 0.0010275068925693631
of O 0 0.0007297243573702872
developing O 1 0.5082308053970337
colorectal B-Disease 1 1.0
, I-Disease 0 0.015717417001724243
breast I-Disease 1 0.9994409680366516
and I-Disease 0 9.157377644442022e-05
other I-Disease 0 7.454561455233488e-06
cancers I-Disease 1 0.9997833371162415
were O 0 8.523993892595172e-05
compared O 0 3.886815829901025e-05
between O 0 1.8499331417842768e-05
genotyped O 0 0.0006829238263890147
I1307K O 0 0.00020393540035001934
carriers O 0 6.327843038889114e-06
and O 0 4.626630015991395e-06
non O 0 1.6022264389903285e-05
- O 0 1.2681433645411744e-06
carriers O 0 1.079281943816568e-07
and O 0 4.6103018291887565e-08
their O 0 5.308854866825641e-08
first O 0 7.396751584565209e-07
- O 0 1.3295276630742592e-06
degree O 0 4.5228392991703004e-05
relatives O 0 6.128362656454556e-06
. O 0 1.4513733503918047e-06

Sperm O 0 2.4020759155973792e-05
DNA O 0 4.796247139893239e-06
analysis O 0 1.817577413021354e-06
in O 0 4.9641494115348905e-06
a O 0 8.12687721918337e-05
Friedreich B-Disease 1 0.9999735355377197
ataxia I-Disease 1 1.0
premutation O 1 0.9999957084655762
carrier O 0 0.0002965680614579469
suggests O 0 1.9469656763249077e-05
both O 0 1.9243725546402857e-06
meiotic O 0 8.917033119359985e-05
and O 0 1.6294898159685545e-06
mitotic O 0 1.1832662494271062e-05
expansion O 0 8.403208084928337e-06
in O 0 1.4815043414273532e-06
the O 0 4.517567504080944e-06
FRDA B-Disease 0 0.00044509427971206605
gene O 0 1.3433623280434404e-05
. O 0 3.932145318685798e-06

Friedreich B-Disease 1 0.9999996423721313
ataxia I-Disease 1 1.0
is O 0 0.026323724538087845
usually O 0 4.3925429054070264e-05
caused O 0 6.27377157798037e-05
by O 0 1.9777638726736768e-07
an O 0 1.491169996370445e-07
expansion O 0 3.0042865546420217e-06
of O 0 1.1883686056535225e-05
a O 0 2.641707942530047e-05
GAA O 0 0.00010986901179421693
trinucleotide O 0 7.591547182528302e-05
repeat O 0 4.168306077190209e-06
in O 0 2.5791114239837043e-06
intron O 0 3.226575790904462e-05
1 O 0 1.2256900845386554e-05
of O 0 8.335739039466716e-06
the O 0 2.593664248706773e-05
FRDA B-Disease 0 0.002413875423371792
gene O 0 3.971823753090575e-05
. O 0 6.7461078288033605e-06

Occasionally O 0 0.0004955799086019397
, O 0 2.065649096039124e-05
a O 0 6.502374617411988e-06
fully O 0 3.182477485097479e-06
expanded O 0 7.3530018198653124e-06
allele O 0 7.451690635207342e-06
has O 0 2.7773564852395793e-06
been O 0 2.1346388621168444e-06
found O 0 5.068678206043842e-07
to O 0 1.2133419602378126e-07
arise O 0 9.203894819620473e-07
from O 0 1.020238414639607e-06
a O 0 1.9757212612603325e-06
premutation O 0 3.109835597570054e-05
of O 0 1.815402356442064e-05
100 O 0 2.9630917197209783e-05
or O 0 3.080876695094048e-06
less O 0 2.2638621430814965e-06
triplet O 0 0.00041844008956104517
repeats O 0 7.599869422847405e-05
. O 0 6.970694357733009e-06

We O 0 2.5463074052822776e-05
have O 0 9.596601557859685e-07
examined O 0 1.8025423287326703e-06
the O 0 3.0997478006611345e-07
sperm O 0 3.288186292138562e-07
DNA O 0 2.5701444883452496e-07
of O 0 4.199519935355056e-06
a O 0 1.601343319634907e-05
premutation O 0 0.0007085290271788836
carrier O 0 7.625771104358137e-05
. O 0 1.4917553926352412e-05

This O 0 3.8861817301949486e-05
mans O 0 0.00043383261072449386
leucocyte O 0 0.0003856378607451916
DNA O 0 1.0289199963153806e-05
showed O 0 2.5521250790916383e-05
one O 0 1.8470454961061478e-06
normal O 0 1.1927900231967214e-05
allele O 0 1.5670563016101369e-06
and O 0 3.5696498912329844e-07
one O 0 9.409158252537964e-08
allele O 0 1.8485945929569425e-07
of O 0 7.853596457607637e-07
approximately O 0 9.617876912670908e-07
100 O 0 5.064545348432148e-06
repeats O 0 6.6027009779645596e-06
. O 0 1.776201429493085e-06

His O 0 0.0004084546526428312
sperm O 0 5.931800842517987e-05
showed O 0 3.466937778284773e-05
an O 0 1.380089884150948e-06
expanded O 0 6.051734089851379e-06
allele O 0 1.38481173053151e-05
in O 0 1.0485460734344088e-05
a O 0 2.1744586774730124e-05
tight O 0 3.067720535909757e-05
range O 0 8.646657079225406e-06
centering O 0 9.269871043215971e-06
on O 0 2.6280195015715435e-06
a O 0 6.566371553162753e-07
size O 0 3.751961799025594e-07
of O 0 2.6608668122207746e-06
approximately O 0 7.252755949593848e-06
320 O 0 2.359366771997884e-05
trinucleotide O 0 0.0002167014463339001
repeats O 0 4.6147852117428556e-05
. O 0 5.417205557023408e-06

His O 0 0.0033111381344497204
affected O 0 0.0007913437439128757
son O 0 0.0010665170848369598
has O 0 6.017113719281042e-06
repeat O 0 2.6839109068532707e-06
sizes O 0 1.482253424001101e-06
of O 0 1.0713630217651371e-05
1040 O 0 2.267434319946915e-05
and O 0 1.9290689579065656e-06
540 O 0 3.789604306803085e-05
. O 0 2.7404219054005807e-06

These O 0 1.7178133930428885e-05
data O 0 2.170252992073074e-05
suggest O 0 4.380840891826665e-06
that O 0 4.360095147148968e-07
expansion O 0 1.1310618901916314e-05
occurs O 0 1.068540200321877e-06
in O 0 1.1112607580798795e-06
two O 0 5.579166781899403e-07
stages O 0 5.322366178006632e-06
, O 0 2.833469920915377e-07
the O 0 2.3296418305562838e-07
first O 0 2.7983548989141127e-07
during O 0 5.128078441885009e-07
meiosis O 0 5.828584335176856e-07
followed O 0 6.369932066263573e-07
by O 0 7.344497277017581e-08
a O 0 6.557053211508901e-07
second O 0 6.1527116486104205e-06
mitotic O 0 2.3434140530298464e-05
expansion O 0 4.645316948881373e-05
. O 0 7.635082511114888e-06

We O 0 9.972858970286325e-05
also O 0 6.461269094870659e-06
show O 0 1.7584102351975162e-06
that O 0 1.3022524569805682e-07
in O 0 5.039171355747385e-07
all O 0 1.8083707686855632e-07
informative O 0 1.1452308399384492e-06
carrier O 0 3.9450737858715e-06
father O 0 9.45639840210788e-06
to O 0 4.231357024764293e-07
affected O 0 1.5537051467617857e-06
child O 0 7.936720976431388e-06
transmissions O 0 1.1315819392621052e-05
, O 0 3.0884731927471876e-07
with O 0 3.348182175955117e-08
the O 0 1.037934794112516e-06
notable O 0 4.091022674401756e-06
exception O 0 4.967279892298393e-06
of O 0 3.2678515708539635e-05
the O 0 3.109710814896971e-05
premutation O 0 0.00020753017452079803
carrier O 0 9.451619916944765e-06
, O 0 9.429601277588517e-07
the O 0 4.4383037334227993e-07
expansion O 0 1.8822072433977155e-06
size O 0 6.149335263216926e-07
decreases O 0 1.0043886504718103e-05
. O 0 5.98618953517871e-07
. O 0 1.2912538522869e-06

The O 0 0.00012109048839192837
R496H O 0 0.00045491784112527966
mutation O 0 1.0390290299255867e-05
of O 0 2.5039502361323684e-05
arylsulfatase O 0 0.0013628327287733555
A O 0 7.635056681465358e-05
does O 0 1.4635869547419134e-06
not O 0 4.36533082392998e-06
cause O 0 0.0020508216693997383
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.9889410143368877e-05

Deficiency B-Disease 1 0.9999994039535522
of I-Disease 0 0.004584205336868763
arylsulfatase I-Disease 1 0.9986456036567688
A I-Disease 0 0.0037238518707454205
( O 0 1.332482679572422e-05
ARSA O 0 0.0007881153142079711
) O 0 1.2195617955512716e-06
enzyme O 0 5.349438652046956e-06
activity O 0 4.383666964713484e-05
causes O 0 0.0017049148445948958
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0001429243420716375
MLD B-Disease 1 1.0
) O 0 4.753873326990288e-06
. O 0 1.9134456579195103e-06

A O 0 5.071653868071735e-05
number O 0 3.315311005280819e-06
of O 0 3.830216883216053e-05
ARSA O 0 0.003693854669108987
gene O 0 2.6386036552139558e-05
mutations O 0 9.760081411513966e-06
responsible O 0 1.631343548069708e-05
for O 0 1.204633190354798e-05
MLD B-Disease 1 1.0
have O 0 2.553806552896276e-06
been O 0 3.5908469726564363e-06
identified O 0 1.7081044916267274e-06
. O 0 8.397794317716034e-07

Recently O 0 0.0005047502345405519
, O 0 1.3809647498419508e-05
the O 0 1.328620328422403e-05
R496H O 0 0.00010042323992820457
mutation O 0 4.5838405640097335e-06
of O 0 5.273372880765237e-05
ARSA O 0 0.0011709025129675865
was O 0 2.2491583877126686e-05
proposed O 0 5.70675865674275e-07
to O 0 1.0203770273164992e-07
be O 0 2.1777363201636035e-07
a O 0 1.2014135108984192e-06
cause O 0 1.046000215865206e-05
of O 0 0.0003336752124596387
MLD B-Disease 1 1.0
( O 0 3.081072281929664e-05
Draghia O 0 0.0007355167181231081
et O 0 0.002214567270129919
al O 0 0.00015318478108383715
. O 0 2.83593521999137e-07
, O 0 2.397086973360274e-07
1997 O 0 2.840373554136022e-06
) O 0 4.4306281665740244e-07
. O 0 6.606193778679881e-07

We O 0 4.0564933442510664e-05
have O 0 3.4086217510775896e-06
investigated O 0 8.775697097007651e-06
the O 0 5.278521712170914e-06
R496H O 0 3.6466604797169566e-05
mutation O 0 1.0418898455100134e-06
and O 0 5.068934569862904e-07
found O 0 2.2781077291256224e-07
this O 0 6.001806696076528e-08
mutation O 0 4.203728849461186e-07
at O 0 9.756712643138599e-06
a O 0 1.3199968407207052e-06
relatively O 0 1.3997137102705892e-06
high O 0 9.672029591456521e-06
frequency O 0 2.8048416425008327e-06
in O 0 1.3053016800768091e-06
an O 0 6.151311708890717e-07
African O 0 1.4773085013075615e-06
American O 0 9.82162987384072e-07
population O 0 9.655375521333553e-08
( O 0 1.502068727177175e-07
f O 0 1.16125575004844e-05
= O 0 3.8268271964625455e-06
0 O 0 1.3113317436364014e-06
. O 0 5.451631679420643e-08
09 O 0 4.5621918616234325e-06
, O 0 2.626315449560934e-07
n O 0 6.4122887124540284e-06
= O 0 1.0337826097384095e-05
61 O 0 9.106430297833867e-06
subjects O 0 9.460592991672456e-06
) O 0 1.61349123573018e-06
. O 0 8.06949003617774e-07

The O 0 0.001128900796175003
ARSA O 0 0.007919383235275745
enzyme O 0 3.5551234759623185e-05
activity O 0 6.846001269877888e-06
in O 0 6.748764462827239e-07
subjects O 0 1.6026427829274326e-06
with O 0 2.688591678179364e-07
and O 0 6.592951535822067e-07
without O 0 1.4897814253345132e-06
the O 0 7.12893688614713e-06
R496H O 0 5.8407946198713034e-05
mutation O 0 2.9443917810567655e-06
was O 0 2.4604503778391518e-05
determined O 0 1.2898741488243104e-06
and O 0 3.528499803451268e-07
found O 0 2.3416610872573074e-07
to O 0 4.8321727064148945e-08
be O 0 8.211431463678309e-07
normal O 0 2.1486424884642474e-05
. O 0 2.9106108740961645e-06

It O 0 1.0388595910626464e-05
is O 0 2.0439269974303897e-06
therefore O 0 7.872898777350201e-07
concluded O 0 1.7899907334140153e-06
that O 0 1.9270946438609826e-07
the O 0 2.4449764168821275e-06
R496H O 0 4.2211893742205575e-05
mutation O 0 3.7427450934046647e-06
of O 0 8.845132833812386e-05
ARSA O 0 0.001566635095514357
does O 0 1.4691540854983032e-06
not O 0 3.8572352423216216e-07
negatively O 0 6.842357720415748e-07
influence O 0 1.8730605688688229e-06
the O 0 1.9927597350033466e-06
activity O 0 7.582113084936282e-06
of O 0 1.05225562947453e-05
ARSA O 0 0.0003533952694851905
and O 0 1.0244971235806588e-06
is O 0 1.8950984781440638e-07
not O 0 6.311614697551704e-08
a O 0 9.936381957231788e-07
cause O 0 1.0708573427109513e-05
of O 0 0.0002874602214433253
MLD B-Disease 1 1.0

Down O 0 0.0012037943815812469
- O 0 3.550552355591208e-05
regulation O 0 5.106807748234132e-06
of O 0 1.0332188139727805e-05
transmembrane O 0 0.0001487612898927182
carbonic O 0 0.0008123224833980203
anhydrases O 0 0.003447466529905796
in O 0 0.005810801405459642
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999992847442627
lines O 0 0.00041823211358860135
by O 0 1.8991814840774168e-06
wild O 0 8.570586942369118e-06
- O 0 2.2806652850704268e-05
type O 0 0.00017869182920549065
von B-Disease 1 0.9999946355819702
Hippel I-Disease 1 0.9999971389770508
- I-Disease 1 0.9986523985862732
Lindau I-Disease 1 0.9982572197914124
transgenes O 0 0.002675231546163559
. O 0 8.9972318164655e-06

To O 0 7.758549145364668e-06
discover O 0 3.3828152936621336e-06
genes O 0 2.4040059543040115e-06
involved O 0 1.9396338757360354e-06
in O 0 9.654059795138892e-06
von B-Disease 1 0.9976904392242432
Hippel I-Disease 1 0.9999985694885254
- I-Disease 1 0.9999990463256836
Lindau I-Disease 1 0.9999994039535522
( O 0 0.000461551477201283
VHL B-Disease 1 0.9764081835746765
) O 0 3.898606337315869e-06
- O 0 2.097005199175328e-05
mediated O 0 0.00014683451445307583
carcinogenesis O 1 0.9417176246643066
, O 0 6.216714041329396e-07
we O 0 3.5799419606519223e-07
used O 0 2.8476741135818884e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.03232114017009735
stably O 0 0.0050614988431334496
transfected O 0 0.00010746170300990343
with O 0 1.0007601076722494e-06
wild O 0 1.4637287677032873e-05
- O 0 8.003822586033493e-05
type O 0 0.0002792159793898463
VHL O 0 0.0176270492374897
- O 0 5.296894596540369e-05
expressing O 0 6.4679943534429185e-06
transgenes O 0 0.00013985461555421352
. O 0 2.31641456593934e-06

Large O 0 6.483065226348117e-05
- O 0 2.0398070773808286e-05
scale O 0 6.0296679293969646e-05
RNA O 0 3.665603435365483e-05
differential O 0 8.551578503102064e-05
display O 0 5.49618671357166e-05
technology O 0 1.370182781101903e-05
applied O 0 2.8156719054095447e-06
to O 0 2.071194700192791e-07
these O 0 2.2225654561225383e-07
cell O 0 7.954808097565547e-06
lines O 0 1.5492604461542214e-06
identified O 0 2.1733545452207181e-07
several O 0 5.083718690457317e-08
differentially O 0 4.421794983500149e-06
expressed O 0 4.7646392431488493e-07
genes O 0 2.8855987466158695e-07
, O 0 5.898004573623439e-08
including O 0 6.735834290338971e-08
an O 0 3.573369156129047e-07
alpha O 0 1.3926864994573407e-05
carbonic O 0 5.0884977099485695e-05
anhydrase O 0 0.0002617300197016448
gene O 0 1.3006756489630789e-05
, O 0 3.1161259812506614e-06
termed O 0 7.689579797443002e-05
CA12 O 0 0.0012028591008856893
. O 0 1.0910357559623662e-05

The O 0 9.717246575746685e-05
deduced O 0 7.045830716378987e-05
protein O 0 1.761631210683845e-05
sequence O 0 7.415733762172749e-06
was O 0 3.164562804158777e-05
classified O 0 2.2899821487953886e-06
as O 0 2.6706470634962898e-06
a O 0 5.09297615280957e-06
one O 0 2.3960408270795597e-06
- O 0 2.7138959922012873e-05
pass O 0 4.0724273276282474e-05
transmembrane O 0 0.00030717672780156136
CA O 0 7.407920202240348e-05
possessing O 0 2.6511974283494055e-05
an O 0 4.5898727876192424e-06
apparently O 0 1.362380771752214e-05
intact O 0 1.4131481293588877e-05
catalytic O 0 1.257652820640942e-05
domain O 0 1.2790438631782308e-05
in O 0 6.237087291083299e-06
the O 0 1.6837468137964606e-05
extracellular O 0 0.0003725770802702755
CA O 0 0.00039696518797427416
module O 0 0.0003128764219582081
. O 0 7.189099505922059e-06

Reintroduced O 0 0.0016150821465998888
wild O 0 0.0002946962777059525
- O 0 0.0007909611449576914
type O 0 0.0004731316876132041
VHL B-Disease 0 0.013239368796348572
strongly O 0 1.1377455848560203e-05
inhibited O 0 4.701349098468199e-06
the O 0 2.709812747525575e-07
overexpression O 0 3.302672666904982e-06
of O 0 1.4251537550080684e-06
the O 0 1.0547717010922497e-06
CA12 O 0 2.2313324734568596e-05
gene O 0 1.6080274178875698e-07
in O 0 1.368374427102026e-07
the O 0 8.81233575000806e-07
parental O 0 0.0009308090666308999
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 1 0.7043781280517578
. O 0 2.725006197579205e-05

Similar O 0 2.673071139724925e-05
results O 0 1.6385220078518614e-05
were O 0 1.402975954079011e-06
obtained O 0 1.2597155318871955e-06
with O 0 6.088478130550357e-07
CA9 O 0 0.0012433495139703155
, O 0 3.7857216739212163e-06
encoding O 0 6.115984888310777e-06
another O 0 1.6820200471556745e-05
transmembrane O 0 0.0001808905799407512
CA O 0 2.720758129726164e-05
with O 0 2.7313657824379334e-07
an O 0 2.3286563646252034e-06
intact O 0 3.029668914678041e-05
catalytic O 0 3.7521553167607635e-05
domain O 0 4.793997868546285e-05
. O 0 4.123627149965614e-06

Although O 0 1.6830019376357086e-05
both O 0 4.270337285561254e-06
domains O 0 2.8765021852450445e-05
of O 0 3.6740202631335706e-05
the O 0 4.4739612349076197e-05
VHL B-Disease 0 0.000503421004395932
protein O 0 7.412813829432707e-06
contribute O 0 4.919238563161343e-07
to O 0 4.828634132536536e-07
regulation O 0 7.745810762571637e-06
of O 0 8.151287329383194e-05
CA12 O 0 0.0021493001841008663
expression O 0 0.00014409309369511902
, O 0 4.377633558760863e-06
the O 0 3.992437086708378e-06
elongin O 0 3.2249732612399384e-05
binding O 0 5.2795285228057764e-06
domain O 0 7.85885004006559e-06
alone O 0 9.321609582002566e-07
could O 0 2.5295742034359137e-07
effectively O 0 1.7630245565669611e-06
regulate O 0 1.585938844073098e-05
CA9 O 0 0.001876605092547834
expression O 0 5.0754271796904504e-05
. O 0 3.2563850709266262e-06

We O 0 7.671284402022138e-05
mapped O 0 0.00021297707280609757
CA12 O 0 0.0038430984131991863
and O 0 5.7761706557357684e-05
CA9 O 0 0.01078122016042471
loci O 0 6.810753984609619e-05
to O 0 1.946412339748349e-06
chromosome O 0 0.00010146415297640488
bands O 0 4.222046845825389e-05
15q22 O 0 0.00022135220933705568
and O 0 1.1425895536376629e-05
17q21 O 0 0.00041705049807205796
. O 0 1.023695404001046e-05

2 O 0 0.0012910448713228106
respectively O 0 0.0006847858894616365
, O 0 1.047062141878996e-05
regions O 0 8.42646295495797e-06
prone O 0 3.1307154131354764e-05
to O 0 6.198687856340257e-07
amplification O 0 1.8629865735420026e-05
in O 0 2.324538399989251e-06
some O 0 6.896279955981299e-07
human O 0 0.00011548684415174648
cancers B-Disease 1 0.9989932179450989
. O 0 1.1164485840708949e-05

Additional O 0 1.8382943380856887e-05
experiments O 0 4.3522348278202116e-05
are O 0 1.1423054502301966e-06
needed O 0 1.1930046639463399e-06
to O 0 1.7287915454744507e-07
define O 0 1.7926164446180337e-06
the O 0 4.036463906231802e-06
role O 0 1.4096646737016272e-05
of O 0 0.00014222299796529114
CA O 0 0.0001675234379945323
IX O 0 0.0015583793865516782
and O 0 3.616665708250366e-05
CA O 0 4.558506407192908e-05
XII O 0 0.0005427687428891659
enzymes O 0 5.897947630728595e-06
in O 0 2.600805146357743e-06
the O 0 2.7328480882715667e-06
regulation O 0 3.2641708003211534e-06
of O 0 9.314480848843232e-06
pH O 0 4.107863787794486e-05
in O 0 8.82625681697391e-06
the O 0 9.063223842531443e-06
extracellular O 0 4.7641693527111784e-05
microenvironment O 0 7.336166891036555e-05
and O 0 3.7830335486432887e-07
its O 0 1.5443924894498195e-07
potential O 0 5.336331128091842e-07
impact O 0 2.6965155939251417e-06
on O 0 2.7178071832167916e-05
cancer B-Disease 0 0.017154866829514503
cell O 0 0.0002729258267208934
growth O 0 3.2500585803063586e-05
. O 0 1.2341553201622446e-06

A O 0 0.00019636642537079751
gene O 0 1.817548763938248e-05
encoding O 0 1.5576855730614625e-05
a O 0 6.9431334850378335e-06
transmembrane O 0 4.424194048624486e-05
protein O 0 7.259967333084205e-06
is O 0 7.868112561482121e-08
mutated O 0 9.603800776858407e-08
in O 0 3.6271462278136823e-08
patients O 0 1.897358856695064e-07
with O 0 4.827713837585179e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.0870352525671478e-05
. O 0 1.0843316431419225e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9981144666671753
WFS B-Disease 1 0.9999998807907104
; O 0 0.0002805312105920166
OMIM O 1 0.9999549388885498
222300 O 0 0.0032281409949064255
) O 0 1.3496767223841744e-06
is O 0 3.6330388297756144e-07
an O 0 2.914660626629484e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 1 0.8499358296394348
by O 0 6.395195214281557e-06
young O 0 2.9262104362715036e-05
- O 0 0.01176944375038147
onset O 1 1.0
non O 1 1.0
- O 1 0.999998927116394
immune O 1 0.999998927116394
insulin B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999704360961914
dependent I-Disease 1 0.9998953342437744
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.32851818203926086
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 2.6216153855784796e-05

Linkage O 0 0.0009739334345795214
to O 0 1.143652480095625e-05
markers O 0 7.082746014930308e-05
on O 0 5.8939942391589284e-05
chromosome O 0 0.0004912341828458011
4p O 0 0.007937201298773289
was O 0 9.959421004168689e-05
confirmed O 0 6.199512881721603e-06
in O 0 1.8336261291551637e-06
five O 0 1.1521003671077779e-06
families O 0 2.3817331396003283e-07
. O 0 1.3428810916593648e-06

On O 0 2.4914641471696086e-05
the O 0 1.1099367611677735e-06
basis O 0 3.726863042174955e-06
of O 0 2.705477163544856e-05
meiotic O 0 0.0036939019337296486
recombinants O 0 0.039052315056324005
and O 0 0.00010252593347104266
disease O 1 0.9993993043899536
- O 0 0.0003272377944085747
associated O 0 4.377434743219055e-05
haplotypes O 0 7.643084245501086e-05
, O 0 1.5532044699284597e-06
the O 0 5.459786279971013e-06
WFS B-Disease 0 0.00031866904464550316
gene O 0 3.715857928909827e-06
was O 0 1.698971573205199e-05
localized O 0 6.783326170989312e-06
to O 0 1.4011735629537725e-06
a O 0 2.627126559673343e-05
BAC O 0 0.0020623088348656893
/ O 0 0.0005565867759287357
P1 O 0 0.0010488919215276837
contig O 0 0.0005107440520077944
of O 0 5.880986282136291e-05
less O 0 3.428757281653816e-06
than O 0 8.967719509200833e-07
250 O 0 5.626451184070902e-06
kb O 0 0.00016139645595103502
. O 0 4.6899613153073005e-06

Mutations O 0 7.354441186180338e-05
in O 0 1.5928399079712108e-05
a O 0 7.649731742276344e-06
novel O 0 8.220997187891044e-06
gene O 0 6.858423148514703e-06
( O 0 2.2355634428095073e-06
WFS1 O 0 0.00013152627798262984
) O 0 9.246369359061646e-07
encoding O 0 2.8986526103835786e-06
a O 0 1.275122122024186e-05
putative O 0 4.329954390414059e-05
transmembrane O 0 2.500561640772503e-05
protein O 0 1.7087893866118975e-05
were O 0 4.312729288358241e-06
found O 0 3.5020590871681634e-07
in O 0 3.818948925982113e-07
all O 0 2.2375847663624882e-07
affected O 0 7.265219323926431e-07
individuals O 0 2.4439734147563286e-07
in O 0 1.1120568160549738e-05
six O 0 8.710256224730983e-05
WFS B-Disease 0 0.006917654536664486
families O 0 1.0092846878251294e-06
, O 0 2.0524618093986646e-07
and O 0 7.401183665933786e-08
these O 0 1.8880768948292825e-08
mutations O 0 2.427087508749537e-07
were O 0 3.258057859056862e-07
associated O 0 1.8867095263885858e-07
with O 0 5.0024691944372535e-08
the O 0 5.360822342481697e-06
disease O 0 0.003005005419254303
phenotype O 0 0.00016691614291630685
. O 0 4.0895324673329014e-06

WFS1 O 0 0.010593188926577568
appears O 0 2.2190288291312754e-05
to O 0 5.944602889940143e-07
function O 0 8.52550601848634e-06
in O 0 1.7703789580991725e-06
survival O 0 8.719778634258546e-06
of O 0 2.3248987417900935e-05
islet O 0 0.0002591414377093315
beta O 0 0.00012811894703190774
- O 0 4.864466973231174e-05
cells O 0 4.169447038293583e-06
and O 0 9.88628471532138e-07
neurons O 0 2.5909446321747964e-06
. O 0 1.5128019015264726e-07
. O 0 5.652911454490095e-07

Stable O 0 0.0008864616975188255
interaction O 0 1.1181727131770458e-05
between O 0 5.272283033264102e-06
the O 0 3.049967517654295e-06
products O 0 7.539719604210404e-07
of O 0 1.4272810631155153e-06
the O 0 3.3332296425214736e-06
BRCA1 O 0 1.0049510819953866e-05
and O 0 4.33894228990539e-06
BRCA2 O 0 4.2613319237716496e-05
tumor B-Disease 0 0.0003848255146294832
suppressor O 0 0.00011008126602973789
genes O 0 7.714706384831516e-07
in O 0 1.065210994966037e-06
mitotic O 0 1.2037419764965307e-05
and O 0 2.293262468811008e-06
meiotic O 0 0.00023563271679449826
cells O 0 2.9036382329650223e-05
. O 0 4.587767762131989e-06

BRCA1 O 0 0.002968238200992346
and O 0 3.788303365581669e-05
BRCA2 O 0 3.434675090829842e-05
account O 0 1.3058215131422912e-07
for O 0 3.508677792751769e-08
most O 0 1.341055178016859e-08
cases O 0 1.532170124107779e-08
of O 0 3.261645531438262e-07
familial O 0 4.975081537850201e-05
, O 0 2.0430502445378806e-06
early O 0 6.922539614606649e-05
onset O 1 0.9999998807907104
breast B-Disease 1 1.0
and I-Disease 1 0.9999275207519531
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.174651621724479e-05
encode O 0 3.79834318664507e-06
products O 0 2.621176008688053e-06
that O 0 4.835915845546879e-08
each O 0 4.2380975173728075e-08
interact O 0 2.0271285450235155e-07
with O 0 1.335004782276883e-07
hRAD51 O 0 3.0028892069822177e-05
. O 0 3.3073688427975867e-06

Results O 0 0.0004918165504932404
presented O 0 4.771548992721364e-05
here O 0 6.050418051017914e-06
show O 0 1.395042772855959e-06
that O 0 2.5213805088242225e-07
BRCA1 O 0 6.605012004001765e-06
and O 0 1.513319830337423e-06
BRCA2 O 0 1.0266283425153233e-05
coexist O 0 1.3885390899304184e-06
in O 0 1.3893550203647465e-06
a O 0 3.125858711428009e-06
biochemical O 0 8.426752901868895e-05
complex O 0 0.00021097938588354737
and O 0 9.671373845776543e-06
colocalize O 0 0.0003528935194481164
in O 0 7.066527177812532e-05
subnuclear O 0 0.0010393218835815787
foci O 0 0.0007709056371822953
in O 0 1.7329362890450284e-05
somatic O 0 1.1696081855916418e-05
cells O 0 8.508031896781176e-07
and O 0 1.692594366886624e-07
on O 0 8.937241204876045e-07
the O 0 3.9209081137414614e-07
axial O 0 2.8041222321917303e-06
elements O 0 1.1980920362475445e-06
of O 0 6.3681018218630925e-06
developing O 0 3.0358811272890307e-05
synaptonemal O 0 0.00052697240607813
complexes O 0 0.0002442803233861923
. O 0 6.3095358200371265e-06

Like O 0 0.0004065721295773983
BRCA1 O 0 0.0003549722896423191
and O 0 4.310997610446066e-05
RAD51 O 0 0.0026473021134734154
, O 0 8.366017027583439e-06
BRCA2 O 0 1.5382658602902666e-05
relocates O 0 7.70827227825066e-06
to O 0 3.4258607684023445e-07
PCNA O 0 1.7961820049094968e-05
+ O 0 9.686083330961992e-07
replication O 0 1.273238723342729e-07
sites O 0 1.3651889219090663e-07
following O 0 4.4587696379494446e-07
exposure O 0 5.404820512922015e-06
of O 0 2.4766513888607733e-05
S O 0 0.0005641212337650359
phase O 0 6.443667371058837e-05
cells O 0 6.423642844310962e-06
to O 0 1.6161430949068745e-06
hydroxyurea O 0 0.0001732775999698788
or O 0 1.5345967767643742e-05
UV O 0 0.0006787733291275799
irradiation O 0 0.0001013853179756552
. O 0 3.2022237519413466e-06

Thus O 0 0.0001941416849149391
, O 0 1.134304784500273e-05
BRCA1 O 0 1.3542496162699535e-05
and O 0 3.0934538699511904e-06
BRCA2 O 0 4.317416369303828e-06
participate O 0 1.416082113792072e-06
, O 0 3.311896819013782e-07
together O 0 1.0690666130130921e-07
, O 0 2.210706213645608e-07
in O 0 1.033991907206655e-06
a O 0 9.175296327157412e-06
pathway O 0 2.863733607227914e-05
( O 0 1.658691758166242e-06
s O 0 2.0337061869213358e-05
) O 0 2.2229322382827377e-07
associated O 0 4.6647400608890166e-07
with O 0 1.7002305696678377e-07
the O 0 5.9988074099237565e-06
activation O 0 1.2577895176946186e-05
of O 0 8.780005009612069e-05
double O 0 7.947276026243344e-05
- O 0 6.029662108630873e-05
strand O 0 2.7899161068489775e-05
break O 0 1.799628444132395e-05
repair O 0 2.000119820877444e-05
and O 0 2.477184807503363e-06
/ O 0 1.834718023019377e-05
or O 0 5.008594143873779e-07
homologous O 0 1.6925116597121814e-06
recombination O 0 2.0166901322227204e-06
. O 0 1.756733922775311e-06

Dysfunction O 1 0.9999969005584717
of O 0 0.03250192850828171
this O 0 8.177898416761309e-05
pathway O 0 0.00025938867474906147
may O 0 4.466226982913213e-06
be O 0 2.3251406844337907e-07
a O 0 2.2973813429416623e-07
general O 0 4.6426205813077104e-07
phenomenon O 0 4.200591092740069e-07
in O 0 3.6814483905800444e-08
the O 0 2.531678156003636e-08
majority O 0 4.0123793176860545e-09
of O 0 5.983392981079305e-08
cases O 0 1.2291604889469454e-07
of O 0 1.4696860489493702e-05
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.730300356139196e-06
. O 0 2.0551894976961194e-06

A O 0 0.00013824102643411607
novel O 0 3.577307143132202e-05
Arg362Ser O 0 0.0002807757700793445
mutation O 0 3.006367478519678e-06
in O 0 3.018600182258524e-06
the O 0 4.947466095472919e-06
sterol O 0 6.084547203499824e-05
27 O 0 0.0003679838264361024
- O 0 0.00022025853104423732
hydroxylase O 0 0.0005804733373224735
gene O 0 2.0036421119584702e-05
( O 0 4.278988399164518e-06
CYP27 O 0 0.0002973369846586138
) O 0 1.3185348279876052e-06
: O 0 1.7769288263025373e-07
its O 0 1.1265134247651076e-07
effects O 0 3.3695530419208808e-06
on O 0 6.029509222571505e-06
pre O 0 1.8908514903159812e-05
- O 0 2.1864734662813134e-06
mRNA O 0 1.3114893135934835e-06
splicing O 0 9.15021018954576e-07
and O 0 2.4627215111650003e-07
enzyme O 0 2.043108452198794e-06
activity O 0 5.9356516430852935e-06
. O 0 1.2637416375582688e-06

A O 0 0.00016692043573129922
novel O 0 2.6352212444180623e-05
C O 0 0.00012841395800933242
to O 0 7.212972263914708e-07
A O 0 5.803496605949476e-06
mutation O 0 4.2969546143467596e-07
in O 0 1.2894522569695255e-06
the O 0 3.618019491113955e-06
sterol O 0 3.8536396459676325e-05
27 O 0 0.00022272767091635615
- O 0 0.00013363646576181054
hydroxylase O 0 0.0003277670475654304
gene O 0 1.3250316442281473e-05
( O 0 2.2588887986785267e-06
CYP27 O 0 9.148622484644875e-05
) O 0 2.4995219405354874e-07
was O 0 2.1779533199151047e-06
identified O 0 1.5217760562791227e-07
by O 0 6.477628744505637e-08
sequencing O 0 3.8668404158670455e-06
amplified O 0 2.8621963792829774e-05
CYP27 O 0 0.00039530982030555606
gene O 0 4.017729679617332e-06
products O 0 1.2981547570234397e-06
from O 0 3.554861791599251e-07
a O 0 7.500147489736264e-07
patient O 0 7.09004689269932e-06
with O 0 7.527630714321276e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 0.00014617209671996534
CTX B-Disease 0 0.018300766125321388
) O 0 3.1832817057875218e-06
. O 0 1.5736081877548713e-06

The O 0 5.2517327276291326e-05
mutation O 0 9.920484444592148e-06
changed O 0 1.4823093806626275e-05
the O 0 5.066873200121336e-06
adrenodoxin O 0 0.00013327327906154096
cofactor O 0 4.091891969437711e-05
binding O 0 8.874340892361943e-06
residue O 0 5.662657713401131e-05
362Arg O 0 2.8091810236219317e-05
to O 0 2.5427225409657694e-06
362Ser O 0 8.789405546849594e-05
( O 0 1.5346246073022485e-05
CGT O 0 0.0009392867796123028
362Arg O 0 6.89271982992068e-05
to O 0 7.3317573878739495e-06
AGT O 0 0.0007463986985385418
362Ser O 0 0.00010400563769508153
) O 0 1.6909338000914431e-06
, O 0 4.912454301120306e-07
and O 0 2.668223544333159e-07
was O 0 1.7229549484909512e-05
responsible O 0 9.182176654576324e-06
for O 0 1.2810799489670899e-05
deficiency O 1 0.9996660947799683
in O 0 0.00039497754187323153
the O 0 0.00015628041001036763
sterol O 0 0.00031935973674990237
27 O 0 0.00132636574562639
- O 0 0.00012424147280398756
hydroxylase O 0 0.0001227084139827639
activity O 0 5.080741175333969e-06
, O 0 4.890232929710692e-08
as O 0 1.5978731227050957e-08
confirmed O 0 1.5963834698595747e-08
by O 0 1.0650790471800065e-08
expression O 0 2.7535048729987466e-07
of O 0 1.0184564871451585e-06
mutant O 0 2.984977754749707e-06
cDNA O 0 8.402574167121202e-06
into O 0 5.196695383347105e-06
COS O 0 0.00023120359401218593
- O 0 2.3561602574773133e-05
1 O 0 1.7172646039398387e-05
cells O 0 2.453515890010749e-06
. O 0 9.69575012277346e-07

Quantitative O 0 0.0001350015081698075
analysis O 0 7.375349014182575e-06
showed O 0 9.494802725384943e-06
that O 0 2.703179404761613e-07
the O 0 1.4572650570698897e-06
expression O 0 4.005418304586783e-06
of O 0 9.264815162168816e-06
CYP27 O 0 9.366100857732818e-05
gene O 0 1.2704117580142338e-06
mRNA O 0 2.5433093924220884e-06
in O 0 7.940831778796564e-07
the O 0 8.443327601526107e-07
patient O 0 3.849723270832328e-06
represented O 0 1.0197723895544186e-05
52 O 0 0.0001347073120996356
. O 0 6.812245828768937e-06

5 O 0 3.382852446520701e-05
% O 0 3.388449613339617e-06
of O 0 4.796173925569747e-06
the O 0 8.513628017681185e-06
normal O 0 0.0001037233741953969
level O 0 0.00046898992150090635
. O 0 8.075501682469621e-06

As O 0 2.1884110537939705e-05
the O 0 3.890806510753464e-06
mutation O 0 1.819689941839897e-06
occurred O 0 2.204399243055377e-05
at O 0 9.5325367510668e-06
the O 0 1.1028305380023085e-06
penultimate O 0 1.8530354282120243e-05
nucleotide O 0 3.0432445328187896e-06
of O 0 3.560717959771864e-05
exon O 0 1.017585691442946e-05
6 O 0 5.548046465264633e-05
( O 0 1.0597536856948864e-06
- O 0 4.73748968943255e-06
2 O 0 1.4739908692718018e-05
position O 0 1.1468658158264589e-05
of O 0 1.75944333022926e-05
exon O 0 6.8339400058903266e-06
6 O 0 1.7428637875127606e-05
- O 0 4.6522832235496026e-06
intron O 0 2.264167051180266e-05
6 O 0 3.451723023317754e-05
splice O 0 1.2868717931269202e-05
site O 0 6.633835255343001e-06
) O 0 2.102814278259757e-07
of O 0 3.6071601243747864e-06
the O 0 5.404547209764132e-06
gene O 0 3.6967287542211125e-06
, O 0 4.648340166113485e-07
we O 0 1.528344313328489e-07
hypothesized O 0 9.591990419721697e-07
that O 0 9.512755383411786e-08
the O 0 6.113957056186337e-07
mutation O 0 4.16542292214217e-07
may O 0 1.2724136695396737e-06
partially O 0 1.2579519079736201e-06
affect O 0 2.557840161898639e-07
the O 0 5.767038828707882e-07
normal O 0 3.653399289760273e-06
splicing O 0 9.527761335448304e-07
efficiency O 0 3.4288946153537836e-06
in O 0 1.9075459931627847e-06
exon O 0 3.5237248994235415e-06
6 O 0 9.666680853115395e-06
and O 0 9.654064569986076e-07
cause O 0 5.216716090217233e-06
alternative O 0 2.12135023502924e-06
splicing O 0 2.4623298031656304e-06
elsewhere O 0 6.138653247944603e-07
, O 0 2.6223702320748998e-08
which O 0 8.129133810541589e-09
resulted O 0 1.133887934656741e-07
in O 0 1.4166735695653188e-07
decreased O 0 1.4327075405162759e-05
transcript O 0 4.852638994634617e-06
in O 0 6.111817469900416e-07
the O 0 2.1712135094276164e-06
patient O 0 1.7793054212233983e-05
. O 0 4.133549282414606e-06

Transfection O 0 0.005113598890602589
of O 0 0.0012146160006523132
constructed O 0 0.001919425674714148
minigenes O 0 0.0013176830252632499
, O 0 5.851899459230481e-06
with O 0 7.298010018530476e-07
or O 0 2.9572156563517638e-06
without O 0 1.1477150110295042e-06
the O 0 6.591847522940952e-06
mutation O 0 2.220884198322892e-06
, O 0 2.2749236450181343e-06
into O 0 4.903930403088452e-06
COS O 0 0.0002507374156266451
- O 0 2.2960522983339615e-05
1 O 0 1.3982787095301319e-05
cells O 0 8.227406738114951e-07
confirmed O 0 5.126963742441148e-07
that O 0 8.813734098112036e-08
the O 0 1.5585432038278668e-06
mutant O 0 1.5484154573641717e-05
minigene O 0 8.229037484852597e-05
was O 0 2.222307193733286e-05
responsible O 0 2.00410886463942e-06
for O 0 2.9578458793366735e-07
a O 0 8.492330039189255e-07
mRNA O 0 1.7006047983159078e-06
species O 0 3.698092854165225e-08
alternatively O 0 6.434112265196745e-07
spliced O 0 4.670229373004986e-06
at O 0 1.8025157260126434e-05
an O 0 9.441632187190407e-07
activated O 0 2.495209082553629e-05
cryptic O 0 1.7660115190665238e-05
5 O 0 1.228613473358564e-05
splice O 0 2.1758773073088378e-05
site O 0 4.62005591543857e-05
88 O 0 6.299958477029577e-05
bp O 0 2.8079517505830154e-05
upstream O 0 3.120188193861395e-05
from O 0 5.5110476750996895e-06
the O 0 3.764071834666538e-06
3 O 0 7.055586138449144e-06
end O 0 4.55405461252667e-06
of O 0 9.110364771913737e-06
exon O 0 1.4653349353466183e-05
6 O 0 3.6436260415939614e-05
. O 0 2.3641230200155405e-06

Our O 0 0.00010418828605907038
data O 0 1.0476215720700566e-05
suggest O 0 1.040198071677878e-06
that O 0 2.829635263879027e-07
the O 0 1.6739998045522952e-06
C O 0 2.3402966689900495e-05
to O 0 2.4255419361907116e-07
A O 0 5.229208454693435e-06
mutation O 0 8.245127105510619e-07
at O 0 1.2182319551357068e-05
the O 0 2.147664417861961e-06
penultimate O 0 9.164688890450634e-06
nucleotide O 0 7.339518788285204e-07
of O 0 5.2869700084556825e-06
exon O 0 3.1733700325276004e-06
6 O 0 1.3472369573719334e-05
of O 0 6.709409262839472e-06
the O 0 9.589680303179193e-06
CYP27 O 0 0.00020941933325957507
gene O 0 2.188724693041877e-06
not O 0 3.2400922123088094e-07
only O 0 4.3450359044072684e-07
causes O 0 4.324268957134336e-06
the O 0 1.3586699424195103e-05
deficiency B-Disease 0 0.0016211438924074173
in I-Disease 0 2.2329459170578048e-05
the I-Disease 0 2.962397047667764e-05
sterol I-Disease 0 0.00018009461928158998
27 I-Disease 0 0.0005663278861902654
- I-Disease 0 0.00017017473874147981
hydroxylase I-Disease 0 0.0004603309207595885
activity I-Disease 0 5.9408026572782546e-05
, O 0 7.616963557666168e-07
but O 0 1.3584342184458364e-07
also O 0 6.753522256985889e-07
partially O 0 7.275291409314377e-06
leads O 0 5.38808649253042e-07
to O 0 5.996519547579737e-08
alternative O 0 4.2328869653829315e-07
pre O 0 6.221261173777748e-06
- O 0 1.2090766858818824e-06
mRNA O 0 6.409822503883333e-07
splicing O 0 2.2893590312378365e-07
of O 0 7.063349016789289e-07
the O 0 1.4317882914838265e-06
gene O 0 4.391653874336043e-06
. O 0 2.2576380160899134e-06

To O 0 4.72080719191581e-05
our O 0 2.9476026611519046e-05
knowledge O 0 2.1605679648928344e-05
, O 0 2.0873883386229863e-06
this O 0 1.8278839775121014e-07
is O 0 4.3965846430182864e-07
the O 0 4.6546526277779776e-07
first O 0 1.5477379520234535e-06
report O 0 6.7864493757952e-07
regarding O 0 1.5222536831061007e-06
effects O 0 1.7504795323475264e-05
on O 0 1.7120253687608056e-05
pre O 0 3.281892713857815e-05
- O 0 2.6810025701706763e-06
mRNA O 0 1.4806428225710988e-06
splicing O 0 4.280516350263497e-07
of O 0 1.9265594346506987e-06
a O 0 2.1336211375455605e-06
mutation O 0 6.883466880935885e-07
at O 0 1.8392429410596378e-05
the O 0 2.2253109364100965e-06
- O 0 2.2667570647172397e-06
2 O 0 5.333606168278493e-06
position O 0 1.8949226614495274e-06
of O 0 1.991576027648989e-06
a O 0 2.817259201037814e-06
5 O 0 6.294912964222021e-06
splice O 0 1.1969001207035035e-05
site O 0 9.14988686417928e-06
. O 0 1.551009290778893e-06

ATM O 0 0.00926938746124506
germline O 0 0.0017177058616653085
mutations O 0 7.313596870517358e-05
in O 0 5.2110695833107457e-05
classical O 1 0.9999994039535522
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.999915599822998
in O 0 5.178853825782426e-05
the O 0 9.749857781571336e-06
Dutch O 0 0.0007290206267498434
population O 0 1.1957189371969434e-06
. O 0 7.547432119281439e-07

Germline O 0 0.0022815477568656206
mutations O 0 8.768635780143086e-06
in O 0 1.8411661812933744e-06
the O 0 1.8425432699586963e-06
ATM O 0 2.2848358639748767e-05
gene O 0 2.6375201400696824e-07
are O 0 7.898889542445886e-09
responsible O 0 4.711411349944683e-08
for O 0 1.2543684135835065e-07
the O 0 0.0010810312815010548
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 0.0013104808749631047
. O 0 1.636427805351559e-05

In O 0 0.00027121693710796535
our O 0 1.417964722350007e-05
study O 0 3.1296885936171748e-06
, O 0 5.105684977024794e-07
we O 0 7.468912599506439e-08
have O 0 3.2349049661206664e-08
determined O 0 1.0427969954207583e-07
the O 0 3.7539658137575316e-07
ATM O 0 5.555441475735279e-06
mutation O 0 3.573042022253503e-07
spectrum O 0 2.3052809865475865e-06
in O 0 3.2736791126808384e-06
19 O 0 5.4976022511254996e-05
classical O 0 0.0026749337557703257
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 2.4539125661249273e-05
, O 0 3.9703209608887846e-07
including O 0 9.457505001364552e-08
some O 0 4.385023189001913e-08
immigrant O 0 1.180730691885401e-06
populations O 0 1.901401986970086e-07
, O 0 1.0707685049737847e-07
as O 0 3.088599669354153e-07
well O 0 1.8251282085657294e-07
as O 0 3.4696765283115383e-07
12 O 0 8.302522473968565e-07
of O 0 4.948302034790686e-07
Dutch O 0 6.498816219391301e-06
ethnic O 0 3.0313083243527217e-07
origin O 0 1.6403104154960602e-06
. O 0 1.7761607296051807e-06

Both O 0 6.677590863546357e-05
the O 0 4.770129453390837e-05
protein O 0 4.244864612701349e-05
truncation O 0 0.00019459221221040934
test O 0 3.579067924874835e-05
( O 0 5.732751560572069e-06
PTT O 0 6.228703568922356e-05
) O 0 3.903879246536235e-07
and O 0 4.0697651115806366e-07
the O 0 9.664381650509313e-07
restriction O 0 2.4658336315042106e-06
endonuclease O 0 1.482828247389989e-05
fingerprinting O 0 7.2630141403351445e-06
( O 0 1.6928183868003543e-06
REF O 0 4.055132012581453e-05
) O 0 1.1369870378530322e-07
method O 0 2.1766484792351548e-07
were O 0 4.996257416678418e-07
used O 0 2.1984112663631095e-07
and O 0 1.9404687634505535e-07
compared O 0 1.2431956974978675e-06
for O 0 1.6222196563830948e-07
their O 0 2.0780740328518732e-07
detection O 0 5.6165495152527e-06
efficiency O 0 6.68532356939977e-06
, O 0 2.318590759387007e-07
identifying O 0 3.131926007426955e-07
76 O 0 9.391886123921722e-06
% O 0 4.536947528777091e-07
and O 0 2.2431098045672115e-07
60 O 0 1.884200742097164e-06
% O 0 7.535895178989449e-07
of O 0 3.6124101825407706e-06
the O 0 7.400685262837214e-06
mutations O 0 3.833833488897653e-06
, O 0 1.116394287237199e-06
respectively O 0 6.5970298237516545e-06
. O 0 1.0292958450008882e-06

Most O 0 6.090381066314876e-05
patients O 0 1.4910641766618937e-05
were O 0 3.880467374983709e-06
found O 0 7.654524551981012e-07
to O 0 1.9005861418008863e-07
be O 0 2.7976288947684225e-06
compound O 0 9.043461614055559e-05
heterozygote O 0 0.00013353406393434852
. O 0 4.518381956586381e-06

Seventeen O 0 0.0010785100748762488
mutations O 0 4.699583587353118e-05
were O 0 3.3198928576894104e-05
distinct O 0 3.6829981127084466e-06
, O 0 9.310024893238733e-07
of O 0 2.3985328425624175e-06
which O 0 7.590068662466365e-07
10 O 0 1.8766205585052376e-06
were O 0 9.665560583016486e-07
not O 0 1.8153014025301673e-07
reported O 0 2.946088443422923e-06
previously O 0 6.876748102513375e-06
. O 0 1.8043929230771028e-06

Mutations O 0 0.0003194026940036565
are O 0 5.3661674428440165e-06
small O 0 2.5937681584764505e-06
deletions O 0 1.7564645531820133e-05
or O 0 8.909344614949077e-06
point O 0 2.1147969164303504e-05
mutations O 0 1.2688523156612064e-06
frequently O 0 1.0372946235293057e-06
affecting O 0 3.400248488105717e-06
splice O 0 1.4386688235390466e-05
sites O 0 4.724162408820121e-06
. O 0 1.9736196463782107e-06

Moreover O 0 0.00040215541957877576
, O 0 1.1696594810928218e-05
a O 0 1.7606753317522816e-05
16 O 0 7.568742148578167e-05
. O 0 6.7346086325414944e-06

7 O 0 0.0009675199398770928
- O 0 0.00013901792408432811
kb O 0 0.0003173247678205371
genomic O 0 2.411645073152613e-05
deletion O 0 2.967172440548893e-05
of O 0 6.01972897129599e-05
the O 0 2.995024260599166e-05
3 O 0 3.288183143013157e-05
end O 0 1.4044555427972227e-05
of O 0 1.7928587112692185e-05
the O 0 1.1496121260279324e-05
gene O 0 3.912540250894381e-06
, O 0 7.360757763308357e-07
most O 0 1.6612278841421357e-07
likely O 0 2.789969073546672e-07
a O 0 2.3687533712291042e-07
result O 0 3.359825768711744e-07
of O 0 1.8815359226209694e-06
recombination O 0 2.0371867037738411e-07
between O 0 3.5153007047483698e-06
two O 0 2.41575003201433e-06
LINE O 0 2.2894710127729923e-05
elements O 0 1.940172296599485e-06
, O 0 4.078608526469907e-07
was O 0 4.9016066441254225e-06
identified O 0 1.3516604440155788e-06
. O 0 6.326282573354547e-07

The O 0 0.00019785301992669702
most O 0 4.809938218386378e-06
frequently O 0 1.703284510767844e-06
found O 0 8.427560374002496e-07
mutation O 0 3.1512956866208697e-07
, O 0 1.4874572684675513e-07
identified O 0 2.0002146072783944e-07
in O 0 6.638452987317578e-07
three O 0 1.429521944373846e-06
unrelated O 0 1.937160595844034e-05
Turkish O 0 0.005052890162914991
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 4.760796855407534e-06
, O 0 2.364718284297851e-06
was O 0 1.2521646567620337e-05
previously O 0 2.085353116854094e-06
described O 0 6.907231977493211e-07
to O 0 3.4817379201967924e-08
be O 0 9.569698988798336e-08
a O 0 7.168357001319237e-07
Turkish O 0 2.441349897708278e-05
A B-Disease 1 0.9999929666519165
- I-Disease 1 0.999994158744812
T I-Disease 1 1.0
founder O 0 0.0009727950673550367
mutation O 0 6.114211828389671e-06
. O 0 1.802645329007646e-06

The O 0 0.00012982121552340686
presence O 0 4.126796920900233e-05
of O 0 0.00021139236923772842
a O 0 0.0002750170533545315
founder O 0 0.0005463444394990802
mutation O 0 3.2190241654461715e-06
among O 0 2.5100038669734204e-07
relatively O 0 3.5351249039194954e-07
small O 0 3.581396157414929e-08
ethnic O 0 4.3506084068667406e-08
population O 0 4.118452423540475e-08
groups O 0 2.6076566683741476e-08
in O 0 5.824200002280122e-07
Western O 0 4.521563369053183e-06
Europe O 0 6.1187388382677455e-06
could O 0 9.934344689099817e-07
indicate O 0 2.098740196743165e-06
a O 0 8.933542403610772e-07
high O 0 3.7750073715869803e-06
carrier O 0 1.1115557896346218e-07
frequency O 0 3.423629948429152e-07
in O 0 1.0614169809741725e-07
such O 0 8.210666635477537e-08
communities O 0 1.3439812107662874e-07
. O 0 6.025515517649183e-07

In O 0 6.944921187823638e-05
patients O 0 1.0190968168899417e-05
of O 0 1.8654487575986423e-05
Dutch O 0 0.00011904616258107126
ethnic O 0 3.7789625366713153e-06
origin O 0 6.038059837010223e-06
, O 0 7.039926117613504e-07
however O 0 4.5231575995785533e-07
, O 0 1.9864779687850387e-07
no O 0 3.095036618105951e-07
significant O 0 3.4130000585719245e-06
founder O 0 4.593679113895632e-05
effect O 0 4.342212832852965e-06
could O 0 5.391581794356171e-07
be O 0 4.551204995095759e-07
identified O 0 1.8256240537084523e-06
. O 0 9.060509569280839e-07

The O 0 1.3860088074579835e-05
observed O 0 1.2092430552002043e-05
genetic O 0 5.469219104270451e-06
heterogeneity O 0 2.2404114133678377e-05
including O 0 4.558682121569291e-06
the O 0 8.053896635829005e-06
relative O 0 0.00012055454135406762
high O 0 0.0005772612057626247
percentage O 0 4.5342487283051014e-05
of O 0 8.094593795249239e-05
splice O 0 0.00012536608846858144
- O 0 7.003172504482791e-05
site O 0 7.954133252496831e-06
mutations O 0 5.573243129219918e-07
had O 0 1.536547301839164e-06
no O 0 3.551452891770168e-07
reflection O 0 4.2827236939047e-06
on O 0 9.874442184809595e-06
the O 0 8.143853847286664e-06
phenotype O 0 6.555252912221476e-05
. O 0 3.087249979216722e-06

All O 0 8.617220373707823e-06
patients O 0 5.240651262283791e-06
manifested O 0 3.443250898271799e-05
classical O 0 0.002089126966893673
A B-Disease 1 0.9999982118606567
- I-Disease 1 0.9942130446434021
T I-Disease 1 0.9999698400497437
and O 0 3.589890980038035e-07
increased O 0 7.73811734688934e-06
cellular O 0 6.633936573052779e-05
radioresistant O 0 9.048275387613103e-05
DNA O 0 6.941942046978511e-06
synthesis O 0 8.199294097721577e-05
. O 0 3.565676479411195e-06

Determination O 0 5.442990004667081e-05
of O 0 2.1703233869629912e-05
the O 0 4.215063654555706e-06
genomic O 0 6.5671501943143085e-06
structure O 0 5.531936494662659e-06
of O 0 2.7773089641414117e-06
the O 0 2.117703843396157e-06
COL4A4 O 0 6.816229870310053e-05
gene O 0 1.7172006039345433e-07
and O 0 1.1094479113182842e-08
of O 0 1.3486560135334003e-07
novel O 0 5.913074346608482e-06
mutations O 0 0.002219026442617178
causing O 0 0.4888222813606262
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0004030396812595427

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00046977962483651936
a O 0 8.446897845715284e-05
progressive O 1 0.9999847412109375
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9999994039535522
by O 0 0.0016427350929006934
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999843835830688
abnormalities I-Disease 1 1.0
and O 0 7.045164966257289e-05
associated O 0 6.463318277383223e-05
with O 0 1.6489667586938594e-06
mutations O 0 1.024019638862228e-05
in O 0 5.887270162929781e-05
either O 0 8.796619113127235e-06
the O 0 2.5567098418832757e-05
COL4A3 O 0 0.00041185831651091576
or O 0 6.671254141110694e-06
the O 0 6.363475222315174e-06
COL4A4 O 0 7.568258297396824e-05
gene O 0 7.829845571905025e-07
, O 0 1.0898131108660891e-07
which O 0 3.323083319628495e-08
encode O 0 2.848892393103597e-07
the O 0 1.9715014332177816e-06
alpha3 O 0 8.602123125456274e-05
and O 0 9.270728696719743e-06
alpha4 O 0 0.0005959850968793035
type O 0 0.0012254536850377917
IV O 1 0.9999994039535522
collagen O 1 0.9919933080673218
chains O 0 0.0013996236957609653
, O 0 6.198401933943387e-06
respectively O 0 2.1821258997078985e-05
. O 0 1.2175362371635856e-06

To O 0 1.6010531908250414e-05
date O 0 2.210550883319229e-05
, O 0 7.045050551823806e-07
mutation O 0 2.6316055823372153e-07
screening O 0 1.0922954061243217e-06
in O 0 4.299083684600191e-06
the O 0 6.937104899407132e-06
two O 0 1.6827649460537941e-06
genes O 0 1.863455395323399e-06
has O 0 1.5076054751261836e-06
been O 0 9.914468819260946e-07
hampered O 0 2.1254672901704907e-06
by O 0 1.690183637492737e-08
the O 0 7.955576819540511e-08
lack O 0 3.604085634378862e-07
of O 0 8.582049986216589e-07
genomic O 0 8.494318535667844e-06
structure O 0 2.7519701689016074e-05
information O 0 2.743821596595808e-06
. O 0 4.201282081339741e-06

We O 0 6.941630999790505e-05
report O 0 6.196120921231341e-06
here O 0 1.789613520486455e-06
the O 0 6.52197343242733e-07
complete O 0 2.7936989681620616e-06
characterization O 0 6.520476745208725e-06
of O 0 1.495384731242666e-05
the O 0 1.0199804819421843e-05
48 O 0 2.6852123482967727e-05
exons O 0 1.7620326616452076e-05
of O 0 5.671428152709268e-05
the O 0 0.00014762180217076093
COL4A4 O 0 0.003881418379023671
gene O 0 2.302643952134531e-05
, O 0 8.624748488728073e-07
a O 0 1.001427563096513e-06
comprehensive O 0 4.009748863609275e-06
gene O 0 3.858938725898042e-06
screen O 0 8.184948455891572e-06
, O 0 1.4578974116830068e-07
and O 0 2.1042900755219307e-08
the O 0 3.0743642298602936e-08
subsequent O 0 7.552328895599203e-08
detection O 0 2.037330517623559e-07
of O 0 1.504988205169866e-07
10 O 0 2.536908993988618e-07
novel O 0 1.6711129546820302e-07
mutations O 0 1.5028697930574708e-07
in O 0 1.0572868802682933e-07
eight O 0 1.3335786661627935e-06
patients O 0 3.7734771467512473e-05
diagnosed O 1 0.999893069267273
with O 0 2.1677913537132554e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0007111422019079328

Furthermore O 0 0.0003452695091255009
, O 0 7.492836175515549e-06
we O 0 1.2968109786015702e-06
identified O 0 2.0268823845981387e-06
a O 0 4.728678959509125e-06
glycine O 0 7.0557948674832005e-06
to O 0 1.3374964282775181e-06
alanine O 0 1.59515820996603e-05
substitution O 0 2.5301553250756115e-05
in O 0 1.3682502867595758e-05
the O 0 3.069973536184989e-05
collagenous O 0 0.00034816598054021597
domain O 0 2.0969473553122953e-05
that O 0 1.0946793054245063e-06
is O 0 1.0104809007316362e-06
apparently O 0 3.6320591334515484e-06
silent O 0 7.425769126712112e-06
in O 0 8.629272656435205e-07
the O 0 1.0914269523709663e-06
heterozygous O 0 6.344698704197071e-07
carriers O 0 2.6517093942857173e-07
, O 0 1.081175469153095e-07
in O 0 6.935100032023911e-07
11 O 0 1.3116796253598295e-05
. O 0 1.9880767467839178e-06

5 O 0 0.0002727083920035511
% O 0 9.036399205797352e-06
of O 0 2.089601184707135e-05
all O 0 2.846235929609975e-06
control O 0 1.5448709746124223e-05
individuals O 0 3.1175773074210156e-07
, O 0 3.6889278476337495e-07
and O 0 1.217301246470015e-07
in O 0 3.668310171178746e-07
one O 0 1.287149586914893e-07
control O 0 3.461615278865793e-07
individual O 0 4.8020453391472984e-08
homozygous O 0 4.42809806600053e-07
for O 0 1.177252499928727e-07
this O 0 1.0299503117039421e-07
glycine O 0 4.559538865578361e-06
substitution O 0 5.477299509948352e-06
. O 0 1.0798487437568838e-06

There O 0 5.218454316491261e-05
has O 0 6.1209098021208774e-06
been O 0 4.386940418044105e-06
no O 0 8.719950415070343e-07
previous O 0 2.4533289888495347e-06
finding O 0 1.3134193750374834e-06
of O 0 1.3647345440404024e-05
a O 0 1.9580409571062773e-05
glycine O 0 2.029370443779044e-05
substitution O 0 1.0464153092470951e-05
that O 0 1.6246161749222665e-07
is O 0 2.3439402241365315e-07
not O 0 4.907528250441828e-08
associated O 0 1.1531663091091104e-07
with O 0 2.3113354785664342e-08
any O 0 2.0307679449160787e-07
obvious O 0 3.485277602521819e-06
phenotype O 0 3.958713023166638e-06
in O 0 8.620998528385826e-07
homozygous O 0 2.8497968287410913e-06
individuals O 0 1.8628445275226113e-07
. O 0 9.987455769078224e-07

Founder O 0 0.007086791563779116
BRCA1 O 0 0.00014236531569622457
and O 0 2.7280125323159155e-06
BRCA2 O 0 7.186865332187153e-06
mutations O 0 3.6096511735195236e-07
in O 0 3.924013185496733e-07
French O 0 8.78020582604222e-05
Canadian O 0 0.005150218028575182
breast B-Disease 1 1.0
and I-Disease 1 0.9999983310699463
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.272715836530551e-06
. O 0 3.248624352636398e-06

We O 0 4.304835601942614e-05
have O 0 1.5890703934928752e-06
identified O 0 5.469816528602678e-07
four O 0 1.6567724969718256e-07
mutations O 0 5.966389693412566e-08
in O 0 9.870329620298435e-08
each O 0 2.7644972533380496e-08
of O 0 2.7858343401021557e-06
the O 0 8.39511922094971e-05
breast B-Disease 1 0.9999995231628418
cancer I-Disease 1 1.0
- O 1 0.9945858716964722
susceptibility O 1 0.7679706811904907
genes O 0 3.541949263308197e-05
, O 0 1.8748638694887632e-06
BRCA1 O 0 2.6467548650543904e-06
and O 0 2.786180175462505e-07
BRCA2 O 0 9.244217835657764e-07
, O 0 5.256427737521108e-09
in O 0 1.0678801842800567e-08
French O 0 2.299519337611855e-06
Canadian O 0 3.894778274116106e-05
breast B-Disease 1 0.9997668862342834
cancer I-Disease 1 0.9999600648880005
and O 0 0.00023608066840097308
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.326139338038047e-06
from O 0 3.931046649086056e-06
Quebec O 0 5.641760799335316e-05
. O 0 7.229552920762217e-06

To O 0 6.091635805205442e-05
identify O 0 5.8079196605831385e-05
founder O 0 0.0010061353677883744
effects O 0 0.0002690719556994736
, O 0 1.0382872233094531e-06
we O 0 1.1293877122398044e-07
examined O 0 5.336051458471047e-07
independently O 0 2.1338948386073753e-07
ascertained O 0 3.611707597883651e-06
French O 0 4.926265683025122e-05
Canadian O 0 5.6354903790634125e-05
cancer B-Disease 0 6.409177149180323e-05
families O 0 1.2090335133052577e-07
for O 0 4.844741852139123e-08
the O 0 9.729729555374433e-08
distribution O 0 2.0414518075995147e-07
of O 0 5.954742050562345e-07
these O 0 2.3510145297223062e-07
eight O 0 5.205966317589628e-06
mutations O 0 7.089986411301652e-06
. O 0 2.567851197454729e-06

Mutations O 0 6.778311217203736e-05
were O 0 1.04319105957984e-05
found O 0 3.6445948126129224e-07
in O 0 3.146940912301943e-07
41 O 0 4.662868377636187e-06
of O 0 3.7037157198938075e-06
97 O 0 7.650273619219661e-05
families O 0 6.996955335125676e-07
. O 0 3.403431037440896e-06

Six O 0 0.00016515249444637448
of O 0 5.7226596254622564e-05
eight O 0 6.700316589558497e-06
mutations O 0 1.0476487659616396e-06
were O 0 1.7998539760810672e-06
observed O 0 2.370898755543749e-06
at O 0 6.651179774053162e-06
least O 0 1.748956464098228e-07
twice O 0 4.734274170914432e-06
. O 0 1.2082836065019364e-06

The O 0 0.00044429118861444294
BRCA1 O 0 0.0006354082725010812
C4446T O 0 0.0009143680217675865
mutation O 0 3.5394645237829536e-05
was O 0 7.932254811748862e-05
the O 0 2.9024836294411216e-06
most O 0 1.7834854304510372e-07
common O 0 1.5530103780747595e-07
mutation O 0 1.9671188056236133e-07
found O 0 1.713928412527821e-07
, O 0 2.7098639776568234e-08
followed O 0 1.4961956651404762e-07
by O 0 4.164607503298612e-08
the O 0 1.5831741393412813e-06
BRCA2 O 0 5.670390237355605e-05
8765delAG O 0 0.00016635350766591728
mutation O 0 2.5908810130204074e-05
. O 0 5.30041415913729e-06

Together O 0 9.563544881530106e-05
, O 0 7.507348527724389e-06
these O 0 2.4456616642964946e-07
mutations O 0 7.624674935868825e-07
were O 0 1.8331260207560263e-06
found O 0 3.497663385587657e-07
in O 0 6.160158818602213e-07
28 O 0 1.0054715858132113e-05
of O 0 6.146764462755527e-06
41 O 0 2.8133339583291672e-05
families O 0 1.8237379606489412e-07
identified O 0 5.193537049308361e-07
to O 0 1.5367568551027944e-07
have O 0 4.2758691165545315e-07
a O 0 2.57333294939599e-06
mutation O 0 5.922211130382493e-06
. O 0 2.9070322398183635e-06

The O 0 7.050427666399628e-05
odds O 0 4.68690886918921e-05
of O 0 1.020311265165219e-05
detection O 0 6.951840077817906e-06
of O 0 7.922179065644741e-06
any O 0 1.0269574204357923e-06
of O 0 2.7337626306689344e-05
the O 0 1.4530391126754694e-05
four O 0 4.910107691102894e-06
BRCA1 O 0 1.0841840776265599e-05
mutations O 0 3.1600307011103723e-06
was O 0 3.738254599738866e-05
18 O 0 2.2655191060039215e-05
. O 0 1.6023402622522553e-06

7x O 0 0.13022661209106445
greater O 0 0.00019440565665718168
if O 0 7.798764272592962e-06
one O 0 1.4991308034950634e-06
or O 0 2.512542494059744e-07
more O 0 1.467768218077481e-08
cases O 0 6.742582741026126e-07
of O 0 0.0014029451413080096
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.00010808696242747828
also O 0 4.3281619355184375e-07
present O 0 1.6617191533896403e-07
in O 0 6.282501203713764e-07
the O 0 1.3025670568822534e-06
family O 0 1.9495555534376763e-06
. O 0 2.1523949271795573e-06

The O 0 7.678633119212463e-05
odds O 0 4.880683991359547e-05
of O 0 1.1387593986000866e-05
detection O 0 6.784897777833976e-06
of O 0 8.364604582311586e-06
any O 0 6.02376871938759e-07
of O 0 1.352952494926285e-05
the O 0 1.2319667803240009e-05
four O 0 4.013528723589843e-06
BRCA2 O 0 1.1851545423269272e-05
mutations O 0 1.6565797977818875e-06
was O 0 2.9129685572115704e-05
5 O 0 6.861295332782902e-06
. O 0 1.0852305649677874e-06

3x O 0 0.012776017189025879
greater O 0 0.00015482003800570965
if O 0 7.0291312113113236e-06
there O 0 2.3173449790192535e-06
were O 0 1.450916670364677e-06
at O 0 1.106683384932694e-06
least O 0 8.475854684775186e-09
five O 0 1.9079296365021037e-08
cases O 0 4.016316879074111e-08
of O 0 4.7224325498973485e-06
breast B-Disease 1 0.9997764229774475
cancer I-Disease 1 0.9998412132263184
in O 0 7.692601502640173e-05
the O 0 5.017160947318189e-05
family O 0 2.409633634670172e-05
. O 0 5.912989763601217e-06

Interestingly O 0 0.00034169157152064145
, O 0 4.727858140540775e-06
the O 0 1.0695372338886955e-06
presence O 0 1.4493124353975873e-06
of O 0 1.2687055459537078e-05
a O 0 3.8172285712789744e-05
breast B-Disease 0 0.2606866657733917
cancer I-Disease 0 0.29118087887763977
case O 0 4.515180626185611e-05
< O 0 9.274319018004462e-05
36 O 0 2.275843871757388e-05
years O 0 2.875351810871507e-06
of O 0 9.739300367073156e-06
age O 0 2.4365330318687484e-05
was O 0 3.3177286240970716e-05
strongly O 0 1.0061345392387011e-06
predictive O 0 1.4890825923430384e-06
of O 0 1.2458708624762949e-06
the O 0 3.9228532955348783e-07
presence O 0 2.2138688393624761e-07
of O 0 7.730408810857625e-07
any O 0 7.329020235147254e-08
of O 0 1.933483872562647e-06
the O 0 1.1799787671407103e-06
eight O 0 1.058760631167388e-06
mutations O 0 8.028154638850538e-07
screened O 0 1.0251842468278483e-05
. O 0 2.7592327569436748e-06

Carriers O 0 4.626660665962845e-05
of O 0 7.467214163625613e-05
the O 0 1.6638974557281472e-05
same O 0 4.394708412291948e-06
mutation O 0 1.2046685924360645e-06
, O 0 1.830294564797441e-07
from O 0 1.0121679849817156e-07
different O 0 6.91566715005365e-09
families O 0 1.0915935710897884e-08
, O 0 3.2032662744541085e-08
shared O 0 1.438660319763585e-07
similar O 0 3.207564702734089e-07
haplotypes O 0 1.3541914995585103e-05
, O 0 1.807374019335839e-06
indicating O 0 8.123136467474978e-06
that O 0 3.3373726182617247e-07
the O 0 3.083295496253413e-06
mutant O 0 1.2646768482227344e-05
alleles O 0 3.660796664917143e-06
were O 0 2.1402690890681697e-06
likely O 0 1.793490440604728e-07
to O 0 1.4642560941524607e-08
be O 0 3.281287774825614e-08
identical O 0 1.234894142498888e-07
by O 0 6.653589679217475e-08
descent O 0 2.38470647673239e-06
for O 0 1.0253872062548908e-07
a O 0 4.977400749339722e-07
mutation O 0 4.159766149314237e-07
in O 0 2.0214790765749058e-06
the O 0 4.510692178882891e-06
founder O 0 4.20782198489178e-05
population O 0 1.8116642763743585e-07
. O 0 8.032681080294424e-07

The O 0 1.5211191566777416e-05
identification O 0 3.1341032808995806e-06
of O 0 2.1493964595720172e-05
common O 0 4.542731767287478e-05
BRCA1 O 0 0.00026335931033827364
and O 0 1.572196197230369e-05
BRCA2 O 0 3.154856676701456e-05
mutations O 0 6.812192054894695e-07
will O 0 4.994680224967851e-08
facilitate O 0 9.829147984419251e-08
carrier O 0 1.2426275475263537e-07
detection O 0 8.53827941682539e-08
in O 0 9.493125219250942e-08
French O 0 1.737404272716958e-05
Canadian O 0 0.0002524340234231204
breast B-Disease 1 0.9999961853027344
cancer I-Disease 1 0.9999970197677612
and O 0 0.0009007968474179506
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.602354460483184e-06
. O 0 2.02514138436527e-06

Are O 0 3.193435986759141e-05
Dp71 O 0 0.0017243579495698214
and O 0 2.3636208425159566e-05
Dp140 O 0 0.0028154575265944004
brain O 0 0.1729109287261963
dystrophin O 0 0.00019974532187916338
isoforms O 0 5.371927727537695e-06
related O 0 1.3893655932406546e-06
to O 0 3.1444508863387455e-07
cognitive B-Disease 1 0.8603063225746155
impairment I-Disease 1 1.0
in O 1 0.9885398745536804
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.0003196195757482201

Molecular O 0 0.002635157899931073
study O 0 1.3131139894539956e-05
and O 0 2.3510037863161415e-06
neuropsychological O 0 9.622164725442417e-06
analysis O 0 2.9246072585920047e-07
were O 0 1.1497599672338765e-07
performed O 0 4.0358224850933766e-07
concurrently O 0 4.102118964510737e-07
on O 0 1.5142828715397627e-06
49 O 0 2.5556446416885592e-05
patients O 0 7.578635631944053e-06
with O 0 3.540726538631134e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0006435979157686234
DMD B-Disease 1 1.0
) O 0 3.9966627696230717e-07
in O 0 6.426752463539742e-08
order O 0 3.1559928004298854e-08
to O 0 1.228060853009083e-08
find O 0 2.2334182503414013e-08
a O 0 1.1879848216267419e-07
molecular O 0 1.4970391930546612e-06
explanation O 0 2.3164689366694802e-07
for O 0 1.717492068564752e-07
the O 0 1.5457982271982473e-06
cognitive B-Disease 0 0.0002717234310694039
impairment I-Disease 0 0.00540584372356534
observed O 0 4.787532361660851e-06
in O 0 2.525565832911525e-06
most O 0 4.113897375646047e-06
DMD B-Disease 1 1.0
patients O 0 2.4474342353641987e-05
. O 0 2.887999016820686e-06

Complete O 0 0.00018205649394076318
analysis O 0 1.3634179595101159e-05
of O 0 3.713142723427154e-05
the O 0 3.0055593015276827e-05
dystrophin O 0 6.586319068446755e-05
gene O 0 4.642944531951798e-06
was O 0 2.1885552996536717e-05
performed O 0 3.0097010039753513e-06
to O 0 1.700337435295296e-07
define O 0 1.3498029147740453e-06
the O 0 3.640089744294528e-06
localization O 0 5.9749138017650694e-05
of O 0 7.163940608734265e-06
deletions O 0 3.4720210351224523e-06
and O 0 1.010481810226338e-06
duplications O 0 3.5898606256523635e-06
in O 0 1.1049096428905614e-06
relation O 0 4.8592660277790856e-06
to O 0 3.733112805548444e-07
the O 0 3.04130048789375e-06
different O 0 5.413136022980325e-06
DMD B-Disease 1 1.0
promoters O 0 0.0007465840899385512
. O 0 5.933631200605305e-06

Qualitative O 0 0.0003448647039476782
analysis O 0 4.736044138553552e-05
of O 0 9.592177229933441e-05
the O 0 7.241671846713871e-05
Dp71 O 0 0.0006553957937285304
transcript O 0 0.00012325441639404744
and O 0 4.365281256468734e-06
testing O 0 1.7251760482395184e-06
for O 0 6.985287086536118e-07
the O 0 1.910313130792929e-06
specific O 0 3.4601762877173314e-07
first O 0 1.1659596566460095e-05
exon O 0 7.903509867901448e-06
of O 0 3.0418279493460432e-05
Dp140 O 0 8.303415961563587e-05
were O 0 8.604500180808827e-06
also O 0 1.2121396366637782e-06
carried O 0 1.1543363598320866e-06
out O 0 5.523094159798347e-07
. O 0 1.2333682661846979e-06

Neuropsychological O 0 0.0020969801116734743
analysis O 0 1.5032645933388267e-05
assessed O 0 4.047860056743957e-05
verbal O 0 0.00021128315711393952
and O 0 4.452356370165944e-05
visuospatial O 0 0.01453176885843277
intelligence O 0 5.470287942443974e-05
, O 0 3.2308957997884136e-06
verbal O 0 0.00032428617123514414
memory O 1 0.9986467957496643
, O 0 3.0930323191569187e-06
and O 0 1.645664383431722e-06
reading O 0 0.00012763863196596503
skills O 0 0.00013638338714372367
. O 0 5.252589744486613e-06

Comparison O 0 0.00021284188551362604
of O 0 0.00016321675502695143
molecular O 0 0.0005396017804741859
and O 0 2.2839036319055595e-05
psychometric O 0 0.0012274413602426648
findings O 0 3.240776641177945e-05
demonstrated O 0 3.496482167975046e-05
that O 0 8.129057391670358e-07
deletions O 0 4.261972662789049e-06
and O 0 1.3311022257767036e-06
duplications O 0 9.07079902390251e-06
that O 0 4.1755563984224864e-07
were O 0 1.4893510069668991e-06
localized O 0 3.6388264561537653e-06
in O 0 5.633829005091684e-06
the O 0 9.126686563831754e-06
distal O 0 4.9952192057389766e-05
part O 0 5.662603143719025e-06
of O 0 0.00010148157161893323
the O 0 3.071783066843636e-05
gene O 0 6.506475074274931e-06
seemed O 0 2.292103545187274e-06
to O 0 2.441922752893788e-08
be O 0 4.655349528093211e-08
preferentially O 0 3.0238390991144115e-07
associated O 0 2.8270781626815733e-07
with O 0 1.9480039270547422e-07
cognitive B-Disease 0 0.005849861074239016
impairment I-Disease 1 0.9999858140945435
. O 0 1.789213638403453e-05

Two O 0 0.0002883935230784118
altered O 0 0.00019954220624640584
Dp71 O 0 0.0011767997639253736
transcripts O 0 0.00013707674224860966
and O 0 4.12724693887867e-06
two O 0 1.2688934702964616e-06
deleted O 0 4.165615791862365e-06
Dp140 O 0 9.265328117180616e-06
DNA O 0 2.2125327348021528e-07
sequences O 0 2.181080560603732e-07
were O 0 1.4903966416568437e-07
found O 0 2.3634724399812512e-08
in O 0 1.7717297851049807e-08
four O 0 1.1487034612400748e-07
patients O 0 9.402912155564991e-07
with O 0 2.011609694818617e-06
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.000297233258606866

These O 0 1.581323340360541e-05
findings O 0 5.039406005380442e-06
suggest O 0 1.6404433154093567e-06
that O 0 9.09991300090951e-08
some O 0 5.702591820977432e-08
sequences O 0 3.558586172403011e-07
located O 0 3.805750793617335e-06
in O 0 1.3496137398760766e-06
the O 0 3.3336204978695605e-06
distal O 0 8.76194826560095e-06
part O 0 2.326711864952813e-06
of O 0 4.280237408238463e-05
the O 0 1.4109276889939792e-05
gene O 0 1.2992445590498392e-06
and O 0 6.367781679728068e-07
, O 0 1.2929231729685853e-07
in O 0 1.243182197185888e-07
particular O 0 2.4074719817690493e-07
, O 0 2.459316021941049e-07
some O 0 1.6127052049341728e-07
DMD B-Disease 1 0.9996328353881836
isoforms O 0 1.4800506505707745e-05
expressed O 0 3.6902333704347257e-06
in O 0 7.525850378442556e-06
the O 0 1.2672134289459791e-05
brain O 0 0.00026790800620801747
may O 0 1.5852772321522934e-06
be O 0 3.1128294608606666e-08
related O 0 1.0435251596163653e-07
to O 0 2.2133638921673082e-08
the O 0 1.0950885780403041e-06
cognitive B-Disease 0 0.0017366200918331742
impairment I-Disease 1 0.9999667406082153
associated O 0 8.914431964512914e-05
with O 0 1.5521825844189152e-05
DMD B-Disease 1 1.0
. O 0 6.812024821556406e-06
. O 0 4.0326126509171445e-06

I1307K O 0 0.01813460886478424
APC O 0 0.0021779483649879694
and O 0 1.6467225577798672e-05
hMLH1 O 0 0.00013702642172574997
mutations O 0 6.74408147460781e-06
in O 0 3.5224584280513227e-06
a O 0 6.992571798036806e-06
non O 0 3.379225745447911e-05
- O 0 5.669000529451296e-06
Jewish O 0 1.2056385685355053e-06
family O 0 2.534601719617058e-07
with O 0 1.641047617795266e-07
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005211833049543202

We O 0 3.1276358640752733e-06
describe O 0 1.1084981679232442e-06
a O 0 6.142963684396818e-07
French O 0 1.3276931895234156e-05
Canadian O 0 6.316357030300424e-05
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9997510313987732
HNPCC B-Disease 1 1.0
) O 0 4.986293333786307e-06
kindred O 0 5.3689258493250236e-05
which O 0 7.287009395895439e-08
carries O 0 5.362579145185009e-07
a O 0 2.4430929101981746e-07
novel O 0 7.867254225857323e-07
truncating O 0 1.3728328667639289e-05
mutation O 0 1.6823972828206024e-06
in O 0 5.00511669088155e-06
hMLH1 O 0 7.089929567882791e-05
. O 0 3.872934030368924e-06

Interestingly O 0 0.0009471916127949953
, O 0 2.5494977307971567e-05
the O 0 2.7392896299716085e-05
I1307K O 0 0.00042532000225037336
APC O 0 0.00010978251521009952
polymorphism O 0 7.695800377405249e-06
, O 0 2.490119470621721e-07
associated O 0 7.711898319939792e-08
with O 0 6.029743815361144e-09
an O 0 3.609038046192836e-08
increased O 0 5.512261850526556e-06
risk O 0 0.00018654618179425597
of O 1 0.9999954700469971
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.901763117639348e-05
is O 0 8.992718676381628e-07
also O 0 6.921608530774392e-08
present O 0 6.818120823481877e-08
in O 0 3.576556935058761e-07
this O 0 1.9200686551812396e-07
family O 0 1.1678064311126946e-06
. O 0 1.455553842788504e-06

The O 0 0.0007088524871505797
I1307K O 0 0.001113319885917008
polymorphism O 0 9.726249118102714e-05
has O 0 1.3112081433064304e-05
previously O 0 5.613106168311788e-06
only O 0 2.728194772316783e-07
been O 0 6.814271955590812e-07
identified O 0 3.297132309398876e-07
in O 0 4.564575704080198e-07
individuals O 0 1.0892978252741159e-07
of O 0 3.462451559244073e-06
self O 0 3.0031067581148818e-05
- O 0 6.88518412061967e-05
reported O 0 7.232835741888266e-06
Ashkenazi O 0 1.981986679311376e-05
Jewish O 0 1.765750494087115e-05
origins O 0 1.5511572200921364e-05
. O 0 2.593238605186343e-06

In O 0 0.00028574257157742977
addition O 0 3.7625028198817745e-05
, O 0 6.790452061977703e-06
in O 0 6.451823537645396e-06
this O 0 1.7020245195453754e-06
family O 0 2.9593797989946324e-06
, O 0 4.976745344720257e-07
there O 0 4.035426286463917e-07
appears O 0 1.2736484222841682e-06
to O 0 1.0900917857270542e-07
be O 0 3.8110576383587613e-07
no O 0 3.521718667798268e-07
relationship O 0 5.070089628134156e-07
between O 0 2.810405703712604e-06
the O 0 5.683822564606089e-06
I1307K O 0 1.3687670616491232e-05
polymorphism O 0 1.1034596809622599e-06
and O 0 2.3863847786742554e-07
the O 0 3.0324534350256727e-07
presence O 0 4.895029519502714e-07
or O 0 6.915912535987445e-07
absence O 0 4.15032127421e-06
of O 0 5.104592673887964e-06
cancer B-Disease 0 0.00018193796859122813
. O 0 6.437463753172779e-07
. O 0 8.896813028513861e-07

Identification O 0 1.2998720194445923e-05
of O 0 6.0359006965882145e-06
a O 0 2.5687184006528696e-06
novel O 0 1.819696876736998e-06
mutation O 0 1.0129750762644107e-06
of O 0 8.933260687626898e-06
the O 0 1.5680767319281586e-05
CPO O 0 0.00047266221372410655
gene O 0 1.500086227679276e-06
in O 0 1.4458073565037921e-06
a O 0 7.889051630627364e-06
Japanese O 0 0.00014603917952626944
hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9999743700027466
family O 0 9.929181396728382e-05
. O 0 6.191702141222777e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 1 0.6006349325180054
HCP B-Disease 1 1.0
) O 0 1.4116988495516125e-05
is O 0 1.2588700428750599e-06
an O 0 1.6919113932090113e-06
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 0.0006235892069526017
by O 0 3.0653845897177234e-06
a O 0 0.0021991177927702665
deficiency B-Disease 1 1.0
of I-Disease 1 1.0
coproporphyrinogen I-Disease 1 1.0
oxidase I-Disease 1 0.9999223947525024
( O 0 5.369237987906672e-05
CPO O 0 0.043684735894203186
) O 0 3.058727315874421e-07
caused O 0 8.770306294536567e-07
by O 0 4.3291770168707444e-08
a O 0 2.7637494781629357e-07
mutation O 0 2.3313219799092622e-07
in O 0 1.312674271503056e-06
the O 0 5.840970970893977e-06
CPO O 0 0.00047599789104424417
gene O 0 6.792129624955123e-06
. O 0 1.92872494153562e-06

Only O 0 4.8097143007908016e-05
11 O 0 5.331156717147678e-05
mutations O 0 2.3530808448413154e-06
of O 0 1.397753476339858e-05
the O 0 7.149962584662717e-06
gene O 0 1.552943786009564e-06
have O 0 3.04426691855042e-07
been O 0 5.419977355813899e-07
reported O 0 9.653779216023395e-07
in O 0 4.0706954678171314e-06
HCP B-Disease 1 0.998528003692627
patients O 0 2.3816361135686748e-05
. O 0 7.065706995490473e-06

We O 0 4.1380593756912276e-05
report O 0 3.5495741030899808e-06
another O 0 7.012607170509e-07
mutation O 0 6.231149427549099e-07
in O 0 7.257387437675789e-07
a O 0 2.95525933324825e-06
Japanese O 0 1.349393369309837e-05
family O 0 5.701400823454605e-06
. O 0 3.409733608350507e-06

Polymerase O 0 0.02078099362552166
chain O 0 0.001414356054738164
reaction O 0 6.65989937260747e-05
- O 0 2.4338392904610373e-05
single O 0 1.015729935716081e-06
strand O 0 1.386247390655626e-06
conformational O 0 2.7016355375053536e-07
polymorphism O 0 2.6172941147706297e-07
and O 0 4.035421596881861e-08
direct O 0 1.7008922270633775e-07
sequence O 0 3.3489462225588795e-07
analyses O 0 5.698812515220197e-07
demonstrated O 0 8.464099664706737e-06
a O 0 8.747680112719536e-06
C O 0 3.7952937418594956e-05
to O 0 5.424455480351753e-07
T O 0 9.067995961231645e-06
substitution O 0 3.872140155181114e-07
in O 0 3.204660004030302e-07
exon O 0 2.4133612441801233e-07
1 O 0 1.0746667840066948e-06
of O 0 2.1835166990058497e-06
the O 0 4.155965143581852e-06
CPO O 0 9.848069021245465e-05
gene O 0 2.3150894321588567e-06
at O 0 2.4189374016714282e-05
nucleotide O 0 6.7426990426611155e-06
position O 0 1.7649894289206713e-05
85 O 0 1.3652459529112093e-05
, O 0 3.310330782824167e-07
which O 0 1.5100862071903975e-07
lies O 0 1.1768723879868048e-06
in O 0 1.0144113957721856e-06
the O 0 3.6653100323746912e-06
putative O 0 2.397165008005686e-05
presequence O 0 4.190166509943083e-05
for O 0 7.184988248809532e-07
targeting O 0 2.3212776341097197e-06
to O 0 5.829590463690693e-07
mitochondria O 0 1.9434706700849347e-05
. O 0 3.283559180999873e-06

This O 0 8.391106348426547e-06
mutation O 0 2.5712920432852115e-06
changes O 0 1.9068056644755416e-06
the O 0 2.7157993827131577e-06
codon O 0 6.1386813285935204e-06
for O 0 3.338661827001488e-07
glutamine O 0 2.591883685454377e-07
to O 0 6.40050075162435e-08
a O 0 8.005073937056295e-07
termination O 0 9.892557500279509e-06
codon O 0 4.0334030927624553e-05
at O 0 0.00012928026262670755
amino O 0 1.2399263141560368e-05
acid O 0 5.791626335849287e-06
position O 0 2.2270678528002463e-05
29 O 0 0.00016714243975002319
. O 0 5.478751518239733e-06

MaeI O 0 0.01951414719223976
restriction O 0 0.0005533911753445864
analysis O 0 2.7604046408669092e-05
showed O 0 2.8184686016174965e-05
two O 0 7.079399324538826e-07
other O 0 2.162112480164069e-07
carriers O 0 4.1100409475802735e-07
in O 0 5.884132292521826e-07
the O 0 2.6141660782741383e-06
family O 0 2.6365898975200253e-06
. O 0 1.6248761767201358e-06

The O 0 0.003485565073788166
C O 1 0.9618383646011353
- O 1 0.5284808874130249
T O 0 0.0013985981931909919
mutation O 0 1.0942471817543264e-06
is O 0 2.440629032207653e-07
located O 0 3.6584057738764386e-07
within O 0 9.615732921020026e-08
a O 0 4.1305207787445397e-07
recently O 0 9.130457669925818e-07
proposed O 0 1.1902216101589147e-06
putative O 0 1.1087434359069448e-05
alternative O 0 2.2714918941346696e-06
translation O 0 1.421729120920645e-05
initiation O 0 1.6036079614423215e-05
codon O 0 2.6851916118175723e-05
( O 0 1.3723006304644514e-06
TIC O 0 8.961052117228974e-06
- O 0 4.2512069740041625e-06
1 O 0 7.78463072492741e-06
) O 0 1.772748134953872e-07
, O 0 1.0553165452620306e-07
supporting O 0 4.718525019598019e-07
that O 0 3.892484983225586e-07
TIC O 0 2.2106307369540446e-05
- O 0 1.0692520845623221e-05
1 O 0 3.155985177727416e-05
is O 0 1.665957256591355e-06
the O 0 6.198390110512264e-06
real O 0 5.825753396493383e-05
TIC O 0 9.031240915646777e-05
rather O 0 4.5833639887860045e-06
than O 0 8.963641562331759e-07
TIC O 0 1.2471839909267146e-05
- O 0 3.3492221973574487e-06
2 O 0 3.0196106308721937e-06
. O 0 9.118625854398488e-08
. O 0 1.6494418275669886e-07

Human B-Disease 0 2.0924884665873833e-05
complement I-Disease 0 7.428952085319906e-05
factor I-Disease 0 0.1097022294998169
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.0001718385610729456
with O 0 0.0004690136411227286
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.12530280649662018

This O 0 2.9375594294833718e-06
study O 0 6.463373551923723e-07
reports O 0 5.105811737848853e-07
on O 0 9.221624850397347e-07
six O 0 5.651655214933271e-07
cases O 0 3.942235196063848e-07
of O 0 2.376510929025244e-05
deficiency B-Disease 1 0.9999951124191284
in I-Disease 0 2.2471474949270487e-05
the I-Disease 0 6.280850811890559e-06
human I-Disease 0 5.660130227624904e-06
complement I-Disease 0 5.393986612034496e-06
regulatory I-Disease 0 2.388184111623559e-05
protein I-Disease 0 0.00018790611648000777
Factor I-Disease 0 0.00035515427589416504
H I-Disease 1 0.9999960660934448
( O 0 1.8386026567895897e-06
FH O 0 9.801814485399518e-06
) O 0 7.105871890900062e-09
in O 0 4.019771182584009e-09
the O 0 5.684833048746896e-09
context O 0 1.625458700971194e-08
of O 0 9.601181716334395e-08
an O 0 3.0423968837567372e-06
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0002014550700550899

Five O 0 3.96806062781252e-05
of O 0 3.5361435948289e-06
the O 0 6.666431886515056e-07
cases O 0 7.400520729561322e-08
were O 0 7.866326967587156e-08
observed O 0 1.1341777650386575e-07
in O 0 2.361080042589947e-08
children O 0 4.184098756354615e-08
presenting O 0 3.567968747120176e-07
with O 0 6.145809038571315e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.07261884957551956
. O 0 3.767433008761145e-05

Two O 0 1.1791231372626498e-05
of O 0 6.162900717754383e-06
the O 0 2.040205345110735e-06
children O 0 1.173051487057819e-06
exhibited O 0 0.00010266398021485656
a O 0 2.0530293113552034e-05
homozygous O 0 0.00014060930698178709
deficiency O 1 0.9999196529388428
characterized O 0 2.654336640262045e-05
by O 0 8.795795451987942e-07
the O 0 4.366380380815826e-06
absence O 0 3.1315244996221736e-05
of O 0 3.745977664948441e-05
the O 0 1.2604577023012098e-05
150 O 0 4.799463567906059e-06
- O 0 2.4907421902753413e-06
kD O 0 9.027889063872863e-06
form O 0 2.744334551607608e-06
of O 0 0.00011029120651073754
Factor O 0 0.00020825646060984582
H O 1 0.9999967813491821
and O 0 4.7572748371749185e-06
the O 0 3.3334297313558636e-06
presence O 0 1.8406711888019345e-06
, O 0 3.05882366546939e-07
upon O 0 1.1335868066453259e-06
immunoblotting O 0 2.1413863578345627e-05
, O 0 5.327295298229728e-07
of O 0 2.477971747794072e-06
the O 0 2.796452463371679e-06
42 O 0 1.7791748177842237e-05
- O 0 7.075524536048761e-06
kD O 0 5.234937998466194e-05
Factor O 0 8.285367221105844e-05
H O 1 0.9714748859405518
- O 0 1.7017055142787285e-05
like O 0 3.212136562069645e-06
protein O 0 4.125841769564431e-06
1 O 0 7.050057320157066e-06
( O 0 4.2308968772886146e-07
FHL O 0 1.479316870245384e-05
- O 0 1.9888295810233103e-06
1 O 0 3.077408337048837e-06
) O 0 6.288843223956064e-08
and O 0 1.3931133935329854e-07
other O 0 2.660691791334102e-07
FH O 0 5.7141747674904764e-05
- O 0 1.8467053450876847e-05
related O 0 1.7613068848731928e-05
protein O 0 2.73102104983991e-05
( O 0 2.1976034076942597e-06
FHR O 0 0.00010938938794424757
) O 0 7.893137308201403e-07
bands O 0 5.26886515217484e-06
. O 0 1.0105474075317034e-06

Southern O 0 0.00023132133355829865
blot O 0 0.00017629220383241773
and O 0 4.323114808357786e-06
PCR O 0 9.112050065596122e-06
analysis O 0 2.9299758352863137e-07
of O 0 7.937621262499306e-07
DNA O 0 8.176922392522101e-07
of O 0 7.759562322462443e-06
one O 0 4.1480379877611995e-06
patient O 0 2.0033287000842392e-05
with O 0 6.648776434303727e-06
homozygous O 0 0.00038167688762769103
deficiency O 1 0.9998376369476318
ruled O 0 4.865297523792833e-05
out O 0 6.29442354238563e-07
the O 0 3.0187305810613907e-07
presence O 0 1.9711958998414048e-07
of O 0 6.624388220188848e-07
a O 0 3.6829695204687596e-07
large O 0 2.498773596926185e-07
deletion O 0 1.542587710900989e-06
of O 0 2.009132458624663e-06
the O 0 3.975431809521979e-06
FH O 0 5.846468047820963e-05
gene O 0 1.0127229188583442e-06
as O 0 3.925068767784978e-07
the O 0 1.3864549828213057e-06
underlying O 0 8.318537584273145e-05
defect O 0 4.453069777810015e-05
for O 0 4.573892965709092e-06
the O 0 0.0001907087571453303
deficiency O 1 1.0
. O 0 6.208736886037514e-05

The O 0 7.156613719416782e-05
other O 0 1.002928001980763e-06
four O 0 8.707925189810339e-07
children O 0 2.6441134082233475e-07
presented O 0 2.211036189692095e-06
with O 0 1.4510272876577801e-06
heterozygous O 0 4.846806405112147e-05
deficiency O 1 0.997617781162262
and O 0 3.293199597464991e-06
exhibited O 0 0.0024309915024787188
a O 0 2.1892838049097918e-05
normal O 0 0.00012062226596754044
immunoblotting O 0 0.00015650663408450782
pattern O 0 1.1456338143034372e-05
of O 0 9.212701115757227e-06
proteins O 0 1.0848559668374946e-06
of O 0 1.0049108823295683e-05
the O 0 1.7876853235065937e-05
FH O 0 0.0003637041081674397
family O 0 4.483445991354529e-06
. O 0 1.6301302139254403e-06

Factor B-Disease 1 0.999953031539917
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
is O 0 4.3537270357774105e-06
the O 0 1.4990978343121242e-06
only O 0 2.757375341388979e-06
complement B-Disease 1 0.9999902248382568
deficiency I-Disease 1 1.0
associated O 0 0.00011416493362048641
with O 0 8.963094842329156e-06
HUS B-Disease 1 1.0
. O 0 2.406397834420204e-05

These O 0 2.355503511353163e-06
observations O 0 9.005257197713945e-06
suggest O 0 2.5636034024500987e-06
a O 0 2.3989355213416275e-06
role O 0 3.3648389035079163e-06
for O 0 3.0870087357470766e-06
FH O 0 0.00021281243243720382
and O 0 8.746812454774044e-06
/ O 0 0.00012413975491654128
or O 0 8.050372343859635e-06
FH O 0 7.570748130092397e-05
receptors O 0 2.6737766347650904e-06
in O 0 6.220438422133157e-07
the O 0 2.2426957002608106e-06
pathogenesis O 0 0.0006222696392796934
of O 0 9.77323652477935e-05
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 7.293930593732512e-06
. O 0 2.2590052140003536e-06

Further O 0 6.777950716241321e-07
evidence O 0 2.8523152195703005e-07
for O 0 1.0729213073545907e-07
a O 0 4.724062989680533e-07
major O 0 2.9823058866895735e-06
ancient O 0 6.211538129718974e-05
mutation O 0 0.03614874929189682
underlying O 1 0.9999905824661255
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.708073952817358e-05
linkage O 0 4.590057869791053e-05
disequilibrium O 0 5.7048477174248546e-05
studies O 0 2.8422052764653927e-06
in O 0 8.609084716226789e-07
the O 0 1.2700156730716117e-06
Japanese O 0 5.495151071954751e-06
population O 0 7.504103223254788e-07
. O 0 1.3344106264412403e-06

The O 0 0.19436979293823242
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0010377928847447038
DM B-Disease 1 1.0
) O 0 2.2375330445356667e-05
mutation O 0 1.182260166388005e-05
is O 0 6.508442766062217e-06
an O 0 4.8916131163423415e-06
unstable O 0 0.00011184478353243321
( O 0 2.7850242076965515e-06
CTG O 0 0.0001553466427139938
) O 0 1.7562012999405852e-06
n O 0 1.7423137251171283e-05
repeat O 0 5.608098035736475e-06
, O 0 7.420024417115201e-07
present O 0 8.726022997507243e-07
at O 0 6.991851932980353e-06
a O 0 5.242693532636622e-07
copy O 0 5.591359695245046e-07
number O 0 3.9019624864522484e-07
of O 0 8.600619366916362e-06
5 O 0 8.469444765069056e-06
- O 0 6.449995908042183e-06
37 O 0 2.104977647832129e-05
repeats O 0 5.660486749547999e-06
on O 0 3.0130981031106785e-05
normal O 0 3.332463529659435e-05
chromosomes O 0 5.0027406359731685e-06
but O 0 3.32535392999489e-07
amplified O 0 1.3261466165204183e-06
to O 0 1.4396388792192738e-07
50 O 0 1.285823600483127e-06
- O 0 1.019932938106649e-06
3000 O 0 2.1567427666013828e-06
copies O 0 1.1409466651457478e-06
on O 0 2.6789428375195712e-05
DM B-Disease 1 0.9999655485153198
chromosomes O 0 9.432849765289575e-05
. O 0 5.352418611437315e-06

Previous O 0 0.00011023431579815224
findings O 0 8.737374628253747e-06
in O 0 3.4628046705620363e-06
Caucasian O 0 1.7614782336750068e-05
populations O 0 7.791454095240624e-07
of O 0 2.386731284786947e-05
a O 0 0.0009093878325074911
DM B-Disease 1 1.0
founder O 1 0.9999327659606934
chromosome O 0 0.00016410625539720058
raise O 0 2.442629693177878e-06
a O 0 1.9733449789782753e-06
question O 0 3.207472900612629e-07
about O 0 6.036500366235487e-08
the O 0 2.537760792620247e-07
molecular O 0 1.4784120594413253e-06
events O 0 2.260452589553097e-07
involved O 0 1.0330569466532324e-07
in O 0 2.3925647951728024e-07
the O 0 4.20536878209532e-07
expansion O 0 8.175346010830253e-06
mutation O 0 2.9819191240676446e-06
. O 0 2.350019713048823e-06

To O 0 7.6233322943153325e-06
investigate O 0 4.237036591803189e-06
whether O 0 2.237839453300694e-06
a O 0 2.0538122043944895e-05
founder O 0 0.00013766066695097834
chromosome O 0 4.66488090751227e-05
for O 0 9.808472896111198e-06
the O 0 9.4512892246712e-05
DM B-Disease 1 1.0
mutation O 0 1.4204903891368303e-05
exists O 0 1.594140144334233e-06
in O 0 9.495586255070521e-07
the O 0 1.119685862249753e-06
Japanese O 0 3.0047394830035046e-06
population O 0 1.4799947223309573e-07
, O 0 1.4666466086055152e-07
we O 0 2.0563273039897467e-07
genotyped O 0 1.224437710334314e-05
families O 0 1.7402713581304852e-07
using O 0 4.784797624779458e-07
polymorphic O 0 3.708621761688846e-06
markers O 0 1.3361908713704906e-05
near O 0 0.0001804175553843379
the O 0 1.7747010133462027e-05
( O 0 2.706424083953607e-06
CTG O 0 0.00012128207890782505
) O 0 8.446339734291541e-07
n O 0 1.1648659892671276e-05
repeat O 0 3.716297442224459e-06
region O 0 2.3619190869794693e-06
and O 0 1.218432885252696e-06
constructed O 0 0.00011328449181746691
haplotypes O 0 7.16845752322115e-05
. O 0 2.9121436000423273e-06

Six O 0 6.731963367201388e-05
different O 0 2.07191328627232e-06
haplotypes O 0 4.937657286063768e-05
were O 0 1.1644061487459112e-05
found O 0 2.5749213818926364e-06
and O 0 3.6734145396621898e-06
DM B-Disease 1 0.9999994039535522
alleles O 0 2.1400164769147523e-05
were O 0 6.9240040829754435e-06
always O 0 2.856879973478499e-06
haplotype O 0 4.512903979048133e-05
A O 0 2.218309418822173e-05
. O 0 2.003140252782032e-06

To O 0 9.761655746842735e-06
find O 0 1.3882319080948946e-06
an O 0 5.573859880314558e-07
origin O 0 1.274732312595006e-06
of O 0 1.13582682388369e-05
the O 0 1.868323852249887e-05
( O 0 4.217270998196909e-06
CTG O 0 0.00012474777759052813
) O 0 8.970824865173199e-07
n O 0 1.146925933426246e-05
repeat O 0 3.076387429246097e-06
mutation O 0 4.3813867023345665e-07
and O 0 2.8329023393780517e-07
to O 0 1.5565601074740698e-07
investigate O 0 3.1753995699546067e-07
the O 0 2.055281584034674e-06
mechanism O 0 4.288294348953059e-06
of O 0 1.2829321349272504e-05
the O 0 7.297826869034907e-06
expansion O 0 1.6498035620315932e-05
mutation O 0 5.733242574024189e-07
in O 0 7.703149549342925e-07
the O 0 5.589466809396981e-07
Japanese O 0 7.789411142766767e-07
population O 0 2.801237997118733e-08
we O 0 2.6144046927356612e-08
have O 0 7.322188366742921e-08
studied O 0 6.06690855420311e-06
90 O 0 1.5250830983859487e-05
Japanese O 0 3.290403765277006e-05
DM B-Disease 1 0.9996138215065002
families O 0 1.4686385156892356e-06
comprising O 0 1.3783733265881892e-06
190 O 0 4.333541710366262e-06
affected O 0 8.94737127055123e-07
and O 0 1.2758414413838182e-06
130 O 0 1.0940751963062212e-05
unaffected O 0 2.402616519248113e-05
members O 0 8.101969797280617e-07
. O 0 1.4164643289404921e-06

The O 0 0.0002940227568615228
results O 0 0.00011559481208678335
suggest O 0 7.563430699519813e-06
that O 0 7.011664706624288e-07
a O 0 4.539744622888975e-06
few O 0 2.0929537640768103e-06
common O 0 6.012306585034821e-06
ancestral O 0 5.885243808734231e-05
mutations O 0 3.6959356748411665e-06
in O 0 1.0171345820708666e-05
both O 0 4.169259682385018e-06
Caucasian O 0 1.8205355445388705e-05
and O 0 2.9272239316924242e-06
Japanese O 0 8.439410521532409e-06
populations O 0 2.1892266488521273e-07
have O 0 9.387754573708662e-08
originated O 0 1.281818384768485e-07
by O 0 4.0174970905582086e-08
expansion O 0 5.223160428613483e-07
of O 0 1.107705543290649e-06
an O 0 3.9541598084724683e-07
ancestral O 0 5.963140665699029e-06
n O 0 1.556282222736627e-05
= O 0 6.02877298661042e-06
5 O 0 1.916570226967451e-06
repeat O 0 1.4191401760399458e-06
to O 0 1.3127657894074218e-06
n O 0 3.6786022974411026e-05
= O 0 2.153881905542221e-05
19 O 0 2.1604093490168452e-05
- O 0 7.141893547668587e-06
37 O 0 6.245467830012785e-06
copies O 0 1.932587792907725e-06
. O 0 1.3623006225316203e-06

These O 0 1.912495008582482e-06
data O 0 4.403212187753525e-06
support O 0 2.2531103240908124e-06
multistep O 0 7.468117837561294e-05
models O 0 1.9900946426787414e-05
of O 0 0.00013199591194279492
triplet O 0 0.001937622088007629
repeat O 0 0.00011213707330171019
expansion O 0 2.961137579404749e-05
that O 0 1.8639391896613233e-07
have O 0 4.248294516173701e-08
been O 0 6.654147455265047e-08
proposed O 0 6.684116726773937e-08
for O 0 3.290165579983295e-07
both O 0 5.249279638519511e-06
DM B-Disease 1 0.9999998807907104
and O 0 6.441640289267525e-05
Friedreichs B-Disease 1 0.940887987613678
ataxia I-Disease 1 0.999995231628418
. O 0 8.590405741415452e-06
. O 0 5.3334638323576655e-06

The O 0 1.5246337170538027e-05
molecular O 0 7.460679626092315e-05
basis O 0 0.00013122460222803056
of O 0 0.23622776567935944
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 0.00032090587774291635
the O 0 2.680162106116768e-05
western O 0 1.0590802048682235e-05
Cape O 0 1.3229571777628735e-05
, O 0 3.4544197546892974e-07
South O 0 6.631398150602763e-07
Africa O 0 5.135052560945041e-07
. O 0 5.391052013692388e-07

Deficiency B-Disease 1 0.9999514818191528
of I-Disease 0 0.001948884571902454
the I-Disease 0 0.000209397345315665
sixth I-Disease 0 0.0011667535873129964
component I-Disease 0 0.00011151625221827999
of I-Disease 0 0.00011875014752149582
human I-Disease 0 0.00015514603001065552
complement I-Disease 0 7.318914140341803e-05
( O 0 2.2011789042153396e-05
C6 O 0 0.0005987880867905915
) O 0 6.896115678500792e-07
has O 0 6.271396841839305e-07
been O 0 1.0112714790011523e-06
reported O 0 8.473020329802239e-07
in O 0 3.578112455215887e-07
a O 0 4.7020927240737365e-07
number O 0 3.8681685055053094e-07
of O 0 2.6545178570813732e-06
families O 0 3.4116618508051033e-07
from O 0 1.3045897730989964e-06
the O 0 2.668106390046887e-06
western O 0 5.177986167836934e-06
Cape O 0 1.4500531506200787e-05
, O 0 8.535533311260224e-07
South O 0 1.2165949101472506e-06
Africa O 0 1.2770881312462734e-06
. O 0 8.690321351423336e-07

Meningococcal B-Disease 1 0.9999979734420776
disease I-Disease 1 0.9999717473983765
is O 0 4.090866059414111e-05
endemic O 0 6.51025538900285e-06
in O 0 1.8491001583242905e-06
the O 0 3.369758815097157e-06
Cape O 0 2.2880415144754807e-06
and O 0 5.9294631427064814e-08
almost O 0 1.2387654635404033e-07
all O 0 1.9552809149558925e-08
pedigrees O 0 8.495238148498174e-07
of O 0 1.2084601621609181e-05
total O 1 0.9785538911819458
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 8.434776100330055e-05
C6Q0 O 0 0.0007651909254491329
) O 0 1.9938821083087532e-07
have O 0 3.5753078719835685e-08
been O 0 1.2888420997114736e-07
ascertained O 0 3.982452483342058e-07
because O 0 3.516777624668066e-08
of O 0 1.0664510909919045e-06
recurrent O 1 0.6397604942321777
disease O 1 0.9915673136711121
. O 0 1.271006385650253e-05

We O 0 1.3368026884563733e-05
have O 0 9.946506906999275e-07
sequenced O 0 1.6151631143657141e-06
the O 0 1.19829883260536e-06
expressed O 0 1.4608217497880105e-06
exons O 0 1.2126993169658817e-05
of O 0 3.584238584153354e-05
the O 0 6.134049181127921e-05
C6 O 0 0.0005264642531983554
gene O 0 4.976839136361377e-06
from O 0 1.0120760407517082e-06
selected O 0 2.5657314495219907e-07
cases O 0 6.373383598656801e-08
and O 0 7.530263701482909e-08
have O 0 1.3257125885957066e-07
found O 0 5.209793130234175e-07
three O 0 3.180125986546045e-06
molecular O 0 0.019017040729522705
defects O 1 0.9993258714675903
leading O 0 0.007259808015078306
to O 0 6.192351975187194e-06
total O 0 0.07629237323999405
deficiency O 1 1.0
879delG O 0 0.102162666618824
, O 0 1.781021819624584e-05
which O 0 2.5926699436240597e-06
is O 0 2.667732360350783e-06
the O 0 5.94010271015577e-06
common O 0 1.9907914975192398e-05
defect O 0 7.68427926232107e-05
in O 0 1.1027285836462397e-05
the O 0 1.0736664080468472e-05
Cape O 0 1.5661416910006665e-05
and O 0 1.507710294390563e-06
hitherto O 0 4.540323425317183e-05
unreported O 0 2.859470623661764e-05
, O 0 1.1302997791062808e-06
and O 0 1.351222181256162e-06
1195delC O 0 1.4939749235054478e-05
and O 0 6.984907031437615e-06
1936delG O 0 6.486813072115183e-05
, O 0 2.86548333860992e-06
which O 0 5.655845143337501e-07
have O 0 4.014227101833967e-07
been O 0 6.346114673760894e-07
previously O 0 1.3136071856933995e-06
reported O 0 1.0263220246997662e-06
in O 0 1.1230491736569093e-06
African O 0 5.1859719860658515e-06
- O 0 6.907588158355793e-06
Americans O 0 6.799211860197829e-07
. O 0 7.967677220221958e-07

We O 0 5.023035191698e-05
also O 0 3.7817385418748017e-06
show O 0 1.3738365396420704e-06
that O 0 2.4797489572847553e-07
the O 0 1.966762056326843e-06
879delG O 0 3.701931200339459e-05
and O 0 8.522303687641397e-06
1195delC O 0 0.0006422516307793558
defects O 0 0.06825776398181915
are O 0 4.419053141191398e-07
associated O 0 2.4776431928330567e-06
with O 0 1.0345096370656393e-06
characteristic O 1 0.9997397065162659
C6 O 1 1.0
/ O 1 0.9999582767486572
C7 O 1 0.9991713762283325
region O 0 9.271533781429753e-05
DNA O 0 2.2816158889327198e-05
marker O 0 0.00011275478027528152
haplotypes O 0 2.071440758300014e-05
, O 0 2.63566704461482e-07
although O 0 4.772434181177232e-08
small O 0 6.300429333805369e-08
variations O 0 6.31820341823186e-07
were O 0 1.135007096308982e-06
observed O 0 6.09586686550756e-06
. O 0 9.849854905041866e-07

The O 0 0.00097941467538476
1936delG O 0 0.0018490639049559832
defect O 0 0.0006680553779006004
was O 0 0.0002798388304654509
observed O 0 1.834997965488583e-05
only O 0 1.6192301472983672e-06
once O 0 4.323369921621634e-06
in O 0 2.7217888600716833e-06
the O 0 5.259988483885536e-06
Cape O 0 8.173980859282892e-06
, O 0 1.6047000883645524e-07
but O 0 3.656661107243053e-08
its O 0 1.441561039428052e-07
associated O 0 2.9236832688184222e-06
haplotype O 0 2.3776490706950426e-05
could O 0 1.1091051419498399e-06
be O 0 1.285894654756703e-06
deduced O 0 1.4296009794634301e-05
. O 0 2.0149445845163427e-06

The O 0 0.00020550008048303425
data O 0 3.514393392833881e-05
from O 0 4.2628344090189785e-06
the O 0 1.645374027248181e-06
haplotypes O 0 5.175365004106425e-06
indicate O 0 1.2058937954861904e-06
that O 0 7.515384226053357e-08
these O 0 7.953482850098226e-08
three O 0 2.6173815967922565e-06
molecular O 0 0.0011297216406092048
defects O 0 0.03544030338525772
account O 0 3.4925444651889848e-06
for O 0 1.4244733392843045e-05
the O 0 0.00021832155471201986
defects O 1 0.9750210046768188
in O 0 3.335048313601874e-05
all O 0 4.5992010200279765e-06
the O 0 2.3922277250676416e-05
38 O 0 0.00018909091886598617
unrelated O 0 3.6027377063874155e-05
C6Q0 O 0 0.0003737049410119653
individuals O 0 6.231803695300187e-07
we O 0 6.770314939785749e-07
have O 0 2.857883316664811e-07
studied O 0 9.26117536437232e-06
from O 0 2.4278569981106557e-06
the O 0 3.158952267767745e-06
Cape O 0 2.0688326912932098e-05
. O 0 1.4543967381541734e-06

We O 0 3.8664387830067426e-05
have O 0 1.3520600532501703e-06
also O 0 4.3574846131377853e-07
observed O 0 1.2013872492389055e-06
the O 0 1.6984863577818032e-06
879delG O 0 2.031021904258523e-05
defect O 0 1.1977347639913205e-05
in O 0 4.636528956325492e-06
two O 0 9.693739229987841e-06
Dutch O 1 0.9983829259872437
C6 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
kindreds O 0 0.026177598163485527
, O 0 4.275455921742832e-06
but O 0 4.630994965282298e-07
the O 0 5.2634309213317465e-06
879delG O 0 9.662204683991149e-05
defect O 0 0.00014277042646426708
in O 0 3.7502879422390833e-05
the O 0 7.604335405630991e-05
Cape O 0 0.00012436888937372714
probably O 0 1.2823045835830271e-05
did O 0 1.0651835964381462e-06
not O 0 2.0133202838223951e-07
come O 0 1.7416627429156506e-07
from O 0 1.9308842524878855e-07
The O 0 3.504902394979581e-07
Netherlands O 0 1.9024571429326897e-06
. O 0 4.478060589008237e-07
. O 0 9.782211236597504e-07

Complement B-Disease 1 0.9999834299087524
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.9037630409002304e-05
seven O 0 3.8535986277565826e-06
further O 0 5.436218998511322e-06
molecular O 1 0.9863725304603577
defects O 1 0.9082609415054321
and O 0 1.5184114090516232e-06
their O 0 6.502820042442181e-07
associated O 0 2.194436456193216e-05
marker O 0 0.00020913657499477267
haplotypes O 0 7.83523719292134e-05
. O 0 2.7572359613259323e-06

Seven O 0 1.4020092748978641e-05
further O 0 2.4519279122614535e-06
molecular O 0 0.00010059391934191808
bases O 0 7.372016261797398e-05
of O 1 0.9996132254600525
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.9870454707415774e-05
described O 0 1.346476528851781e-05
. O 0 1.0186614645135705e-06

All O 0 5.12686438014498e-06
these O 0 4.6153300559126365e-07
new O 0 3.3088958844018634e-06
molecular O 0 0.0003308689338155091
defects O 0 0.00045097924885340035
involve O 0 8.095411430986132e-06
single O 0 2.348555608477909e-05
- O 0 6.341367407003418e-05
nucleotide O 0 3.676614142023027e-05
events O 0 4.174257628619671e-05
, O 0 2.4199537165259244e-06
deletions O 0 2.385188736298005e-06
and O 0 2.1822445432917448e-06
substitutions O 0 2.202244104410056e-06
, O 0 3.231824621252599e-07
some O 0 5.896463406429575e-08
of O 0 1.7257833633266273e-06
which O 0 7.553192062914604e-07
alter O 0 3.7853899357287446e-06
splice O 0 1.0026842574006878e-05
sites O 0 2.2610247469856404e-06
, O 0 4.726703934920806e-07
and O 0 3.599355693495454e-07
others O 0 7.399178798550565e-07
codons O 0 1.2155071090091951e-05
. O 0 2.1600114905595547e-06

They O 0 6.0081279116275255e-06
are O 0 3.8081290654190525e-07
distributed O 0 4.100053843103524e-07
along O 0 1.54891472448071e-06
the O 0 9.806508387555368e-06
C7 O 0 0.0004610978940036148
gene O 0 4.1352286643814296e-06
, O 0 2.6847894218917645e-07
but O 0 3.026821815410585e-08
predominantly O 0 4.526048158481899e-08
towards O 0 4.0153756231120497e-07
the O 0 9.605062132322928e-07
3 O 0 7.233993983390974e-06
end O 0 9.947912076313514e-06
. O 0 1.5615544270985993e-06

All O 0 2.931726885435637e-05
were O 0 8.020021596166771e-06
found O 0 1.097472363653651e-06
in O 0 1.0177001286137966e-06
compound O 0 1.9713552319444716e-05
heterozygous O 0 1.0986095730913803e-06
individuals O 0 1.6559197035803663e-07
. O 0 1.2860982678830624e-06

The O 0 0.0015295043122023344
C6 O 1 0.9965834021568298
/ O 1 0.5215378403663635
C7 O 0 0.06690045446157455
marker O 0 0.00024107137869577855
haplotypes O 0 5.348765625967644e-05
associated O 0 1.9007826267625205e-05
with O 0 4.6516665861418005e-06
most O 0 0.000914254691451788
C7 B-Disease 1 1.0
defects I-Disease 1 1.0
are O 0 5.591382887359941e-06
tabulated O 0 0.00011940918193431571
. O 0 3.384466253919527e-07
. O 0 8.30532599138678e-07

A O 0 0.00043335501686669886
genome O 0 3.96751202060841e-05
- O 0 1.4765852938580792e-05
wide O 0 5.620139290840598e-06
search O 0 9.076933338292292e-07
for O 0 1.3795529412163887e-06
chromosomal O 0 0.29566875100135803
loci O 0 0.0005916135851293802
linked O 0 7.961931260069832e-05
to O 0 7.015082132966199e-07
mental O 1 0.9912267327308655
health O 0 0.00011489271855680272
wellness O 0 0.00036611143150366843
in O 0 1.4135831634121132e-06
relatives O 0 1.919449459819589e-06
at O 0 1.2795147995348088e-05
high O 0 0.00023148504260461777
risk O 0 2.5930659830919467e-05
for O 0 5.418064756668173e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 8.615240403742064e-06
the O 0 5.724916718463646e-06
Old O 0 1.950483419932425e-05
Order O 0 2.642870867930469e-06
Amish O 0 2.6002966478699818e-05
. O 0 2.0411064269865165e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999985694885254
BPAD B-Disease 1 1.0
; O 1 0.9999996423721313
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 1.2800394870282616e-05
is O 0 5.2793546956309e-07
characterized O 0 4.058773015458428e-07
by O 0 4.076118997886624e-08
episodes O 0 2.073692257908988e-06
of O 0 0.00019386144413147122
mania B-Disease 1 0.9998688697814941
and O 0 0.0001898040936794132
/ O 1 0.988111138343811
or O 0 2.889707866415847e-05
hypomania B-Disease 0 0.09946577250957489
interspersed O 0 3.4782115108100697e-06
with O 0 3.97117645434264e-08
periods O 0 1.414725738868583e-05
of O 0 3.5916611523134634e-05
depression B-Disease 1 0.9311339259147644
. O 0 1.6452893760288134e-05

Compelling O 0 3.309231760795228e-05
evidence O 0 3.025667183464975e-06
supports O 0 7.277118925230752e-07
a O 0 2.34657491660073e-07
significant O 0 3.333094298341166e-07
genetic O 0 3.3441476716689067e-06
component O 0 1.592798980709631e-05
in O 0 1.2347981055427226e-06
the O 0 2.4158307496691123e-06
susceptibility O 0 5.032024273532443e-05
to O 0 3.543911816450418e-06
develop O 0 0.00014425725385081023
BPAD B-Disease 1 1.0
. O 0 4.091755545232445e-05

To O 0 5.210195013205521e-05
date O 0 0.00018608145182952285
, O 0 5.141127076058183e-06
however O 0 1.2946187553097843e-06
, O 0 4.656952512505086e-07
linkage O 0 3.52079246113135e-06
studies O 0 6.067737672310614e-07
have O 0 2.4373773044317204e-07
attempted O 0 2.7782516553997993e-06
only O 0 2.140827035645998e-07
to O 0 2.5115315338553046e-07
identify O 0 1.6779796396804159e-06
chromosomal O 0 0.0006677909404970706
loci O 0 3.294404086773284e-05
that O 0 3.9385673744618543e-07
cause O 0 2.1187038328207564e-06
or O 0 2.356361363808901e-07
increase O 0 2.089899169277487e-07
the O 0 1.0483585128895356e-06
risk O 0 3.5886660043615848e-06
of O 0 3.7512396374950185e-05
developing O 0 0.0005829908768646419
BPAD B-Disease 1 1.0
. O 0 5.4962340072961524e-05

To O 0 4.252696817275137e-05
determine O 0 1.883178083517123e-05
whether O 0 5.951199000264751e-06
there O 0 6.246802058740286e-06
could O 0 2.234514795418363e-06
be O 0 1.0556461802480044e-06
protective O 0 2.0514298739726655e-06
alleles O 0 2.259965583562007e-07
that O 0 7.617778408075537e-08
prevent O 0 3.12007898628508e-07
or O 0 3.621018720423308e-07
reduce O 0 3.2973304087136057e-07
the O 0 4.333351625973592e-06
risk O 0 1.1863282452395651e-05
of O 0 0.00014361478679347783
developing O 0 0.0004750940133817494
BPAD B-Disease 1 1.0
, O 0 1.562856482451025e-06
similar O 0 6.848423339533838e-08
to O 0 1.871947929998896e-08
what O 0 5.906095612573381e-09
is O 0 2.106036767202113e-08
observed O 0 1.5324950197737053e-07
in O 0 3.1355571650237835e-07
other O 0 2.7623182177194394e-06
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.1677708446077304e-06
we O 0 4.708056167146424e-07
used O 0 5.109048743179301e-06
mental O 1 0.9990479350090027
health O 0 0.0010889008408412337
wellness O 0 0.29802170395851135
( O 0 2.663456598384073e-06
absence O 0 1.580149182700552e-05
of O 0 1.1341954632371198e-05
any O 0 1.5446572433575056e-05
psychiatric B-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
) O 0 2.3257534849108197e-06
as O 0 1.7208577673955006e-06
the O 0 1.4817164810665417e-06
phenotype O 0 6.018146450514905e-06
in O 0 4.113077466172399e-06
our O 0 3.786205752476235e-06
genome O 0 4.509418886300409e-06
- O 0 6.578464308404364e-06
wide O 0 1.903294469229877e-05
linkage O 0 2.2108564735390246e-05
scan O 0 1.2390314623189624e-05
of O 0 1.179597711598035e-05
several O 0 1.7271383967454312e-06
large O 0 1.1288807399978396e-05
multigeneration O 0 0.0005252285045571625
Old O 0 7.796391582814977e-05
Order O 0 2.9729351354035316e-06
Amish O 0 1.3238860447017942e-05
pedigrees O 0 7.069656476232922e-06
exhibiting O 0 9.502882676315494e-06
an O 0 5.139383461028046e-07
extremely O 0 2.58791715168627e-06
high O 0 6.689318252028897e-05
incidence O 0 0.2905540466308594
of O 1 0.7088375687599182
BPAD B-Disease 1 1.0
. O 0 0.00010673570795916021

We O 0 7.162881956901401e-05
have O 0 2.4581299840065185e-06
found O 0 5.702433441001631e-07
strong O 0 2.8303128374318476e-07
evidence O 0 2.976749158278835e-07
for O 0 3.156294496875489e-07
a O 0 1.5298244306904962e-06
locus O 0 1.4090975128056016e-05
on O 0 2.391404086665716e-05
chromosome O 0 0.00038092679460532963
4p O 0 0.00986449234187603
at O 0 0.0006865711184218526
D4S2949 O 0 0.00014315362204797566
( O 0 2.723559646256035e-06
maximum O 0 6.36497134109959e-05
GENEHUNTER O 0 0.0004980528610758483
- O 0 2.0544412109302357e-05
PLUS O 0 8.670463103044312e-06
nonparametric O 0 2.1295440092217177e-05
linkage O 0 7.225499757623766e-06
score O 0 4.5292799768503755e-06
= O 0 2.6454401904629776e-06
4 O 0 1.2475770745368209e-06
. O 0 1.0198769473390712e-07
05 O 0 2.5509280021651648e-05
, O 0 1.0277530009261682e-06
P O 0 4.045487366965972e-05
= O 0 3.13694999931613e-06
5 O 0 9.94095898931846e-07
. O 0 5.73584095775459e-08
22 O 0 3.2810862649057526e-06
x O 0 1.2558671187434811e-05
10 O 0 2.3828649773349753e-06
( O 0 2.2480567452021205e-07
- O 0 1.0077073966385797e-06
4 O 0 2.907181851696805e-06
) O 0 1.1364819130221804e-07
; O 0 1.0996875943192208e-07
SIBPAL O 0 1.7153299268102273e-05
Pempirical O 0 1.5110286767594516e-05
value O 0 7.657527930859942e-06
< O 0 1.7258807929465547e-05
3 O 0 1.3468696124618873e-05
x O 0 2.7083993700216524e-05
10 O 0 5.564826551562874e-06
( O 0 3.5905279105463705e-07
- O 0 1.4000902410771232e-06
5 O 0 2.4541877792216837e-06
) O 0 9.00907366485626e-08
) O 0 3.271189186193624e-08
and O 0 7.134148916065897e-08
suggestive O 0 7.431440280925017e-07
evidence O 0 1.9799341544057825e-07
for O 0 2.0994117733152962e-07
a O 0 1.3375054095376981e-06
locus O 0 1.2247448466951028e-05
on O 0 5.096097447676584e-05
chromosome O 0 0.0014021624810993671
4q O 1 0.9648719429969788
at O 0 0.000434195069829002
D4S397 O 0 0.00012654128659050912
( O 0 1.1302382745270734e-06
maximum O 0 3.8791804399807006e-05
GENEHUNTER O 0 0.0002467698650434613
- O 0 1.918998168548569e-05
PLUS O 0 1.0548880709393416e-05
nonparametric O 0 2.3417098418576643e-05
linkage O 0 7.091453426255612e-06
score O 0 4.8383144530816935e-06
= O 0 2.934709300461691e-06
3 O 0 1.2372192941256799e-06
. O 0 6.25274623189398e-08
29 O 0 4.540169356914703e-06
, O 0 4.716540615845588e-07
P O 0 4.1311632230645046e-05
= O 0 3.234515133954119e-06
2 O 0 1.9807623630185844e-06
. O 0 9.846110060607316e-08
57 O 0 4.113034265174065e-06
x O 0 1.5892606825218536e-05
10 O 0 4.317478214943549e-06
( O 0 3.3869815752041177e-07
- O 0 1.0912250445471727e-06
3 O 0 2.0445158952497877e-06
) O 0 9.451770210944233e-08
; O 0 8.77172325886022e-08
SIBPAL O 0 9.720149137137923e-06
Pempirical O 0 1.1610663023020606e-05
value O 0 6.3573916122550145e-06
< O 0 1.54213048517704e-05
1 O 0 1.4498774362436961e-05
x O 0 2.9777909730910324e-05
10 O 0 5.979450634185923e-06
( O 0 5.675734087162709e-07
- O 0 2.234254679933656e-06
3 O 0 3.281593308201991e-06
) O 0 4.8166583610509406e-08
) O 0 9.874373319007645e-09
that O 0 3.630002742838201e-09
are O 0 2.5598502872981044e-08
linked O 0 1.2747019582093344e-06
to O 0 2.726823993270955e-07
mental O 0 0.17733658850193024
health O 0 0.00036941823782399297
wellness O 0 0.0049511585384607315
. O 0 1.3170130841899663e-05

These O 0 1.1880275451403577e-05
findings O 0 1.4666589777334593e-05
are O 0 5.560862064157845e-07
consistent O 0 1.247996010533825e-06
with O 0 6.097506854985113e-08
the O 0 8.940667726164975e-07
hypothesis O 0 4.812590077563073e-07
that O 0 3.025898109854097e-08
certain O 0 2.2501394880691805e-07
alleles O 0 1.2247834320078255e-06
could O 0 3.7002698149990465e-07
prevent O 0 4.6581740775764047e-07
or O 0 2.907984253397444e-07
modify O 0 1.150547532802193e-07
the O 0 1.949459118577579e-07
clinical O 0 2.3948388843564317e-05
manifestations O 0 0.0022402487229555845
of O 0 0.0055452026426792145
BPAD B-Disease 1 1.0
and O 0 8.114983756968286e-06
perhaps O 0 1.7559199250172242e-06
other O 0 5.763508852396626e-07
related O 0 0.0004261946596670896
affective B-Disease 1 0.9999997615814209
disorders I-Disease 1 1.0
. O 0 2.669820241862908e-05

Segregation O 1 0.8155950307846069
distortion O 1 0.9997677206993103
in O 0 0.43888425827026367
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.639358667191118e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9928135275840759
DM B-Disease 1 1.0
) O 0 0.00020197665435262024
is O 0 1.1359112249920145e-05
an O 0 7.596153864142252e-06
autosomal B-Disease 1 0.9999783039093018
dominant I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999998807907104
which O 0 4.333044489612803e-05
, O 0 8.54334302857751e-07
in O 0 1.545008103676082e-06
the O 0 4.757043370773317e-06
typical O 0 1.0906593161053024e-05
pedigree O 0 8.33340163808316e-06
, O 0 1.1004345168430518e-07
shows O 0 1.8398867496216553e-07
a O 0 8.114874958664586e-07
three O 0 8.242524813795171e-07
generation O 0 7.645575351489242e-06
anticipation O 0 1.5262281522154808e-05
cascade O 0 0.0003226382250431925
. O 0 6.1011473917460535e-06

This O 0 9.09515620151069e-07
results O 0 1.177531885332428e-05
in O 0 2.3213582608150318e-05
infertility B-Disease 1 1.0
and O 1 0.9999920129776001
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0015833337092772126
CDM B-Disease 1 0.9954386353492737
) O 0 4.51932010037126e-07
with O 0 1.3255608166673483e-07
the O 0 1.5095898561412469e-05
disappearance O 0 0.0012744057457894087
of O 0 0.006267517805099487
DM B-Disease 1 1.0
in O 0 9.439426503377035e-05
that O 0 2.8716358428937383e-06
pedigree O 0 6.497214053524658e-05
. O 0 2.3191907985165017e-06

The O 0 4.765059566125274e-05
concept O 0 1.9754179447772913e-05
of O 0 6.514845154015347e-05
segregation O 0 0.0002600361476652324
distortion O 0 0.0006331749027594924
, O 0 1.3046084177403827e-06
where O 0 4.2761794816215115e-07
there O 0 1.1492644347299574e-07
is O 0 1.2379599922951456e-07
preferential O 0 9.09326558939938e-07
transmission O 0 3.9948745325091295e-06
of O 0 3.3984979381784797e-06
the O 0 2.0397480966494186e-06
larger O 0 1.0815359701155103e-06
allele O 0 4.696747055277228e-06
at O 0 7.402490155072883e-05
the O 0 2.232258157164324e-05
DM B-Disease 1 0.9996466636657715
locus O 0 0.00010511155414860696
, O 0 2.099232688124175e-06
has O 0 1.0229019835605868e-06
been O 0 1.1543572782102274e-06
put O 0 6.502112910311553e-07
forward O 0 1.6522849364264403e-06
to O 0 1.597276479969878e-07
explain O 0 1.0793853562063305e-06
partially O 0 1.4666547940578312e-05
the O 0 4.13604948334978e-06
maintenance O 0 6.441400910262018e-05
of O 0 0.00010619934619171545
DM B-Disease 1 1.0
in O 0 1.542988138680812e-05
the O 0 5.366965979192173e-06
population O 0 1.095911898119084e-06
. O 0 1.0526141522859689e-06

In O 0 0.00013540957297664136
a O 0 4.894339872407727e-05
survey O 0 2.2915353838470764e-05
of O 0 8.548122423235327e-05
DM B-Disease 1 0.9999998807907104
in O 0 0.00015335196803789586
Northern O 0 3.7634359614457935e-05
Ireland O 0 5.458120540424716e-06
, O 0 1.4471137319560512e-06
59 O 0 1.6196492651943117e-05
pedigrees O 0 6.876131465105573e-06
were O 0 4.885552243649727e-06
ascertained O 0 1.1964983968937304e-05
. O 0 1.4667630239273421e-06

Sibships O 0 0.010408786125481129
where O 0 9.145483636530116e-05
the O 0 1.9299932318972424e-05
status O 0 1.557975156174507e-05
of O 0 4.227897079545073e-05
all O 0 3.6351534618006554e-06
the O 0 1.0245832527289167e-05
members O 0 1.0688622751331422e-06
had O 0 6.154425136628561e-06
been O 0 1.5994990008039167e-06
identified O 0 3.326115063373436e-07
were O 0 3.6241246448298625e-07
examined O 0 2.1588364518265735e-07
to O 0 5.391243362851128e-08
determine O 0 2.9579757665487705e-07
the O 0 6.125914296717383e-06
transmission O 0 9.942910401150584e-05
of O 0 0.00037264529964886606
the O 0 0.0017449985025450587
DM B-Disease 1 1.0
expansion O 0 0.004013370256870985
from O 0 1.7223801478394307e-05
affected O 0 1.5038417586765718e-06
parents O 0 1.2765860901708947e-07
to O 0 7.583926731058455e-08
their O 0 1.747049367395448e-07
offspring O 0 2.5735537292348454e-06
. O 0 1.2786186971425195e-06

Where O 0 0.00015113211702555418
the O 0 3.40680344379507e-05
transmitting O 0 0.0005110674537718296
parent O 0 3.1101528293220326e-05
was O 0 0.00010058318002847955
male O 0 1.2661128494073637e-05
, O 0 1.2646698905882658e-06
58 O 0 2.414114169368986e-05
. O 0 2.3815837266738527e-06

3 O 0 0.0004202483396511525
% O 0 2.5038523745024577e-05
of O 0 6.264593685045838e-05
the O 0 4.341478052083403e-05
offspring O 0 8.748939762881491e-06
were O 0 1.4188007298798766e-05
affected O 0 5.112304734211648e-06
, O 0 4.429128352967382e-07
and O 0 2.3812945926238172e-07
in O 0 6.037640787326382e-07
the O 0 6.92876653829444e-07
case O 0 7.117906193343515e-07
of O 0 1.7399157741238014e-06
a O 0 3.1539404972136253e-06
female O 0 1.572547080286313e-05
transmitting O 0 0.00020235369447618723
parent O 0 1.4832157830824144e-05
, O 0 3.054924945899984e-06
68 O 0 6.481495074694976e-05
. O 0 3.116523885182687e-06

7 O 0 0.0003947214281652123
% O 0 1.3446326192934066e-05
were O 0 5.5605614761589095e-06
affected O 0 4.5820661398465745e-06
. O 0 2.919540293078171e-06

Studies O 0 0.0002985012251883745
on O 0 0.00021282379748299718
meiotic O 0 0.0007553343311883509
drive O 0 6.86826606397517e-05
in O 0 1.8413526049698703e-05
DM B-Disease 1 0.9999445676803589
have O 0 6.456935466303548e-07
shown O 0 7.820427185833978e-07
increased O 0 1.451755451853387e-06
transmission O 0 2.0637212401197758e-06
of O 0 1.0317853593733162e-06
the O 0 6.134112027211813e-07
larger O 0 7.635356951141148e-07
allele O 0 2.258944959976361e-06
at O 0 1.6429312381660566e-05
the O 0 8.817557500151452e-06
DM B-Disease 1 0.9835083484649658
locus O 0 4.8176090786000714e-05
in O 0 1.2984794011572376e-05
non O 0 0.0002929655893240124
- O 0 0.0007639334071427584
DM O 1 0.9999998807907104
heterozygotes O 0 0.00045773916644975543
for O 0 1.631911436561495e-05
CTGn O 0 0.0015247762203216553
. O 0 1.1145953976665623e-05

This O 0 4.099086709175026e-06
study O 0 1.3708657888855669e-06
provides O 0 3.814155320469581e-07
further O 0 1.2606417953975324e-07
evidence O 0 1.1934347412534407e-06
that O 0 1.4606517879656167e-06
the O 0 4.680869824369438e-05
DM B-Disease 1 0.9999998807907104
expansion O 0 0.0003521198814269155
tends O 0 5.935724857408786e-06
to O 0 2.5961438154809e-07
be O 0 4.170932470515254e-07
transmitted O 0 2.642938625285751e-06
preferentially O 0 1.8293869743502e-06
. O 0 9.285887472287868e-07

Diagnosis O 1 0.9999945163726807
of O 1 0.9894084930419922
hemochromatosis B-Disease 1 1.0
. O 0 0.00039292368455789983

If O 0 0.0024900613352656364
untreated O 1 0.999997615814209
, O 0 0.00027375819627195597
hemochromatosis B-Disease 1 1.0
can O 0 0.00010912071593338624
cause O 0 0.20350979268550873
serious O 1 0.9845442175865173
illness O 1 0.9999979734420776
and O 0 1.397087089571869e-05
early B-Disease 0 4.3855401600012556e-05
death I-Disease 0 0.00015142539632506669
, O 0 4.1057668909161293e-07
but O 0 9.900742981017174e-08
the O 0 1.2060709195793606e-06
disease O 0 1.61954576469725e-05
is O 0 6.114779580457252e-07
still O 0 3.470699141416844e-07
substantially O 0 5.318453986546956e-06
under O 0 4.060603168909438e-05
- O 0 0.0018967854557558894
diagnosed O 1 0.7737837433815002
. O 0 7.922964869067073e-06

The O 0 0.00018265703693032265
cornerstone O 0 0.00032862593070603907
of O 0 6.311142442427808e-06
screening O 0 2.12813438338344e-06
and O 0 3.9585478361914284e-07
case O 0 4.013576244688011e-07
detection O 0 7.921823907963699e-07
is O 0 9.965233971342968e-08
the O 0 1.8693543779590982e-07
measurement O 0 5.116123702464392e-06
of O 0 9.285832675232086e-06
serum O 0 7.608455780427903e-05
transferrin O 0 0.00013428459351416677
saturation O 0 6.0002545069437474e-05
and O 0 2.272947995152208e-06
the O 0 4.936914137942949e-06
serum O 0 7.441381603712216e-05
ferritin O 0 0.0005691025871783495
level O 0 0.00021858942636754364
. O 0 6.691057023999747e-06

Once O 0 0.0004894155426882207
the O 0 3.452384771662764e-05
diagnosis O 0 0.00102366937790066
is O 0 8.5144565673545e-06
suspected O 0 2.4180772015824914e-05
, O 0 3.9829461684348644e-07
physicians O 0 3.5596653447100834e-07
must O 0 2.279496413848392e-07
use O 0 3.8412883895944105e-07
serum O 0 0.0001147794901044108
ferritin O 0 0.005855603609234095
levels O 0 0.001215741503983736
and O 0 0.00012139930913690478
hepatic O 1 1.0
iron O 1 0.9999990463256836
stores O 0 0.00021873264631722122
on O 0 0.0001976878265850246
liver O 1 0.97254478931427
biopsy O 0 0.0002929228649009019
specimens O 0 1.3666364111486473e-06
to O 0 6.994013546091082e-08
assess O 0 5.552701054511999e-07
patients O 0 6.299059123193729e-07
for O 0 5.309548214427195e-07
the O 0 2.7611752102529863e-06
presence O 0 1.1839548278658185e-05
of O 0 0.00025969944545067847
iron B-Disease 1 0.9998095631599426
overload I-Disease 0 0.017619388177990913
. O 0 9.509882147540338e-06

Liver O 1 0.9999998807907104
biopsy O 1 0.9999774694442749
is O 0 9.50857502175495e-05
also O 0 3.0807441362412646e-06
used O 0 4.137285998240259e-07
to O 0 6.789674245055721e-08
establish O 0 7.137741704354994e-07
the O 0 4.6825916797388345e-06
presence O 0 1.034015258483123e-05
or O 0 1.7518255845061503e-05
absence O 0 0.00010408977686893195
of O 0 0.00016913651779759675
cirrhosis B-Disease 1 1.0
, O 0 8.301509524244466e-07
which O 0 1.1900327478997497e-07
can O 0 1.2481049793677812e-07
affect O 0 1.8746886780718341e-06
prognosis O 0 0.000671155285090208
and O 0 5.7343804655829445e-06
management O 0 2.3285911083803512e-05
. O 0 2.802627705023042e-06

A O 0 0.000315744400722906
DNA O 0 1.3427463272819296e-05
- O 0 9.129786121775396e-06
based O 0 8.957121622188424e-07
test O 0 6.756517336725665e-07
for O 0 1.595347725924512e-06
the O 0 1.0929832569672726e-05
HFE O 0 0.0005926864687353373
gene O 0 6.718949407513719e-06
is O 0 7.238738248815935e-07
commercially O 0 2.7293580728837696e-07
available O 0 8.443426224857831e-08
, O 0 3.381626356713241e-08
but O 0 6.641199590262659e-09
its O 0 2.3172857410713732e-08
place O 0 2.5754346211215307e-07
in O 0 4.352575615484966e-07
the O 0 2.350181148358388e-06
diagnosis O 0 0.0004693539522122592
of O 0 0.0010692455107346177
hemochromatosis B-Disease 1 1.0
is O 0 9.88020037766546e-05
still O 0 1.8893396145358565e-06
being O 0 1.3732798151977477e-06
evaluated O 0 2.6251636882079765e-06
. O 0 8.239027806666854e-07

Currently O 0 0.00029411190189421177
, O 0 4.542646365734981e-06
the O 0 2.2495332814287394e-06
most O 0 1.42054958018889e-07
useful O 0 1.5039579182030138e-07
role O 0 7.935494181765534e-07
for O 0 2.2351404993514734e-07
this O 0 6.83645566823543e-08
test O 0 1.8378436550392507e-07
is O 0 1.2549273264994554e-07
in O 0 2.699299841424363e-07
the O 0 7.500962624362728e-07
detection O 0 6.080242656025803e-06
of O 0 0.0003006303741130978
hemochromatosis B-Disease 1 1.0
in O 0 0.011291277594864368
the O 0 0.00011639739386737347
family O 0 1.4895754247845616e-06
members O 0 1.2214294997647812e-07
of O 0 6.421331590900081e-07
patients O 0 4.788267347066721e-07
with O 0 6.08941803648122e-08
a O 0 2.514340621928568e-06
proven O 0 1.6909461919567548e-05
case O 0 1.4510882238027989e-06
of O 0 6.3544152908434626e-06
the O 0 3.305301652289927e-05
disease O 0 0.03084343858063221
. O 0 9.352024790132418e-06

It O 0 1.3822868822899181e-06
is O 0 6.602149937862123e-07
crucial O 0 2.801340087899007e-06
to O 0 2.7675498586177127e-06
diagnose O 1 0.9990028738975525
hemochromatosis B-Disease 1 1.0
before O 1 0.9999912977218628
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.002309235744178295
because O 0 2.3734351998427883e-05
phlebotomy O 1 0.9999998807907104
therapy O 1 0.9994623064994812
can O 0 3.4854404020734364e-06
avert O 0 0.0005291553097777069
serious O 1 0.9999908208847046
chronic O 1 1.0
disease O 1 1.0
and O 0 2.3248634533956647e-05
can O 0 8.448772632618784e-07
even O 0 3.0427315778069897e-07
lead O 0 4.6622449190181214e-07
to O 0 6.59326673257965e-08
normal O 0 4.8492529458599165e-06
life O 0 2.2784756765759084e-06
expectancy O 0 1.2654936654143967e-05
. O 0 1.5594753222103463e-07
. O 0 3.899351099789783e-07

Prevalence O 0 0.004669941030442715
of O 0 0.0007987363496795297
the O 0 0.0003513220581226051
I1307K O 0 0.0031009716913104057
APC B-Disease 0 0.0002963817969430238
gene O 0 2.832147856679512e-06
variant O 0 1.0201682698607328e-06
in O 0 9.498850062072961e-08
Israeli O 0 2.0776342068984377e-07
Jews O 0 8.778401650033629e-08
of O 0 3.751538812934996e-08
differing O 0 2.8547717079163704e-08
ethnic O 0 3.11571639599606e-08
origin O 0 1.5748572934626281e-07
and O 0 2.107077960999959e-07
risk O 0 5.518384114111541e-06
for O 0 7.428973913192749e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.11773580708541e-05

BACKGROUND O 0 0.0014461101964116096
& O 0 0.00037860777229070663
AIMS O 0 4.025080124847591e-05
Israeli O 0 3.2690822990844026e-05
Jews O 0 1.4162363186187577e-05
of O 0 3.7012712709838524e-05
European O 0 5.470997348311357e-05
birth O 0 0.0003152622375637293
, O 0 6.519269845739473e-06
i O 0 5.894495188840665e-06
. O 0 4.452573989510711e-07
e O 0 3.983355782111175e-06
. O 0 1.0769645086838864e-07
, O 0 2.130525444954401e-07
Ashkenazim O 0 3.857849151245318e-06
, O 0 3.171247087152551e-08
have O 0 2.1383863568757988e-08
the O 0 6.987852998463495e-07
highest O 1 0.9998204112052917
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.999900221824646
of O 0 5.890123065910302e-05
any O 0 8.310428825097915e-07
Israeli O 0 4.67324280180037e-05
ethnic O 0 5.314236204867484e-06
group O 0 8.029885066207498e-06
. O 0 1.7884021872305311e-06

The O 0 0.00038442894583567977
I1307K O 0 0.001497542834840715
APC B-Disease 0 0.0002510735357645899
gene O 0 9.674261491454672e-06
variant O 0 1.8774097043205984e-05
was O 0 4.001004344900139e-05
found O 0 7.196385922725312e-07
in O 0 1.1341610388626577e-06
6 O 0 2.324052002222743e-05
. O 0 1.9695282844622852e-06

1 O 0 0.00016147679707501084
% O 0 3.932137587980833e-06
of O 0 3.7548684304056223e-06
American O 0 2.103344741044566e-06
Jews O 0 7.853176953176444e-07
, O 0 7.932605683436122e-08
28 O 0 1.3737147810388706e-06
% O 0 1.2247841141288518e-07
of O 0 3.8468792240564653e-07
their O 0 8.028943739191163e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 1 0.66355961561203
, O 0 1.7849160940386355e-06
but O 0 1.297863434501778e-07
not O 0 1.0367521241505528e-07
in O 0 8.802786055639444e-07
non O 0 1.1057308256567921e-05
- O 0 4.683690349338576e-06
Jews O 0 3.474491904853494e-06
. O 0 9.0439004907239e-07

We O 0 9.897004201775417e-05
assessed O 0 7.375081622740254e-05
the O 0 1.0965560250042472e-05
I1307K O 0 7.483466470148414e-05
prevalence O 0 1.6918931578402407e-05
in O 0 3.498901151033351e-07
Israeli O 0 5.370439453145082e-07
Jews O 0 2.2285593104243162e-07
of O 0 7.767314968987193e-08
differing O 0 2.982209323931784e-08
ethnic O 0 3.1192126215273674e-08
origin O 0 1.6410287173584948e-07
and O 0 1.2813100624953222e-07
risk O 0 9.409673111804295e-06
for O 0 0.00011389918654458597
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.125955016817898e-05

METHODS O 0 0.00012621904897969216
DNA O 0 5.045416401117109e-06
samples O 0 5.25766154169105e-06
from O 0 4.524107680481393e-06
500 O 0 3.0980506835476262e-06
unrelated O 0 2.1399587240011897e-06
Jews O 0 3.838454176730011e-06
of O 0 2.380702608206775e-05
European O 0 3.60797748726327e-05
or O 0 1.3443864190776367e-05
non O 0 2.9241849915706553e-05
- O 0 5.623651304631494e-06
European O 0 3.792728875851026e-06
origin O 0 5.134224920766428e-07
, O 0 1.6067275510067702e-07
with O 0 6.894268267387815e-08
or O 0 6.217651389306411e-07
without O 0 4.0508803067496046e-07
a O 0 2.352351657464169e-06
personal O 0 1.7102207493735477e-05
and O 0 1.5975576388882473e-05
/ O 0 0.0005107595934532583
or O 0 1.1072683264501393e-05
family O 0 1.9977737792942207e-06
history O 0 2.0711542674689554e-05
of O 0 0.00017130425840150565
neoplasia B-Disease 0 0.01361321285367012
, O 0 2.147326540580252e-06
were O 0 9.572278258929146e-07
examined O 0 1.3221688277553767e-06
for O 0 4.0473858575751365e-07
the O 0 1.9461617739580106e-06
I1307K O 0 2.1499314243556e-05
variant O 0 2.614619916130323e-06
by O 0 6.327260280158953e-07
the O 0 1.4600682334275916e-06
allele O 0 2.1613466287817573e-06
- O 0 3.5568393741414184e-06
specific O 0 5.674240810549236e-07
oligonucleotide O 0 0.00010583772382233292
( O 0 1.2524022167781368e-05
ASO O 0 0.0010485337115824223
) O 0 9.352258416583936e-07
method O 0 5.6242301980091725e-06
. O 0 3.1557453894492937e-06

RESULTS O 0 0.00018120216554962099
In O 0 8.008212716958951e-06
persons O 0 3.689374807436252e-06
at O 0 9.087161743082106e-06
average O 0 8.746812454774044e-06
risk O 0 1.3224766007624567e-05
for O 0 0.00016272382345050573
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.707383024855517e-05
I1307K O 0 0.00011207155330339447
was O 0 2.0783623767783865e-05
found O 0 5.474962563312147e-07
in O 0 6.970773256398388e-07
5 O 0 8.420687663601711e-06
. O 0 2.2143785827211104e-06

0 O 0 0.00013029470574110746
% O 0 3.9854380702308845e-06
of O 0 6.478242084995145e-06
120 O 0 9.859556485025678e-06
European O 0 6.022750767442631e-06
and O 0 3.3802580219344236e-06
1 O 0 4.2455692891962826e-05
. O 0 3.143304411423742e-06

6 O 0 0.00047441787319257855
% O 0 1.9294504454592243e-05
of O 0 3.69738663721364e-05
188 O 0 4.691899084718898e-05
non O 0 7.116461347322911e-05
- O 0 1.3326859516382683e-05
European O 0 6.245015356398653e-06
Jews O 0 4.3977897803415544e-06
( O 0 6.496651963061595e-07
P O 0 4.13624475186225e-05
= O 0 3.4989320738532115e-06
0 O 0 9.058686032403784e-07
. O 0 1.0679537609803447e-07
08 O 0 5.895687081647338e-06
) O 0 2.189163836874286e-07
. O 0 5.009569008507242e-07

It O 0 4.649320544558577e-06
occurred O 0 3.210927752661519e-05
in O 0 3.815792297245935e-06
15 O 0 1.7309279428445734e-05
. O 0 3.519865913403919e-06

4 O 0 7.259704580064863e-05
% O 0 2.4985786239994923e-06
of O 0 2.531749032641528e-06
52 O 0 1.6767458873800933e-05
Ashkenazi O 0 3.58527267962927e-06
Israelis O 0 7.822919201316836e-07
with O 0 2.8357757742014655e-07
familial O 0 0.0036634213756769896
cancer B-Disease 1 0.9999949932098389
( O 0 3.9836097130319104e-05
P O 0 0.46747270226478577
= O 0 7.489248673664406e-05
0 O 0 1.6668262105667964e-05
. O 0 7.054281354612613e-07
02 O 0 4.9029455112759024e-05
) O 0 2.283356224097588e-07
and O 0 5.450850721899769e-07
was O 0 7.545498647232307e-06
not O 0 2.8415988140295667e-07
detected O 0 3.72570116269344e-06
in O 0 3.295555870863609e-06
51 O 0 2.1466987163876183e-05
non O 0 1.2675154721364379e-05
- O 0 2.0617030713765416e-06
European O 0 4.2664845523177064e-07
Jews O 0 2.580730438239698e-07
at O 0 1.5534830026808777e-06
increased O 0 4.848920070799068e-06
cancer B-Disease 0 0.000131406428408809
risk O 0 4.722230187326204e-06
. O 0 1.4079379297982086e-06

Colorectal B-Disease 1 0.9999980926513672
neoplasia I-Disease 1 0.9999904632568359
occurred O 1 0.9887400269508362
personally O 0 0.00016110278374981135
or O 0 9.326374311058316e-06
in O 0 3.536632448231103e-06
the O 0 2.7611727091425564e-06
families O 0 1.70183966474724e-07
of O 0 7.084518074407242e-06
13 O 0 3.679356450447813e-05
of O 0 0.0001224526495207101
20 O 0 0.0002575753314886242
Ashkenazi O 0 0.0001758354192133993
I1307K O 0 0.00026521566906012595
carriers O 0 9.528138434689026e-06
, O 0 3.0432588573603425e-06
8 O 0 1.5440888091688976e-05
of O 0 1.2038728527841158e-05
whom O 0 5.135329956829082e-06
also O 0 2.620368604766554e-06
had O 0 2.9476368581526913e-06
a O 0 1.752216348904767e-06
personal O 0 3.8013254197721835e-06
or O 0 1.6579389239268494e-06
family O 0 6.960450491533265e-07
history O 0 4.494469521887368e-06
of O 0 5.754778248956427e-05
noncolonic O 1 0.849947452545166
neoplasia B-Disease 1 0.9999469518661499
. O 0 7.79224355937913e-05

CONCLUSIONS O 0 0.0012785070575773716
The O 0 0.00031959882471710443
I1307K O 0 0.002312559401616454
APC O 0 0.00028114597080275416
variant O 0 2.023117122007534e-05
may O 0 2.6673890261008637e-06
represent O 0 4.322098448028555e-07
a O 0 9.87476028058154e-07
susceptibility O 0 3.009196007042192e-05
gene O 0 1.5925803381833248e-05
for O 0 4.1902385419234633e-05
colorectal B-Disease 1 1.0
, I-Disease 0 0.0013488715048879385
or I-Disease 0 6.951177056180313e-05
other I-Disease 0 2.6390853236080147e-06
, I-Disease 0 5.677088665834162e-06
cancers I-Disease 0 0.03051791340112686
in O 0 1.6238760508713312e-05
Ashkenazi O 0 2.9571243430837058e-05
Jews O 0 3.667939608931192e-06
, O 0 1.5464070202142466e-07
and O 0 5.8101868205540086e-08
partially O 0 1.8942541828437243e-06
explains O 0 1.5540786080237012e-07
the O 0 1.2475148025714589e-07
higher O 0 6.680186288576806e-06
incidence O 0 0.11298266053199768
of O 1 0.9984681010246277
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 0.00031164722167886794
European O 0 2.5402683604625054e-05
Israelis O 0 6.3042730289453175e-06
. O 0 1.7674385617283406e-06

Systematic O 0 2.2301495846477337e-05
analysis O 0 2.707229441512027e-06
of O 0 3.507964720483869e-05
coproporphyrinogen O 1 0.8793630003929138
oxidase O 1 0.997129499912262
gene O 1 0.9800312519073486
defects O 1 0.9999724626541138
in O 0 0.00016174616757780313
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.999811589717865
and O 0 7.428460776282009e-06
mutation O 0 1.728446841298137e-05
update O 0 2.2360442017088644e-05
. O 0 2.103731958413846e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999949932098389
( O 0 0.0004116673080716282
HC B-Disease 1 1.0
) O 0 1.2028675882902462e-05
is O 0 9.220155448019796e-07
an O 0 4.6132713578117546e-06
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9999954700469971
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 1 0.9999669790267944
caused O 1 0.9994103908538818
by O 0 2.175161398554337e-06
deficient B-Disease 0 0.00023342965869233012
activity I-Disease 0 3.140987973893061e-05
of I-Disease 0 0.00012182163482066244
coproporphyrinogen I-Disease 0 0.13507533073425293
III I-Disease 1 0.9999910593032837
oxidase I-Disease 0 0.0004729180072899908
( O 0 9.39733308769064e-06
CPO O 0 0.0005351389991119504
) O 0 1.1605928875724203e-06
. O 0 7.018388146207144e-07

Clinical O 0 0.012954956851899624
manifestations O 0 0.19212906062602997
of O 0 0.00011880994134116918
the O 0 3.67385582649149e-05
disease O 0 0.08124816417694092
are O 0 3.432737827324672e-08
characterized O 0 1.4497753397790802e-07
by O 0 1.9111784155256828e-08
acute O 1 0.9819561839103699
attacks O 0 9.026781481225044e-05
of O 1 0.9999978542327881
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 0.0009224191890098155
precipitated O 0 0.00040757915121503174
by O 0 2.7511137545843667e-07
drugs O 0 8.672396347719769e-07
, O 0 1.0886954271427385e-07
fasting O 0 7.289563200174598e-06
, O 0 7.732236895208189e-07
cyclical O 0 0.00047350797103717923
hormonal O 0 0.0007748407078906894
changes O 0 3.6067647215531906e-06
, O 0 3.236249085603049e-06
or O 0 1.8453341908752918e-05
infectious B-Disease 1 0.9909620881080627
diseases I-Disease 1 0.999518632888794
. O 0 7.6008345786249265e-06

Skin O 1 1.0
photosensitivity O 1 0.9999997615814209
may O 0 0.4777412414550781
also O 0 2.4040009520831518e-05
be O 0 1.0221627917417209e-06
present O 0 1.9223127765144454e-06
. O 0 1.6690263464624877e-06

The O 0 0.00022973440354689956
seven O 0 5.8017190895043314e-05
exons O 0 0.00010740648576756939
, O 0 6.179008323670132e-06
the O 0 1.817597330955323e-05
exon O 0 4.969988367520273e-05
/ O 0 5.4555446695303544e-05
intron O 0 5.6542026868555695e-05
boundaries O 0 7.465041107934667e-06
and O 0 1.6803610378701705e-06
part O 0 1.6423076658611535e-06
of O 0 2.0942472474416718e-05
3 O 0 1.3897676581109408e-05
noncoding O 0 1.2270900697330944e-05
sequence O 0 5.166522896615788e-06
of O 0 5.038069502916187e-05
the O 0 6.369458424160257e-05
CPO O 0 0.0005956686800345778
gene O 0 2.5652200292825e-06
were O 0 1.7569954025020706e-06
systematically O 0 9.829707323660841e-07
analyzed O 0 6.621514785365434e-07
by O 0 2.5191380359501636e-07
an O 0 5.903463033973821e-07
exon O 0 1.550954607409949e-06
- O 0 4.054666987940436e-06
by O 0 2.2215599528863095e-06
- O 0 2.175906229240354e-05
exon O 0 5.845525811309926e-05
denaturing O 0 0.0011747085954993963
gradient O 0 0.0017613103846088052
gel O 0 0.0005702118505723774
electrophoresis O 0 0.0002885387802962214
( O 0 9.93074536381755e-06
DGGE O 0 0.00016617086657788604
) O 0 2.810540422615304e-07
strategy O 0 1.1878511685381454e-07
followed O 0 9.010516777152588e-08
by O 0 6.633844140679912e-09
direct O 0 1.0555701379644233e-07
sequencing O 0 9.763124353412422e-07
in O 0 1.0202529665548354e-06
seven O 0 3.990343884652248e-06
unrelated O 0 1.6312174921040423e-05
heterozygous O 0 9.93718822428491e-06
HC B-Disease 0 0.04234195128083229
patients O 0 2.71673416136764e-05
from O 0 1.5542475011898205e-05
France O 0 2.773810047074221e-05
, O 0 2.3006050469120964e-06
Holland O 0 3.5658531487570144e-06
, O 0 2.5267246428484214e-07
and O 0 2.3042272800921637e-07
Czech O 0 1.2525455531431362e-05
Republic O 0 3.2172352803172544e-05
. O 0 9.45282863540342e-06

Seven O 0 0.0003195738245267421
novel O 0 2.102973303408362e-05
mutations O 0 4.212741259834729e-06
and O 0 6.021092531227623e-07
two O 0 2.420384248580376e-07
new O 0 3.3680160527183034e-07
polymorphisms O 0 4.950330549036153e-06
were O 0 5.1456786422932055e-06
detected O 0 3.252154783695005e-05
. O 0 2.137772071364452e-06

Among O 0 1.6690848497091793e-05
these O 0 7.718077199569962e-07
mutations O 0 2.311526486664661e-06
two O 0 1.8602646605359041e-06
are O 0 7.67208575780387e-07
missense O 0 2.001904067583382e-05
( O 0 2.3906952719698893e-06
G197W O 0 7.744647155050188e-05
, O 0 7.040925993351266e-06
W427R O 0 4.9647023843135685e-05
) O 0 1.3114968169247732e-06
, O 0 5.6719522945059e-07
two O 0 6.905493137310259e-07
are O 0 1.1725190915967687e-06
nonsense O 0 6.0212332755327225e-05
( O 0 4.7416979214176536e-06
Q306X O 0 0.00011354684829711914
, O 0 7.546765118604526e-06
Q385X O 0 6.958862650208175e-05
) O 0 1.6868556258486933e-06
, O 0 5.123386017658049e-07
two O 0 3.6462216712607187e-07
are O 0 1.9775430359914026e-07
small O 0 3.8547972280866816e-07
deletions O 0 3.933360403607367e-06
( O 0 3.5302905416756403e-06
662de14bp O 0 8.098640682874247e-05
; O 0 4.02809610022814e-06
1168del3bp O 0 0.0001250651985174045
removing O 0 3.267595820943825e-05
a O 0 3.8684076571371406e-05
glycine O 0 3.31780465785414e-05
at O 0 0.00022902361524756998
position O 0 2.556197978265118e-05
390 O 0 7.737113264738582e-06
) O 0 1.6481037334870052e-07
, O 0 1.0382778015127769e-07
and O 0 9.584019977637581e-08
one O 0 1.8248496758133115e-07
is O 0 3.1701711122877896e-07
a O 0 1.369841129417182e-06
splicing O 0 3.8305042835418135e-06
mutation O 0 2.781942384899594e-06
( O 0 1.8625652273840387e-06
IVS1 O 0 0.00012543688353616744
- O 0 2.098143522744067e-05
15c O 0 8.569995407015085e-05
- O 0 1.661696660448797e-05
- O 0 2.441205651848577e-05
> O 0 1.7862928871181794e-05
g O 0 1.3825433597958181e-05
) O 0 9.660053734705798e-08
which O 0 7.899750897877311e-08
creates O 0 2.5512989054732316e-07
a O 0 4.6624495553260203e-07
new O 0 4.877759351984423e-07
acceptor O 0 1.948683802766027e-06
splice O 0 1.4735019249201287e-05
site O 0 5.822361799801001e-06
. O 0 1.3607294704343076e-06

The O 0 6.338766979752108e-05
pathological O 0 0.0004624605062417686
significance O 0 3.0243601941037923e-05
of O 0 8.49689677124843e-05
the O 0 4.567526775645092e-05
point O 0 6.41496226307936e-05
mutations O 0 3.942730472772382e-06
G197W O 0 6.637568003498018e-05
, O 0 3.192959411535412e-06
W427R O 0 3.707240830408409e-05
, O 0 2.6417644676257623e-06
and O 0 1.598611447661824e-06
the O 0 5.890128704777453e-06
in O 0 1.7698655938147567e-05
- O 0 5.9951293224003166e-05
frame O 0 0.00020880202646367252
deletion O 0 5.111652717459947e-05
390delGly O 0 4.2826748540392146e-05
were O 0 3.0349756343639456e-06
assessed O 0 1.3590021126219654e-06
by O 0 4.666577524403692e-08
their O 0 7.83249092251026e-08
respective O 0 1.4585915550924256e-06
expression O 0 8.60158797877375e-06
in O 0 1.5638286186003825e-06
a O 0 1.0732073860708624e-06
prokaryotic O 0 1.1455509820734733e-06
system O 0 1.1937557928831666e-06
using O 0 1.4542092685587704e-07
site O 0 6.820370117566199e-07
- O 0 5.656783628182893e-07
directed O 0 3.771326362311811e-07
mutagenesis O 0 2.183222932217177e-05
. O 0 1.7710103747958783e-06

These O 0 3.0263654480222613e-06
mutations O 0 5.037728897150373e-06
resulted O 0 1.2476064512156881e-05
in O 0 3.0768683245696593e-06
the O 0 2.0634261090890504e-06
absence O 0 7.327354069275316e-06
or O 0 4.782279461323924e-07
a O 0 3.8172592553564755e-07
dramatic O 0 6.584226866834797e-06
decrease O 0 7.302126323338598e-05
of O 0 0.0003517117875162512
CPO O 0 0.03173725679516792
activity O 0 0.00014226746861822903
. O 0 6.760199084965279e-06

The O 0 0.00018902042938861996
two O 0 6.919917723280378e-06
polymorphisms O 0 1.1010997695848346e-05
were O 0 3.874890808219789e-06
localized O 0 5.022162895329529e-06
in O 0 2.551245643189759e-06
noncoding O 0 4.5433830564434174e-06
part O 0 9.645910949984682e-07
of O 0 4.791012543137185e-06
the O 0 2.441551487208926e-06
gene O 0 4.606162065101671e-07
1 O 0 2.146040969819296e-06
) O 0 8.677784535393585e-08
a O 0 1.2448067536752205e-06
C O 0 5.091036291560158e-05
/ O 0 2.318840597581584e-05
G O 0 5.909983883611858e-05
polymorphism O 0 2.9193008685979294e-06
in O 0 5.566328582062852e-06
the O 0 1.0568877769401297e-05
promotor O 0 0.00018423232540953904
region O 0 8.202217941288836e-06
, O 0 2.464472345309332e-06
142 O 0 6.9782358878001105e-06
bp O 0 8.601112313044723e-06
upstream O 0 6.6421534938854165e-06
from O 0 1.8122532310371753e-06
the O 0 1.765122419783438e-06
transcriptional O 0 1.541351230116561e-05
initiation O 0 1.2481074918468948e-05
site O 0 1.223645085701719e-05
( O 0 7.846768994568265e-07
- O 0 8.69066298037069e-06
142C O 0 8.556537795811892e-05
/ O 0 5.7467881561024114e-05
G O 0 0.00012984870409127325
) O 0 6.420387990146992e-07
, O 0 3.126610863546375e-07
and O 0 4.193858273993101e-07
2 O 0 3.695812210935401e-06
) O 0 1.8825971892511006e-07
a O 0 1.834093154684524e-06
6 O 0 1.651613820286002e-05
bp O 0 5.9775234149128664e-06
deletion O 0 1.8535988601797726e-06
polymorphism O 0 1.4500728866551071e-06
in O 0 1.8761212459139642e-06
the O 0 2.0412289813975804e-06
3 O 0 2.9464592898875708e-06
noncoding O 0 3.6906067180098034e-06
part O 0 2.9916152470832458e-06
of O 0 2.7579737434280105e-05
the O 0 4.7465153329540044e-05
CPO O 0 0.0005479357787407935
gene O 0 8.566713404434267e-06
, O 0 3.5446553283691173e-06
574 O 0 4.281829751562327e-05
bp O 0 2.1478022972587496e-05
downstream O 0 1.415119731973391e-05
of O 0 1.0467347237863578e-05
the O 0 4.686532520281617e-06
last O 0 5.576875992119312e-06
base O 0 3.282000079707359e-06
of O 0 2.525621312088333e-06
the O 0 3.5662067148223286e-06
normal O 0 2.6171514036832377e-05
termination O 0 5.13612394570373e-05
codon O 0 5.15053397975862e-05
( O 0 1.6022271438487223e-06
+ O 0 1.560958662594203e-05
574 O 0 4.1088660509558395e-05
delATTCTT O 0 4.749844083562493e-05
) O 0 2.5483789158897707e-06
. O 0 2.066640263365116e-06

Five O 0 0.003328955266624689
intragenic O 0 0.042835500091314316
dimorphisms O 0 0.017622286453843117
are O 0 1.3040589692536741e-05
now O 0 1.0509540970815578e-06
well O 0 3.37990542220723e-07
characterized O 0 8.608625421402394e-07
and O 0 1.8388149669590348e-07
the O 0 6.780691705898789e-07
high O 0 1.2488562788348645e-05
degree O 0 4.79137925140094e-05
of O 0 1.6883113858057186e-05
allelic O 0 0.00014241065946407616
heterogeneity O 0 0.00023123578284867108
in O 0 5.440296808956191e-05
HC B-Disease 1 0.9951637983322144
is O 0 1.0095118341268972e-05
demonstrated O 0 8.239268936449662e-06
with O 0 1.1652704756670573e-07
seven O 0 2.597463719666848e-07
new O 0 3.6249396373477794e-08
different O 0 9.490968011505174e-09
mutations O 0 3.342764998137682e-08
making O 0 6.245785044711738e-08
a O 0 2.0983229376270174e-07
total O 0 1.1647155133687193e-06
of O 0 2.2644542696070857e-05
nineteen O 0 0.0018259063363075256
CPO O 1 0.9997022747993469
gene B-Disease 0 0.0302762221544981
defects I-Disease 1 0.978959858417511
reported O 0 1.9887553207809106e-05
so O 0 3.8803909774287604e-07
far O 0 5.32387218754593e-07
. O 0 1.3819348509969132e-07
. O 0 4.111652174287883e-07

Coincidence O 0 0.0001563725236337632
of O 0 1.879184492281638e-05
two O 0 2.886060428863857e-06
novel O 0 1.14416297947173e-05
arylsulfatase O 0 0.00014134153025224805
A O 0 1.3214794307714328e-05
alleles O 0 1.6909241367102368e-06
and O 0 8.601887202530634e-07
mutation O 0 3.811242777373991e-06
459 O 0 9.804758883547038e-05
+ O 0 0.00015208333206828684
1G O 0 0.002130973618477583
> O 0 3.9157530409283936e-05
A O 0 5.554117251449497e-06
within O 0 6.684123263767106e-07
a O 0 1.2538043847598601e-06
family O 0 8.776356139605923e-07
with O 0 1.6001108633645345e-06
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
: O 0 1.7436370569612336e-07
molecular O 0 4.478885102798813e-07
basis O 0 1.4814970938914485e-07
of O 0 1.3615161833513412e-06
phenotypic O 0 0.0001976002095034346
heterogeneity O 0 0.0007332596578635275
. O 0 3.0281436920631677e-05

In O 0 0.00040972212445922196
a O 0 6.715895142406225e-05
family O 0 5.527416760742199e-06
with O 0 5.698491918337822e-07
three O 0 2.7649564344756072e-06
siblings O 0 5.368071924749529e-06
, O 0 9.960007929521453e-08
one O 0 7.258308443169881e-08
developed O 0 1.2695301165877027e-06
classical O 0 0.0007706808391958475
late O 1 0.9907859563827515
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00016711950593162328
MLD B-Disease 1 1.0
) O 0 5.188648174225818e-06
, O 0 1.1184478125869646e-06
fatal O 0 0.00011302520579192787
at O 0 5.954198059043847e-05
age O 0 9.366125595988706e-06
5 O 0 4.829813406104222e-06
years O 0 2.3034722289594356e-06
, O 0 2.903702522871754e-07
with O 0 5.511381573342078e-07
deficient O 0 0.0012884314637631178
arylsulfatase O 0 0.00358322961255908
A O 0 0.0013685600133612752
( O 0 1.0281254617439117e-05
ARSA O 0 0.0001671994978096336
) O 0 2.5672585479696863e-07
activity O 0 1.5922286138447816e-06
and O 0 2.6869767566495284e-07
increased O 0 2.7910524295293726e-05
galactosylsulfatide O 0 0.0006754841888323426
( O 0 2.1446072423714213e-05
GS O 1 0.9999923706054688
) O 0 2.419637439743383e-06
excretion O 0 1.6891748600755818e-05
. O 0 9.206721074406232e-07

The O 0 0.0004229696642141789
two O 0 2.4414244762738235e-05
other O 0 4.314777925173985e-06
siblings O 0 2.3611517462995835e-05
, O 0 5.014395355829038e-06
apparently O 0 2.071824019367341e-05
healthy O 0 1.324446657235967e-05
at O 0 3.309341991553083e-05
12 O 0 4.58940485259518e-06
( O 0 3.037741862499388e-07
1 O 0 5.715621227864176e-06
/ O 0 6.115279575169552e-06
2 O 0 8.778500159678515e-06
) O 0 2.574113295850111e-07
and O 0 1.1178527756783296e-06
15 O 0 1.2936959137732629e-05
years O 0 9.978059097193182e-06
, O 0 1.1297738637949806e-06
respectively O 0 4.609111329045845e-06
, O 0 2.970776336042036e-07
and O 0 4.186856870092015e-07
their O 0 9.316819387095165e-07
father O 0 5.5378175602527335e-05
, O 0 2.8378933620842872e-06
apparently O 0 5.705953753931681e-06
healthy O 0 2.156853724954999e-06
as O 0 4.23551966832747e-07
well O 0 1.931116457853932e-07
, O 0 9.66643156630198e-08
presented O 0 4.283083399059251e-06
ARSA O 0 0.0005117686232551932
and O 0 1.9035323930438608e-05
GS O 1 0.9999992847442627
values O 0 2.7273076739220414e-06
within O 0 2.455205674323224e-07
the O 0 3.9479726865465636e-07
range O 0 2.7043704449170036e-06
of O 0 2.2266833184403367e-05
MLD B-Disease 1 1.0
patients O 0 6.988330278545618e-05
. O 0 8.900513421394862e-06

Mutation O 0 1.0152873983315658e-05
screening O 0 2.6633754259819398e-06
and O 0 4.715960812973208e-07
sequence O 0 1.151789547293447e-06
analysis O 0 1.0097131735165021e-06
disclosed O 0 3.47530044564337e-06
the O 0 2.3351324216491776e-06
involvement O 0 1.2790828805009369e-05
of O 0 1.740843799780123e-05
three O 0 4.408825589052867e-06
different O 0 8.581199040236243e-07
ARSA O 0 0.0003439510765019804
mutations O 0 1.0308185665053315e-06
being O 0 3.788340734445228e-07
the O 0 5.565393479400882e-08
molecular O 0 3.177680980570585e-07
basis O 0 2.86753163436515e-07
of O 0 1.655692130952957e-06
intrafamilial O 0 0.00011050849570892751
phenotypic O 0 0.000271466065896675
heterogeneity O 0 0.0009049035725183785
. O 0 1.8427859686198644e-05

The O 0 0.00023532893101219088
late O 0 0.0034812449011951685
infantile O 1 0.9999270439147949
patient O 0 0.0011123991571366787
inherited O 0 0.10054446756839752
from O 0 7.289047789527103e-05
his O 0 4.5315515308175236e-05
mother O 0 4.74788284918759e-05
the O 0 7.704524250584655e-06
frequent O 0 3.2260124953609193e-06
0 O 0 1.7687907529762015e-05
- O 0 3.616056801547529e-06
type O 0 8.414842341153417e-06
mutation O 0 9.288755791203585e-06
459 O 0 0.0001231235364684835
+ O 0 7.201935659395531e-05
1G O 0 0.0012208567932248116
> O 0 4.47551065008156e-05
A O 0 2.5429273591726087e-05
, O 0 1.101393650060345e-06
and O 0 1.1145996268169256e-06
from O 0 1.7329326738035888e-06
his O 0 7.116872438928112e-06
father O 0 1.6152729585883208e-05
a O 0 1.411487005498202e-06
novel O 0 7.154622494454088e-07
, O 0 1.7091963400162058e-07
single O 0 5.356762926567171e-07
basepair O 0 3.0035591407795437e-05
microdeletion O 0 4.190965773887001e-05
of O 0 4.084507963852957e-05
guanine O 0 2.4908655177569017e-05
at O 0 4.650916162063368e-05
nucleotide O 0 3.706132702063769e-06
7 O 0 8.777328730502632e-06
in O 0 2.166010062865098e-06
exon O 0 4.729887677967781e-06
1 O 0 1.1566413377295248e-05
( O 0 1.3822711935063126e-06
7delG O 0 2.1364114218158647e-05
) O 0 1.8182951180278906e-06
. O 0 1.4108061350270873e-06

The O 0 0.00019000635074917227
two O 0 3.29142676491756e-05
clinically O 0 0.007611482869833708
unaffected O 0 9.820338163990527e-05
siblings O 0 1.5620727253917721e-06
carried O 0 4.0515411114938615e-07
the O 0 3.582052556794224e-07
maternal O 0 2.786424920486752e-05
mutation O 0 5.410772246250417e-06
459 O 0 7.453731814166531e-05
+ O 0 7.703348819632083e-05
1G O 0 0.0013987320708110929
> O 0 8.083455759333447e-05
A O 0 4.261786671122536e-05
and O 0 3.22807773045497e-06
, O 0 8.445855996797036e-07
on O 0 2.5538529371260665e-06
their O 0 4.2413364553794963e-07
paternal O 0 5.1690643886104226e-05
allele O 0 2.94601522909943e-06
, O 0 1.4001807357999496e-07
a O 0 1.3122858888436895e-07
novel O 0 2.4658729103066435e-07
cytosine O 0 6.019961347192293e-07
to O 0 1.6315908624164877e-07
thymidine O 0 1.5818408428458497e-05
transition O 0 5.546533066080883e-05
at O 0 7.284892490133643e-05
nucleotide O 0 2.1518000721698627e-05
2435 O 0 0.00013788505748379976
in O 0 4.328700470068725e-06
exon O 0 4.65459561382886e-06
8 O 0 6.577943622687599e-06
, O 0 1.0296302122014822e-07
resulting O 0 2.2250935671763727e-07
in O 0 2.2676296396184625e-07
substitution O 0 1.743289203659515e-06
of O 0 8.692826668266207e-06
alanine O 0 2.0647687051678076e-05
464 O 0 4.767055361298844e-05
by O 0 3.871822173096007e-06
valine O 0 0.0002718753239605576
( O 0 3.7470736060640775e-06
A464V O 0 0.00010282680159434676
) O 0 2.1352616386138834e-06
. O 0 2.0707022940769093e-06

The O 0 9.030983346747234e-05
fathers O 0 6.599762127734721e-05
genotype O 0 1.3123602911946364e-05
thus O 0 5.050509571447037e-06
was O 0 3.7105302908457816e-05
7delG O 0 0.0001277102273888886
/ O 0 0.00014526337326969951
A464V O 0 0.00020170473726466298
. O 0 5.806502940686187e-06

Mutation O 0 0.000359773519448936
A464V O 0 0.0015168794197961688
was O 0 9.959316230379045e-05
not O 0 4.7553604076711053e-07
found O 0 3.073716641210922e-07
in O 0 7.384100513263547e-07
18 O 0 2.1083487808937207e-05
unrelated O 0 4.5929256884846836e-05
MLD B-Disease 1 1.0
patients O 0 1.1992937288596295e-05
and O 0 4.360409093351336e-06
50 O 0 3.614186425693333e-05
controls O 0 6.496532296296209e-05
. O 0 9.547521585773211e-06

A464V O 0 0.005704887211322784
, O 0 2.230400605185423e-05
although O 0 5.19286049893708e-06
clearly O 0 1.6665066141285934e-05
modifying O 0 4.7380002797581255e-05
ARSA O 0 0.0059088896960020065
and O 0 0.0003296884533483535
GS O 1 1.0
levels O 0 0.0008569950005039573
, O 0 2.0292322915338445e-06
apparently O 0 1.1036502201022813e-06
bears O 0 3.850839789265592e-07
little O 0 1.59950133138409e-08
significance O 0 5.8313254669428716e-08
for O 0 8.632913761630334e-08
clinical O 0 1.4195668882166501e-05
manifestation O 0 0.0006248524878174067
of O 0 0.005429219454526901
MLD B-Disease 1 1.0
, O 0 2.0775856683030725e-05
mimicking O 0 4.438215182744898e-05
the O 0 5.9973253883072175e-06
frequent O 0 3.681915404740721e-05
ARSA O 0 0.07275298982858658
pseudodeficiency O 0 0.0035409738775342703
allele O 0 0.0001460234634578228
. O 0 1.2312608305364847e-05

Our O 0 5.733404395869002e-05
results O 0 9.648519153415691e-06
demonstrate O 0 1.0092924185300944e-06
that O 0 3.675667059610532e-08
in O 0 1.7145578112831572e-07
certain O 0 3.6470598274718213e-07
genetic O 0 1.985274320759345e-05
conditions O 0 0.002552210818976164
MLD B-Disease 1 1.0
- O 1 0.8646949529647827
like O 0 0.00010239628318231553
ARSA O 0 0.014338376931846142
and O 0 0.00010431414557388052
GS O 1 0.9999998807907104
values O 0 5.9593148762360215e-06
need O 0 2.0546788448427833e-07
not O 0 4.062048475361735e-08
be O 0 4.867536063102307e-08
paralleled O 0 4.352284861397493e-07
by O 0 6.91233310590178e-08
clinical O 0 3.661086520878598e-05
disease O 0 4.0010694647207856e-05
, O 0 1.05972780772845e-07
a O 0 1.8245262367599935e-07
finding O 0 1.3978565505112783e-07
with O 0 9.501422937319148e-08
serious O 0 1.5673427697038278e-05
diagnostic O 0 0.00022594181064050645
and O 0 1.0702294275688473e-05
prognostic O 1 0.9962300658226013
implications O 0 0.00027978623984381557
. O 0 8.51642107591033e-06

Moreover O 0 0.0006927766953594983
, O 0 2.274299185955897e-05
further O 0 1.5956025890773162e-05
ARSA O 0 0.0047401851043105125
alleles O 0 7.661509880563244e-05
functionally O 0 7.686486060265452e-05
similar O 0 1.528132997918874e-06
to O 0 1.4268293853092473e-06
A464V O 0 3.1282623240258545e-05
might O 0 9.870834674075013e-07
exist O 0 3.8952029512984154e-07
which O 0 2.0305162706790725e-07
, O 0 5.975762462639977e-08
together O 0 1.8020829273268646e-08
with O 0 1.1772659291864329e-07
0 O 0 1.588336454005912e-05
- O 0 7.864157851145137e-06
type O 0 6.582989499293035e-06
mutations O 0 4.0373070078203455e-06
, O 0 8.7103671830846e-07
may O 0 7.66711491451133e-06
cause O 0 6.270553421927616e-05
pathological O 1 0.999618649482727
ARSA O 1 0.7491974234580994
and O 0 0.00032876539626158774
GS O 1 1.0
levels O 0 7.02162942616269e-05
, O 0 9.181891869047831e-08
but O 0 4.0532466272225065e-09
not O 0 5.8025424465313336e-09
clinical O 0 6.665929390692327e-07
outbreak O 0 1.2680466170422733e-06
of O 0 2.3672680526942713e-06
the O 0 7.121340331650572e-06
disease O 0 0.000173918015207164
. O 0 7.197051559160172e-07
. O 0 1.5400858046632493e-06

Human O 1 0.9997922778129578
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.020642543211579323
to O 0 3.4339085686951876e-05
hematological B-Disease 1 0.999998927116394
malignancy I-Disease 1 0.9999927282333374
and O 0 5.042058546678163e-05
neurofibromatosis B-Disease 1 0.9999998807907104
type I-Disease 1 0.8993017077445984
1 I-Disease 1 0.8219656944274902
. O 0 1.8752320102066733e-05

Heterozygous O 0 0.0014902252005413175
germ O 0 0.0039565302431583405
- O 0 9.564201172906905e-05
line O 0 4.772361535287928e-06
mutations O 0 7.995737405508407e-08
in O 0 5.0911612703430364e-08
the O 0 1.4241224732813862e-07
DNA O 0 1.1661493317660643e-06
mismatch O 0 0.00010554304026300088
repair O 0 5.733715806854889e-05
genes O 0 3.5269054023956414e-06
lead O 0 8.727930435270537e-06
to O 0 4.763012839248404e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00015047812485136092

The O 0 0.00028154271421954036
disease O 0 0.2295648604631424
susceptibility O 0 0.0005799884092994034
of O 0 0.00020788269466720521
individuals O 0 2.649517682584701e-06
who O 0 1.6027153833420016e-05
constitutionally O 0 0.00016552156012039632
lack O 0 2.537435466365423e-05
both O 0 3.646232244136627e-06
wild O 0 8.033669473661575e-06
- O 0 8.214907211367972e-06
type O 0 3.7546105886576697e-06
alleles O 0 2.311272965016542e-06
is O 0 6.150067974886042e-07
unknown O 0 4.3468739931995515e-06
. O 0 6.99243287272111e-07

We O 0 1.8767956134979613e-05
have O 0 5.957724624749972e-07
identified O 0 3.4757007938424067e-07
three O 0 1.2525933357210306e-07
offspring O 0 2.3652408742691478e-07
in O 0 2.718084886055294e-07
a O 0 2.065897388092708e-05
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.9998480081558228
who O 0 0.00010560152441030368
developed O 0 0.0006226825062185526
hematological B-Disease 1 0.9999984502792358
malignancy I-Disease 1 0.9999997615814209
at O 1 0.6515113711357117
a O 0 1.509306275693234e-05
very O 0 9.83634777185216e-07
early O 0 5.172616511117667e-06
age O 0 8.568494195060339e-06
, O 0 4.1790300997490704e-07
and O 0 2.622045940370299e-07
at O 0 5.206179594097193e-06
least O 0 8.710917143162078e-08
two O 0 6.32185646054495e-08
of O 0 3.020884662419121e-07
them O 0 3.1234275610358964e-08
displayed O 0 1.0611882316879928e-05
signs O 0 2.5699393518152647e-05
of O 0 1.470169718231773e-05
neurofibromatosis B-Disease 1 0.9858300089836121
type I-Disease 0 0.0007301417645066977
1 I-Disease 0 0.0007790698437020183
( O 0 1.1189236829522997e-05
NF1 B-Disease 0 0.0007489381241612136
) O 0 4.187027116131503e-06
. O 0 1.9162614535161993e-06

DNA O 0 2.153894274670165e-05
sequence O 0 9.976555702451151e-06
analysis O 0 3.341871206430369e-06
and O 0 1.6492984968863311e-06
allele O 0 2.921289024016005e-06
- O 0 2.556314029789064e-06
specific O 0 9.790118582486684e-08
amplification O 0 4.174754394625779e-06
in O 0 9.310237487625272e-07
two O 0 8.170110277205822e-07
siblings O 0 8.409371730522253e-06
revealed O 0 1.28513265735819e-05
a O 0 1.7896043573273346e-05
homozygous O 0 6.624643719987944e-05
MLH1 O 0 0.0013947456609457731
mutation O 0 6.954864147701301e-06
( O 0 1.1454319519543787e-06
C676T O 0 1.9979845092166215e-05
- O 0 2.7445688829175197e-05
- O 0 6.606140959775075e-05
> O 0 7.165668648667634e-05
Arg226Stop O 0 0.00013177708024159074
) O 0 1.9543767848517746e-06
. O 0 1.46427521485748e-06

Thus O 0 7.76728629716672e-05
, O 0 3.890283096552594e-06
a O 0 2.960243364213966e-06
homozygous O 0 1.9706632883753628e-05
germ O 0 0.001266869017854333
- O 0 0.0001507697015767917
line O 0 3.423530506552197e-05
MLH1 O 0 0.0005548849585466087
mutation O 0 1.2542349168143119e-06
and O 0 6.10567781222926e-07
consequent O 1 0.8515149354934692
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 0.01966637186706066
in O 0 1.1767718206101563e-05
a O 0 1.7725393263390288e-05
mutator O 1 0.7640076279640198
phenotype O 0 3.815081072389148e-05
characterized O 0 2.6655554847820895e-06
by O 0 3.7068039659970964e-07
leukemia B-Disease 1 0.9999977350234985
and O 0 0.00030729564605280757
/ O 1 1.0
or O 1 0.9999995231628418
lymphoma B-Disease 1 1.0
associated O 1 0.9999946355819702
with O 0 8.210036321543157e-05
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.9997478127479553
1 I-Disease 1 0.6464466452598572
. O 0 2.0140973902016412e-06
. O 0 2.8479573757067556e-06

Missense O 0 0.0016466813394799829
mutations O 0 6.17982295807451e-05
in O 0 1.1014590199920349e-05
the O 0 3.68439259545994e-06
most O 0 3.462193092218513e-07
ancient O 0 1.8008361166721443e-06
residues O 0 1.2106493159080856e-06
of O 0 2.598903392936336e-06
the O 0 6.9510638240899425e-06
PAX6 O 0 0.0014270948013290763
paired O 0 1.368802350043552e-05
domain O 0 1.0007048331317492e-05
underlie O 0 1.430252905265661e-05
a O 0 1.0913853429883602e-06
spectrum O 0 1.8479317077435553e-05
of O 0 0.00013212260091677308
human O 1 1.0
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.0004812719998881221

Mutations O 0 6.925107300048694e-06
of O 0 3.2330872272723354e-06
the O 0 3.3021244689734885e-06
human O 0 4.228768011671491e-05
PAX6 O 1 0.9751604199409485
gene O 0 0.0029839351773262024
underlie O 1 0.9997153878211975
aniridia B-Disease 1 1.0
( O 1 0.9982700347900391
congenital B-Disease 1 1.0
absence I-Disease 1 0.9999958276748657
of I-Disease 1 0.999908447265625
the I-Disease 0 0.0077121565118432045
iris I-Disease 0 0.18806351721286774
) O 0 7.752438477837131e-07
, O 0 1.558580322580383e-07
a O 0 9.54588699642045e-07
rare O 0 8.185037586372346e-05
dominant O 1 0.9999886751174927
malformation B-Disease 1 1.0
of I-Disease 1 0.9999990463256836
the I-Disease 1 0.9999768733978271
eye I-Disease 1 1.0
. O 0 7.630856998730451e-05

The O 0 5.8061970776179805e-05
spectrum O 0 0.000137115697725676
of O 0 9.744471753947437e-05
PAX6 O 0 0.030529124662280083
mutations O 0 7.637721864739433e-05
in O 0 0.00019222054106649011
aniridia B-Disease 1 1.0
patients O 0 8.988181798486039e-05
is O 0 1.4984204881329788e-06
highly O 0 6.46830017103639e-07
biased O 0 1.383471271765302e-06
, O 0 2.5995671393275188e-08
with O 0 7.4081718537399865e-09
92 O 0 2.6503339540795423e-06
% O 0 1.6991704399060836e-07
of O 0 6.547749649143952e-07
all O 0 6.170288884277397e-07
reported O 0 9.468888492847327e-06
mutations O 0 5.8135119616054e-06
leading O 0 9.066482743946835e-05
to O 0 1.0517211421756656e-06
premature O 0 3.104146890109405e-05
truncation O 0 4.1223993321182206e-05
of O 0 5.500612314790487e-05
the O 0 3.54380754288286e-05
protein O 0 2.1567697331192903e-05
( O 0 1.4684522966490476e-06
nonsense O 0 1.5970335880410857e-05
, O 0 9.211902920469583e-07
splicing O 0 9.252738095710811e-07
, O 0 6.900201015014318e-07
insertions O 0 1.4951372122595785e-06
and O 0 1.758824396347336e-06
deletions O 0 3.3039641493814997e-06
) O 0 3.828554042684118e-07
and O 0 3.3059203019547567e-07
just O 0 9.83467771220603e-07
2 O 0 2.2426336272474146e-06
% O 0 4.3437844965410477e-07
leading O 0 1.7550560187373776e-06
to O 0 7.159298576198125e-08
substitution O 0 1.4888724990669289e-06
of O 0 9.359322575619444e-06
one O 0 4.267674739821814e-06
amino O 0 3.2537434435653267e-06
acid O 0 6.968766115278413e-07
by O 0 1.6106042721730773e-07
another O 0 5.275962280393287e-07
( O 0 3.969745705489913e-07
missense O 0 4.5508809307648335e-06
) O 0 4.4911351437804115e-07
. O 0 7.089473115229339e-07

The O 0 1.9389442968531512e-05
extraordinary O 0 1.3368077816267032e-05
conservation O 0 1.9880674244632246e-06
of O 0 2.717084043979412e-06
the O 0 3.360388063811115e-06
PAX6 O 0 0.00013195336214266717
protein O 0 1.5842701031942852e-05
at O 0 2.7969568691332825e-05
the O 0 6.128444965725066e-06
amino O 0 1.2304767551540863e-05
acid O 0 9.488928299106192e-06
level O 0 8.440561214229092e-05
amongst O 0 1.1660708878480364e-05
vertebrates O 0 4.535918196779676e-05
predicts O 0 1.0413800737296697e-05
that O 0 3.007107522989827e-07
pathological O 0 0.0007950114668346941
missense O 0 0.00010141432721866295
mutations O 0 9.868380402622279e-06
should O 0 2.9940524655103218e-06
in O 0 3.4147581118304515e-06
fact O 0 1.1081154980274732e-06
be O 0 1.9018966668227222e-06
common O 0 8.725598377168353e-07
even O 0 2.0019207624955015e-07
though O 0 8.443232957233704e-08
they O 0 4.473164594287482e-08
are O 0 5.76973491206445e-08
hardly O 0 4.7452218154830916e-07
ever O 0 5.870663812856947e-07
seen O 0 3.625200179158128e-06
in O 0 6.729299457219895e-06
aniridia B-Disease 1 0.9999973773956299
patients O 0 3.186752292094752e-05
. O 0 5.665282060363097e-06

This O 0 4.923424785374664e-05
indicates O 0 4.1665538446977735e-05
that O 0 4.812534939446778e-07
there O 0 8.236867188315955e-07
is O 0 4.6145291321408877e-07
a O 0 1.1599070148804458e-06
heavy O 0 2.9601946152979508e-05
ascertainment O 0 0.000848659488838166
bias O 0 8.853950930642895e-06
in O 0 9.375306717629428e-07
the O 0 3.7478670833479555e-07
selection O 0 2.73224117108839e-07
of O 0 6.173491442496015e-07
patients O 0 3.988293997281289e-07
for O 0 3.5964907851848693e-07
PAX6 O 0 0.00016357759886886925
mutation O 0 5.634713602375996e-07
analysis O 0 9.712263704386714e-08
and O 0 4.364288130886962e-08
that O 0 3.758981037549347e-08
the O 0 1.224888592332718e-06
missing O 0 1.7207041310030036e-05
PAX6 O 0 0.003117635380476713
missense O 0 0.00019635033095255494
mutations O 0 3.3464857551734895e-05
frequently O 0 4.607674327417044e-06
may O 0 1.3593620678875595e-05
underlie O 0 8.530532068107277e-05
phenotypes O 0 2.094335104629863e-05
distinct O 0 2.3245981992658926e-06
from O 0 7.3795845310087316e-06
textbook O 0 0.0012598201865330338
aniridia B-Disease 1 0.9999996423721313
. O 0 2.0694680642918684e-05

Here O 0 3.989216929767281e-05
we O 0 1.3219696484156884e-06
present O 0 7.474826588804717e-07
four O 0 1.0232239446850144e-06
novel O 0 6.89182252244791e-06
PAX6 O 0 0.0008145633619278669
missense O 0 8.489924221066758e-05
mutations O 0 7.521014595113229e-06
, O 0 6.575106681339093e-07
two O 0 2.446389544275007e-07
in O 0 8.673098932376888e-07
association O 0 3.016441951331217e-06
with O 0 1.6135668090555555e-07
atypical O 0 0.0022997043561190367
phenotypes O 0 0.04277082160115242
ectopia B-Disease 1 0.9993730187416077
pupillae I-Disease 1 0.9982534050941467
( O 0 1.1986157005594578e-05
displaced B-Disease 0 1.6076184692792594e-05
pupils I-Disease 0 0.00012637488543987274
) O 0 1.969231743714772e-05
and O 0 0.008431478403508663
congenital B-Disease 1 1.0
nystagmus I-Disease 1 1.0
( O 0 0.0003808072942774743
searching B-Disease 0 0.00017943931743502617
gaze I-Disease 0 0.0809781476855278
) O 0 1.9546564544725697e-06
, O 0 3.7198321933828993e-07
and O 0 3.411336422232125e-07
two O 0 5.379307026487368e-07
in O 0 5.513776159205008e-06
association O 0 7.77468903834233e-06
with O 0 1.2346256994533178e-07
more O 0 4.995461608814367e-07
recognizable O 0 0.00034849377698265016
aniridia B-Disease 1 1.0
phenotypes O 0 0.0007978776120580733
. O 0 5.880307071493007e-06

Strikingly O 0 0.0021839921828359365
, O 0 2.3601858629263006e-05
all O 0 2.478969008734566e-06
four O 0 1.7604605773158255e-06
mutations O 0 6.718461236232542e-07
are O 0 2.4667244247211784e-07
located O 0 1.4946482451705378e-06
within O 0 5.045571356276923e-07
the O 0 4.595316568156704e-06
PAX6 O 0 0.00037804461317136884
paired O 0 1.4386935617949348e-05
domain O 0 2.400047378614545e-05
and O 0 1.0275334716425277e-05
affect O 0 3.499003651086241e-05
amino O 0 2.5100682250922546e-05
acids O 0 3.0383089324459434e-06
which O 0 3.886913475525944e-07
are O 0 8.136428419902586e-08
highly O 0 2.518088422220899e-07
conserved O 0 1.0099519158757175e-06
in O 0 4.5058328623781563e-07
all O 0 2.5359850042150356e-07
known O 0 1.3082438954370446e-06
paired O 0 1.6054882507887669e-06
domain O 0 3.2723462481953902e-06
proteins O 0 1.8218812556369812e-06
. O 0 1.1183433343830984e-06

Our O 0 0.0001995501952478662
results O 0 7.57489469833672e-05
support O 0 5.2805053201154806e-06
the O 0 3.916277364623966e-06
hypothesis O 0 7.948089546516712e-07
that O 0 3.998812658778661e-08
the O 0 2.7633697641249455e-07
under O 0 8.439801604254171e-07
- O 0 6.276051180975628e-07
representation O 0 9.968387075787177e-07
of O 0 5.521869297808735e-06
missense O 0 0.00012562503980007023
mutations O 0 2.0727487935801037e-05
is O 0 4.508176516537787e-06
caused O 0 7.091378847690066e-06
by O 0 6.753329557795951e-07
ascertainment O 0 0.0002383416285738349
bias O 0 6.23586174697266e-06
and O 0 4.289179287297884e-07
suggest O 0 1.7023299392349145e-07
that O 0 1.7836070398402626e-08
a O 0 2.636232636632485e-07
substantial O 0 3.974460923927836e-06
burden O 0 3.572033529053442e-05
of O 0 0.0014120787382125854
PAX6 B-Disease 1 0.9999982118606567
- I-Disease 1 0.9998440742492676
related I-Disease 1 0.929491400718689
disease I-Disease 1 0.9703996181488037
remains O 0 1.279273237742018e-05
to O 0 8.764281034245869e-08
be O 0 2.0798029254365247e-07
uncovered O 0 5.889067324460484e-06
. O 0 2.0296683089782164e-07
. O 0 7.627489821970812e-07

The O 0 3.7447702197823673e-05
chromosomal O 0 0.0001684767339611426
order O 0 5.2362947826622985e-06
of O 0 2.2013531634001993e-05
genes O 0 8.265066753665451e-06
controlling O 0 5.894988862564787e-05
the O 0 5.056137888459489e-05
major O 0 0.0002976021496579051
histocompatibility O 1 0.548883318901062
complex O 0 0.001099271234124899
, O 0 2.1397627278929576e-06
properdin O 0 3.8207133911782876e-05
factor O 0 6.902386303409003e-06
B O 0 3.3454613003414124e-05
, O 0 2.9405933332782297e-07
and O 0 5.919919772168214e-07
deficiency B-Disease 0 0.00014781084610149264
of I-Disease 0 3.484000626485795e-05
the I-Disease 0 1.4234548871172592e-05
second I-Disease 0 2.0397408661665395e-05
component I-Disease 0 1.6625146599835716e-05
of I-Disease 0 9.618659532861784e-06
complement I-Disease 0 1.462553882447537e-05
. O 0 6.172611847432563e-06

The O 0 3.8027239497751e-05
relationship O 0 6.355063760565827e-06
of O 0 2.816807864292059e-05
the O 0 1.0395006938779261e-05
genes O 0 3.8938801480981056e-06
coding O 0 1.8210670532425866e-05
for O 0 3.980181190854637e-06
HLA O 0 2.0913295884383842e-05
to O 0 3.285045693246502e-07
those O 0 2.3981615981938376e-07
coding O 0 4.248572622600477e-06
for O 0 1.6593404552622815e-06
properdin O 0 0.00011275274300714955
Factor O 0 3.2821368222357705e-05
B O 0 8.430948219029233e-05
allotypes O 0 3.7298366805771366e-05
and O 0 1.3759187140749418e-06
for O 0 2.9667946819245117e-06
deficiency B-Disease 0 0.0005729970289394259
of I-Disease 0 0.00010644755093380809
the I-Disease 0 4.251119389664382e-05
second I-Disease 0 0.00010531000589253381
component I-Disease 0 4.917638216284104e-05
of I-Disease 0 3.7321995478123426e-05
complement I-Disease 0 4.89733720314689e-05
( O 0 8.262512892542873e-06
C2 O 0 4.092446397407912e-05
) O 0 5.4668131355128935e-08
was O 0 1.5870243430526898e-07
studied O 0 8.65225047164131e-08
in O 0 1.4917695523308794e-08
families O 0 1.6452079698581201e-09
of O 0 6.386684248127494e-08
patients O 0 2.8345689315756317e-06
with O 0 9.408129699295387e-06
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.0006971432594582438

Patients O 0 0.00016604099073447287
were O 0 1.783166590030305e-05
selected O 0 1.3986034446134e-06
because O 0 8.930938122375665e-08
they O 0 1.5055100277550082e-08
were O 0 1.353379417423639e-07
heterozygous O 0 2.0247772170023381e-07
or O 0 4.544937439732166e-07
homozygous O 0 8.363798770005815e-06
for O 0 7.789376832079142e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.4574091841932386e-05

12 O 0 9.261380910174921e-05
families O 0 3.7490073623303033e-07
with O 0 1.918432275260784e-07
15 O 0 5.638461971102515e-06
matings O 0 6.231675070011988e-05
informative O 0 7.362987525993958e-05
for O 0 0.00045340045471675694
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.8641736207646318e-05
found O 0 1.8688978116188082e-06
. O 0 7.573113407488563e-07

Of O 0 0.001434409525245428
57 O 0 0.0007209949544630945
informative O 0 5.599203723249957e-05
meioses O 0 0.0004824747738894075
, O 0 1.9831702502415283e-06
two O 0 2.1476489564520307e-07
crossovers O 0 5.251755510471412e-07
were O 0 3.8364413512681494e-07
noted O 0 5.823822561978886e-07
between O 0 5.378238256525947e-06
the O 0 0.0003310888714622706
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.5844103220151737e-05
and O 0 8.587063348386437e-06
the O 0 1.8693932361202314e-05
HLA O 0 0.00015081367746461183
- O 0 0.0001089575671358034
B O 0 0.00031948857940733433
gene O 0 7.179193630690861e-07
, O 0 6.268616203897182e-08
with O 0 8.09453837291585e-09
a O 0 1.9656317817862146e-07
recombinant O 0 1.1140629112560418e-06
fraction O 0 1.395680214955064e-06
of O 0 1.5150068975344766e-05
0 O 0 3.887679486069828e-05
. O 0 2.789870222841273e-06

035 O 0 0.09542932361364365
. O 0 0.00016879143367987126

A O 0 0.00036500528221949935
lod O 0 0.0010317660635337234
score O 0 2.3088356101652607e-05
of O 0 1.2151014743722044e-05
13 O 0 1.0263151125400327e-05
was O 0 4.1810894799709786e-06
calculated O 0 2.056850462395232e-06
for O 0 8.834871323415427e-07
linkage O 0 0.00010632357589202002
between O 0 0.0025135502219200134
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 9.485580812906846e-05
HLA O 0 0.0004315551486797631
- O 0 5.8103240007767454e-05
B O 0 3.428705531405285e-05
at O 0 8.59598344504775e-07
a O 0 2.3583300645668714e-08
maximum O 0 8.3740445688818e-08
likelihood O 0 9.693201974414478e-08
value O 0 2.2564680079995014e-07
of O 0 4.4193734538566787e-07
the O 0 2.8146871500212e-07
recombinant O 0 4.607660457622842e-07
fraction O 0 3.478128007827763e-07
of O 0 2.824086095642997e-06
0 O 0 1.4957640814827755e-05
. O 0 1.7183142517751548e-06

04 O 0 0.03823006525635719
. O 0 0.00010518274211790413

18 O 0 0.0003000748693011701
families O 0 1.310622906203207e-06
with O 0 2.3946739702296327e-07
21 O 0 1.199738744617207e-05
informative O 0 1.0183408676311956e-06
matings O 0 6.646614110650262e-06
for O 0 1.4588614476451767e-06
both O 0 4.235941560182255e-06
properdin O 0 0.00029086158610880375
Factor O 0 0.00010371823736932129
B O 0 0.0002104718441842124
allotype O 0 8.947875903686509e-05
and O 0 1.043122392729856e-05
HLA O 0 7.863103382987902e-05
- O 0 3.922540054190904e-05
B O 0 6.10588540439494e-05
were O 0 1.3035811434747302e-06
found O 0 9.300405281464919e-07
. O 0 6.003489829708997e-07

Of O 0 0.003510410664603114
72 O 0 0.0023072604089975357
informative O 0 0.00011673909466480836
meioses O 0 0.0013808943331241608
, O 0 1.3776907508145086e-05
three O 0 6.274924089666456e-06
recombinants O 0 7.392677798634395e-05
were O 0 5.433326805359684e-06
found O 0 4.758340992339072e-07
, O 0 2.1786828341419096e-08
giving O 0 1.3346757476995208e-08
a O 0 9.073655604652231e-08
recombinant O 0 3.68561160257741e-07
fraction O 0 6.317745828710031e-07
of O 0 1.0894566003116779e-05
0 O 0 4.0249993617180735e-05
. O 0 3.3051237551262602e-06

042 O 0 0.030693983659148216
. O 0 0.0002820373047143221

A O 0 0.0007622179691679776
lod O 0 0.0013679710682481527
score O 0 7.938043563626707e-05
of O 0 9.805974696064368e-05
16 O 0 5.080909249954857e-05
between O 0 2.9543396522058174e-05
HLA O 0 0.00019843000336550176
- O 0 5.513105497811921e-05
B O 0 4.799120870302431e-05
and O 0 7.683376566092193e-07
Factor O 0 4.743330919154687e-06
B O 0 2.1506060875253752e-05
allotypes O 0 1.3405943718680646e-05
was O 0 3.6212643408362055e-06
calculated O 0 9.69613893175847e-07
at O 0 1.0568973038971308e-06
a O 0 5.701710747985089e-08
maximum O 0 1.7696906695618964e-07
likelihood O 0 1.7570043553405412e-07
value O 0 3.8373781308109756e-07
of O 0 7.197237437139847e-07
the O 0 5.356415044843743e-07
recombinant O 0 5.024041342949204e-07
fraction O 0 7.329090294661e-07
of O 0 5.859080374648329e-06
0 O 0 1.897071888379287e-05
. O 0 1.2939843827552977e-06

04 O 0 0.03446745127439499
. O 0 0.00012321631947997957

A O 0 0.00033704869565553963
crossover O 0 3.157770697725937e-05
was O 0 4.2148334614466876e-05
shown O 0 9.968405265681213e-07
to O 0 2.1250100701308838e-07
have O 0 7.40102876761739e-08
occurred O 0 1.6485814740008209e-06
between O 0 3.281604392668669e-07
genes O 0 2.5976024176088686e-07
for O 0 8.420964263677888e-07
Factor O 0 6.5769027060014196e-06
B O 0 2.556673098297324e-05
and O 0 1.4440503264268045e-06
HLA O 0 2.494014916010201e-05
- O 0 2.8528333132271655e-05
D O 0 3.2559404644416645e-05
, O 0 3.40817564392637e-07
in O 0 6.065156981094333e-07
which O 0 1.0806966201926116e-06
HLA O 0 3.8867121475050226e-05
- O 0 9.524264169158414e-05
D O 0 0.00019967429398093373
segregared O 0 8.674355922266841e-05
with O 0 2.249496674266993e-06
HLA O 0 0.00019006359798368067
- O 0 4.208692553220317e-05
A O 0 3.8966132706264034e-05
and O 0 3.968651071772911e-06
B O 0 0.00013345092884264886
. O 0 1.6051698139563086e-06

These O 0 2.032067413892946e-06
studies O 0 1.255863935512025e-06
suggest O 0 2.8860500833616243e-07
that O 0 2.0934454170173922e-08
the O 0 2.060149029148306e-07
genes O 0 1.8670561985345557e-07
for O 0 7.69927169130824e-07
Factor O 0 3.668649515020661e-05
B O 0 0.00196396978572011
and O 0 0.00046089247916825116
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 6.675862096017227e-06
located O 0 8.915992111724336e-06
outside O 0 2.358569645366515e-06
those O 0 1.6569053684634127e-07
for O 0 6.424461389542557e-07
HLA O 0 1.2260840776434634e-05
, O 0 3.60436416713128e-07
that O 0 5.0430219999952897e-08
the O 0 6.590474868062302e-07
order O 0 9.379125458508497e-07
of O 0 2.230413338111248e-05
genese O 0 0.00020772496645804495
is O 0 1.4767781976843253e-05
HLA O 0 2.790339021885302e-05
- O 0 1.0044988812296651e-05
A O 0 3.4516375308157876e-05
, O 0 6.558785798915778e-07
- O 0 1.1607988881223719e-06
B O 0 6.387801931850845e-06
, O 0 2.1655172588452842e-07
- O 0 1.837715558394848e-06
D O 0 9.620695891499054e-06
, O 0 2.125723597146134e-07
Factor O 0 1.0695866876631044e-05
B O 0 0.0006491278181783855
allotype O 0 0.0019440933829173446
, O 0 0.00036949411150999367
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.4147908561644726e-07
that O 0 9.718431392968796e-09
the O 0 2.620893440052896e-07
genes O 0 1.2969024965059361e-06
coding O 0 8.277043525595218e-05
for O 0 0.00019902839267160743
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 3.887027196469717e-05
Factor O 0 4.454824374988675e-05
B O 0 5.423741095000878e-05
allotypes O 0 9.929306543199345e-06
are O 0 1.0595499588816892e-07
approximately O 0 2.3704888008069247e-07
3 O 0 1.1970413424933213e-06
- O 0 7.158096195780672e-07
- O 0 2.032478278124472e-06
5 O 0 5.5841087487351615e-06
centimorgans O 0 1.660594170971308e-05
from O 0 3.429732032600441e-06
the O 0 7.3946325755969156e-06
HLA O 0 2.663971099536866e-05
- O 0 1.1808741874119733e-05
A O 0 2.9687320420634933e-05
and O 0 7.333484063565265e-06
HLA O 0 0.00010759807628346607
- O 0 8.20806308183819e-05
B O 0 0.00010169895540457219
loci O 0 1.9631791019492084e-06
, O 0 8.990757294213836e-08
and O 0 1.982798103483674e-08
that O 0 6.74142297540925e-09
the O 0 1.1888802475823468e-07
apparent O 0 1.7448627431804198e-06
lack O 0 1.5305190572689753e-06
of O 0 3.8987627704045735e-06
recombinants O 0 8.583658200222999e-06
between O 0 4.488090894483321e-07
the O 0 1.716433985166077e-06
Factor O 0 2.0896390196867287e-05
B O 0 0.0004066616529598832
gene O 0 5.583660822594538e-05
and O 0 0.0002606484922580421
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.839330020127818e-05
suggests O 0 2.319268332939828e-06
that O 0 1.1780228703628381e-07
these O 0 5.6578034701715296e-08
two O 0 3.6200000863573223e-07
genes O 0 2.901393145293696e-06
lie O 0 1.7637710698181763e-05
in O 0 4.162990535405697e-06
close O 0 1.2974533092346974e-05
proximity O 0 7.074472250678809e-06
to O 0 9.216155945068749e-07
one O 0 2.7403643798606936e-06
another O 0 4.475585228647105e-06
. O 0 2.2527149212692166e-06

Distribution O 0 0.00015098434232641011
of O 0 0.00016219822282437235
emerin O 0 0.0009220351930707693
and O 0 1.7294445569859818e-05
lamins O 0 0.00036980409640818834
in O 0 6.373739324772032e-06
the O 0 7.680566341150552e-06
heart O 0 0.0003027285565622151
and O 0 9.258845921067405e-07
implications O 0 8.52073571877554e-06
for O 0 4.999373231839854e-06
Emery B-Disease 1 0.7789835333824158
- I-Disease 1 0.9999970197677612
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 3.366985765751451e-05

Emerin O 0 0.017857743427157402
is O 0 0.00011054611968575045
a O 0 4.183395503787324e-05
nuclear O 0 8.89478251338005e-05
membrane O 0 2.7566855351324193e-05
protein O 0 1.0961231964756735e-05
which O 0 7.412272680085152e-07
is O 0 8.522722509951564e-07
missing O 0 1.907444129756186e-06
or O 0 1.1861751545438892e-06
defective O 0 1.4920244211680256e-05
in O 0 1.6431380572612397e-05
Emery B-Disease 1 0.9999045133590698
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.001343869953416288
EDMD B-Disease 1 1.0
) O 0 1.107285152102122e-05
. O 0 2.3578434138471493e-06

It O 0 1.276910916203633e-05
is O 0 3.868865405820543e-06
one O 0 9.256127668777481e-07
member O 0 2.3244231215358013e-06
of O 0 9.967759069695603e-06
a O 0 2.1528776414925233e-05
family O 0 1.5908164641587064e-05
of O 0 0.0002663084596861154
lamina O 0 0.005291150417178869
- O 0 0.0003355925437062979
associated O 0 2.6763409550767392e-05
proteins O 0 1.3412901580522885e-06
which O 0 5.763558306171035e-07
includes O 0 1.2039323564749793e-06
LAP1 O 0 0.00037310528568923473
, O 0 6.751688033546088e-06
LAP2 O 0 0.0006788276950828731
and O 0 3.381304122740403e-05
lamin O 0 0.0022704254370182753
B O 0 0.002140505937859416
receptor O 0 0.00028032908448949456
( O 0 9.129934369411785e-06
LBR O 0 0.00041511922609061003
) O 0 1.465113200538326e-06
. O 0 1.7239838143723318e-06

A O 0 0.0009435720276087523
panel O 0 0.00019443810742814094
of O 0 0.0001177349331555888
16 O 0 0.00011944380821660161
monoclonal O 0 6.470317021012306e-05
antibodies O 0 3.0649305699625984e-05
( O 0 8.47487444843864e-06
mAbs O 0 3.866265615215525e-05
) O 0 8.471469072901527e-07
has O 0 4.1919670934476017e-07
been O 0 4.625680674053001e-07
mapped O 0 1.5967373201419832e-07
to O 0 6.709330335752384e-08
six O 0 1.549901753605809e-07
specific O 0 4.693974275937762e-08
sites O 0 8.980334200714424e-07
throughout O 0 1.2252951364644105e-06
the O 0 4.022253506263951e-06
emerin O 0 5.242995757726021e-05
molecule O 0 3.8093567127361894e-06
using O 0 1.0409742117190035e-06
phage O 0 6.499125902337255e-06
- O 0 3.970661055063829e-06
displayed O 0 1.273690395464655e-05
peptide O 0 5.981686172162881e-06
libraries O 0 1.920472868732759e-06
and O 0 2.836295038832759e-07
has O 0 2.550865758621512e-07
been O 0 3.4817486493921024e-07
used O 0 1.393631805512996e-07
to O 0 1.774728843884077e-07
localize O 0 1.2502566278271843e-05
emerin O 0 0.00010993074829457328
in O 0 6.61543890601024e-06
human O 0 2.8471200494095683e-05
and O 0 8.389458344026934e-06
rabbit O 0 7.002773054409772e-05
heart O 0 0.2837769389152527
. O 0 4.117237494938308e-06

Several O 0 5.116198371979408e-05
mAbs O 0 0.00018293313041795045
against O 0 2.1419480617623776e-05
different O 0 2.476093641234911e-06
emerin O 0 0.000285562826320529
epitopes O 0 8.91305462573655e-05
did O 0 1.8905508341049426e-06
not O 0 3.351268844653532e-07
recognize O 0 1.920408749356284e-06
intercalated O 0 7.932179141789675e-05
discs O 0 6.778026727261022e-05
in O 0 1.4631188605562784e-05
the O 0 2.5723571525304578e-05
heart O 0 0.002886056201532483
, O 0 1.150553316620062e-06
though O 0 1.4331050124383182e-07
they O 0 4.391518260149496e-08
recognized O 0 1.3377032246353338e-06
cardiomyocyte O 0 3.521902544889599e-05
nuclei O 0 1.308793252974283e-05
strongly O 0 8.888824595487677e-06
, O 0 1.133106934503303e-06
both O 0 1.872106963674014e-06
at O 0 9.460765431867912e-05
the O 0 1.8603266653371975e-05
rim O 0 3.848516280413605e-05
and O 0 2.7098280952486675e-06
in O 0 9.658175258664414e-06
intranuclear O 0 0.0001729210780467838
spots O 0 1.0944351743091829e-05
or O 0 2.3038194285618374e-06
channels O 0 8.508125574735459e-06
. O 0 2.592232476672507e-06

A O 0 0.001966167474165559
polyclonal O 0 0.001920593436807394
rabbit O 0 0.000361229496775195
antiserum O 0 0.0005145792383700609
against O 0 7.487392576877028e-05
emerin O 0 0.0007238107500597835
did O 0 6.68346137899789e-06
recognize O 0 6.569599463546183e-06
both O 0 4.383653504191898e-06
nuclear O 0 5.311401400831528e-05
membrane O 0 2.241324182250537e-05
and O 0 2.580341515567852e-06
intercalated O 0 4.1530667658662423e-05
discs O 0 1.3124142242304515e-05
but O 0 1.608834310218299e-07
, O 0 3.5792176333870884e-08
after O 0 1.3311652935499296e-07
affinity O 0 4.758499869694788e-07
purification O 0 5.244131443760125e-06
against O 0 1.92267930287926e-06
a O 0 5.015471288061235e-06
pure O 0 4.79376976727508e-05
- O 0 2.450245665386319e-05
emerin O 0 0.00016532267909497023
band O 0 2.1092115275678225e-05
on O 0 1.6124380636028945e-05
a O 0 6.9348620854725596e-06
western O 0 9.159219189314172e-06
blot O 0 3.306168946437538e-05
, O 0 1.5434441138495458e-06
it O 0 1.900854300629362e-07
stained O 0 3.096128421020694e-05
only O 0 6.90196429786738e-07
the O 0 5.001676527172094e-06
nuclear O 0 2.7650366973830387e-05
membrane O 0 3.395412568352185e-05
. O 0 2.8830952487624018e-06

These O 0 4.765668563777581e-05
results O 0 7.905364327598363e-05
would O 0 2.8114297947468003e-06
not O 0 5.344576834431791e-07
be O 0 7.109805437721661e-07
expected O 0 2.3200027499115095e-06
if O 0 9.197208328259876e-07
immunostaining O 0 4.095737313036807e-05
at O 0 6.13090451224707e-05
intercalated O 0 6.570248660864308e-05
discs O 0 2.335605677217245e-05
were O 0 3.4808599593816325e-06
due O 0 5.653753760270774e-06
to O 0 2.3744574662032392e-07
a O 0 1.8812596636053058e-06
product O 0 3.4891022551164497e-06
of O 0 3.0809958843747154e-05
the O 0 5.476927253766917e-05
emerin O 0 0.0007571471505798399
gene O 0 2.7750695153372362e-05
and O 0 7.122589977370808e-06
, O 0 7.865243674132216e-07
therefore O 0 5.805976570627536e-07
, O 0 6.626170545587229e-08
cast O 0 1.1472495486941625e-07
some O 0 7.483654584916621e-09
doubt O 0 5.3751744388819134e-08
upon O 0 8.400023432386661e-08
the O 0 2.233444291732667e-07
hypothesis O 0 1.2742145827360218e-06
that O 0 1.3921043091613683e-06
cardiac B-Disease 1 0.9999998807907104
defects I-Disease 1 0.9999403953552246
in O 0 0.0013764421455562115
EDMD B-Disease 1 1.0
are O 0 8.16941428638529e-06
caused O 0 2.099452649417799e-05
by O 0 6.131047598501027e-07
absence O 0 2.7166564905201085e-05
of O 0 5.279808829072863e-05
emerin O 0 0.000860354513861239
from O 0 3.1186442356556654e-05
intercalated O 0 0.0005293298163451254
discs O 0 0.0003342705895192921
. O 0 4.9996165216725785e-06

Although O 0 0.00022700568661093712
emerin O 0 0.0015158354071900249
was O 0 0.00021135772112756968
abundant O 0 1.385122141073225e-05
in O 0 8.707795132067986e-06
the O 0 9.589935871190391e-06
membranes O 0 2.1669440684490837e-05
of O 0 0.0001530752779217437
cardiomyocyte O 0 0.0006434310926124454
nuclei O 0 0.00012185952073195949
, O 0 3.6915287182637258e-06
it O 0 3.3345568795084546e-07
was O 0 2.9112632546457462e-05
absent O 0 1.4241718417906668e-05
from O 0 1.052120410349744e-06
many O 0 7.766470133674375e-08
non O 0 7.237941645144019e-06
- O 0 1.1814531717391219e-05
myocyte O 0 0.00017012038733810186
cells O 0 1.4524617881761515e-06
in O 0 9.902345254886313e-07
the O 0 4.783917574968655e-06
heart O 0 0.000699095893651247
. O 0 4.9921745812753215e-06

This O 0 1.2693687494902406e-05
distribution O 0 2.2636553694610484e-05
of O 0 6.956593279028311e-05
emerin O 0 0.0005504479049704969
was O 0 6.715740892104805e-05
similar O 0 5.435537673292856e-07
to O 0 2.0023406932523358e-07
that O 0 1.7449578137984645e-07
of O 0 1.3706546269531827e-05
lamin O 0 0.0002715062000788748
A O 0 2.7613605197984725e-05
, O 0 5.278936896502273e-07
a O 0 5.752043534812401e-07
candidate O 0 7.29040039004758e-07
gene O 0 3.273237325629452e-07
for O 0 8.518694727399634e-08
an O 0 1.8299752468919905e-07
autosomal O 0 1.1647937753878068e-05
form O 0 1.2729920854326338e-05
of O 1 0.9987179040908813
EDMD B-Disease 1 1.0
. O 0 0.0004190778126940131

In O 0 0.00039961322909221053
contrast O 0 0.00021294094040058553
, O 0 6.998534081503749e-05
lamin O 0 0.003356712171807885
B1 O 0 0.019956424832344055
was O 0 0.0015286972047761083
absent O 0 0.0004507878329604864
from O 0 2.3055508791003376e-05
cardiomyocyte O 0 0.00026022637030109763
nuclei O 0 6.52124872431159e-05
, O 0 2.2224796794034773e-06
showing O 0 2.0504208805505186e-05
that O 0 4.213950433040736e-06
lamin O 0 0.0013089173007756472
B1 O 0 0.003006699262186885
is O 0 5.845585064889747e-07
not O 0 9.427967029296269e-08
essential O 0 8.92477146408055e-07
for O 0 5.701791678802692e-07
localization O 0 8.586200419813395e-05
of O 0 1.96567052626051e-05
emerin O 0 0.00016633541963528842
to O 0 2.4223525088018505e-06
the O 0 1.539977347420063e-05
nuclear O 0 0.0003382827271707356
lamina O 0 0.005493091885000467
. O 0 3.108394594164565e-05

Lamin O 1 0.9805715084075928
B1 O 1 0.9808446168899536
is O 0 3.061956522287801e-05
also O 0 6.806985311413882e-06
almost O 0 8.222627911891323e-06
completely O 0 2.0955958461854607e-05
absent O 0 8.109196642180905e-05
from O 0 1.2145338587288279e-05
skeletal O 0 0.010720507241785526
muscle O 0 0.00019417279690969735
nuclei O 0 0.00015472943778149784
. O 0 4.124980023334501e-06

In O 0 0.0011092204367741942
EDMD B-Disease 1 0.9999983310699463
, O 0 4.184240879112622e-06
the O 0 8.231754691223614e-07
additional O 0 5.202450097385736e-07
absence O 0 5.777867772849277e-05
of O 0 0.00028443060000427067
lamin O 0 0.01827933080494404
B1 O 1 0.9990899562835693
from O 0 0.0005504642031155527
heart O 1 0.999998927116394
and O 0 0.0021082949824631214
skeletal O 1 1.0
muscle O 1 0.9932957291603088
nuclei O 0 0.002864438807591796
which O 0 7.931469554023352e-06
already O 0 8.887485819286667e-06
lack O 0 3.0144374250085093e-05
emerin O 0 0.0001687708281679079
may O 0 1.672653070272645e-06
offer O 0 1.0044099951755925e-07
an O 0 1.5641015238543332e-07
alternative O 0 3.832532513570186e-07
explanation O 0 8.694863140590314e-07
of O 0 7.017094958428061e-06
why O 0 3.140263515888364e-06
these O 0 7.071072900544095e-07
tissues O 0 1.8419390471535735e-05
are O 0 2.583394689281704e-07
particularly O 0 1.4962526506678842e-07
affected O 0 1.0215181589501299e-07
. O 0 7.554879033477846e-08
. O 0 3.9509669136350567e-07

Genetic O 0 6.0502530686790124e-05
mapping O 0 0.00012447852350305766
of O 0 0.0002598039573058486
the O 0 0.0008188515203073621
copper B-Disease 1 0.994195818901062
toxicosis I-Disease 1 0.9084568619728088
locus O 0 0.0004742080927826464
in O 0 7.620480027981102e-05
Bedlington O 0 0.0004867789684794843
terriers O 0 0.00015188030374702066
to O 0 3.1931390367390122e-06
dog O 0 3.1449144444195554e-05
chromosome O 0 5.3008156100986525e-05
10 O 0 1.094585513783386e-05
, O 0 4.469715406685282e-07
in O 0 9.534333003102802e-07
a O 0 3.7075042200740427e-06
region O 0 4.982585323887179e-06
syntenic O 0 7.921626092866063e-05
to O 0 1.2969122735739802e-06
human O 0 2.646655229909811e-05
chromosome O 0 0.00021566257055383176
region O 0 4.85011660202872e-05
2p13 O 0 0.0007412935374304652
- O 0 0.00023180971038527787
p16 O 0 0.00013721534924115986
. O 0 2.384608478678274e-06

Abnormal O 1 0.9999998807907104
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999994039535522
accumulation I-Disease 0 0.008682114072144032
is O 0 2.4652904357935768e-06
recognized O 0 1.04967909919651e-06
as O 0 1.7719683000905206e-06
an O 0 7.83685300120851e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 1 0.9993032217025757
man O 1 0.740344226360321
, O 0 7.568546607217286e-06
mouse O 0 2.4622198907309212e-05
, O 0 3.7699883250752464e-06
rat O 0 3.831283902400173e-05
and O 0 5.930270617682254e-06
dog O 0 8.02496142568998e-05
. O 0 5.145320756128058e-06

The O 0 4.64943477709312e-05
major O 0 9.832519572228193e-05
cause O 0 0.00015464152966160327
of O 0 0.025160647928714752
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 0.9991021156311035
in O 0 0.00013933602895122021
man O 0 0.00013614248018711805
is O 0 1.020389163386426e-06
a O 0 2.489103508196422e-06
dysfunctional O 0 2.7097636120743118e-05
ATP7B O 0 0.0005377477500587702
gene O 0 1.0727656444942113e-05
, O 0 2.8547119654831477e-06
causing O 0 9.101008618017659e-05
Wilson B-Disease 0 0.00019753712695091963
disease I-Disease 0 0.0016370760276913643
( O 0 3.5687926356331445e-06
WD B-Disease 0 0.0003316673100925982
) O 0 5.466158199851634e-06
. O 0 2.8228557766851736e-06

Mutations O 0 0.00018175988225266337
in O 0 0.00010260887211188674
the O 0 6.301617395365611e-05
ATP7B O 0 0.0003761077532544732
genes O 0 2.7074540867033647e-06
have O 0 8.46575062496413e-07
also O 0 7.104017072379065e-07
been O 0 1.4434666582019418e-06
demonstrated O 0 6.31235889159143e-06
in O 0 5.295755727274809e-06
mouse O 0 2.0331941414042376e-05
and O 0 6.864429906272562e-06
rat O 0 7.676033419556916e-05
. O 0 1.5645624671378755e-06

The O 0 0.0013354263501241803
ATP7B O 0 0.00883928406983614
gene O 0 2.5441306206630543e-05
has O 0 1.3510856433640583e-06
been O 0 6.504680527541495e-07
excluded O 0 4.5963415118421835e-07
in O 0 1.1084139828199113e-07
the O 0 2.2444537250976282e-07
much O 0 4.521876633134525e-07
rarer O 0 7.025715603958815e-05
human O 0 0.003909052349627018
copper B-Disease 1 0.9999985694885254
overload I-Disease 1 0.9999786615371704
disease O 1 0.9994150400161743
non B-Disease 0 0.0018248690757900476
- I-Disease 0 0.00011091789201600477
Indian I-Disease 0 1.0164519153477158e-05
childhood I-Disease 0 0.49786874651908875
cirrhosis I-Disease 1 1.0
, O 0 1.159895873570349e-06
indicating O 0 8.00192265160149e-06
genetic O 0 7.779540283081587e-06
heterogeneity O 0 0.00010305159230483696
. O 0 5.62596278541605e-06

By O 0 1.1902216101589147e-06
investigating O 0 2.318144879609463e-06
the O 0 4.635379355022451e-06
common O 0 9.234694152837619e-05
autosomal O 1 0.9999995231628418
recessive O 1 1.0
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 0.001497551565989852
CT B-Disease 1 0.999996542930603
) O 0 1.748279100866057e-05
in O 0 0.0001955506595550105
Bedlington O 1 0.989300549030304
terriers O 0 0.00464003486558795
, O 0 4.296126689951052e-07
we O 0 1.6699031490929883e-08
have O 0 3.1817755097307554e-09
identified O 0 5.073090392215818e-09
a O 0 3.4198683884767433e-09
new O 0 2.0041579507079632e-09
locus O 0 1.7626197745812533e-07
involved O 0 4.66237821683535e-08
in O 0 4.598174655257026e-06
progressive O 1 0.9999997615814209
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.9727210858254693e-05

We O 0 1.8091373931383714e-05
examined O 0 1.7841872249846347e-05
whether O 0 1.0653369599822327e-06
the O 0 1.0658803148544393e-05
WD B-Disease 0 0.0006214001914486289
gene O 0 5.510488335858099e-05
ATP7B O 0 0.0010255302768200636
was O 0 6.08581758569926e-05
also O 0 1.5070750123413745e-06
causative O 0 9.493362995272037e-06
for O 0 1.682081347098574e-06
CT B-Disease 0 0.00015982853074092418
by O 0 8.205646508940845e-07
investigating O 0 3.854701390082482e-06
the O 0 1.9888368115061894e-05
chromosomal O 0 0.00304089835844934
co O 0 0.00900022592395544
- O 0 0.0016417180886492133
localization O 1 0.627721905708313
of O 0 0.0014912162441760302
ATP7B O 0 0.02619967982172966
and O 0 2.120930548699107e-05
C04107 O 0 6.757419760106131e-05
, O 0 4.5696714323639753e-07
using O 0 2.1529048410684481e-07
fluorescence O 0 4.701089437730843e-06
in O 0 4.564677055896027e-06
situ O 0 5.382864401326515e-05
hybridization O 0 2.9934358281025197e-06
( O 0 1.4664160516986158e-06
FISH O 0 6.003912858432159e-06
) O 0 4.7002276915009134e-07
. O 0 1.0091335980177973e-06

C04107 O 0 0.005987034644931555
is O 0 1.0289788406225853e-05
an O 0 9.821865205594804e-07
anonymous O 0 3.6941946746082976e-06
microsatellite O 0 3.245181142119691e-05
marker O 0 6.348325405269861e-05
closely O 0 2.5158253720292123e-06
linked O 0 1.2780878023477271e-05
to O 0 2.146462520613568e-06
CT B-Disease 0 0.2564418315887451
. O 0 1.3382797988015227e-05

However O 0 0.0003825115563813597
, O 0 5.139411223353818e-05
BAC O 0 0.0005536011303775012
clones O 0 5.292607966111973e-05
containing O 0 1.1710423677868675e-05
ATP7B O 0 0.0003195287717971951
and O 0 5.49365222468623e-06
C04107 O 0 4.132526373723522e-05
mapped O 0 2.965459543702309e-06
to O 0 1.5451938679689192e-06
the O 0 1.1162015653098933e-05
canine O 0 0.0004054332966916263
chromosome O 0 0.0009552420815452933
regions O 0 0.00012759312812704593
CFA22q11 O 0 0.022092768922448158
and O 0 6.875264807604253e-05
CFA10q26 O 0 0.002459511160850525
, O 0 4.509255632001441e-06
respectively O 0 7.710279533057474e-06
, O 0 1.3580857682882197e-07
demonstrating O 0 1.1808094768639421e-06
that O 0 1.7270183150230878e-07
WD B-Disease 0 3.368109537404962e-05
cannot O 0 1.0123859510713373e-06
be O 0 2.456545189488679e-07
homologous O 0 1.2118367749280878e-06
to O 0 1.4122707625574549e-06
CT B-Disease 0 0.000865184236317873
. O 0 7.547088443971006e-06

The O 0 0.001815764931961894
copper O 0 0.006495229434221983
transport O 0 0.0005401266389526427
genes O 0 0.0001505213149357587
CTR1 O 0 0.0033602267503738403
and O 0 5.643143231282011e-05
CTR2 O 0 0.0010126357665285468
were O 0 1.7161153664346784e-05
also O 0 2.307335307705216e-06
excluded O 0 4.452885605132906e-06
as O 0 2.0668451270466903e-06
candidate O 0 1.8126283976016566e-06
genes O 0 5.48778018583107e-07
for O 0 1.5738919501018245e-06
CT B-Disease 0 0.000279372587101534
since O 0 2.3107838842406636e-06
they O 0 6.452275869150981e-08
both O 0 5.101951572328289e-08
mapped O 0 2.083626498006197e-07
to O 0 2.2542634781075321e-07
canine O 0 5.277779564494267e-05
chromosome O 0 0.00048522380529902875
region O 0 0.00012679565406870097
CFA11q22 O 0 0.26553261280059814
. O 0 2.490064980520401e-05

2 O 0 0.00119133316911757
- O 0 0.0003267097345087677
22 O 0 0.00025657136575318873
. O 0 6.995880539761856e-06

5 O 0 0.0004912351141683757
. O 0 2.737012255238369e-05

A O 0 0.0003646710538305342
transcribed O 0 8.023568807402626e-05
sequence O 0 1.9076869648415595e-05
identified O 0 1.7479240341344848e-05
from O 0 8.145858373609371e-06
the O 0 1.1574402378755622e-05
C04107 O 0 0.0001054746171575971
- O 0 4.966311826137826e-05
containing O 0 1.599069764779415e-05
BAC O 0 0.0002806494594551623
was O 0 6.306305294856429e-05
found O 0 5.223299694989691e-07
to O 0 4.990118895875639e-08
be O 0 1.0738569500290396e-07
homologous O 0 2.019947800135924e-07
to O 0 1.2241979163718497e-07
a O 0 1.1423512660257984e-06
gene O 0 1.3613330338557716e-06
expressed O 0 3.3850451472972054e-06
from O 0 7.942786396597512e-06
human O 0 3.271443347330205e-05
chromosome O 0 0.0001994801714317873
2p13 O 0 0.00033189315581694245
- O 0 0.00010480399214429781
p16 O 0 4.302750312490389e-05
, O 0 3.0312418175526545e-07
a O 0 3.2414337169939245e-07
region O 0 2.6141410103264207e-07
devoid O 0 4.364406777312979e-06
of O 0 1.0631243867464946e-06
any O 0 5.108212803861534e-07
positional O 0 5.198839426157065e-05
candidate O 0 1.9070555936195888e-05
genes O 0 4.572244506562129e-06
. O 0 2.690605015231995e-06

Molecular O 0 0.0007595742936246097
analysis O 0 2.2137233827379532e-05
of O 0 4.365369750303216e-05
the O 0 3.74158589693252e-05
APC B-Disease 0 3.828982517006807e-05
gene O 0 1.016607939163805e-06
in O 0 1.1256998959652265e-06
205 O 0 4.91881110065151e-06
families O 0 2.3745026567212335e-07
: O 0 4.0028004377745674e-07
extended O 0 1.9193877960788086e-05
genotype O 0 5.526064342120662e-05
- O 0 8.110549242701381e-05
phenotype O 0 3.430308061069809e-05
correlations O 0 2.944582411146257e-05
in O 0 6.176775059429929e-06
FAP B-Disease 0 8.887434887583368e-06
and O 0 3.1739823214138596e-08
evidence O 0 3.074153198667773e-08
for O 0 1.651345549191774e-08
the O 0 3.67685224489378e-08
role O 0 2.8058695988875115e-07
of O 0 2.505042175471317e-06
APC B-Disease 0 2.7638976462185383e-05
amino O 0 1.7795433677747496e-06
acid O 0 4.903739068140567e-07
changes O 0 8.45893907808204e-07
in O 0 0.0012553870910778642
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999996423721313
. O 0 2.3575223167426884e-05

BACKGROUND O 0 0.0023187592159956694
/ O 0 0.001174422912299633
AIMS O 0 2.6841626095119864e-05
The O 0 5.496021003636997e-06
development O 0 3.7859485018998384e-05
of O 0 0.014467529021203518
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.137864956035628e-06
a O 0 3.7812841924278473e-07
variable O 0 4.2920805753965396e-07
range O 0 2.8046252964486484e-07
of O 0 2.0356517325126333e-06
extracolonic O 0 0.0005309413536451757
manifestations O 0 0.05161651223897934
in O 0 0.00022512850409839302
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0018987463554367423
FAP B-Disease 0 0.0016682633431628346
) O 0 4.428418947099999e-07
is O 0 6.154996157192727e-08
the O 0 6.251339357277175e-08
result O 0 2.466926787292323e-07
of O 0 1.9947674445575103e-06
the O 0 5.4493621064466424e-06
dominant O 0 0.00011112815991509706
inheritance O 0 6.254548497963697e-05
of O 0 0.0003878404968418181
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.000244942435529083
APC B-Disease 0 0.0005925960722379386
) O 0 2.2018302843207493e-06
gene O 0 7.085964170983061e-06
mutations O 0 9.74909562501125e-06
. O 0 4.651680228562327e-06

In O 0 1.4406458831217606e-05
this O 0 1.8486227304492786e-07
study O 0 1.2110737657167192e-07
, O 0 1.8514098698574344e-08
direct O 0 7.222086395586302e-08
mutation O 0 1.1762470109033529e-07
analysis O 0 2.1176724374072364e-07
of O 0 5.183371740713483e-06
the O 0 1.4366135474119801e-05
APC B-Disease 0 1.9191280443919823e-05
gene O 0 1.1620404620771296e-06
was O 0 7.290022494998993e-06
performed O 0 2.2195119981915923e-06
to O 0 1.0306696651696257e-07
determine O 0 1.096986807169742e-06
genotype O 0 2.473172571626492e-05
- O 0 3.6443976568989456e-05
phenotype O 0 1.6828238585731015e-05
correlations O 0 1.6499892808496952e-05
for O 0 6.42609393253224e-06
nine O 0 3.6781497328775004e-05
extracolonic O 0 0.00013593690528068691
manifestations O 0 4.4668075133813545e-05
and O 0 2.0155565039203793e-07
to O 0 2.3458762044015202e-08
investigate O 0 7.106714861038199e-08
the O 0 6.407511818906642e-07
incidence O 0 0.00010804234625538811
of O 0 5.363158925320022e-05
APC B-Disease 0 0.0001181046391138807
mutations O 0 2.0663840132328914e-06
in O 0 6.863971520942869e-06
non O 1 0.912220299243927
- O 1 0.9999903440475464
FAP O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.107602636504453e-06

METHODS O 0 0.00023330995463766158
The O 0 8.121594146359712e-05
APC B-Disease 0 8.813105523586273e-05
gene O 0 3.012908564414829e-06
was O 0 7.42146403354127e-06
analysed O 0 1.0227186066913418e-06
in O 0 6.186209589031932e-07
190 O 0 2.2777524009143235e-06
unrelated O 0 1.992575334952562e-06
FAP B-Disease 0 6.536035016324604e-06
and O 0 4.536899780305248e-07
15 O 0 1.7642421880736947e-05
non O 0 0.25900718569755554
- O 1 0.9999957084655762
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.36105687590316e-05
using O 0 3.3950448141695233e-06
denaturing O 0 0.0004562328103929758
gradient O 0 0.0006334594800136983
gel O 0 0.00011697522131726146
electrophoresis O 0 2.7875121304532513e-05
, O 0 1.0020925174103468e-06
the O 0 1.1942704531975323e-06
protein O 0 3.130488494207384e-06
truncation O 0 1.6645277355564758e-05
test O 0 5.558804900829273e-07
, O 0 5.3165358337992075e-08
and O 0 3.677714843774993e-08
direct O 0 4.798237114300719e-07
sequencing O 0 9.027079613588285e-06
. O 0 4.254159193806117e-06

RESULTS O 0 0.009013032540678978
Chain O 0 0.0005345410318113863
terminating O 0 4.5094882807461545e-05
signals O 0 2.3428288841387257e-05
were O 0 1.5521324030487449e-06
only O 0 1.226195962544807e-07
identified O 0 2.7964662763224624e-07
in O 0 3.8831413462503406e-07
patients O 0 6.134006866886921e-07
belonging O 0 1.7849262121671927e-06
to O 0 1.7810820907016023e-07
the O 0 4.8386468733951915e-06
FAP B-Disease 0 4.196269219391979e-05
group O 0 2.2807237201050157e-06
( O 0 4.401636033435352e-07
105 O 0 1.615704422874842e-05
patients O 0 1.5598591289744945e-06
) O 0 8.986331181404239e-07
. O 0 1.8474963781045517e-06

Amino O 0 0.000700126402080059
acid O 0 3.685062984004617e-05
changes O 0 2.8883459890494123e-06
were O 0 5.667000550602097e-06
identified O 0 1.1683622460623155e-06
in O 0 8.364879136024683e-07
four O 0 9.033753940457245e-07
patients O 0 5.714709345738811e-07
, O 0 4.2358709606560296e-07
three O 0 6.061733870410535e-07
of O 0 1.6521902580279857e-05
whom O 0 9.588236025592778e-06
belonged O 0 3.1945688533596694e-05
to O 0 8.202547974178742e-07
the O 0 6.823468083894113e-06
non O 0 0.0002614177647046745
- O 0 9.572358248988166e-05
FAP O 0 6.322364788502455e-05
group O 0 2.215958829765441e-06
of O 0 0.00043217738857492805
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.032877471297979355
. O 0 4.580278982757591e-06

Genotype O 0 0.021108346059918404
- O 0 0.0030045942403376102
phenotype O 0 0.00013899538316763937
correlations O 0 3.94506350858137e-05
identified O 0 8.216601941057888e-07
significant O 0 4.639239250536775e-07
differences O 0 3.884345005644718e-07
in O 0 7.132698556233663e-07
the O 0 3.744805212591018e-07
nature O 0 7.01910437328479e-07
of O 0 1.3883139899917296e-06
certain O 0 2.595405931060668e-06
extracolonic O 0 0.00026101432740688324
manifestations O 0 0.0001587292499607429
in O 0 7.352216925937682e-06
FAP B-Disease 0 2.3456321287085302e-05
patients O 0 3.1785691589902854e-07
belonging O 0 3.945281719097693e-07
to O 0 5.31167039241609e-08
three O 0 4.1397450445401773e-07
mutation O 0 8.745110790187027e-06
subgroups O 0 0.00039567722706124187
. O 0 1.2290365702938288e-05

CONCLUSIONS O 0 0.0017501817783340812
Extended O 0 0.0016376590356230736
genotype O 0 0.0007705039461143315
- O 0 0.0003913739637937397
phenotype O 0 8.33826488815248e-05
correlations O 0 4.750590960611589e-05
made O 0 1.2213810805405956e-05
in O 0 4.317004822951276e-06
this O 0 5.84785425417067e-07
study O 0 1.25725034649804e-06
may O 0 1.2767349062414723e-06
have O 0 2.0383002663493244e-07
the O 0 4.786819545188337e-07
potential O 0 3.6824252447331673e-07
to O 0 1.3126989983902604e-07
determine O 0 5.098318638374622e-07
the O 0 7.677861049160128e-07
most O 0 1.2138848148879333e-07
appropriate O 0 3.194742816958751e-07
surveillance O 0 4.306227310735267e-06
and O 0 9.961182740880759e-07
prophylactic O 0 0.0033550597727298737
treatment O 0 0.00023072661133483052
regimens O 0 2.38968768826453e-05
for O 0 3.3468421634097467e-07
those O 0 6.975255928409752e-08
patients O 0 1.443025894332095e-07
with O 0 3.554298544372614e-08
mutations O 0 1.4884479924148764e-06
associated O 0 2.1575694972852943e-06
with O 0 2.952693876068224e-07
life O 0 8.755241651670076e-06
threatening O 0 3.473908509477042e-05
conditions O 0 5.728206451749429e-05
. O 0 3.924371412722394e-06

This O 0 4.551488473225618e-06
study O 0 1.038883510773303e-06
also O 0 1.749303351061826e-07
provided O 0 4.447557344633424e-08
evidence O 0 6.637504412765338e-08
for O 0 1.623157430685751e-07
the O 0 1.2723930922220461e-06
pathological O 0 0.00047169948811642826
nature O 0 2.824387775035575e-05
of O 0 0.00010623043635860085
amino O 0 3.0994226108305156e-05
acid O 0 4.787970738107106e-06
changes O 0 1.0691721854527714e-06
in O 0 5.87888234804268e-06
APC O 0 1.689714554231614e-05
associated O 0 5.682168762177753e-07
with O 0 4.5578417484648526e-08
both O 0 6.518752115880488e-07
FAP B-Disease 0 2.1049938368378207e-05
and O 0 1.903929273794347e-06
non O 1 0.9991313815116882
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.916369552025571e-05
. O 0 3.003903259468643e-07
. O 0 4.324753888340638e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 0.24186067283153534
cancer B-Disease 1 1.0
risk O 0 0.0002538674743846059
of O 0 0.0005190116935409606
the O 0 0.00029516161885112524
APC O 0 0.0008666165522299707
I1307K O 0 0.0004974137409590185
polymorphism O 0 5.317062095855363e-05
. O 0 6.079257218516432e-06

Germ O 0 0.04927583038806915
- O 0 0.0009780904510989785
line O 0 6.718879012623802e-05
and O 0 3.291117536718957e-06
somatic O 0 1.356714801659109e-05
truncating O 0 1.7951237168745138e-05
mutations O 0 2.727770606725244e-06
of O 0 2.03546787815867e-05
the O 0 1.8030179489869624e-05
APC B-Disease 0 3.300397293060087e-05
gene O 0 5.100346243125387e-07
are O 0 1.4116358748594848e-08
thought O 0 2.579538893598965e-08
to O 0 1.1759885509832202e-08
initiate O 0 7.563271992694354e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.999984860420227
formation O 0 0.00011372315202606842
in O 0 0.00011430164886405692
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9999996423721313
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 0.0020474360790103674
respectively O 0 0.00048378383507952094
. O 0 1.972073050637846e-06

Recently O 0 0.001420204876922071
, O 0 2.331808536837343e-05
an O 0 1.3514436432160437e-05
isoleucine O 0 0.0002799279463943094
- O 0 5.0869690312538296e-05
- O 0 0.0001552457979414612
> O 0 0.00013531974400393665
lysine O 0 3.7773370422655717e-05
polymorphism O 0 4.9073223635787144e-06
at O 0 8.248552330769598e-05
codon O 0 5.545025851461105e-05
1307 O 0 8.027426520129666e-05
( O 0 1.3889761021346203e-06
I1307K O 0 1.9104052626062185e-05
) O 0 5.253844506114547e-07
of O 0 1.0898867913056165e-05
the O 0 1.515842268418055e-05
APC B-Disease 0 2.5232106054318137e-05
gene O 0 1.4900626865710365e-06
has O 0 1.23865834211756e-06
been O 0 1.1997191222690162e-06
identified O 0 2.451345437748387e-07
in O 0 5.414934776126756e-07
6 O 0 3.3105338843597565e-06
% O 0 6.778952865715837e-07
- O 0 1.852121613410418e-06
7 O 0 1.5729430742794648e-05
% O 0 1.0605907618810306e-06
of O 0 4.7149987949524075e-06
the O 0 6.24196673015831e-06
Ashkenazi O 0 2.137723822670523e-05
Jewish O 0 6.595671038667206e-06
population O 0 7.117138807188894e-07
. O 0 6.928092943780939e-07

To O 0 5.832743681821739e-06
assess O 0 7.898612238932401e-06
the O 0 2.8208482945046853e-06
risk O 0 1.3819850437357672e-06
of O 0 1.974078941202606e-06
this O 0 4.1780936044233385e-07
common O 0 5.010317636333639e-06
APC B-Disease 0 4.3140036723343655e-05
allelic O 0 3.5792043490801007e-05
variant O 0 0.0004057313781231642
in O 0 0.0011419414076954126
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.0926080904027913e-05
we O 0 2.825741205469967e-07
have O 0 4.6511956952599576e-08
analyzed O 0 2.1650960491115256e-07
a O 0 1.8361899378760427e-07
large O 0 3.1864814786786155e-07
cohort O 0 5.746041097154375e-06
of O 0 4.8031038204499055e-06
unselected O 0 0.0007918785559013486
Ashkenazi O 0 9.391992352902889e-05
Jewish O 0 2.8912789275636896e-05
subjects O 0 2.9362738132476807e-05
with O 0 3.1387005492433673e-06
adenomatous B-Disease 0 0.025544969365000725
polyps I-Disease 0 0.15436945855617523
and O 0 5.422984486358473e-06
. O 0 3.200187393304077e-06
or O 1 0.9962118864059448
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 4.470551630220143e-06
for O 0 8.998251814773539e-07
the O 0 1.4984452718636021e-05
APC O 0 0.00022567201813217252
I1307K O 0 0.00023099426471162587
polymorphism O 0 6.0380454669939354e-05
. O 0 1.165317098639207e-05

The O 0 0.0009628462139517069
APC O 0 0.0007321352022700012
I1307K O 0 0.000437610229710117
allele O 0 5.699464600184001e-05
was O 0 0.00010724611638579518
identified O 0 3.0115154459053883e-06
in O 0 3.6422359244170366e-06
48 O 0 1.4665792150481138e-05
( O 0 3.392719918338116e-07
10 O 0 4.3739970578826615e-07
. O 0 5.508575995349929e-08
1 O 0 1.3073982927380712e-06
% O 0 1.8886069597101596e-07
) O 0 4.065497449801114e-08
of O 0 1.0953058335871901e-06
476 O 0 5.5170075938804075e-05
patients O 0 7.140545221773209e-06
. O 0 3.8133985071908683e-06

Compared O 0 0.0001755154662532732
with O 0 1.5724846207376686e-06
the O 0 3.1291456252802163e-06
frequency O 0 3.2029840895120287e-06
in O 0 5.812769359181402e-07
two O 0 8.311777577318935e-08
separate O 0 4.558059174541995e-08
population O 0 6.866552126894021e-08
control O 0 2.2749170511815464e-06
groups O 0 4.2205036265841045e-07
, O 0 1.2921985899083666e-06
the O 0 1.6566080375923775e-05
APC O 0 0.00018805167928803712
I1307K O 0 0.00021348150039557368
allele O 0 1.8313317923457362e-05
is O 0 7.127456456146319e-07
associated O 0 2.2972149338329473e-07
with O 0 9.478558382625124e-09
an O 0 3.468733211775543e-08
estimated O 0 2.3657462122628203e-07
relative O 0 4.444188562047202e-06
risk O 0 1.492675323788717e-06
of O 0 1.0937152183032595e-05
1 O 0 6.892969395266846e-05
. O 0 3.2559503324591788e-06

5 O 0 0.0007149775046855211
- O 0 0.00020511168986558914
1 O 0 0.0001095227780751884
. O 0 5.65413120057201e-06

7 O 0 0.0008952811476774514
for O 0 8.372222509933636e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.999992847442627
( O 0 2.8679696697508916e-05
both O 0 3.4981097996933386e-05
P O 1 0.8543970584869385
= O 0 5.508774847839959e-05
. O 0 1.2743495290123974e-06
01 O 0 6.23172236373648e-05
) O 0 7.368223577941535e-07
. O 0 5.934559226261626e-07

Furthermore O 0 0.000522762886248529
, O 0 2.2980302674113773e-05
compared O 0 3.8296398997772485e-05
with O 0 2.868411456802278e-06
noncarriers O 0 0.001294291578233242
, O 0 2.7793657864094712e-05
APC O 0 9.958481678040698e-05
I1307K O 0 4.7323774197138846e-05
carriers O 0 7.273795290529961e-07
had O 0 6.309544460236793e-07
increased O 0 1.5264884041243931e-06
numbers O 0 7.300836841750424e-07
of O 0 9.46488853514893e-06
adenomas B-Disease 1 0.9986798167228699
and O 0 0.00018849974730983377
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 0.00045147305354475975
patient O 0 8.491153857903555e-05
( O 0 3.7990894270478748e-06
P O 0 0.0028924511279910803
= O 0 2.7702628358383663e-05
. O 0 1.0713634992498555e-06
03 O 0 5.255906216916628e-05
) O 0 3.6255903523851885e-07
, O 0 1.1045666070685911e-07
as O 0 1.4786897395424603e-07
well O 0 1.472448616368638e-07
as O 0 3.483459067865624e-07
a O 0 5.081368499304517e-07
younger O 0 9.540972314425744e-07
age O 0 8.556098691769876e-06
at O 0 2.0722725821542554e-05
diagnosis O 0 6.234433385543525e-05
. O 0 2.7208388928556815e-06

We O 0 1.943459574249573e-05
conclude O 0 1.8799661120283417e-05
that O 0 9.6754297373991e-07
the O 0 1.0033997568825725e-05
APC O 0 9.344565478386357e-05
I1307K O 0 0.0001044004166033119
variant O 0 4.778533548233099e-05
leads O 0 1.9384746337891556e-05
to O 0 3.3457295103289653e-06
increased O 0 0.0008511526393704116
adenoma B-Disease 1 1.0
formation O 0 0.0010674785589799285
and O 0 2.0169067283859476e-05
directly O 0 2.745889560173964e-06
contributes O 0 1.4658387499366654e-06
to O 0 3.661812399968767e-07
3 O 0 2.5563285817042924e-06
% O 0 2.2885775763370475e-07
- O 0 2.3266845516900503e-07
4 O 0 3.9231974824360805e-07
% O 0 1.9259108086089327e-08
of O 0 5.5772950702248636e-08
all O 0 2.0878393058865186e-07
Ashkenazi O 0 0.00011974485823884606
Jewish O 0 0.11933305859565735
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2686450645560399e-05

The O 0 4.630911644198932e-05
estimated O 0 1.771374991221819e-05
relative O 0 8.716637967154384e-05
risk O 0 9.029654393089004e-06
for O 0 1.32021216359135e-06
carriers O 0 6.831958216935163e-07
may O 0 8.494225198774075e-07
justify O 0 1.6712516526240506e-07
specific O 0 2.459202796956106e-08
clinical O 0 1.5963552186804009e-06
screening O 0 1.6001717995095532e-06
for O 0 1.4519866908813128e-06
the O 0 5.320844138623215e-06
360 O 0 1.1558341611817013e-05
, O 0 6.417388931367896e-07
000 O 0 4.340825398685411e-06
Americans O 0 1.9138290952014358e-07
expected O 0 1.704810642877419e-06
to O 0 3.6839705330748984e-07
harbor O 0 2.6404837626614608e-05
this O 0 2.0958390223313472e-07
allele O 0 6.424908747248992e-07
, O 0 1.6458027118915197e-07
and O 0 6.215611847437685e-08
genetic O 0 5.16055649768532e-07
testing O 0 8.686948262948135e-07
in O 0 1.6462311123177642e-06
the O 0 3.76209777641634e-06
setting O 0 1.044239161274163e-05
of O 0 2.1044515960966237e-05
long O 0 1.3157276043784805e-05
- O 0 2.385038351349067e-05
term O 0 1.561905628477689e-05
- O 0 2.369784169786726e-06
outcome O 0 9.539808161207475e-07
studies O 0 4.876104071627196e-07
may O 0 3.032629649624141e-07
impact O 0 7.512144861721026e-07
significantly O 0 3.7753959531983128e-06
on O 0 0.0005505113513208926
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 6.705923442495987e-05
in O 0 4.5967274786562484e-07
this O 0 4.585483281971392e-08
population O 0 1.245708887154251e-07
. O 0 5.488847705237276e-07

Localization O 0 0.005555986892431974
of O 0 0.0002543340960983187
human O 0 8.765851089265198e-05
BRCA1 O 0 1.9533856175257824e-05
and O 0 1.7753631027517258e-06
its O 0 2.141232698704698e-06
loss O 0 2.3173241061158478e-05
in O 0 4.838065251533408e-06
high O 0 0.0005429340526461601
- O 0 0.0001380389730911702
grade O 0 0.10653460770845413
, O 0 1.1396263289498165e-05
non B-Disease 1 0.9957352876663208
- I-Disease 1 0.9999969005584717
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00043314811773598194

Although O 0 6.218633188836975e-06
the O 0 1.5153619870034163e-06
link O 0 1.9512629023665795e-06
between O 0 2.1128259959368734e-06
the O 0 1.5358471500803716e-05
BRCA1 O 0 0.0007355675334110856
tumour B-Disease 1 1.0
- O 0 0.2226797491312027
suppressor O 1 0.6501802206039429
gene O 0 9.176303137792274e-06
and O 0 5.103253897686955e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 0.0002196071727667004
established O 0 7.129725872800918e-06
, O 0 3.271445905284054e-07
the O 0 1.2669997886405326e-06
role O 0 4.382357474241871e-06
, O 0 4.107360496163892e-07
if O 0 3.786692914786727e-08
any O 0 4.4437754809223406e-08
, O 0 1.1615414052812412e-07
of O 0 1.4511103927361546e-06
BRCA1 O 0 2.3132435671868734e-05
in O 0 3.0574748961953446e-05
non B-Disease 1 0.6986684799194336
- I-Disease 1 0.7567905783653259
familial I-Disease 1 0.9946117401123047
cancers I-Disease 1 1.0
is O 0 2.9694569093408063e-05
unclear O 0 5.9221888477623e-06
. O 0 1.3396718259173213e-06

BRCA1 O 0 0.0028243258129805326
mutations O 0 4.1546190914232284e-05
are O 0 9.254503083866439e-07
rare O 0 2.6241875730192987e-06
in O 0 4.860749868385028e-06
sporadic B-Disease 0 0.00046688367729075253
cancers I-Disease 1 0.9999958276748657
, O 0 2.740981244642171e-06
but O 0 1.219276413166881e-07
loss O 0 8.00750967755448e-06
of O 0 7.288228516699746e-06
BRCA1 O 0 1.0717299119278323e-05
resulting O 0 8.900021384761203e-06
from O 0 2.3052282358548837e-06
reduced O 0 1.8706095943343826e-05
expression O 0 5.2925672207493335e-05
or O 0 1.270431857847143e-05
incorrect O 0 1.7179050701088272e-05
subcellular O 0 0.0009377934038639069
localization O 0 0.00023818579211365432
is O 0 1.0907151590799913e-06
postulated O 0 1.3730218597629573e-06
to O 0 2.0781962817295607e-08
be O 0 3.3639096841397986e-08
important O 0 5.0106820026485366e-08
in O 0 3.0572078912882716e-07
non B-Disease 0 6.207334081409499e-05
- I-Disease 0 0.0008048041490837932
familial I-Disease 1 0.999426007270813
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.000916389690246433

Epigenetic O 1 0.8571650385856628
loss O 1 0.9981069564819336
, O 0 3.068774094572291e-05
however O 0 1.7109705368056893e-06
, O 0 1.364176398510608e-07
has O 0 2.5530821901043055e-08
not O 0 1.161769169755189e-08
received O 0 2.0223069441271946e-07
general O 0 1.1689519396895776e-06
acceptance O 0 7.067499609547667e-06
due O 0 6.954399850656046e-06
to O 0 1.5355556115537183e-07
controversy O 0 1.0070339158119168e-06
regarding O 0 2.1677872155123623e-06
the O 0 1.2000946298940107e-05
subcellular O 0 0.0008184014004655182
localization O 0 0.0006466221529990435
of O 0 0.0001204909713123925
BRCA1 O 0 4.4146272557554767e-05
proteins O 0 1.0370827112637926e-05
, O 0 2.7416924694989575e-06
reports O 0 1.0890314570133341e-06
of O 0 6.095837306929752e-06
which O 0 6.568482149305055e-07
have O 0 7.885801096563227e-07
ranged O 0 4.817728768102825e-05
from O 0 3.084798436248093e-06
exclusively O 0 8.644247486699896e-07
nuclear O 0 8.119968697428703e-06
, O 0 3.477497898529691e-07
to O 0 2.1419380402676325e-07
conditionally O 0 6.093756383052096e-06
nuclear O 0 1.329966471530497e-05
, O 0 3.3408500144105346e-07
to O 0 3.5550922916627314e-07
the O 0 9.64861101238057e-06
ER O 0 0.0012444189051166177
/ O 0 0.0003325186553411186
golgi O 0 0.0006807161262258887
, O 0 3.352868588990532e-06
to O 0 8.831619879856589e-07
cytoplasmic O 0 2.296871207363438e-05
invaginations O 0 0.00015551186515949667
into O 0 4.3667964746418875e-06
the O 0 7.0344021878554486e-06
nucleus O 0 1.7932861737790518e-05
. O 0 1.931298129420611e-06

In O 0 0.00036908575566485524
an O 0 2.717039933486376e-05
attempt O 0 1.5545661881333217e-05
to O 0 2.3884551865194226e-06
resolve O 0 1.0140845006390009e-05
this O 0 2.024871037065168e-06
issue O 0 2.441006699882564e-06
, O 0 4.953075745106617e-07
we O 0 1.5158489929945063e-07
have O 0 1.315005704327632e-07
comprehensively O 0 5.1434954002615996e-06
characterized O 0 4.960964361089282e-06
19 O 0 4.438223913894035e-05
anti O 0 4.11957771575544e-05
- O 0 1.9665254512801766e-05
BRCA1 O 0 9.910546395985875e-06
antibodies O 0 3.3399785479559796e-06
. O 0 3.366556256878539e-06

These O 0 3.5960918467026204e-05
reagents O 0 0.00023931919713504612
detect O 0 5.687546945409849e-05
a O 0 2.276310624438338e-05
220 O 0 1.0536131412663963e-05
- O 0 4.179455117991893e-06
kD O 0 1.3704586308449507e-05
protein O 0 3.2968539471767144e-06
localized O 0 1.6712577917132876e-06
in O 0 1.9423846424615476e-06
discrete O 0 1.7525540897622705e-05
nuclear O 0 7.448913675034419e-05
foci O 0 0.000113392568891868
in O 0 5.3731523621536326e-06
all O 0 2.0554286948026856e-06
epithelial O 0 8.956225792644545e-05
cell O 0 5.419919762061909e-05
lines O 0 3.1258527997124474e-06
, O 0 7.070777030548925e-08
including O 0 3.432973372241577e-08
those O 0 3.421599004127529e-08
derived O 0 9.732445960253244e-07
from O 0 4.404539140523411e-06
breast B-Disease 0 0.0009941154858097434
malignancies I-Disease 0 0.010639341548085213
. O 0 7.184110017988132e-06

Immunohistochemical O 0 0.01035349816083908
staining O 0 0.0012568967649713159
of O 0 0.00012223937665112317
human O 0 0.00013506280083674937
breast O 0 0.0006156812887638807
specimens O 0 1.1465804163890425e-05
also O 0 6.9377460931718815e-06
revealed O 0 4.702318619820289e-05
BRCA1 O 0 0.00017120385018642992
nuclear O 0 0.0001761902094585821
foci O 0 0.0012769723543897271
in O 0 3.028481478395406e-05
benign O 1 0.9999033212661743
breast O 1 0.9998725652694702
, O 0 4.79222035210114e-05
invasive B-Disease 1 0.9922131896018982
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 1 0.956809937953949
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0003122759808320552

Conversely O 0 0.0007238965481519699
, O 0 1.6475583834107965e-05
BRCA1 O 0 1.7547416064189747e-05
expression O 0 2.0803134248126298e-05
was O 0 2.1675226889783517e-05
reduced O 0 2.526765683796839e-06
or O 0 8.517879450664623e-07
undetectable O 0 5.866768788109766e-06
in O 0 2.907027578658017e-07
the O 0 4.0980484072861145e-07
majority O 0 1.5093937122401258e-07
of O 0 7.350611213041702e-06
high O 0 0.004770938772708178
- O 0 0.008067385293543339
grade O 1 0.9999006986618042
, O 0 0.0001752656389726326
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 3.0048486223677173e-05
suggesting O 0 8.446375431958586e-06
that O 0 4.6340082349161094e-07
absence O 0 3.5126642615068704e-05
of O 0 2.0214123651385307e-05
BRCA1 O 0 4.216176239424385e-05
may O 0 3.4895813314506086e-06
contribute O 0 1.4473936005288124e-07
to O 0 7.698685777768333e-08
the O 0 4.721293009879446e-07
pathogenesis O 0 1.2191664609417785e-05
of O 0 3.0740332590539765e-07
a O 0 1.6814112768770428e-07
significant O 0 1.4195609310263535e-07
percentage O 0 2.173504753955058e-06
of O 0 3.5054849831794854e-06
sporadic B-Disease 0 0.06520407646894455
breast I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.247736145160161e-05
. O 0 3.831830326816998e-06

